term,subset,value,odds_ratio,p_value,exact_matches,conceptual_matches,Text 1,Text 2,Text 3,total_matches
customer,Segmentation,,250.166666667,4.33934371192e-19,14,0,"A number of significant customers have brought up the Opdivo commercial, and while they ""mainly"" agree in DTC, they have issue with this commercial. This was feedback, unrequested at two payers, and one IDN. They feel the commercial overstates the value and due to the specialty drug class can not convey the story well to bring value to patients. Not popular feedback, but wanted to ensure the brand team heard this from our customers. Please reach out if you would like additional information.","Medical Mutual (Regional payer/ESI downstream):  During a recent post-ESMO call w/ MM clinical pharmacists and BMS HSL/HEOR, MM revealed their current medical policies for PD-1 agents (ie Keytruda) are non-restrictive; currently no PD-L1 testing requirement language is included in medical policy for use in NSCLC; MM uses Care Continuum to manage medical policies; also mentioned they monitor drug spend based on annualized cost; will follow up with customer in early Q1 around updates they have related to medical policy and management of PD-1s","HEOR and I met with large academic IDN who shared that they are planning to head in a direction of managing access to oncology medications. Customers were interested in discussions/partnership pertaining to a need and development of a tool - using Epidemiological data and Budget modeling. Examples of current gaps include, EPI data, ability to estimate cost when there is an indication update or change of therapy and adjust for things like site of care and risk stratification. 

They are interested in Combining this type of data with clinical outcomes to make the best health economic and outcomes decision. Customer shared that they are interested in having best opportunity to leverage tools and technology at their disposal to treat disease.",14
DOP,Segmentation,,187.625,1.73564537081e-05,3,93,"Dickenson Community Hospital has recently been affected by the 340-b orphan drug court order and the enforcement of our policy around this issue.  In a previous meeting, The Director of Pharmacy Laura Casanova and the Oncology Pharmacist Mark Hagen stated they were going to contact each Pharmaceutical company and request they supply a contract to compensate for their lack of pricing for the 340-b orphan drugs. They stated they would move all utilization to drugs that have contracts and restrict those that do not. 

I  followed-up with the account and reinforced the BMS policy as it relates to ?newly eligible? 340-b entities and orphan drugs.  I then shifted the conversation away from cost and moved into value of our medicines, patient assistance program and our reimbursement support. 

Mark Hagen did not mention Merck or anything they might be offering to address this situation.  The conversation moved away from what he addressed in our last discussion of restricting one agent over another based on contract offering.  I believe Mark realized he needs to move his energy away from restricting these important drugs and focus on other ways to address the 340-b issue.   He said he is going to check into other wholesalers for potential better contracts for specialty drugs, look into getting his class of trade status changed, and potentially setting up his purchasing into in-patient and out-patient outlets to potentially move away from in-patient bundle payments from Medicaid/Medicare where he feels he is losing money.","Spoke with DOP at RWJ UH, which purchases Oncology medicine for the Cancer Institute of NJ. Discussed SCCHN, 10/05 approvals/tumors and NSCLC (017/057 & 026).  DOP said they are seeing a lot of Opdivo utilized. DOP also prefers that Keytruda be used to label/NCCN guidelines in 1L NSCLC, so patients have more options, including Opdivo, in 2L NSCLC. Made the analogy to antibiotics, why use your big gun antibiotic 1st line, should reserve for when its truly needed.
They have a Pharmacy Business manager that is looking at Value, asked for data on Quality of Life in Opdivo trials.","Highmark launched McKesson Clear Value Pathways early in 2016.  During meeting DOP of Allegheny Health Network Cancer Institute provided lens into how currently PD-1 status is set up in 2L NSCLC pathway.  Under PD-1 status: Positive, Negative, or Unknown is listed.  Positive ? all drugs listed, Negative & Unknown ? Keytruda is removed.",96
net,Segmentation,,187.625,1.73564537081e-05,3,18,"Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","Below, you will find excerpts from an article published in the Boston Business Journal, ""New immunotherapy cancer drugs boost revenues at Dana-Farber.""  The full article may be found here: http://www.bizjournals.com/boston/blog/health-care/2016/06/new-immunotherapy-cancerdrugs-boost-revenues-at.html

""Newly-approved immunotherapy drugs for cancer have contributed to growing revenue at Dana-Farber Cancer Institute, as more patients visit the hospital for access to the life-saving treatments.

""The hospital?s net patient service revenue skyrocketed in the second quarter, according to financials released last week. For the first two quarters ending March 31, the hospital reported net patient service revenue of $441.4 million, a 23 percent increase from the two quarters the year prior.

""Hospital spokesman John Noble said the uptick is mainly because of two new immunotherapy drugs approved by the FDA toward the end of 2015 ? one for the treatment of lung and renal cell cancer called Opdivo, sold by Bristol-Myers Squibb (NYSE: BMY) and one, called Keytruda and sold by Merck & Co. (NYSE: MRK) for the treatment of melanoma...""

""The hospital also saw an increase in volume, which contributed to higher patient revenue. According to financials, the hospital saw a 3,216 patient uptick in infusion visits to 76,647, and a 2,634 patient uptick to 38,201 clinic visits...""

""Though the patient revenue contributed to a 17 percent increase in operating revenue to $682.4 million, the high cost of the pharmacy drugs contributed to an uptick in expenses, with operating expenses increasing 17 percent to $655 million.

""The hospital still reported impressive year-over-year gains in operating income, seeing a 20 percent increase to $27.3 million compared to the same period the year prior.""","GHNW Onc Pharmacy lead informed that mixed dosing approach -wt. based up to 80Kg; 240mg beyond -(background- Insight entered 11/9/2016) will result in significant net savings to health plan.  
Result: OPDIVO preferred PD agent for 2L lung cancer at GHNW.

Also informed that Kaiser will be performing similar analysis.",21
IDN,Segmentation,,125.083333333,1.83935348245e-09,8,100,"A number of significant customers have brought up the Opdivo commercial, and while they ""mainly"" agree in DTC, they have issue with this commercial. This was feedback, unrequested at two payers, and one IDN. They feel the commercial overstates the value and due to the specialty drug class can not convey the story well to bring value to patients. Not popular feedback, but wanted to ensure the brand team heard this from our customers. Please reach out if you would like additional information.",Regional IDN has an ACO that has grown to almost 60K lives. The ACO has risk for Medical and Hospital costs. They are working to control costs and looking at Oncology class. Non employed Oncologists are the physicians driving cost. Efforts are being made to 'educate' them on cost and efficacy of drugs.  IDN will be looking to implement pathways in the future as a means to streamline and control costs.,"Oncology Clinical Pharmacist at Beth Israel Deaconness Hospital in Boston stated that he believes that if A-Z's PD-1 product is approved in December it could lead to IDNs choosing 1 preferred agent if it enters the market at a reduced price.  He said it would be difficult if an IDN chose one product and a payer chose another product as their preferred agent, if that happened.",108
AIM,Segmentation,,93.8125,4.28376458352e-05,4,12,"Last week, the U.S. Dept of Veterans Affairs conduced a LaunchPad: Pathways to InnoVAtion conference in which select participants and attendees were able to share and discuss the latest innovations in precision oncology and explore various ways to improve cancer screening, treatment and cures.  The VA Precision Oncology Program (POP) currently helps Veterans who have been newly diagnosed with non-small cell lung cancer (and now Prostate cancer) through targeted genomic sequencing which identifies specific mutations and allows patients to benefit from targeted therapies as well as clinical trials aimed towards those specific mutations.  Such advancements are a cornerstone of Vice President Biden?s Cancer Moonshot initiative.","Most recent update to AIM clinical pathways utilized by Anthem effective 5-1-16 include a new pathway for kidney cancer.   Other updates can be viewed:
 
https://anthem.aimoncology.com/","BCBS Alabama has recently expanded their Oncology Select Pathways to include new tumor types affecting BMS.  BCBS Alabama partnered with AIM in development of their Oncology Select Pathways that began as a pilot in Q2 2015 with NSCLC being the only pathway that affected BMS which began full implementation in late 2015 and now with an expansion of pathways.

The updated and expanded pathways now include: 
-CML, (Gleevec is 1L recommendation, Sprycel and Tasigna are 1L recommendation for Intermediate to High Risk Disease,)
-Metastatic Melanoma (Opdivo is listed as only PD-1 as 1L recommendation as montherapy regardless of BRAF status, Yervoy listed as 2L regardless of BRAF status)
-Kidney Cancer (Opdivo is listed as 2L recommendation for Clear Cell)
-Myeloma (Empliciti not listed on pathway)  
-NSCLC (Opdivo remains the only PD-1 recommended for NSCLC 2L; updated to include any histology/pathology)  

Worksheets for the pathways summarized above can be reviewed here: https://www.bcbsal.org/providers/oncology.cfm",16
PBM,Segmentation,,93.8125,4.28376458352e-05,4,122,"Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.","In meeting with Florida State Medicaid this past week, they are going to review Opdivo Emplicit and Sprycel n September. Currently, state has very limited knowledge, even thinking at this meeting that our products are in the chemotherapy class. 

Working closely with internal team on plan, but initial feedback from State is this is more procedural this year for their own compliance in reviewing these classes, versus a competitive review. This will be a Mass review. In speaking with PBM, they mentioned that Florida is 1st, but also that Minnesota is also considering a review in the future.",126
budget,Segmentation,,93.8125,4.28376458352e-05,4,162,"Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","A customer in Mid MO provided this concern to his TBM: ""They currently have only three patients on Opdivo and all of them are on doses of under 200 mg. One was only receiving 129mgs. He was concerned about the increased cost to his patients and to his budget.  According to his calculations the flat dosing will increase his budget for these 3 patients by over $100,000. (Based on a annual cost). He asked if he could leave these patients on their current weight based dosing""","HEOR and I met with large academic IDN who shared that they are planning to head in a direction of managing access to oncology medications. Customers were interested in discussions/partnership pertaining to a need and development of a tool - using Epidemiological data and Budget modeling. Examples of current gaps include, EPI data, ability to estimate cost when there is an indication update or change of therapy and adjust for things like site of care and risk stratification. 

They are interested in Combining this type of data with clinical outcomes to make the best health economic and outcomes decision. Customer shared that they are interested in having best opportunity to leverage tools and technology at their disposal to treat disease.",166
medical policy,Segmentation,,75.05,9.80749104181e-09,10,161,"PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.","BCBSMI/Blue Care Network:

oAE:  How are you viewing PDL testing at this point? LS: A: ?Haven?t we killed that off in previous discussions?? She then rattled through the inconsistencies and conflicting data sets indicating that they haven?t built this into their policies beyond FDA labeling for the relevant products.
o	How do clinical trials influence medical policy/criteria?  Depending on level of evidence and applicability to our population they might be considered for significant differentiators.
o	Do you consider FDA label or NCCN guidelines more important when making policy changes? General consensus was NCCN.  AH/LC: we find the guidelines to be a better guide especially when it comes to patient/treatment nuances.
?	BCN Subject matter expert (R.Cook) has a different view on NCCN guidelines ? often too broad would prefer the restrictions of label and NCCN cat1/2A.
o	How are you considering applying the new Keytruda 1L data?etc?  Most likely to labeled indication i.e. >50%.  Likely to mandate testing for 1L usage.  
o	Overall ? we feel the customer has a good grasp on this 1L population and the applicability of the new data in light of the many options in 1L NSCLC.  
o	Tumor types appear to be very unique and specific - no clear policy shortcuts pertaining to management.
o	Key question - if they mandate testing how strong will the management be of a PA for these patients.
o	Keytruda update - will they monitor PDL1 expression in 1L and eventually mandate more >1% in 2L broadly?  Possibility in future.",Group Health NW has CONFIRMED that the P&T decision 'against' coverage for Opdivo ns-NSCLC coverage has been OVERTURNED by Medical Policy Committee.  Medical Policy will be published for coverage at a future date.,171
contract,Segmentation,,72.9652777778,6.42943875343e-10,12,83,"Per the DBM:
""Apparently, Genetech is currently providing a discount with several large community privately owned accounts across the nation, as well as a rebate similar to ours.  What they offer is as follows:

1)	1% rebate through McKesson (similar to our contract) for all infusible products (Tecentriq was included in this when approved for bladder cancer).
2)	In addition to the 1% rebate for all customers, for the large community private accounts, they are also offering an upfront discount of 4.3% + ASP.  It is not performance based (no growth or volume component) and is adjusted quarterly based on ASP.  This discount may be also occurring through McKesson, but not entirely sure if this is how it is executed or goes directly to the account. Hopefully it is through McKesson, so internal folks can follow up.""","Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","Josh Whittington, HSL reports that at CCK in Wichita, KS, that they are already receiving contracting discounts on all infusible Genentech products, including Tecentriq.  I believe it is 4.3%.",95
BCBS,Segmentation,,62.5416666667,4.95413217825e-06,7,81,BCBS SC Jan 1st they are moving to incorporate ICER recommendations in their reviews. HEOR provided update on ICER and outlined the methodology. Pharmacy Director said that he would allow us to provide additional updates/ information that is not included in the 1 year assessment period.  They are also reviewing the drugs that are rejected by the EU and looking for consistency with their formulary management.,Cigna AVP of Pharma Contracting inquired about the BMS position on recent NICE and ICER negative comments on Opdivo and I/O therapy in general.  NAE and HEOR Director deferred the question to a later date as we did not feel adequately prepared to respond at this time.,"BCBS Vermont: Keytruda - PA Criteria
Updated 2016-12-13
Updated indications. Added coverage for Keytruda as first line treatment for metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death receptor-ligand1 (PD-L1) as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Revised 11/2016.",88
discount,Segmentation,,62.5416666667,4.95413217825e-06,7,98,"Per the DBM:
""Apparently, Genetech is currently providing a discount with several large community privately owned accounts across the nation, as well as a rebate similar to ours.  What they offer is as follows:

1)	1% rebate through McKesson (similar to our contract) for all infusible products (Tecentriq was included in this when approved for bladder cancer).
2)	In addition to the 1% rebate for all customers, for the large community private accounts, they are also offering an upfront discount of 4.3% + ASP.  It is not performance based (no growth or volume component) and is adjusted quarterly based on ASP.  This discount may be also occurring through McKesson, but not entirely sure if this is how it is executed or goes directly to the account. Hopefully it is through McKesson, so internal folks can follow up.""","Myself and Francis Lobo, HEOR met  with Michael Lessard, Pharmacy Director at Dartmouth Hitchcock and we had a  discussion around our Oncology portfolio and no real concerns regarding NSCLC and Opdivo.  Customer continues to cover Opdivo to label and have no plans on changing that. We reinforced our strong clinical profile in our approved indications and they believe in our data. Although they did request that we give discount for orphan drug for all classes of 340 b accounts. Currently we give discount for DSH account but not Rural Referral Center which they are.","Josh Whittington, HSL reports that at CCK in Wichita, KS, that they are already receiving contracting discounts on all infusible Genentech products, including Tecentriq.  I believe it is 4.3%.",105
HEOR,Segmentation,,55.5925925926,1.5815244376e-10,16,20,"Myself and Francis Lobo, HEOR met  with Michael Lessard, Pharmacy Director at Dartmouth Hitchcock and we had a  discussion around our Oncology portfolio and no real concerns regarding NSCLC and Opdivo.  Customer continues to cover Opdivo to label and have no plans on changing that. We reinforced our strong clinical profile in our approved indications and they believe in our data. Although they did request that we give discount for orphan drug for all classes of 340 b accounts. Currently we give discount for DSH account but not Rural Referral Center which they are.",BCBS SC Jan 1st they are moving to incorporate ICER recommendations in their reviews. HEOR provided update on ICER and outlined the methodology. Pharmacy Director said that he would allow us to provide additional updates/ information that is not included in the 1 year assessment period.  They are also reviewing the drugs that are rejected by the EU and looking for consistency with their formulary management.,Cigna AVP of Pharma Contracting inquired about the BMS position on recent NICE and ICER negative comments on Opdivo and I/O therapy in general.  NAE and HEOR Director deferred the question to a later date as we did not feel adequately prepared to respond at this time.,36
policy,Segmentation,,52.1180555556,5.48828865457e-07,18,128,Group Health NW has CONFIRMED that the P&T decision 'against' coverage for Opdivo ns-NSCLC coverage has been OVERTURNED by Medical Policy Committee.  Medical Policy will be published for coverage at a future date.,"Medical Mutual (Regional payer/ESI downstream):  During a recent post-ESMO call w/ MM clinical pharmacists and BMS HSL/HEOR, MM revealed their current medical policies for PD-1 agents (ie Keytruda) are non-restrictive; currently no PD-L1 testing requirement language is included in medical policy for use in NSCLC; MM uses Care Continuum to manage medical policies; also mentioned they monitor drug spend based on annualized cost; will follow up with customer in early Q1 around updates they have related to medical policy and management of PD-1s","PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.",146
pharmacy,Segmentation,,47.8259803922,1.74373724388e-15,29,48,"Myself and Francis Lobo, HEOR met  with Michael Lessard, Pharmacy Director at Dartmouth Hitchcock and we had a  discussion around our Oncology portfolio and no real concerns regarding NSCLC and Opdivo.  Customer continues to cover Opdivo to label and have no plans on changing that. We reinforced our strong clinical profile in our approved indications and they believe in our data. Although they did request that we give discount for orphan drug for all classes of 340 b accounts. Currently we give discount for DSH account but not Rural Referral Center which they are.","Michael Lessard, Pharmacy Operations Director at Dartmouth Hitchcock reports that the following companies are giving 340 B discounts on Orphan Drugs: Amgen; J&J; Ipsen; Grifols and Abbvie.",BCBS SC Jan 1st they are moving to incorporate ICER recommendations in their reviews. HEOR provided update on ICER and outlined the methodology. Pharmacy Director said that he would allow us to provide additional updates/ information that is not included in the 1 year assessment period.  They are also reviewing the drugs that are rejected by the EU and looking for consistency with their formulary management.,77
health,Segmentation,,41.6944444444,7.796652154e-10,25,0,"Met with Director, Oncology Pharmacy for Monterfiore Health with fHEOR. Discussed NSCLC, were informed that demand for Opdivo hasn't slowed down, in spite of 1L Lung (026) trial results. Lung cancer is their #1 tumor they see. They havent seen much increase in demand for Keytruda.  Oncology DOP said they will look to evaluate and narrow PD-1, PD-L1 inhibitors as more continue to come to market. Very interested in understanding the value that Opdivo brings, and wants to continua to meet & discuss.",Group Health NW has CONFIRMED that the P&T decision 'against' coverage for Opdivo ns-NSCLC coverage has been OVERTURNED by Medical Policy Committee.  Medical Policy will be published for coverage at a future date.,OpdivoFlat Dose: Group Health NW shared that for their 'closed' book of business (450K lives) they will be enforcing a blended dosing approach (weight based up to 80Kg and 240 mg flat dose above 80Kg).  The rationale provided was cost savings and minimization of waste.,25
feedback,Segmentation,,35.7380952381,2.24002614025e-05,10,8,"A number of significant customers have brought up the Opdivo commercial, and while they ""mainly"" agree in DTC, they have issue with this commercial. This was feedback, unrequested at two payers, and one IDN. They feel the commercial overstates the value and due to the specialty drug class can not convey the story well to bring value to patients. Not popular feedback, but wanted to ensure the brand team heard this from our customers. Please reach out if you would like additional information.","In meeting with Florida State Medicaid this past week, they are going to review Opdivo Emplicit and Sprycel n September. Currently, state has very limited knowledge, even thinking at this meeting that our products are in the chemotherapy class. 

Working closely with internal team on plan, but initial feedback from State is this is more procedural this year for their own compliance in reviewing these classes, versus a competitive review. This will be a Mass review. In speaking with PBM, they mentioned that Florida is 1st, but also that Minnesota is also considering a review in the future.","Feedback from Large Payor that they are updating their Opdivo Policy for RCC, based on the NCCN Guidelines update.",18
class,Segmentation,,29.1861111111,5.52973169687e-08,21,0,"Dickenson Community Hospital has recently been affected by the 340-b orphan drug court order and the enforcement of our policy around this issue.  In a previous meeting, The Director of Pharmacy Laura Casanova and the Oncology Pharmacist Mark Hagen stated they were going to contact each Pharmaceutical company and request they supply a contract to compensate for their lack of pricing for the 340-b orphan drugs. They stated they would move all utilization to drugs that have contracts and restrict those that do not. 

I  followed-up with the account and reinforced the BMS policy as it relates to ?newly eligible? 340-b entities and orphan drugs.  I then shifted the conversation away from cost and moved into value of our medicines, patient assistance program and our reimbursement support. 

Mark Hagen did not mention Merck or anything they might be offering to address this situation.  The conversation moved away from what he addressed in our last discussion of restricting one agent over another based on contract offering.  I believe Mark realized he needs to move his energy away from restricting these important drugs and focus on other ways to address the 340-b issue.   He said he is going to check into other wholesalers for potential better contracts for specialty drugs, look into getting his class of trade status changed, and potentially setting up his purchasing into in-patient and out-patient outlets to potentially move away from in-patient bundle payments from Medicaid/Medicare where he feels he is losing money.","PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.","Montefiore Health Pharmacy team is looking to do PD-1, & PD-L1 inhibitor class review as more products come out. Breadth of indications and having Phase III trials will be important considerations of value. They are trying to determine Biomarker.PD-L1 testing strategy. Want to learn from the cetuximab-KRAS mutation efficacy issue. They understand BMS strategy of all comers in trials, no PD-L1 testing required, efficacy in  expressors and non-expressors.",21
models,Segmentation,,27.7962962963,4.72046316299e-05,12,4,"Customer discussed future possibility of establishing a ""PDL 1"" preferred agent based on broad clinical profile, efficacy and cost.  Inquired if BMS would consider any preferred pricing model when these types of decisions are being made.","Oncology Care Model (OCM):  during meeting with CEO of large community oncology (OCM) practice, was informed that CMS has near term intention of 'expanding' the number of OCM sites.  No ETA was given; only the suggestion that it would be soon.  CEO sited CMS lead comments during recent teleconference.","HEOR and I met with large academic IDN who shared that they are planning to head in a direction of managing access to oncology medications. Customers were interested in discussions/partnership pertaining to a need and development of a tool - using Epidemiological data and Budget modeling. Examples of current gaps include, EPI data, ability to estimate cost when there is an indication update or change of therapy and adjust for things like site of care and risk stratification. 

They are interested in Combining this type of data with clinical outcomes to make the best health economic and outcomes decision. Customer shared that they are interested in having best opportunity to leverage tools and technology at their disposal to treat disease.",16
product,Segmentation,,22.3363095238,7.71614115636e-10,37,20,"Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","Oncology Clinical Pharmacist at Beth Israel Deaconness Hospital in Boston stated that he believes that if A-Z's PD-1 product is approved in December it could lead to IDNs choosing 1 preferred agent if it enters the market at a reduced price.  He said it would be difficult if an IDN chose one product and a payer chose another product as their preferred agent, if that happened.","Per the DBM:
""Apparently, Genetech is currently providing a discount with several large community privately owned accounts across the nation, as well as a rebate similar to ours.  What they offer is as follows:

1)	1% rebate through McKesson (similar to our contract) for all infusible products (Tecentriq was included in this when approved for bladder cancer).
2)	In addition to the 1% rebate for all customers, for the large community private accounts, they are also offering an upfront discount of 4.3% + ASP.  It is not performance based (no growth or volume component) and is adjusted quarterly based on ASP.  This discount may be also occurring through McKesson, but not entirely sure if this is how it is executed or goes directly to the account. Hopefully it is through McKesson, so internal folks can follow up.""",57
Director,Segmentation,,17.0568181818,6.15371889214e-06,41,32,"Myself and Francis Lobo, HEOR met  with Michael Lessard, Pharmacy Director at Dartmouth Hitchcock and we had a  discussion around our Oncology portfolio and no real concerns regarding NSCLC and Opdivo.  Customer continues to cover Opdivo to label and have no plans on changing that. We reinforced our strong clinical profile in our approved indications and they believe in our data. Although they did request that we give discount for orphan drug for all classes of 340 b accounts. Currently we give discount for DSH account but not Rural Referral Center which they are.","Michael Lessard, Pharmacy Operations Director at Dartmouth Hitchcock reports that the following companies are giving 340 B discounts on Orphan Drugs: Amgen; J&J; Ipsen; Grifols and Abbvie.",BCBS SC Jan 1st they are moving to incorporate ICER recommendations in their reviews. HEOR provided update on ICER and outlined the methodology. Pharmacy Director said that he would allow us to provide additional updates/ information that is not included in the 1 year assessment period.  They are also reviewing the drugs that are rejected by the EU and looking for consistency with their formulary management.,73
large academic center stated,Segmentation,  Access Influencers,38.2857142857,9.57083335361e-10,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,NTL at a large academic center  stated that there needs ot be F/u discussion on the Lugano Classification updates just published and implementation into practice and clarification for clinicians making clinical assesemen.   He stated that discussion on the abscopal effect seen in Lymphoma how it affects management ? discussion points to be clarified,372
NCCN institution,Segmentation,  Access Influencers,26.5054945055,4.7218577687e-05,16,109,"A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.","A NSCLC guidelines panelist representing a Northeast NCCN institution admitted that the evidence blocks are inaccurate and subjective.  As a surgeon, he routinely abstain from commenting on these.  According to this panelist, neither the guidelines nor the evidence blocks are intended to be used as tools to exclude any therapy from clinical consideration or reimbursement.  In this institution, there is a formal process to solicit comments from medical oncologists on potential treatment updates to the guidelines, which are consolidated and presented at the panel by their representative (a surgeon).","I met with possible new NCCN panel member in renal at NCCN institution.

On the renal agents (Cabo, Nivo mostly) she felt there was not a big difference from efficacy standpoint right now.  Stated that a different MOA means essentially nothing if results and safety data are same.  Does not safety issues are ""different"" but she has a lot of concern for the ""itis"" AEs of IO agents.  Stated she sees much less renal than in past.  Mostly bladder and prostate.",125
NTL,Segmentation,  Access Influencers,5.62742282843,6.46550803633e-06,311,710,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center  stated that there needs ot be F/u discussion on the Lugano Classification updates just published and implementation into practice and clarification for clinicians making clinical assesemen.   He stated that discussion on the abscopal effect seen in Lymphoma how it affects management ? discussion points to be clarified,NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,1021
context of an online lecture,Segmentation,  Clinical Practice Influencers,76.0739299611,2.46124919813e-07,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NCCN 2016 Webex Congress Series,Segmentation,  Clinical Practice Influencers,76.0739299611,2.46124919813e-07,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
comers,Segmentation,  Clinical Practice Influencers,11.9544747082,2.93001353078e-07,20,0,"TLs state the OAK data is intriguing in that the agent works in the all comer population, has apparent efficacy in the PDL1 non-expressing population, has q3w convenience, and a highly tolerable safety profile. When questioned about how to choose between agents in the 2L the TLs in general still feel that atezo is a ""me too"" drug and that nivo has such broad indications across tumor types with proven efficacy and support for many others that there is an established loyalty to nivo. Hence, the TLs predict varied physician preference (""choose one or the other and neither are wrong"") in the 2L.",TLs with close Roche relationships have all stated the indication for atezolizumab will be in an all comer 2L NSCLC population (not restricted by PDL1).,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",20
member,Segmentation,  Clinical Practice Influencers,6.64137483787,1.48144630649e-05,37,111,"Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","The following unsolicited insights were provided by speakers from the podium at a recent oncology conference attended by national AI?s/TL?s in various tumor types and hematological malignancies.  

Breast 
?	While there is limited data, panel believed for metastatic triple negative breast immunotherapy is a high viable option
?	Sited studies currently ongoing with Merck and Roche in the neoadjuvant setting using IO with taxane.

Developmental Therapeutics
?	One panelist made a comment to the audience about VALUE of care; the importance of consideration of value in oncology care.  
o	For example, the importance of consideration of the idea of limiting lines of therapy before patient goes to hospice.  Also, he mentioned some pathways are thinking of limiting to 2 lines before hospice.

Hematological malignancies Board
?	Panelist said RVD is strong 1st line therapy, based upon the SWOG trial presented at ASH 2015, because of OS with RVD.  He says he believes KRD may be treatment of future, even though KRD not indicated for 1L currently.
?	Panelist says there is trial of RD v. KRD which may show whether it is a good 1st line treatment.

Lung 
Testing
?	Consensus with the lung panel that ordering broad molecular testing should always be an option and should be standard of care however the known issue is limitation of tissue
?	Concerns around timing of results from NGS may delay treatment for patients, ~3 weeks is too long especially when 15% of these patients waiting never receive treatment
?	Consensus that liquid biopsy is an exploratory option now as concerns around false negative rates but should be explored in the setting of a clinical trial and in cases where tissue is not available
?	Huge focus on targeted therapy during the meeting given that the chair is a huge believer of testing in all lines.  
?	A case was presented focusing on the following scenario:  For second line treatment of a patient with NSCLC?squamous histology, Zubrod PS 1:
o	70% of the audience selected, Nivolumab without sending for PD?L1 testing.
o	10% of the audience selected, Nivolumab only if PD?L1 testing is positive (>1%)
o	18% of the audience selected, Pembrolizumab if PD?L1 positive (>1%)
?	TL chairing the meeting stated that PD1 data in a ?chaotic state?
?	Panel members expressed that PD-L1 may not be the best marker in dealing with tumor heterogeneity in lung
?	One panel member said If he happens to have PDL1 info already and if it?s positive and more than 1%, then he might use pembro, given more patient friendly Q3w schedule.  If PDL1 info is not available, then he goes straight to Nivo without PDL1 testing and would argue that Q2w dosing is not that bad.  
?	A few RTLs mentioned that in the setting of >1% PD-L1 expression they would give pembrolizumab for patients needing the Q3W dosing schedule and would do the same in adeno histology in the 2L setting.
?	Panel discussed managing immune-mediated AEs from PD1 agents are often responsive to immunosuppression.  
?	One panelist said data for SQ and NSQ very different.  The case being discussed was a SQ patient.  He mentioned that IASCLC is doing studies around PDL1 testing.  He says he would change treatment approach of going straight to nivo if this was a NSQ patient (didn?t elaborate more).
?	Lung panelist mentioned to the audience about the availability of the ASCO/MSKCC DrugAbacus tool (assesses the value of drugs compared to pricing given consideration of factors such as cost, toxicity, and efficacy). He mentioned the idea that If you can?t show that a drug is better, it supports considering restrictions.


Melanoma
Adjuvant
?	Panel presented a case where patient was given adjuvant ipilimumab as part of the EORTC trial and after 2 cycles of 10 mg/kg dose patient developed severe GI perforations.  Issues raised were 1) why the 10 mg/kg dose was even chosen 2) significant cost but was later amended to the dose being supported through BMS APP 3) significant toxicities leading to discontinuation
?	Panel discussed while the incidence low, case of myocarditis and it is a significant concern to monitor for 
?	One RTL said the toxicities of ipilimumab at 10 mg/kg are quite sobering comparing it to IL2

Testing	
?	One RTL mentioned he is not testing outside of clinical trials, and is not done routinely as data is still revolving
?	Discussion on which types of patients would tolerate regimen best and consensus on those who are healthy and with good performance status
?	Some community oncologist are using PD-1 inhibitors off label for cutaneous SCC as they?ve seen positive responses to PD1-inhibitors and have not been turned down by insurance companies, often challenging for some patients to participate in a clinical trial program because of location
?	RTL mentioned that we are in a unique space where knowledge of drug is going to move faster than a FDA approval 
?	TL panel member mentioned his experience has been that grade of immune-mediated AE likely correlated to depth of response
?	Consensus that the direction moving forward would be combination checkpoint inhibitor with targeted strategy.  Interesting how ?one major company going for targeted approach and another company doing immune checkpoint combination.?","National lung TL volunteered the following when asked by a audience member during an iplan about whether the 026 results mean physicians shouldn't treat PDL1- patients with nivo: he said ""No, this doesn't mean you shouldn't treat PDL1- patients"". He said remember that there is still about a 10% ORR in the PDL1- folks and the durability of responses in those patients is as good as in the PDL1+.",148
podium,Segmentation,  Clinical Practice Influencers,6.37072319871,1.27573768469e-07,46,474,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",520
NCCN,Segmentation,  Clinical Practice Influencers,4.9810311284,6.30902110978e-08,229,106,"2.	Met with regional Lung AI, who is also on the Head and Neck NCCN committee, who provided the following unsolicited insights:
a.	AI disclosed membership on the Head and Neck NCCN panel and is also the chair for the upcoming updates.
b.	AI shared some unsolicited insights on the topic of how NCCN committees in general consider and review guidelines and updates.  AI says that although the consent and approval of all panelists is sought, the process for doing that can be rather informal, depending on the specific chair of the committee.  For example, review/consent/approval may be done through email communication.","Met with national Lymphoma/cHL NCCN panelist AI/TL and cHL external disease chair for the VIA pathway, who shared the following unsolicited insights
?	In light of the Bleomycin shortage, she has been either shortening Bleomycin to 2-3 cycles and then discontinuing or substituting Brentuximab Vedotin (BV) in place of Bleomycin.  
?	AI thinks that BV is moving to front line status in practice, especially with Bleomycin shortage, which elevates the need for combination trials involving nivolumab with other agents.
?	She stated that BV moving into the front line was an opportunity for Nivo to conduct more trials using combinations of agents, particularly because the current BV data in the 2L will no longer be applicable. 
?	She is interested in T-cell lymphoma trials, involving the various subtypes.  Medical will continue follow-up with AI to discuss any ISR interests she may have.","a national/regional lung AI and NCCN NSCLC Panelist provided the following insights from the podium at a lung CME event.

?	CM 017 (SQ NSCLC)
?	Field should be moving from focusing on median improvement of PFS/OS to focusing on evaluating for the tail of the curve (as sign of on-going response)
?	Showed CM 017, urged to focus on tail of the curve.  Showed percentage of patients who had prolonged on-going duration of response, in responders
?	In regards to CM 057
o	Showed PDL1 expression demographics of patients
o	Said mDOR of 17.2 months with Nivo versus 5months with Docetaxel  is incredible, compared to OS seen with chemo treatments.  
?	Emphasized this as impressive
o	He said some doctors say Nivo is good choice even in non-expressors, considering its much more tolerable AE profile, and perhaps should be SOC.
?	In regards to CM 057, highlighted ~9% response in non-expressors
o	Said this is as good a response as docetaxel (response rate), with a better AE profile
?	PDL1 expression is affected by where in the tumor you acquire tissue to do the PDL1 analysis
?	He described a patient who has been off treatment for 2.5 y, and has had no clinical signs of progression to this day (got PD1 inhibitor starting in 2/12).
?	In regards to CM 012,?
o	In melanoma, this regimen much more toxic
o	In lung, CM 012, have not seen this toxicity
?	In regards to KN 024,?
o	Small trial for today?s standards (n=305)
o	PDL1 greater than 50%
o	Did allow for cross-over, keep in mind when think about data that is public.
?	PDL1 testing should be incorporated into initial evaluation of NSCLC treatment in 1L.",335
TLs,Segmentation,  Clinical Practice Influencers,4.46352140078,1.55701787072e-07,98,6,"Numerous community TLs all had high level knowledge of -026 not meeting primary endpoint and KN -024 having very positive data. When I described the differences in trial design the TLs seemed very satisfied about why the outcomes were divergent and did not see the data as impacting 2L treatment choices. However, did state that when Pembro is indicated in 1L PDL1 testing will become a standard practice - which is not what is occurring today.","NTLs and local TLs agree that pembro will not be the ""end of the story for 1L, with significant potential of Ipi/Nivo to affect a broader patient population."" However these TLs caution that there is a significant safety concern that has to be overcome with the combination (especially for the community).","When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",104
panelist,Segmentation,  Clinical Practice Influencers,4.07538910506,4.45725058208e-05,134,164,"a national/regional lung AI and NCCN NSCLC Panelist provided the following insights from the podium at a lung CME event.

?	CM 017 (SQ NSCLC)
?	Field should be moving from focusing on median improvement of PFS/OS to focusing on evaluating for the tail of the curve (as sign of on-going response)
?	Showed CM 017, urged to focus on tail of the curve.  Showed percentage of patients who had prolonged on-going duration of response, in responders
?	In regards to CM 057
o	Showed PDL1 expression demographics of patients
o	Said mDOR of 17.2 months with Nivo versus 5months with Docetaxel  is incredible, compared to OS seen with chemo treatments.  
?	Emphasized this as impressive
o	He said some doctors say Nivo is good choice even in non-expressors, considering its much more tolerable AE profile, and perhaps should be SOC.
?	In regards to CM 057, highlighted ~9% response in non-expressors
o	Said this is as good a response as docetaxel (response rate), with a better AE profile
?	PDL1 expression is affected by where in the tumor you acquire tissue to do the PDL1 analysis
?	He described a patient who has been off treatment for 2.5 y, and has had no clinical signs of progression to this day (got PD1 inhibitor starting in 2/12).
?	In regards to CM 012,?
o	In melanoma, this regimen much more toxic
o	In lung, CM 012, have not seen this toxicity
?	In regards to KN 024,?
o	Small trial for today?s standards (n=305)
o	PDL1 greater than 50%
o	Did allow for cross-over, keep in mind when think about data that is public.
?	PDL1 testing should be incorporated into initial evaluation of NSCLC treatment in 1L.","Spoke with a key advisor to a melanoma NCCN panelist.  They have continued to use nivo monotherapy in 1L melanoma, but his thought process has recently changed.  He attended AACR and saw the OS data from 069, and spoke with Dr. Hodi about OS in patients that discontinue treatment and Dr. Freidman about AE management, he has come to a conclusion that Regimen is practice changing and has distinct benefits over monotherapy in both high and low expression.","Brian Carriere and I met with a NTL/ NSCLC NCCN panelist at an NCI-designated academic institution in the mid-Atlantic who volunteered these unsolicited views regarding the rapidly evolving NSCLC treatment landscape:
Current Immunotherapy landscape:
?	This panelist believes that because of the MoA, anti-PD1s will eventually be seen as interchangeable, and believes that payers will prefer whichever pharma/ biotech company?s therapy is most cost-effective
o	Upon review of Keynote-010 versus Checkmate 057 mOS and HR to illustrate outcome differences, panelist pointed out BMS omitting Squamous NSCLC
?	Believes that the difference (if any) is negligible when introducing Squamous population in to Checkmate data
?	Acknowledges that BMS is dominating in 2L market share because of no testing strategy
o	As long as new efficacy and safety data matches Merck?s and timing of indications is roughly the same, panelist believes BMS will maintain its lead in 1L because oncologists are accustomed to using Nivo and habits are difficult to break
I-O shift to first line:
?	Awaiting Merck to release results of Keynote-024
o	Expects presentation of data at ESMO, and hopes to see BMS present findings from Checkmate-026 at that time
o	Understands why BMS would be a little anxious after Merck?s most recent press release, but views Keynote-024 as only impacting 15% (at best) of NSCLC because of its PD-L1 >50% requirement
?	Review of Checkmate-012:
o	Panelist expressed befuddlement at amount of press Checkmate-012 garnered post-ASCO considering how few patients were involved in trial 
?	Appreciated the 57% versus 28% ORR in PD-L1 expressers in the Nivo+Ipi versus Nivo mono groups, respectively, and found it impactful
?	Expressed concern with combination of Nivo+Ipi because of its toxicity profile
?	Upon review of Checkmate-012 safety data, panelist acknowledged that 19% versus 33% Grade 3-4 AEs was NOT drastically different, and 13% versus 10% and 8% versus 10% discontinuation rates for all Grade AEs and Grade 3-4 AEs, respectively, were essentially the same
o	Nevertheless, panelist mentioned multiple times throughout meeting that Ipi was toxic 
?	Bryan and I then differentiated Nivo+Ipi dosing in melanoma versus NSCLC, stressing small Ipi dose of 1mg/kg in NSCLC
o	Panelist mentioned at least twice that Nivo+Ipi should only be used in a clinical trial setting and not in a community setting
?	When asked what evidence/ data is missing to calm safety concerns, panelist responded that BMS would need much more safety data than what was presented on 30+ patients
?	Expressed how often Phase 1 data can?t be replicated in a Phase 3 setting
PD-L1 testing:
?	Does not believe that PD-L1 is an accurate marker of disease in NSCLC
o	This panelist believes that too much time is spent on PD1 inhibitors in NSCLC when PD-L1 doesn?t fully explain disease outcome
?	Adamantly believes that someone will one day be able to explain how NSCLC can best be managed, and doesn?t believe PD-1 will be a relevant factor
?	Doesn?t believe that anyone in the community practice setting cares about PD-L1 levels for treatment
o	Community oncologists only want to know PD-L1 cutoffs so that they know what to prescribe in order for payers to reimburse
?	This will become less of an issue when Merck is also indicated for all PD-L1 expressers
Payers and NCCN:
?	Mentioned that several NCCN panel members had received angry and disturbing letters from payers when NCCN had decided to include testing for use of Pembro because it added to payer?s expenses 
?	Laughed at the idea that payers and pathway companies use guidelines to create their medical policies when guidelines are only meant to be one group?s opinion
?	When asked about how NCCN would communicate PD-L1 cutoffs for therapeutic recommendations, (i.e., Checkmate-012 presentation where Nivo+Ipi PD-L1 status cutoff was 1% but Nivo monotherapy cutoff in Gettinger paper was 5% ), the panelist mentioned similarly to what they?ve done in the past for Pembro
o	This panelist believes that NCCN panel has gone far enough in clearly stating Pembro?s required testing and cutoff in the Guidelines, and doesn?t need additional or more forceful language
Financial Concerns:
?	This panelist says that Nivo?s introduction and applicability across tumor types is unprecedented in oncology, and that its cost as it continues to gain indications is unsustainable to the healthcare system
o	Several times used the term ?financially toxic? to describe the cost of Nivo+Ipi 
?	Recently co-authored and submitted a commentary to Francisco Tartari?s article on economic stability of PD1 inhibitors - Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges, where calculated cost of Nivo was $44k and Pembro was $130k: (http://www.cancertreatmentreviews.com/article/S0305-7372(16)30041-X/abstract)",298
national,Segmentation,  Clinical Practice Influencers,3.67584115358,2.32658243235e-06,183,979,"Attended the California cancer consortium conference where a national/regional AI/TL provided the following unsolicited insights from the podium.

?	PDL1 agents seem to work as well as PD1 agents 
?	PD1 inhibitor therapy is active only in small subset of pts
o	response rate 15-25% (unselected pts)
o	response can be durable
?	Biomarker enrichment: not yet universal
?	Optimal dose/schedule: undefined and to be determined
?	Curative potential: not yet established
?	Cost is prohibitive (can bankrupt us)
?	1L lung, if effective, would be transformative
?	Regarding KN 024?
o	Will be transformative for 1L, only for subset of high PDL1 expressors though
?	Regarding Checkmate 026?
o	FDA unlikely to reconsider PDL1 subset analysis (?you make your bed, you lie in it?)
?	In RCC, PDL1 not predictive of response (CM 025), OS regardless of PDL1
?	Why are results divergent in RCC and lung cancer?
o	PDL1 expression highly dynamic
o	Cutpoint selection issues
o	Assay variability (not yet harmonized)
o	Patient and tumor heterogeneitiy
o	Or just bad luck
?	Prohibitive cost of Immunotherapy: Who pays?
o	Nivo/ipi ?approximately 400 times the cost of gold? (Saltz, ASCO 2015)
?	Immunotherapy is now a cornerstone of cancer therapeutics
?	Harmonized pt selection strategies must be evolved.
?	Cost effectiveness needs to be established, can?t keep using for everyone, must find way to select pts.","2.	Met with regional Lung AI, who is also on the Head and Neck NCCN committee, who provided the following unsolicited insights:
a.	AI disclosed membership on the Head and Neck NCCN panel and is also the chair for the upcoming updates.
b.	AI shared some unsolicited insights on the topic of how NCCN committees in general consider and review guidelines and updates.  AI says that although the consent and approval of all panelists is sought, the process for doing that can be rather informal, depending on the specific chair of the committee.  For example, review/consent/approval may be done through email communication.","a national/regional lung AI and NCCN NSCLC Panelist provided the following insights from the podium at a lung CME event.

?	CM 017 (SQ NSCLC)
?	Field should be moving from focusing on median improvement of PFS/OS to focusing on evaluating for the tail of the curve (as sign of on-going response)
?	Showed CM 017, urged to focus on tail of the curve.  Showed percentage of patients who had prolonged on-going duration of response, in responders
?	In regards to CM 057
o	Showed PDL1 expression demographics of patients
o	Said mDOR of 17.2 months with Nivo versus 5months with Docetaxel  is incredible, compared to OS seen with chemo treatments.  
?	Emphasized this as impressive
o	He said some doctors say Nivo is good choice even in non-expressors, considering its much more tolerable AE profile, and perhaps should be SOC.
?	In regards to CM 057, highlighted ~9% response in non-expressors
o	Said this is as good a response as docetaxel (response rate), with a better AE profile
?	PDL1 expression is affected by where in the tumor you acquire tissue to do the PDL1 analysis
?	He described a patient who has been off treatment for 2.5 y, and has had no clinical signs of progression to this day (got PD1 inhibitor starting in 2/12).
?	In regards to CM 012,?
o	In melanoma, this regimen much more toxic
o	In lung, CM 012, have not seen this toxicity
?	In regards to KN 024,?
o	Small trial for today?s standards (n=305)
o	PDL1 greater than 50%
o	Did allow for cross-over, keep in mind when think about data that is public.
?	PDL1 testing should be incorporated into initial evaluation of NSCLC treatment in 1L.",1162
NTL,Segmentation,  Clinical Practice Influencers,3.44256470986,5.64821172631e-11,311,710,A NTL who attended SITC stated that they saw some 'great' data presented at the meeting.  Particularly they were impressed with the Keynote 45 data in mUC.,"Post 026 release:
- 2 NTL and 2 RTL mentioned that had BMS selected a different PDL-1 cut-off the 026 trial may have been positive, perception is NOT that nivo is less effective than pembro from the 026 read-out
-  2 RTLs have stated that PFS may not have been the best endpoint and are waiting for OS readout
-  1 community TL and 2 academic TLs stated that they currently have patients who are asking for 1L monotherapy pembro based on the 024 press release, some patients are willing to pay out of pocket for treatment vs enrolling in clinical trials
-  1 RTL was less optimistic stating ?you shot yourselves in the foot by selecting a 5% cut-point and endpoint of PFS?.  Combo therapy (ipi+nivo) will have to demonstrate ?cure? or high % of CR to compete against monotherapy pembro in + expressers based on a more favorable toxicity profile
-  Consensus from academic to community TLs stating that they see pem and nivo as being the same and the Q3week is the key advantage that pembro has despite the differences in trial design because they now have a better understanding of MOA, activity, and safety in a collection of trials across nivo and pembro",A NTL who was SITC stated that they feel that the decrease TRAE rate with N1I3 in bladder on the -032 study as compared to melanoma is due to the bladder patients on -032  having had prior chemotherapy.  The NTL feels that the prior chemo dampens the immune response so the combination is less toxic.  The NTL feels that there will likely be higher TRAE rates in the frontline setting.,1021
IO,Segmentation,  Clinical Practice Influencers,3.21684046693,6.20736891643e-08,242,52,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 ~80% of patients in 1L setting are PD-L1 low or negative. The future lies in combination therapies with the goal of obtaining durable responses and shifting survival KM curves higher. It is too early to tell if best results will be achieved by combining PD-1/PD-L1 inhibitors with other IO agents, chemo, RT, or targeted agents.",294
cost,Segmentation,  Clinical Practice Influencers,3.08589133881,2.41326554639e-05,103,168,"Met with a nationally recognized TL/AI NCCN lung panelist who shared the following unsolicited insights:
?	AI had a question about clarifying the cost of Opdivo, given that it?s Q2w dosing, and in comparison to Keytruda, given that it?s Q3w dosing. 
?	He stated that his understanding is that Opdivo is more expensive than Keytruda, given that Opdivo is dosed more frequently at Q2w dosing compared to Keytruda which is dosed Q3w dosing.  He said that this was simple math, with more frequent Q2w dosing being more frequent and thus more expensive than Q3w dosing.  He stated that he thinks Opdivo is 20-30% more expensive than Keytruda.
o	Reactively shared HEOR reactive deck with him. 
o	Walked him through the HEOR Opdivo reactive approved cost slides.  Started with slide 2 (shows Opdivo available as both 40mg and 100mg; shows example for cost of infusion for 80kg patient). 
o	AI stated he was not aware that Opdivo is available in both 100mg and 40mg vials and thus was unaware of flexibility and less wastage with both available vials.
o	He stated he was not aware that Keytruda is only available in 100mg vials.  He thought that it was still available as 50mg vial.  
?	Reactively shared slide which shows Opdivo available as both 40mg and 100mg vials, effectively communicating to him that Opdivo cost per mg is same with either vial size, and that this allows for less wastage in acquiring product, which allows for stepwise increase in price per infusion/month as weight increases.  This leads to Opdivo, for example, being less expensive than Keytruda at patient weights such as 70kg, and roughly equivalent monthly pricing at 80kg. 
?	Reactively shared with him that Keytruda is no longer available in the 50mg vial, although it is still listed in the PI which adds to confusion, and that it is only now available in 100mg vial.
?	AI seemed receptive, stating that he was previously unaware of this information and it was something new to him.  
o	Then proceeded to review with him a table comparing costs associated with Keytruda compared with Opdivo, providing ranges of costs associated per dose and month with increasing patient weights.  Communicated to him that the price per infusion between Keytruda and Opdivo is not the same.  Between 55-100kg, Keytruda per dose is $8632 (Keytruda only available 100mg, not 50mg anymore).  For Opdivo, it ranges from $4381 to $7302 due to availability of both 40mg and 100mg vials.  I linked cost per infusion to monthly price that is calculated by annualizing the cost and then extrapolating back to monthly cost, which takes into account different Q2 v. Q3w dosing frequencies.  
?	AI indicated that with this explanation, he now follows logic of annualizing cost and then extrapolating back to monthly cost.   
?	He acknowledged this way of annualizing the cost ?because in some months, patients will receive more than 1 dose of Keytruda?.  
?	The above realization seems to have addressed his misperception that due to simple math, Opdivo Q2w dosing is always more expensive than Keytruda Q3w dosing, because he acknowledged understanding of logic behind annualizing cost and then extrapolating back to monthly cost.   
?	He asked a colleague (value person in dept.) to come into the meeting and proceeded to demonstrate his understanding of the above logic, by walking his colleague through an example for a 70kg patient, which resulted in Opdivo actually being cheaper than Keytruda. 
o	Reviewed table with him for costs associated with 70 through 90kg patients, noting that Opdivo is cheaper per month for some, about same, and more expensive for some higher weight patients.
o	Slide 7 showed him comparison of Opdivo v. Keytruda in terms of cost per month curves.  Keytruda is same cost per month from 50-100kg pts, while Opdivo is more stepwise increase in cost per month as increase weights due to availability of both 40mg and 100mg (equivalent cost per mg basis), which allows for less wastage in terms of ordering vials to meet a pts dose requirement.
?	AI seemed receptive to this graph as something new to him, and he also asked another colleague to take a look at this graph.  
o	Covered Slide 10, 11, 12 run through calculation process for range of patient weights, at 70, 80, and 90kg.  Noted how cost per month is calculated, by annualizing cost first and then extrapolating back to monthly cost to account for differences in Q2 and Q3w dosing.  
o	Slide 13 walked AI through an example of an inaccurate monthly cost calculation, due to ordering wrong vial size of Opdivo and not accounting for the fact that Keytruda is only available as 100mg vial (no longer available as 50mg vial).  
?	AI was intrigued by this slide and asked colleague to join the meeting to examine slide.   
?	Reiterated that due to Keytruda only being available in 100mg vial, and not 50mg vials, this leads to common under-pricing cost calculations per month.  
?	Reiterated that Opdivo monthly cost may commonly be inaccurately calculated with a higher price due to more wastage using a sub-optimal combination of vial sizes.  This occurs when the optimal combination of vial sizes combos are not ordered to minimize monthly/infusion cost.","Brian Carriere and I met with a NTL/ NSCLC NCCN panelist at an NCI-designated academic institution in the mid-Atlantic who volunteered these unsolicited views regarding the rapidly evolving NSCLC treatment landscape:
Current Immunotherapy landscape:
?	This panelist believes that because of the MoA, anti-PD1s will eventually be seen as interchangeable, and believes that payers will prefer whichever pharma/ biotech company?s therapy is most cost-effective
o	Upon review of Keynote-010 versus Checkmate 057 mOS and HR to illustrate outcome differences, panelist pointed out BMS omitting Squamous NSCLC
?	Believes that the difference (if any) is negligible when introducing Squamous population in to Checkmate data
?	Acknowledges that BMS is dominating in 2L market share because of no testing strategy
o	As long as new efficacy and safety data matches Merck?s and timing of indications is roughly the same, panelist believes BMS will maintain its lead in 1L because oncologists are accustomed to using Nivo and habits are difficult to break
I-O shift to first line:
?	Awaiting Merck to release results of Keynote-024
o	Expects presentation of data at ESMO, and hopes to see BMS present findings from Checkmate-026 at that time
o	Understands why BMS would be a little anxious after Merck?s most recent press release, but views Keynote-024 as only impacting 15% (at best) of NSCLC because of its PD-L1 >50% requirement
?	Review of Checkmate-012:
o	Panelist expressed befuddlement at amount of press Checkmate-012 garnered post-ASCO considering how few patients were involved in trial 
?	Appreciated the 57% versus 28% ORR in PD-L1 expressers in the Nivo+Ipi versus Nivo mono groups, respectively, and found it impactful
?	Expressed concern with combination of Nivo+Ipi because of its toxicity profile
?	Upon review of Checkmate-012 safety data, panelist acknowledged that 19% versus 33% Grade 3-4 AEs was NOT drastically different, and 13% versus 10% and 8% versus 10% discontinuation rates for all Grade AEs and Grade 3-4 AEs, respectively, were essentially the same
o	Nevertheless, panelist mentioned multiple times throughout meeting that Ipi was toxic 
?	Bryan and I then differentiated Nivo+Ipi dosing in melanoma versus NSCLC, stressing small Ipi dose of 1mg/kg in NSCLC
o	Panelist mentioned at least twice that Nivo+Ipi should only be used in a clinical trial setting and not in a community setting
?	When asked what evidence/ data is missing to calm safety concerns, panelist responded that BMS would need much more safety data than what was presented on 30+ patients
?	Expressed how often Phase 1 data can?t be replicated in a Phase 3 setting
PD-L1 testing:
?	Does not believe that PD-L1 is an accurate marker of disease in NSCLC
o	This panelist believes that too much time is spent on PD1 inhibitors in NSCLC when PD-L1 doesn?t fully explain disease outcome
?	Adamantly believes that someone will one day be able to explain how NSCLC can best be managed, and doesn?t believe PD-1 will be a relevant factor
?	Doesn?t believe that anyone in the community practice setting cares about PD-L1 levels for treatment
o	Community oncologists only want to know PD-L1 cutoffs so that they know what to prescribe in order for payers to reimburse
?	This will become less of an issue when Merck is also indicated for all PD-L1 expressers
Payers and NCCN:
?	Mentioned that several NCCN panel members had received angry and disturbing letters from payers when NCCN had decided to include testing for use of Pembro because it added to payer?s expenses 
?	Laughed at the idea that payers and pathway companies use guidelines to create their medical policies when guidelines are only meant to be one group?s opinion
?	When asked about how NCCN would communicate PD-L1 cutoffs for therapeutic recommendations, (i.e., Checkmate-012 presentation where Nivo+Ipi PD-L1 status cutoff was 1% but Nivo monotherapy cutoff in Gettinger paper was 5% ), the panelist mentioned similarly to what they?ve done in the past for Pembro
o	This panelist believes that NCCN panel has gone far enough in clearly stating Pembro?s required testing and cutoff in the Guidelines, and doesn?t need additional or more forceful language
Financial Concerns:
?	This panelist says that Nivo?s introduction and applicability across tumor types is unprecedented in oncology, and that its cost as it continues to gain indications is unsustainable to the healthcare system
o	Several times used the term ?financially toxic? to describe the cost of Nivo+Ipi 
?	Recently co-authored and submitted a commentary to Francisco Tartari?s article on economic stability of PD1 inhibitors - Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges, where calculated cost of Nivo was $44k and Pembro was $130k: (http://www.cancertreatmentreviews.com/article/S0305-7372(16)30041-X/abstract)",Numerous TLs are not happy about the flat dose for NSCLC patients as they state the majority of their population is under the 80kg mean seen in the BMS clinical trials. The main concerns surround safety and the increase in cost. Most would have preferred the label to have weight based dosing remain as an option for underweight patients.,271
1L,Segmentation,  Clinical Practice Influencers,2.39089494163,4.18556750423e-06,288,292,"Attended an International Lung Congress where a lung AI/NTL speaker made these comments from the podium.  The topic was discussion of whether PDL1 testing is clinically relevant for immune checkpoint inhibitor therapy. 
o	Checkpoint inhibition is relevant biologically
o	Sophisticated pre-clinical testing in animal models demonstrated biologic relevance
o	PDL1+ expressers demonstrate higher response in many different cancers
?	057 KM curves by PDL1 show higher response for higher expressers
?	017 not same, but different beast
?	012 shows higher response in higher expressors
o	the problem is not PDL1 (a good test), it?s Pharma that has confused with different cuts of data, etc.
o	PDL1 (life cycle of PDL1 as biomarker), PDL1 testing validated in 1st and 2L NSCLC
o	PD1 oversold as good for everybody, but actually only good for smaller percentages
o	Checkpoint IO only cost effective when they are employed for pts most likely to benefit (defined as predictive biomarker)
?	Testing will save 3.4 billion in US (jokingly)
o	PDL1 measurement by alt. methods (CfRNA) will help measure response.
o	PDL1 testing will become SOC for 1L in advanced NSCLC
o	Can learn from not meeting 026, is different trial than KN
?	Was trying to capture larger proportion, and reason that endpoint not met, versus Merck trial looking at enriched pop.
?	Not because Nivo is less effective, than Pembro, but failure due to PDL1 enrichment pop. Versus not.","The following unsolicited insights were provided by speakers from the podium at a recent oncology conference attended by national AI?s/TL?s in various tumor types and hematological malignancies.  

Breast 
?	While there is limited data, panel believed for metastatic triple negative breast immunotherapy is a high viable option
?	Sited studies currently ongoing with Merck and Roche in the neoadjuvant setting using IO with taxane.

Developmental Therapeutics
?	One panelist made a comment to the audience about VALUE of care; the importance of consideration of value in oncology care.  
o	For example, the importance of consideration of the idea of limiting lines of therapy before patient goes to hospice.  Also, he mentioned some pathways are thinking of limiting to 2 lines before hospice.

Hematological malignancies Board
?	Panelist said RVD is strong 1st line therapy, based upon the SWOG trial presented at ASH 2015, because of OS with RVD.  He says he believes KRD may be treatment of future, even though KRD not indicated for 1L currently.
?	Panelist says there is trial of RD v. KRD which may show whether it is a good 1st line treatment.

Lung 
Testing
?	Consensus with the lung panel that ordering broad molecular testing should always be an option and should be standard of care however the known issue is limitation of tissue
?	Concerns around timing of results from NGS may delay treatment for patients, ~3 weeks is too long especially when 15% of these patients waiting never receive treatment
?	Consensus that liquid biopsy is an exploratory option now as concerns around false negative rates but should be explored in the setting of a clinical trial and in cases where tissue is not available
?	Huge focus on targeted therapy during the meeting given that the chair is a huge believer of testing in all lines.  
?	A case was presented focusing on the following scenario:  For second line treatment of a patient with NSCLC?squamous histology, Zubrod PS 1:
o	70% of the audience selected, Nivolumab without sending for PD?L1 testing.
o	10% of the audience selected, Nivolumab only if PD?L1 testing is positive (>1%)
o	18% of the audience selected, Pembrolizumab if PD?L1 positive (>1%)
?	TL chairing the meeting stated that PD1 data in a ?chaotic state?
?	Panel members expressed that PD-L1 may not be the best marker in dealing with tumor heterogeneity in lung
?	One panel member said If he happens to have PDL1 info already and if it?s positive and more than 1%, then he might use pembro, given more patient friendly Q3w schedule.  If PDL1 info is not available, then he goes straight to Nivo without PDL1 testing and would argue that Q2w dosing is not that bad.  
?	A few RTLs mentioned that in the setting of >1% PD-L1 expression they would give pembrolizumab for patients needing the Q3W dosing schedule and would do the same in adeno histology in the 2L setting.
?	Panel discussed managing immune-mediated AEs from PD1 agents are often responsive to immunosuppression.  
?	One panelist said data for SQ and NSQ very different.  The case being discussed was a SQ patient.  He mentioned that IASCLC is doing studies around PDL1 testing.  He says he would change treatment approach of going straight to nivo if this was a NSQ patient (didn?t elaborate more).
?	Lung panelist mentioned to the audience about the availability of the ASCO/MSKCC DrugAbacus tool (assesses the value of drugs compared to pricing given consideration of factors such as cost, toxicity, and efficacy). He mentioned the idea that If you can?t show that a drug is better, it supports considering restrictions.


Melanoma
Adjuvant
?	Panel presented a case where patient was given adjuvant ipilimumab as part of the EORTC trial and after 2 cycles of 10 mg/kg dose patient developed severe GI perforations.  Issues raised were 1) why the 10 mg/kg dose was even chosen 2) significant cost but was later amended to the dose being supported through BMS APP 3) significant toxicities leading to discontinuation
?	Panel discussed while the incidence low, case of myocarditis and it is a significant concern to monitor for 
?	One RTL said the toxicities of ipilimumab at 10 mg/kg are quite sobering comparing it to IL2

Testing	
?	One RTL mentioned he is not testing outside of clinical trials, and is not done routinely as data is still revolving
?	Discussion on which types of patients would tolerate regimen best and consensus on those who are healthy and with good performance status
?	Some community oncologist are using PD-1 inhibitors off label for cutaneous SCC as they?ve seen positive responses to PD1-inhibitors and have not been turned down by insurance companies, often challenging for some patients to participate in a clinical trial program because of location
?	RTL mentioned that we are in a unique space where knowledge of drug is going to move faster than a FDA approval 
?	TL panel member mentioned his experience has been that grade of immune-mediated AE likely correlated to depth of response
?	Consensus that the direction moving forward would be combination checkpoint inhibitor with targeted strategy.  Interesting how ?one major company going for targeted approach and another company doing immune checkpoint combination.?","?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians",580
Executive Director,Segmentation,  Economic/Value Influencers,174.461538462,7.59881320581e-06,4,56,"During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++CM-227+++
?	Indicated that CM-227 might be BMS last chance in lung.
*       Since enrollment is nearly complete would not change anything (e.g., adding a new cohort would not be scientifically sound). 
*       Concerned about cohorts with PDL1 <1% (concerns only partially alleviated by review of CM-012 latest results).","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++New NCCN guidelines+++
?	At first wondered if there might be a role for PD1 inhibitors in 1L NSLCL for patients with PDL1 5%-to-50%. However was sensitive to the arguments that: 1) there is no data with pembro in 1L for PDL1<50%NSCLC; 2) no parallel should be made between exploratory results of CM-057 in patients with <1% PDL1 - a trial that met its primary endpoint - and results of CM-026 ? a negative study not designed as a non-inferiority trial.","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++CM-024+++
?	Knew only what had been published in the press release and the ESMO abstract. Was shocked to see that CM-024 had missed all of its endpoints.
?	 Suggested that the following factors probably contributed to the negative results: inclusion of very low PDL1 expressors and low power resulting in major imbalances between groups. 
?	Commented that the PFS KM curves were baffling. Asked if pseudoprogressions in the nivo arm might have played a role (noted that pseudoprogressions seem to be rarer with NSCLC than melanoma, but first follow-up assessment in CM-026 took place early at 6 wks).
?	Suggested that nivo had shown no clinical activity in CM-026. After being reminded that PFS, OS, and ORR were similar in both study arms, agreed that it was more appropriate to conclude that nivo had an efficacy similar to that of CT in PDL1 ?5% NSCLC, with a better safety profile.",60
NAI,Segmentation,  Economic/Value Influencers,69.7846153846,4.16218469807e-05,7,282,"During a meeting to proactively discuss the results of CM-026, a NAI, chair of a pathway committee for lung cancer shared the following insight:
?	When asked what advices he would give to BMS at this point, said: 1) all-comer approach unlikely to succeed in the long term ? critical importance of developing better predictive biomarkers; 2) cut your price by 10%; 3) propose a dose schedule more convenient to the patients.","During a meeting to proactively discuss the results of CM-026, a NAI, chair of a pathway committee for lung cancer shared the following insight:
?	When probed about PD-L1 testing in 1L, mentioned that Roche has the best test, because it assesses PD-L1 expression on both the tumor and the immune cells. During a brief discussion about concordance of PD-L1 expression levels across tests, initially stated that evidence thus far indicates that all tests are equivalent; then agreed that SP142 is fundamentally different from the other tests. Eventually mentioned that his main concern is with PDL1 testing in general clinical setting: hospitals proposing the test are generally equipped with only one platform; commercial test results reported as + or ? without further comment.","During a meeting to proactively discuss the results of CM-026, a NAI, chair of a pathway committee for lung cancer shared the following insight:
?	When asked about what he learned at ESMO that was important, his response was: ?Opdivo has had a nice ride, but based on ESMO data Keytruda has now won in the 1L setting and Tecentriq in the 2L setting?. 
?	For 1L, further explained that Keytruda will become SOC for patients with tumor PDL1 expression ?50% (PL-based CT still best option for patients with PDL1 expression <50%).
?	For 2L, and when asked ?why Tecentriq??, explained that nivo, pembro, and atezo are all equivalent. Rationale for giving preference to Tecentriq: 1) more experience with the agent (his institution has contributed to multiple atezo trials); 2) convenience of q3w for the patients (unnecessary to see patients more frequently than q3w to ensure optimal safety; insensitive to the argument that median number of doses is similar with q2w and q3w for a majority of patients given median duration of treatment of ~3mo). ?I also love nivo, but I have no reason to use it?. ?In 2L pembro is at the bottom of the list? (personal unhappiness with Merck in recent times ? bad customer experience).",289
proactive meeting to discuss CM-026,Segmentation,  Economic/Value Influencers,69.7846153846,4.16218469807e-05,7,257,"During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++New NCCN guidelines+++
?	At first wondered if there might be a role for PD1 inhibitors in 1L NSLCL for patients with PDL1 5%-to-50%. However was sensitive to the arguments that: 1) there is no data with pembro in 1L for PDL1<50%NSCLC; 2) no parallel should be made between exploratory results of CM-057 in patients with <1% PDL1 - a trial that met its primary endpoint - and results of CM-026 ? a negative study not designed as a non-inferiority trial.","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++CM-227+++
?	Indicated that CM-227 might be BMS last chance in lung.
*       Since enrollment is nearly complete would not change anything (e.g., adding a new cohort would not be scientifically sound). 
*       Concerned about cohorts with PDL1 <1% (concerns only partially alleviated by review of CM-012 latest results).","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++CM-024+++
?	Knew only what had been published in the press release and the ESMO abstract. Was shocked to see that CM-024 had missed all of its endpoints.
?	 Suggested that the following factors probably contributed to the negative results: inclusion of very low PDL1 expressors and low power resulting in major imbalances between groups. 
?	Commented that the PFS KM curves were baffling. Asked if pseudoprogressions in the nivo arm might have played a role (noted that pseudoprogressions seem to be rarer with NSCLC than melanoma, but first follow-up assessment in CM-026 took place early at 6 wks).
?	Suggested that nivo had shown no clinical activity in CM-026. After being reminded that PFS, OS, and ORR were similar in both study arms, agreed that it was more appropriate to conclude that nivo had an efficacy similar to that of CT in PDL1 ?5% NSCLC, with a better safety profile.",264
member,Segmentation,  Economic/Value Influencers,24.2307692308,7.40678930639e-06,37,111,"The advisory board member for GU cancers for a large provider pathway organization expressed his confidence in nivolumab in second line renal cell carcinoma.  He considers nivolumab to be superior to cabozantinib in this setting, as he weights the longer survival with nivolumab more than the PFS results with cabozantinib.   He did not have any particular position on testing for PD-L1 in this population as he does not test in GU cancers.  He believes that his pathways ranks the different agents according to the relative merits in efficacy, safety and cost, with efficacy receiving the highest weightage and cost the lowest.   He believes this system of ranking will provide results consistent with NCCN guidelines.","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++CM-227+++
?	Indicated that CM-227 might be BMS last chance in lung.
*       Since enrollment is nearly complete would not change anything (e.g., adding a new cohort would not be scientifically sound). 
*       Concerned about cohorts with PDL1 <1% (concerns only partially alleviated by review of CM-012 latest results).","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++New NCCN guidelines+++
?	At first wondered if there might be a role for PD1 inhibitors in 1L NSLCL for patients with PDL1 5%-to-50%. However was sensitive to the arguments that: 1) there is no data with pembro in 1L for PDL1<50%NSCLC; 2) no parallel should be made between exploratory results of CM-057 in patients with <1% PDL1 - a trial that met its primary endpoint - and results of CM-026 ? a negative study not designed as a non-inferiority trial.",148
CM-026,Segmentation,  Economic/Value Influencers,18.1730769231,2.53721695304e-05,52,177,"During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++New NCCN guidelines+++
?	At first wondered if there might be a role for PD1 inhibitors in 1L NSLCL for patients with PDL1 5%-to-50%. However was sensitive to the arguments that: 1) there is no data with pembro in 1L for PDL1<50%NSCLC; 2) no parallel should be made between exploratory results of CM-057 in patients with <1% PDL1 - a trial that met its primary endpoint - and results of CM-026 ? a negative study not designed as a non-inferiority trial.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","During a proactive meeting to discuss CM-026 data, a member of the NCCN Board of Directors and Executive Director of a large regional cancer center made the following comments:
+++CM-024+++
?	Knew only what had been published in the press release and the ESMO abstract. Was shocked to see that CM-024 had missed all of its endpoints.
?	 Suggested that the following factors probably contributed to the negative results: inclusion of very low PDL1 expressors and low power resulting in major imbalances between groups. 
?	Commented that the PFS KM curves were baffling. Asked if pseudoprogressions in the nivo arm might have played a role (noted that pseudoprogressions seem to be rarer with NSCLC than melanoma, but first follow-up assessment in CM-026 took place early at 6 wks).
?	Suggested that nivo had shown no clinical activity in CM-026. After being reminded that PFS, OS, and ORR were similar in both study arms, agreed that it was more appropriate to conclude that nivo had an efficacy similar to that of CT in PDL1 ?5% NSCLC, with a better safety profile.",229
pathway,Segmentation,  Economic/Value Influencers,16.2830769231,1.41661994481e-06,56,48,"1.	Opdivo Renal PVP presentation was given to an Access Influencer for a major health system, who makes P&T recommendations.  The following unsolicited insights were provided by the AI.  
a.	Insights/Notes: 
i.	AI expressed excitement with dual pathway MOA of Empliciti, as compared to competitors.  
ii.	AI was interested in BMS oncology pipeline from the perspective of planning for potential costs associated with new product indication launches in the next 1-2 years.  
iii.	AI was familiar with Opdivo RCC indication and significant OS advantage.
iv.	AI seemed receptive to discussion of potential treatment population numbers, as it applies to his organization, with respect to national incidence of disease.","Met with RCC AI who disclosed the following unsolicited insights:

?	AI is on her institution?s P&T so is interested in the topic of value and pathways in oncology and oncology meds
?	AI is interested in learning and connecting with BMS HSL and HEOR resources on the topic of value and pathways in oncology
?	AI does not have many non-clear cell RCC patients, consistent with low incidence of disease generally.  She thinks even though Nivo label does not have non-clear cell patients, she?s treated these patients with nivolumab and she says it makes sense to her to try these patients given limited treatment options available for non-clear cell patients.  
?	She says her institution does not treat RCC patients in first line with Avastin so prior Avastin therapy does not limit her use of nivo in 2nd line.
?	She?s interested in potential ISR?s in non-clear cell patients, perhaps using nivo monotherapy or regimen.  
?	She said she?s seen that regimen is not well tolerated, mostly due to ipi.  She has seen severe AE?s with thyroid AE?s.  
?	Due to severe AE?s with regimen, she thinks BMS study design in trials with regimen would have been better if patients were allowed to stay on study even if they did not receive all 4 doses of regimen, due to severe AE?s.","The advisory board member for GU cancers for a large provider pathway organization expressed his confidence in nivolumab in second line renal cell carcinoma.  He considers nivolumab to be superior to cabozantinib in this setting, as he weights the longer survival with nivolumab more than the PFS results with cabozantinib.   He did not have any particular position on testing for PD-L1 in this population as he does not test in GU cancers.  He believes that his pathways ranks the different agents according to the relative merits in efficacy, safety and cost, with efficacy receiving the highest weightage and cost the lowest.   He believes this system of ranking will provide results consistent with NCCN guidelines.",104
cost,Segmentation,  Economic/Value Influencers,9.69230769231,9.51081501821e-06,103,168,"Met with a nationally recognized TL/AI NCCN lung panelist who shared the following unsolicited insights:
?	AI had a question about clarifying the cost of Opdivo, given that it?s Q2w dosing, and in comparison to Keytruda, given that it?s Q3w dosing. 
?	He stated that his understanding is that Opdivo is more expensive than Keytruda, given that Opdivo is dosed more frequently at Q2w dosing compared to Keytruda which is dosed Q3w dosing.  He said that this was simple math, with more frequent Q2w dosing being more frequent and thus more expensive than Q3w dosing.  He stated that he thinks Opdivo is 20-30% more expensive than Keytruda.
o	Reactively shared HEOR reactive deck with him. 
o	Walked him through the HEOR Opdivo reactive approved cost slides.  Started with slide 2 (shows Opdivo available as both 40mg and 100mg; shows example for cost of infusion for 80kg patient). 
o	AI stated he was not aware that Opdivo is available in both 100mg and 40mg vials and thus was unaware of flexibility and less wastage with both available vials.
o	He stated he was not aware that Keytruda is only available in 100mg vials.  He thought that it was still available as 50mg vial.  
?	Reactively shared slide which shows Opdivo available as both 40mg and 100mg vials, effectively communicating to him that Opdivo cost per mg is same with either vial size, and that this allows for less wastage in acquiring product, which allows for stepwise increase in price per infusion/month as weight increases.  This leads to Opdivo, for example, being less expensive than Keytruda at patient weights such as 70kg, and roughly equivalent monthly pricing at 80kg. 
?	Reactively shared with him that Keytruda is no longer available in the 50mg vial, although it is still listed in the PI which adds to confusion, and that it is only now available in 100mg vial.
?	AI seemed receptive, stating that he was previously unaware of this information and it was something new to him.  
o	Then proceeded to review with him a table comparing costs associated with Keytruda compared with Opdivo, providing ranges of costs associated per dose and month with increasing patient weights.  Communicated to him that the price per infusion between Keytruda and Opdivo is not the same.  Between 55-100kg, Keytruda per dose is $8632 (Keytruda only available 100mg, not 50mg anymore).  For Opdivo, it ranges from $4381 to $7302 due to availability of both 40mg and 100mg vials.  I linked cost per infusion to monthly price that is calculated by annualizing the cost and then extrapolating back to monthly cost, which takes into account different Q2 v. Q3w dosing frequencies.  
?	AI indicated that with this explanation, he now follows logic of annualizing cost and then extrapolating back to monthly cost.   
?	He acknowledged this way of annualizing the cost ?because in some months, patients will receive more than 1 dose of Keytruda?.  
?	The above realization seems to have addressed his misperception that due to simple math, Opdivo Q2w dosing is always more expensive than Keytruda Q3w dosing, because he acknowledged understanding of logic behind annualizing cost and then extrapolating back to monthly cost.   
?	He asked a colleague (value person in dept.) to come into the meeting and proceeded to demonstrate his understanding of the above logic, by walking his colleague through an example for a 70kg patient, which resulted in Opdivo actually being cheaper than Keytruda. 
o	Reviewed table with him for costs associated with 70 through 90kg patients, noting that Opdivo is cheaper per month for some, about same, and more expensive for some higher weight patients.
o	Slide 7 showed him comparison of Opdivo v. Keytruda in terms of cost per month curves.  Keytruda is same cost per month from 50-100kg pts, while Opdivo is more stepwise increase in cost per month as increase weights due to availability of both 40mg and 100mg (equivalent cost per mg basis), which allows for less wastage in terms of ordering vials to meet a pts dose requirement.
?	AI seemed receptive to this graph as something new to him, and he also asked another colleague to take a look at this graph.  
o	Covered Slide 10, 11, 12 run through calculation process for range of patient weights, at 70, 80, and 90kg.  Noted how cost per month is calculated, by annualizing cost first and then extrapolating back to monthly cost to account for differences in Q2 and Q3w dosing.  
o	Slide 13 walked AI through an example of an inaccurate monthly cost calculation, due to ordering wrong vial size of Opdivo and not accounting for the fact that Keytruda is only available as 100mg vial (no longer available as 50mg vial).  
?	AI was intrigued by this slide and asked colleague to join the meeting to examine slide.   
?	Reiterated that due to Keytruda only being available in 100mg vial, and not 50mg vials, this leads to common under-pricing cost calculations per month.  
?	Reiterated that Opdivo monthly cost may commonly be inaccurately calculated with a higher price due to more wastage using a sub-optimal combination of vial sizes.  This occurs when the optimal combination of vial sizes combos are not ordered to minimize monthly/infusion cost.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",271
NTL in the Boston area mentioned,Segmentation,  High Disease Burden Clinicians,27.55126498,2.70106043268e-05,9,137,RTL mentioned that he avoids Bleomycin in all patients > 60 y/o. Brentuximab is very effective alone with decent PFS. Other options for these patients are BV + DTIC or BV + Bendamustine.,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.",RTL at a large academic center stated that they are participating in the ABVD and AVD + brent study and depending on the results will possibly use Brentuximab upfront in cHL.  If that is the case then we can move Nivo to earlier lines of therapy as it would make clinical sense too.,146
territory,Segmentation,  High Disease Burden Clinicians,13.77563249,3.24793860524e-08,35,349,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",384
regional TL shared,Segmentation,  High Disease Burden Clinicians,11.4796937417,1.11502292814e-06,18,18,A regional TL shared with me that he is now doing PDL1 testing in his firstline NSCLC patients because of the KN-24 approval.  He acknowledged that most patients will not be over 50% positive and confirmed that Nivo will still be SOC for those patients 2nd line.,A regional TL shared that he has had no problems getting insurance to approve off-label 1L usage of Nivo monotherapy in RCC.  He said that he has seen durable responses approaching 2 years.,A Regional TL shared that he is not testing any other tumor types (outside of Lung) for PD-L1 status.,36
large academic center stated,Segmentation,  High Disease Burden Clinicians,10.2041722148,3.70263175535e-08,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will","NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,372
shared the following unsolicited insights,Segmentation,  High Disease Burden Clinicians,6.12250332889,1.81275125175e-05,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
Ipi+Nivo,Segmentation,  High Disease Burden Clinicians,3.64434721958,1.78650967626e-05,45,338,"NTL predicts that, even with durable responses seen with PD1 monotherapy, eventually almost all NSCLC patients will progress.  With basically all NSCLC patients receiving PD1 monotherapy at some point in their treatment plan, there will be a huge unmet need for effective treatments post-PD1.  This NTL, who is an investigator on several studies with IO+IO combinations, voiced opinion (based on her experience) that Ipi+Nivo seems to be the only IO+IO combo that can resurrect a response in patients who have failed PD1 monotherapy.  4-1BB, anti-KIR, OX40 etc do not seem to have this activity. TL said this speaks to the ability of Ipi to prime new T cells, rather than just relieving inhibition of existing lymphocyte populations.","Melanoma RTL with lots of I/O experience (Investigator on 209-067), stated his belief that PDL1+ patients don't benefit from adding Ipi to Nivo.  He is testing for PDL1 to determine treatment choice between PD1 monotherapy and Ipi+Nivo combination. PDL1+ patients receive anti-PD1 mono therapy; PDL1neg patients receive Ipi+Nivo Regimen.","There is growing interest from my academic TLs in using Ipi to re-invigorate the T cell response in patients who progress on Nivo.  These could be patients who are on the Nivo maintenance after Ipi+Nivo regimen, or patients who only received Nivo monotherapy.

Rationale is similar as for MDX010-20 study with Ipi, except that in this case, the patient would continue to receive Nivo while adding a few doses of Ipi. TLs favor a Q6W Ipi dosing when added to Nivo.",383
international GI conference,Segmentation,  Scientific Experts,42.5977011494,8.11795660193e-09,17,43,"At an international GI conference, two NTLs had a brief discussion about atezo in CRC.

NTL1:  How do you sell a trial patient on a trial (NCT02788279), knowing that they could be placed on a study arm for Atezolizumab monotherapy? This is something that is understood to be a very expensive placebo in this setting.
NTL2: We don?t know that atezolizumab has no effect in this setting because our experience is limited and the alternatives, such as regorafenib, have a very low response rate.
NTL1:  This phase III was launched after a phase I with a response rate of less than 20% in a population of fewer than 50 patients.  It seems we are desperate for immunotherapy to work in every cancer.","At an international GI conference, three HCC NTLs had a brief discussion of PD1s:

NTL1:  We are all tempted to use pembrolizumab and jump on the bandwagon; Merck has made it very available through access support.  However, we need more data before using it when systemic therapies that have shown benefit are exhausted.
NTL2: We use PD1 inhibitors in patients that are MSI high.
NTL3: There may be rationale in MSI high patients for the use of PD1 inhibitors but data is still not conclusive and it is inappropriate to use without testing.","At an international GI conference, three NTLs had a discussion about immunotherapy in CRC:

NTL1:  Why is there a difference between single agent nivo and pembro in MSI high.  
NTL2:  Pembro study is a higher response rate but not a global study.  Both look to have very durable responses.  This could be due to different populations and there are questions about the dosing that is used for pembro.
NTL2:  There is a potential that pts with Lynch syndrome do worse but we need a better sample size to really judge.  It seems that these patients can have very late responses.
NTL2:  BMS may have more data in BRAF mutated pts in MSI CRC study but all of the pts that I have treated have responded
NTL3:   pseudoprogression real?
NTL2:  I think that there were a couple but they are not common.  Most responses are quite early.
NTL3:  I think it?s more of a myth.  Are you trying to lie to yourself and say it?s pseudoprogression to keep treating.
NTL3:  Do you think that there is potential for treating in the adjuvant setting rather than in tumor reductive setting?  
NTL2:  Melanoma data shows that there is great potential for immunotherapy in adjuvant.
NTL3:  When I see high responses across tumor types, I am now seeing that MSI testing is the most important thing.  Should we be testing for MSI in all patients?
NTL2:  It is hard to globally recommend MSI but if there is a potential for immunotherapy use, you should try.",60
NTL said,Segmentation,  Scientific Experts,13.3639846743,8.03153779535e-07,24,14,"At an international GI conference, a NTL said, about advances in immunotherapy in CRC:

We continue to pursue immunotherapy because although conventional therapies push survival curves to the right, IO pushes it up

ORR about 16% with nivolumab. Interestingly, the responses were across the board and were durable.

In GI cancers, there are nice and deep responses with MMR deficiency.  Responses are durable and pt are ready for treatment holiday after 2 years of therapy with maintained response.","At an international GI conference, a NTL said, in reference to not wanting to put a second line patient on regorafenib, that QOL is very important in later line patients. 3rd and 4th line goal is palliative therapy.  You should keep an asymptomatic patient asymptomatic.  Many patients will not feel the disease but can feel AEs of their therapy within a few days.","At an international GI conference, a NTL said that a ?thorny? question is if you should give treatment in absence of positive margins after surgery.  She said she would give additional treatment up through six months of total treatment.  Even though there is a lack of evidence, she gives a full six month course from start of treatment to end (including surgery/recovery time). Her preference is to continue the treatment that they were already receiving if they were responding prior to surgery and/or tolerating it well.",38
large academic center stated,Segmentation,  Scientific Experts,8.35249042146,5.02362166103e-07,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will","NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,372
National TL,Segmentation,  Scientific Experts,6.55349248453,8.9028871754e-10,51,544,"A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented that there is no difference in pembro or nivo biologically, just in the biomarker strategy.",A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented how most patients we don't know the driver mutations.  KRas is an important target that we still do not have any drugs to target.,A National TL at a lung cancer lecture at the PR Hem Onc Symposium noted that because of the complexity of the microenvironment not one biomarker would be truly predictive.,595
NTL,Segmentation,  Scientific Experts,2.75384090133,1.95406855722e-12,311,710,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,1021
said,Segmentation,  Scientific Experts,1.83898179666,2.08859026657e-08,479,0,"Regional lung TL said that he ""doesn?t think there is ultimately any difference between nivo and pembro even with 026 press release"". He is impressed that pembro hit both pfs and OS data. He said BMS gambled right for second line but not so much for 1st line. He also said that it?s clear that PDL1 positive patients do better. ""It always better to be PDL1 positive"". He wants to see the data from pembro and from 026 to really see if there is any difference.","Academic lung TL voiced his opinions that the ""OAK data  is bad"". He said that it is clear that the assay used is not as good as the 22C3 or 28-8 based assays. He also said that he doesn?t think much of the never smoker data in OAK.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",479
NCCN institution,Segmentation, Access Decision Makers,35.7701612903,6.81892296234e-10,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A leading medical oncologist at an NCCN institution in New England reiterated his preference for Opdivo in second line NSCLC, in spite of the results from CheckMate 026.  According to him, the different results from CheckMate 026 and Keynote 024 do not arise from a difference in efficacy, but due to the variations in clinical trial designs and PD-L1 cutoffs.  He considers himself one of the leading prescribers of Opdivo in the country, not from his new starts but from the prolonged responses in his patients.  He believes that Keytruda in the first line will be limited to a tiny slice of the population, as there are few patients who are PD-L1>50%, EGRF/ALK wild type and has an adequate performance status.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",125
Path TL,Segmentation, Access Decision Makers,26.4964157706,1.20506546543e-05,18,230,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer",NTL from a major academic institution sends out both 28-8 and 22C3 PD-L1 assays for readouts when looking for PD-L1 expression.  NTL shared that she receives similar results for both assays from a tumor sample.,248
large academic center stated,Segmentation, Access Decision Makers,19.872311828,3.88920472142e-09,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,NTL at a large academic center  stated that there needs ot be F/u discussion on the Lugano Classification updates just published and implementation into practice and clarification for clinicians making clinical assesemen.   He stated that discussion on the abscopal effect seen in Lymphoma how it affects management ? discussion points to be clarified,372
NTL,Segmentation, Access Decision Makers,4.25076188833,6.43574637418e-08,311,710,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center  stated that there needs ot be F/u discussion on the Lugano Classification updates just published and implementation into practice and clarification for clinicians making clinical assesemen.   He stated that discussion on the abscopal effect seen in Lymphoma how it affects management ? discussion points to be clarified,NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,1021
AI stated,Segmentation, Access Influencers,127.552795031,2.17358112281e-18,24,171,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.",195
provided the following unsolicited insights,Segmentation, Access Influencers,76.1773636991,1.66375780236e-30,45,146,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",191
shared the following unsolicited insights,Segmentation, Access Influencers,58.4616977226,7.45488018318e-16,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
NCCN panelist for NSCLC,Segmentation, Access Influencers,58.4616977226,1.79944484432e-08,11,482,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
RAI,Segmentation, Access Influencers,58.4616977226,1.79944484432e-08,15,701,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.",716
Met with a national/regional lung,Segmentation, Access Influencers,53.1469979296,1.02385170275e-07,10,211,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national melanoma and genitourinary AI/TL post-ESMO, who provided the following unsolicited insights from the podium and in conversation.
?	He expressed that we shouldn't forget about IL2 in kidney Ca, because of the durable CR?s seen in select patients.
?	When he was asked whether tumor burden is associated with response, he responded that with IL2 there is some evidence for this hypothesis.
?	He reitereated that we don't know the significance of Biomarker testing PDL1 yet in melanoma and genitourinary cancers.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",221
AI/TL post-ESMO,Segmentation, Access Influencers,47.8322981366,5.78882294097e-07,9,660,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
AI/TL,Segmentation, Access Influencers,45.1749482402,3.9425053789e-12,27,661,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",688
advisor,Segmentation, Access Influencers,44.2891649413,3.32626159851e-17,27,231,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.",258
NSCLC NCCN panelist,Segmentation, Access Influencers,42.5175983437,2.16784059807e-11,17,665,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",682
AI,Segmentation, Access Influencers,42.0344438171,1.52848371728e-54,121,70,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",191
context of an online lecture,Segmentation, Access Influencers,37.2028985507,1.80274520196e-05,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NAI,Segmentation, Access Influencers,37.2028985507,1.80274520196e-05,7,282,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",289
NCCN 2016 Webex Congress Series,Segmentation, Access Influencers,37.2028985507,1.80274520196e-05,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
proactive meeting to discuss CM-026,Segmentation, Access Influencers,37.2028985507,1.80274520196e-05,7,257,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",264
southeast region,Segmentation, Access Influencers,37.2028985507,1.80274520196e-05,7,169,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
Met with a national,Segmentation, Access Influencers,37.2028985507,6.45705905431e-10,25,644,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
panelist,Segmentation, Access Influencers,36.4436557232,1.5435930323e-30,134,164,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
SP142-based PDL1 assay and Roche?s complex PDL1 expression algorithm will be a problem in clinical practice down the road.",298
Met with a regional,Segmentation, Access Influencers,31.8881987578,4.22529405724e-12,21,174,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
NCCN center in the midwest stated,Segmentation, Access Influencers,29.2308488613,9.96575563471e-08,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
international GI conference,Segmentation, Clinical Practice Influencers,25.8866832093,1.77976856722e-06,17,43,"At an international GI conference, two NTLs had a brief discussion about atezo in CRC.

NTL1:  How do you sell a trial patient on a trial (NCT02788279), knowing that they could be placed on a study arm for Atezolizumab monotherapy? This is something that is understood to be a very expensive placebo in this setting.
NTL2: We don?t know that atezolizumab has no effect in this setting because our experience is limited and the alternatives, such as regorafenib, have a very low response rate.
NTL1:  This phase III was launched after a phase I with a response rate of less than 20% in a population of fewer than 50 patients.  It seems we are desperate for immunotherapy to work in every cancer.","At an international GI conference, three HCC NTLs had a brief discussion of PD1s:

NTL1:  We are all tempted to use pembrolizumab and jump on the bandwagon; Merck has made it very available through access support.  However, we need more data before using it when systemic therapies that have shown benefit are exhausted.
NTL2: We use PD1 inhibitors in patients that are MSI high.
NTL3: There may be rationale in MSI high patients for the use of PD1 inhibitors but data is still not conclusive and it is inappropriate to use without testing.","At an international GI conference, three NTLs had a discussion about immunotherapy in CRC:

NTL1:  Why is there a difference between single agent nivo and pembro in MSI high.  
NTL2:  Pembro study is a higher response rate but not a global study.  Both look to have very durable responses.  This could be due to different populations and there are questions about the dosing that is used for pembro.
NTL2:  There is a potential that pts with Lynch syndrome do worse but we need a better sample size to really judge.  It seems that these patients can have very late responses.
NTL2:  BMS may have more data in BRAF mutated pts in MSI CRC study but all of the pts that I have treated have responded
NTL3:   pseudoprogression real?
NTL2:  I think that there were a couple but they are not common.  Most responses are quite early.
NTL3:  I think it?s more of a myth.  Are you trying to lie to yourself and say it?s pseudoprogression to keep treating.
NTL3:  Do you think that there is potential for treating in the adjuvant setting rather than in tumor reductive setting?  
NTL2:  Melanoma data shows that there is great potential for immunotherapy in adjuvant.
NTL3:  When I see high responses across tumor types, I am now seeing that MSI testing is the most important thing.  Should we be testing for MSI in all patients?
NTL2:  It is hard to globally recommend MSI but if there is a potential for immunotherapy use, you should try.",60
ie,Segmentation, Clinical Practice Influencers,3.8576233802,2.80092014694e-06,52,0,Very positive early feedback around AE management app.  Nurse manager requested a similar web-based version to be used at triage desks (ie wiht hyperlinks for the different AEs),"Med Academic lung TL inquired if there were any efforts to examine was to examine PDL1 in either a plasma/liquid biopsy form (ie, RNAexpression, etc.). Challenges around this were discussed (ie, systemic vs. local tumor environment, etc).","TL stated that he would like to see more molecular and immunological (ie T cell profiles,etc) comparing Nivo responders from Nivo Progressors to identify new biomarkers or differential characteristics, rather than continuing to ""fit"" the PDL1 biomarker to the data.",52
RTL,Segmentation, Clinical Practice Influencers,2.15896189537,7.66290240094e-12,690,801,"Lung RTL today at a large Academic site in NYC considers Atezolizumab a ?me too drug?.  Also since the Roche PD-L1 testing is complicated, does not see himself using it at all as a monotherapy.  Feels that it will be used just in the Bladder setting for foreseeable future.",RTL from a large community institution was very impressed with CheckMate 153 from ASCO in decreasing the nivolumab administration time from 60 min to 30 min as it would benefit a lot of his patients within the community.,"RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.",1491
billing,Segmentation, Economic/Value Influencers,108.5,1.12108991432e-05,9,11,"Dawn Holcombe (Exec Director, Connecticut Oncology Association) described the efforts of CTOA to stop widespread implementation of clinical pathways in oncology care.  CTOA is spearheading an effort in Connecticut legislature to regulate clinical pathways in the state.  CT SB00435 is intended to set requirements for pathways and force disclosure of all financial incentives provided to physicians for adhering to the pathways.  This bill has been referred by the Senate to Committee on Appropriation, and will be taken up again in the next session.","regional TL has expressed his opinion re: more favorable billing to hospitals vs. private oncology practices based on recent publication by genentech on therapies cost sold to hospitals. TL expressed his concern that 430 billing is what is making a negative impact on revenue for private practices and growing difficulty to compete. He suggested that BMS will follow Genentech example and publish its data on chemo costs to the hospital thus "" uncovering one of the primary drivers of rising drug costs""","Specialty pharmacist at an academic SP stated he believes that I/O therapy will eventually be billed under the pharmacy benefit as PBMs will want to demonstrate their value in an increasingly generic blended market. As the health system with an integrated payor looks at total cost of care, he thinks the payor will demand white bagging as a cost saving through their own SP; however, he was uncomfortable with the concept of an outside SP delivering an infusible to his infusion clinic.",20
Local lung TL commented,Segmentation, High Disease Burden Clinicians,41.310880829,5.58885457566e-08,14,0,"Local lung TL commented that even with the 026 trial results, he still thinks pembro and nivo are basically the same agent.",Local lung TL commented that he isnt worried about the 026 data as you cant go back and retrospectively analyze the data using a 50% cutoff. He said the study wasnt designed that way and thus you cant get meaningful data from that kind of analysis.,Local lung TL commented that he is impressed with the data on Nivo plus Ipi data in SCLC and is happy to see it included in the NCCN guidelines. He was curious as to why the dose of ipi used in the combination is higher than in the NSCLC trials.,14
Local TL,Segmentation, High Disease Burden Clinicians,11.1473805412,3.68719864218e-13,52,1414,Local TL in a large community practice stated that many HCP's are upset with the direct to consumer marketing that BMS is doing with Opdivo.   She said that the commercial has led to many patients coming into clinics wanting Opdivo with high hopes and expecting a cure.     She further stated that the commercials reflect everyone looking healthy and feels that is leading to false hopes for many patients..  She further stated that she is aware that the speaker bureau has no funds for speaking so why isn't the money better utilized for this instead of the money being put into commericals.,Lung RTL in large community commented that he's surprised BMS hasn't leveraged the 017 data more in light of everything that's unfolded in the market lately. The fact that we have specific data showing superiority of nivo in squamous histology with no apparent effect of PDL1 status is something he feels like we should focus on more during promotional talks given that this would possibly urge more physicians to reserve nivo for squamous pts despite other competitors given that none of their studies looked at this independently.,Lung RTL commented that atezo is starting to gain traction speaking to the fact that they demonstrated activity in the PDL1 non-expressors (making the comparison to 057 not really showing any benefit in this group). He feels it's important for BMS to somehow explain to physicians that the nature of the PDL1 assays is likely very responsible for the result shown in the OAK trial in that population of pts.,1466
LTL,Segmentation, High Disease Burden Clinicians,7.3127956747,2.97294797359e-17,79,800,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",LTL from a large community institution is glad to see nivo +/- ipi into the NCCN guidelines for SCLC.  LTL is more inclined to use nivo monotherapy than the combination due to the higher dose of ipi (vs. in 026).,879
Community TL,Segmentation, High Disease Burden Clinicians,6.45482512953,1.5880796571e-10,73,820,Largest Community Practice in state: Community TL stated Insurance companies are requiring PDL-1 status for opdivo NSCLC in all settings. Interesting that pts had to be 50% exp for Keytruda to work.,Largest Community Practice in state: Community TL stated no use of opdivo in HL yet. Has a pt progressing on BV so opdivo will be next step.,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.",893
community oncologist,Segmentation, High Disease Burden Clinicians,6.05685846741,3.96487803268e-11,57,939,Local TL in a large community practice stated that many HCP's are upset with the direct to consumer marketing that BMS is doing with Opdivo.   She said that the commercial has led to many patients coming into clinics wanting Opdivo with high hopes and expecting a cure.     She further stated that the commercials reflect everyone looking healthy and feels that is leading to false hopes for many patients..  She further stated that she is aware that the speaker bureau has no funds for speaking so why isn't the money better utilized for this instead of the money being put into commericals.,Largest Community Practice in state: Community TL stated Insurance companies are requiring PDL-1 status for opdivo NSCLC in all settings. Interesting that pts had to be 50% exp for Keytruda to work.,Largest Community Practice in state: Community TL stated no use of opdivo in HL yet. Has a pt progressing on BV so opdivo will be next step.,996
HCP,Segmentation, High Disease Burden Clinicians,5.18621447637,3.77047885188e-14,115,124,"[026 Top 300] HCP from a community institution mentioned that 026 was disappointing, but indicates that single-agent nivo was no worse than standard of care.

Interestingly, HCP has given nivo monotherapy for a first-line NSCLC patient about 9 months ago.  Patient has been doing fine thus far, so HCP thinks that the addition of ipi 1 mg/kg q6w (227) would be very advantageous to see higher expected response rates.","Flat-dose Opdivo (<80 kg): LTL from a community institution mentioned that if the steady-state concentration and drug exposure is the same, it seems ""pointless"" to increase the dose to 240 mg for patients <80 kg (vs. weight-based dosing) and he would be ""charging them more for the same efficacy.""  LTL mentioned that 40% of his patients are <80 kg.","Flat-dose Opdivo (>80 kg): LTL from a community institution mentioned for patients already receiving >240 mg, it would be ""a tough sell"" to those who are responding to treatment to tell them that their dose would be reduced.

FMS reactively mentioned that the efficacy in terms of steady-state concentrations were steady across various weight groups and this may actually save the patient on the cost aspect as less vials would be needed for patients >80 kg.",239
Local,Segmentation, High Disease Burden Clinicians,3.63172578717,2.10195687225e-11,184,1056,Community TL questioned the 067 data and wanted to use PD-L1 testing in melanoma to determine use of monotherapy or regimen. He shared that he has decided not to do this based on attending a local conference and hearing the opinion of a NTL and that it makes sense to not test. He further shared that he does not test for PD-L1 in RCC but could not recall the data (which I was able to share and refresh his memory after he requested to see it).,"Local community TL told me that when she gets her reports back for PDL1 testing, the company provides her with a % positive for PDL1 for pembro as well as a % positive for nivo on the same sheet. I asked her if the numbers match up based on Blueprint analysis and she said they are usually about 10% different with the nivo number being lower. This was based on a single patient and she couldnt remember the company's name that did this testing but she said she would let me know.","Local community TL stated that BMS needs to come up with another means, beyond prednisone to alleviate immune AE associated with nivolumab therapy.",1240
IMAR management,Segmentation, N/A,79.3333333333,9.41215438015e-11,11,373,"While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,Nursing TL from Johns Hopkins spoke at National Meeting and praised the BMS resources for IO patients and providers.  Made special note of the new APP for IMAR management,384
dinner,Segmentation, N/A,79.3333333333,5.97194636974e-06,11,199,"NP attending dinner program in Colorado indicated that the provider she works with was unfamiliar with what labs should be drawn on IO patients and did not know rationale for drawing TSH, etc.  Stated she would be taking information from the dinner back to the practice and will help implement a change in order sets to insure that appropriate labs are being done on their IO patients.","Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,210
IMAR,Segmentation, N/A,26.4444444444,1.96738854587e-08,27,141,"HCP has questions around management of IMARs and fevers.  Reviewed IMAR guide, algorithm.  Also discussion around fevers and recommended febrile work-up.  Possible cytokine release and treat as IMAR if no source of febrile episode. Also questions around efficacy with steroids and IMARs.","While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",Nurses at a proactive dinner presentation for ONS chapter mentioned they had been using Sandostatin for treatment of colitis induced by Opdivo. Proper symptom management and use of algorithms reviewed in detail and nurses shared they would institute use of IMAR guides in their clinics and hospitals.,168
administration,Segmentation, N/A,23.8,1.83095794197e-06,15,0,"A community HCP is dividing doses of nivolumab into two bags and infusing only half of the indicated dose at a time due to his concern for infusion reaction and the high cost of nivolumab. He felt it is more appropriate to wait and see how the patient tolerates nivo before mixing the entire dose to prevent drug wastage. When discussing the risk of infusion reaction and safety in dosing and administration per the PI, the HCP reiterated the drug was too expensive to waste and he would not administer in one dose.","Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.","Large rural community practice - physicians uncertain as to how to monitor thyroid function and frequency of testing.  This seems to be an increasing theme in community practices.  Recommendations and algorithms discussed for IMAR management.
Two physicians in the group have starting using for RCC in 2nd line and feel that Nivolumab is the appropriate 2nd line agent over using another VEGFi or mTORi.  
Nurses in this same practice (following a lecture that discussed IMAR management as well as administration issues) noted that they had not been flushing IV lines post infusion of IO agents.They now understand the rationale for this and the practice's pharmacist was also present.",15
nurse,Segmentation, N/A,22.037037037,1.44838558389e-13,41,193,"Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.","Physician at larger rural practice noted disappointment at lack of responses seen in lung patients receiving Nivolumab.  Discussed with him the line of therapy he has noted this in.  He acknowledged that the majority of these patients were 3rd line and beyond.  He then also noted that he does not do PDL-1 testing on these patients and felt that it might have been he was treating more lower expressors and this may also contribute to what he is perceiving as fewer beneficial responses.  Overall, he has been very happy with the lack of side effects seen with treatment.
Same physician also noted he has started a patient on Regimen who had progressed on Nivolumab mono therapy.  Reviewed algorithms for monitoring and IMAR management as this is his first patient on Regimen.  Also reviewed with the clinic's NP and nursing staff.","Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.",234
staff,Segmentation, N/A,13.2222222222,5.54624485113e-06,27,72,"Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,"Rural practice in northern Minnesota visited.  Spoke with staff who identified that they administer Nivolumab via primary IV line and are flushing at end of infusion at the port site.  Discussed with pharmacist and nursing staff that when using a 100 ml bag to administer Nivolumab with primary tubing that they still have almost 25% of drug remaining in the tubing at the end of infusion and noted the importance of being sure to flush the entire line to insure patient receives full dose of drug.  
This finding has been noted in multiple practices and the IONL team is working to address this along with other colleagues in Medical and Marketing.",99
algorithms,Segmentation, N/A,12.6933333333,1.57825804385e-06,32,234,"HCP has questions around management of IMARs and fevers.  Reviewed IMAR guide, algorithm.  Also discussion around fevers and recommended febrile work-up.  Possible cytokine release and treat as IMAR if no source of febrile episode. Also questions around efficacy with steroids and IMARs.","Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.","While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",266
large community practice,Segmentation, N/A,12.0202020202,1.3163910716e-07,42,1884,LTL at a large community practice stated that he is ?really impressed? with the response rates of OPDIVO in cHL patients.  He stated  that he would move use of OPDIVO to earlier lines to possibly avoid transplant as salvage therapy.  The goal other salvage therapy might be met with OPDIVO to maintain the durability of remission in this patient population and avoid transplant.  He is impressed with the solid tumor experience now with the great tolerability and ease of administration to patients.  So far he has only seen maybe increases in transaminases no immune related s/e.,"Large community practice noted that they have been treating several patients ""off label"" with Opdivo including ovarian and cervical CA.",Meeting with physicians at large community practice who are considered high volume users of Nivolumab and have recent uptake in use of Regimen.  There was a fair amount of uncertainty regarding the monitoring and recognition of endocrinopathies.   Several questions regarding both evaluation of thyroid function as well as how to evaluate for adrenal insufficiency were discussed.  This practice has not been involving endocrinologists in patient care as yet.,1926
IMARs,Segmentation, N/A,9.91666666667,2.669563936e-05,34,278,"While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.","HCP has questions around management of IMARs and fevers.  Reviewed IMAR guide, algorithm.  Also discussion around fevers and recommended febrile work-up.  Possible cytokine release and treat as IMAR if no source of febrile episode. Also questions around efficacy with steroids and IMARs.","Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.",312
indicated,Segmentation, N/A,5.66666666667,4.45399814261e-05,79,459,"Oncologist in large community practice notes Nivolumab is 2nd line choice in RCC and does not consider another TKI or mTOR inhibitor first.
Has SCC on Nivo who has been in a CR for approximately one year, indicates she would like to try taking patient off treatment at two years if still in CR
Using Nivolumab for patients with lung cancer over Pembrolizumab
Expressed concerns over use of Regimen in Met Melanoma due to toxicity.  Reviewed data from 067 trial and the ability to manage IMARs with early recognition and prompt intervention","Large metro practice indicated that they have had difficulty previously obtaining PDL-1 testing and do not bother with it, they go directly to Nivolumab in second line NSCLC.",Nurses from large Nebraska practice indicated they feel incidence of adrenal insufficiency and hyperglycemia are higher than reported in clinical trials based on their clinic experience with Nivolumab,538
noted,Segmentation, N/A,4.91989664083,1.96944136637e-06,144,0,"Physician at larger rural practice noted disappointment at lack of responses seen in lung patients receiving Nivolumab.  Discussed with him the line of therapy he has noted this in.  He acknowledged that the majority of these patients were 3rd line and beyond.  He then also noted that he does not do PDL-1 testing on these patients and felt that it might have been he was treating more lower expressors and this may also contribute to what he is perceiving as fewer beneficial responses.  Overall, he has been very happy with the lack of side effects seen with treatment.
Same physician also noted he has started a patient on Regimen who had progressed on Nivolumab mono therapy.  Reviewed algorithms for monitoring and IMAR management as this is his first patient on Regimen.  Also reviewed with the clinic's NP and nursing staff.","Large rural community practice - physicians uncertain as to how to monitor thyroid function and frequency of testing.  This seems to be an increasing theme in community practices.  Recommendations and algorithms discussed for IMAR management.
Two physicians in the group have starting using for RCC in 2nd line and feel that Nivolumab is the appropriate 2nd line agent over using another VEGFi or mTORi.  
Nurses in this same practice (following a lecture that discussed IMAR management as well as administration issues) noted that they had not been flushing IV lines post infusion of IO agents.They now understand the rationale for this and the practice's pharmacist was also present.","Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.",144
practice,Segmentation, N/A,4.06224899598,9.95761589567e-06,258,718,Meeting with physicians at large community practice who are considered high volume users of Nivolumab and have recent uptake in use of Regimen.  There was a fair amount of uncertainty regarding the monitoring and recognition of endocrinopathies.   Several questions regarding both evaluation of thyroid function as well as how to evaluate for adrenal insufficiency were discussed.  This practice has not been involving endocrinologists in patient care as yet.,"Contacted by a large community practice regarding a melanoma ECOG study that they are involved in.  They had concerned that the protocol does not address safety/dose modifications surrounding potential infusion reactions.  They were advised that the PI of the study should be contacted and the question addressed.  It appears that there may need to be an amendment to this study.  A MIRF was filed specifically related to the topic of infusion reactions.  PI for this ECOG study is Dr. Hodi who, per the practice, is being contacted by the treating physician.","Large rural community practice - physicians uncertain as to how to monitor thyroid function and frequency of testing.  This seems to be an increasing theme in community practices.  Recommendations and algorithms discussed for IMAR management.
Two physicians in the group have starting using for RCC in 2nd line and feel that Nivolumab is the appropriate 2nd line agent over using another VEGFi or mTORi.  
Nurses in this same practice (following a lecture that discussed IMAR management as well as administration issues) noted that they had not been flushing IV lines post infusion of IO agents.They now understand the rationale for this and the practice's pharmacist was also present.",976
NW territory,Segmentation, Scientific Experts,20.7443977591,5.67895164412e-08,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
Dako,Segmentation, Scientific Experts,11.8539415766,9.3398582809e-07,17,124,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,141
Lung RTL shared,Segmentation, Scientific Experts,9.69867947179,2.37720246638e-05,15,59,Lung RTL shared that BMS will have an uphill climb trying to convince physicians how to use the regimen if CM-227 is positive.  He feels that physicians are scared off by the noise Ipi is creating in the adjuvant melanoma setting.  He commented that lung treaters at the institution level are asking their melanoma colleagues for guidance on how to manage toxicities with IO agents and if they haven't had positive experiences with Ipi then the rest of the treaters at the institution will have a skewed view of the drug.,"Pathology TL at a mid-size academic center has completed validation of 22C3 IVD 12/2/2016, testing is now available in-house.
-TL reported validation of platform and antibody were simple and straightforward
-TL reported training by watching Dako online module for scoring
-TL reported training on scoring was an ""uphill battle""",Lung RTL shared that BMS better hope FDA doesn't add the KN-010 data to Pembro's data using the 1% cut-off.  He thinks that if that happens it will be simply a two way race between Merck and Roche because both agents are Q3W.,74
SP142,Segmentation, Scientific Experts,9.42927170868,9.61771723105e-06,17,146,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,163
pathologist,Segmentation, Scientific Experts,4.84933973589,2.37599890303e-06,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
PD-1,Segmentation, Scientific Experts,4.24317226891,7.22743637314e-08,133,215,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Regional meeting TL stated "" PD-1, PD-L1 and CTLA4 are not the whole story with respect to the immune system, there is much more that we need to find out""","A RTL in melanoma from Boston, is prospectively looking to coordinate vetaligo with efficacy. Vetaligo is mostly seen in melanoma pts that have been treated with anti CTLA4 or PD-1/L1 therapy.",348
sent,Segmentation, Scientific Experts,3.35262994087,4.37622813096e-05,64,529,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",593
PD-L1 testing,Segmentation, Scientific Experts,2.84973544974,2.73512871574e-06,123,444,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",567
cases,Segmentation, Scientific Experts,2.84102732002,1.389289926e-05,117,0,"Regional Academic TL shared that they have been routinely adding budesonide if a patient is refractory to steroids. In about 50% of cases, patients will not require the use of infliximab. He is going to write up some case studies with this treatment paradigm.","CRC RTL shared that he thought a better trial and registrational strategy would be that instead of treating MSI-high patient populations, treat for high mutational load. He shared that he using Foundation Medicine diagnostic test for most CRC patients and that he sees MSI high patients about 5% of the time and high mutational load patients about 25% of the time. He further shared that he has been using Nivolumab and pembro off-label  in these patients and has seen some responses. He has written his results with two proof of principal cases and it will be published in Anals of Oncology.",Derm-path TL reported 0-5 cases of SCCHN per week come through the derm-path lab for diagnosis due to squamous cell presentation. TL works closely with ENT pathologists to determine who will follow the case.,117
pts,Segmentation, Scientific Experts,2.49419445197,4.62971862936e-06,164,1624,"RTL has nivolumab experience with 30+ relapsed GBM patients, seeing variable responses and quick ability to monitor with scans.  He routinely sees stable disease and believes that this is a very clinically meaningful endpoint for this difficult to treat population.  He is writing up a report of his experience of giving nivo to his pts.  Was going to submit for ASCO 2016 but missed the deadline.",Lung RTL shared that she is stretching out her scans past the 8 week mark.  She feels a majority of her patients are receiving clinical benefit (i.e. stable disease) but the early scan doesn't help much.  In fact she says that it probably induces unnecessary anxiety in pts. and they get discouraged when they hear that nothing much has changed with their scans.,Lung RTL shared that the patient population that she is seeing at her institution is changing.  With the approval of the PD1 inhibitors she is seeing less newly diagnosed metastatic pts. and more pts. that have failed PD1 therapy.  She added that she doesn't have many options for these pts. but that she was excited to note that they will be opening a Pembro + chemo study in pts. that progressed on PD1 inhibitors.,1788
NTL,Segmentation, Scientific Experts,2.20782947325,1.23901897974e-05,311,710,"NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.","In discussing 209-003 update, NTL noted that there is no apparent dose-response to Nivo, and that ""you just need a touch of that drug.""",NTL shared that it is very difficult to enroll patients onto melanoma trials that required being P-1/L1 nave because every patient who he receives as a referral has already been treated in the community with checkpoint inhibitors.,1021
TL,Segmentation, Scientific Experts,1.80584839997,2.40656393752e-05,1157,51,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",1208
2L,Territory,,4.17830817831,1.25767575475e-05,215,404,"A community oncologist prefers Nivolumab in 2L mRCC over cabozantinib because of their distinct MOA. The TL stated "" it makes more sense to use a drug with a different mechanism of action in patients who have failed TKI therapy in 1L than using another TKI"".","BCBSMI/Blue Care Network:

oAE:  How are you viewing PDL testing at this point? LS: A: ?Haven?t we killed that off in previous discussions?? She then rattled through the inconsistencies and conflicting data sets indicating that they haven?t built this into their policies beyond FDA labeling for the relevant products.
o	How do clinical trials influence medical policy/criteria?  Depending on level of evidence and applicability to our population they might be considered for significant differentiators.
o	Do you consider FDA label or NCCN guidelines more important when making policy changes? General consensus was NCCN.  AH/LC: we find the guidelines to be a better guide especially when it comes to patient/treatment nuances.
?	BCN Subject matter expert (R.Cook) has a different view on NCCN guidelines ? often too broad would prefer the restrictions of label and NCCN cat1/2A.
o	How are you considering applying the new Keytruda 1L data?etc?  Most likely to labeled indication i.e. >50%.  Likely to mandate testing for 1L usage.  
o	Overall ? we feel the customer has a good grasp on this 1L population and the applicability of the new data in light of the many options in 1L NSCLC.  
o	Tumor types appear to be very unique and specific - no clear policy shortcuts pertaining to management.
o	Key question - if they mandate testing how strong will the management be of a PA for these patients.
o	Keytruda update - will they monitor PDL1 expression in 1L and eventually mandate more >1% in 2L broadly?  Possibility in future.",An academic GU TL does not use cabozantinib or lenvatinib/everolimus combo in 2L mRCC. This TL prefers Nivolumab because of its efficacy and safety profile.,619
lung TL said,Territory,"  
CLEVELAND",168.461538462,8.07821583641e-19,16,1110,National lung TL said that the KN10 data in the squamous population was ?disappointing? however he wouldn?t steer away from using pembro in a squamous patient based on the KN10 data.,"National lung TL said that they do not enforce everyone testing for PDL1 but if they do test and it is positive, pembro is the choice. He said that even in his clinic, he rarely bothers testing for PDL1 and most often checks the box on the pathway that says ?PDL1 not tested?. He did mention that the PDL1 test is readily available for them and said it is reflexive to do just like EGFR or alk.","National lung TL said that he expects to see first line IO trials like CA209-026 to look like the data from 057. he stated that ""There wont be too much of a mOS difference but the curves will look like the 057 data since most of the patients will be adeno"".",1126
atezi,Territory,"  
CLEVELAND",112.307692308,9.0623455182e-07,5,27,"At Fall ECOG meeting thoracic TL in the audience voiced his opinion that since atezi is approved now does it replace nivo second line since 026 was negative.
1.	Audience member stated  that since we don?t have atezi first line data (in a similar study design like 026), so we cant make changes based on nivo fail first line. She said if we are making decisions on stopping use of nivo in 2nd line setting based on first line data, then we need atezi first line data as well to make a fair comparison.
2.	Thoracic chair said ""HR are all same between atezi and pembro and nivo in salvage setting""
3.	National lung TL said that toxicity is better with atezi (1% pneum) vs nivo (6%)
4.	Comment was made on atezi efficacy in PDL1 neg patients is based on sp142 antibody which misses about half of positive patients","Local lung TL commented that he currently uses about 80% nivo in his second line NSCLC patients vs 20% pembro. He doesnt think there is much room for atezi in that space. He did say that with the 026 results, he expects some hit to the amount of nivo being used second line.",Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,32
Regional lung TL told,Territory,"  
CLEVELAND",101.076923077,4.34208902411e-21,21,2,"Regional lung TL told me that he hasn?t treated any patient with autoimmune disease with IO intentionally, he has however seen a patient develop RA following nivo treatment. Patient has been managed with steroids and will be restarting nivo.","Regional lung TL told me about a recent op-edd piece that he saw in either The New York Times or Wall Street Journal where someone (he suspects this person was from merck) wrote in and criticized oncologists about not using pembro in pdl1-. He said the piece basically called out the oncologists as being very dumb people. He said that it ""is typical Merck tactics"".","Regional lung TL told me that he isn?t convinced that the Keynote 024 data is that great, he said ?lets wait to see the data before we get too excited?.",23
Fall ECOG,Territory,"  
CLEVELAND",89.8461538462,1.71205620441e-05,4,148,"At Fall ECOG meeting thoracic TL in the audience voiced his opinion that since atezi is approved now does it replace nivo second line since 026 was negative.
1.	Audience member stated  that since we don?t have atezi first line data (in a similar study design like 026), so we cant make changes based on nivo fail first line. She said if we are making decisions on stopping use of nivo in 2nd line setting based on first line data, then we need atezi first line data as well to make a fair comparison.
2.	Thoracic chair said ""HR are all same between atezi and pembro and nivo in salvage setting""
3.	National lung TL said that toxicity is better with atezi (1% pneum) vs nivo (6%)
4.	Comment was made on atezi efficacy in PDL1 neg patients is based on sp142 antibody which misses about half of positive patients","At Fall ECOG meeting, thoracic chair polled the audience about how is PDL1 testing being handled at their institutions.
i.	Mass Gen reflex testing but not with 22C3. 
ii.	More institutions sending out samples vs in house testing
1.	Audience responded that they are getting results within 3-5 days of sending out samples
2.	They are getting actual % positive PDL1","At Fall ECOG meeting thoracic presenter told the audience that 026 is technically a negativestudy and she commented that the forest plots of 026 subsets showed most actually favored chemo (she said ""the dots in the forest plots were mostly on the chemo arm vs the nivo arm"").",152
voiced his opinion,Territory,"  
CLEVELAND",67.3846153846,1.8073479167e-07,7,16,"Academic lung TL voiced his opinions that the ""OAK data  is bad"". He said that it is clear that the assay used is not as good as the 22C3 or 28-8 based assays. He also said that he doesn?t think much of the never smoker data in OAK.","Academic lung TL voiced his opinion that Keynote 024 and pembro first line ""is the single best thing that has ever happened in NSCLC for patients"".","Academic lung TL voiced his opinion that Keynote 024 and pembro first line ""is the single best thing that has ever happened in NSCLC for patients"".",23
Local lung TL commented,Territory,"  
CLEVELAND",44.9230769231,7.11846286708e-11,14,0,"Local lung TL commented that even with the 026 trial results, he still thinks pembro and nivo are basically the same agent.",Local lung TL commented that he isnt worried about the 026 data as you cant go back and retrospectively analyze the data using a 50% cutoff. He said the study wasnt designed that way and thus you cant get meaningful data from that kind of analysis.,Local lung TL commented that he is impressed with the data on Nivo plus Ipi data in SCLC and is happy to see it included in the NCCN guidelines. He was curious as to why the dose of ipi used in the combination is higher than in the NSCLC trials.,14
isn,Territory,"  
CLEVELAND",44.9230769231,5.92688721385e-09,11,106,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",Community TL shared that he uses mostly nivo (vs pembro) for his lung patients. He said it wasn?t due to any specific reason (i.e. better efficacy or better toxicity) other than the fact that he is comfortable with nivo and doesn?t see any reason to even try pembro. He said he thinks nivo is better especially in squamous patients.,117
GR,Territory,"  
CLEVELAND",44.9230769231,4.95492170287e-05,5,0,"National H&N TL indicated during GR that KN-012 showed ""only a smattering of CRs"" and that one should remember the tail of the curve ""represents only 4 patients"".",Melanoma NTL said from GR podium that the incidence of nivolumab-related myocarditis/myositis is ~ 0.25%.  Estimates deaths in nivo clinical development program to be 5 from myositits and 6 from myocarditis.,"National H&N TL said during GR that in Checkmate 141, nivo and ic OS tracked during the first three months which was surprising to them.   They said the OS rate was similar to KN-012 and that PD-L1- patients ""derived little benefit"" from nivo.",5
second,Territory,"  
CLEVELAND",44.9230769231,4.95492170287e-05,5,0,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.",Local RCC TL said his strategy for second line RCC it that he was always under the impression that its best to switch MOAs when failure occurs. He said that was how he was trained. He said that he doesn?t think anything can replace nivo second line given the very limited toxicity profile seen with it. He said he doesn?t think cabo can replace it,"Local lung TL commented that pathway company at his institution does not differentiate % of cell positive for PDL1 to determine who can get pembro second line. He said ""positive is positive"" according to the medical director of the pathway and doesnt think it will change first line. He said he thinks the same will hold true for first line use of pembro, any positivity will result in use of pembro first line.",5
H&N TL,Territory,"  
CLEVELAND",28.0769230769,1.69965923429e-05,20,432,"National H&N TL provided the following comment regarding pembro approval in H&N: He said that pembro got approved based on the 141 data set. His exact words were ?pembro was approved based on Checkmate data? because everyone expects Keynote 40 to be positive just like checkmate 141 was. He said Merck was lucky that they hit the sweet spot in terms of timing and that?s why they got approval. He said that everyone expects pembro to ultimately have as strong of data as nivo but as of right now, nivo has the best data out there and thus should be the preferred option on their institutional pathway.","Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.",Regional H&N TL told me that KESTREL will close (due to full accrual)  in October 2016.,452
sutent,Territory,"  
CLEVELAND",28.0769230769,1.69965923429e-05,8,3,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.","Local RCC TL told me that Pazop toxicities are the same but less significant vs sutent. She said they only use pazop for frail older patients first line. Everyone else gets sutent first line. She said that they use 2 on, one off dosing of sutent even though it isn?t recommended in their PI.","Local RCC TL said his strategy for 1st line RCC used to be pazopanib first line but he said he really likes the 2 weeks on, 1 week off Sutent strategy. He said he has been using that in his new patients. He said that the biggest issues he used to have with sutent every four weeks was weight loss as a result of significant diarrhea coupled with taste issues. He said patient won?t eat because of the taste problems.",11
TL told,Territory,"  
CLEVELAND",12.4786324786,1.88631056051e-10,65,938,"Local H&N TL told me that the RTOG 3504 study in locally advanced H&N is very important because that is most common type of patient that they see. She said that they only see 10-15% of patients being metastatic at presentation and at least at their institution, the h&n isnt treated at the community sites, instead all of the patients are referred to the main hospital.","Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.",Local H&N TL told me that it was first time she has seen standing room only space at a H&N presentation when referring to the 141 data presented by DR Ferris at ASCO.,1003
Local,Territory,"  
CLEVELAND",9.70560303894,5.95366712416e-19,184,1056,"Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.","Local community TL told me that when she gets her reports back for PDL1 testing, the company provides her with a % positive for PDL1 for pembro as well as a % positive for nivo on the same sheet. I asked her if the numbers match up based on Blueprint analysis and she said they are usually about 10% different with the nivo number being lower. This was based on a single patient and she couldnt remember the company's name that did this testing but she said she would let me know.","Local H&N TL told me that the RTOG 3504 study in locally advanced H&N is very important because that is most common type of patient that they see. She said that they only see 10-15% of patients being metastatic at presentation and at least at their institution, the h&n isnt treated at the community sites, instead all of the patients are referred to the main hospital.",1240
t,Territory,"  
CLEVELAND",7.29270729271,5.00781418171e-12,117,0,Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",117
doesn,Territory,"  
CLEVELAND",7.21978021978,2.48864767972e-05,36,94,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,130
TL said,Territory,"  
CLEVELAND",6.17692307692,1.15759629663e-05,86,62,Regional GU TL said he does not order PD-L1 testing in RCC or bladder outside of a clinical trial.  Said there is no data to support treatment decision making in RCC.,Regional TL said no data supports testing for PD-L1 in RCC in any line.,"National H&N TL said during GR that in Checkmate 141, nivo and ic OS tracked during the first three months which was surprising to them.   They said the OS rate was similar to KN-012 and that PD-L1- patients ""derived little benefit"" from nivo.",148
said,Territory,"  
CLEVELAND",5.89615384615,2.85420644098e-27,479,0,Local RCC TL said his strategy for second line RCC it that he was always under the impression that its best to switch MOAs when failure occurs. He said that was how he was trained. He said that he doesn?t think anything can replace nivo second line given the very limited toxicity profile seen with it. He said he doesn?t think cabo can replace it,"Local H&N TL said that at the recent ASCO review, the speaker highlighted the 1 yr OS as being very important.Local TL also said that ORR is OK as an endpoint, but OS is the king of outcomes. He said that ORR is tough to use due to the potential for pseudoprogression with immunotherapy. He said EXTREME regimen very difficult for most patients. He isn?t a fan. He uses some weekly taxotere, some gem","Regional lung TL said that he ""doesn?t think there is ultimately any difference between nivo and pembro even with 026 press release"". He is impressed that pembro hit both pfs and OS data. He said BMS gambled right for second line but not so much for 1st line. He also said that it?s clear that PDL1 positive patients do better. ""It always better to be PDL1 positive"". He wants to see the data from pembro and from 026 to really see if there is any difference.",479
line,Territory,"  
CLEVELAND",4.75147928994,5.90756762208e-08,345,108,"Local RCC TL said his strategy for 1st line RCC used to be pazopanib first line but he said he really likes the 2 weeks on, 1 week off Sutent strategy. He said he has been using that in his new patients. He said that the biggest issues he used to have with sutent every four weeks was weight loss as a result of significant diarrhea coupled with taste issues. He said patient won?t eat because of the taste problems.",Regional lung TL told me he heard about the 026 press release and said that we now need to know if nivo can be effective in patients that fail first line pembro. He said he has tried to use nivo in a NSCLC patient that failed a first line anti-PDL1 antibody (EMD Serono antibody) and it didn't work.,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.",453
told,Territory,"  
CLEVELAND",4.62443438914,1.48224821259e-05,136,65,Regional lung TL told me that the Merck people are telling him that 70% of 2nd line patients are getting tested for pdl1. He laughed and said he doesn't believe that.,"Local pharmacist told me that the ""Merck people are pushing the fact that they achieved an OS benefit in their 024 study even with cross over"" and are telling him that ""BMS cant use cross over as an explanation why nivolumab failed to achieve any OS benefit in 026"".",Local lung TL told me that the Merck sales folks visited him yesterday and his description of them was ?they were salivating about their data at ESMO and the incoming first line business?,201
national,Territory,"  
CLEVELAND",4.08391608392,4.87316891553e-05,183,979,"National H&N TL provided the following comment regarding pembro approval in H&N: He said that pembro got approved based on the 141 data set. His exact words were ?pembro was approved based on Checkmate data? because everyone expects Keynote 40 to be positive just like checkmate 141 was. He said Merck was lucky that they hit the sweet spot in terms of timing and that?s why they got approval. He said that everyone expects pembro to ultimately have as strong of data as nivo but as of right now, nivo has the best data out there and thus should be the preferred option on their institutional pathway.","National lung TL said that they do not enforce everyone testing for PDL1 but if they do test and it is positive, pembro is the choice. He said that even in his clinic, he rarely bothers testing for PDL1 and most often checks the box on the pathway that says ?PDL1 not tested?. He did mention that the PDL1 test is readily available for them and said it is reflexive to do just like EGFR or alk.",National lung TL said that the KN10 data in the squamous population was ?disappointing? however he wouldn?t steer away from using pembro in a squamous patient based on the KN10 data.,1162
HCP,Territory,"  
FL PANHANDLE",20.8125,1.34846388469e-08,115,124,HCP is frustrated over Opdivo flat dosing reporting difficulty justifying changing the dose for patients that have done well on weight based dosing. He feels the change has been overnight and he wanted more notice before such drastic changes in dosing happen. He is concerned about patients receiving higher doses that will now receive the 240mg flat dose despite whatever the science reports. States that his practice will continue to use weight based dosing until payers push back.,After recent visit from competitor small community HCP expressed confusion about PD-L1 testing and what tx to use for 1st line NSCLC. Reviewed NCCN guidelines and reactive clinical data looking at PD-L1 expression. HCP shared they have had success getting pembrolizumab approved for patients expressing less than 50% in the 1st line setting.,HCP was visibly impressed with ORR by PD-L1 status particularly at the 50% level in Checkmate 012 for 1st line NSCLC.,239
PD-L1 testing,Territory,  ACTICES & IMPLEMENTATION,15.6501547988,2.77200594888e-08,123,444,"Regional lung TL stated the despite performing all diagnostic tests in-house up to this point, the pathologist at their major academic institution is reluctant to implement their own testing procedures for PDL1 assessment and is persistent in continuing to send out samples for this IHC assessment to a commercial company (which is not using the Dako platform and does not provide an actual level of expression but rather just a ""positive"" or ""negative"" designation.","A Lung RTL from NY City mentioned that his site does not routinely test for PD-L1 in any line of therapy for NSCLC patients.  He noted that of >200 patients treated in 2015 with I-O agents, a PD-L1 test was obtained in less than 10.  Primary reason to test was patient's request.  The Dermatopathology lab has chosen to use their own system with an IHC antibody from Cell Signaling.  The TL added that since his site is so busy, they often need 3-4 days ahead of time to get an open slot in the Infusion Center.  Thus, the TL and his colleagues are very uninterested in adding any delay for a test they see no value in.","Lung TL stated that Foundation is providing additional markers to their initial PD-L1 testing.  New analysis includes PD-L2 and PD-L1 expression on T-cells.  Tl added that Foundation seems to be able to pick up additional mutations (EGFR,ALK, etc) that IHC testing is missing.  TL indicated a preference for Foundation testing over his own lab's Pathology testing",567
NW territory,Territory,  AK,3036.0,8.33386102995e-30,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
sky-rocketed,Territory,  AK,650.571428571,5.71534680333e-07,3,577,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",580
NeoGenomics,Territory,  AK,433.714285714,2.84130171907e-12,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  AK,361.428571429,2.89813476965e-10,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
clone,Territory,  AK,216.857142857,2.8324859683e-06,5,149,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",154
diagnostics,Territory,  AK,173.485714286,1.03958511784e-07,8,1288,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",1296
medical director,Territory,  AK,173.485714286,1.03958511784e-07,8,365,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",373
healthcare,Territory,  AK,162.642857143,4.93497565307e-06,6,688,"Insights from 1:1 meeting with chief of pathology at large healthcare network in NW territory: i) within network, payment in regards to PD-L1 testing is not an issue, whatever medical oncologists order for testing is ultimately covered including PD-L1 testing; ii) no in-house PD-L1 testing is performed, all testing sent out to NeoGenomics; iii) medical oncologists only order 22C3 test but are not reflex testing although TL suggests this will happen very soon; iv) currently reconsidering using ARUP as the prices may be better; v) reports provided by paper/PDF copy which is then scanned and entered into patient records upon receipt; vi) PD-L1 reported as % positive tumor cells and binned into one of the three bins: >50% (high expressers), 1-49% (low expressers), <1% (non-expressers);",Pathologist (IHC lab director) practicing in community hospital setting affiliated with large university medical center in NW territory mentioned 3 RCC patient success stories on nivolumab. TL is not testing for nivolumab use in RCC setting but has done investigational studies on these 3 patients treated with nivolumab looking at PD-L1 status and mutation burden. At least one of the responders to nivolumab lacked PD-L1 expression but had high mutation burden.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",694
Ventana platform,Territory,  AK,130.114285714,7.86113526667e-06,7,145,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",152
reflex testing,Territory,  AK,123.918367347,2.69576798449e-07,11,91,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.",102
medical oncologists,Territory,  AK,89.2941176471,7.35500176948e-11,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
platform,Territory,  AK,86.7428571429,8.05617792021e-07,18,149,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",167
IHC,Territory,  AK,79.8947368421,1.38045570756e-10,25,536,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",561
insights,Territory,  AK,72.2857142857,6.80940292148e-14,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
molecular,Territory,  AK,61.9591836735,2.41434585398e-06,17,42,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from medical oncologist giving featured podium presentation at pathology conference in NW territory: i) TL stated that only 22C3 guides 1L NSCLC decisions; ii) TL stated the following: ""In 2L NSCLC setting: if the tissue is PD-L1 positive, pembrolizumab is the therapy of choice. If the tissue is PD-L1 negative, atezolizumab and nivolumab are therapies of choice. Pembrolizumab is favored for PD-L1 positive patients""; iii) TL made the statement that ""FDA invented the term 'complementary diagnostics' just for the sake of 28-8 assay as FDA did not know what to do with this assay""; iv) TL is reflex testing using 22C3 for PD-L1 along with molecular testing (EGFR, ALK, ROS1); v) TL stated that ""22C3 is the test to do"".",59
SP142,Territory,  AK,61.9591836735,2.41434585398e-06,17,146,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",163
pathologist,Territory,  AK,60.2380952381,3.13304006788e-13,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
network,Territory,  AK,57.8285714286,3.04305772666e-06,18,441,"Insights from 1:1 meeting with chief of pathology at large healthcare network in NW territory: i) within network, payment in regards to PD-L1 testing is not an issue, whatever medical oncologists order for testing is ultimately covered including PD-L1 testing; ii) no in-house PD-L1 testing is performed, all testing sent out to NeoGenomics; iii) medical oncologists only order 22C3 test but are not reflex testing although TL suggests this will happen very soon; iv) currently reconsidering using ARUP as the prices may be better; v) reports provided by paper/PDF copy which is then scanned and entered into patient records upon receipt; vi) PD-L1 reported as % positive tumor cells and binned into one of the three bins: >50% (high expressers), 1-49% (low expressers), <1% (non-expressers);",Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,"Insight from three different TLs from the same large healthcare network in NW territory: i) all NSCLC samples are sent out for testing to Neogenomics; ii) none of the pathologists have any granularity on the numbers of cases sent out, exact tests performed, nor whether PD-L1 is currently reflex tested for; iii) no near future effort will be made to bring testing in-house.",459
pathology,Territory,  AK,54.2142857143,3.78503245281e-06,19,213,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",232
gained,Territory,  AK,54.2142857143,3.78503245281e-06,19,86,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",105
Pediatric,Territory,  AL,56.8107344633,8.29034326703e-08,11,367,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,378
regional TL shared,Territory,  AL,35.1685499058,2.5762217319e-12,18,18,A regional TL shared with me that he is now doing PDL1 testing in his firstline NSCLC patients because of the KN-24 approval.  He acknowledged that most patients will not be over 50% positive and confirmed that Nivo will still be SOC for those patients 2nd line.,A regional TL shared that he has had no problems getting insurance to approve off-label 1L usage of Nivo monotherapy in RCC.  He said that he has seen durable responses approaching 2 years.,"A regional TL shared with me that he believes hypophysitis is exclusive to Ipi rather than Nivo.  He hypothesizes that Ipi cross-reacts with common proto-antigens shared between melanosomes and the pituitary as both originate from a common cell lineage in the neural crest.  He does not think that Nivo recognizes that common antigen, hence the higher incidence of primary thyroiditis with that drug.",36
achieved a CR,Territory,  AL,11.8048279404,6.39128055401e-06,18,356,"A national melanoma TL shared that if a patient achieves a CR, he will stop Opdivo treatment at 1 year.  If the best response is PR, he will stop treatment at 2 years.",A melanoma and GU NTL offered that he stops PD1 therapy when a patient achieves a CR or PR that plateaus.  He gives 1 month worth of therapy extra after they achieve their best response and has done this is approximately 30 patients?he said that he has not experienced a single relapse in these patients.,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.",374
offered,Territory,  AL,5.32979171937,1.32974687842e-08,88,0,"A national H&N TL at an NCI designated cancer center offered that she substitutes Taxol for 5FU in the EXTREME regimen. She said that she ""loves"" weekly taxol and erbitux because she always sees responses.",A local HCP offered that she was able to get Nivolumab for a prostate cancer patient and he achieved a CR.,"A regional TL offered that he will readily use pembro 1L when they receive their FDA indication for NSCLC.  He said that he will use pembro preferentially because of the positive experience he had with their compassionate use, and he had an extremely bad experience with BMS's program involving ""more than 100 emails back and forth"".  With further discussion, he did not use the local ARM but rather used the online compassionate use link on the BMS website; regardless, the ARM has been notified of this.",88
TL shared,Territory,  AL,5.31217257319,2.49854558133e-07,119,1081,Academic RCC TL shared that he would consider cabozatinib over nivolumab in a patient with bone mets based on METEOR data presented at ASCO with the caveat being that the patient must be tolerating prior TKI as the toxicity with cabo is much worse than nivolumab. If patient had a tough time with prior TKI then he would go straight to nivolumab,"A national melanoma TL shared that he has seen a few thyroids preserved with steroids using Nivo, but he never saw that with adrenal insufficiency.",A regional HNSCC TL and lung TL shared that he was very impressed by the -141 data presented at AACR.  He expressed that he is very anxious for the FDA to approve it as he believes it is superior to any other therapeutic options.  He said that he will use it in patients who are PDL1 negative and always prefers an agent that does not require PDL1 testing.,1200
academic center,Territory,  AL,4.8093743461,3.1589270334e-06,103,319,NTL for MM at a large academic center thinks a trial with Urelumab and Nivolumab would be interesting.,NTL for MM at a large academic center thinks the check point inhibitors will remain only in the RR space secondary to their safety profile.,Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,422
Regional TL,Territory,  AL,4.40180024897,8.09099631353e-06,100,1088,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.","A regional TL shared with me that he has been treating SCCHN patients with nivolumab off-label but has yet to see any good responders.  Even with pembro being approved in that space, he offered that he is going to continue using nivo off-label because of his preference for the drug.","A regional TL shared that she was able to get Nivo approved for a SCCHN patient.  This patient is under 50 years old and had failed 5 lines of prior therapy, and after 6 months of Nivo he is near a complete response.",1188
nivolumab,Territory,  AL,2.63381302633,6.43510046016e-07,335,5,Academic RCC TL shared that he would consider cabozatinib over nivolumab in a patient with bone mets based on METEOR data presented at ASCO with the caveat being that the patient must be tolerating prior TKI as the toxicity with cabo is much worse than nivolumab. If patient had a tough time with prior TKI then he would go straight to nivolumab,"A regional TL offered that he had a young metastatic anal sq-carcinoma patient who had failed multiple lines of therapy and received Nivo off-label through our access support.  This patient achieved a CR and he now refers to her as his ""poster child patient"" for nivolumab.",TL at an academic center described a patient who she has treated with nivolumab for cHL with the Nivolumab given prior to transplant. She described that the patient was placed on Brentuximab and did not respond so Nivolumab was added to it. The patient subsequently achieved a CR within 3 months and then proceeded to ASCT. The patient is doing well and had no IMARs.,340
said,Territory,  AL,2.45093115715,3.56480921551e-07,479,0,"A national TL mentioned that he has treated ~8 GBM pts with Nivo and saw ?only a couple responders.? ?Nivo or Pembro monotherapy is not going to be the answer.?
Same TL said he was skeptical of the efficacy of anti-PD1 plus radiation. He said that he thinks PD1 plus another checkpoint inhibitor is going to be key, saying that he has not given up on Nivo plus Ipi.","At a local Best of ASCO meeting, a regional lung TL approached me and offered the following comments about -026.  He said that BMS should not worry about it failing because the -012 publication shows that OS and ORRs are better with Nivo than chemo.  He said that he believes most physicians feel comfortable giving chemo upfront and a good portion will continue to do that and use Nivo 2L.  He said that 5 community physicians have contacted him since the press release specifically asking if they can use Nivo 1L--not a PD1 inhibitor or Keytruda.  He believes that the majority of doctors will prefer using Nivo 1L because of their overwhelming familiarity with it now in the 2L assuming it eventually gets approval in that setting.","A regional TL at a rural community practice told me that the hospital is now doing PDL1 testing on all of their NSCLC patients.  He said the pathologists are also providing the percentage of PDL1 positivity.  When asked if this was due to Pembro's data/label, he admitted that he did not really know the answer but doubted it had to do with Pembro because their group only really uses Nivo.",479
Biodesix,Territory,  APE/COMPETITOR INFORMATION,677.111111111,2.13941885293e-05,4,34,"A TL from Puerto Rico shared that a company called Biodesix is offering molecular testing for lung biomarkers such as ALK, EGFR, ROS, KRAS, BRAF and T790M mutations using only 20mls of peripheral blood.",TL shared that he was one of the top enrollers in the Biodesix lung biomarker study comparing tissue based vs blood based (circulating tumor cells) PDL1 assessment and said that the data show concordanance between tissue and blood based PDL1 testing and hopes that when PD1s move into 1L setting that FDA/payers will allow blood based assays for PDL1. He did not share info on what antibody(s) was used in the Biodesix biomarker study. Note - this is the third insight regarding this biomarker trial that I have heard.,A National TL at a lung cancer lecture at the PR Hem Onc Symposium noted that because of the complexity of the microenvironment not one biomarker would be truly predictive.,38
cabozatanib,Territory,  AR,119.608695652,1.28222730163e-12,13,190,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",203
trx,Territory,  AR,92.0066889632,9.64506361396e-10,10,0,"RTL, who is IL-2 referral center, stated that he has believes that all RCC patients should get any and all IO options as soon as possible.  For patients who are good candidates (~10% of RCC pts largely due to organ fxn), starts with IL-2.  Currently dissapointed that nivo PI and 025 trial req'd anti-angiogenic, rather than any prior trx (ie, IL-2 only). Has given several patients a short course of pazaponib until 'any first toxicity' as a pass-through to fulfill insurance requirements per PI.","pan-tumor community RTL states that in RCC he commonly sees patients with mixed responses (both to IO and TKI).  he states that he often sees a similiar phenomenon in SCCHN, but rarely sees mixed responses in lung.  

Due to this, in RCC, he very commonly adds nivolumab to a TKI (typically sunitinib or axitinib) if a patient is beginning to progress rather than switch trx completely.  He states that it has worked very well and he has had no toxicity issues, possibly as most patients are by then on a dose-reduced level of TKI.   He would like to see more nivo+TKI (ie cabo) and nivo-rescue trials being done.","GU RTL shared some factors he considers when deciding between nivo (~70% of pts) and TKI (now cabo, ~30% of pts) for 2L RCC trx:
- pace of progression (20% of pts exhibiting faster progression prefers TKI) 
- toxicity of 1L VEGF TKI (if had minimal tox/dose reduction, more likely to give cabo 2L due to convience of oral dosing)
- compliance to taking oral meds and reporting of side effects
- Performance status (lower PS would always get nivo)",10
pace,Territory,  AR,73.6053511706,7.78347209077e-08,8,208,"GU RTL states that while he prefers to give nivolumab 2L in RCC patients, that he uses cabozatanib in patients who are progressing ""fast"" as he is concerned that IO works too slowly.  When asked to elaborate on his definition of 'fast progressors' he stated that it is at most 25% of patients and that he can often tell speed of progression by clinical appearances (PS, pain, fatigue) rather than scans.  

He stated that even in 'moderate pace' progressors, that at least 50% of the patients have their disease 'explode' once they come off of their 1L TKI, sometimes to the point he has no choice by to put them back on.  He had considered 'bridging' in nivolumab while weaning off the TKI but was concerned about safety.  Reactively reviewed TKI+nivo safety data from 209-017 and he thought that this was very acceptable and that he may begin to do this.","Academic TL stated that his nivo non-benefittors (ie, PD w/o any SD/PR) tend to progress at a much faster pace than their 1L progression, sometimes causing them to not be able to get a 3L therapy.  However if they have had any benefit, even a short term slowing of disease prior to progression, their progression is much more tapered and they tend to do better on 3L chemos","TL stated that while he initially treated 'everyone with aPD-1 regardless of PDL1 expression', his experience (pan-tumor) is that ""those who don't respond to IO, actually increase their speed of progression, compared to a chemo or TKI where even non-responders tend to get a temporary slow-down, and thus he feels IO can have a negative impact on ability to response to subsequent therapy.  In nonsq-NSCLC, he has started to test for PD-L1 and will often treat those with <1% with chemo+/-ramucirumab prior to IO in order to 'slow pace before moving on to IO'",216
aPD1,Territory,  AR,64.4046822742,6.90413069806e-07,7,635,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","RTL reports that he has utilized ipi/nivo regimen 2L in several patients who have been referred to him following 1L pembro monotherapy failure.  While still early in treatment, he reports that so far patients have done extremely well, either stabilizing or responding. Physician would like to see a a trial specifically looking at 'rescuing' aPD1 non-responders with regimen second line.","NTL in lung stated that at this point, and ""maybe it will change if the numbers for KN-024 are actually much better than I think they will be"" he sees his use of pembro (or any aPD-1 monotherapy) in the first line to be very limited. He expects that the magnitude of benefit may be somewhat modest. ""significant doesn't always mean incredibly meaningful""  

He's states that either in 1L for trials, or in 2L, that he has seen such a ""tiny, maybe 15%"" of patients with >50% PDL1.  ""Whatever the trials data says for proportion of the population, I figure my experience is half of that it almost makes me questioning if I should bother holding up starting chemo for such a tiny fraction"".",642
Pan-tumor,Territory,  AR,34.5025083612,2.73855459853e-12,18,464,"Community Pan-tumor TL at research-focused site stated that while their practice has started ordering PDL1 testing in NSCLC whenever possible, however he said ""I'm not really sure why I bother... I treat the negatives with nivo anyways...""

He wasn't sure what exact test they ordered and but stated that he gets an exact % expression reported back.","Community Pan-tumor TL seemed only very moderately aware of the outcomes of KN-024 and CM-026 reported at ESMO, but stated that he ""doesn't think we will be using platinum doublets in 1L in a couple years"".  He did not mention pembro's 1L approval (a few days after) and my impression was that he was not aware. When probed, this is because he thinks this is because IO+IO combinations will be SOC (rather than PD1 monotherapies being used widespread).","Community Pan-tumor TL at research focused site states that while the he is convinced that the efficacy is worth it, that managing toxicity for ipi+nivo in melanoma is ""high maintenance"".  Between him and one other partner (the two that see most of the melanomas), they have treated about 6 patients, and have ended up having to hospitaized a majority of those patients due to GI toxicity.  However they state that the toxicities resolved well with steroids or infliximab and that the majority of these patients have had profound responses.  He stated that he struggles with whether to put these patients back on nivo monotherapy, and has not to date based on the durability off trx in 069 and 067, but he sometimes feels very nervous ""not doing anything more""",482
Pediatric,Territory,  AR,32.2023411371,2.83443729093e-06,11,367,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,378
ie,Territory,  AR,31.4356187291,3.58490106943e-30,52,0,Very positive early feedback around AE management app.  Nurse manager requested a similar web-based version to be used at triage desks (ie wiht hyperlinks for the different AEs),"pan-tumor TL reports that he is not performing PDL1 testing in RCC patients.  He states that, of all his tumor types, he actually does the least amount of any genomic analysis (ie Foundation One, etc) in RCC patients as there aren't those 'characteristic and target-able' mutations like in other tumor types.","Med Academic lung TL inquired if there were any efforts to examine was to examine PDL1 in either a plasma/liquid biopsy form (ie, RNAexpression, etc.). Challenges around this were discussed (ie, systemic vs. local tumor environment, etc).",52
modest,Territory,  AR,21.4682274247,8.62120070346e-06,9,142,"Despite being impressed by the efficacy benefit, LTL has been hesitant to prescribe commercial ipi3+nivo1 regimen for melanoma due what he considers an unacceptable toxicity profile, especially given lack of long term OS data to justify the toxicity. However, 'jumped' at chance to participate in CA209-568 1L NSCLC trial (ipi q6w, nivo q2w) as he was very impressed with the improvement in toxicity with this dosing in 012.  He hopes to that this dosing schedule will also be examined in melanoma.","Based on the median time to response and higher number of 'late' responses in 025, coupled with the overall slower progression of RCC patients, TL is considering doing first scan at 12 weeks rather than 8-9 weeks as he think it may better reflect the benefit without showing as much pseudoprogression.","GBM: RTL who attended SNO stated that 'each year the progress for GBM seems so incremental and they are still waiting for the 'break' that all these others tumor are seeming to have'.

Stated that he was 'so hopeful' around IO, but that it has been largely dampened due to the ""very modest"" data from nivo (143) and pembro (KN028).   He hopes that possibly 1L treatment will produce stronger results.",151
2L+,Territory,  AR,20.7015050167,4.67465806427e-07,12,334,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.",346
GU RTL stated,Territory,  AR,16.5612040134,1.1905774342e-06,13,433,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",446
Pan,Territory,  AR,16.1011705686,2.16371647987e-05,10,0,"Pan tumor TL stated that the was ""Thrilled"" that pembro was added to the 1L NCCN guidelines so quickly.  He acknowledged that this was a very selected population, however believes that the magnitude of benefit 'absolutely' makes it worthwhile to put forth the effort to find these patients.","Pan Tumor community research TL:

Surprised at and impressed by how big the magnitude of benefit was in KN024.  Acknowledges that it is going to fit for a very small portion of patients (he estimated 20% for his practice based on his own synthesis of PDL1 prevalence reported and PS/brain mets/etc in his own patients), however think that it is worth testing everyone at diagnosis and would try to treat anyone with >50% PDL1 with pembro 1L.  He is completely perplexed by the CM026 >50% negative data.  Thinks that this is likely ?a fluke?, but given the magnitude of benefit in 024 doesn?t think that small difference in patient populations could make data from ?super positive? to ?solidly negative? between trials so ?could be a real difference?. 

Note that prior to ESMO data, TL had low expectations overall for KN024 data, thinking magnitude would likely be reasonably small and that he would not likely make a huge push to PDL1 test everyone at 1L, so this is a marked shift in his attitude after seeing data.  He was, and remains, strongly pro-nivo regardless of PDL1 expression, for 2L - views haven?t changed.","Pan tumor TL stated that his concern in giving IO earlier (across any tumor type) is that for the patients that is DOESN'T work for, it is almost detrimental.  He finds that these patients (lung, mel, GI, RCC) tend to have their disease 'explode' and progress quickly, making it impossible/challenging to get it a subsequent line of therapy.  He states that in the 2L and beyond, this is a gamble you take because there aren't a lot of other options, but in the 1L settings it is dangerous and there is still a lot to be said for chemo which at least 'slows down' almost everyone.",10
IL-2,Territory,  AR,15.3344481605,4.33977673326e-07,16,48,"RCC TL shared that manuscript had just been accepted for publication around the RCC portion of the PROCLAIM registry and outcome based on sequences of IL-2, chkpt inhib, and TKIs (NCT01415167, PROMETHEUS).  Journal of Urologic Oncology.  
TL did not share any specific data but stated that 'IO first is always best'.","RTL in GU stated that he will be participating in an upcoming Nivolumab+HD-IL2 trial that is being sponsored by Prometheus - did not state specifically, but during implied that this was an ISR (possibly led by Michigan?) that will be bringing on about 10 sites nationwide.   TL had not seen final protocol yet, but believed that there would be a nivolumab lead in (~2 cycles) followed by a standard course of HD-IL2, 1 nivo dose between cycle 1 and 2 of IL2, and nivo mono therapy after completion of IL-2.","Melanoma RTL who has traditionally been a strong proponent and regional referral center for HD IL-2 stated that he hasn't treated a melanoma patient with IL-2 in over a year and that the efficacy of checkpoint inhibitors has nearly 'killed' IL-2.  He states that the 'CRs and cures from IL-2 can't be downplayed, but that you can't refute that way more patients are getting benefit from chkpt inhib without the ICU-type toxicity"" 

TL states that despite it being dropped from NCCN guidelines as a 1L recommendation, that he would still use IL-2 upfront in a young, fit patient as he feels the best strategy is to ""stimulate the immune system by as many different mechanisms that we can"".",64
not test for PDL1,Territory,  AR,14.7210702341,7.66101784373e-06,14,651,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.","GU RTL stated the he has used Opdivo in 2 non-clear cell RCC patients.  Stated that in both cases was initially denied by insurance, but easily approved once he appealed and spoke with company.  Stated that this is incredibly common to agents when they first come on the RCC market due (experienced the same with axitinib) and does not concern him, however was thrilled to hear that we were already doing a study with nonCC patients (374) and he hopes this data will be incorporated into PI eventually.",665
axitinib,Territory,  AR,10.5150501672,3.18088844119e-05,14,482,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",496
HN,Territory,  AR,9.20066889632,2.36863921091e-06,21,1,"HN RTL stated that at their institution (NCCN), it is most common for Merkel Cell Carcinomas that are on the head to be seen by the HN team, rather than the melanoma team. This is in contrast to most other institutions in my region. 

Stated that he has used and seen some good responses to pembro, but is overall much more impressed by the avelumab data.","RTL in lung&HN shared that he is not currently, and does not plan, to test for PDL1 in HN. He likened the 141 data to being ""extremely reminiscent to the 057 and the lung space. Clearly PDL1 is enriching for nivo efficacy, but in 2L even it it was dead even with SOC, I would use it in everyone 2L based on safety and QOL one.  However, this argument might change in 1L HN like it does in 1L lung."" 

He stated that has several HN patients currently nivo off-label, however has started new patients on pembro since their approval due to ""similar data and ease of them having the approval"".  He sees himself using primarily nivo again if approved for HN.","Regarding HN choice of pembro vs. nivo.  Overall opinion is that data ""is very similar"" and few seem to be concerned with lack of OS or comparator for pembro.   Trend seems to be developing where pan-tumor physicians  who have already heavily utilized nivo over pembro to date (ie in lung) are stating that they will continue to use nivo for HN (""all things being pretty equal, we use what we are most comfortable with""). 

HN specialists or those with more limited PD1 experience, are utilizing pembro due to its first approved status and more sites having experience with pembro HN trials",22
GU,Territory,  AR,8.17837235229,1.96643017228e-11,84,815,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","RTL who splits time between Academic GU specialists and community generalist (ie, also treats lung) shared that he is NOT testing for PDL1 in RCC  (Note that TL is also not currently testing NSCLC patients for PDL1 outside of trials).  TL did state that he thinks it is very 'intriguing' why PDL1 is enriching in some tumor types (ie, nonsq lung; mel) and not others (RCC).  

TL prefers to give nivo 2L in RCC (~70% of 2L cases), however if patient travels long distances will sometimes utilized cabozatanib due to oral conveniences and ""predictable toxicities that can almost be managed over the phone with dose reduction"".","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.",899
nearly,Territory,  AR,6.57190635452,4.95317449156e-05,23,0,"LTL shared story of a PDL1 negative patient enrolled on CA209-153 who experienced a rapid near CR and has maintained response for nearly 1 year.  Based on this experience, TL stated that he ""would deny a 2L+ NSCLC patient nivo based on lack of PDL1 status""","NTL in sarcoma shared that he has personally treated nearly 100 sarcoma patients with I-O therapy/  About half were on trial (SARC028 or ALLIANCE A091401) and half off protocol.  Over half of the patient have been treated with ipi+nivo combination, and he shared that he has seen ""just amazing results, including probably 6-7 CRs, particularly good responses in Uterine Leiomyeosarcomas, Liposarcomas, and Osteosarcomas.  He shared that this is his standard 2L or 3L treatment for many patients now.  He stated that BMS Access support has been ""beyond wonderful"" and hat he has also had sporadic success in getting insurance reimbursement.","RTL shared that in his ~8 RCC patients (a few started off-label prior to approval and out ~5 months) he has not seen any response that would have qualified as RECIST responders, however nearly all have stabilized disease or modest shrinkage and are feeling markedly better.  States that he is perfectly comfortable with this and similar to many agents in GU landscape.  States that unless patients are feeling worse or have other 'triggers', he is starting to scan no earlier than 12-16 weeks as he would not discontinue drug based on that scan anyway.",23
completely,Territory,  AR,6.32545986622,2.70478336898e-05,26,3,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","RTL stated that as more data has come out pan tumor, he has decided that 'psudoprogression is a extremely rare occurrence and not something that 'any longer plays into his decisions making'.  He stated that in RCC, given numerous trx options, he typically won't treat beyond progression with nivo alone.  State that he has found many people with PD on nivo have a mixed response and he hesitates to completely stop nivo. Instead, if patient is fit and experiencing minimal AE, he will continue nivo while adding in his next line of therapy at a reduced dose (3L typically cabo or axitinib).  To date has not experienced any addidive/unexpected toxicity","TL is not testing for PDL1 in bladder (and has no interest in doing so) and was completely unaware of the atezo data around responses in PDL1 neg vs. positive patients.  Reviewed our 275 data and TL stated that he like the fact that responses more consistent across all patients regardless of PDL1.  Stated that once approved, could see himself 'preferring' nivo over atezo due to thins, even though he believe all class agents are essentially the same.",29
testing for PDL1,Territory,  AR,6.13377926421,2.95808453161e-06,39,575,"3 RCC TLs from distinct institutions (small academic, large academic/VA and community practice) state that they have never tested for PDL1 in RCC and see absolutely no value in it as the data has clearly shown no predictive benefit (note that some of the same TLs do routinely perform PDL1 testing in lung).  Multiple TLs also stated that they don't even typically run NGS-type panels in RCC patients (even though they may in other tumor types) as they rarely see any actionable mutations in these patients.","RTL at NCCN institution stated that he sees no value in testing for PDL1 in the rec/met setting.  Stated that he feels story in HN will be the same as in NSCLC... when aPD1 moves into initial treatment/pre-platinum setting, that patient selection by PDL1 will be necessary.  

He states that they 'try' to perform HPV testing, but it is not a reflex test, and rarely occurs outside of oropharyngeal.","LTL in large community practice has not yet used ipi/nivo combination and would reserve for only a young, fit, patient who was PDL1 negative. Otherwise would start with single agent PD-1 (preference for nivo due to familiarity, but feels that pembro is equivalent)  TL does not test for PDL1 in NSCLC and does not value test in that setting, but based on 067 PFS, 069 OS w/ crossover, and due to tox concerns with ipi believes that single agents probably have the best balance of tox and efficacy based on data right now and would reserve combo for PDL1neg.",614
Ipi+Nivo,Territory,  AR,5.39349555991,1.02812140956e-06,45,338,"Community Pan-tumor TL at research focused site states that while the he is convinced that the efficacy is worth it, that managing toxicity for ipi+nivo in melanoma is ""high maintenance"".  Between him and one other partner (the two that see most of the melanomas), they have treated about 6 patients, and have ended up having to hospitaized a majority of those patients due to GI toxicity.  However they state that the toxicities resolved well with steroids or infliximab and that the majority of these patients have had profound responses.  He stated that he struggles with whether to put these patients back on nivo monotherapy, and has not to date based on the durability off trx in 069 and 067, but he sometimes feels very nervous ""not doing anything more""","GU/melanoma RTL stated that in a few patients that he has treated with Nivo monotherapy he has seen dramatic and near complete responses in all but one isolated lesion/LN/brain met that is resistant to treatment.  He has been successful treating lesion with RT or surgery, effectively transforming patients to CR's.  He has not seen this phenomenon with ipi+nivo yet, so is wondering if the CR rate for nivo monotherapy is functionally under reported due to strict RECIST criteria.","Community Pan-tumor TL shared that he is almost universally treating his 2L RCC patients with nivolumab.  He stated that while he has seen mostly SD and only one or two PRs, that that the disease seems to be ""well controlled"" and the ""safety and QOL"" trumps using another TKI.  Stated that he is however, excited for some ""better"" TKI to be approved in 1L (ie cabozatanib).  When reactively discussed, was very impressed with 016 ipi+nivo 1L data and happy to see that the N3+I1 dose was chosen base on safety",383
PTCL,Territory,  ATION/ ISRS,828.818181818,3.06165550408e-07,3,139,"TL interested in doing a PTCL using CHOEP frontline f/b Nivo, in all PTCL patients not just CD30+.","TL interested in doing a PTCL using CHOEP frontline f/b Nivo, in all PTCL patients not just CD30+.",RTL noted that Merck has approached her regarding a PTCL/Testicular lymphoma trial using pembrolizumab.,142
Numerous TLs,Territory,  AZ,150.612244898,2.30896330214e-07,6,253,"Numerous TLs expressed maintains a rigid threshold for pembro use 1L to only those with >50% PDL1 expression. With them stating the reasoning is the current science and that you ""don't want to burn a therapeutic bridge by using an IO in the wrong setting (using in the wrong PDL1 population in 1L when all comers can derive benefit from 2L).","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.","TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",259
tone,Territory,  AZ,120.489795918,5.71517363505e-06,4,0,"With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",4
restriction,Territory,  AZ,40.1632653061,3.78817068623e-05,6,16,"TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",Many community TLs aware of Pembro 1L press release and asking about Nivo data in the 1L NSCLC. When review -026 trial design many express surprise that Nivo had a PdL1 restriction in the trial design. They then emphasize the problems with pdl1 testing and why they like Nivo in 2L is because it is unrestricted. State the main differentiating factor in 1L given both Nivo and pembro will require testing is which company makes the testing process easier/faster/more understandable.,"Many community TLs are supportive of the biomarker label restriction for Merck because it provides clear direction for using IO, otherwise ""there is no clear guidelines on the use of PDL1 expression as a biomarker of response"" which leaves too much room for interpretation/confusion and inconsistent clinical practice.",22
AE profile,Territory,  AZ,26.3571428571,2.33009374538e-07,14,338,"In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",Several NTLs/RTLs have commented that there is significant hesitancy to incorporate Ipi into treatment in RCC (either bad previous experience with Ipi from melanoma or prostate or heard about the combination from melanoma colleagues). When discuss the different dosing of Nivo+Ipi in RCC vs melanoma they become a little more supportive. State the key deciding factor between Ipi+Nivo and Cabo in the 1L will not be efficacy rather it will be the safety profiles and the QoL data.,TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,352
comers,Territory,  AZ,22.5918367347,1.12153840548e-08,20,0,"TLs state the OAK data is intriguing in that the agent works in the all comer population, has apparent efficacy in the PDL1 non-expressing population, has q3w convenience, and a highly tolerable safety profile. When questioned about how to choose between agents in the 2L the TLs in general still feel that atezo is a ""me too"" drug and that nivo has such broad indications across tumor types with proven efficacy and support for many others that there is an established loyalty to nivo. Hence, the TLs predict varied physician preference (""choose one or the other and neither are wrong"") in the 2L.",TLs with close Roche relationships have all stated the indication for atezolizumab will be in an all comer 2L NSCLC population (not restricted by PDL1).,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",20
q3wk,Territory,  AZ,20.0816326531,5.16036658931e-06,14,425,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.",TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,439
TLs,Territory,  AZ,17.4710204082,1.09087264566e-21,98,6,"Numerous community TLs all had high level knowledge of -026 not meeting primary endpoint and KN -024 having very positive data. When I described the differences in trial design the TLs seemed very satisfied about why the outcomes were divergent and did not see the data as impacting 2L treatment choices. However, did state that when Pembro is indicated in 1L PDL1 testing will become a standard practice - which is not what is occurring today.","NTLs and local TLs agree that pembro will not be the ""end of the story for 1L, with significant potential of Ipi/Nivo to affect a broader patient population."" However these TLs caution that there is a significant safety concern that has to be overcome with the combination (especially for the community).","Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.",104
established,Territory,  AZ,15.0612244898,1.75138203282e-05,17,0,"NTL regards PD1/PDL1 inhibitors as the same and regards the lack of testing as a significant advantage for Nivo. When thinking about 1L NSCLC TL believes PDL1 testing will be required across all agents, hence the differentiating factor will be the agent with the most diagnostic support to help practitioners establish SOPs for ordering and understanding the PDL1 diagnostic.","TL was very upset that BMS had ""such a stupid trial design for 1L NSCLC."" Specifically pointing out the PFS endpoint and treatment arm imbalances.  In addition, TL was upset that they are now forced to test for PD-L1 status even though the assays are complicated and not fully established. When asked about testing the TL stated they solely leave the process to the pathologists stating they call the pathologist and say ""I want to use pembro in 1L test PDL1."" Further TL was upset because does not want to be in a position to decide on treatment if less than 50% but close to the threshold (e.g 45-50%, below 45 they were very clear they would choose chemo). Nivo was still regarded as the agent of choice for 2L.","TL applauded BMS for its scientific integrity and rigor. However, given the 1L data states that Merck applied a smart strategy with their approach. Specifically stating that using the PDL1 biomarker in a restricted population proved the utility of the biomarker and established its utility to select for patient's with maximal benefit. The approach is one that many physicians feel very good about because they feel their treatment has a higher likelihood of impact and that they are using the agent in an appropriate patient. In addition, payers like the approach because of the clear value in these patients. Hence, Merck has generated a more clear and useful message regarding the use of IO, compared with the the more muddled/confusing idea of using IO in an all comer population for mixed efficacy/value results.",17
IO-IO,Territory,  AZ,14.0571428571,4.98722777625e-06,21,757,TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.","In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",778
highly,Territory,  AZ,12.3228200371,5.58937023641e-07,30,34,"Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.","In regards to -026, thinks if the data is equivalent to chemo then it will still be practice changing based on AE profile. Highly excited for IO in front line and would prefer not to have to test for PDL1.","TL summarized how he is communicating testing and clinical implications in NSCLC that has resonated well with community HCPs: ""Focus on Merck's assay for testing given pembro's 1L lung indication but realize that using Merck's test does not exclude other therapies (e.g. Nivo) for 2L."" The TL then expands ""In fact projects like Blueprint and NCCN specifically support the idea that the Merck assay and the BMS assay are highly alike so the assay you use only matters if you are thinking about Atezo.""",64
key,Territory,  AZ,8.03265306122,3.07250970583e-05,37,0,"Per NTL a large question in bladder field is how the geriatric oncology patients will respond to IO. Hence increased data on efficacy, safety, and QoL in that specific population will be a key differentiator between agents.","Mixed TL opinions regarding IO+Chemo, some are excited about the potential to overcome PDL1 and the ORR, others feel the strategy is a ""shame"" as it does not seem to provide added efficacy and more toxicity. All TLs have applauded BMS forthe -227 trial design as addressing the key IO+Chemo or IO+IO question.","NTL who does not believe in PDL1 testing in 2L NSCLC, stated that the key impact from -026 is the renewed emphasis on PDL1 as a biomarker. While the data is unknown the -026 and KN-024 press releases leads one to assume that there will be a specific threshold of PDL1 expression that adequately identifies a population that derives clinical benefit from checkpoint inhibition. The consequence will be 1L PDL1 expression level will be used for treatment decisions, in 2L the expression level may start being used for clinical decisions to ensure economic justification.",37
PDL1 status,Territory,  AZ,7.5306122449,4.54231119634e-05,39,874,TL stated he was testing all patients for PD-L1 and using Opdivo if patients were 2L+ and high PDL1 expressors in non-indicated disease states. Only using expression for treatment decisions in 1L lung (not 2L or SCCHN or Mel or RCC). Inquired about testing time and TL stated they have an agreement with Caris where the PDL1 status is expeditidly  reported within 3 days and the rest of the genomic panel is then reported later.,Complete change in perception regarding PDL1 testing in NSCLC over last year - went from believing needed to test patients based on MOA and cost rationale to using clinical experience determine that PDL1 status is unnecessary for treatment decisions (had patients respond who were PDL1 non expressors). Now only tests when planning on using Opdivo in a non-indicated disease states.,"Does not feel that PDL1 status should be used to make treatment decisions with Opdivo, hence is looking toward novel Biomarkers. Heard that Foundation One will be releasing data at ASCO that reports a tumor mutational index score and how that score correlates with response to checkpoint inhibitors. Believes the score will start being reported by Foundation One in addition to their current mutation panel.",913
SOC,Territory,  AZ,6.76218242399,4.78973069153e-06,69,492,"NCCN panelist expects Cabo to be SOC in 1L with Nivo remaining SOC in 2L with lenvantinib/Everolimus or axitinib in 3L. The TL is highly skeptical of Ipi/Nivo adoption in 1L mostly due to ""bad Ipi experiences in melanoma and prostate"" (a theme that has been echoed by several GU TLs with Ipi experience in prostate). However, willing to change opinion if the HR significantly outperforms sunitinib, has an AE profile similar to Nivo monotherapy, and good QoL outcomes.","All GU treating TLs at academic cancer center (including RCC NCCN panelist) met to develop institutional RCC treatment algorithm (so practice decisions are standardized across all providers). Evaluated all RCC asco data. For 2L have decided to keep Nivo as SOC (even though the cabo and lenvantinib is good, all would prefer to give a patient an IO agent sooner than later). 
There were key populations that were discussed as exceptions: 
1) bone met population (initially were thinking cabo but as increasing Nivo data in that population have decided Nivo in that group) 
2) Those with autoimmune disease will most likely receive a TKI, until additional data with Nivo
3) Those with non-clear cell histology will be decided in a case by case, sarcomatoid will most likely get Nivo but others are debated until -374 data is available.","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",561
specifically,Territory,  AZ,6.45481049563,4.48180875897e-05,50,48,"During a talk on IO in SCLC the TL stated from the podium ""the data for IO in SCLC is small but apparently big enough to get in the NCCN guidelines...controversially and surprisingly."" I discussed the statement with the TL after the presentation and the TL has no concerns with the inclusion of Nivo but has significant concerns about Ipi. Specifically, the TL does think the combination has added efficacy however they are greatly concerned with the AE profile and that there were 3 deaths on trial...to the TL the AE profile warrants a larger trial before being able to be used as a treatment option.","Several TLs have mentioned they are concerned about Nivo in SCCHN due to the length of time for indication. Specifically, these TLs were under the impression KN -012 and checkmate -141 were similar trial designs and were confused how Merck had already received the indication, hence they started questioning the integrity of -141... After review of the trial designs and a reminder of the -141 data the concerns appeared alleviated.","TL generally regards PD1s/PDL1s as the same but is beginning to doubt that perception and has expressed ""concern"" for Nivo. Specifically with durvalumab recently announcing they will not be pursuing a monotherapy indication based on lack of efficacy in NSCLC and Nivo not showing an efficacy difference in CM026 in the >50% population there may true differences in agents with the benefit of doubt leaning toward pembro.",98
regards,Territory,  AZ,5.33418367347,3.57310354323e-07,112,0,"In regards to nccRCC the NCCN panelist stated there will. It be any updates to the guidelines until there is evidence for use in that population because of the transition of the panel to emphasizing evidence blocks. Panelist specifically stated ""everyone should receive Nivo in principle but there is just no evidence to support it in nccRCC.""","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",112
increase,Territory,  AZ,4.91795085381,1.89325708214e-06,113,36,"Increasing concern among community physicians around infusion chair time. With the continual Nivo dosing and the increased OS in patients, several community clinics are struggling to manage the increased demand. Numerous community HCPs emphasized a need for shorter infusion times and a more robust effort in studying when to stop IO therapy (especially if a patient had a PR/CR). These physicians are now considering switching to keytruda in NSCLC because of the q3wk 30min infusion convenience.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.",149
indication,Territory,  AZ,4.50105559465,3.45338836194e-05,99,0,"Several TLs have mentioned they are concerned about Nivo in SCCHN due to the length of time for indication. Specifically, these TLs were under the impression KN -012 and checkmate -141 were similar trial designs and were confused how Merck had already received the indication, hence they started questioning the integrity of -141... After review of the trial designs and a reminder of the -141 data the concerns appeared alleviated.","When discussing SCCHN, the TL stated they were surprised by the news of the FDA indication as they have been using Nivo for that population since Spring with no push back from payers and thought it was already indicated.","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.",99
population,Territory,  AZ,4.11745705476,2.5921857908e-06,222,248,"NTL who does not believe in PDL1 testing in 2L NSCLC, stated that the key impact from -026 is the renewed emphasis on PDL1 as a biomarker. While the data is unknown the -026 and KN-024 press releases leads one to assume that there will be a specific threshold of PDL1 expression that adequately identifies a population that derives clinical benefit from checkpoint inhibition. The consequence will be 1L PDL1 expression level will be used for treatment decisions, in 2L the expression level may start being used for clinical decisions to ensure economic justification.","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","TL generally regards PD1s/PDL1s as the same but is beginning to doubt that perception and has expressed ""concern"" for Nivo. Specifically with durvalumab recently announcing they will not be pursuing a monotherapy indication based on lack of efficacy in NSCLC and Nivo not showing an efficacy difference in CM026 in the >50% population there may true differences in agents with the benefit of doubt leaning toward pembro.",470
IO,Territory,  AZ,4.00228343085,3.72958033311e-06,242,52,"TLs very split about the role of IO+Chemo in 1L. Some find the atezo and pembro plus chemo data highly impressive others consider it a ""waste"" with added toxicity for minimal benefit.",TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.",294
1L,Territory,  AZ,2.98510755654,4.62670024205e-05,288,292,"NCCN panelist expects Cabo to be SOC in 1L with Nivo remaining SOC in 2L with lenvantinib/Everolimus or axitinib in 3L. The TL is highly skeptical of Ipi/Nivo adoption in 1L mostly due to ""bad Ipi experiences in melanoma and prostate"" (a theme that has been echoed by several GU TLs with Ipi experience in prostate). However, willing to change opinion if the HR significantly outperforms sunitinib, has an AE profile similar to Nivo monotherapy, and good QoL outcomes.",TLs still do not like the PDL1 assay and find the landscape confusing...however all agree that with KN-024 the Merck assay will become SOC for testing in 1L. These TLs then say those patients with >50% will receive pembro and everyone else will receive chemo. Nivo is still regarded as SOC in 2L for those progressing on chemo.,"Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",580
Numerous TLs,Territory,  CO,92.1337579618,2.26614051678e-06,6,253,"Numerous TLs expressed maintains a rigid threshold for pembro use 1L to only those with >50% PDL1 expression. With them stating the reasoning is the current science and that you ""don't want to burn a therapeutic bridge by using an IO in the wrong setting (using in the wrong PDL1 population in 1L when all comers can derive benefit from 2L).","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.","TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",259
tone,Territory,  CO,73.7070063694,3.56879451564e-05,4,0,"With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",4
AE profile,Territory,  CO,16.1234076433,4.95035004207e-06,14,338,"In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",Several NTLs/RTLs have commented that there is significant hesitancy to incorporate Ipi into treatment in RCC (either bad previous experience with Ipi from melanoma or prostate or heard about the combination from melanoma colleagues). When discuss the different dosing of Nivo+Ipi in RCC vs melanoma they become a little more supportive. State the key deciding factor between Ipi+Nivo and Cabo in the 1L will not be efficacy rather it will be the safety profiles and the QoL data.,TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,352
like to see a trial,Territory,  CO,14.3319179052,8.38876001969e-06,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
comers,Territory,  CO,13.8200636943,5.33369979659e-07,20,0,"TLs state the OAK data is intriguing in that the agent works in the all comer population, has apparent efficacy in the PDL1 non-expressing population, has q3w convenience, and a highly tolerable safety profile. When questioned about how to choose between agents in the 2L the TLs in general still feel that atezo is a ""me too"" drug and that nivo has such broad indications across tumor types with proven efficacy and support for many others that there is an established loyalty to nivo. Hence, the TLs predict varied physician preference (""choose one or the other and neither are wrong"") in the 2L.",TLs with close Roche relationships have all stated the indication for atezolizumab will be in an all comer 2L NSCLC population (not restricted by PDL1).,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",20
TLs,Territory,  CO,10.6875159236,8.51656137261e-17,98,6,"Numerous community TLs all had high level knowledge of -026 not meeting primary endpoint and KN -024 having very positive data. When I described the differences in trial design the TLs seemed very satisfied about why the outcomes were divergent and did not see the data as impacting 2L treatment choices. However, did state that when Pembro is indicated in 1L PDL1 testing will become a standard practice - which is not what is occurring today.","NTLs and local TLs agree that pembro will not be the ""end of the story for 1L, with significant potential of Ipi/Nivo to affect a broader patient population."" However these TLs caution that there is a significant safety concern that has to be overcome with the combination (especially for the community).","Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.",104
highly,Territory,  CO,7.53821656051,2.22668016024e-05,30,34,"Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.","In regards to -026, thinks if the data is equivalent to chemo then it will still be practice changing based on AE profile. Highly excited for IO in front line and would prefer not to have to test for PDL1.","TL summarized how he is communicating testing and clinical implications in NSCLC that has resonated well with community HCPs: ""Focus on Merck's assay for testing given pembro's 1L lung indication but realize that using Merck's test does not exclude other therapies (e.g. Nivo) for 2L."" The TL then expands ""In fact projects like Blueprint and NCCN specifically support the idea that the Merck assay and the BMS assay are highly alike so the assay you use only matters if you are thinking about Atezo.""",64
regards,Territory,  CO,3.72455617292,9.48558215294e-06,112,0,"In regards to nccRCC the NCCN panelist stated there will. It be any updates to the guidelines until there is evidence for use in that population because of the transition of the panel to emphasizing evidence blocks. Panelist specifically stated ""everyone should receive Nivo in principle but there is just no evidence to support it in nccRCC.""","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",112
IO,Territory,  CO,3.20465245084,7.56281361351e-06,242,52,"TLs very split about the role of IO+Chemo in 1L. Some find the atezo and pembro plus chemo data highly impressive others consider it a ""waste"" with added toxicity for minimal benefit.",TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.",294
Path TL,Territory,  CT,232.063492063,2.29484191042e-13,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
southeast region,Territory,  CT,162.444444444,1.94657730425e-09,7,169,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
cHD,Territory,  CT,139.238095238,3.91920251403e-08,6,318,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,RTL perspective for cHD is the bar for deferring transplant is a durable PFS at 2 years then can consider the treatment instead of transplant.,324
gathered the following unsolicited,Territory,  CT,139.238095238,3.91920251403e-08,6,175,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",181
Ritchie,Territory,  CT,139.238095238,3.91920251403e-08,6,170,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
Path,Territory,  CT,92.8253968254,4.60569666798e-10,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
NCI-designated,Territory,  CT,81.2222222222,8.42404649313e-09,8,157,"Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).",165
Joseph,Territory,  CT,69.619047619,1.50928368649e-07,7,170,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",177
1st line NSCLC,Territory,  CT,23.2063492063,6.60982188165e-07,17,26,"A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).","A LTL in Boston stated that based on all the data coming out around 1st line NSCLC, they should be testing all pts for PD-L1 status.  However, he added that ""he has requested testing on 15 or so samples (1st line pts) and all of them have come back negative"".",43
evolving,Territory,  CT,19.3386243386,4.99610710343e-05,10,77,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",87
reflex testing,Territory,  CT,19.3386243386,4.99610710343e-05,11,91,Path TL stated 1-3 cases come in per day since pembro 1L approval and all are reflex tested on 22C3 IVD in-house,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",102
comparable,Territory,  CT,17.4047619048,1.29014000129e-05,13,498,"A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen",511
score,Territory,  CT,13.2607709751,2.03075797135e-06,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
Boston,Territory,  CT,10.8296296296,2.40994694678e-05,40,82,"A Melanoma NTL from Boston, stated that ""there is no value in doing PD-L1 testing in melanoma pts.""  He added that ""I don't test any of my pts""","A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",122
pathologist,Territory,  CT,10.1527777778,5.41824222436e-09,45,211,"NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN panelist (medical oncologist) at an NCI-designated cancer center in NYC
-Believes that the term ?value? is currently more of a talking point than something actionable. However, in light of -024 and -026, he sees ?value? as defining a population and not just giving expensive drugs to every patient that walks through the door.
-Also believes ORR is crucial and may even be the most important of endpoints to any conversation around value
-PD-L1 testing is as big a change as there has been in a long time when it comes to directing decision-making in oncology. If pathologists aren?t testing regularly for PD-L1, it is the duty of the medical oncologists to speak with their pathologists to better educate them (because pathologists aren?t reading the most recent oncology literature).
-However, this panelist said that he wouldn?t necessarily send a patient back in for a biopsy if not enough tissue was available or testing was indeterminate in 1L setting.",256
22C3,Territory,  CT,7.25198412698,8.58888217309e-06,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
order,Territory,  CT,5.95034595035,3.61173195204e-05,55,550,"Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone","A LTL is requesting PD-L1 testing for all 1st line NSCLC pts.  She shared that she is having a difficult time figuring out what test to order and ""its very confusing"".","A Lung RTL shared that he has ""ordered merck's PD-L1 test multiple times"" as part of his routine biomarker test prior to 1st line platinum doublet treatment, and ""it has come back negative every single time"". He inquired further around ""does PD-L1 levels go up after Pt resistance?""",605
1st line,Territory,  CT,5.92502532928,6.75255075917e-06,69,712,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","A RTL for Lung shared that he was surprised to hear that CM26 was negative. He is looking forward to seeing the subgroup analysis based on other PD-L1 cut offs, but he added that this increases the need to do PD-L1 testing in all 1st line NSCLC pts. He also suggested the need to choose PD-1 agents in the 2nd line settting based on PD-L1 results.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",781
pts,Territory,  CT,5.80158730159,7.73320270184e-13,164,1624,"An RTL shared that when a pts runs into toxicity with Nivo/Ipi combo, if the pts has a CR or PR at that time, then they stop treatment.  However, at the time of toxicity with the combo, if the pt only has SD or PD, then they continue PD-1 monotherapy.  The added that about 1 out of 4 times they continue with Pembro as oppose to Nivo.","A NTL in melanoma shared that combination IO therapy (mostly regimen) is their primary method of treatment all melanoma pts at their institution.  Even if the pts has bully, BRAF+ melanoma, because of the rapid RR scene with Nivo/Ipi, they would choose Nivo/Ipi over BRAF+MEK combo.",A RTL stated that he does not test PD-L1 for his RCC pts.,1788
PD-L1,Territory,  CT,5.46031746032,9.68967254702e-11,306,375,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",681
corticosteroids,Territory,  DE,20.4173913043,1.66351290787e-07,17,260,"Community HCP holding treatment versus initiating corticosteroids to manage IMARs.  An APN from practice was present at our dinner program.  Discussion around MOA, half life of drug and incidence of IMARs off treatment.  HCP thought is ""drug will leave system"" and IMAR should resolve.",PCP in a community practice does not test for PD-L1 to make treatment decisions.  He uses OPDIVO on and off label. Discussion around using low dose corticosteroids to manage fatigue and continue to treat.  Advised NOT to use as such unless he has treated an IMAR and is tapering.  We had discussion around masking symptoms of potential IMAR and efficacy in absence of IMAR.  Reviewed IMAR guide and algorithm.,"Continued hesitancy of community HCPs in utilizing high dose corticosteroids in managing IMARs.  In some of these practices, nurse are well aware of benefits and efficacy in treating IMARs with corticosteroids.  Physicians do not have comfort using high dose, thus reporting inability to taper corticosteroids in some cases.",277
thought leader,Territory,  DE,13.5115089514,3.68481538393e-07,25,22,Thought leader in a major institution treating patient with PEMBRO vs OPDIVO due to travel inconvenience for patient.,Community thought leader reporting that our competitor MERCK is offering 100% guaranteed coverage for their product on all off label use.  Thought leader continues to use OPDIVO for his patients because no testing required.,Thought leaders in a major institute having concerns using regimen in patients with comorbid conditions and/or older age.,47
National TL,Territory,  DE,9.75831202046,2.37504859757e-08,51,544,National TL who sits on advisory board for T-vec expressed that there has not been a concept presented for T-vec + regimen. He has been unofficially encouraged to do so.,National TL and NCCN panel member is concerned about the combination of nivo/ipi in the community settings. He feels that there is a general lack of knowledge in how to manage IMAEs in the community and not all of these docs are currently treating melanoma patients,National TL and NCCN panel member explained that he has had very high rate of PDL1 screen failures during an 1L atezo lung study. He struggles to find PDL1+ patients and wonders if there is a geographical relation. Is there higher rates of PDL1 positivity in the tobacco belt? He has turned down Merck studies with PDL1 >50% cut off because he seldom finds a patient with that high of expression.,595
competitor,Territory,  DE,7.85284280936,3.86833847018e-05,33,0,"Patient was a close college colleague/friend of competitor Pharma, thus use of competitor PD-1 inhibitor.","In a large community practice, patient influenced use of competitor product because knows Merck employee.","Questions around competitor data in First-line Pembro KN 024, why such a positive trial versus CM 026.  Discussed trial design of 026 was not stratified according to PDL-1 testing.  Referred to trial CM 0227 with 3 arm study.  Concerns around testing.",33
major,Territory,  DE,7.54051383399,2.79681234264e-07,90,483,A major academic institute utilizing Regimen as standard of care in melanoma,NP at academic practice says that the number one major complaint that she is receiving from patients is a radiated arthralgia,Thought leaders in a major institute having concerns using regimen in patients with comorbid conditions and/or older age.,573
PDL-1,Territory,  DE,7.4095371669,1.92550941113e-05,50,881,"?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians",Questions around PDL-1 testing.  Currently not testing in 2nd line.  Considering testing all patients since negative trial of CM 026.  Discussed questions around appropriate assay not yet determined.  Discussed data from trials CM 057 and 017.  Patients respond regardless of testing and Duration of response achieved in negative expressors versus chemotherapy.,"Thought leader in major institution treating PDL-1 negative patients with OPDIVO, PDL-1 positive patients with PEMBRO or may consider clinical trial.",931
Regional TL,Territory,  DE,6.92114959469,3.8059592402e-08,100,1088,Regional TL who treats GU patients says he is participating in a CTEP study exploring cabo+nivo+ipi in prostate cancer and they is seeing great results.,"Regional TL who treats GU patients says that of all the departments they feel the least need for PDL1 testing. However, because of the recent 1st line lung indication with an IO agent requiring testing their institution is now working on doing an in house test. he doesn't feel like he will use it",Regional TL who treats GU patients says that he has treated double digits worth of patients with cabo and only one person has been able to tolerate the 60mg indicated dose. he starts patients at 20mg and then tried to increase as their tolerability allows.,1188
reported,Territory,  DE,3.33617504973,2.26364733629e-05,182,10,"TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",192
auto,Territory,  FL,45.7575757576,5.75739539325e-07,15,204,"HCP at large institutional practice in S FL reports he has one patient to begin opdivo for cHL. 
Pt is s/p auto, s/p auto BV and s/p MRD allo transplant (approx 1 year ago).","RTL at community transplant center reported has one patient on opdivo for cHL who relapsed (post auto, post auto BV and post mismatched allo transplant). Currently receiving opdivo. Has received 2 doses. Reported ""watching patient like a hawk"". Patient did not have a history of GVH.",RTL at academic center has pt on nivo for HL. Dialysis pt so intent was to be able to take off dialysis. MRD caused the nephritis resulting in dialysis. Increased Cr so had to stop Nivo and give steroids. Did short taper and restarted Nivo but Cr increased again. Explained needing longer taper so IMAR could resolve and not re-occur.  He has 6 HL pts now on ABVD. No issues with Bleo shortage. He has an ISR Pembro/ICE then Auto.,219
pt,Territory,  FL,17.3563218391,6.24614534693e-09,67,23,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.",Community HCP has pt on Genentech's PDL-1 for bladder ca with no response.,Largest Community Practice in state: Community TL stated no use of opdivo in HL yet. Has a pt progressing on BV so opdivo will be next step.,90
reported,Territory,  FL,8.17916666667,1.74819546216e-07,182,10,RTL and transplanter at large community center reports treating one cHL patient post allo (mismatched unrelated donor) with nivolumab. Reports patient has received 4 cycles and is doing well (without any s/s GVHD).,"RTL at large academic center in Ga reports using Nivo off label for several different refractory/relapsed heme malignancies including AML, lymphoma, etc. Reports no issues with infusion reactions.",LTL heme only focused reports has utitilized nivo prior to approval and after approval for cHL. Reports has seen pr more than cr.,192
regional TL shared,Territory,  GA,12.2658517953,2.93774704786e-07,18,18,A regional TL shared with me that he is now doing PDL1 testing in his firstline NSCLC patients because of the KN-24 approval.  He acknowledged that most patients will not be over 50% positive and confirmed that Nivo will still be SOC for those patients 2nd line.,A regional TL shared that he has had no problems getting insurance to approve off-label 1L usage of Nivo monotherapy in RCC.  He said that he has seen durable responses approaching 2 years.,"A regional TL shared with me that he believes hypophysitis is exclusive to Ipi rather than Nivo.  He hypothesizes that Ipi cross-reacts with common proto-antigens shared between melanosomes and the pituitary as both originate from a common cell lineage in the neural crest.  He does not think that Nivo recognizes that common antigen, hence the higher incidence of primary thyroiditis with that drug.",36
anti-PD1,Territory,  GA,6.13292589763,2.45344924209e-07,38,55,"A national TL mentioned that he has treated ~8 GBM pts with Nivo and saw ?only a couple responders.? ?Nivo or Pembro monotherapy is not going to be the answer.?
Same TL said he was skeptical of the efficacy of anti-PD1 plus radiation. He said that he thinks PD1 plus another checkpoint inhibitor is going to be key, saying that he has not given up on Nivo plus Ipi.",Melanoma TL believes HLA-DR may be a better biomarker for use as a patient selection marker in utilization of anti-PD1 therapies,"A TL shared that he felt we are overtreating patients with anti-PD1 therapy. He believes chronic PD1 blockade encourages resistance and we need to identify the optimal induction schedule to ""let the immune system kick in and get out of the way""",93
TL told,Territory,  GA,5.91071843757,1.71588742491e-07,65,938,A SCCHN TL told me that his site participated in the AZN Durvalumab+Tremelimumab 1st line H&N trial that had a recent clinical hold for bleeding.  The TL confirmed the hold was lifted and that the adverse event was not due to the treatment but most likely a result of the nature of the disease and its proximity to significant amounts of vasculature.  The TL stated he had enrolled 4 patients on trial and none had any issues with bleeding,A SCCHN TL told me that he hasn't seen any data that makes him think testing for PD-L1 testing is necessary for his H&N patients.  This TL also treat Lung and has recently begun asking for the results on all new patients he sees,"A large regional GU TL told me that his order of using agents for metastatic RCC is first pazopanib, 2nd line nivolumab, 3rd line cabo, 4th line axitinib, and 5th line levantinib.",1003
TL shared,Territory,  GA,4.45204991087,2.29858194191e-08,119,1081,Academic RCC TL shared that he would consider cabozatinib over nivolumab in a patient with bone mets based on METEOR data presented at ASCO with the caveat being that the patient must be tolerating prior TKI as the toxicity with cabo is much worse than nivolumab. If patient had a tough time with prior TKI then he would go straight to nivolumab,"A national melanoma TL shared that he has seen a few thyroids preserved with steroids using Nivo, but he never saw that with adrenal insufficiency.",Community lung TL shared pdl1 testing is now reflexive for all nsclc patients and they are working to establish pdl1 testing In house.,1200
commented,Territory,  GA,2.14652406417,3.92567586078e-05,295,327,A local TL when discussing OS data in squamous vs. non-squamous NSCLC based on PD-L1 expression commented that with a higher cut-off our 1L trial would have been positive.,"A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented that there is no difference in pembro or nivo biologically, just in the biomarker strategy.",Regional lung TL commented that he was stunned by how much of an overreaction there has been to the 026 study. He feels the vast majority of it all has been negative coverage from the media and investors who clearly don't understand how clinical research works. He said none of the investigators or any physician that's ever participated in a trial should be surprised...sometimes clinical trials fail...even with the best drugs.,622
cytology,Territory,  HI,406.0,4.4868917678e-05,4,159,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",163
volume,Territory,  HI,121.8,9.33045716196e-06,31,9,"?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",40
in-house,Territory,  HI,110.727272727,4.91640716262e-07,25,127,"Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a Regional TL in West territory that is part of a network of mid to large size community hospitals. Receives approximately 6 tests for PDL1 testing per week, most of which are 22C3, and has no plans to bring staining in-house. Does not believe pathologists are incentivized at his institution to stain slides in-house based on their reimbursement rate. Had negative views on using a 1% cutoff, stating that the company thought it was smart to have any staining be positive, but it ended up hurting them in the end.",152
score,Territory,  HI,96.1578947368,1.74548273723e-05,21,156,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",177
requests,Territory,  HI,42.0,1.67161390826e-05,61,545,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",606
RTL from a major academic institution,Territory,  IA,733.086419753,6.36120816392e-30,20,232,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
community institution,Territory,  IA,659.777777778,5.37316307233e-27,31,221,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
026 Top 300,Territory,  IA,256.580246914,1.00668811665e-10,7,245,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
large community institution,Territory,  IA,219.925925926,2.57888732363e-17,13,1371,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",1384
NOT Top 300,Territory,  IA,146.617283951,2.7355538191e-06,4,248,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
academic institution mentioned,Territory,  IA,91.6358024691,3.15376820396e-07,14,47,"[026 Top 300] NTL from a top academic institution pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients.
- At his institution, 20% exhibit mutations (e.g, EGFR, ALK, ROS1) with the remaining 80% eligible for PD-1/L1 inhibitors.  Of these, only 20-25% of those will exhibit PD-L1 50% or higher.
- This equates to more like 16-20% of NSCLC patients in the real world that would be eligible for first-line pembrolizumab.","RTL from an academic institution mentioned that that data for NSCLC patients who have ALK or ROS1 mutations is unclear for I-O therapies.  RTL is aware of trials looking at crizotinib and nivolumab, but mentioned there would be overlapping toxicities.","RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.",61
single-agent,Territory,  IA,73.3086419753,8.02207120746e-06,5,0,"RTL from a community institution mentioned that 026 was an ""unfair"" trial due to the negative press and attention she was hearing from the media.  Moreover, RTL highlighted that it's pretty clear that single-agent I-O doesn't seem to be the ""cure-all"" for all comers in first-line NSCLC.  RTL is remaining hopeful and excited for 227, especially after hearing about the positive 012 WCLC results from the press.","RTL from a community institution mentioned that the ESMO data from 026 was disappointing, but mentioned that it's clear that single-agent I-O is insufficient in the front line.  RTL was excited for 227 based on the 012 data from ASCO presented earlier in the year.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",5
KEYNOTE-024,Territory,  IA,68.0723104056,5.82175444213e-16,19,76,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.",95
opted,Territory,  IA,48.8724279835,1.82976637235e-05,6,246,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
CheckMate 227,Territory,  IA,45.8179012346,1.80375627271e-06,8,8,"RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.","HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",16
progressive,Territory,  IA,36.6543209877,3.57742355602e-05,7,245,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
second-line,Territory,  IA,36.6543209877,4.21353248491e-10,17,63,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",RTL at a major academic institution has been using nivolumab in second-line RCC with great results.  RTL is now encountering the problem of patients relapsing after progressing through nivolumab.,80
eager,Territory,  IA,30.5452674897,6.30503463835e-06,10,7,"HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""] NTL from a major academic institution expressed disappointment in 026 results from ESMO, as she was hoping for better efficacy.  NTL shared that female patients at her institution fare better than male patients, so she does agree this partly explaining higher OS with chemotherapy arm for 026.

NTL understands that it's impossible to cross-compare 026 with KEYNOTE-024.  NTL expressed little enthusiasm for pembro as not a lot of patients are at or above PD-L1 50%.  NTL is highly eager for CheckMate 227.",17
first-line,Territory,  IA,25.199845679,8.21522202045e-11,26,54,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",80
major academic institution,Territory,  IA,24.4362139918,1.79430111657e-06,34,225,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",259
top,Territory,  IA,21.9925925926,2.80056695698e-06,23,0,"RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",23
RTL mentioned,Territory,  IA,13.5042235218,5.2194270077e-06,27,0,RTL at a major academic institution has the top accrual in the US at his institution for IMvigor 010 (atezolizumab as adjuvant therapy for high risk muscle invasive disease).  RTL mentioned that patients are doing well in terms of efficacy and safety on atezo with about 40% of patients being PD-L1 positive according to the SP142 assay.,"RTL from a large community institution mentioned that he was ""surprised that the safety of PD-L1 inhibitors (i.e., avelumab) wasn't as good as PD-1 inhibitors"" in terms of reducing immune-mediated AEs (as originally thought).  RTL was actually one of the authors for the JAVELIN solid tumor trial for avelumab (anti-PD-L1) presented at ASCO.  Interestingly in that poster, RTL mentioned that there was also a 16% infusion-related reaction rate from the 1,300 patients enrolled (pan-tumor), which mandated a premed regimen of APAP and Benadryl into the protocol.","RTL from a major academic institution was not concerned that CheckMate 026 did not meet its primary endpoint.  Rationale: RTL was extremely encouraged with positive data from CheckMate 012 at ASCO on combination therapy.  RTL mentioned that PD-1 monotherapy is not likely to work as you would need something ""harder hitting"" such as nivo + ipi in the front-line setting.",27
Checkmate,Territory,  IA,9.70261437908,2.50109647261e-06,87,792,"[026 Top 300]  HCP from a community institution mentioned that he is still going to use nivo as he and his staff are extremely comfortable with the safety profile of nivo.

Discussed CheckMate 017 and 057 as well as KEYNOTE-010 reactively as it was evident he was getting nivo, pembro, and atezo mixed up.  When reactively discussing the Blueprint project and OS data, it became clear to him that he would choose nivo based on the efficacy and safety vs. the convenience factor of q3 weeks of pembro/atezo.","RTL from a large community practice questioned the difference between all the assays available and if there's any correlation between all 4.  Reactively presented the FDA blueprint project from AACR.  From here, RTL asked about OS data from both KN-010 and CheckMate 057.  RTL was surprised by the higher OS from nivo when compared at the 1% level.","RTL who's actually a lung speaker for both Merck and BMS let me know he tests for PD-L1 occasionally.  In those who are PD-L1 expressors, he uses pembrolizumab, but those who are negative, he uses nivolumab.  Reactively discussed data from Keynote 010 on OS data stratified by PD-L1 status as well as data from OS on 057 stratified by PD-L1 status.

RTL was shocked to hear the longer OS data with nivolumab at the 1% level compared to pembro.  He further mentioned that even though the Merck rep is his long-time friend, this OS data is important for him and his care for patients.",879
PD-L1 expression,Territory,  IA,9.16358024691,1.07409703785e-07,72,703,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",775
I-O,Territory,  IA,8.0460704607,9.22833116879e-06,60,0,"RTL from a major academic institution was excited for nivo in SCCHN.  However, for those patients who progress on or after I-O therapy, RTL suggested perhaps liri +/- nivo may be something of interest to investigate.","RTL from an academic institution mentioned that that data for NSCLC patients who have ALK or ROS1 mutations is unclear for I-O therapies.  RTL is aware of trials looking at crizotinib and nivolumab, but mentioned there would be overlapping toxicities.","RTL from a major academic institution prefers to use platinum-based therapy up front in rec/met setting, then cetuximab in platinum refractory patients.

RTL said that she?s not a big fan of the EXTREME regimen, but would not hesitate to open up an I-O study with EXTREME as a comparator arm.

RTL was very impressed with CheckMate 141 post-AACR and post-ASCO.  She's eagerly anticipating the approval for Opdivo in SCCHN.",60
NW territory,Territory,  ID,347.86440678,5.50660117215e-19,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
ASCO'16,Territory,  ID,124.237288136,5.66705011285e-07,5,394,Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,"RTL, a NP with lots of I-O experience, stated that some physicians in their group are 'short-coursing' steroids when treating irAE's, as they are afraid steroids will negatively impact the anti-tumor T cell response.
This is a No-Access site, so there is no opportunity for me to educate those physicians.
TL said that the data from Hodi's ASCO'16 poster from CM-069 will be helpful in educating colleagues that steroid used to treat irAE's don't diminish the tumor response to Ipi+Nivo Regimen.
However, TL said that similar data for Nivo monotherapy in NSCLC would be even more impactful. The perception of irAE's on Nivo are less severe than when on Regimen. So physicians may still want to shorten the steroid treatment on Nivo monotherapy, unless they're shown that there's no reason to do so.","NP at a community hospital reported continued ""difficulty convincing some of my doctor colleagues to initiate steroids appropriately"". NP asked if we ""have a reference for anything published that demonstrates that if patients receive steroids for toxicity from immunotherapy, they don?t suffer worse outcomes?""
I reviewed the 209-069 Hodi poster from ASCO'16 and mentioned other similar analyses from prior Ipi studies. NP was very appreciative and is working to arrange a face-to-face meeting with HCPs to facilitate education on IMAR algorithms.",399
NeoGenomics,Territory,  ID,49.6949152542,2.99404493177e-07,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  ID,41.4124293785,4.93826438552e-06,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
like to see a trial,Territory,  ID,19.3258003766,1.33490987745e-06,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
Academic TL stated,Territory,  ID,17.393220339,2.18818801025e-06,16,162,"Academic TL stated he is using Nivo for all of his 2L RCC patients. ?It's a no-brainier versus Everolimus and is probably better than Cabo, due to better tolerability.?","Academic TL stated he would probably use Pembro (once approved) for 1L NSCLC that is >50% PDL1+, assuming ESMO data confirm everyone's expectations. Everyone else would receive 1L Chemo and then 2L Nivo.",Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,178
Ipi+Nivo,Territory,  ID,10.8707627119,2.46996126187e-09,45,338,"NTL predicts that, even with durable responses seen with PD1 monotherapy, eventually almost all NSCLC patients will progress.  With basically all NSCLC patients receiving PD1 monotherapy at some point in their treatment plan, there will be a huge unmet need for effective treatments post-PD1.  This NTL, who is an investigator on several studies with IO+IO combinations, voiced opinion (based on her experience) that Ipi+Nivo seems to be the only IO+IO combo that can resurrect a response in patients who have failed PD1 monotherapy.  4-1BB, anti-KIR, OX40 etc do not seem to have this activity. TL said this speaks to the ability of Ipi to prime new T cells, rather than just relieving inhibition of existing lymphocyte populations.","Melanoma RTL with lots of I/O experience (Investigator on 209-067), stated his belief that PDL1+ patients don't benefit from adding Ipi to Nivo.  He is testing for PDL1 to determine treatment choice between PD1 monotherapy and Ipi+Nivo combination. PDL1+ patients receive anti-PD1 mono therapy; PDL1neg patients receive Ipi+Nivo Regimen.","There is growing interest from my academic TLs in using Ipi to re-invigorate the T cell response in patients who progress on Nivo.  These could be patients who are on the Nivo maintenance after Ipi+Nivo regimen, or patients who only received Nivo monotherapy.

Rationale is similar as for MDX010-20 study with Ipi, except that in this case, the patient would continue to receive Nivo while adding a few doses of Ipi. TLs favor a Q6W Ipi dosing when added to Nivo.",383
medical oncologists,Territory,  ID,10.2313060818,3.0207702543e-05,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
insights,Territory,  ID,9.42489772063,3.610969978e-07,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
TL said,Territory,  ID,8.50044603033,9.10340444105e-08,86,62,"ENT/H&N surgeon is excited to add Opdivo to his arsenal of Tx options in SCCHN. TL said he would be referring several patients to the local med-onc. However, TL said his ENT office staff could use education around IMARs because patients often will call his office for advice, even after being handed off to the med-onc.  TL said patients strike up a very strong relationship with the surgeon, who is often the first physician to correctly diagnose and treat the disease.  TL requested an in-service by our IOCL (currently in training).","NTL at a large community hospital said he was previous dismissive of Ipi+Nivo for NSCLC but then saw the ""impressive"" Hellman ASCO'16 CM-012 presentation.  However, TL also said regimen may not be a slam-dunk, as KN-021 Pembro+Carbo+Pem data seem equally as impressive as CM-012 regimen data.","I met recently with an RTL and Opdivo Melanoma/NSCLC speaker, who is aware of CA209-384 (although is not participating in that study) and asked if we have addressed the same question in melanoma patients. 
TL stated he would consider stopping treatment for patients who show a CR or near-CR. 
In his opinion, the question 'when can we stop treatment with I/O agents' is interesting in lung but sadly not relevant for most patients due to the low CR rate.  
However, TL said that it's a very relevant question in melanoma, where the Ipi/Nivo combo is producing a higher frequency of CRs.",148
pathologist,Territory,  ID,6.90207156309,1.17810900981e-05,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
TL,Territory,  ID,2.91923682504,8.61972953493e-08,1157,51,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",1208
large academic center stated,Territory,  IN,72.05,6.13271692434e-22,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center stated that they will be opening up a Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission.  She anticipates this will answer a good clinical question.,NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,372
Lung RTL shared,Territory,  IN,28.5912698413,2.00927524028e-09,15,59,Lung RTL shared that BMS will have an uphill climb trying to convince physicians how to use the regimen if CM-227 is positive.  He feels that physicians are scared off by the noise Ipi is creating in the adjuvant melanoma setting.  He commented that lung treaters at the institution level are asking their melanoma colleagues for guidance on how to manage toxicities with IO agents and if they haven't had positive experiences with Ipi then the rest of the treaters at the institution will have a skewed view of the drug.,Lung RTL shared that BMS better hope FDA doesn't add the KN-010 data to Pembro's data using the 1% cut-off.  He thinks that if that happens it will be simply a two way race between Merck and Roche because both agents are Q3W.,"Lung RTL shared that starting in September tumor mutation burden score will be available through Foundation One testing.  Scores will be stratified based on low, intermediate, and high.",74
midwest,Territory,  IN,16.0825892857,2.99490092483e-11,42,124,AI at University Center in midwest (former NCCN panelist) shared at her institution for new Dx lung CA they are getting PDL-1 status as well as TTF1 marker (non-squamous) and P40 in squamous   Also feels re-bx is best option if changing therapy,AI and NCCN panelist in midwest stated that for both PD1 agents in cHL the RR is very good (60-70) but the 10-20% cRR still need to do better.  Noted heavily pre-treated pop.  Felt a big step will be first line w/o bleo,"I met with a NCCN NSCLC panelist in the midwest.  He offered these insights

On OAK at ESMO he stated he and the panel viewed the data to be good, roughly like Opdivo.  On the issue of the ESMO data showing ""positive"" results in the PDL-1 negative population, we went over the issues and he stated the panel recently discussed this.  Stated there was not strong enthusiasm of panel for the PDL-1 negative argument due to reasons we discussed internally, but also due to low numbers and at this point unpublished data (he stressed this).  That said given indication of atezo unlikely to get NCCN recommendation more restrictive than label.

Agreed with just about everybody else that 026 was surprise, likely trial design, etc.

On KN 021 stated panel felt the data way to early to recommend Chemo/Pembro in any way.  Had no opinion on whether IO/IO or IO/chemo likely to be superior

Stated NCCN was working on recommendation on how to use PDL-1 cutoffs in some future statement.  This is second NCCN panelist to mention this to me.  Other was in cHL.  Stated majority of effort was in the 1-100% area (as opposed to 0-3+)  Commended BMS for working with Ventana

Noted when voting any member whose name was on relevant paper must recuse self.",166
mostly,Territory,  IN,10.1369047619,3.02029169608e-08,34,0,"An academic TL who treats mostly H&N cancer patients, stated that he tried to attend the -141 presentation, but he could not because ?the room was full?.","NTL in midwest noted her institution had a number of patients that went through numerous lines of chemo in NSCLC prior to Nivo approval.  They went on Nivo on approval and a number of them are still doing well.  Got impression they were still getting Nivo q 2 but did not ask specifically

Same TL also sees fair bit of sarcoma (70 a yr., mostly peds)  and has had decent sucess with nivo generally through expanded access.","RTL at university center in midwest noted that like most others results of 026/024 were surprise without clear explanation

Noted atezo would have strong potential at his institution mostly due to q 3 dosing

Noted little usage of pembro in first line so far

Felt chemo/IO had strong potential",34
cut-off,Territory,  IN,10.0910364146,1.16681949735e-06,26,695,"I met with a NCCN NSCLC panelist in the midwest.  He offered these insights

On OAK at ESMO he stated he and the panel viewed the data to be good, roughly like Opdivo.  On the issue of the ESMO data showing ""positive"" results in the PDL-1 negative population, we went over the issues and he stated the panel recently discussed this.  Stated there was not strong enthusiasm of panel for the PDL-1 negative argument due to reasons we discussed internally, but also due to low numbers and at this point unpublished data (he stressed this).  That said given indication of atezo unlikely to get NCCN recommendation more restrictive than label.

Agreed with just about everybody else that 026 was surprise, likely trial design, etc.

On KN 021 stated panel felt the data way to early to recommend Chemo/Pembro in any way.  Had no opinion on whether IO/IO or IO/chemo likely to be superior

Stated NCCN was working on recommendation on how to use PDL-1 cutoffs in some future statement.  This is second NCCN panelist to mention this to me.  Other was in cHL.  Stated majority of effort was in the 1-100% area (as opposed to 0-3+)  Commended BMS for working with Ventana

Noted when voting any member whose name was on relevant paper must recuse self.","TL stated that last in-person meeting was 1-2 months ago.  Stated there is a call coming up in 1-2 weeks.  On the topic of PDL-1 cutoffs in first line, he stated that pembro would definitely not get a rating until the data was published.  On the possibility this would happen in the near future, he stated that he was somewhat new to panel, but his impression was that the NSCLC panel tried to be more ?inclusive? than ?exclusive?.   On the 50% cut-off issue he stated there could be different possibilities.  He mention there could be a certain recommendation but also some sort of footnote or comment.  It was difficult to tell if this was a general PDL-1 positive listing for pembro with a footnote stating the trial was 50% or greater, or if there could be a listing using a 50% cut-off with a footnote stating a wider range of patients may be appropriate.
 
In other notes he agreed with many that a cut-off is good but we don?t know what it is yet.  Someplace between 5 and 50.  Stated he was heavily involved in adjuvant trials but not metastatic disease.  Inquired as to whether 026 would include results at varying degrees of expression (answered affirmatively).",Lung TL shared that based on the results of -012 study he sees no reason why -227 should not read out positive.  He believes that a HR of .75 in regards to survival would all that be needed in order to out compete the chemo arm.  He also shared that BMS should not be concerned about the PDL1 cut-off (1%) with -227 since the regimen has been able to demonstrate greater activity vs. single agent Nivo in PDL1 expressors.,721
submitted,Territory,  IN,9.80272108844,1.58633140705e-05,21,96,"-NTL at a large academic center stated he has currently submitted manuscript with Armand, etc with titled: ?Redefining the response criteria.?  He stated that there will be examples of tumor Flare ups with PD-1 inhibitors and examples of responses.  There",An academic TL shared that he has observed ?pseudoprogression? in a patient receiving Opdivo for mHCC. The patient is currently experiencing a partial response.   Opdivo was obtained through our access program. The TL is planning on submitting a case report for publication.,A community oncologist shared that he has treated a patient with Opdivo for anaplastic thyroid carcinoma. The patient is currently in CR. The oncologist is planning on submitting a case report for publication. Opdivo was obtained through our access program.,117
PDL-1,Territory,  IN,7.35204081633,1.40984459566e-06,50,881,Lung TL shared that based on the results of -012 study he sees no reason why -227 should not read out positive.  He believes that a HR of .75 in regards to survival would all that be needed in order to out compete the chemo arm.  He also shared that BMS should not be concerned about the PDL1 cut-off (1%) with -227 since the regimen has been able to demonstrate greater activity vs. single agent Nivo in PDL1 expressors.,"I met with NCCN panelist in NSCLC  He shared the following

He stated the NSCLC panel met recently.  He stated that Merck will get a first line listing for pembro in the greater than 50% staining population

Stated panel was surprised by 026 data.  Stated he felt that PFS was a poor choice for primary endpoint.

NCCN is working on a ?guideline? for PDL-1 testing in first line as it was becoming very important.  At this point it will involve only tumor staining.  It will not include the Roche method of including tumor infiltrating cells.  Stated the guideline will have a number cut-off, i.e. ~1-100%....Roche?s 0-3+ method will not be part of guideline.  Stated there would be some recommendation for pathologists who use Roche assay to convert the Roche result to a 0-100% scale.

Panel not impressed with atezo data

Stated that while  ipi/nivo data impressive in NSCLC the panel laughed a bit at it?s attention as the data was so early.  That said he felt there was great potential here

Stated he heard Merck was fairly far along with ipi/pembro data.  More so in melanoma but also lung

Stated he heard AZ combo data will likely come out shortly after BMS combo data in first line NSCLC

On the subject of likely CMSTO 2016 presentation of 026.  He stated if we had OS data that was positive at a particular cut-off there would be a good chance BMS could get a NCCN listing in first line consistent with that given 026 was a large phase 3 trial.","TL stated that last in-person meeting was 1-2 months ago.  Stated there is a call coming up in 1-2 weeks.  On the topic of PDL-1 cutoffs in first line, he stated that pembro would definitely not get a rating until the data was published.  On the possibility this would happen in the near future, he stated that he was somewhat new to panel, but his impression was that the NSCLC panel tried to be more ?inclusive? than ?exclusive?.   On the 50% cut-off issue he stated there could be different possibilities.  He mention there could be a certain recommendation but also some sort of footnote or comment.  It was difficult to tell if this was a general PDL-1 positive listing for pembro with a footnote stating the trial was 50% or greater, or if there could be a listing using a 50% cut-off with a footnote stating a wider range of patients may be appropriate.
 
In other notes he agreed with many that a cut-off is good but we don?t know what it is yet.  Someplace between 5 and 50.  Stated he was heavily involved in adjuvant trials but not metastatic disease.  Inquired as to whether 026 would include results at varying degrees of expression (answered affirmatively).",931
second line,Territory,  IN,5.43234126984,8.55686376168e-08,78,247,"NTL in midwest noted that now they are using Nivo first line, patients who progress move to cisP/pem or cisP/gem second line.  Taxol/Ram third","I met with presumed NCCN panel member for bladder at NCCN institution in midwest.

She stated that about 20% of her patients are not Cis candidates.  Multiple reasons but mostly age and renal status

Prefers DDMVAC for MIBC neo-adjuvant based on 8710 SWOG (2001, University Penn, 317 pts.  1/2 received no neo-adjuvant   Results: 5 yr overall survival was 57% vs 42% favoring the MVAC arm
Patients with a pathologic complete response had an overall survival of 85% at 5 years)

Stated best option for second line systemic is clinical trial.  Has used atezo a few times.  Too early to tell.  Otherwise uses Pem.  Feels taxol is useless

From a guideline standpoint feels FDA approval is important.  Will accept published data but if only a presentation this would mean little unless the results were shockingly good

Believes q3 beats q2","Lung RTL shared that once Pembro is approved in the front-line space this will effect Opdivo use in the second line setting.  She stated Merck reps having been flying into her office touting that they got the ""PDL1 story right"" and that's why they won in firstline.   She also shared that they are ""aggressivley"" telling the physicians to test in the second line space because of the negative outcome from -026.",325
pts,Territory,  IN,4.28869047619,6.48647817391e-10,164,1624,Breast TL shared that she was able to get Opdivo for two of her triple negative pts. through our access support program.  Both pts. had failed at least 4 prior lines of therapy and both now have stable disease.  She commented that she thinks that the prior chemo regimens completely wiped out the patients' marrows and that limited the ability of Opdivo to work even better.,Melanoma NTL shared that at his institution all the pts. on PD1 that have stable disease eventually relapse.  He added that Merck has already shared with him a timeframe when pts. end up progressing after having stable disease based on their data.  He wondered whether we have this data as well?,Lung RTL shared that she is stretching out her scans past the 8 week mark.  She feels a majority of her patients are receiving clinical benefit (i.e. stable disease) but the early scan doesn't help much.  In fact she says that it probably induces unnecessary anxiety in pts. and they get discouraged when they hear that nothing much has changed with their scans.,1788
line,Territory,  IN,4.03641456583,2.4467422955e-07,345,108,"NTL in midwest stated at her institution they generally push trials, especially after first line.  That said she stated in second line they almost always use Nivo over pembro.  She felt even though Roche had some ""iffy"" data in PDL-1 neg she felt it was minor and still thought her institution would use Nivo second line.  They have just started using pembro in first line in greater than 50% stainers.  They send out tissue (turnaround 10-14 days) but are working on getting test in house","RTL in a large community center shared that in the last 9 months, he has treated 3 young men with relapsed HL.  He stated that on patient failed standard first line relatively fast and started 2nd line.  Disease is ?not as responsive? after 1st relapse.   Therefore, at second line therapy after 3-4 cycles, patient was responding and he was able to obtain Opdivo through patient access and patient has continued in response.  He is impressed with the favorable side effect profile and feels this would have a great place in therapy.",Lung RTL shared that if the PFS is similar and the OS and safety profile is better for Nivo vs. Chemo on -026 that she will still consider using Nivo in her first line patients.,453
added,Territory,  IN,2.97169103862,4.57147969936e-05,148,0,Lung RTL shared that the patient population that she is seeing at her institution is changing.  With the approval of the PD1 inhibitors she is seeing less newly diagnosed metastatic pts. and more pts. that have failed PD1 therapy.  She added that she doesn't have many options for these pts. but that she was excited to note that they will be opening a Pembro + chemo study in pts. that progressed on PD1 inhibitors.,"Lung RTL shared that he has treated multiple Small cell pts. with Nivo but is hesitant to add Ipi.  He feels that these pts. are already ""beat up"" from prior lines of therapy and would not be able to handle the toxicities.  He added that the melanoma treaters at his institution put the ""fear of God"" into him that Ipi is not for the faint of heart and induces horrendous toxicities.","RTL at a large academic center stated that Elotuzumab is a?good drug.? There is much confusion with all the new drug approval elo and ixazomib.  Currently, his recommendation is to add elo after transplant and progression on maintenance therapy.  However, it really depends on patient?s response to revlimid prior.",148
NTL,Territory,  IN,2.71851418163,1.67288865376e-05,311,710,NTL at a large academic center stated that they will be opening up a Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission.  She anticipates this will answer a good clinical question.,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center  stated that there needs ot be F/u discussion on the Lugano Classification updates just published and implementation into practice and clarification for clinicians making clinical assesemen.   He stated that discussion on the abscopal effect seen in Lymphoma how it affects management ? discussion points to be clarified,1021
shared,Territory,  IN,2.59384716086,7.24187586165e-07,507,1,Melanoma NTL shared that at his institution all the pts. on PD1 that have stable disease eventually relapse.  He added that Merck has already shared with him a timeframe when pts. end up progressing after having stable disease based on their data.  He wondered whether we have this data as well?,"Lung RTL at an academic institution shared that based on the recent approval with Atezolizumab that it will be a ""no brainer"" that he'll be using this in the second line space given the Q3W dosing.","Lung RTL in Illinois shared that he has been having difficulty obtaining enough tissue with his first line pts. to do PDL1 testing.  He shared that it's been frustrating because he knows that some of these pts. may be ""high expressors"" but won't have enough tissue to ever find out.",508
CLL,Territory,  KS,77.2051282051,4.6940921577e-05,5,98,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,103
like to see a trial,Territory,  KS,60.0484330484,1.10284505016e-09,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
GVHD,Territory,  KS,22.7073906486,1.05004233994e-05,21,118,GVHD can be managed with PD-1 inhibitor and allo transplants.,TL indicated that a trial should be done to mitigate GVHD following SCT with PD-1 inhibition by reducing the dose and/or waiting more time following the transplant to initiate PD-1 inhibition.,TL said that about 60% of patients who had problems with GVHD (grade 3-4 and acute) when re-challenged would react again.,139
TL commented,Territory,  KY,19.0152365678,1.73402449885e-13,83,892,"TL commented that nivolumab is SOC for 2L RCC at their institution based on efficacy, tolerability, and patients demanding I-O treatment. RCC patients see the lung DTC marketing and ask for nivo treatment.","National lung TL commented that ROVA-T and ipi/nivo appear to be the most promising potential agents in SCLC. Regarding ORR reported for ipi/nivo, he mentioned that this is likely not the best outcome for I/O in general but that duration of response or even maintaining stable disease (duration of disease control) should be considered as more important measures of activity.","National lung TL commented that even in a never-smoker, low mutation burden, PDL1 non-expressing lung patient he?d still want to try one of the PD1 agents based on the current data showing that even this subset of patients, while more unlikely, still have a chance of having a long term benefit from this class of drug.",975
presenter,Territory,  KY,17.2325581395,4.90645919616e-05,14,1,"During a Highlights from ASCO meeting, the theme across tumor types (melanoma, lung, H&N, bladder) from academic TL presenters was that PD-L1 as a biomarker is 'a mess' and shouldn't be used to make treatment decisions.","During Q&A at symposium, presenter was asked if PD-1 and PD-L1 inhibitors were the same. Presenter stated inhibition of PD-1 vs PD-L1 is 'similar but different'. There are no H2H trials and data currently available doesn't support the generalization of a class effect.","During highlights from ASCO review, question was posed about how long to continue anti PD-1 therapy in responders. Both the melanoma and lung presenters acknowledged this is an important question. Melanoma TL commented that he will stop treatment after 2 consecutive scans in patient with CR (did not mention how long on therapy before making this decision). TL has also done this with combination targeted therapy--5 out of 6 patients continue to do well after stopping treatment.",15
Local TL,Territory,  KY,10.44397463,4.25356888972e-07,52,1414,Regional TL commented that cabozantinib being used in the phase 1 trial of cabo+nivo with or w/o ipilimumab in metastatic GU tumors was a different formulation. They are seeing less toxicity with this formulation of cabo. TL also shared that the combination of agents has a better AE profile than using as monotherapy.,A lung RTL commented that as the data keeps evolving he is starting to be more selective with which patients receive Opdivo. For patients that are PDL1 negative and have a notably low tumor mutation burden he's beginning to use the cyramza/docetaxel combination 2nd line given the higher response rate seen vs. the 9% that is reported in PDL1 negative pts from 057. He feels that he can always reserve nivo for 3L if pts fail this regimen. He did note it is quite toxic so he wouldn't use this approach with everyone but at least in those that could tolerate it in order to give them more overall treatment options.,"Local TL focused on lung commented that given the new data available with pembro it would now be unethical to not test for PDL1 for 1L treatment decision making. He added that despite a rather high volume of NSCLC, he's yet to see anyone express greater than 50% and feels the true number of high expressors must be much less than the 25-30% Merck has in their studies.",1466
I/O,Territory,  KY,9.50761828388,1.02317428905e-05,36,184,"Regarding 1L use of PD1 agents in NSCLC, RTL commented that he'd have to be really impressed with 024 results to consider replacing platinum doublet therapy. He's still much more comfortable reserving the I/O class of agents for platinum-refractory and given how restrictive the use would likely be (>50%) he may not bother unless the data is extremely compelling.",Local TL believes the best opportunity for increasing the utility of PD1 agents may be in the combination with RT setting. He's surprised there hasn't been more attention to this strategy in larger clinical trials across various tumor types given the rationale behind antigen release/exposure associated with RT and obvious synergistic potential of I/O with this modality.,"Local TL commented that he feels we may be jumping the gun trying to replace platinum doublet therapy as a 1L standard for NSCLC. He believe the role of immunotherapy may be better suited to work after chemotherapy due to the increased antigen presentation, etc, along with the fact that relegating chemo for later line will be more difficult to give once pts have already failed a 1L treatment. The best chance at getting a good response to doublet therapy will likely be in the 1L and the role for I/O may be better in the maintenance or 2L setting due to it's superior tox profile.",220
Academic TL,Territory,  KY,8.61627906977,1.86489245084e-06,65,167,Academic TL shared that he is not that excited about the Eisai trial investigating lenvatinib/everolimus or lenvatinib/pembrolizumab vs sunitinib alone in 1L aRCC. It's another TKI study...unsure if they will participate.,"Academic TL shared that he will be meeting with their P&T committee to discuss atezolizumab. P&T is concerned about cost and favors PD-L1 testing for access. TL does not support PD-L1 testing for atezolizumab based on the current label and too many variables with PD-L1 as a biomarker (i.e. multiple assays and cut-points, staining of tumor vs IC, etc). Also referred to response data in PD-L1 negative patients; these patients have a chance at responding and should have access to therapy.","During a Highlights from ASCO meeting, the theme across tumor types (melanoma, lung, H&N, bladder) from academic TL presenters was that PD-L1 as a biomarker is 'a mess' and shouldn't be used to make treatment decisions.",232
commented,Territory,  KY,4.83720930233,1.3826167511e-08,295,327,"Local TL focused on lung commented that given the new data available with pembro it would now be unethical to not test for PDL1 for 1L treatment decision making. He added that despite a rather high volume of NSCLC, he's yet to see anyone express greater than 50% and feels the true number of high expressors must be much less than the 25-30% Merck has in their studies.","Local TL commented that BMS should really consider pulling the DTC Ad for Opdivo; that it just frustrates physicians because pts come in expecting Opdivo to be a ""miracle, homerun drug"" every time. She stated the only positive that's come from it is awareness of the drug among pts which encourages ongoing clinical trial participation.","Local TL commented that the 026 press release was disappointing but that it might finally answer the question of which PDL1 expression level is necessary. He feels the 50% level excludes many patients that could have benefit and suspects the right level is probably closer to 20%. He also feels that the results of this study now further support that testing is probably important and if nothing else, will give the physician a better idea of what to expect going into treatment.",622
Pediatric Oncology/ Hematology,Territory,  LA,199.333333333,8.63244054662e-07,4,319,Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,"Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.",Director of Pediatric Oncology/ Hematology at a large academic center would like to see a study in pediatrics in first relapse looking at Nivolumab vs. Brentuximab vs the combination of Nivolumab and Brentuximab. She stated that she would like to see regimens that reduce the amount of chemotherapy given in this setting due to the risk of long term toxicities.,323
Pediatric,Territory,  LA,174.416666667,6.12255114998e-11,11,367,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,378
Brentuximab vedotin,Territory,  LA,35.5952380952,2.60717271251e-06,11,135,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.",RTL at an academic medical mentioned that they have used Brentuximab vedotin off label in place of Bleomycin due to the shortage of Bleo.,"Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.",146
described,Territory,  LA,16.1225490196,2.29077199646e-09,44,0,"RTL from a large academic center presented the 209-205 data at an ASCO review. He described the data as very impressive, commenting on the indication in the post ASCT/BV space and the approval of Opdivo prior to ASCO. He commented on the ""very impressive reduction in tumor volume"" seen in the trial.","Community Pharmacist stated they had a few patients they thought had progressed on Opdivo when it was really pseudoprogression because they were clinically stable as you have described in this ""unbranded"" deck.",NTL for Pediatric lymphoma at a large academic center thinks Nivolumab should be studied in the first relapse setting. She described a COG trial which is being developed with Nivolumab and Brentuximab vedotin.,44
academic center,Territory,  LA,14.7654320988,2.67079618685e-12,103,319,NTL for MM at a large academic center thinks a trial with Urelumab and Nivolumab would be interesting.,NTL for MM at a large academic center thinks the check point inhibitors will remain only in the RR space secondary to their safety profile.,Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,422
lymphoma,Territory,  LA,8.44632768362,1.99765463559e-06,73,12,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,NTL for Pediatric lymphoma at a large academic center discussed that increased IRR could be related to fact that cHL is an immune driven and mediated disease with paraneoplastic phenomenon.,NTL for Pediatric lymphoma at a large academic center thinks Nivolumab should be studied in the first relapse setting. She described a COG trial which is being developed with Nivolumab and Brentuximab vedotin.,85
transplant,Territory,  LA,8.13605442177,2.44146031415e-05,92,193,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.",RTL at an academic medical described a cHL patient who had failed induction and salvage chemotherapy. The patient was placed on Brentuximab vendotin but only achieved a PR. They decided to add Nivolumab prior to its approval and the patient then achieved a CR and was able to go to an Autologous transplant. Unfortunately the patient experienced a transplant related complication with an RSV infection and subsequent pneumonia and expired.,"NTL BM transplanter feels there is a large unmet need in the post Allo transplant area with check 
Point inhibitors and feels we need phase 1 trials investigating different doses and schedules of these agents to reduce impact on exacerbating GVHD.",285
cHL,Territory,  LA,6.30801687764,1.97851417889e-05,116,190,RTL at an academic medical described a cHL patient who had failed induction and salvage chemotherapy. The patient was placed on Brentuximab vendotin but only achieved a PR. They decided to add Nivolumab prior to its approval and the patient then achieved a CR and was able to go to an Autologous transplant. Unfortunately the patient experienced a transplant related complication with an RSV infection and subsequent pneumonia and expired.,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.","Pharmacist at a large community hospital described the first cHL patient they used Opdivo on after approval. The patient was a hospitalized 89 y/o male who had failed both AVD and BV. Three hours after the first dose the patient experienced a severe reaction with acute respiratory failure, SOB and bilateral stridor requiring a rapid response team intervention. He was treated with Xopenex and Racemic Epinephrine and the symptoms resolved over the next 24 hours. The patient was discharged home 3 days later and future plans for Opdivo was discontinued. (The event has been reported as an AE.)",306
PR Hem Onc Symposium,Territory,  LANDSCAPE,104.172413793,2.043225083e-05,5,142,"A National TL at a lung cancer lecture at the PR Hem Onc Symposium highlighted that because of the complexities in PD-L1 testing, he does not use it to make treatment decisions.  He also highlighted that PD-L1 expression denotes properties of the microenvironment, not the tumor.","A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented that there is no difference in pembro or nivo biologically, just in the biomarker strategy.",A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented how most patients we don't know the driver mutations.  KRas is an important target that we still do not have any drugs to target.,147
Path TL,Territory,  MA,413.611111111,1.17425601759e-15,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
NTL in the Boston area mentioned,Territory,  MA,372.25,3.98579345777e-14,9,137,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.",NTL in the Boston area mentioned that those patients who don't achieve a CR with BV then their response will be short lived. Also mentioned that BV is easy to give with a focused toxicity. Regarding Nivo - toxicity is broader and harder to manage but that Nivo CRs seem to do better,NTL in the Boston area mentioned that regarding AVD - A is the most active agent. Also mentioned that stopping A  after 6 cycles patient are doing fine 20 years out,146
Boston area,Territory,  MA,186.125,2.13934488099e-13,19,27,RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,NTL in the Boston area mentioned that he does not like pembro cause there is more drug wastage and inconvenience. He also mentioned that it makes sense what nivo did with flat dosing.,NTL from the Boston area mentioned that AVD with BV better have a big KM curve separation otherwise its useless data.,46
Path,Territory,  MA,165.444444444,6.61823238307e-12,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
IVD,Territory,  MA,55.1481481481,1.16779284163e-05,6,146,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Pathology TL at a mid-size academic center has completed validation of 22C3 IVD 12/2/2016, testing is now available in-house.
-TL reported validation of platform and antibody were simple and straightforward
-TL reported training by watching Dako online module for scoring
-TL reported training on scoring was an ""uphill battle""",152
score,Territory,  MA,19.3018518519,7.11626966681e-07,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
pathologist,Territory,  MA,16.2937710438,9.67830064712e-11,45,211,"Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",256
Boston,Territory,  MA,15.5104166667,1.19204729802e-05,40,82,NTL in Boston mentioned that patients who have progressive cHL disease may have other pathways for tumor cell death via CD4 and NK. She also mentioned that [patients who progress on Nivo have a change in the micro environment which is being researched,NTL in Boston mentioned that 026 and 024 are looking at two different patient populations based on PDL1 expression. He mentioned that there are differences in the trial designs and comparing them should not be done.,Pharmacist in the Boston are mentioned that in cHL Opdivo has a higher rate of infusion related reactions. Since this rate is higher than what we see in other indications is there a need for pre-medication?,122
22C3,Territory,  MA,12.9253472222,7.29236007833e-08,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
BV,Territory,  MA,10.7232510288,1.70670565932e-05,33,158,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.","RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",NTL from the Boston area mentioned that AVD with BV better have a big KM curve separation otherwise its useless data.,191
stop,Territory,  MA,8.09239130435,8.56774157589e-06,67,137,NTL in the Boston area mentioned that he currently has patients on commercial nivo for cHL. For his patients he does not consider stopping treatment and continues until progression of toxicities. He does not stop treatment at a fixed duration even thought patients seem to have a good second response rate.,RTL at a teaching hospital mentioned that some patients are asking if they can stop Opdivo after a certain period of time. Some are asking to stop at the one year mark and others are saying they will stay on as long as the drug is working and keeping disease under control.,NTL in the Boston area mentioned that he would not stop nivo in cHL patients. Lots of these patients are last graspers so you would be wrong stopping the drug.,204
mentioned,Territory,  MA,6.14273927393,3.19728963928e-12,289,130,"RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,NTL in Boston mentioned that patients who have progressive cHL disease may have other pathways for tumor cell death via CD4 and NK. She also mentioned that [patients who progress on Nivo have a change in the micro environment which is being researched,419
reported,Territory,  MA,3.92668776371,4.24519120941e-05,182,10,Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,"Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer",192
standardized,Territory,  MD,32.6246575342,4.25241868983e-05,8,132,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",140
Path TL,Territory,  ME,214.264705882,4.76271288921e-13,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
Boston area,Territory,  ME,214.264705882,4.76271288921e-13,19,27,RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,"A TL from the Boston area made the following comments around irRECIST in NSCLC treated with Nivolumab. There was a correlation between site of tumor. Example, liver mets had less overall response, vs. adrenal lesions had the most overall response.",NTL in the Boston area mentioned that he does not like pembro cause there is more drug wastage and inconvenience. He also mentioned that it makes sense what nivo did with flat dosing.,46
NTL in the Boston area mentioned,Territory,  ME,192.838235294,9.08145791457e-12,9,137,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.",NTL in the Boston area mentioned that those patients who don't achieve a CR with BV then their response will be short lived. Also mentioned that BV is easy to give with a focused toxicity. Regarding Nivo - toxicity is broader and harder to manage but that Nivo CRs seem to do better,NTL in the Boston area mentioned that regarding AVD - A is the most active agent. Also mentioned that stopping A  after 6 cycles patient are doing fine 20 years out,146
Path,Territory,  ME,85.7058823529,8.26544514294e-10,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
Boston,Territory,  ME,30.9493464052,1.67449006602e-12,40,82,"A Melanoma NTL from Boston, stated that ""there is no value in doing PD-L1 testing in melanoma pts.""  He added that ""I don't test any of my pts""","A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",122
rounds,Territory,  ME,26.7830882353,2.10496808992e-05,8,5,"A Local RPH in Maine asked, that their average pt receiving Opdivo over the last 12 months has been 67 Kgs.  Therefore, the flat dosing (based on a 80 kgs) would result in most of their pts receiving above 3mg/kg, and result in higher cost.  Therefore, the RPh suggested that for most pts they will stick with 3mg/kg dosing (rounded to nearest vial size), but for pts over 80kgs, they would use falt dosing of 240mg.",An RPh at a community site informed me that they are dose rounding Opdivo to the nearest full vial size (increments of 20mg) to prevent wastage.,"A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""",13
1st line NSCLC,Territory,  ME,21.4264705882,1.08772479516e-06,17,26,"A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).","A LTL in Boston stated that based on all the data coming out around 1st line NSCLC, they should be testing all pts for PD-L1 status.  However, he added that ""he has requested testing on 15 or so samples (1st line pts) and all of them have come back negative"".",43
score,Territory,  ME,9.99901960784,3.87410742662e-05,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
pathologist,Territory,  ME,8.44073083779,1.1362960061e-07,45,211,"NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times",256
22C3,Territory,  ME,6.69577205882,1.62199833236e-05,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
1st line,Territory,  ME,5.47058823529,1.39950600914e-05,69,712,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","A RTL for Lung shared that he was surprised to hear that CM26 was negative. He is looking forward to seeing the subgroup analysis based on other PD-L1 cut offs, but he added that this increases the need to do PD-L1 testing in all 1st line NSCLC pts. He also suggested the need to choose PD-1 agents in the 2nd line settting based on PD-L1 results.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",781
pts,Territory,  ME,5.35661764706,4.74512563821e-12,164,1624,"An RTL shared that when a pts runs into toxicity with Nivo/Ipi combo, if the pts has a CR or PR at that time, then they stop treatment.  However, at the time of toxicity with the combo, if the pt only has SD or PD, then they continue PD-1 monotherapy.  The added that about 1 out of 4 times they continue with Pembro as oppose to Nivo.","A NTL in melanoma shared that combination IO therapy (mostly regimen) is their primary method of treatment all melanoma pts at their institution.  Even if the pts has bully, BRAF+ melanoma, because of the rapid RR scene with Nivo/Ipi, they would choose Nivo/Ipi over BRAF+MEK combo.",A RTL stated that he does not test PD-L1 for his RCC pts.,1788
LTL,Territory,  ME,4.54500891266,1.78457526353e-05,79,800,"An LTL informed me that he doesn't test for PD-L1 status in the 2nd line NSCLC setting and stated that there is no need for it. He did add that his colleague is testing some of his/her pts for PD-L1 status in the 2nd line setting and is ordering PD-L1 status upon initial biopsy (pre-1st line treatment). Upon inquiring why? The LTL shared that by having this information, for PD-L1+ pts, both Pembro and Nivo would be good options with high ORR in the 2nd line setting, and if the pt was PD-L1 negative then opdivo (only) would still be an ""ok"" option.","An LTL/RTL stated/suggested that his plan for 2nd line NSCLC is to start nivolumab while waiting for PL-L1 test expression.  If the PD-L1 test comes back at 50%+ positive, he would switch the pt to Keytruda (view the data stronger as this sub-population was specifically studied by Merck).  If the test comes back between 1-49%, he said that it's a 50/50 choice between Opdivo/Keytruda and it would be up to the pts on q2w drug or q3w drug.  If the PD-L1<1%, he would choose Nivo...but if insurance had an issue, then he would switch to docetaxel.",A LTL stated that no one in her practice test for PD-L1 for her RCC pts.,879
PD-L1,Territory,  ME,3.77105882353,1.747786517e-06,306,375,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",681
mentioned,Territory,  ME,3.30458004097,2.97771805355e-07,289,130,"RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,NTL in Boston mentioned that patients who have progressive cHL disease may have other pathways for tumor cell death via CD4 and NK. She also mentioned that [patients who progress on Nivo have a change in the micro environment which is being researched,419
NCI,Territory,  MI,227.23655914,2.97840209697e-12,16,112,"RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.","RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.",128
hematologic malignancies,Territory,  MI,97.3870967742,2.46139723761e-05,5,4,"TL presenting at a national congress stated that even though cHL is the ""poster child"" for  PD-1 blockade in hematologic malignancies, there may be a role in DLBCL and FL, but will be limited to certain populations.",NTL mentioned the requirement for more education and understanding around the development and/or persistence of AEs over time following IO therapy in hematologic malignancies.,"NTL at an academic center noted that although the topic of pseudoprogression is being understood in solid tumors, there is a gap in the understanding of how to interpret responses when using IO agents in hematologic malignancies.  NTL suggested that either BMS internally, or in partnership, review available PET data from trials  in HL and correlate with outcomes for patients. This information would  help clinicians understand responses of hematologic malignancies during treatment with IO agents.",9
PET,Territory,  MI,48.6935483871,6.64296855871e-06,11,0,"RTL from an NCI Cancer Center stated that be believes in a PET directed approach to treating lymphoma,  but that changing treatment modifications based on PET results should only be done on trail at this point. In addition, if changes to therapy are going to be made based on a positive PET result, a second biopsy should be conducted to prove disease.","A NTL commented that at the recent IWNHL meeting there was a major discussion on the use of scans in lymphoma trials. There is concern that FDA is too heavy on scans for therapies (ie. requiring both contrast CT and PET). Moreover, as scans become utilized more frequently, and the ability to detect MRD increases patients will develop ""scan-xiety"" and always be afraid of what the next scan will say. Thus, there is a need to have a healthy balance between understanding MRD and what level of disease really affects QoL and survival.","NTL at an academic center confirmed that the shortage of bleomycin has had an impact on their practice, even though this institution has a stock pile.  As a result, they are treating patients according to the RATHL study by dropping bleomycin from ABVD after two cycles if the PET scan is negative.  In addition, belomycin is not being used for treatment of testicular lymphoma.",11
cancer center,Territory,  MI,23.0653650255,3.69187359031e-09,46,130,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.","RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.",176
lymphoma,Territory,  MI,16.5062875888,9.38088029829e-09,73,12,TL at academic center noted that there is a big gap in secondary CNS lymphoma and that the population is bigger than primary. Offered that Merck is doing a trial in primary CNS lymphoma and is missing an bigger opportunity.,A NTL and NCCN panel member noted that the International Workshop on Non-Hodgkin Lymphoma has a manuscript in review that proposes updated response evaluation criteria. This criteria will be ?uni-dimensional? (one rather than two measurements).  One impetus for the update was to reduce compounding errors that occur in the two dimension criteria. There was no clear timeline for publication as it is only the review process.,"RTL and academic center spoke positively about anti-PD1 therapy in lymphoma, noted that transformed lymphoma and EBV-driven lymphomas are gaps in research, offered anecdote that they treated nasal NK driven lymphoma off-study with promising reuslts.",85
academic center,Territory,  MI,12.5660770031,1.51167160874e-06,103,319,"NTL at an academic center confirmed that the shortage of bleomycin has had an impact on their practice, even though this institution has a stock pile.  As a result, they are treating patients according to the RATHL study by dropping bleomycin from ABVD after two cycles if the PET scan is negative.  In addition, belomycin is not being used for treatment of testicular lymphoma.",TL at academic center noted that there is a big gap in secondary CNS lymphoma and that the population is bigger than primary. Offered that Merck is doing a trial in primary CNS lymphoma and is missing an bigger opportunity.,"RTL and academic center spoke positively about anti-PD1 therapy in lymphoma, noted that transformed lymphoma and EBV-driven lymphomas are gaps in research, offered anecdote that they treated nasal NK driven lymphoma off-study with promising reuslts.",422
noted,Territory,  MI,9.59115347019,3.12947174814e-08,144,0,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","RTL noted that he is still trying to wrap his head around the ATHERA trial data for high-risk young HL patients noting the PFS benefit with BV but not OS benefit. Thus, not sure if maintenance in cHL is useful.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.",144
RTL from a major academic institution,Territory,  MN,529.54954955,1.86190911224e-27,20,232,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
community institution,Territory,  MN,476.594594595,9.32778144874e-25,31,221,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
026 Top 300,Territory,  MN,185.342342342,8.28680382978e-10,7,245,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
large community institution,Territory,  MN,158.864864865,8.73944874811e-16,13,1371,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",1384
NCI,Territory,  MN,105.90990991,1.74923411733e-10,16,112,"RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.","RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.",128
NOT Top 300,Territory,  MN,105.90990991,9.26509232324e-06,4,248,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
academic institution mentioned,Territory,  MN,66.1936936937,1.42822477905e-06,14,47,"[026 Top 300] NTL from a top academic institution pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients.
- At his institution, 20% exhibit mutations (e.g, EGFR, ALK, ROS1) with the remaining 80% eligible for PD-1/L1 inhibitors.  Of these, only 20-25% of those will exhibit PD-L1 50% or higher.
- This equates to more like 16-20% of NSCLC patients in the real world that would be eligible for first-line pembrolizumab.","RTL from an academic institution mentioned that that data for NSCLC patients who have ALK or ROS1 mutations is unclear for I-O therapies.  RTL is aware of trials looking at crizotinib and nivolumab, but mentioned there would be overlapping toxicities.","RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.",61
single-agent,Territory,  MN,52.954954955,2.69522861826e-05,5,0,"RTL from a community institution mentioned that 026 was an ""unfair"" trial due to the negative press and attention she was hearing from the media.  Moreover, RTL highlighted that it's pretty clear that single-agent I-O doesn't seem to be the ""cure-all"" for all comers in first-line NSCLC.  RTL is remaining hopeful and excited for 227, especially after hearing about the positive 012 WCLC results from the press.","RTL from a community institution mentioned that the ESMO data from 026 was disappointing, but mentioned that it's clear that single-agent I-O is insufficient in the front line.  RTL was excited for 227 based on the 012 data from ASCO presented earlier in the year.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",5
KEYNOTE-024,Territory,  MN,49.1724581725,2.4830280371e-14,19,76,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.",95
CheckMate 227,Territory,  MN,33.0968468468,8.03289029015e-06,8,8,"RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.","HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",16
second-line,Territory,  MN,26.4774774775,5.74934641285e-09,17,63,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",RTL at a major academic institution has been using nivolumab in second-line RCC with great results.  RTL is now encountering the problem of patients relapsing after progressing through nivolumab.,80
eager,Territory,  MN,22.0645645646,2.76145468446e-05,10,7,"HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""] NTL from a major academic institution expressed disappointment in 026 results from ESMO, as she was hoping for better efficacy.  NTL shared that female patients at her institution fare better than male patients, so she does agree this partly explaining higher OS with chemotherapy arm for 026.

NTL understands that it's impossible to cross-compare 026 with KEYNOTE-024.  NTL expressed little enthusiasm for pembro as not a lot of patients are at or above PD-L1 50%.  NTL is highly eager for CheckMate 227.",17
first-line,Territory,  MN,21.181981982,1.01977639502e-10,26,54,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",80
top,Territory,  MN,20.5935935936,8.99147204882e-07,23,0,"RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",23
major academic institution,Territory,  MN,17.6516516517,1.02846503519e-05,34,225,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",259
RTL mentioned,Territory,  MN,9.75486012328,3.67138849815e-05,27,0,RTL at a major academic institution has the top accrual in the US at his institution for IMvigor 010 (atezolizumab as adjuvant therapy for high risk muscle invasive disease).  RTL mentioned that patients are doing well in terms of efficacy and safety on atezo with about 40% of patients being PD-L1 positive according to the SP142 assay.,"RTL from a large community institution mentioned that he was ""surprised that the safety of PD-L1 inhibitors (i.e., avelumab) wasn't as good as PD-1 inhibitors"" in terms of reducing immune-mediated AEs (as originally thought).  RTL was actually one of the authors for the JAVELIN solid tumor trial for avelumab (anti-PD-L1) presented at ASCO.  Interestingly in that poster, RTL mentioned that there was also a 16% infusion-related reaction rate from the 1,300 patients enrolled (pan-tumor), which mandated a premed regimen of APAP and Benadryl into the protocol.","RTL from a major academic institution was not concerned that CheckMate 026 did not meet its primary endpoint.  Rationale: RTL was extremely encouraged with positive data from CheckMate 012 at ASCO on combination therapy.  RTL mentioned that PD-1 monotherapy is not likely to work as you would need something ""harder hitting"" such as nivo + ipi in the front-line setting.",27
Checkmate,Territory,  MN,7.00874403816,2.73105344076e-05,87,792,"[026 Top 300]  HCP from a community institution mentioned that he is still going to use nivo as he and his staff are extremely comfortable with the safety profile of nivo.

Discussed CheckMate 017 and 057 as well as KEYNOTE-010 reactively as it was evident he was getting nivo, pembro, and atezo mixed up.  When reactively discussing the Blueprint project and OS data, it became clear to him that he would choose nivo based on the efficacy and safety vs. the convenience factor of q3 weeks of pembro/atezo.","RTL from a large community practice questioned the difference between all the assays available and if there's any correlation between all 4.  Reactively presented the FDA blueprint project from AACR.  From here, RTL asked about OS data from both KN-010 and CheckMate 057.  RTL was surprised by the higher OS from nivo when compared at the 1% level.","RTL who's actually a lung speaker for both Merck and BMS let me know he tests for PD-L1 occasionally.  In those who are PD-L1 expressors, he uses pembrolizumab, but those who are negative, he uses nivolumab.  Reactively discussed data from Keynote 010 on OS data stratified by PD-L1 status as well as data from OS on 057 stratified by PD-L1 status.

RTL was shocked to hear the longer OS data with nivolumab at the 1% level compared to pembro.  He further mentioned that even though the Merck rep is his long-time friend, this OS data is important for him and his care for patients.",879
PD-L1 expression,Territory,  MN,6.61936936937,2.38676696074e-06,72,703,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",775
pembrolizumab,Territory,  MN,6.49447560768,1.13926870888e-06,65,45,RTL from a major academic institution mentioned that nivolumab still has a prominent place in second-line for the 70% of NSCLC patients out there because pembrolizumab from KEYNOTE-024 at its 50% or higher cutoff limits its use in the real world.,"NTL commented that the cancer center is opening a pembrolizumab vs. brentuximab vendotin trial, but noted that this trial does set up one drug to lose and ""neglects sequencing"" which could be an important part of using these new therapies.",RTL from a major academic institution mentioned that the anti-drug antibodies for nivolumab were reported to be higher than for pembrolizumab from a recent paper.,110
RTL,Territory,  MN,4.47136209057,2.84136784925e-14,690,801,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",RTL from a large community institution was very impressed with CheckMate 153 from ASCO in decreasing the nivolumab administration time from 60 min to 30 min as it would benefit a lot of his patients within the community.,1491
cabozatanib,Territory,  MO,122.324232082,9.93155643111e-13,13,190,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",203
trx,Territory,  MO,94.0955631399,7.91989027854e-10,10,0,"RTL, who is IL-2 referral center, stated that he has believes that all RCC patients should get any and all IO options as soon as possible.  For patients who are good candidates (~10% of RCC pts largely due to organ fxn), starts with IL-2.  Currently dissapointed that nivo PI and 025 trial req'd anti-angiogenic, rather than any prior trx (ie, IL-2 only). Has given several patients a short course of pazaponib until 'any first toxicity' as a pass-through to fulfill insurance requirements per PI.","pan-tumor community RTL states that in RCC he commonly sees patients with mixed responses (both to IO and TKI).  he states that he often sees a similiar phenomenon in SCCHN, but rarely sees mixed responses in lung.  

Due to this, in RCC, he very commonly adds nivolumab to a TKI (typically sunitinib or axitinib) if a patient is beginning to progress rather than switch trx completely.  He states that it has worked very well and he has had no toxicity issues, possibly as most patients are by then on a dose-reduced level of TKI.   He would like to see more nivo+TKI (ie cabo) and nivo-rescue trials being done.","GU RTL shared some factors he considers when deciding between nivo (~70% of pts) and TKI (now cabo, ~30% of pts) for 2L RCC trx:
- pace of progression (20% of pts exhibiting faster progression prefers TKI) 
- toxicity of 1L VEGF TKI (if had minimal tox/dose reduction, more likely to give cabo 2L due to convience of oral dosing)
- compliance to taking oral meds and reporting of side effects
- Performance status (lower PS would always get nivo)",10
pace,Territory,  MO,75.2764505119,6.6470103768e-08,8,208,"GU RTL states that while he prefers to give nivolumab 2L in RCC patients, that he uses cabozatanib in patients who are progressing ""fast"" as he is concerned that IO works too slowly.  When asked to elaborate on his definition of 'fast progressors' he stated that it is at most 25% of patients and that he can often tell speed of progression by clinical appearances (PS, pain, fatigue) rather than scans.  

He stated that even in 'moderate pace' progressors, that at least 50% of the patients have their disease 'explode' once they come off of their 1L TKI, sometimes to the point he has no choice by to put them back on.  He had considered 'bridging' in nivolumab while weaning off the TKI but was concerned about safety.  Reactively reviewed TKI+nivo safety data from 209-017 and he thought that this was very acceptable and that he may begin to do this.","Academic TL stated that his nivo non-benefittors (ie, PD w/o any SD/PR) tend to progress at a much faster pace than their 1L progression, sometimes causing them to not be able to get a 3L therapy.  However if they have had any benefit, even a short term slowing of disease prior to progression, their progression is much more tapered and they tend to do better on 3L chemos","TL stated that while he initially treated 'everyone with aPD-1 regardless of PDL1 expression', his experience (pan-tumor) is that ""those who don't respond to IO, actually increase their speed of progression, compared to a chemo or TKI where even non-responders tend to get a temporary slow-down, and thus he feels IO can have a negative impact on ability to response to subsequent therapy.  In nonsq-NSCLC, he has started to test for PD-L1 and will often treat those with <1% with chemo+/-ramucirumab prior to IO in order to 'slow pace before moving on to IO'",216
aPD1,Territory,  MO,65.866894198,6.01339431218e-07,7,635,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","RTL reports that he has utilized ipi/nivo regimen 2L in several patients who have been referred to him following 1L pembro monotherapy failure.  While still early in treatment, he reports that so far patients have done extremely well, either stabilizing or responding. Physician would like to see a a trial specifically looking at 'rescuing' aPD1 non-responders with regimen second line.","NTL in lung stated that at this point, and ""maybe it will change if the numbers for KN-024 are actually much better than I think they will be"" he sees his use of pembro (or any aPD-1 monotherapy) in the first line to be very limited. He expects that the magnitude of benefit may be somewhat modest. ""significant doesn't always mean incredibly meaningful""  

He's states that either in 1L for trials, or in 2L, that he has seen such a ""tiny, maybe 15%"" of patients with >50% PDL1.  ""Whatever the trials data says for proportion of the population, I figure my experience is half of that it almost makes me questioning if I should bother holding up starting chemo for such a tiny fraction"".",642
Pan-tumor,Territory,  MO,35.2858361775,2.0532119767e-12,18,464,"Community Pan-tumor TL at research-focused site stated that while their practice has started ordering PDL1 testing in NSCLC whenever possible, however he said ""I'm not really sure why I bother... I treat the negatives with nivo anyways...""

He wasn't sure what exact test they ordered and but stated that he gets an exact % expression reported back.","Community Pan-tumor TL seemed only very moderately aware of the outcomes of KN-024 and CM-026 reported at ESMO, but stated that he ""doesn't think we will be using platinum doublets in 1L in a couple years"".  He did not mention pembro's 1L approval (a few days after) and my impression was that he was not aware. When probed, this is because he thinks this is because IO+IO combinations will be SOC (rather than PD1 monotherapies being used widespread).","Community Pan-tumor TL at research focused site states that while the he is convinced that the efficacy is worth it, that managing toxicity for ipi+nivo in melanoma is ""high maintenance"".  Between him and one other partner (the two that see most of the melanomas), they have treated about 6 patients, and have ended up having to hospitaized a majority of those patients due to GI toxicity.  However they state that the toxicities resolved well with steroids or infliximab and that the majority of these patients have had profound responses.  He stated that he struggles with whether to put these patients back on nivo monotherapy, and has not to date based on the durability off trx in 069 and 067, but he sometimes feels very nervous ""not doing anything more""",482
ie,Territory,  MO,32.1493174061,1.69041601928e-30,52,0,Very positive early feedback around AE management app.  Nurse manager requested a similar web-based version to be used at triage desks (ie wiht hyperlinks for the different AEs),"pan-tumor TL reports that he is not performing PDL1 testing in RCC patients.  He states that, of all his tumor types, he actually does the least amount of any genomic analysis (ie Foundation One, etc) in RCC patients as there aren't those 'characteristic and target-able' mutations like in other tumor types.","Med Academic lung TL inquired if there were any efforts to examine was to examine PDL1 in either a plasma/liquid biopsy form (ie, RNAexpression, etc.). Challenges around this were discussed (ie, systemic vs. local tumor environment, etc).",52
modest,Territory,  MO,21.9556313993,7.53707390132e-06,9,142,"Despite being impressed by the efficacy benefit, LTL has been hesitant to prescribe commercial ipi3+nivo1 regimen for melanoma due what he considers an unacceptable toxicity profile, especially given lack of long term OS data to justify the toxicity. However, 'jumped' at chance to participate in CA209-568 1L NSCLC trial (ipi q6w, nivo q2w) as he was very impressed with the improvement in toxicity with this dosing in 012.  He hopes to that this dosing schedule will also be examined in melanoma.","Based on the median time to response and higher number of 'late' responses in 025, coupled with the overall slower progression of RCC patients, TL is considering doing first scan at 12 weeks rather than 8-9 weeks as he think it may better reflect the benefit without showing as much pseudoprogression.","GBM: RTL who attended SNO stated that 'each year the progress for GBM seems so incremental and they are still waiting for the 'break' that all these others tumor are seeming to have'.

Stated that he was 'so hopeful' around IO, but that it has been largely dampened due to the ""very modest"" data from nivo (143) and pembro (KN028).   He hopes that possibly 1L treatment will produce stronger results.",151
2L+,Territory,  MO,21.1715017065,3.93717019684e-07,12,334,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.",346
IL-2,Territory,  MO,20.7010238908,2.12931219653e-08,16,48,"RCC TL shared that manuscript had just been accepted for publication around the RCC portion of the PROCLAIM registry and outcome based on sequences of IL-2, chkpt inhib, and TKIs (NCT01415167, PROMETHEUS).  Journal of Urologic Oncology.  
TL did not share any specific data but stated that 'IO first is always best'.","RTL in GU stated that he will be participating in an upcoming Nivolumab+HD-IL2 trial that is being sponsored by Prometheus - did not state specifically, but during implied that this was an ISR (possibly led by Michigan?) that will be bringing on about 10 sites nationwide.   TL had not seen final protocol yet, but believed that there would be a nivolumab lead in (~2 cycles) followed by a standard course of HD-IL2, 1 nivo dose between cycle 1 and 2 of IL2, and nivo mono therapy after completion of IL-2.","Melanoma RTL who has traditionally been a strong proponent and regional referral center for HD IL-2 stated that he hasn't treated a melanoma patient with IL-2 in over a year and that the efficacy of checkpoint inhibitors has nearly 'killed' IL-2.  He states that the 'CRs and cures from IL-2 can't be downplayed, but that you can't refute that way more patients are getting benefit from chkpt inhib without the ICU-type toxicity"" 

TL states that despite it being dropped from NCCN guidelines as a 1L recommendation, that he would still use IL-2 upfront in a young, fit patient as he feels the best strategy is to ""stimulate the immune system by as many different mechanisms that we can"".",64
GU RTL stated,Territory,  MO,16.9372013652,1.00467477369e-06,13,433,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",446
Pan,Territory,  MO,16.4667235495,1.89514723286e-05,10,0,"Pan tumor TL stated that the was ""Thrilled"" that pembro was added to the 1L NCCN guidelines so quickly.  He acknowledged that this was a very selected population, however believes that the magnitude of benefit 'absolutely' makes it worthwhile to put forth the effort to find these patients.","Pan Tumor community research TL:

Surprised at and impressed by how big the magnitude of benefit was in KN024.  Acknowledges that it is going to fit for a very small portion of patients (he estimated 20% for his practice based on his own synthesis of PDL1 prevalence reported and PS/brain mets/etc in his own patients), however think that it is worth testing everyone at diagnosis and would try to treat anyone with >50% PDL1 with pembro 1L.  He is completely perplexed by the CM026 >50% negative data.  Thinks that this is likely ?a fluke?, but given the magnitude of benefit in 024 doesn?t think that small difference in patient populations could make data from ?super positive? to ?solidly negative? between trials so ?could be a real difference?. 

Note that prior to ESMO data, TL had low expectations overall for KN024 data, thinking magnitude would likely be reasonably small and that he would not likely make a huge push to PDL1 test everyone at 1L, so this is a marked shift in his attitude after seeing data.  He was, and remains, strongly pro-nivo regardless of PDL1 expression, for 2L - views haven?t changed.","Pan tumor TL stated that his concern in giving IO earlier (across any tumor type) is that for the patients that is DOESN'T work for, it is almost detrimental.  He finds that these patients (lung, mel, GI, RCC) tend to have their disease 'explode' and progress quickly, making it impossible/challenging to get it a subsequent line of therapy.  He states that in the 2L and beyond, this is a gamble you take because there aren't a lot of other options, but in the 1L settings it is dangerous and there is still a lot to be said for chemo which at least 'slows down' almost everyone.",10
not test for PDL1,Territory,  MO,15.0552901024,6.59230827222e-06,14,651,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.","GU RTL stated the he has used Opdivo in 2 non-clear cell RCC patients.  Stated that in both cases was initially denied by insurance, but easily approved once he appealed and spoke with company.  Stated that this is incredibly common to agents when they first come on the RCC market due (experienced the same with axitinib) and does not concern him, however was thrilled to hear that we were already doing a study with nonCC patients (374) and he hopes this data will be incorporated into PI eventually.",665
axitinib,Territory,  MO,10.7537786446,2.74746832092e-05,14,482,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",496
HN,Territory,  MO,9.40955631399,1.94505780286e-06,21,1,"HN RTL stated that at their institution (NCCN), it is most common for Merkel Cell Carcinomas that are on the head to be seen by the HN team, rather than the melanoma team. This is in contrast to most other institutions in my region. 

Stated that he has used and seen some good responses to pembro, but is overall much more impressed by the avelumab data.","RTL in lung&HN shared that he is not currently, and does not plan, to test for PDL1 in HN. He likened the 141 data to being ""extremely reminiscent to the 057 and the lung space. Clearly PDL1 is enriching for nivo efficacy, but in 2L even it it was dead even with SOC, I would use it in everyone 2L based on safety and QOL one.  However, this argument might change in 1L HN like it does in 1L lung."" 

He stated that has several HN patients currently nivo off-label, however has started new patients on pembro since their approval due to ""similar data and ease of them having the approval"".  He sees himself using primarily nivo again if approved for HN.","Regarding HN choice of pembro vs. nivo.  Overall opinion is that data ""is very similar"" and few seem to be concerned with lack of OS or comparator for pembro.   Trend seems to be developing where pan-tumor physicians  who have already heavily utilized nivo over pembro to date (ie in lung) are stating that they will continue to use nivo for HN (""all things being pretty equal, we use what we are most comfortable with""). 

HN specialists or those with more limited PD1 experience, are utilizing pembro due to its first approved status and more sites having experience with pembro HN trials",22
GU,Territory,  MO,8.36405005688,1.30322047237e-11,84,815,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","RTL who splits time between Academic GU specialists and community generalist (ie, also treats lung) shared that he is NOT testing for PDL1 in RCC  (Note that TL is also not currently testing NSCLC patients for PDL1 outside of trials).  TL did state that he thinks it is very 'intriguing' why PDL1 is enriching in some tumor types (ie, nonsq lung; mel) and not others (RCC).  

TL prefers to give nivo 2L in RCC (~70% of 2L cases), however if patient travels long distances will sometimes utilized cabozatanib due to oral conveniences and ""predictable toxicities that can almost be managed over the phone with dose reduction"".","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.",899
3L,Territory,  MO,7.69872789327,4.84255226895e-05,19,518,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",537
sunitinib,Territory,  MO,7.69872789327,4.84255226895e-05,19,348,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.","RTL believes that the data suggests that RCC patients should see nivolumab (or some PD-1 inhibitor) as early in therapy as possible due to possibility of long-term durable response.  Will continue to prefer nivo prior to cabozatanib even with OS benefit. 

Believes in MOA-switching more than recycling ('patients should see as many classes as possible because you never know what one they will respond to) and typically moves from sunitinib-->nivo-->everolimus-->axitinib/cabo.",367
nearly,Territory,  MO,6.72111165285,4.17050835106e-05,23,0,"LTL shared story of a PDL1 negative patient enrolled on CA209-153 who experienced a rapid near CR and has maintained response for nearly 1 year.  Based on this experience, TL stated that he ""would deny a 2L+ NSCLC patient nivo based on lack of PDL1 status""","NTL in sarcoma shared that he has personally treated nearly 100 sarcoma patients with I-O therapy/  About half were on trial (SARC028 or ALLIANCE A091401) and half off protocol.  Over half of the patient have been treated with ipi+nivo combination, and he shared that he has seen ""just amazing results, including probably 6-7 CRs, particularly good responses in Uterine Leiomyeosarcomas, Liposarcomas, and Osteosarcomas.  He shared that this is his standard 2L or 3L treatment for many patients now.  He stated that BMS Access support has been ""beyond wonderful"" and hat he has also had sporadic success in getting insurance reimbursement.","RTL shared that in his ~8 RCC patients (a few started off-label prior to approval and out ~5 months) he has not seen any response that would have qualified as RECIST responders, however nearly all have stabilized disease or modest shrinkage and are feeling markedly better.  States that he is perfectly comfortable with this and similar to many agents in GU landscape.  States that unless patients are feeling worse or have other 'triggers', he is starting to scan no earlier than 12-16 weeks as he would not discontinue drug based on that scan anyway.",23
completely,Territory,  MO,6.46906996587,2.24257613913e-05,26,3,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","RTL stated that as more data has come out pan tumor, he has decided that 'psudoprogression is a extremely rare occurrence and not something that 'any longer plays into his decisions making'.  He stated that in RCC, given numerous trx options, he typically won't treat beyond progression with nivo alone.  State that he has found many people with PD on nivo have a mixed response and he hesitates to completely stop nivo. Instead, if patient is fit and experiencing minimal AE, he will continue nivo while adding in his next line of therapy at a reduced dose (3L typically cabo or axitinib).  To date has not experienced any addidive/unexpected toxicity","TL is not testing for PDL1 in bladder (and has no interest in doing so) and was completely unaware of the atezo data around responses in PDL1 neg vs. positive patients.  Reviewed our 275 data and TL stated that he like the fact that responses more consistent across all patients regardless of PDL1.  Stated that once approved, could see himself 'preferring' nivo over atezo due to thins, even though he believe all class agents are essentially the same.",29
testing for PDL1,Territory,  MO,6.27303754266,2.33841481249e-06,39,575,"3 RCC TLs from distinct institutions (small academic, large academic/VA and community practice) state that they have never tested for PDL1 in RCC and see absolutely no value in it as the data has clearly shown no predictive benefit (note that some of the same TLs do routinely perform PDL1 testing in lung).  Multiple TLs also stated that they don't even typically run NGS-type panels in RCC patients (even though they may in other tumor types) as they rarely see any actionable mutations in these patients.","RTL at NCCN institution stated that he sees no value in testing for PDL1 in the rec/met setting.  Stated that he feels story in HN will be the same as in NSCLC... when aPD1 moves into initial treatment/pre-platinum setting, that patient selection by PDL1 will be necessary.  

He states that they 'try' to perform HPV testing, but it is not a reflex test, and rarely occurs outside of oropharyngeal.","LTL in large community practice has not yet used ipi/nivo combination and would reserve for only a young, fit, patient who was PDL1 negative. Otherwise would start with single agent PD-1 (preference for nivo due to familiarity, but feels that pembro is equivalent)  TL does not test for PDL1 in NSCLC and does not value test in that setting, but based on 067 PFS, 069 OS w/ crossover, and due to tox concerns with ipi believes that single agents probably have the best balance of tox and efficacy based on data right now and would reserve combo for PDL1neg.",614
Pediatric,Territory,  MS,57.5,7.67915896938e-08,11,367,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,378
regional TL shared,Territory,  MS,35.5952380952,2.24349709114e-12,18,18,A regional TL shared with me that he is now doing PDL1 testing in his firstline NSCLC patients because of the KN-24 approval.  He acknowledged that most patients will not be over 50% positive and confirmed that Nivo will still be SOC for those patients 2nd line.,A regional TL shared that he has had no problems getting insurance to approve off-label 1L usage of Nivo monotherapy in RCC.  He said that he has seen durable responses approaching 2 years.,"A regional TL shared with me that he believes hypophysitis is exclusive to Ipi rather than Nivo.  He hypothesizes that Ipi cross-reacts with common proto-antigens shared between melanosomes and the pituitary as both originate from a common cell lineage in the neural crest.  He does not think that Nivo recognizes that common antigen, hence the higher incidence of primary thyroiditis with that drug.",36
achieved a CR,Territory,  MS,11.9480519481,5.88831535011e-06,18,356,"A national melanoma TL shared that if a patient achieves a CR, he will stop Opdivo treatment at 1 year.  If the best response is PR, he will stop treatment at 2 years.",A melanoma and GU NTL offered that he stops PD1 therapy when a patient achieves a CR or PR that plateaus.  He gives 1 month worth of therapy extra after they achieve their best response and has done this is approximately 30 patients?he said that he has not experienced a single relapse in these patients.,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.",374
offered,Territory,  MS,5.39445628998,1.09811116819e-08,88,0,"A national H&N TL at an NCI designated cancer center offered that she substitutes Taxol for 5FU in the EXTREME regimen. She said that she ""loves"" weekly taxol and erbitux because she always sees responses.",A local HCP offered that she was able to get Nivolumab for a prostate cancer patient and he achieved a CR.,"A regional TL offered that he will readily use pembro 1L when they receive their FDA indication for NSCLC.  He said that he will use pembro preferentially because of the positive experience he had with their compassionate use, and he had an extremely bad experience with BMS's program involving ""more than 100 emails back and forth"".  With further discussion, he did not use the local ARM but rather used the online compassionate use link on the BMS website; regardless, the ARM has been notified of this.",88
TL shared,Territory,  MS,5.37662337662,2.13161954477e-07,119,1081,Academic RCC TL shared that he would consider cabozatinib over nivolumab in a patient with bone mets based on METEOR data presented at ASCO with the caveat being that the patient must be tolerating prior TKI as the toxicity with cabo is much worse than nivolumab. If patient had a tough time with prior TKI then he would go straight to nivolumab,"A national melanoma TL shared that he has seen a few thyroids preserved with steroids using Nivo, but he never saw that with adrenal insufficiency.",A regional HNSCC TL and lung TL shared that he was very impressed by the -141 data presented at AACR.  He expressed that he is very anxious for the FDA to approve it as he believes it is superior to any other therapeutic options.  He said that he will use it in patients who are PDL1 negative and always prefers an agent that does not require PDL1 testing.,1200
described,Territory,  MS,5.31512605042,4.60856686799e-05,44,0,"RTL from a large academic center presented the 209-205 data at an ASCO review. He described the data as very impressive, commenting on the indication in the post ASCT/BV space and the approval of Opdivo prior to ASCO. He commented on the ""very impressive reduction in tumor volume"" seen in the trial.","Community Pharmacist stated they had a few patients they thought had progressed on Opdivo when it was really pseudoprogression because they were clinically stable as you have described in this ""unbranded"" deck.",NTL for Pediatric lymphoma at a large academic center thinks Nivolumab should be studied in the first relapse setting. She described a COG trial which is being developed with Nivolumab and Brentuximab vedotin.,44
academic center,Territory,  MS,4.86772486772,2.74865928165e-06,103,319,NTL for MM at a large academic center thinks a trial with Urelumab and Nivolumab would be interesting.,NTL for MM at a large academic center thinks the check point inhibitors will remain only in the RR space secondary to their safety profile.,Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,422
Regional TL,Territory,  MS,4.45520581114,7.06201928589e-06,100,1088,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.","A regional TL shared with me that he has been treating SCCHN patients with nivolumab off-label but has yet to see any good responders.  Even with pembro being approved in that space, he offered that he is going to continue using nivo off-label because of his preference for the drug.","A regional TL shared that she was able to get Nivo approved for a SCCHN patient.  This patient is under 50 years old and had failed 5 lines of prior therapy, and after 6 months of Nivo he is near a complete response.",1188
nivolumab,Territory,  MS,2.66576819407,4.93017129352e-07,335,5,Academic RCC TL shared that he would consider cabozatinib over nivolumab in a patient with bone mets based on METEOR data presented at ASCO with the caveat being that the patient must be tolerating prior TKI as the toxicity with cabo is much worse than nivolumab. If patient had a tough time with prior TKI then he would go straight to nivolumab,"A regional TL offered that he had a young metastatic anal sq-carcinoma patient who had failed multiple lines of therapy and received Nivo off-label through our access support.  This patient achieved a CR and he now refers to her as his ""poster child patient"" for nivolumab.",TL at an academic center described a patient who she has treated with nivolumab for cHL with the Nivolumab given prior to transplant. She described that the patient was placed on Brentuximab and did not respond so Nivolumab was added to it. The patient subsequently achieved a CR within 3 months and then proceeded to ASCT. The patient is doing well and had no IMARs.,340
said,Territory,  MS,2.48066748067,2.63472988283e-07,479,0,"A national TL mentioned that he has treated ~8 GBM pts with Nivo and saw ?only a couple responders.? ?Nivo or Pembro monotherapy is not going to be the answer.?
Same TL said he was skeptical of the efficacy of anti-PD1 plus radiation. He said that he thinks PD1 plus another checkpoint inhibitor is going to be key, saying that he has not given up on Nivo plus Ipi.","At a local Best of ASCO meeting, a regional lung TL approached me and offered the following comments about -026.  He said that BMS should not worry about it failing because the -012 publication shows that OS and ORRs are better with Nivo than chemo.  He said that he believes most physicians feel comfortable giving chemo upfront and a good portion will continue to do that and use Nivo 2L.  He said that 5 community physicians have contacted him since the press release specifically asking if they can use Nivo 1L--not a PD1 inhibitor or Keytruda.  He believes that the majority of doctors will prefer using Nivo 1L because of their overwhelming familiarity with it now in the 2L assuming it eventually gets approval in that setting.","A regional TL at a rural community practice told me that the hospital is now doing PDL1 testing on all of their NSCLC patients.  He said the pathologists are also providing the percentage of PDL1 positivity.  When asked if this was due to Pembro's data/label, he admitted that he did not really know the answer but doubted it had to do with Pembro because their group only really uses Nivo.",479
HCP,Territory,  MSL,35.0114942529,4.22548788338e-05,115,124,"An HCP commented how he was not convinced of the activity of Yervoy in the regimen, he feels most of the activity is coming from Opdivo.","An HCP shared that in pancreatic cancer, checkpoint inhibitors have not shown efficacy because the microenvironment is not ideal.","An HCP shared that MSI testing for all CRC specimens is routinely done in Puerto Rico, part of a standard panel.",239
NW territory,Territory,  MT,347.86440678,5.50660117215e-19,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
ASCO'16,Territory,  MT,124.237288136,5.66705011285e-07,5,394,Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,"RTL, a NP with lots of I-O experience, stated that some physicians in their group are 'short-coursing' steroids when treating irAE's, as they are afraid steroids will negatively impact the anti-tumor T cell response.
This is a No-Access site, so there is no opportunity for me to educate those physicians.
TL said that the data from Hodi's ASCO'16 poster from CM-069 will be helpful in educating colleagues that steroid used to treat irAE's don't diminish the tumor response to Ipi+Nivo Regimen.
However, TL said that similar data for Nivo monotherapy in NSCLC would be even more impactful. The perception of irAE's on Nivo are less severe than when on Regimen. So physicians may still want to shorten the steroid treatment on Nivo monotherapy, unless they're shown that there's no reason to do so.","NP at a community hospital reported continued ""difficulty convincing some of my doctor colleagues to initiate steroids appropriately"". NP asked if we ""have a reference for anything published that demonstrates that if patients receive steroids for toxicity from immunotherapy, they don?t suffer worse outcomes?""
I reviewed the 209-069 Hodi poster from ASCO'16 and mentioned other similar analyses from prior Ipi studies. NP was very appreciative and is working to arrange a face-to-face meeting with HCPs to facilitate education on IMAR algorithms.",399
NeoGenomics,Territory,  MT,49.6949152542,2.99404493177e-07,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  MT,41.4124293785,4.93826438552e-06,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
like to see a trial,Territory,  MT,19.3258003766,1.33490987745e-06,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
Academic TL stated,Territory,  MT,17.393220339,2.18818801025e-06,16,162,"Academic TL stated he is using Nivo for all of his 2L RCC patients. ?It's a no-brainier versus Everolimus and is probably better than Cabo, due to better tolerability.?","Academic TL stated he would probably use Pembro (once approved) for 1L NSCLC that is >50% PDL1+, assuming ESMO data confirm everyone's expectations. Everyone else would receive 1L Chemo and then 2L Nivo.",Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,178
Ipi+Nivo,Territory,  MT,10.8707627119,2.46996126187e-09,45,338,"NTL predicts that, even with durable responses seen with PD1 monotherapy, eventually almost all NSCLC patients will progress.  With basically all NSCLC patients receiving PD1 monotherapy at some point in their treatment plan, there will be a huge unmet need for effective treatments post-PD1.  This NTL, who is an investigator on several studies with IO+IO combinations, voiced opinion (based on her experience) that Ipi+Nivo seems to be the only IO+IO combo that can resurrect a response in patients who have failed PD1 monotherapy.  4-1BB, anti-KIR, OX40 etc do not seem to have this activity. TL said this speaks to the ability of Ipi to prime new T cells, rather than just relieving inhibition of existing lymphocyte populations.","Melanoma RTL with lots of I/O experience (Investigator on 209-067), stated his belief that PDL1+ patients don't benefit from adding Ipi to Nivo.  He is testing for PDL1 to determine treatment choice between PD1 monotherapy and Ipi+Nivo combination. PDL1+ patients receive anti-PD1 mono therapy; PDL1neg patients receive Ipi+Nivo Regimen.","There is growing interest from my academic TLs in using Ipi to re-invigorate the T cell response in patients who progress on Nivo.  These could be patients who are on the Nivo maintenance after Ipi+Nivo regimen, or patients who only received Nivo monotherapy.

Rationale is similar as for MDX010-20 study with Ipi, except that in this case, the patient would continue to receive Nivo while adding a few doses of Ipi. TLs favor a Q6W Ipi dosing when added to Nivo.",383
medical oncologists,Territory,  MT,10.2313060818,3.0207702543e-05,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
insights,Territory,  MT,9.42489772063,3.610969978e-07,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
TL said,Territory,  MT,8.50044603033,9.10340444105e-08,86,62,"ENT/H&N surgeon is excited to add Opdivo to his arsenal of Tx options in SCCHN. TL said he would be referring several patients to the local med-onc. However, TL said his ENT office staff could use education around IMARs because patients often will call his office for advice, even after being handed off to the med-onc.  TL said patients strike up a very strong relationship with the surgeon, who is often the first physician to correctly diagnose and treat the disease.  TL requested an in-service by our IOCL (currently in training).","NTL at a large community hospital said he was previous dismissive of Ipi+Nivo for NSCLC but then saw the ""impressive"" Hellman ASCO'16 CM-012 presentation.  However, TL also said regimen may not be a slam-dunk, as KN-021 Pembro+Carbo+Pem data seem equally as impressive as CM-012 regimen data.","I met recently with an RTL and Opdivo Melanoma/NSCLC speaker, who is aware of CA209-384 (although is not participating in that study) and asked if we have addressed the same question in melanoma patients. 
TL stated he would consider stopping treatment for patients who show a CR or near-CR. 
In his opinion, the question 'when can we stop treatment with I/O agents' is interesting in lung but sadly not relevant for most patients due to the low CR rate.  
However, TL said that it's a very relevant question in melanoma, where the Ipi/Nivo combo is producing a higher frequency of CRs.",148
pathologist,Territory,  MT,6.90207156309,1.17810900981e-05,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
TL,Territory,  MT,2.91923682504,8.61972953493e-08,1157,51,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",1208
tolerance,Territory,  N. FL,239.289473684,3.21366071546e-06,4,0,"NSCL metastatic lung pt who was treated with opdivo in academia with good tolerance and improved ECOG, however was found to have progressive disease on imaging while under care in academia and was switched to chemotherapy. The current oncology practice would like to offer him treatment with opdivo again if disease progression on chemo noted. Request for information on resuming opdivo therapy. MIRF was sent.","nsclc patient with presumed hx of colitis in the past who has been treated with opdivo and developed  G2 diarrhea. he was evaluated with colonoscopy that showed mild colitis. complete resolution with steroids however, patient has refused to continue with opdivo despite noticeble improvement in tumor burden. subsequent disease progression and poor tolerance of cytotoxic therapy. Decision to resume opdivo, subsequent diarrhea grade 2. opdivo was placed on hold, prednisone initiated and patient was  further kept on prednisone 10mg po qd and continued on opdivo with good response.",large GYN oncology practice has used opdivo in ovarian cancer with good tolerance and results in one patient. Opdivo was offered for another patient who refused treatment after reading about potential side effects.,4
oncology,Territory,  N. FL,14.8396572827,6.58994130154e-07,97,148,"Pharmacist in a large hematology/oncology practice in Tupelo, MS stated that PI for opdivo  is not clear if premedication is needed. This practice has been premeditating with steroids due to it being a monoclonal antibody. discussed that in ordering guide it is stated that premedication including corticosteroids is not required.","Provider in VA reported a new decision in oncology clinic to no longer request opdivo use if not FDA approved for a specific tumor type. Previously, a non formulary request was filed in order to obtain drug that may not be FDA approved but is being studied.","regional TL has expressed his opinion re: more favorable billing to hospitals vs. private oncology practices based on recent publication by genentech on therapies cost sold to hospitals. TL expressed his concern that 430 billing is what is making a negative impact on revenue for private practices and growing difficulty to compete. He suggested that BMS will follow Genentech example and publish its data on chemo costs to the hospital thus "" uncovering one of the primary drivers of rising drug costs""",245
practice,Territory,  N. FL,8.25136116152,1.32760286486e-05,258,718,"Pharmacist in a large hematology/oncology practice in Tupelo, MS stated that PI for opdivo  is not clear if premedication is needed. This practice has been premeditating with steroids due to it being a monoclonal antibody. discussed that in ordering guide it is stated that premedication including corticosteroids is not required.",physician in a large oncology practice has been changing opdivo schedule to q 3 weeks after patients were on the therapy for a year with good results. Stated that he observed that patient continue to respond after changing schedule to q 3 weeks.,large practice in california has been using opdivo in non-hodgkins lymphoma off label  with very positive results.,976
NW territory,Territory,  N.CA,1279.93939394,7.05591128621e-26,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
sky-rocketed,Territory,  N.CA,274.272727273,5.97298854689e-06,3,577,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",580
NeoGenomics,Territory,  N.CA,182.848484848,2.35344595492e-10,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  N.CA,152.373737374,1.23159271145e-08,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
clone,Territory,  N.CA,91.4242424242,2.93253800625e-05,5,149,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",154
diagnostics,Territory,  N.CA,73.1393939394,2.18833085337e-06,8,1288,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",1296
medical director,Territory,  N.CA,73.1393939394,2.18833085337e-06,8,365,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",373
reflex testing,Territory,  N.CA,52.2424242424,5.61827547844e-06,11,91,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.",102
medical oncologists,Territory,  N.CA,37.6452762923,1.0747133483e-08,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
platform,Territory,  N.CA,36.5696969697,1.65411534858e-05,18,149,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",167
IHC,Territory,  N.CA,33.68261563,1.99533579223e-08,25,536,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",561
insights,Territory,  N.CA,30.4747474747,5.61699333585e-11,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
molecular,Territory,  N.CA,26.1212121212,4.85980608334e-05,17,42,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from medical oncologist giving featured podium presentation at pathology conference in NW territory: i) TL stated that only 22C3 guides 1L NSCLC decisions; ii) TL stated the following: ""In 2L NSCLC setting: if the tissue is PD-L1 positive, pembrolizumab is the therapy of choice. If the tissue is PD-L1 negative, atezolizumab and nivolumab are therapies of choice. Pembrolizumab is favored for PD-L1 positive patients""; iii) TL made the statement that ""FDA invented the term 'complementary diagnostics' just for the sake of 28-8 assay as FDA did not know what to do with this assay""; iv) TL is reflex testing using 22C3 for PD-L1 along with molecular testing (EGFR, ALK, ROS1); v) TL stated that ""22C3 is the test to do"".",59
SP142,Territory,  N.CA,26.1212121212,4.85980608334e-05,17,146,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",163
pathologist,Territory,  N.CA,25.3956228956,2.49881406191e-10,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
in-house,Territory,  N.CA,21.7676767677,1.19497706421e-05,25,127,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",152
22C3,Territory,  N.CA,21.5115864528,3.96498818543e-08,49,112,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",161
Community TL,Territory,  N.CA,17.0091613813,1.91888353648e-07,73,820,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Local TL in a large community practice stated that many HCP's are upset with the direct to consumer marketing that BMS is doing with Opdivo.   She said that the commercial has led to many patients coming into clinics wanting Opdivo with high hopes and expecting a cure.     She further stated that the commercials reflect everyone looking healthy and feels that is leading to false hopes for many patients..  She further stated that she is aware that the speaker bureau has no funds for speaking so why isn't the money better utilized for this instead of the money being put into commericals.,Local community TL in large practice offered that he would like to see trials with Nivolumab in patients with MDS.    He offered that many trials being done have limitations with regards to platelet or neutrophil count which leads to ineligibility for trials as many still involve chemotherapy.   He feels this is a huge unmet need and that immunotherapy could potentially help these patients.,893
sent,Territory,  N.CA,14.6931818182,1.10325079614e-07,64,529,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",593
utilized,Territory,  N.CA,13.7136363636,1.7368986934e-05,45,0,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Community TL offered information that they have utilized Opdivo off-label for a patient with leiomyosarcoma who had gone through multiple treatments including going to a local academic center.   Patient came back to this site and MD started Opdivo.  The patient had a full response to therapy and continues to do well.    The staff stated that BMS has exceeded their expectations for help with this patient.,Community TL in large practice offered information that they utilized Opdivo in patients before the FDA approval with good results and stated this now gives multiple patients hope.   He further offered that Opdivo is becoming the go-to drug for multiple tumor types and patients.,45
NW territory,Territory,  N.NV,3036.0,8.33386102995e-30,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
sky-rocketed,Territory,  N.NV,650.571428571,5.71534680333e-07,3,577,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",580
NeoGenomics,Territory,  N.NV,433.714285714,2.84130171907e-12,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  N.NV,361.428571429,2.89813476965e-10,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
clone,Territory,  N.NV,216.857142857,2.8324859683e-06,5,149,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",154
diagnostics,Territory,  N.NV,173.485714286,1.03958511784e-07,8,1288,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",1296
medical director,Territory,  N.NV,173.485714286,1.03958511784e-07,8,365,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",373
healthcare,Territory,  N.NV,162.642857143,4.93497565307e-06,6,688,"Insights from 1:1 meeting with chief of pathology at large healthcare network in NW territory: i) within network, payment in regards to PD-L1 testing is not an issue, whatever medical oncologists order for testing is ultimately covered including PD-L1 testing; ii) no in-house PD-L1 testing is performed, all testing sent out to NeoGenomics; iii) medical oncologists only order 22C3 test but are not reflex testing although TL suggests this will happen very soon; iv) currently reconsidering using ARUP as the prices may be better; v) reports provided by paper/PDF copy which is then scanned and entered into patient records upon receipt; vi) PD-L1 reported as % positive tumor cells and binned into one of the three bins: >50% (high expressers), 1-49% (low expressers), <1% (non-expressers);",Pathologist (IHC lab director) practicing in community hospital setting affiliated with large university medical center in NW territory mentioned 3 RCC patient success stories on nivolumab. TL is not testing for nivolumab use in RCC setting but has done investigational studies on these 3 patients treated with nivolumab looking at PD-L1 status and mutation burden. At least one of the responders to nivolumab lacked PD-L1 expression but had high mutation burden.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",694
Ventana platform,Territory,  N.NV,130.114285714,7.86113526667e-06,7,145,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",152
reflex testing,Territory,  N.NV,123.918367347,2.69576798449e-07,11,91,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.",102
medical oncologists,Territory,  N.NV,89.2941176471,7.35500176948e-11,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
platform,Territory,  N.NV,86.7428571429,8.05617792021e-07,18,149,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",167
IHC,Territory,  N.NV,79.8947368421,1.38045570756e-10,25,536,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",561
insights,Territory,  N.NV,72.2857142857,6.80940292148e-14,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
molecular,Territory,  N.NV,61.9591836735,2.41434585398e-06,17,42,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from medical oncologist giving featured podium presentation at pathology conference in NW territory: i) TL stated that only 22C3 guides 1L NSCLC decisions; ii) TL stated the following: ""In 2L NSCLC setting: if the tissue is PD-L1 positive, pembrolizumab is the therapy of choice. If the tissue is PD-L1 negative, atezolizumab and nivolumab are therapies of choice. Pembrolizumab is favored for PD-L1 positive patients""; iii) TL made the statement that ""FDA invented the term 'complementary diagnostics' just for the sake of 28-8 assay as FDA did not know what to do with this assay""; iv) TL is reflex testing using 22C3 for PD-L1 along with molecular testing (EGFR, ALK, ROS1); v) TL stated that ""22C3 is the test to do"".",59
SP142,Territory,  N.NV,61.9591836735,2.41434585398e-06,17,146,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",163
pathologist,Territory,  N.NV,60.2380952381,3.13304006788e-13,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
network,Territory,  N.NV,57.8285714286,3.04305772666e-06,18,441,"Insights from 1:1 meeting with chief of pathology at large healthcare network in NW territory: i) within network, payment in regards to PD-L1 testing is not an issue, whatever medical oncologists order for testing is ultimately covered including PD-L1 testing; ii) no in-house PD-L1 testing is performed, all testing sent out to NeoGenomics; iii) medical oncologists only order 22C3 test but are not reflex testing although TL suggests this will happen very soon; iv) currently reconsidering using ARUP as the prices may be better; v) reports provided by paper/PDF copy which is then scanned and entered into patient records upon receipt; vi) PD-L1 reported as % positive tumor cells and binned into one of the three bins: >50% (high expressers), 1-49% (low expressers), <1% (non-expressers);",Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,"Insight from three different TLs from the same large healthcare network in NW territory: i) all NSCLC samples are sent out for testing to Neogenomics; ii) none of the pathologists have any granularity on the numbers of cases sent out, exact tests performed, nor whether PD-L1 is currently reflex tested for; iii) no near future effort will be made to bring testing in-house.",459
pathology,Territory,  N.NV,54.2142857143,3.78503245281e-06,19,213,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",232
gained,Territory,  N.NV,54.2142857143,3.78503245281e-06,19,86,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",105
Neuro-ONC,Territory,  NC,48.404494382,1.84056592588e-09,11,39,"When discussing some contradicting data surrounding the effect of WBR and SRT on Tcell infiltration into GBM tumors, one study saying that if facilitated Tcell infiltration, and another study said that RT reduces Tcell's ability to infiltrate the tumor, Neuro-ONC expressed his frustration as ""F- me, we can't seem to figure out anything with this disease.""","Neuro-ONC stated that MGMT as a bio marker for GBM is just as bad as PDL1 status.  ""It can change after RT, or Chemo.  Recurrent tumors can change MGMT status as well.  It also has the same problems as PDL1 status in that there is heterogeneity within the tumor, intratumor and intertumor differences as well.  It is not a great bio marker, but it is all we have to go with now.""","Neuro-ONC stated that in ""slow growth"" recurrent GBM patients that he will try combinations of Opdivo, Opdivo+Bev, Opdivo+Yervoy.  Has had limited success with each possible, but stated that ""limited success is still success in GMB.""",50
National Thought leader,Territory,  NC,37.6479400749,2.71798589994e-07,9,0,"A National Thought leader stated, when asked about the future of bio markers in NSCLC:  To solve the puzzle (in lung), people are going to have to forget about PDL1.  PD1 inhibitors work but that doesn't mean that PDL1 expression is the first place that people should look.","National Thought leader answering questions about PDL1 testing at a recent dinner presentation stated:
1.  I think PDL1 data will be big at ASCO this year, but I think it will take a big step back.  I think the data will muddy the water more than it already is.  
2. PDL1 (expression) will be something big in the future, but right now we just don't know enough about it to use the data correctly.  
3.  Regardless of the PDL1 expression you are doing your patients a disservice if you are not using Opdivo 2L in your NSCLC patients.","A National Thought leader stated, when asked about the future of bio markers in NSCLC: I think investigators should start looking at it from the end and work backwards.  We should focus on the responders.  Find out what commonalities they have and work from there.  We are currently testing for a bio marker (PDL1) from samples where we know the expression can be different than when treatment starts (biopsy before 1L treatmen) and then assuming that the marker we looked at is the same when determining the use of 2L treatment.",9
respect,Territory,  NC,12.1011235955,1.47871143543e-06,20,122,"Regional meeting TL stated "" PD-1, PD-L1 and CTLA4 are not the whole story with respect to the immune system, there is much more that we need to find out""","With respect to Opdivo ""Cancer is the nail and you guys own the hammer""","With respect to 026, KOL in my territory noted, ""So single agent Nivo didn't meet PFS end point, big deal!  We're all waiting for the combination data with ipilimumab anyway in the front line!""",142
GBM,Territory,  NC,5.09520993495,3.06941013789e-05,49,79,"Neuro-ONC stated that they look forward to seeing OPDIVO + OPTUNE in GBM patients.  When asked why she thought this combination would benefit patients she stated that OPTUNE will keep the tumor at bay, giving Opdivo time to mount a response.  She is an OPTUNE speaker, and stated that she will be submitting an ISR for this concept, and has already been told by NOVOCURE that they would like to participate jointly with an IO company.","Neuro-ONC stated that in ""slow growth"" recurrent GBM patients that he will try combinations of Opdivo, Opdivo+Bev, Opdivo+Yervoy.  Has had limited success with each possible, but stated that ""limited success is still success in GMB.""","Neuro-ONC stated that 18months is her average from initial diagnosis with GBM to death.  Recurrence at about 10-12 months and roughly 6 months post recurrence till death.  Patients where recurrence isn't until 20months are on the far end of the GBM spectrum, and not representative of the normal patient.  Stated this in discussion around the Pembro GBM population of -028.",128
IO therapy,Territory,  NC,4.42916942058,2.66011600489e-05,64,26,"When asked what his criteria was for determining treatment beyond progression for RCC, National Thought leaders stated, that if the progression appears to be a ""slow growing"" or 1-2 new lesions, he will treat beyond this ""progression"" because he feels this is likely an IO induced progression/Non-traditional response.

However, if the primary grows rapidly, or if there are more than 2 new lesions then that is most likely true progression and it is unlikely that continuing IO therapy will sway the balance.",A National Lung TL stated that she thinks that Chemotherapy plus IO therapy is a mistake.  The tails of the OS curves will minimize 1L IO therapy because basically you are giving chemo to patients that don't need it.  So when those patients come off treatment because of the toxicities (likely from the chemo) you have lost the benefit of the IO therapy.,"A National Thought Leader (and NCCN member) stated that she feels community treaters of NSCLC with IO therapy are not experienced enough to treat appropriately.  She stated she has patients that show up to her that are 6 months past NSCLC diagnosis and have gone through sometimes 2 IO agents (used one PD1 fail, try other PD1).  

She says that she does not think community treaters wait long enough for IO agents to work and are too quick to call a treatment ""a failure"" and aren't providing the patients immune system with enough time to actually mount a response.

Too often they are associating a decrease in performance status, or more often, AEs with no tumors shrinkage seen within the first 3-6 weeks as an IO failure when that may not be the case.",90
NCI,Territory,  ND,206.980392157,5.29197999052e-12,16,112,"RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.","RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.",128
hematologic malignancies,Territory,  ND,88.7058823529,3.18892283084e-05,5,4,"TL presenting at a national congress stated that even though cHL is the ""poster child"" for  PD-1 blockade in hematologic malignancies, there may be a role in DLBCL and FL, but will be limited to certain populations.",NTL mentioned the requirement for more education and understanding around the development and/or persistence of AEs over time following IO therapy in hematologic malignancies.,"NTL at an academic center noted that although the topic of pseudoprogression is being understood in solid tumors, there is a gap in the understanding of how to interpret responses when using IO agents in hematologic malignancies.  NTL suggested that either BMS internally, or in partnership, review available PET data from trials  in HL and correlate with outcomes for patients. This information would  help clinicians understand responses of hematologic malignancies during treatment with IO agents.",9
PET,Territory,  ND,44.3529411765,9.30596448229e-06,11,0,"RTL from an NCI Cancer Center stated that be believes in a PET directed approach to treating lymphoma,  but that changing treatment modifications based on PET results should only be done on trail at this point. In addition, if changes to therapy are going to be made based on a positive PET result, a second biopsy should be conducted to prove disease.","A NTL commented that at the recent IWNHL meeting there was a major discussion on the use of scans in lymphoma trials. There is concern that FDA is too heavy on scans for therapies (ie. requiring both contrast CT and PET). Moreover, as scans become utilized more frequently, and the ability to detect MRD increases patients will develop ""scan-xiety"" and always be afraid of what the next scan will say. Thus, there is a need to have a healthy balance between understanding MRD and what level of disease really affects QoL and survival.","NTL at an academic center confirmed that the shortage of bleomycin has had an impact on their practice, even though this institution has a stock pile.  As a result, they are treating patients according to the RATHL study by dropping bleomycin from ABVD after two cycles if the PET scan is negative.  In addition, belomycin is not being used for treatment of testicular lymphoma.",11
cancer center,Territory,  ND,21.0092879257,7.36228258141e-09,46,130,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.","RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.",176
lymphoma,Territory,  ND,15.0348953141,1.97012771657e-08,73,12,TL at academic center noted that there is a big gap in secondary CNS lymphoma and that the population is bigger than primary. Offered that Merck is doing a trial in primary CNS lymphoma and is missing an bigger opportunity.,A NTL and NCCN panel member noted that the International Workshop on Non-Hodgkin Lymphoma has a manuscript in review that proposes updated response evaluation criteria. This criteria will be ?uni-dimensional? (one rather than two measurements).  One impetus for the update was to reduce compounding errors that occur in the two dimension criteria. There was no clear timeline for publication as it is only the review process.,"RTL and academic center spoke positively about anti-PD1 therapy in lymphoma, noted that transformed lymphoma and EBV-driven lymphomas are gaps in research, offered anecdote that they treated nasal NK driven lymphoma off-study with promising reuslts.",85
academic center,Territory,  ND,11.4459203036,2.74846782088e-06,103,319,"NTL at an academic center confirmed that the shortage of bleomycin has had an impact on their practice, even though this institution has a stock pile.  As a result, they are treating patients according to the RATHL study by dropping bleomycin from ABVD after two cycles if the PET scan is negative.  In addition, belomycin is not being used for treatment of testicular lymphoma.",TL at academic center noted that there is a big gap in secondary CNS lymphoma and that the population is bigger than primary. Offered that Merck is doing a trial in primary CNS lymphoma and is missing an bigger opportunity.,"RTL and academic center spoke positively about anti-PD1 therapy in lymphoma, noted that transformed lymphoma and EBV-driven lymphomas are gaps in research, offered anecdote that they treated nasal NK driven lymphoma off-study with promising reuslts.",422
noted,Territory,  ND,8.73618538324,7.53534212771e-08,144,0,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","RTL noted that he is still trying to wrap his head around the ATHERA trial data for high-risk young HL patients noting the PFS benefit with BV but not OS benefit. Thus, not sure if maintenance in cHL is useful.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.",144
Numerous TLs,Territory,  NE,108.805970149,1.04978432174e-06,6,253,"Numerous TLs expressed maintains a rigid threshold for pembro use 1L to only those with >50% PDL1 expression. With them stating the reasoning is the current science and that you ""don't want to burn a therapeutic bridge by using an IO in the wrong setting (using in the wrong PDL1 population in 1L when all comers can derive benefit from 2L).","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.","TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",259
tone,Territory,  NE,87.0447761194,1.92626860849e-05,4,0,"With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",4
AE profile,Territory,  NE,19.0410447761,1.77698544685e-06,14,338,"In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",Several NTLs/RTLs have commented that there is significant hesitancy to incorporate Ipi into treatment in RCC (either bad previous experience with Ipi from melanoma or prostate or heard about the combination from melanoma colleagues). When discuss the different dosing of Nivo+Ipi in RCC vs melanoma they become a little more supportive. State the key deciding factor between Ipi+Nivo and Cabo in the 1L will not be efficacy rather it will be the safety profiles and the QoL data.,TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,352
like to see a trial,Territory,  NE,16.9253731343,3.03172801203e-06,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
comers,Territory,  NE,16.3208955224,1.46223823367e-07,20,0,"TLs state the OAK data is intriguing in that the agent works in the all comer population, has apparent efficacy in the PDL1 non-expressing population, has q3w convenience, and a highly tolerable safety profile. When questioned about how to choose between agents in the 2L the TLs in general still feel that atezo is a ""me too"" drug and that nivo has such broad indications across tumor types with proven efficacy and support for many others that there is an established loyalty to nivo. Hence, the TLs predict varied physician preference (""choose one or the other and neither are wrong"") in the 2L.",TLs with close Roche relationships have all stated the indication for atezolizumab will be in an all comer 2L NSCLC population (not restricted by PDL1).,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",20
q3wk,Territory,  NE,14.5074626866,2.90609620772e-05,14,425,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.",TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,439
TLs,Territory,  NE,12.6214925373,1.91129995902e-18,98,6,"Numerous community TLs all had high level knowledge of -026 not meeting primary endpoint and KN -024 having very positive data. When I described the differences in trial design the TLs seemed very satisfied about why the outcomes were divergent and did not see the data as impacting 2L treatment choices. However, did state that when Pembro is indicated in 1L PDL1 testing will become a standard practice - which is not what is occurring today.","NTLs and local TLs agree that pembro will not be the ""end of the story for 1L, with significant potential of Ipi/Nivo to affect a broader patient population."" However these TLs caution that there is a significant safety concern that has to be overcome with the combination (especially for the community).","Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.",104
IO-IO,Territory,  NE,10.1552238806,3.53393778425e-05,21,757,TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.","In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",778
highly,Territory,  NE,8.90230664858,6.54221885504e-06,30,34,"Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.","In regards to -026, thinks if the data is equivalent to chemo then it will still be practice changing based on AE profile. Highly excited for IO in front line and would prefer not to have to test for PDL1.","TL summarized how he is communicating testing and clinical implications in NSCLC that has resonated well with community HCPs: ""Focus on Merck's assay for testing given pembro's 1L lung indication but realize that using Merck's test does not exclude other therapies (e.g. Nivo) for 2L."" The TL then expands ""In fact projects like Blueprint and NCCN specifically support the idea that the Merck assay and the BMS assay are highly alike so the assay you use only matters if you are thinking about Atezo.""",64
regards,Territory,  NE,3.85354477612,1.69924207092e-05,112,0,"In regards to nccRCC the NCCN panelist stated there will. It be any updates to the guidelines until there is evidence for use in that population because of the transition of the panel to emphasizing evidence blocks. Panelist specifically stated ""everyone should receive Nivo in principle but there is just no evidence to support it in nccRCC.""","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",112
increase,Territory,  NE,3.81381751039,1.90786538866e-05,113,36,"Increasing concern among community physicians around infusion chair time. With the continual Nivo dosing and the increased OS in patients, several community clinics are struggling to manage the increased demand. Numerous community HCPs emphasized a need for shorter infusion times and a more robust effort in studying when to stop IO therapy (especially if a patient had a PR/CR). These physicians are now considering switching to keytruda in NSCLC because of the q3wk 30min infusion convenience.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.",149
Path TL,Territory,  NH,304.432989691,1.91401667404e-14,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
Path,Territory,  NH,121.773195876,6.27147940217e-11,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
IVD,Territory,  NH,40.5910652921,3.64254652058e-05,6,146,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Pathology TL at a mid-size academic center has completed validation of 22C3 IVD 12/2/2016, testing is now available in-house.
-TL reported validation of platform and antibody were simple and straightforward
-TL reported training by watching Dako online module for scoring
-TL reported training on scoring was an ""uphill battle""",152
1st line NSCLC,Territory,  NH,30.4432989691,1.19840397856e-07,17,26,"A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).","A LTL in Boston stated that based on all the data coming out around 1st line NSCLC, they should be testing all pts for PD-L1 status.  However, he added that ""he has requested testing on 15 or so samples (1st line pts) and all of them have come back negative"".",43
score,Territory,  NH,14.2068728522,4.67519714649e-06,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
Boston,Territory,  NH,14.2068728522,4.67519714649e-06,40,82,"A Melanoma NTL from Boston, stated that ""there is no value in doing PD-L1 testing in melanoma pts.""  He added that ""I don't test any of my pts""","A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",122
pathologist,Territory,  NH,11.9928147454,2.69155192572e-09,45,211,"NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times",256
22C3,Territory,  NH,9.51353092784,9.40880821166e-07,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
1st line,Territory,  NH,7.77275718359,5.28226276269e-07,69,712,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","A RTL for Lung shared that he was surprised to hear that CM26 was negative. He is looking forward to seeing the subgroup analysis based on other PD-L1 cut offs, but he added that this increases the need to do PD-L1 testing in all 1st line NSCLC pts. He also suggested the need to choose PD-1 agents in the 2nd line settting based on PD-L1 results.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",781
pts,Territory,  NH,7.61082474227,1.42930363781e-15,164,1624,"An RTL shared that when a pts runs into toxicity with Nivo/Ipi combo, if the pts has a CR or PR at that time, then they stop treatment.  However, at the time of toxicity with the combo, if the pt only has SD or PD, then they continue PD-1 monotherapy.  The added that about 1 out of 4 times they continue with Pembro as oppose to Nivo.","A NTL in melanoma shared that combination IO therapy (mostly regimen) is their primary method of treatment all melanoma pts at their institution.  Even if the pts has bully, BRAF+ melanoma, because of the rapid RR scene with Nivo/Ipi, they would choose Nivo/Ipi over BRAF+MEK combo.",A RTL stated that he does not test PD-L1 for his RCC pts.,1788
LTL,Territory,  NH,5.3723468769,1.43046736794e-05,79,800,"An LTL informed me that he doesn't test for PD-L1 status in the 2nd line NSCLC setting and stated that there is no need for it. He did add that his colleague is testing some of his/her pts for PD-L1 status in the 2nd line setting and is ordering PD-L1 status upon initial biopsy (pre-1st line treatment). Upon inquiring why? The LTL shared that by having this information, for PD-L1+ pts, both Pembro and Nivo would be good options with high ORR in the 2nd line setting, and if the pt was PD-L1 negative then opdivo (only) would still be an ""ok"" option.","An LTL/RTL stated/suggested that his plan for 2nd line NSCLC is to start nivolumab while waiting for PL-L1 test expression.  If the PD-L1 test comes back at 50%+ positive, he would switch the pt to Keytruda (view the data stronger as this sub-population was specifically studied by Merck).  If the test comes back between 1-49%, he said that it's a 50/50 choice between Opdivo/Keytruda and it would be up to the pts on q2w drug or q3w drug.  If the PD-L1<1%, he would choose Nivo...but if insurance had an issue, then he would switch to docetaxel.",A LTL stated that no one in her practice test for PD-L1 for her RCC pts.,879
PD-L1,Territory,  NH,5.07388316151,4.23958791432e-08,306,375,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",681
PD-L1 testing,Territory,  NH,4.83678581752,1.17177465409e-06,123,444,"Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",567
added,Territory,  NH,3.92072789753,1.38251305171e-05,148,0,A Regional TL shared that they are testing all there NSCLC pts for PD-L1.  He added that his institution is still trying to figure out if they should internalize the PD-L1 test or just continue to send it out.,"An Academic TL shared that if a pt fails monotherapy PD-1 (either pembro or Nivo), they then add ipilimumab on top especially if the pt did not experience any AEs to monotherapy anti-PD-1 therapy.  The TL was hinting toward lack of toxicity equals 'not enough IO blockade' and hence they need to use combo IO in those pts.","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",148
southeast region,Territory,  NJ,148.839416058,3.42635357765e-09,7,169,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
cHD,Territory,  NJ,127.576642336,6.37202611259e-08,6,318,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,RTL perspective for cHD is the bar for deferring transplant is a durable PFS at 2 years then can consider the treatment instead of transplant.,324
gathered the following unsolicited,Territory,  NJ,127.576642336,6.37202611259e-08,6,175,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",181
Ritchie,Territory,  NJ,127.576642336,6.37202611259e-08,6,170,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
NCI-designated,Territory,  NJ,74.4197080292,1.47795051788e-08,8,157,"Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).",165
Joseph,Territory,  NJ,63.7883211679,2.44601983771e-07,7,170,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",177
NCCN panel member,Territory,  NJ,21.2627737226,4.18967639243e-05,9,561,National TL and NCCN panel member is concerned about the combination of nivo/ipi in the community settings. He feels that there is a general lack of knowledge in how to manage IMAEs in the community and not all of these docs are currently treating melanoma patients,"National TL and NCCN panel member feels that with Merck's recent press release and based on the -026 inclusion criteria that testing up front will become standard and he is now ""preparing his lab"" for 1st line testing. He believe that Merck has us beat in that they already have their tests in central labs and BMS should make sure that our test is broadly available prior to the publication being related. BMS potentially has an advantage if the PDL1 cutoff includes a broader population otherwise dosing Q2W vs Q3W will become a major barrier to using nivo.",National TL and NCCN panel member explained that he has had very high rate of PDL1 screen failures during an 1L atezo lung study. He struggles to find PDL1+ patients and wonders if there is a geographical relation. Is there higher rates of PDL1 positivity in the tobacco belt? He has turned down Merck studies with PDL1 >50% cut off because he seldom finds a patient with that high of expression.,570
corticosteroids,Territory,  NJ,17.0102189781,6.02006192268e-07,17,260,"Community HCP holding treatment versus initiating corticosteroids to manage IMARs.  An APN from practice was present at our dinner program.  Discussion around MOA, half life of drug and incidence of IMARs off treatment.  HCP thought is ""drug will leave system"" and IMAR should resolve.",PCP in a community practice does not test for PD-L1 to make treatment decisions.  He uses OPDIVO on and off label. Discussion around using low dose corticosteroids to manage fatigue and continue to treat.  Advised NOT to use as such unless he has treated an IMAR and is tapering.  We had discussion around masking symptoms of potential IMAR and efficacy in absence of IMAR.  Reviewed IMAR guide and algorithm.,"Continued hesitancy of community HCPs in utilizing high dose corticosteroids in managing IMARs.  In some of these practices, nurse are well aware of benefits and efficacy in treating IMARs with corticosteroids.  Physicians do not have comfort using high dose, thus reporting inability to taper corticosteroids in some cases.",277
comparable,Territory,  NJ,15.947080292,2.05136342385e-05,13,498,"A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen",511
thought leader,Territory,  NJ,11.256762559,1.49747478334e-06,25,22,Thought leader in a major institution treating patient with PEMBRO vs OPDIVO due to travel inconvenience for patient.,Community thought leader reporting that our competitor MERCK is offering 100% guaranteed coverage for their product on all off label use.  Thought leader continues to use OPDIVO for his patients because no testing required.,Thought leaders in a major institute having concerns using regimen in patients with comorbid conditions and/or older age.,47
member,Territory,  NJ,9.56824817518,4.21167621637e-06,37,111,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",148
National TL,Territory,  NJ,8.12988407042,1.62568379011e-07,51,544,National TL who sits on advisory board for T-vec expressed that there has not been a concept presented for T-vec + regimen. He has been unofficially encouraged to do so.,National TL and NCCN panel member is concerned about the combination of nivo/ipi in the community settings. He feels that there is a general lack of knowledge in how to manage IMAEs in the community and not all of these docs are currently treating melanoma patients,National TL and NCCN panel member explained that he has had very high rate of PDL1 screen failures during an 1L atezo lung study. He struggles to find PDL1+ patients and wonders if there is a geographical relation. Is there higher rates of PDL1 positivity in the tobacco belt? He has turned down Merck studies with PDL1 >50% cut off because he seldom finds a patient with that high of expression.,595
patients respond,Territory,  NJ,7.59384775808,6.6024784023e-06,37,22,"Local TL explains that she believes she experiences more immune related AEs than is quoted in the study. she claims that ""the adverse events are killing her"". She has even experienced an incidence of encephalitis, the patient did respond to steroids however whenever she begins to taper the steroids his headaches and other symptoms return. She is now going to try IVIG.","A community HCP using OPDIVO off-label in many patients with poor performance status.  He feels these patients cannot tolerate chemo.  He is treating most of these patients with off-label OPDIVO and patients are responding and having improved performance status, ie some patients presenting in wheelchairs and now are walking.  Also some of these patients would probably be on hospice, but with OPDIVO surviving even 6,8, 10 months later.","BIG question in HD, is How is systemic immunity different in HD than in other tumors? The belief is there in that questions lies the answer as to why cHD patients respond to Nivo whereas other lymphomas have not seem the same efficacy.",59
major,Territory,  NJ,6.28218314532,1.78965992935e-06,90,483,A major academic institute utilizing Regimen as standard of care in melanoma,NP at academic practice says that the number one major complaint that she is receiving from patients is a radiated arthralgia,Thought leaders in a major institute having concerns using regimen in patients with comorbid conditions and/or older age.,573
Regional TL,Territory,  NJ,6.23219229801,6.20440176791e-08,100,1088,Regional TL who treats GU patients says he is participating in a CTEP study exploring cabo+nivo+ipi in prostate cancer and they is seeing great results.,"Regional TL who treats GU patients says that of all the departments they feel the least need for PDL1 testing. However, because of the recent 1st line lung indication with an IO agent requiring testing their institution is now working on doing an in house test. he doesn't feel like he will use it","Regional TL for Hodgkin Lymphoma reports that he currently has 13 patients on anti-PD1 with HL. All patients were previously heavily treated. 12 are on Keytruda and 1 is on Opdivo. The reason for more Keytruda, as per the RTL, simply because the insurance companies were quicker to approve Keytruda than OPDIVO. He believes this is because Keytruda was approved first.",1188
opinion,Territory,  NJ,5.21539732819,9.9220901502e-06,72,109,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",181
reported,Territory,  NJ,3.2602919708,8.75781397376e-06,182,10,"TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",192
Numerous TLs,Territory,  NM,147.5,2.54542695758e-07,6,253,"Numerous TLs expressed maintains a rigid threshold for pembro use 1L to only those with >50% PDL1 expression. With them stating the reasoning is the current science and that you ""don't want to burn a therapeutic bridge by using an IO in the wrong setting (using in the wrong PDL1 population in 1L when all comers can derive benefit from 2L).","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.","TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",259
tone,Territory,  NM,118.0,6.18060483315e-06,4,0,"With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",4
restriction,Territory,  NM,39.3333333333,4.09227983647e-05,6,16,"TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",Many community TLs aware of Pembro 1L press release and asking about Nivo data in the 1L NSCLC. When review -026 trial design many express surprise that Nivo had a PdL1 restriction in the trial design. They then emphasize the problems with pdl1 testing and why they like Nivo in 2L is because it is unrestricted. State the main differentiating factor in 1L given both Nivo and pembro will require testing is which company makes the testing process easier/faster/more understandable.,"Many community TLs are supportive of the biomarker label restriction for Merck because it provides clear direction for using IO, otherwise ""there is no clear guidelines on the use of PDL1 expression as a biomarker of response"" which leaves too much room for interpretation/confusion and inconsistent clinical practice.",22
AE profile,Territory,  NM,25.8125,2.65696864168e-07,14,338,"In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",Several NTLs/RTLs have commented that there is significant hesitancy to incorporate Ipi into treatment in RCC (either bad previous experience with Ipi from melanoma or prostate or heard about the combination from melanoma colleagues). When discuss the different dosing of Nivo+Ipi in RCC vs melanoma they become a little more supportive. State the key deciding factor between Ipi+Nivo and Cabo in the 1L will not be efficacy rather it will be the safety profiles and the QoL data.,TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,352
comers,Territory,  NM,22.125,1.32397452436e-08,20,0,"TLs state the OAK data is intriguing in that the agent works in the all comer population, has apparent efficacy in the PDL1 non-expressing population, has q3w convenience, and a highly tolerable safety profile. When questioned about how to choose between agents in the 2L the TLs in general still feel that atezo is a ""me too"" drug and that nivo has such broad indications across tumor types with proven efficacy and support for many others that there is an established loyalty to nivo. Hence, the TLs predict varied physician preference (""choose one or the other and neither are wrong"") in the 2L.",TLs with close Roche relationships have all stated the indication for atezolizumab will be in an all comer 2L NSCLC population (not restricted by PDL1).,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",20
q3wk,Territory,  NM,19.6666666667,5.77160000567e-06,14,425,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.",TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,439
TLs,Territory,  NM,17.11,1.76149122261e-21,98,6,"Numerous community TLs all had high level knowledge of -026 not meeting primary endpoint and KN -024 having very positive data. When I described the differences in trial design the TLs seemed very satisfied about why the outcomes were divergent and did not see the data as impacting 2L treatment choices. However, did state that when Pembro is indicated in 1L PDL1 testing will become a standard practice - which is not what is occurring today.","NTLs and local TLs agree that pembro will not be the ""end of the story for 1L, with significant potential of Ipi/Nivo to affect a broader patient population."" However these TLs caution that there is a significant safety concern that has to be overcome with the combination (especially for the community).","Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.",104
established,Territory,  NM,14.75,1.95549164313e-05,17,0,"NTL regards PD1/PDL1 inhibitors as the same and regards the lack of testing as a significant advantage for Nivo. When thinking about 1L NSCLC TL believes PDL1 testing will be required across all agents, hence the differentiating factor will be the agent with the most diagnostic support to help practitioners establish SOPs for ordering and understanding the PDL1 diagnostic.","TL was very upset that BMS had ""such a stupid trial design for 1L NSCLC."" Specifically pointing out the PFS endpoint and treatment arm imbalances.  In addition, TL was upset that they are now forced to test for PD-L1 status even though the assays are complicated and not fully established. When asked about testing the TL stated they solely leave the process to the pathologists stating they call the pathologist and say ""I want to use pembro in 1L test PDL1."" Further TL was upset because does not want to be in a position to decide on treatment if less than 50% but close to the threshold (e.g 45-50%, below 45 they were very clear they would choose chemo). Nivo was still regarded as the agent of choice for 2L.","TL applauded BMS for its scientific integrity and rigor. However, given the 1L data states that Merck applied a smart strategy with their approach. Specifically stating that using the PDL1 biomarker in a restricted population proved the utility of the biomarker and established its utility to select for patient's with maximal benefit. The approach is one that many physicians feel very good about because they feel their treatment has a higher likelihood of impact and that they are using the agent in an appropriate patient. In addition, payers like the approach because of the clear value in these patients. Hence, Merck has generated a more clear and useful message regarding the use of IO, compared with the the more muddled/confusing idea of using IO in an all comer population for mixed efficacy/value results.",17
IO-IO,Territory,  NM,13.7666666667,5.66375568628e-06,21,757,TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.","In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",778
highly,Territory,  NM,12.0681818182,6.55894155256e-07,30,34,"Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.","In regards to -026, thinks if the data is equivalent to chemo then it will still be practice changing based on AE profile. Highly excited for IO in front line and would prefer not to have to test for PDL1.","TL summarized how he is communicating testing and clinical implications in NSCLC that has resonated well with community HCPs: ""Focus on Merck's assay for testing given pembro's 1L lung indication but realize that using Merck's test does not exclude other therapies (e.g. Nivo) for 2L."" The TL then expands ""In fact projects like Blueprint and NCCN specifically support the idea that the Merck assay and the BMS assay are highly alike so the assay you use only matters if you are thinking about Atezo.""",64
key,Territory,  NM,7.86666666667,3.52356789589e-05,37,0,"Per NTL a large question in bladder field is how the geriatric oncology patients will respond to IO. Hence increased data on efficacy, safety, and QoL in that specific population will be a key differentiator between agents.","Mixed TL opinions regarding IO+Chemo, some are excited about the potential to overcome PDL1 and the ORR, others feel the strategy is a ""shame"" as it does not seem to provide added efficacy and more toxicity. All TLs have applauded BMS forthe -227 trial design as addressing the key IO+Chemo or IO+IO question.","NTL who does not believe in PDL1 testing in 2L NSCLC, stated that the key impact from -026 is the renewed emphasis on PDL1 as a biomarker. While the data is unknown the -026 and KN-024 press releases leads one to assume that there will be a specific threshold of PDL1 expression that adequately identifies a population that derives clinical benefit from checkpoint inhibition. The consequence will be 1L PDL1 expression level will be used for treatment decisions, in 2L the expression level may start being used for clinical decisions to ensure economic justification.",37
SOC,Territory,  NM,6.62244897959,5.73428746736e-06,69,492,"NCCN panelist expects Cabo to be SOC in 1L with Nivo remaining SOC in 2L with lenvantinib/Everolimus or axitinib in 3L. The TL is highly skeptical of Ipi/Nivo adoption in 1L mostly due to ""bad Ipi experiences in melanoma and prostate"" (a theme that has been echoed by several GU TLs with Ipi experience in prostate). However, willing to change opinion if the HR significantly outperforms sunitinib, has an AE profile similar to Nivo monotherapy, and good QoL outcomes.","All GU treating TLs at academic cancer center (including RCC NCCN panelist) met to develop institutional RCC treatment algorithm (so practice decisions are standardized across all providers). Evaluated all RCC asco data. For 2L have decided to keep Nivo as SOC (even though the cabo and lenvantinib is good, all would prefer to give a patient an IO agent sooner than later). 
There were key populations that were discussed as exceptions: 
1) bone met population (initially were thinking cabo but as increasing Nivo data in that population have decided Nivo in that group) 
2) Those with autoimmune disease will most likely receive a TKI, until additional data with Nivo
3) Those with non-clear cell histology will be decided in a case by case, sarcomatoid will most likely get Nivo but others are debated until -374 data is available.","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",561
regards,Territory,  NM,5.22395833333,4.61489424081e-07,112,0,"In regards to nccRCC the NCCN panelist stated there will. It be any updates to the guidelines until there is evidence for use in that population because of the transition of the panel to emphasizing evidence blocks. Panelist specifically stated ""everyone should receive Nivo in principle but there is just no evidence to support it in nccRCC.""","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",112
increase,Territory,  NM,4.81632653061,2.40131136789e-06,113,36,"Increasing concern among community physicians around infusion chair time. With the continual Nivo dosing and the increased OS in patients, several community clinics are struggling to manage the increased demand. Numerous community HCPs emphasized a need for shorter infusion times and a more robust effort in studying when to stop IO therapy (especially if a patient had a PR/CR). These physicians are now considering switching to keytruda in NSCLC because of the q3wk 30min infusion convenience.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.",149
indication,Territory,  NM,4.40804597701,4.1873993938e-05,99,0,"Several TLs have mentioned they are concerned about Nivo in SCCHN due to the length of time for indication. Specifically, these TLs were under the impression KN -012 and checkmate -141 were similar trial designs and were confused how Merck had already received the indication, hence they started questioning the integrity of -141... After review of the trial designs and a reminder of the -141 data the concerns appeared alleviated.","When discussing SCCHN, the TL stated they were surprised by the news of the FDA indication as they have been using Nivo for that population since Spring with no push back from payers and thought it was already indicated.","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.",99
population,Territory,  NM,4.03237410072,3.37384640995e-06,222,248,"NTL who does not believe in PDL1 testing in 2L NSCLC, stated that the key impact from -026 is the renewed emphasis on PDL1 as a biomarker. While the data is unknown the -026 and KN-024 press releases leads one to assume that there will be a specific threshold of PDL1 expression that adequately identifies a population that derives clinical benefit from checkpoint inhibition. The consequence will be 1L PDL1 expression level will be used for treatment decisions, in 2L the expression level may start being used for clinical decisions to ensure economic justification.","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","TL generally regards PD1s/PDL1s as the same but is beginning to doubt that perception and has expressed ""concern"" for Nivo. Specifically with durvalumab recently announcing they will not be pursuing a monotherapy indication based on lack of efficacy in NSCLC and Nivo not showing an efficacy difference in CM026 in the >50% population there may true differences in agents with the benefit of doubt leaning toward pembro.",470
IO,Territory,  NM,3.91958041958,4.84273430501e-06,242,52,"TLs very split about the role of IO+Chemo in 1L. Some find the atezo and pembro plus chemo data highly impressive others consider it a ""waste"" with added toxicity for minimal benefit.",TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.",294
q3wk,Territory,  NV,28.1488595438,3.522172091e-08,14,425,Lung TL stated that convenience of dosing is critical for many of his patients if patients are stable (efficacy and safety) on nivo at 3 mg/kg q2weeks instead of switching to pembro q3week he switches some of his patients to nivo at q3wk interval.  Has not observed additional toxicities in the 3 patients thus far.,"Lung TL has a patient who has been stable on nivo for over 1 year with almost a complete response, however recently switched the patient to q4wk dosing using 3mg/kg dosing.","SCCHN RTL uses a modified version of EXTREME, PTC (platinum/taxane/cetuximab) due to toxicities from 5-FU.  He mentioned EXTREME is SOC because of the Vemorken study in Belgium where taxanes were not approved at the time.  

Patient selection: For patients who are young and fit (i.e. good ECOG PS) uses PTC in the metastatic setting.  Does not see benefit of single agent cetxuimab in recurrent metastatic setting based on low response rates and toxicities.  For patients with worse PS, would use a PD1 inhibitor

Dosing: majority of patients are started on pembro because of the convenience of the q3 week dosing, which has been echoed across two other TLs in the region.  RTL mentioned only one of his patient being on Opdivo but responding well to therapy.",439
myocarditis,Territory,  NV,21.1116446579,5.56289224523e-06,12,62,Several local lung TLs are not clear if there are differences in the toxicities profiles between the PD-1s vs PD-L1 as they've seen both hyperglycemia and myocarditis in both nivo and pembro and more recently use of atezo leading to hyperglycemia in some of their patients including myocarditis.,Melanoma RTL has observed a few cases of acute heart failure due to immune-mediated myocarditis in patients on regimen or monotherapy nivo or pembro and is looking at routine troponin levels/ECG.,Melanoma RTL has observed a few cases of acute heart failure due to immune-mediated myocarditis in patients on regimen or monotherapy nivo or pembro and is looking at routine troponin levels/ECG.,74
TLs have stated,Territory,  NV,12.3151260504,1.19298374795e-05,21,203,Local H&N TLs have stated that pseudo-progression not observed at all with use of nivo or pembro vs melanoma.,"Several local RCC TLs have stated that while PDL1 testing is a ""hot topic"" for lung, in RCC patients they do not find the need to test.","Few local and regional lung TLs have stated that the best approach in the 1L setting is not combination therapy of IO-IO, or IO-Chemo/TKIs  but learning best how to sequence these agents or doing dosing holidays to minimize toxicities.",224
IO-IO,Territory,  NV,11.4941176471,1.6869327883e-05,21,757,"RTL stated that regardless of what combinations in the 1L for lung, he feels that sequencing of agents should be the direction to minimize toxicities observed with either chemo-IO, IO-IO, or even targeted-IO.","Several lung RTLs have brought up sequencing agents either IO-IO, IO-Chemo, or IO-TKIs as oppose to combining agents to minimize toxicity and that may be the best approach in the future.","Few local and regional lung TLs have stated that the best approach in the 1L setting is not combination therapy of IO-IO, or IO-Chemo/TKIs  but learning best how to sequence these agents or doing dosing holidays to minimize toxicities.",778
PDL-1,Territory,  NV,10.5558223289,4.13408869008e-08,50,881,Academic TL mentioned the community lung TLs are testing for PDL-1 because they believe pembro is more effective in PDL1+ patients.  He said that because we do not need to test there seems to be a perceived absence of benefit in the positive expressers.  He stated that when he shared with the community TLs BMS's data in the PDL1 >5% and >10% they were very surprised and frustrated to why they have not heard of the data but will likely switch to nivo.,"Post 026 release:
- 2 NTL and 2 RTL mentioned that had BMS selected a different PDL-1 cut-off the 026 trial may have been positive, perception is NOT that nivo is less effective than pembro from the 026 read-out
-  2 RTLs have stated that PFS may not have been the best endpoint and are waiting for OS readout
-  1 community TL and 2 academic TLs stated that they currently have patients who are asking for 1L monotherapy pembro based on the 024 press release, some patients are willing to pay out of pocket for treatment vs enrolling in clinical trials
-  1 RTL was less optimistic stating ?you shot yourselves in the foot by selecting a 5% cut-point and endpoint of PFS?.  Combo therapy (ipi+nivo) will have to demonstrate ?cure? or high % of CR to compete against monotherapy pembro in + expressers based on a more favorable toxicity profile
-  Consensus from academic to community TLs stating that they see pem and nivo as being the same and the Q3week is the key advantage that pembro has despite the differences in trial design because they now have a better understanding of MOA, activity, and safety in a collection of trials across nivo and pembro",Lung RTL shared that despite 026 not meeting primary endpoint with 5% PDL-1 cut-off she would consider using nivo if the PFS is similar to chemotherapy in higher expressers given nivo's safety profile.,931
Community TL,Territory,  NV,6.77331932773,5.23479311358e-06,73,820,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Local TL in a large community practice stated that many HCP's are upset with the direct to consumer marketing that BMS is doing with Opdivo.   She said that the commercial has led to many patients coming into clinics wanting Opdivo with high hopes and expecting a cure.     She further stated that the commercials reflect everyone looking healthy and feels that is leading to false hopes for many patients..  She further stated that she is aware that the speaker bureau has no funds for speaking so why isn't the money better utilized for this instead of the money being put into commericals.,Local community TL in large practice offered that he would like to see trials with Nivolumab in patients with MDS.    He offered that many trials being done have limitations with regards to platelet or neutrophil count which leads to ineligibility for trials as many still involve chemotherapy.   He feels this is a huge unmet need and that immunotherapy could potentially help these patients.,893
large academic center stated,Territory,  OH,72.5065868263,5.46029960957e-22,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center stated that they will be opening up a Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission.  She anticipates this will answer a good clinical question.,NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,372
midwest,Territory,  OH,16.184505988,2.76361553124e-11,42,124,AI at University Center in midwest (former NCCN panelist) shared at her institution for new Dx lung CA they are getting PDL-1 status as well as TTF1 marker (non-squamous) and P40 in squamous   Also feels re-bx is best option if changing therapy,AI and NCCN panelist in midwest stated that for both PD1 agents in cHL the RR is very good (60-70) but the 10-20% cRR still need to do better.  Noted heavily pre-treated pop.  Felt a big step will be first line w/o bleo,"I met with a NCCN NSCLC panelist in the midwest.  He offered these insights

On OAK at ESMO he stated he and the panel viewed the data to be good, roughly like Opdivo.  On the issue of the ESMO data showing ""positive"" results in the PDL-1 negative population, we went over the issues and he stated the panel recently discussed this.  Stated there was not strong enthusiasm of panel for the PDL-1 negative argument due to reasons we discussed internally, but also due to low numbers and at this point unpublished data (he stressed this).  That said given indication of atezo unlikely to get NCCN recommendation more restrictive than label.

Agreed with just about everybody else that 026 was surprise, likely trial design, etc.

On KN 021 stated panel felt the data way to early to recommend Chemo/Pembro in any way.  Had no opinion on whether IO/IO or IO/chemo likely to be superior

Stated NCCN was working on recommendation on how to use PDL-1 cutoffs in some future statement.  This is second NCCN panelist to mention this to me.  Other was in cHL.  Stated majority of effort was in the 1-100% area (as opposed to 0-3+)  Commended BMS for working with Ventana

Noted when voting any member whose name was on relevant paper must recuse self.",166
TL commented,Territory,  OH,9.52467478835,1.66741606871e-09,83,892,"TL commented that nivolumab is SOC for 2L RCC at their institution based on efficacy, tolerability, and patients demanding I-O treatment. RCC patients see the lung DTC marketing and ask for nivo treatment.","National lung TL commented that ROVA-T and ipi/nivo appear to be the most promising potential agents in SCLC. Regarding ORR reported for ipi/nivo, he mentioned that this is likely not the best outcome for I/O in general but that duration of response or even maintaining stable disease (duration of disease control) should be considered as more important measures of activity.","National lung TL commented that even in a never-smoker, low mutation burden, PDL1 non-expressing lung patient he?d still want to try one of the PD1 agents based on the current data showing that even this subset of patients, while more unlikely, still have a chance of having a long term benefit from this class of drug.",975
PDL-1,Territory,  OH,7.39863130881,1.32747415204e-06,50,881,"Academic TL commented that the results from KN-024 will be practice changing. He was excited to hear that pembro was superior for both PFS and OS. He is awaiting the data, but stated that he would follow the -024 design and use pembro 1L only in patients with >50% PD-L1 expression. His use of PD-1 inhibitors 1L will be data driven; does not plan to utilize haphazardly.","I met with NCCN panelist in NSCLC  He shared the following

He stated the NSCLC panel met recently.  He stated that Merck will get a first line listing for pembro in the greater than 50% staining population

Stated panel was surprised by 026 data.  Stated he felt that PFS was a poor choice for primary endpoint.

NCCN is working on a ?guideline? for PDL-1 testing in first line as it was becoming very important.  At this point it will involve only tumor staining.  It will not include the Roche method of including tumor infiltrating cells.  Stated the guideline will have a number cut-off, i.e. ~1-100%....Roche?s 0-3+ method will not be part of guideline.  Stated there would be some recommendation for pathologists who use Roche assay to convert the Roche result to a 0-100% scale.

Panel not impressed with atezo data

Stated that while  ipi/nivo data impressive in NSCLC the panel laughed a bit at it?s attention as the data was so early.  That said he felt there was great potential here

Stated he heard Merck was fairly far along with ipi/pembro data.  More so in melanoma but also lung

Stated he heard AZ combo data will likely come out shortly after BMS combo data in first line NSCLC

On the subject of likely CMSTO 2016 presentation of 026.  He stated if we had OS data that was positive at a particular cut-off there would be a good chance BMS could get a NCCN listing in first line consistent with that given 026 was a large phase 3 trial.","TL stated that last in-person meeting was 1-2 months ago.  Stated there is a call coming up in 1-2 weeks.  On the topic of PDL-1 cutoffs in first line, he stated that pembro would definitely not get a rating until the data was published.  On the possibility this would happen in the near future, he stated that he was somewhat new to panel, but his impression was that the NSCLC panel tried to be more ?inclusive? than ?exclusive?.   On the 50% cut-off issue he stated there could be different possibilities.  He mention there could be a certain recommendation but also some sort of footnote or comment.  It was difficult to tell if this was a general PDL-1 positive listing for pembro with a footnote stating the trial was 50% or greater, or if there could be a listing using a 50% cut-off with a footnote stating a wider range of patients may be appropriate.
 
In other notes he agreed with many that a cut-off is good but we don?t know what it is yet.  Someplace between 5 and 50.  Stated he was heavily involved in adjuvant trials but not metastatic disease.  Inquired as to whether 026 would include results at varying degrees of expression (answered affirmatively).",931
mostly,Territory,  OH,6.90538922156,1.57141906693e-05,34,0,"NTL in midwest noted her institution had a number of patients that went through numerous lines of chemo in NSCLC prior to Nivo approval.  They went on Nivo on approval and a number of them are still doing well.  Got impression they were still getting Nivo q 2 but did not ask specifically

Same TL also sees fair bit of sarcoma (70 a yr., mostly peds)  and has had decent sucess with nivo generally through expanded access.","RTL at university center in midwest noted that like most others results of 026/024 were surprise without clear explanation

Noted atezo would have strong potential at his institution mostly due to q 3 dosing

Noted little usage of pembro in first line so far

Felt chemo/IO had strong potential",RTL in SCCHN noted at his center (Major university in midwest) they were using mostly pembro off trial for HN cancer because it has been approved longer and his center feels access is easier.  This contrasts with another major center in same city who has been using nivo all yr without any insurance issues.,34
meeting,Territory,  OH,3.79551535227,2.11110062968e-08,239,35,"During a Highlights from ASCO meeting, the theme across tumor types (melanoma, lung, H&N, bladder) from academic TL presenters was that PD-L1 as a biomarker is 'a mess' and shouldn't be used to make treatment decisions.","During joint meeting with HSL Jamie Wong, SCLC NCCN chair shared that the panel will be adding nivolumab +/- ipilimumab to the NCCN guidelines as category 2A under subsequent therapy based on the -032 publication.","During presentation at regional meeting, TL discussed CM-012 data and referred to the results as a breakthrough for NSCLC. Regimen is changing the tumor biology, and we look forward to results from the phase 3 CM-227 study.",274
line,Territory,  OH,3.45269461078,9.76710893881e-06,345,108,"Local TL commented that even with positive data in 1L NSCLC (referring to pembro and if 026 had been positive) with PD1 agents, he feels it's still going to be an enormous shift to move away from platinum doublet therapy as initial therapy. He believes there's such a benefit to immunotherapy following chemo that's already been established that he would be cautious to relegate chemo to later line therapy after initial progression on PD1 therapy. Believes there is a great need to do thorough sequencing studies to figure out where the best place for each treatment option truly is.","Local TL commented that he feels we may be jumping the gun trying to replace platinum doublet therapy as a 1L standard for NSCLC. He believe the role of immunotherapy may be better suited to work after chemotherapy due to the increased antigen presentation, etc, along with the fact that relegating chemo for later line will be more difficult to give once pts have already failed a 1L treatment. The best chance at getting a good response to doublet therapy will likely be in the 1L and the role for I/O may be better in the maintenance or 2L setting due to it's superior tox profile.","NTL in midwest stated at her institution they generally push trials, especially after first line.  That said she stated in second line they almost always use Nivo over pembro.  She felt even though Roche had some ""iffy"" data in PDL-1 neg she felt it was minor and still thought her institution would use Nivo second line.  They have just started using pembro in first line in greater than 50% stainers.  They send out tissue (turnaround 10-14 days) but are working on getting test in house",453
BMS-sponsored,Territory,  OK,608.0,4.24066384578e-05,2,50,"A regional CLL RTL, who is PI on BMS-sponsored study stated there is no standard of care in the treatment of Richter's transformation, which occurs in about 5-10% patients with CLL and an unmet need remains how to treat Richter transformation. Richter's transformation has an escape mechanism for Ibrutinib that's certainly real and important to recognize. Interestingly, Nivolumab + Ibrutinib combination is showing convincing clinical benefit in patients with Richter's transformation.","A RTL who is PI of BMS-sponsored study stated that combination of hypo-methylating agent and Nivolumab has generated remarkable clinical efficacy in patients with relapsed AML. Study results show an increase in frequency of CD3 T-cells and decrease in T-regs in post-treatment tumor samples among responder-patients, and identified novel biomarkers of response. All immune mediated toxicities (pneumonitis, the most common) respond to steroids.","A regional lymphoma TL delivered a presentation on ""therapeutic potential of MAbs in cHL"", at a regional hematology-oncology meeting. A national TL asked him ? out of these, which one is your favorite antibody and why? The speaker said-NIVOLUMAB; because of its safety, durable clinical benefit/remission, and potential for combination with other small molecules and checkpoint inhibitors.",52
novel,Territory,  OK,114.0,9.68952467963e-06,10,9,"A RTL who is PI of BMS-sponsored study stated that combination of hypo-methylating agent and Nivolumab has generated remarkable clinical efficacy in patients with relapsed AML. Study results show an increase in frequency of CD3 T-cells and decrease in T-regs in post-treatment tumor samples among responder-patients, and identified novel biomarkers of response. All immune mediated toxicities (pneumonitis, the most common) respond to steroids.","A national MDS TL stated that some of the toxicities observed in patients treated with IO agents such as Nivolumab and Ipilimumab may not be associated with treatment alone as most investigators don?t have much experience with these novel agents. However, as we develop better understanding of MOAs of these therapies, we will be able to interpret the associated toxicities effectively.","A national lymphoma TL at a scientific workshop highlighted the clinical/survival benefit of Nivolumab across various tumor types and emphasized that it causes almost negligible toxicity. However, this novel drug can lead to ?financial toxicity?.",19
uveal,Territory,  OM,168.444444444,5.52364195921e-06,5,424,"A melanoma TL from NY told me that he had two recent patients that for clinical reasons he chose to start their initial metastatic melanoma treatment with Opdivo monotherapy.  One patient (uveal) had no initial response to Opdivo, the 2nd patient a cutaneous melanoma patient had a Partial response but later developed disease progression in the brain.  In both cases the physician added Yervoy while continuing Opdivo.  Both patients immediately began to feel better and subsequent scans revealed Objective responses (2nd patient brain met completely resolved)","Several RTL in NY have all noted at least one patient case where a patient is currently responding to the Regimen and the ORR appears to be better than prior responses to a prior PD-1 / PD-L1 therapy.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.",429
years old,Territory,  OM,134.755555556,2.47211809362e-07,8,0,"Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.","A melanoma NTL from DC volunteered that his site has performed an analysis of their experience with the Opdivo-Yervoy regimen (n=38 patients).  Stated that the Overall Survival data looks to be plateauing at about 70% at 12 months.  He recommends the Regimen for all patients under 80 years old irregardless of BRaf mutation status or PD-L1 status.  TL stated they do not perform PD-L1 testing at all.  TL stated about the Regimen ""I am a big fan""",8
objective responses,Territory,  OM,84.2222222222,2.28262314044e-05,8,3,"A melanoma TL from NY told me that he had two recent patients that for clinical reasons he chose to start their initial metastatic melanoma treatment with Opdivo monotherapy.  One patient (uveal) had no initial response to Opdivo, the 2nd patient a cutaneous melanoma patient had a Partial response but later developed disease progression in the brain.  In both cases the physician added Yervoy while continuing Opdivo.  Both patients immediately began to feel better and subsequent scans revealed Objective responses (2nd patient brain met completely resolved)","Several RTL in NY have all noted at least one patient case where a patient is currently responding to the Regimen and the ORR appears to be better than prior responses to a prior PD-1 / PD-L1 therapy.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.",11
BRAF/MEK,Territory,  OM,63.1666666667,4.43560116493e-05,10,362,"Following up on a previous insight from MB regarding the EA6134 trial, an melanoma NTL from MD relayed a conversation he had recently with Novartis.  The reason by the trial hold / insufficient drug supply resulted from unexpected greater commercial demand for the drugs.  GSK initially transferred the remaining inventory of the BRaf/Mek inhibitors to Novartis which allocated a small fraction for R&D purposes.  Novartis has been unable to get their own production going.  They asked GSK to make some additional drug but this will take time.  All Novartis would commit to was that drugs would be available for the trial sometime after April 1st.  The TL added that he did not expect the drugs to show up in April and had no clear idea when they would be available.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.",372
BRAF,Territory,  OM,31.1934156379,2.57041474126e-06,38,209,"A community oncologist was positively impressed by the -067 efficacy data. However, he commented that he still prefers to use molecularly targeted therapies in 1L setting if a patient with metastatic melanoma harbors BRAF mutations. He further stated ?that is because it is targeted therapy?.","Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.","A melanoma NTL from DC volunteered that his site has performed an analysis of their experience with the Opdivo-Yervoy regimen (n=38 patients).  Stated that the Overall Survival data looks to be plateauing at about 70% at 12 months.  He recommends the Regimen for all patients under 80 years old irregardless of BRaf mutation status or PD-L1 status.  TL stated they do not perform PD-L1 testing at all.  TL stated about the Regimen ""I am a big fan""",247
regimen,Territory,  OM,7.43137254902,3.03084981851e-05,243,465,"Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.","An HCP was considering nivo monotherapy for a first line melanoma patient.  When presented the data for Regimen, questioned why if Regimen had better efficacy than monotherapy it was category 2 in the guidelines while nivo monotherapy was category 1.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.",708
NW territory,Territory,  OR,421.714285714,4.86238078827e-20,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
ASCO'16,Territory,  OR,150.612244898,2.30896330214e-07,5,394,Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,"RTL, a NP with lots of I-O experience, stated that some physicians in their group are 'short-coursing' steroids when treating irAE's, as they are afraid steroids will negatively impact the anti-tumor T cell response.
This is a No-Access site, so there is no opportunity for me to educate those physicians.
TL said that the data from Hodi's ASCO'16 poster from CM-069 will be helpful in educating colleagues that steroid used to treat irAE's don't diminish the tumor response to Ipi+Nivo Regimen.
However, TL said that similar data for Nivo monotherapy in NSCLC would be even more impactful. The perception of irAE's on Nivo are less severe than when on Regimen. So physicians may still want to shorten the steroid treatment on Nivo monotherapy, unless they're shown that there's no reason to do so.","NP at a community hospital reported continued ""difficulty convincing some of my doctor colleagues to initiate steroids appropriately"". NP asked if we ""have a reference for anything published that demonstrates that if patients receive steroids for toxicity from immunotherapy, they don?t suffer worse outcomes?""
I reviewed the 209-069 Hodi poster from ASCO'16 and mentioned other similar analyses from prior Ipi studies. NP was very appreciative and is working to arrange a face-to-face meeting with HCPs to facilitate education on IMAR algorithms.",399
NeoGenomics,Territory,  OR,60.2448979592,1.03519468088e-07,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  OR,50.2040816327,2.03473272033e-06,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
Academic TL stated,Territory,  OR,43.0320699708,3.06139360321e-11,16,162,Academic TL stated that he would not omit bleomycin in the first couple of cycles of ABVD for newly diagnosed HL patients as the cure rate drops 8% if it is totally omitted during this time.  He would only do it if patients are over the age of 60 to prevent potential fatal toxicity.,Academic TL stated that Immunotherapy or allo SCT are still not front line therapies.  These are for R/R disease.  Patients need to get in remission.  He feels that IO therapy is preferable over chemo to get patient to remission and bridge to allo SCT.  He went on to say that Immunotherapy TRM is very low compared to allo SCT.  Patients have the option to get other therapies if they relapse vs. patients who die from complication of allo transplant don't.,Academic TL stated at an oncology conference that AML patients have had nothing new for treatment in many years.   Those that undergo transplant still have issues with relapse.   He discussed the recent Yervoy data in post transplant and stated that there should be more trials moving forward with checkpoint inhibitors in this patient population as the data looks promising.,178
community hospital,Territory,  OR,21.5160349854,2.56638774334e-05,19,551,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",570
Ipi+Nivo,Territory,  OR,13.1785714286,2.64787305711e-10,45,338,"NTL predicts that, even with durable responses seen with PD1 monotherapy, eventually almost all NSCLC patients will progress.  With basically all NSCLC patients receiving PD1 monotherapy at some point in their treatment plan, there will be a huge unmet need for effective treatments post-PD1.  This NTL, who is an investigator on several studies with IO+IO combinations, voiced opinion (based on her experience) that Ipi+Nivo seems to be the only IO+IO combo that can resurrect a response in patients who have failed PD1 monotherapy.  4-1BB, anti-KIR, OX40 etc do not seem to have this activity. TL said this speaks to the ability of Ipi to prime new T cells, rather than just relieving inhibition of existing lymphocyte populations.","Melanoma RTL with lots of I/O experience (Investigator on 209-067), stated his belief that PDL1+ patients don't benefit from adding Ipi to Nivo.  He is testing for PDL1 to determine treatment choice between PD1 monotherapy and Ipi+Nivo combination. PDL1+ patients receive anti-PD1 mono therapy; PDL1neg patients receive Ipi+Nivo Regimen.","There is growing interest from my academic TLs in using Ipi to re-invigorate the T cell response in patients who progress on Nivo.  These could be patients who are on the Nivo maintenance after Ipi+Nivo regimen, or patients who only received Nivo monotherapy.

Rationale is similar as for MDX010-20 study with Ipi, except that in this case, the patient would continue to receive Nivo while adding a few doses of Ipi. TLs favor a Q6W Ipi dosing when added to Nivo.",383
medical oncologists,Territory,  OR,12.4033613445,9.52386322863e-06,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
insights,Territory,  OR,11.4257565095,6.22234430371e-08,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
IHC,Territory,  OR,11.0977443609,1.70344601158e-05,25,536,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",561
TL said,Territory,  OR,9.26844583987,1.08147008904e-07,86,62,"ENT/H&N surgeon is excited to add Opdivo to his arsenal of Tx options in SCCHN. TL said he would be referring several patients to the local med-onc. However, TL said his ENT office staff could use education around IMARs because patients often will call his office for advice, even after being handed off to the med-onc.  TL said patients strike up a very strong relationship with the surgeon, who is often the first physician to correctly diagnose and treat the disease.  TL requested an in-service by our IOCL (currently in training).","NTL at a large community hospital said he was previous dismissive of Ipi+Nivo for NSCLC but then saw the ""impressive"" Hellman ASCO'16 CM-012 presentation.  However, TL also said regimen may not be a slam-dunk, as KN-021 Pembro+Carbo+Pem data seem equally as impressive as CM-012 regimen data.","I met recently with an RTL and Opdivo Melanoma/NSCLC speaker, who is aware of CA209-384 (although is not participating in that study) and asked if we have addressed the same question in melanoma patients. 
TL stated he would consider stopping treatment for patients who show a CR or near-CR. 
In his opinion, the question 'when can we stop treatment with I/O agents' is interesting in lung but sadly not relevant for most patients due to the low CR rate.  
However, TL said that it's a very relevant question in melanoma, where the Ipi/Nivo combo is producing a higher frequency of CRs.",148
pathologist,Territory,  OR,8.36734693878,2.50054152873e-06,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
TL,Territory,  OR,2.90726049133,8.94831972233e-07,1157,51,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",1208
MedOncs,Territory,  PA,913.5,1.17669588842e-07,4,131,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.",135
machines,Territory,  PA,609.0,2.69684184422e-05,3,147,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",150
standardized,Territory,  PA,487.2,4.33151984154e-09,8,132,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",140
complementary,Territory,  PA,406.0,4.4868917678e-05,4,138,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.",142
SP263,Territory,  PA,304.5,9.79727372844e-07,8,144,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",152
tumor cells,Territory,  PA,128.210526316,2.93484741697e-07,22,82,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",104
Dako,Territory,  PA,121.8,9.33045716196e-06,17,124,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.",141
staining,Territory,  PA,84.0,1.32143733614e-06,32,620,"TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",652
22C3,Territory,  PA,64.1052631579,3.53131630726e-06,49,112,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",161
aware,Territory,  PA,45.1111111111,1.28447242544e-05,57,0,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",57
PD-L1,Territory,  PA,21.4436619718,4.01692364035e-05,306,375,"?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.",681
Path TL,Territory,  RI,304.432989691,1.91401667404e-14,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
Path,Territory,  RI,121.773195876,6.27147940217e-11,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
IVD,Territory,  RI,40.5910652921,3.64254652058e-05,6,146,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Pathology TL at a mid-size academic center has completed validation of 22C3 IVD 12/2/2016, testing is now available in-house.
-TL reported validation of platform and antibody were simple and straightforward
-TL reported training by watching Dako online module for scoring
-TL reported training on scoring was an ""uphill battle""",152
1st line NSCLC,Territory,  RI,30.4432989691,1.19840397856e-07,17,26,"A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).","A LTL in Boston stated that based on all the data coming out around 1st line NSCLC, they should be testing all pts for PD-L1 status.  However, he added that ""he has requested testing on 15 or so samples (1st line pts) and all of them have come back negative"".",43
score,Territory,  RI,14.2068728522,4.67519714649e-06,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
Boston,Territory,  RI,14.2068728522,4.67519714649e-06,40,82,"A Melanoma NTL from Boston, stated that ""there is no value in doing PD-L1 testing in melanoma pts.""  He added that ""I don't test any of my pts""","A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",122
pathologist,Territory,  RI,11.9928147454,2.69155192572e-09,45,211,"NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times",256
22C3,Territory,  RI,9.51353092784,9.40880821166e-07,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
1st line,Territory,  RI,7.77275718359,5.28226276269e-07,69,712,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","A RTL for Lung shared that he was surprised to hear that CM26 was negative. He is looking forward to seeing the subgroup analysis based on other PD-L1 cut offs, but he added that this increases the need to do PD-L1 testing in all 1st line NSCLC pts. He also suggested the need to choose PD-1 agents in the 2nd line settting based on PD-L1 results.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",781
pts,Territory,  RI,7.61082474227,1.42930363781e-15,164,1624,"An RTL shared that when a pts runs into toxicity with Nivo/Ipi combo, if the pts has a CR or PR at that time, then they stop treatment.  However, at the time of toxicity with the combo, if the pt only has SD or PD, then they continue PD-1 monotherapy.  The added that about 1 out of 4 times they continue with Pembro as oppose to Nivo.","A NTL in melanoma shared that combination IO therapy (mostly regimen) is their primary method of treatment all melanoma pts at their institution.  Even if the pts has bully, BRAF+ melanoma, because of the rapid RR scene with Nivo/Ipi, they would choose Nivo/Ipi over BRAF+MEK combo.",A RTL stated that he does not test PD-L1 for his RCC pts.,1788
LTL,Territory,  RI,5.3723468769,1.43046736794e-05,79,800,"An LTL informed me that he doesn't test for PD-L1 status in the 2nd line NSCLC setting and stated that there is no need for it. He did add that his colleague is testing some of his/her pts for PD-L1 status in the 2nd line setting and is ordering PD-L1 status upon initial biopsy (pre-1st line treatment). Upon inquiring why? The LTL shared that by having this information, for PD-L1+ pts, both Pembro and Nivo would be good options with high ORR in the 2nd line setting, and if the pt was PD-L1 negative then opdivo (only) would still be an ""ok"" option.","An LTL/RTL stated/suggested that his plan for 2nd line NSCLC is to start nivolumab while waiting for PL-L1 test expression.  If the PD-L1 test comes back at 50%+ positive, he would switch the pt to Keytruda (view the data stronger as this sub-population was specifically studied by Merck).  If the test comes back between 1-49%, he said that it's a 50/50 choice between Opdivo/Keytruda and it would be up to the pts on q2w drug or q3w drug.  If the PD-L1<1%, he would choose Nivo...but if insurance had an issue, then he would switch to docetaxel.",A LTL stated that no one in her practice test for PD-L1 for her RCC pts.,879
PD-L1,Territory,  RI,5.07388316151,4.23958791432e-08,306,375,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",681
PD-L1 testing,Territory,  RI,4.83678581752,1.17177465409e-06,123,444,"Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",567
added,Territory,  RI,3.92072789753,1.38251305171e-05,148,0,A Regional TL shared that they are testing all there NSCLC pts for PD-L1.  He added that his institution is still trying to figure out if they should internalize the PD-L1 test or just continue to send it out.,"An Academic TL shared that if a pt fails monotherapy PD-1 (either pembro or Nivo), they then add ipilimumab on top especially if the pt did not experience any AEs to monotherapy anti-PD-1 therapy.  The TL was hinting toward lack of toxicity equals 'not enough IO blockade' and hence they need to use combo IO in those pts.","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",148
cabozatanib,Territory,  S. IL,145.6,1.34774584415e-13,13,190,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",203
trx,Territory,  S. IL,112.0,1.69498449363e-10,10,0,"RTL, who is IL-2 referral center, stated that he has believes that all RCC patients should get any and all IO options as soon as possible.  For patients who are good candidates (~10% of RCC pts largely due to organ fxn), starts with IL-2.  Currently dissapointed that nivo PI and 025 trial req'd anti-angiogenic, rather than any prior trx (ie, IL-2 only). Has given several patients a short course of pazaponib until 'any first toxicity' as a pass-through to fulfill insurance requirements per PI.","pan-tumor community RTL states that in RCC he commonly sees patients with mixed responses (both to IO and TKI).  he states that he often sees a similiar phenomenon in SCCHN, but rarely sees mixed responses in lung.  

Due to this, in RCC, he very commonly adds nivolumab to a TKI (typically sunitinib or axitinib) if a patient is beginning to progress rather than switch trx completely.  He states that it has worked very well and he has had no toxicity issues, possibly as most patients are by then on a dose-reduced level of TKI.   He would like to see more nivo+TKI (ie cabo) and nivo-rescue trials being done.","GU RTL shared some factors he considers when deciding between nivo (~70% of pts) and TKI (now cabo, ~30% of pts) for 2L RCC trx:
- pace of progression (20% of pts exhibiting faster progression prefers TKI) 
- toxicity of 1L VEGF TKI (if had minimal tox/dose reduction, more likely to give cabo 2L due to convience of oral dosing)
- compliance to taking oral meds and reporting of side effects
- Performance status (lower PS would always get nivo)",10
pace,Territory,  S. IL,89.6,1.93242781919e-08,8,208,"GU RTL states that while he prefers to give nivolumab 2L in RCC patients, that he uses cabozatanib in patients who are progressing ""fast"" as he is concerned that IO works too slowly.  When asked to elaborate on his definition of 'fast progressors' he stated that it is at most 25% of patients and that he can often tell speed of progression by clinical appearances (PS, pain, fatigue) rather than scans.  

He stated that even in 'moderate pace' progressors, that at least 50% of the patients have their disease 'explode' once they come off of their 1L TKI, sometimes to the point he has no choice by to put them back on.  He had considered 'bridging' in nivolumab while weaning off the TKI but was concerned about safety.  Reactively reviewed TKI+nivo safety data from 209-017 and he thought that this was very acceptable and that he may begin to do this.","Academic TL stated that his nivo non-benefittors (ie, PD w/o any SD/PR) tend to progress at a much faster pace than their 1L progression, sometimes causing them to not be able to get a 3L therapy.  However if they have had any benefit, even a short term slowing of disease prior to progression, their progression is much more tapered and they tend to do better on 3L chemos","TL stated that while he initially treated 'everyone with aPD-1 regardless of PDL1 expression', his experience (pan-tumor) is that ""those who don't respond to IO, actually increase their speed of progression, compared to a chemo or TKI where even non-responders tend to get a temporary slow-down, and thus he feels IO can have a negative impact on ability to response to subsequent therapy.  In nonsq-NSCLC, he has started to test for PD-L1 and will often treat those with <1% with chemo+/-ramucirumab prior to IO in order to 'slow pace before moving on to IO'",216
aPD1,Territory,  S. IL,78.4,2.03912234329e-07,7,635,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","RTL reports that he has utilized ipi/nivo regimen 2L in several patients who have been referred to him following 1L pembro monotherapy failure.  While still early in treatment, he reports that so far patients have done extremely well, either stabilizing or responding. Physician would like to see a a trial specifically looking at 'rescuing' aPD1 non-responders with regimen second line.","NTL in lung stated that at this point, and ""maybe it will change if the numbers for KN-024 are actually much better than I think they will be"" he sees his use of pembro (or any aPD-1 monotherapy) in the first line to be very limited. He expects that the magnitude of benefit may be somewhat modest. ""significant doesn't always mean incredibly meaningful""  

He's states that either in 1L for trials, or in 2L, that he has seen such a ""tiny, maybe 15%"" of patients with >50% PDL1.  ""Whatever the trials data says for proportion of the population, I figure my experience is half of that it almost makes me questioning if I should bother holding up starting chemo for such a tiny fraction"".",642
Pan-tumor,Territory,  S. IL,42.0,2.15272393048e-13,18,464,"Community Pan-tumor TL at research-focused site stated that while their practice has started ordering PDL1 testing in NSCLC whenever possible, however he said ""I'm not really sure why I bother... I treat the negatives with nivo anyways...""

He wasn't sure what exact test they ordered and but stated that he gets an exact % expression reported back.","Community Pan-tumor TL seemed only very moderately aware of the outcomes of KN-024 and CM-026 reported at ESMO, but stated that he ""doesn't think we will be using platinum doublets in 1L in a couple years"".  He did not mention pembro's 1L approval (a few days after) and my impression was that he was not aware. When probed, this is because he thinks this is because IO+IO combinations will be SOC (rather than PD1 monotherapies being used widespread).","Community Pan-tumor TL at research focused site states that while the he is convinced that the efficacy is worth it, that managing toxicity for ipi+nivo in melanoma is ""high maintenance"".  Between him and one other partner (the two that see most of the melanomas), they have treated about 6 patients, and have ended up having to hospitaized a majority of those patients due to GI toxicity.  However they state that the toxicities resolved well with steroids or infliximab and that the majority of these patients have had profound responses.  He stated that he struggles with whether to put these patients back on nivo monotherapy, and has not to date based on the durability off trx in 069 and 067, but he sometimes feels very nervous ""not doing anything more""",482
ie,Territory,  S. IL,38.2666666667,4.78177002523e-33,52,0,Very positive early feedback around AE management app.  Nurse manager requested a similar web-based version to be used at triage desks (ie wiht hyperlinks for the different AEs),"pan-tumor TL reports that he is not performing PDL1 testing in RCC patients.  He states that, of all his tumor types, he actually does the least amount of any genomic analysis (ie Foundation One, etc) in RCC patients as there aren't those 'characteristic and target-able' mutations like in other tumor types.","Med Academic lung TL inquired if there were any efforts to examine was to examine PDL1 in either a plasma/liquid biopsy form (ie, RNAexpression, etc.). Challenges around this were discussed (ie, systemic vs. local tumor environment, etc).",52
modest,Territory,  S. IL,26.1333333333,2.6247289885e-06,9,142,"Despite being impressed by the efficacy benefit, LTL has been hesitant to prescribe commercial ipi3+nivo1 regimen for melanoma due what he considers an unacceptable toxicity profile, especially given lack of long term OS data to justify the toxicity. However, 'jumped' at chance to participate in CA209-568 1L NSCLC trial (ipi q6w, nivo q2w) as he was very impressed with the improvement in toxicity with this dosing in 012.  He hopes to that this dosing schedule will also be examined in melanoma.","Based on the median time to response and higher number of 'late' responses in 025, coupled with the overall slower progression of RCC patients, TL is considering doing first scan at 12 weeks rather than 8-9 weeks as he think it may better reflect the benefit without showing as much pseudoprogression.","GBM: RTL who attended SNO stated that 'each year the progress for GBM seems so incremental and they are still waiting for the 'break' that all these others tumor are seeming to have'.

Stated that he was 'so hopeful' around IO, but that it has been largely dampened due to the ""very modest"" data from nivo (143) and pembro (KN028).   He hopes that possibly 1L treatment will produce stronger results.",151
2L+,Territory,  S. IL,25.2,1.02309468411e-07,12,334,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.",346
GU RTL stated,Territory,  S. IL,20.16,2.64660453767e-07,13,433,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",446
Pan,Territory,  S. IL,19.6,6.68765713147e-06,10,0,"Pan tumor TL stated that the was ""Thrilled"" that pembro was added to the 1L NCCN guidelines so quickly.  He acknowledged that this was a very selected population, however believes that the magnitude of benefit 'absolutely' makes it worthwhile to put forth the effort to find these patients.","Pan Tumor community research TL:

Surprised at and impressed by how big the magnitude of benefit was in KN024.  Acknowledges that it is going to fit for a very small portion of patients (he estimated 20% for his practice based on his own synthesis of PDL1 prevalence reported and PS/brain mets/etc in his own patients), however think that it is worth testing everyone at diagnosis and would try to treat anyone with >50% PDL1 with pembro 1L.  He is completely perplexed by the CM026 >50% negative data.  Thinks that this is likely ?a fluke?, but given the magnitude of benefit in 024 doesn?t think that small difference in patient populations could make data from ?super positive? to ?solidly negative? between trials so ?could be a real difference?. 

Note that prior to ESMO data, TL had low expectations overall for KN024 data, thinking magnitude would likely be reasonably small and that he would not likely make a huge push to PDL1 test everyone at 1L, so this is a marked shift in his attitude after seeing data.  He was, and remains, strongly pro-nivo regardless of PDL1 expression, for 2L - views haven?t changed.","Pan tumor TL stated that his concern in giving IO earlier (across any tumor type) is that for the patients that is DOESN'T work for, it is almost detrimental.  He finds that these patients (lung, mel, GI, RCC) tend to have their disease 'explode' and progress quickly, making it impossible/challenging to get it a subsequent line of therapy.  He states that in the 2L and beyond, this is a gamble you take because there aren't a lot of other options, but in the 1L settings it is dangerous and there is still a lot to be said for chemo which at least 'slows down' almost everyone.",10
IL-2,Territory,  S. IL,18.6666666667,8.25362688047e-08,16,48,"RCC TL shared that manuscript had just been accepted for publication around the RCC portion of the PROCLAIM registry and outcome based on sequences of IL-2, chkpt inhib, and TKIs (NCT01415167, PROMETHEUS).  Journal of Urologic Oncology.  
TL did not share any specific data but stated that 'IO first is always best'.","RTL in GU stated that he will be participating in an upcoming Nivolumab+HD-IL2 trial that is being sponsored by Prometheus - did not state specifically, but during implied that this was an ISR (possibly led by Michigan?) that will be bringing on about 10 sites nationwide.   TL had not seen final protocol yet, but believed that there would be a nivolumab lead in (~2 cycles) followed by a standard course of HD-IL2, 1 nivo dose between cycle 1 and 2 of IL2, and nivo mono therapy after completion of IL-2.","Melanoma RTL who has traditionally been a strong proponent and regional referral center for HD IL-2 stated that he hasn't treated a melanoma patient with IL-2 in over a year and that the efficacy of checkpoint inhibitors has nearly 'killed' IL-2.  He states that the 'CRs and cures from IL-2 can't be downplayed, but that you can't refute that way more patients are getting benefit from chkpt inhib without the ICU-type toxicity"" 

TL states that despite it being dropped from NCCN guidelines as a 1L recommendation, that he would still use IL-2 upfront in a young, fit patient as he feels the best strategy is to ""stimulate the immune system by as many different mechanisms that we can"".",64
not test for PDL1,Territory,  S. IL,17.92,2.02294043031e-06,14,651,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.","GU RTL stated the he has used Opdivo in 2 non-clear cell RCC patients.  Stated that in both cases was initially denied by insurance, but easily approved once he appealed and spoke with company.  Stated that this is incredibly common to agents when they first come on the RCC market due (experienced the same with axitinib) and does not concern him, however was thrilled to hear that we were already doing a study with nonCC patients (374) and he hopes this data will be incorporated into PI eventually.",665
axitinib,Territory,  S. IL,12.8,8.6598497752e-06,14,482,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",496
HN,Territory,  S. IL,11.2,4.10850980759e-07,21,1,"HN RTL stated that at their institution (NCCN), it is most common for Merkel Cell Carcinomas that are on the head to be seen by the HN team, rather than the melanoma team. This is in contrast to most other institutions in my region. 

Stated that he has used and seen some good responses to pembro, but is overall much more impressed by the avelumab data.","RTL in lung&HN shared that he is not currently, and does not plan, to test for PDL1 in HN. He likened the 141 data to being ""extremely reminiscent to the 057 and the lung space. Clearly PDL1 is enriching for nivo efficacy, but in 2L even it it was dead even with SOC, I would use it in everyone 2L based on safety and QOL one.  However, this argument might change in 1L HN like it does in 1L lung."" 

He stated that has several HN patients currently nivo off-label, however has started new patients on pembro since their approval due to ""similar data and ease of them having the approval"".  He sees himself using primarily nivo again if approved for HN.","Regarding HN choice of pembro vs. nivo.  Overall opinion is that data ""is very similar"" and few seem to be concerned with lack of OS or comparator for pembro.   Trend seems to be developing where pan-tumor physicians  who have already heavily utilized nivo over pembro to date (ie in lung) are stating that they will continue to use nivo for HN (""all things being pretty equal, we use what we are most comfortable with""). 

HN specialists or those with more limited PD1 experience, are utilizing pembro due to its first approved status and more sites having experience with pembro HN trials",22
GU,Territory,  S. IL,9.95555555556,5.06681101403e-13,84,815,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","RTL who splits time between Academic GU specialists and community generalist (ie, also treats lung) shared that he is NOT testing for PDL1 in RCC  (Note that TL is also not currently testing NSCLC patients for PDL1 outside of trials).  TL did state that he thinks it is very 'intriguing' why PDL1 is enriching in some tumor types (ie, nonsq lung; mel) and not others (RCC).  

TL prefers to give nivo 2L in RCC (~70% of 2L cases), however if patient travels long distances will sometimes utilized cabozatanib due to oral conveniences and ""predictable toxicities that can almost be managed over the phone with dose reduction"".","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.",899
3L,Territory,  S. IL,9.16363636364,1.38360802522e-05,19,518,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",537
sunitinib,Territory,  S. IL,9.16363636364,1.38360802522e-05,19,348,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.","RTL believes that the data suggests that RCC patients should see nivolumab (or some PD-1 inhibitor) as early in therapy as possible due to possibility of long-term durable response.  Will continue to prefer nivo prior to cabozatanib even with OS benefit. 

Believes in MOA-switching more than recycling ('patients should see as many classes as possible because you never know what one they will respond to) and typically moves from sunitinib-->nivo-->everolimus-->axitinib/cabo.",367
nearly,Territory,  S. IL,8.0,1.06704179087e-05,23,0,"LTL shared story of a PDL1 negative patient enrolled on CA209-153 who experienced a rapid near CR and has maintained response for nearly 1 year.  Based on this experience, TL stated that he ""would deny a 2L+ NSCLC patient nivo based on lack of PDL1 status""","NTL in sarcoma shared that he has personally treated nearly 100 sarcoma patients with I-O therapy/  About half were on trial (SARC028 or ALLIANCE A091401) and half off protocol.  Over half of the patient have been treated with ipi+nivo combination, and he shared that he has seen ""just amazing results, including probably 6-7 CRs, particularly good responses in Uterine Leiomyeosarcomas, Liposarcomas, and Osteosarcomas.  He shared that this is his standard 2L or 3L treatment for many patients now.  He stated that BMS Access support has been ""beyond wonderful"" and hat he has also had sporadic success in getting insurance reimbursement.","RTL shared that in his ~8 RCC patients (a few started off-label prior to approval and out ~5 months) he has not seen any response that would have qualified as RECIST responders, however nearly all have stabilized disease or modest shrinkage and are feeling markedly better.  States that he is perfectly comfortable with this and similar to many agents in GU landscape.  States that unless patients are feeling worse or have other 'triggers', he is starting to scan no earlier than 12-16 weeks as he would not discontinue drug based on that scan anyway.",23
completely,Territory,  S. IL,7.7,5.07336130043e-06,26,3,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","RTL stated that as more data has come out pan tumor, he has decided that 'psudoprogression is a extremely rare occurrence and not something that 'any longer plays into his decisions making'.  He stated that in RCC, given numerous trx options, he typically won't treat beyond progression with nivo alone.  State that he has found many people with PD on nivo have a mixed response and he hesitates to completely stop nivo. Instead, if patient is fit and experiencing minimal AE, he will continue nivo while adding in his next line of therapy at a reduced dose (3L typically cabo or axitinib).  To date has not experienced any addidive/unexpected toxicity","TL is not testing for PDL1 in bladder (and has no interest in doing so) and was completely unaware of the atezo data around responses in PDL1 neg vs. positive patients.  Reviewed our 275 data and TL stated that he like the fact that responses more consistent across all patients regardless of PDL1.  Stated that once approved, could see himself 'preferring' nivo over atezo due to thins, even though he believe all class agents are essentially the same.",29
testing for PDL1,Territory,  S. IL,7.46666666667,3.62119604792e-07,39,575,"3 RCC TLs from distinct institutions (small academic, large academic/VA and community practice) state that they have never tested for PDL1 in RCC and see absolutely no value in it as the data has clearly shown no predictive benefit (note that some of the same TLs do routinely perform PDL1 testing in lung).  Multiple TLs also stated that they don't even typically run NGS-type panels in RCC patients (even though they may in other tumor types) as they rarely see any actionable mutations in these patients.","RTL at NCCN institution stated that he sees no value in testing for PDL1 in the rec/met setting.  Stated that he feels story in HN will be the same as in NSCLC... when aPD1 moves into initial treatment/pre-platinum setting, that patient selection by PDL1 will be necessary.  

He states that they 'try' to perform HPV testing, but it is not a reflex test, and rarely occurs outside of oropharyngeal.","LTL in large community practice has not yet used ipi/nivo combination and would reserve for only a young, fit, patient who was PDL1 negative. Otherwise would start with single agent PD-1 (preference for nivo due to familiarity, but feels that pembro is equivalent)  TL does not test for PDL1 in NSCLC and does not value test in that setting, but based on 067 PFS, 069 OS w/ crossover, and due to tox concerns with ipi believes that single agents probably have the best balance of tox and efficacy based on data right now and would reserve combo for PDL1neg.",614
HCP,Territory,  S. TN,20.8125,1.34846388469e-08,115,124,HCP is frustrated over Opdivo flat dosing reporting difficulty justifying changing the dose for patients that have done well on weight based dosing. He feels the change has been overnight and he wanted more notice before such drastic changes in dosing happen. He is concerned about patients receiving higher doses that will now receive the 240mg flat dose despite whatever the science reports. States that his practice will continue to use weight based dosing until payers push back.,After recent visit from competitor small community HCP expressed confusion about PD-L1 testing and what tx to use for 1st line NSCLC. Reviewed NCCN guidelines and reactive clinical data looking at PD-L1 expression. HCP shared they have had success getting pembrolizumab approved for patients expressing less than 50% in the 1st line setting.,HCP was visibly impressed with ORR by PD-L1 status particularly at the 50% level in Checkmate 012 for 1st line NSCLC.,239
cytology,Territory,  S.CA,406.0,4.4868917678e-05,4,159,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",163
volume,Territory,  S.CA,121.8,9.33045716196e-06,31,9,"?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",40
in-house,Territory,  S.CA,110.727272727,4.91640716262e-07,25,127,"Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a Regional TL in West territory that is part of a network of mid to large size community hospitals. Receives approximately 6 tests for PDL1 testing per week, most of which are 22C3, and has no plans to bring staining in-house. Does not believe pathologists are incentivized at his institution to stain slides in-house based on their reimbursement rate. Had negative views on using a 1% cutoff, stating that the company thought it was smart to have any staining be positive, but it ended up hurting them in the end.",152
score,Territory,  S.CA,96.1578947368,1.74548273723e-05,21,156,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",177
requests,Territory,  S.CA,42.0,1.67161390826e-05,61,545,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",606
cytology,Territory,  S.NV,406.0,4.4868917678e-05,4,159,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",163
volume,Territory,  S.NV,121.8,9.33045716196e-06,31,9,"?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",40
in-house,Territory,  S.NV,110.727272727,4.91640716262e-07,25,127,"Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a Regional TL in West territory that is part of a network of mid to large size community hospitals. Receives approximately 6 tests for PDL1 testing per week, most of which are 22C3, and has no plans to bring staining in-house. Does not believe pathologists are incentivized at his institution to stain slides in-house based on their reimbursement rate. Had negative views on using a 1% cutoff, stating that the company thought it was smart to have any staining be positive, but it ended up hurting them in the end.",152
score,Territory,  S.NV,96.1578947368,1.74548273723e-05,21,156,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",177
requests,Territory,  S.NV,42.0,1.67161390826e-05,61,545,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",606
GYN ONC,Territory,  SC,67.7647058824,4.86513262337e-05,4,69,Spoke with GYN/ONC who wondered if BMS would start any Opdivo/Yervoy cervical cancer trials.  Mentioned that his institution already has a Pembro trial (Phase 1?) looking at Cervical.,"GYN ONC spoke with me about IO in cervical cancer.  He stated, ""I know that there are trials looking at HPV+/- cervical patients and Nivo, but I really think that the combination (like the -012 Lung) will turn out to be better.""","GYN ONC spoke with me and stated:  It is unfortunate that GYN ONC is the last to ever get trials.  It is almost a secondary thought.  I would think that BMS would have been more aggressive in the cervical cancer space, since we know it can be driven by a virus, and we know that the immune system can be used to target the virus (referring to the vaccine).  You would think this would be an easy win.""",73
Neuro-ONC,Territory,  SC,50.8235294118,1.24003412856e-09,11,39,"When discussing some contradicting data surrounding the effect of WBR and SRT on Tcell infiltration into GBM tumors, one study saying that if facilitated Tcell infiltration, and another study said that RT reduces Tcell's ability to infiltrate the tumor, Neuro-ONC expressed his frustration as ""F- me, we can't seem to figure out anything with this disease.""","Neuro-ONC stated that MGMT as a bio marker for GBM is just as bad as PDL1 status.  ""It can change after RT, or Chemo.  Recurrent tumors can change MGMT status as well.  It also has the same problems as PDL1 status in that there is heterogeneity within the tumor, intratumor and intertumor differences as well.  It is not a great bio marker, but it is all we have to go with now.""","Neuro-ONC stated that in ""slow growth"" recurrent GBM patients that he will try combinations of Opdivo, Opdivo+Bev, Opdivo+Yervoy.  Has had limited success with each possible, but stated that ""limited success is still success in GMB.""",50
National Thought leader,Territory,  SC,39.5294117647,1.99854733424e-07,9,0,"A National Thought leader stated, when asked about the future of bio markers in NSCLC:  To solve the puzzle (in lung), people are going to have to forget about PDL1.  PD1 inhibitors work but that doesn't mean that PDL1 expression is the first place that people should look.","National Thought leader answering questions about PDL1 testing at a recent dinner presentation stated:
1.  I think PDL1 data will be big at ASCO this year, but I think it will take a big step back.  I think the data will muddy the water more than it already is.  
2. PDL1 (expression) will be something big in the future, but right now we just don't know enough about it to use the data correctly.  
3.  Regardless of the PDL1 expression you are doing your patients a disservice if you are not using Opdivo 2L in your NSCLC patients.","A National Thought leader stated, when asked about the future of bio markers in NSCLC: I think investigators should start looking at it from the end and work backwards.  We should focus on the responders.  Find out what commonalities they have and work from there.  We are currently testing for a bio marker (PDL1) from samples where we know the expression can be different than when treatment starts (biopsy before 1L treatmen) and then assuming that the marker we looked at is the same when determining the use of 2L treatment.",9
respect,Territory,  SC,12.7058823529,1.0185475299e-06,20,122,"Regional meeting TL stated "" PD-1, PD-L1 and CTLA4 are not the whole story with respect to the immune system, there is much more that we need to find out""","With respect to Opdivo ""Cancer is the nail and you guys own the hammer""","With respect to 026, KOL in my territory noted, ""So single agent Nivo didn't meet PFS end point, big deal!  We're all waiting for the combination data with ipilimumab anyway in the front line!""",142
GBM,Territory,  SC,5.34984520124,1.98248897721e-05,49,79,"Neuro-ONC stated that they look forward to seeing OPDIVO + OPTUNE in GBM patients.  When asked why she thought this combination would benefit patients she stated that OPTUNE will keep the tumor at bay, giving Opdivo time to mount a response.  She is an OPTUNE speaker, and stated that she will be submitting an ISR for this concept, and has already been told by NOVOCURE that they would like to participate jointly with an IO company.","Neuro-ONC stated that in ""slow growth"" recurrent GBM patients that he will try combinations of Opdivo, Opdivo+Bev, Opdivo+Yervoy.  Has had limited success with each possible, but stated that ""limited success is still success in GMB.""","Neuro-ONC stated that 18months is her average from initial diagnosis with GBM to death.  Recurrence at about 10-12 months and roughly 6 months post recurrence till death.  Patients where recurrence isn't until 20months are on the far end of the GBM spectrum, and not representative of the normal patient.  Stated this in discussion around the Pembro GBM population of -028.",128
IO therapy,Territory,  SC,4.65051903114,1.63145940311e-05,64,26,"When asked what his criteria was for determining treatment beyond progression for RCC, National Thought leaders stated, that if the progression appears to be a ""slow growing"" or 1-2 new lesions, he will treat beyond this ""progression"" because he feels this is likely an IO induced progression/Non-traditional response.

However, if the primary grows rapidly, or if there are more than 2 new lesions then that is most likely true progression and it is unlikely that continuing IO therapy will sway the balance.",A National Lung TL stated that she thinks that Chemotherapy plus IO therapy is a mistake.  The tails of the OS curves will minimize 1L IO therapy because basically you are giving chemo to patients that don't need it.  So when those patients come off treatment because of the toxicities (likely from the chemo) you have lost the benefit of the IO therapy.,"A National Thought Leader (and NCCN member) stated that she feels community treaters of NSCLC with IO therapy are not experienced enough to treat appropriately.  She stated she has patients that show up to her that are 6 months past NSCLC diagnosis and have gone through sometimes 2 IO agents (used one PD1 fail, try other PD1).  

She says that she does not think community treaters wait long enough for IO agents to work and are too quick to call a treatment ""a failure"" and aren't providing the patients immune system with enough time to actually mount a response.

Too often they are associating a decrease in performance status, or more often, AEs with no tumors shrinkage seen within the first 3-6 weeks as an IO failure when that may not be the case.",90
RTL from a major academic institution,Territory,  SD,544.814814815,1.12906091676e-27,20,232,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
community institution,Territory,  SD,490.333333333,5.9256489862e-25,31,221,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
026 Top 300,Territory,  SD,190.685185185,6.8926961162e-10,7,245,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
large community institution,Territory,  SD,163.444444444,6.41787056118e-16,13,1371,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",1384
NCI,Territory,  SD,108.962962963,1.41957708687e-10,16,112,"RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.","RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.",128
NOT Top 300,Territory,  SD,108.962962963,8.33033572817e-06,4,248,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
academic institution mentioned,Territory,  SD,68.1018518519,1.25201895373e-06,14,47,"[026 Top 300] NTL from a top academic institution pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients.
- At his institution, 20% exhibit mutations (e.g, EGFR, ALK, ROS1) with the remaining 80% eligible for PD-1/L1 inhibitors.  Of these, only 20-25% of those will exhibit PD-L1 50% or higher.
- This equates to more like 16-20% of NSCLC patients in the real world that would be eligible for first-line pembrolizumab.","RTL from an academic institution mentioned that that data for NSCLC patients who have ALK or ROS1 mutations is unclear for I-O therapies.  RTL is aware of trials looking at crizotinib and nivolumab, but mentioned there would be overlapping toxicities.","RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.",61
single-agent,Territory,  SD,54.4814814815,2.42526421148e-05,5,0,"RTL from a community institution mentioned that 026 was an ""unfair"" trial due to the negative press and attention she was hearing from the media.  Moreover, RTL highlighted that it's pretty clear that single-agent I-O doesn't seem to be the ""cure-all"" for all comers in first-line NSCLC.  RTL is remaining hopeful and excited for 227, especially after hearing about the positive 012 WCLC results from the press.","RTL from a community institution mentioned that the ESMO data from 026 was disappointing, but mentioned that it's clear that single-agent I-O is insufficient in the front line.  RTL was excited for 227 based on the 012 data from ASCO presented earlier in the year.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",5
KEYNOTE-024,Territory,  SD,50.5899470899,1.78773142719e-14,19,76,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.",95
CheckMate 227,Territory,  SD,34.0509259259,7.0536803906e-06,8,8,"RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.","HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",16
second-line,Territory,  SD,27.2407407407,4.57835472849e-09,17,63,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",RTL at a major academic institution has been using nivolumab in second-line RCC with great results.  RTL is now encountering the problem of patients relapsing after progressing through nivolumab.,80
eager,Territory,  SD,22.700617284,2.42889176589e-05,10,7,"HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""] NTL from a major academic institution expressed disappointment in 026 results from ESMO, as she was hoping for better efficacy.  NTL shared that female patients at her institution fare better than male patients, so she does agree this partly explaining higher OS with chemotherapy arm for 026.

NTL understands that it's impossible to cross-compare 026 with KEYNOTE-024.  NTL expressed little enthusiasm for pembro as not a lot of patients are at or above PD-L1 50%.  NTL is highly eager for CheckMate 227.",17
first-line,Territory,  SD,21.7925925926,7.58015519138e-11,26,54,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",80
top,Territory,  SD,21.1872427984,7.53179974268e-07,23,0,"RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",23
major academic institution,Territory,  SD,18.1604938272,8.83821838019e-06,34,225,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",259
RTL mentioned,Territory,  SD,10.0360623782,3.10225978306e-05,27,0,RTL at a major academic institution has the top accrual in the US at his institution for IMvigor 010 (atezolizumab as adjuvant therapy for high risk muscle invasive disease).  RTL mentioned that patients are doing well in terms of efficacy and safety on atezo with about 40% of patients being PD-L1 positive according to the SP142 assay.,"RTL from a large community institution mentioned that he was ""surprised that the safety of PD-L1 inhibitors (i.e., avelumab) wasn't as good as PD-1 inhibitors"" in terms of reducing immune-mediated AEs (as originally thought).  RTL was actually one of the authors for the JAVELIN solid tumor trial for avelumab (anti-PD-L1) presented at ASCO.  Interestingly in that poster, RTL mentioned that there was also a 16% infusion-related reaction rate from the 1,300 patients enrolled (pan-tumor), which mandated a premed regimen of APAP and Benadryl into the protocol.","RTL from a major academic institution was not concerned that CheckMate 026 did not meet its primary endpoint.  Rationale: RTL was extremely encouraged with positive data from CheckMate 012 at ASCO on combination therapy.  RTL mentioned that PD-1 monotherapy is not likely to work as you would need something ""harder hitting"" such as nivo + ipi in the front-line setting.",27
Checkmate,Territory,  SD,7.21078431373,2.22390391802e-05,87,792,"[026 Top 300]  HCP from a community institution mentioned that he is still going to use nivo as he and his staff are extremely comfortable with the safety profile of nivo.

Discussed CheckMate 017 and 057 as well as KEYNOTE-010 reactively as it was evident he was getting nivo, pembro, and atezo mixed up.  When reactively discussing the Blueprint project and OS data, it became clear to him that he would choose nivo based on the efficacy and safety vs. the convenience factor of q3 weeks of pembro/atezo.","RTL from a large community practice questioned the difference between all the assays available and if there's any correlation between all 4.  Reactively presented the FDA blueprint project from AACR.  From here, RTL asked about OS data from both KN-010 and CheckMate 057.  RTL was surprised by the higher OS from nivo when compared at the 1% level.","RTL who's actually a lung speaker for both Merck and BMS let me know he tests for PD-L1 occasionally.  In those who are PD-L1 expressors, he uses pembrolizumab, but those who are negative, he uses nivolumab.  Reactively discussed data from Keynote 010 on OS data stratified by PD-L1 status as well as data from OS on 057 stratified by PD-L1 status.

RTL was shocked to hear the longer OS data with nivolumab at the 1% level compared to pembro.  He further mentioned that even though the Merck rep is his long-time friend, this OS data is important for him and his care for patients.",879
pembrolizumab,Territory,  SD,6.68169112509,8.55837599655e-07,65,45,RTL from a major academic institution mentioned that nivolumab still has a prominent place in second-line for the 70% of NSCLC patients out there because pembrolizumab from KEYNOTE-024 at its 50% or higher cutoff limits its use in the real world.,"NTL commented that the cancer center is opening a pembrolizumab vs. brentuximab vendotin trial, but noted that this trial does set up one drug to lose and ""neglects sequencing"" which could be an important part of using these new therapies.",RTL from a major academic institution mentioned that the anti-drug antibodies for nivolumab were reported to be higher than for pembrolizumab from a recent paper.,110
cancer center,Territory,  SD,6.45175438596,4.68195291453e-05,46,130,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.","RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.",176
PD-L1 expression,Territory,  SD,6.11526832955,1.13413607914e-05,72,703,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",775
PTCL,Territory,  SRs,828.818181818,3.06165550408e-07,3,139,"TL interested in doing a PTCL using CHOEP frontline f/b Nivo, in all PTCL patients not just CD30+.","TL interested in doing a PTCL using CHOEP frontline f/b Nivo, in all PTCL patients not just CD30+.",RTL noted that Merck has approached her regarding a PTCL/Testicular lymphoma trial using pembrolizumab.,142
pt,Territory,  TN,28.9142857143,8.44882129419e-09,67,23,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.",Community HCP has pt on Genentech's PDL-1 for bladder ca with no response.,Largest Community Practice in state: Community TL stated no use of opdivo in HL yet. Has a pt progressing on BV so opdivo will be next step.,90
large community practice,Territory,  TN,28.5338345865,4.12072489789e-06,42,1884,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.",Largest Community Practice in state: Community TL stated Insurance companies are requiring PDL-1 status for opdivo NSCLC in all settings. Interesting that pts had to be 50% exp for Keytruda to work.,Largest Community Practice in state: Community TL stated no use of opdivo in HL yet. Has a pt progressing on BV so opdivo will be next step.,1926
voluntarily,Territory,  TX,281.513513514,5.52533191953e-11,7,0,"Local TL voluntarily made a general comment regarding the data he has seen with nivolumab in lymphoma, sharing that he thinks nivolumab will be much safer than any other treatment options for HL patients",Regional lung TL voluntarily shared that he has recently received a grant specific to looking at patients with autoimmune diseases and the use of I-O agents in this population,NTL voluntarily shared that KESTREL is accruing well and they expect it to be done by year-end; KN-048 not yet done but could be this year with potential to see pembro monotherapy in the 1L R/M SCCHN setting,7
I-O agents,Territory,  TX,35.1891891892,3.76560012019e-08,14,6,TL inquired as to incidence of autoimmune disease development while on I-O agents; referencing recent publication from Johns Hopkins in Ann of Rheum (June 2016) of 13 patients that received either ipi or nivo that went on to develop rheumatological AEs - TL shared that they were confused as to why there was no mention of pembro at all as he felt the article gave the perception that these may only be caused by ipi or nivo; TL said he had to ask a Merck rep for clarification on whether these AEs could be seen with pembro as well,"Dermatologist expressed opinion that all dermatologists should be educated around the new I-O agents as well as be more closely involved in the treatment process, with oncologists, specifically in the adjuvant setting","RTL stated that there is a high percentage of patients with auto-immune disease, specifically in the NSCLC patient population, that precludes them from qualifying for I-O treatment; RTL feels more information is needed for I-O agents in this population and/or more treatment options are needed for these patients",20
H&N cancer,Territory,  TX,17.5945945946,1.18819483836e-06,22,39,NTL felt that adding nivo to CRT in H&N cancer won't have a significant increase in benefit and perhaps it would be more beneficial to look at nivo with RT alone (referenced data with cetuximab+CRT vs. Bonner study of cetux+RT),NTL stated that buparlisib is the most promising targeted agent currently being researched in H&N cancer with a 40% ORR being extremely remarkable for this patient population,NTL stated he does not feel pseudoprogression is an issue in H&N cancer (only truly in melanoma) and he would not expect that giving a PD1 agent prior to RT would increase the incidence of pseudoprogression although he has had debates with colleagues around this potential issue,61
CM-026,Territory,  TX,11.0941286114,3.62908626292e-06,52,177,NTL commented in regards CM-026 and the various cut-offs of PDL1 expression in -026: seeing ~75% of patients in each arm at >/= 5% PDL1+ seemed very high; NTL also felt that when looking at the 50% cut-off and understanding that the study was not designed to look at this as well as the imbalances that the data is still quite discouraging to see those results,NTL seemed unaware of the fact that CM-026 failed to meet primary endpoint; was surprised and vaguely shocked to the sharing of data and having a conversation around this trial since it had a failed primary endpoint.  He stated multiple times it was very discouraging and he would've expected it to be much more like CM-012,"RTL shared his thoughts on CM-026 presented as ESMO and stated ""it happens"", referencing the failure to meet the primary endpoint of PFS; he felt it was not significant and only continued to highlight the need for further options for patients, in which he thinks combo I-O / I-O will play a critical role",229
TL shared,Territory,  TX,7.91138679663,4.09844945296e-07,119,1081,TL stated that in RCC he always uses nivo prior to cabo stating his preference is to get I-O in as soon as possible in any treatment regimen for patients specifying that he truly believes in the durability we see with I-O - went on to refer to how many physicians are using I-O before a BRAF inhibitor in melanoma; TL also shared that he dislikes everolimus (and associated toxicities) so much that he refuses to use lev+ever,"TL shared that he treated a metastatic H&N patient with the Extreme regimen, followed by Abraxane, in which the patient progressed on both lines of therapy; the TL then used nivo as 3L and the patient has now achieved a CR within a couple months of therapy","TL shared that he doesn't use sorafenib in HCC patients because ""it doesn't work"" and patients can't remotely tolerate the level of fatigue",1200
feels,Territory,  TX,3.22651591419,2.34238826911e-06,397,56,"TL commented on the OS curves by p16 status from AACR -141 presentation, stating that he felt the ICC arm in p16-positive patients should have ""done better"" than what was shown; he felt it looked similar to the ICC arm of the p16-negative patients whereas typically in practice p16-positive patients respond better to treatment than p16-negative patients - thus making it hard to really compare response to nivo vs response to ICC in the p16-positive patients since he felt it underperformed",RTL shared that thus far when using pembro in the 1L NSCLC setting for patients < 50% PDL1 expression they have met no resistance in having it covered by insurance; TL feels that the insurance company only really looking for 1L data in general and the specifics to PDL1 status aren't necessary (so far) in reimbursement,Regional TL felt that the number of patients on CM-026 receiving maintenance with pemetrexed was lower than what he feels he sees in clinical practice going on to reflect whether this affected the time at which patients potentially crossed over from the chemo to the nivo arm,453
lung TL said,Territory,  UPSTATE NY,168.461538462,8.07821583641e-19,16,1110,National lung TL said that the KN10 data in the squamous population was ?disappointing? however he wouldn?t steer away from using pembro in a squamous patient based on the KN10 data.,"National lung TL said that they do not enforce everyone testing for PDL1 but if they do test and it is positive, pembro is the choice. He said that even in his clinic, he rarely bothers testing for PDL1 and most often checks the box on the pathway that says ?PDL1 not tested?. He did mention that the PDL1 test is readily available for them and said it is reflexive to do just like EGFR or alk.","National lung TL said that he expects to see first line IO trials like CA209-026 to look like the data from 057. he stated that ""There wont be too much of a mOS difference but the curves will look like the 057 data since most of the patients will be adeno"".",1126
atezi,Territory,  UPSTATE NY,112.307692308,9.0623455182e-07,5,27,"At Fall ECOG meeting thoracic TL in the audience voiced his opinion that since atezi is approved now does it replace nivo second line since 026 was negative.
1.	Audience member stated  that since we don?t have atezi first line data (in a similar study design like 026), so we cant make changes based on nivo fail first line. She said if we are making decisions on stopping use of nivo in 2nd line setting based on first line data, then we need atezi first line data as well to make a fair comparison.
2.	Thoracic chair said ""HR are all same between atezi and pembro and nivo in salvage setting""
3.	National lung TL said that toxicity is better with atezi (1% pneum) vs nivo (6%)
4.	Comment was made on atezi efficacy in PDL1 neg patients is based on sp142 antibody which misses about half of positive patients","Local lung TL commented that he currently uses about 80% nivo in his second line NSCLC patients vs 20% pembro. He doesnt think there is much room for atezi in that space. He did say that with the 026 results, he expects some hit to the amount of nivo being used second line.",Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,32
Regional lung TL told,Territory,  UPSTATE NY,101.076923077,4.34208902411e-21,21,2,"Regional lung TL told me that he hasn?t treated any patient with autoimmune disease with IO intentionally, he has however seen a patient develop RA following nivo treatment. Patient has been managed with steroids and will be restarting nivo.","Regional lung TL told me about a recent op-edd piece that he saw in either The New York Times or Wall Street Journal where someone (he suspects this person was from merck) wrote in and criticized oncologists about not using pembro in pdl1-. He said the piece basically called out the oncologists as being very dumb people. He said that it ""is typical Merck tactics"".","Regional lung TL told me that he isn?t convinced that the Keynote 024 data is that great, he said ?lets wait to see the data before we get too excited?.",23
Fall ECOG,Territory,  UPSTATE NY,89.8461538462,1.71205620441e-05,4,148,"At Fall ECOG meeting thoracic TL in the audience voiced his opinion that since atezi is approved now does it replace nivo second line since 026 was negative.
1.	Audience member stated  that since we don?t have atezi first line data (in a similar study design like 026), so we cant make changes based on nivo fail first line. She said if we are making decisions on stopping use of nivo in 2nd line setting based on first line data, then we need atezi first line data as well to make a fair comparison.
2.	Thoracic chair said ""HR are all same between atezi and pembro and nivo in salvage setting""
3.	National lung TL said that toxicity is better with atezi (1% pneum) vs nivo (6%)
4.	Comment was made on atezi efficacy in PDL1 neg patients is based on sp142 antibody which misses about half of positive patients","At Fall ECOG meeting, thoracic chair polled the audience about how is PDL1 testing being handled at their institutions.
i.	Mass Gen reflex testing but not with 22C3. 
ii.	More institutions sending out samples vs in house testing
1.	Audience responded that they are getting results within 3-5 days of sending out samples
2.	They are getting actual % positive PDL1","At Fall ECOG meeting thoracic presenter told the audience that 026 is technically a negativestudy and she commented that the forest plots of 026 subsets showed most actually favored chemo (she said ""the dots in the forest plots were mostly on the chemo arm vs the nivo arm"").",152
voiced his opinion,Territory,  UPSTATE NY,67.3846153846,1.8073479167e-07,7,16,"Academic lung TL voiced his opinions that the ""OAK data  is bad"". He said that it is clear that the assay used is not as good as the 22C3 or 28-8 based assays. He also said that he doesn?t think much of the never smoker data in OAK.","Academic lung TL voiced his opinion that Keynote 024 and pembro first line ""is the single best thing that has ever happened in NSCLC for patients"".","Academic lung TL voiced his opinion that Keynote 024 and pembro first line ""is the single best thing that has ever happened in NSCLC for patients"".",23
Local lung TL commented,Territory,  UPSTATE NY,44.9230769231,7.11846286708e-11,14,0,"Local lung TL commented that even with the 026 trial results, he still thinks pembro and nivo are basically the same agent.",Local lung TL commented that he isnt worried about the 026 data as you cant go back and retrospectively analyze the data using a 50% cutoff. He said the study wasnt designed that way and thus you cant get meaningful data from that kind of analysis.,Local lung TL commented that he is impressed with the data on Nivo plus Ipi data in SCLC and is happy to see it included in the NCCN guidelines. He was curious as to why the dose of ipi used in the combination is higher than in the NSCLC trials.,14
isn,Territory,  UPSTATE NY,44.9230769231,5.92688721385e-09,11,106,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",Community TL shared that he uses mostly nivo (vs pembro) for his lung patients. He said it wasn?t due to any specific reason (i.e. better efficacy or better toxicity) other than the fact that he is comfortable with nivo and doesn?t see any reason to even try pembro. He said he thinks nivo is better especially in squamous patients.,117
GR,Territory,  UPSTATE NY,44.9230769231,4.95492170287e-05,5,0,"National H&N TL indicated during GR that KN-012 showed ""only a smattering of CRs"" and that one should remember the tail of the curve ""represents only 4 patients"".",Melanoma NTL said from GR podium that the incidence of nivolumab-related myocarditis/myositis is ~ 0.25%.  Estimates deaths in nivo clinical development program to be 5 from myositits and 6 from myocarditis.,"National H&N TL said during GR that in Checkmate 141, nivo and ic OS tracked during the first three months which was surprising to them.   They said the OS rate was similar to KN-012 and that PD-L1- patients ""derived little benefit"" from nivo.",5
second,Territory,  UPSTATE NY,44.9230769231,4.95492170287e-05,5,0,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.",Local RCC TL said his strategy for second line RCC it that he was always under the impression that its best to switch MOAs when failure occurs. He said that was how he was trained. He said that he doesn?t think anything can replace nivo second line given the very limited toxicity profile seen with it. He said he doesn?t think cabo can replace it,"Local lung TL commented that pathway company at his institution does not differentiate % of cell positive for PDL1 to determine who can get pembro second line. He said ""positive is positive"" according to the medical director of the pathway and doesnt think it will change first line. He said he thinks the same will hold true for first line use of pembro, any positivity will result in use of pembro first line.",5
H&N TL,Territory,  UPSTATE NY,28.0769230769,1.69965923429e-05,20,432,"National H&N TL provided the following comment regarding pembro approval in H&N: He said that pembro got approved based on the 141 data set. His exact words were ?pembro was approved based on Checkmate data? because everyone expects Keynote 40 to be positive just like checkmate 141 was. He said Merck was lucky that they hit the sweet spot in terms of timing and that?s why they got approval. He said that everyone expects pembro to ultimately have as strong of data as nivo but as of right now, nivo has the best data out there and thus should be the preferred option on their institutional pathway.","Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.",Regional H&N TL told me that KESTREL will close (due to full accrual)  in October 2016.,452
sutent,Territory,  UPSTATE NY,28.0769230769,1.69965923429e-05,8,3,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.","Local RCC TL told me that Pazop toxicities are the same but less significant vs sutent. She said they only use pazop for frail older patients first line. Everyone else gets sutent first line. She said that they use 2 on, one off dosing of sutent even though it isn?t recommended in their PI.","Local RCC TL said his strategy for 1st line RCC used to be pazopanib first line but he said he really likes the 2 weeks on, 1 week off Sutent strategy. He said he has been using that in his new patients. He said that the biggest issues he used to have with sutent every four weeks was weight loss as a result of significant diarrhea coupled with taste issues. He said patient won?t eat because of the taste problems.",11
TL told,Territory,  UPSTATE NY,12.4786324786,1.88631056051e-10,65,938,"Local H&N TL told me that the RTOG 3504 study in locally advanced H&N is very important because that is most common type of patient that they see. She said that they only see 10-15% of patients being metastatic at presentation and at least at their institution, the h&n isnt treated at the community sites, instead all of the patients are referred to the main hospital.","Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.",Local H&N TL told me that it was first time she has seen standing room only space at a H&N presentation when referring to the 141 data presented by DR Ferris at ASCO.,1003
Local,Territory,  UPSTATE NY,9.70560303894,5.95366712416e-19,184,1056,"Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.","Local community TL told me that when she gets her reports back for PDL1 testing, the company provides her with a % positive for PDL1 for pembro as well as a % positive for nivo on the same sheet. I asked her if the numbers match up based on Blueprint analysis and she said they are usually about 10% different with the nivo number being lower. This was based on a single patient and she couldnt remember the company's name that did this testing but she said she would let me know.","Local H&N TL told me that the RTOG 3504 study in locally advanced H&N is very important because that is most common type of patient that they see. She said that they only see 10-15% of patients being metastatic at presentation and at least at their institution, the h&n isnt treated at the community sites, instead all of the patients are referred to the main hospital.",1240
t,Territory,  UPSTATE NY,7.29270729271,5.00781418171e-12,117,0,Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",117
doesn,Territory,  UPSTATE NY,7.21978021978,2.48864767972e-05,36,94,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,130
TL said,Territory,  UPSTATE NY,6.17692307692,1.15759629663e-05,86,62,Regional GU TL said he does not order PD-L1 testing in RCC or bladder outside of a clinical trial.  Said there is no data to support treatment decision making in RCC.,Regional TL said no data supports testing for PD-L1 in RCC in any line.,"National H&N TL said during GR that in Checkmate 141, nivo and ic OS tracked during the first three months which was surprising to them.   They said the OS rate was similar to KN-012 and that PD-L1- patients ""derived little benefit"" from nivo.",148
said,Territory,  UPSTATE NY,5.89615384615,2.85420644098e-27,479,0,Local RCC TL said his strategy for second line RCC it that he was always under the impression that its best to switch MOAs when failure occurs. He said that was how he was trained. He said that he doesn?t think anything can replace nivo second line given the very limited toxicity profile seen with it. He said he doesn?t think cabo can replace it,"Local H&N TL said that at the recent ASCO review, the speaker highlighted the 1 yr OS as being very important.Local TL also said that ORR is OK as an endpoint, but OS is the king of outcomes. He said that ORR is tough to use due to the potential for pseudoprogression with immunotherapy. He said EXTREME regimen very difficult for most patients. He isn?t a fan. He uses some weekly taxotere, some gem","Regional lung TL said that he ""doesn?t think there is ultimately any difference between nivo and pembro even with 026 press release"". He is impressed that pembro hit both pfs and OS data. He said BMS gambled right for second line but not so much for 1st line. He also said that it?s clear that PDL1 positive patients do better. ""It always better to be PDL1 positive"". He wants to see the data from pembro and from 026 to really see if there is any difference.",479
line,Territory,  UPSTATE NY,4.75147928994,5.90756762208e-08,345,108,"Local RCC TL said his strategy for 1st line RCC used to be pazopanib first line but he said he really likes the 2 weeks on, 1 week off Sutent strategy. He said he has been using that in his new patients. He said that the biggest issues he used to have with sutent every four weeks was weight loss as a result of significant diarrhea coupled with taste issues. He said patient won?t eat because of the taste problems.",Regional lung TL told me he heard about the 026 press release and said that we now need to know if nivo can be effective in patients that fail first line pembro. He said he has tried to use nivo in a NSCLC patient that failed a first line anti-PDL1 antibody (EMD Serono antibody) and it didn't work.,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.",453
told,Territory,  UPSTATE NY,4.62443438914,1.48224821259e-05,136,65,Regional lung TL told me that the Merck people are telling him that 70% of 2nd line patients are getting tested for pdl1. He laughed and said he doesn't believe that.,"Local pharmacist told me that the ""Merck people are pushing the fact that they achieved an OS benefit in their 024 study even with cross over"" and are telling him that ""BMS cant use cross over as an explanation why nivolumab failed to achieve any OS benefit in 026"".",Local lung TL told me that the Merck sales folks visited him yesterday and his description of them was ?they were salivating about their data at ESMO and the incoming first line business?,201
national,Territory,  UPSTATE NY,4.08391608392,4.87316891553e-05,183,979,"National H&N TL provided the following comment regarding pembro approval in H&N: He said that pembro got approved based on the 141 data set. His exact words were ?pembro was approved based on Checkmate data? because everyone expects Keynote 40 to be positive just like checkmate 141 was. He said Merck was lucky that they hit the sweet spot in terms of timing and that?s why they got approval. He said that everyone expects pembro to ultimately have as strong of data as nivo but as of right now, nivo has the best data out there and thus should be the preferred option on their institutional pathway.","National lung TL said that they do not enforce everyone testing for PDL1 but if they do test and it is positive, pembro is the choice. He said that even in his clinic, he rarely bothers testing for PDL1 and most often checks the box on the pathway that says ?PDL1 not tested?. He did mention that the PDL1 test is readily available for them and said it is reflexive to do just like EGFR or alk.",National lung TL said that the KN10 data in the squamous population was ?disappointing? however he wouldn?t steer away from using pembro in a squamous patient based on the KN10 data.,1162
ONS,Territory,  UT,182.848484848,2.68433276953e-07,5,198,"While meeting with a community oncology NP who treats solid tumor patients, she mentioned that she attended an Advisory Board for Pfizer at ONS congress. She stated the first half of the session was surrounding how she would choose a patient for Sutent and asking about treatment sequencing and safety for the Pfizer drugs. She stated the last half of the session was the representatives ""drilling"" her about how she would choose OPdivo for a patient with RCC and reactions to the Opdivo presence on the market.","During ONS Congress medical presentation for Research to Practice TL hypothesized that PDL status will be needed for 1st line NSCLC. This TL likes to have PD-l1 status for his patients, though believes other oncologist will simply give nivo without any testing. He believes the differences between Opdivo and Atezo is that ""PD2  goes free""  and has yet to know what this will unveil in practice. These comments gathered during lung presentation portions.",Nurses at a proactive dinner presentation for ONS chapter mentioned they had been using Sandostatin for treatment of colitis induced by Opdivo. Proper symptom management and use of algorithms reviewed in detail and nurses shared they would institute use of IMAR guides in their clinics and hospitals.,203
California,Territory,  UT,73.1393939394,2.18833085337e-06,8,290,"Community Oncologist in Northern California volunteered that he had heard many of the releases from Asco via his email and colleagues surrounding 1st line lung. He mentioned that he believed PDL1 testing in 1st line will be no problem as testing is getting easier and cheaper, and they will have tissue due to newer diagnosis. He mentioned positive impression from the data he saw come across.","Community Oncology Clinic in Northern California had internal discussions, meetings and challenges surrounding BMS materials. Nurses were wanting to use patient care check sheets, and they felt ""legally"" liable if they did not call the doc for any items that would be checked by nurse or patients regarding ongoing symptoms related or not found during assessments. The site did in the end favor using check sheets and made an internal plan on ""when to call the doc"", but the language on the form made them uncomfortable until a full plan was in place internally. Rep and Nurse Liaison worked with team to discuss their current practices and feeling safe in their care and administration of the immuno oncology drugs. Nurses feel confident with tools and plans in place at this time.",Speaking with Community Oncologist in California (very tough to access account) who disclosed that he knows that any denial he gets from insurance for Keytruda will be covered by Merck.,298
PD,Territory,  UT,45.7121212121,6.12979388772e-07,14,3,"Spoke with Community Onc in Arizona, who mentioned he uses Biocept liquid bx for PD status for any 2nd line lung pt due to underwhelming efficacy in his practice. He will use Opdivo if biocept comes back positive for pd, otherwise chemo. 

Same physician mentioned that Opdivo is a blockbuster in Melanoma and far more effective than lung. He uses Monotherapy due to past bad experiences with Yervoy, unless the patient is young and it is a more tough call, he will do pd testing through caris and if positive, use Opdivo monotherapy and if negative will use combination. Stated he has a young pd+ pt on monotherapy who is doing wonderful for a long period of time now. He does not do pd testing across the board due to time and expense for Melanoma pts.","Oncologist reports after hearing data presented at asco regarding SCLC, that this is encouraging but that ""chemo can control disease quite well"". It will be hard to distinguish who will respond to IO vs chemo best. 

Oncologist also mentioned H&N data looking good but no distinction between nivo and pembro. The main advantage is that bms has ""ipi"" to add to opdivo and get the best efficacy. He believes that Opdivo is exclusively used in 2nd line lung due to no testing requirements. He believes pd status will be more readily available in 1st line lung and the testing will not pose any challenges for clinicians.","Lung Presenters at Conference from podium stated:
SHOW ME THE DATA: in reference to 026 negative trial release. Believes docs need to look closer and decide for themselves. 
-Highlighted that NCCN supports use of Nivo in SCLC
-Believes Cabo is a tough drug to five in Ret NSCLS and always needs dose mods. 
-Believes all Lung pts should get comprehensive Next Gen Seq (NGS) and advised audience to get a very comprehensive tissue BX even if it means multiple attempts as the data is invaluable
-Had a small discussion point discussing IO tx and future: believes the real questions will begin to creep up as what to do with IO refractory disease and where to go with future trials. 

Other presenter mentioned the excitment around the DLL3 Molecule for SCLC (rovalpituzumab tesirine). 
-Has not experienced psuedoprogression, believes the pts who respond will respond, and has not experienced delayed responses either. 

In private conversation regarding lung info presenter shared she believes PD status in not reliable and would never test or use data unless a pt had a very aggressive autoimmune co-morbidity and was hesitant to use IO. 
Also mentioned she believes clinicians are getting more used to imAEs and that she is gearing up for 1st line txs",17
surrounding,Territory,  UT,36.5696969697,1.65411534858e-05,13,0,"While meeting with a community oncology NP who treats solid tumor patients, she mentioned that she attended an Advisory Board for Pfizer at ONS congress. She stated the first half of the session was surrounding how she would choose a patient for Sutent and asking about treatment sequencing and safety for the Pfizer drugs. She stated the last half of the session was the representatives ""drilling"" her about how she would choose OPdivo for a patient with RCC and reactions to the Opdivo presence on the market.","Renal/GU Onc TL discussed Pseudo-progression. His RCC patients had slight progression and he continued the Opdivo tx for additional 2-3 cycles with no regression and ended tx. Once pt returned to community, the Onc there called back to TL to challenge him for continuing tx. TL feels there is still some confusion in medical community and even Academic surrounding this concept. 

He also mentioned that he takes calls often from community asking about psuedo progression and how to determine what to do with a pt on Opdivo or ImmunoTherapy.","Community Oncology Clinic in Northern California had internal discussions, meetings and challenges surrounding BMS materials. Nurses were wanting to use patient care check sheets, and they felt ""legally"" liable if they did not call the doc for any items that would be checked by nurse or patients regarding ongoing symptoms related or not found during assessments. The site did in the end favor using check sheets and made an internal plan on ""when to call the doc"", but the language on the form made them uncomfortable until a full plan was in place internally. Rep and Nurse Liaison worked with team to discuss their current practices and feeling safe in their care and administration of the immuno oncology drugs. Nurses feel confident with tools and plans in place at this time.",13
tx,Territory,  UT,35.5538720539,1.47528853211e-08,24,100,Renal TL mentioned he puts in central line port for his RCC pts starting Opdivo because he anticipates them being on tx for an extended period of time. He has several patients on tx for many months currently.,"Renal/GU Onc TL discussed Pseudo-progression. His RCC patients had slight progression and he continued the Opdivo tx for additional 2-3 cycles with no regression and ended tx. Once pt returned to community, the Onc there called back to TL to challenge him for continuing tx. TL feels there is still some confusion in medical community and even Academic surrounding this concept. 

He also mentioned that he takes calls often from community asking about psuedo progression and how to determine what to do with a pt on Opdivo or ImmunoTherapy.",NP from large Cancer Academic Center conveyed that all pts with SCCHN are being pre-screened for Hashimotos Disease before starting IO tx. The NP and the providers she works for believe pts have higher incidences with H&N disease and they will be able to intervene or ward off potential thyroiditis with additional info or proper dx of thyroid conditions before starting IO tx.,124
Onc,Territory,  UT,21.7676767677,1.19497706421e-05,44,188,"Renal/GU Onc TL discussed Pseudo-progression. His RCC patients had slight progression and he continued the Opdivo tx for additional 2-3 cycles with no regression and ended tx. Once pt returned to community, the Onc there called back to TL to challenge him for continuing tx. TL feels there is still some confusion in medical community and even Academic surrounding this concept. 

He also mentioned that he takes calls often from community asking about psuedo progression and how to determine what to do with a pt on Opdivo or ImmunoTherapy.","Community ONc reports concerns with his patient being hospitalized for diarrhea with suspected collitis with RCC. He advised treating physician to institute steroid dose 1mg/kg. He was asking for info on remicade if refractory to steroids. Physician feels ER and hospitals do not know how to treat these IO patients, if he is unable to follow them in hospital.","Spoke with Community Onc in Arizona, who mentioned he uses Biocept liquid bx for PD status for any 2nd line lung pt due to underwhelming efficacy in his practice. He will use Opdivo if biocept comes back positive for pd, otherwise chemo. 

Same physician mentioned that Opdivo is a blockbuster in Melanoma and far more effective than lung. He uses Monotherapy due to past bad experiences with Yervoy, unless the patient is young and it is a more tough call, he will do pd testing through caris and if positive, use Opdivo monotherapy and if negative will use combination. Stated he has a young pd+ pt on monotherapy who is doing wonderful for a long period of time now. He does not do pd testing across the board due to time and expense for Melanoma pts.",232
NP,Territory,  UT,21.0979020979,1.96250485298e-06,31,704,"Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.",NP from large practice volunteered she uses minocyline for rash r/t Opdivo and/or Yervoy if refractory to hydro-cortisone cream. She reports some anecdotal benefit. Same event: Pharmacist also mentioned - why dont we put everyone on zyrtec as prophylactic for potential of rash with regimen pts. We discussed incidence rates and he decided it would not be necessary to use a premed or prophylaxis approach.,NP from large Cancer Center shared their facility has transitioned all Opdivo pts to 30 min infusion time with no issues. This has helped streamline their infusion process for pts and has been a positive switch. The NP and her nurse also metnioned the flat dosing transition has helped Opdivo be a much easier infusion process with these two changes occurring.,735
symptoms,Territory,  UT,19.0467171717,2.09010661632e-05,28,195,"nurse reported rheumatoid arthritis flares with several opdivo and regimen patients. One case was a pt who had a distant history of mild RA and it flared up until she could not walk, drug had to be stopped. Nurse reported seeing pts have unprovoked RA type inflammation and pain in joints of knees spreading bilaterally as well with no medical  history. (AE's reported to safety). Nurse mentioned drug would need to be held and steroids used to control these symptoms.",Nurses at a proactive dinner presentation for ONS chapter mentioned they had been using Sandostatin for treatment of colitis induced by Opdivo. Proper symptom management and use of algorithms reviewed in detail and nurses shared they would institute use of IMAR guides in their clinics and hospitals.,"Community ONc reports concerns with his patient being hospitalized for diarrhea with suspected collitis with RCC. He advised treating physician to institute steroid dose 1mg/kg. He was asking for info on remicade if refractory to steroids. Physician feels ER and hospitals do not know how to treat these IO patients, if he is unable to follow them in hospital.",223
nurse,Territory,  UT,18.2848484848,6.791720092e-07,41,193,"Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.","Community Oncology Clinic in Northern California had internal discussions, meetings and challenges surrounding BMS materials. Nurses were wanting to use patient care check sheets, and they felt ""legally"" liable if they did not call the doc for any items that would be checked by nurse or patients regarding ongoing symptoms related or not found during assessments. The site did in the end favor using check sheets and made an internal plan on ""when to call the doc"", but the language on the form made them uncomfortable until a full plan was in place internally. Rep and Nurse Liaison worked with team to discuss their current practices and feeling safe in their care and administration of the immuno oncology drugs. Nurses feel confident with tools and plans in place at this time.",NP from large Cancer Center shared their facility has transitioned all Opdivo pts to 30 min infusion time with no issues. This has helped streamline their infusion process for pts and has been a positive switch. The NP and her nurse also metnioned the flat dosing transition has helped Opdivo be a much easier infusion process with these two changes occurring.,234
release,Territory,  UT,15.762800418,4.64622988245e-05,61,66,"GI Onc mentioned he was very underwhelmed by Gastric Data at ASCO. He mentioned he knows that it is a small sampling size, but he was hoping for more efficacy.He is hoping there will be more data released at GI Asco in January with more mature data. He has Taiho trail and will put pts on that if they are refractory to standard of care tx.","Community Oncologist volunteered he had ""just read""  2 yr OS from 2nd line Lung data released at ASCO and was very impressed. He has a patient on Opdivo with 1 year of treatment and is hoping he joins this group of long term survivors.","Community Oncologist in Northern California volunteered that he had heard many of the releases from Asco via his email and colleagues surrounding 1st line lung. He mentioned that he believed PDL1 testing in 1st line will be no problem as testing is getting easier and cheaper, and they will have tissue due to newer diagnosis. He mentioned positive impression from the data he saw come across.",127
large,Territory,  UT,9.37684537685,1.09764789504e-07,283,242,"Met with a Regional TL in West territory that is part of a network of mid to large size community hospitals. Receives approximately 6 tests for PDL1 testing per week, most of which are 22C3, and has no plans to bring staining in-house. Does not believe pathologists are incentivized at his institution to stain slides in-house based on their reimbursement rate. Had negative views on using a 1% cutoff, stating that the company thought it was smart to have any staining be positive, but it ended up hurting them in the end.",NP from large Cancer Academic Center conveyed that all pts with SCCHN are being pre-screened for Hashimotos Disease before starting IO tx. The NP and the providers she works for believe pts have higher incidences with H&N disease and they will be able to intervene or ward off potential thyroiditis with additional info or proper dx of thyroid conditions before starting IO tx.,"Pathologist TL that is a medical director for IHC at a large reference lab. Noticed a 4x increase in the number of requests over the last few months, stating approval in 1L lung as a factor. Stated he was surprised at how many people still request E1L3N. Is leading a survey of pathologists for CAP PD-L1 practices. When discussing concordance data and 1L data, he stated that both concordance and CM-026 were in a few small percentage of all patients, and this may be why CM-026 did not meet its endpoint.",525
pts,Territory,  UT,7.17052881759,1.46968992306e-06,164,1624,Renal TL mentioned he puts in central line port for his RCC pts starting Opdivo because he anticipates them being on tx for an extended period of time. He has several patients on tx for many months currently.,"Spoke with Community Onc in Arizona, who mentioned he uses Biocept liquid bx for PD status for any 2nd line lung pt due to underwhelming efficacy in his practice. He will use Opdivo if biocept comes back positive for pd, otherwise chemo. 

Same physician mentioned that Opdivo is a blockbuster in Melanoma and far more effective than lung. He uses Monotherapy due to past bad experiences with Yervoy, unless the patient is young and it is a more tough call, he will do pd testing through caris and if positive, use Opdivo monotherapy and if negative will use combination. Stated he has a young pd+ pt on monotherapy who is doing wonderful for a long period of time now. He does not do pd testing across the board due to time and expense for Melanoma pts.","Biomedical Learning Institute 1st Annual Symposium on Integrating Immune Therapies & Target Therapies into Standards of Care for Heme and Solid Malignancies; San Fran Sept 10, 2016 
Well Attended with over 200 attendees/ Merck was a sponsor as well as other companies (foundation medicine).   BMS was not one of the major sponsors.  

Lung: One of the major questions was: Are antiPD-1 agents interchangeable, and the presenters overall argued for yes they are the same (nivo/pembro). The schedule differences were mentioned several times highlighting Pembro
Insights 
?	Oak Trial results were mentioned for Atezo (Atezo was alleged as More toxic of the agents)
?	Pembro and Nivo have same toxicity profile
?	We don?t need a cross trial comparison since the populations were very similar and Nivo performs regardless of pd staining percentages
?	Commented that there are so many duplicative 2nd line trials amongst PD-1 inhibitors.  There is pressure to move into front line setting.  
?	In reference to 1st line lung press releases ? ?Merck cherry picked their patients? for trial, and consensus was that no doc on panel board would use off label 1st line IO tx unless on trial, they are all waiting for data; they all concluded that BMS strategy in 1st line did not pay off, and chemo ?isn?t going anywhere?, since only 50% of pts likely have pd expression. One TL did comment that if he did he would use Pembro as the data is there and it has the best schedule. 
?	Awaiting Blueprint project for further information on which testing to use (docs agreed that most facilities will pick one test and use exclusively due to cost and training)
?	All panel board docs advised audience to get PD status on new dx pts.  The question was asked if testing should be mandatory for newly diagnosed patients and they all said yes.  
?	National TL discussed Nivo trial looking at OS by PDL1 expression and stated 10% had better OS and that PDL-1 staining does predict OS. 
?	A lot of excitement over Ipi/Nivo combo in Lung  
1.	Mentioned that it is very alluring to give a boost of Ipi when single agent IO is fizzling to boost responses (no data to support however)
?	*Pseudoprogression mentioned many times ?does not exist in lung? ?pts refuse to be taken off of tx even in the face of wild progression?
?	Mentioned BMS 153 trial looking at early stopping of tx  Discussed the need to look at how long to continue these therapies.  TL went on to say he wasn?t sure how the data would pan out with this trial since many patients don?t survive to 1 year which is the cutoff for the trial to continue without therapy.
Costs: Cost was mentioned many times with one quote from podium for Lung 1st Line ?The only thing more expensive than IO is IO combo? 


Melanoma: Dr. J. Weber was one of the 2 presenters- NTL 
*Discussed BRAF pts to use targeted or IO first line setting (no consensus, both sides argued)
*Weber alleged Ipi/Nivo regimen is ?very toxic? and ?very effective? tx. Targeted Tx?s are less toxic that Combo IO. 
*advised audience to use 8 weeks of Targeted tx and move on to regimen of ipi/nivo
*Tvec treatment cant compare to IO
*064 Trial highlighted as switch approach 
*Encouraged extrapolating data from Lung Trial 012 for melanoma and to use reversed dosing or Ipi Q6w or Q12w
*believes adding braf inh target tx to IO combo will be very effective

Other solid Tumor:
-Pancreas: stated due to hypoxic pancreas tumor micro-environment and no local tcells that single agent antiPD1 hasn?t worked so far
Prostate: Discussed ipi negative trial and that bone disease only arm did much better 
H&N: Stated Nivo is new standard of care",1788
mentioned,Territory,  UT,5.87128162358,2.19824382227e-06,289,130,"Community Oncologist in Northern California volunteered that he had heard many of the releases from Asco via his email and colleagues surrounding 1st line lung. He mentioned that he believed PDL1 testing in 1st line will be no problem as testing is getting easier and cheaper, and they will have tissue due to newer diagnosis. He mentioned positive impression from the data he saw come across.","Physician of large private practice setting mentions he does not test for PD-L1 very often. He feels he does not need the information and does not think he would have enough tissue left after molecular studies. Opdivo would be chosen regardless of PD testing. Mentioned Opdivo pnemonitis is a strong risk, he feels other drugs do not carry. Data presented, physician still likely to use Opdivo in 2nd line melanoma and 2nd line lung.","GI Onc mentioned he was very underwhelmed by Gastric Data at ASCO. He mentioned he knows that it is a small sampling size, but he was hoping for more efficacy.He is hoping there will be more data released at GI Asco in January with more mature data. He has Taiho trail and will put pts on that if they are refractory to standard of care tx.",419
Northeast,Territory,  Upstate NY,301.0,8.78016867068e-14,9,121,"Testing for PD-L1 in NSCLC is now part of the usual pathology and genetic tests conducted in a leading NCCN institution in Northeast US.  This hospital charges the payers a single bundled charge for all the tests they do on a patient.  Now, PD-L1 has been added to the pre-existing battery of tests.  This institution does its own immunohistochemistry assays for PD-L1 using the E1L3N antibody from Cell Signaling Technology.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",130
IME,Territory,  Upstate NY,225.75,1.03059906794e-05,3,0,"In his presentation at an IME on immunotherapy in NSCLC, Naiyer Rizvi MD (Columbia University) summarized the data for nivolumab and pembrolizumab, stratified for PD-L1 levels and tumor histology.  The overall theme of his presentation was that both agents are very similar across all stratifications, even when the slides highlighted the differences (e.g. hazard ratio for pembrolizumab in squamous histology in Keynote-10).  BMS, Merck and Genentech funded this IME program.","Discussing therapeutic options in NSCLC patients expressing low levels of PD-L1, Leora Horn MD (Vanderbilt & NCCN panelist) indicated her preference for chemotherapy over IO agents.  She also believes that chemotherapy (with pemetrexed for NSQ NSCLC) and targeted therapy is more valuable in appropriate patients as first line therapy, instead of IO agents as monotherapy or in combination.  These opinions were expressed during the unscripted discussion following an IME program sponsored by BMS, Merck and Genentech.","Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.",3
New England,Territory,  Upstate NY,150.5,2.506522524e-18,17,970,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.",987
cell carcinoma,Territory,  Upstate NY,75.25,2.50530862486e-06,7,40,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",47
NCCN institution,Territory,  Upstate NY,66.8888888889,4.29123557889e-11,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","A leading academic thought leader and clinical trials expert from a New England NCCN institution underplayed the significance of CheckMate 026 results disclosed so far.  He felt that PFS is not a good endpoint for IO therapies, as many IO trials have already shown positive response rates and overall survival despite a lack of PFS advantage.  In cancers with low T- lymphocyte infiltration, CTLA-4 inhibition using ipilimumab may enhance the efficacy of nivolumab by increasing infiltration.",125
immuno-oncology,Territory,  Upstate NY,53.75,4.00828032701e-07,11,54,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.",65
produce,Territory,  Upstate NY,37.625,1.68991039548e-05,11,0,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Physicians are reacting negatively to the direct-to-consumer advertisements for Opdivo and are raising their displeasure proactively during meetings.  The Medical Director of the Lung Cancer Program in an academic hospital in the Northeast told the HSLs that he had second thoughts about using Opdivo, just as a reaction to the DTC advertisement on television.  Another family practice physician involved in formulary decisions called the Opdivo TV ads ?cringe-inducing?.  He complained that the overall tenor of the TV ad grossly exaggerates the modest improvement in median overall survival produced by Opdivo in NSCLC.","A leading academic thought leader discussed the clinical trial results of cabozantinib and his own personal experience in using this agent.  Toxicity and adverse events remains the major concern with cabozantinib.  Though cabozantinib produced very good results in clinical trials, he is cautious about using this agent in his practice.  He has participated in nivolumab trials, and uses nivolumab frequently in his clinical practice.  However, he stressed that the TKIs will remain a staple part of therapy of RCC, and the right patient can derive significant benefit from them.",11
US,Territory,  Upstate NY,37.625,1.46361607795e-06,14,24,"Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A clinical pharmacist at an academic medical center in the Northeast US indicated that they have added PD-L1 testing (IHC) to their usual battery of genetic tests for all tumors, including NSCLC and RCC.  At present, PD-L1 levels are not being used to make treatment decisions at this center.  But she implied that more granular instructions on the use of anti-PD-1 and anti-PD-L1 agents are expected in future from both regulatory agencies and payers.  This center wants to have all the procedures established before these changes become mandatory requirements.",38
thought leader,Territory,  Upstate NY,33.4444444444,2.42576830707e-09,25,22,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","A national thought leader on renal cancer from a Northeast NCCN institution advocated a Q3W dosing for nivolumab in RCC as a cost-saving measure that also increased patient convenience.  He substantiated his argument by pointing out that the clinical efficacy in ORR, PFS and OS are identical for CheckMate 010 and CheckMate 025, though the former trial uses a Q3W dosing schedule.  He believes that FDA would accept a single arm trial that shows non-inferiority in OS to change the labeling to a Q3W dosing.",47
Boston,Territory,  Upstate NY,28.21875,5.0253285218e-07,40,82,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",122
MD,Territory,  Upstate NY,27.7236842105,6.47806926464e-08,29,71,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",100
ipilimumab,Territory,  Upstate NY,26.5588235294,6.71018488851e-07,22,17,"David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.",39
renal,Territory,  Upstate NY,20.9027777778,1.48378524388e-05,22,26,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",48
cabozantinib,Territory,  Upstate NY,20.5227272727,2.34524140396e-06,27,137,"According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.","Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.",164
IO agents,Territory,  Upstate NY,18.3040540541,2.05728361688e-08,45,174,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A key oncologist from a New England academic hospital shared information on his thinking and his clinical practice in managing IO agents in patients with endocrine-related immune-mediated adverse reactions.  In his opinion, adverse events affecting the endocrine organs such as the thyroid and pituitary glands can be managed by administering the appropriate hormone replacement with discontinuing the IO agent.  He believes that value provided by IO agents including the potential for a complete remission is too important to sacrifice to avoid an adverse event that can be easily managed.","The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.",219
major,Territory,  Upstate NY,16.0106382979,1.11546964675e-08,90,483,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",573
advanced,Territory,  Upstate NY,15.6770833333,4.85954723446e-05,36,0,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","A key NCCN panelist for SCCHN a major academic hospital in New England was profiled to understand the treatment landscape in SCCHN.  This panelist was an investigator in CheckMate 141, and therefore was intimately familiar with the data presented at AACR.  The panelist considers the efficacy in OS to be better than what is seen in clinical practice with single agent therapies (methotrexate, cetuximab, docetaxel etc.).  He has a very negative opinion on the efficacy and toxicity of these standard of care therapies.  

Combination therapies will enhance the potential of immune-oncology in difficult to treat cancers and advanced stage disease.  Robust data needs to be developed for all options with Opdivo such as IO combinations, IO + targeted therapies and IO + chemotherapy/RT.  He also stressed the need to do clinical trials in nasopharyngeal SCCHN due to its unique etiology and response to treatment.  He does not endorse extending the NCCN recommendations to include this population based on data from other types of SCCHN.","The Director of Hematologic Malignancies at a major academic hospital in Boston downplayed the incidence of GVHD in patients who received allogeneic stem cell transplantation after receiving nivolumab previously.  Hodgkin lymphoma patients with advanced disease in later lines of treatment are more susceptible to GVHD after allogeneic SCT generally, even without previous exposure to nivolumab.  As careful management of GVHD can reduce allo-associated mortality, nivolumab provides a good therapeutic option in advanced HL patients.",36
hospital,Territory,  Upstate NY,15.6770833333,1.32785094524e-08,72,479,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The clinical pharmacist responsible for infused products at a leading academic hospital in New England expressed gratitude to BMS for its generous patient assistance program.  Most of their patients on nivolumab in off-label indications in this Disproportionate Share Hospital (DSH) currently receive free medication through the patient assistance program.  This hospital is now attempting to move some of these patients to their insurance plan, to reduce the burden on the assistance program.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",551
improved,Territory,  Upstate NY,14.564516129,1.28660051308e-05,36,0,"The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.",36
care,Territory,  Upstate NY,13.6818181818,1.75918689769e-05,75,12,"The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.",87
RTL stated,Territory,  VA,6.11430921053,2.50619190697e-05,93,556,"A GU RTL stated that the -275 data is very similar to the atezo data, but given that they have been using nivo for RCC patients previously and that the nivo RCC data is 'by far the best data' in the RCC space that they would likely switch to nivolumab when approved.  The RTL feels we need additional data to better define the bladder patient population that will respond to PD1/PDL1 agents and we also need more data on potential resistance mechanisms to these agents.","A GU RTL stated that in 'limited' cases they would use cabozatinib 2L prior to nivolumab.  This included patients w/ visceral crisis, transplant patients, and patients with 'extreme immuno-modulatory issues'.",A GU RTL stated that they have not and will not use the lenvatinib plus everolimus combination in their patients.  They stated that it is a combo of 2 really expensive oral drugs that got approval on non-randomized data.,649
Path TL,Territory,  VT,214.264705882,4.76271288921e-13,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
Boston area,Territory,  VT,214.264705882,4.76271288921e-13,19,27,RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,"A TL from the Boston area made the following comments around irRECIST in NSCLC treated with Nivolumab. There was a correlation between site of tumor. Example, liver mets had less overall response, vs. adrenal lesions had the most overall response.",NTL in the Boston area mentioned that he does not like pembro cause there is more drug wastage and inconvenience. He also mentioned that it makes sense what nivo did with flat dosing.,46
NTL in the Boston area mentioned,Territory,  VT,192.838235294,9.08145791457e-12,9,137,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.",NTL in the Boston area mentioned that those patients who don't achieve a CR with BV then their response will be short lived. Also mentioned that BV is easy to give with a focused toxicity. Regarding Nivo - toxicity is broader and harder to manage but that Nivo CRs seem to do better,NTL in the Boston area mentioned that regarding AVD - A is the most active agent. Also mentioned that stopping A  after 6 cycles patient are doing fine 20 years out,146
Path,Territory,  VT,85.7058823529,8.26544514294e-10,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
Boston,Territory,  VT,30.9493464052,1.67449006602e-12,40,82,"A Melanoma NTL from Boston, stated that ""there is no value in doing PD-L1 testing in melanoma pts.""  He added that ""I don't test any of my pts""","A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",122
rounds,Territory,  VT,26.7830882353,2.10496808992e-05,8,5,"A Local RPH in Maine asked, that their average pt receiving Opdivo over the last 12 months has been 67 Kgs.  Therefore, the flat dosing (based on a 80 kgs) would result in most of their pts receiving above 3mg/kg, and result in higher cost.  Therefore, the RPh suggested that for most pts they will stick with 3mg/kg dosing (rounded to nearest vial size), but for pts over 80kgs, they would use falt dosing of 240mg.",An RPh at a community site informed me that they are dose rounding Opdivo to the nearest full vial size (increments of 20mg) to prevent wastage.,"A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""",13
1st line NSCLC,Territory,  VT,21.4264705882,1.08772479516e-06,17,26,"A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).","A LTL in Boston stated that based on all the data coming out around 1st line NSCLC, they should be testing all pts for PD-L1 status.  However, he added that ""he has requested testing on 15 or so samples (1st line pts) and all of them have come back negative"".",43
score,Territory,  VT,9.99901960784,3.87410742662e-05,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
pathologist,Territory,  VT,8.44073083779,1.1362960061e-07,45,211,"NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times",256
22C3,Territory,  VT,6.69577205882,1.62199833236e-05,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
1st line,Territory,  VT,5.47058823529,1.39950600914e-05,69,712,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","A RTL for Lung shared that he was surprised to hear that CM26 was negative. He is looking forward to seeing the subgroup analysis based on other PD-L1 cut offs, but he added that this increases the need to do PD-L1 testing in all 1st line NSCLC pts. He also suggested the need to choose PD-1 agents in the 2nd line settting based on PD-L1 results.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",781
pts,Territory,  VT,5.35661764706,4.74512563821e-12,164,1624,"An RTL shared that when a pts runs into toxicity with Nivo/Ipi combo, if the pts has a CR or PR at that time, then they stop treatment.  However, at the time of toxicity with the combo, if the pt only has SD or PD, then they continue PD-1 monotherapy.  The added that about 1 out of 4 times they continue with Pembro as oppose to Nivo.","A NTL in melanoma shared that combination IO therapy (mostly regimen) is their primary method of treatment all melanoma pts at their institution.  Even if the pts has bully, BRAF+ melanoma, because of the rapid RR scene with Nivo/Ipi, they would choose Nivo/Ipi over BRAF+MEK combo.",A RTL stated that he does not test PD-L1 for his RCC pts.,1788
LTL,Territory,  VT,4.54500891266,1.78457526353e-05,79,800,"An LTL informed me that he doesn't test for PD-L1 status in the 2nd line NSCLC setting and stated that there is no need for it. He did add that his colleague is testing some of his/her pts for PD-L1 status in the 2nd line setting and is ordering PD-L1 status upon initial biopsy (pre-1st line treatment). Upon inquiring why? The LTL shared that by having this information, for PD-L1+ pts, both Pembro and Nivo would be good options with high ORR in the 2nd line setting, and if the pt was PD-L1 negative then opdivo (only) would still be an ""ok"" option.","An LTL/RTL stated/suggested that his plan for 2nd line NSCLC is to start nivolumab while waiting for PL-L1 test expression.  If the PD-L1 test comes back at 50%+ positive, he would switch the pt to Keytruda (view the data stronger as this sub-population was specifically studied by Merck).  If the test comes back between 1-49%, he said that it's a 50/50 choice between Opdivo/Keytruda and it would be up to the pts on q2w drug or q3w drug.  If the PD-L1<1%, he would choose Nivo...but if insurance had an issue, then he would switch to docetaxel.",A LTL stated that no one in her practice test for PD-L1 for her RCC pts.,879
PD-L1,Territory,  VT,3.77105882353,1.747786517e-06,306,375,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",681
mentioned,Territory,  VT,3.30458004097,2.97771805355e-07,289,130,"RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,NTL in Boston mentioned that patients who have progressive cHL disease may have other pathways for tumor cell death via CD4 and NK. She also mentioned that [patients who progress on Nivo have a change in the micro environment which is being researched,419
NW territory,Territory,  WA,1279.93939394,7.05591128621e-26,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
sky-rocketed,Territory,  WA,274.272727273,5.97298854689e-06,3,577,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",580
NeoGenomics,Territory,  WA,182.848484848,2.35344595492e-10,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  WA,152.373737374,1.23159271145e-08,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
clone,Territory,  WA,91.4242424242,2.93253800625e-05,5,149,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",154
diagnostics,Territory,  WA,73.1393939394,2.18833085337e-06,8,1288,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",1296
medical director,Territory,  WA,73.1393939394,2.18833085337e-06,8,365,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",373
reflex testing,Territory,  WA,52.2424242424,5.61827547844e-06,11,91,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.",102
medical oncologists,Territory,  WA,37.6452762923,1.0747133483e-08,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
platform,Territory,  WA,36.5696969697,1.65411534858e-05,18,149,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",167
IHC,Territory,  WA,33.68261563,1.99533579223e-08,25,536,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",561
insights,Territory,  WA,30.4747474747,5.61699333585e-11,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
molecular,Territory,  WA,26.1212121212,4.85980608334e-05,17,42,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from medical oncologist giving featured podium presentation at pathology conference in NW territory: i) TL stated that only 22C3 guides 1L NSCLC decisions; ii) TL stated the following: ""In 2L NSCLC setting: if the tissue is PD-L1 positive, pembrolizumab is the therapy of choice. If the tissue is PD-L1 negative, atezolizumab and nivolumab are therapies of choice. Pembrolizumab is favored for PD-L1 positive patients""; iii) TL made the statement that ""FDA invented the term 'complementary diagnostics' just for the sake of 28-8 assay as FDA did not know what to do with this assay""; iv) TL is reflex testing using 22C3 for PD-L1 along with molecular testing (EGFR, ALK, ROS1); v) TL stated that ""22C3 is the test to do"".",59
SP142,Territory,  WA,26.1212121212,4.85980608334e-05,17,146,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",163
pathologist,Territory,  WA,25.3956228956,2.49881406191e-10,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
in-house,Territory,  WA,21.7676767677,1.19497706421e-05,25,127,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",152
22C3,Territory,  WA,21.5115864528,3.96498818543e-08,49,112,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",161
Community TL,Territory,  WA,17.0091613813,1.91888353648e-07,73,820,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Local TL in a large community practice stated that many HCP's are upset with the direct to consumer marketing that BMS is doing with Opdivo.   She said that the commercial has led to many patients coming into clinics wanting Opdivo with high hopes and expecting a cure.     She further stated that the commercials reflect everyone looking healthy and feels that is leading to false hopes for many patients..  She further stated that she is aware that the speaker bureau has no funds for speaking so why isn't the money better utilized for this instead of the money being put into commericals.,Local community TL in large practice offered that he would like to see trials with Nivolumab in patients with MDS.    He offered that many trials being done have limitations with regards to platelet or neutrophil count which leads to ineligibility for trials as many still involve chemotherapy.   He feels this is a huge unmet need and that immunotherapy could potentially help these patients.,893
sent,Territory,  WA,14.6931818182,1.10325079614e-07,64,529,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",593
utilized,Territory,  WA,13.7136363636,1.7368986934e-05,45,0,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Community TL offered information that they have utilized Opdivo off-label for a patient with leiomyosarcoma who had gone through multiple treatments including going to a local academic center.   Patient came back to this site and MD started Opdivo.  The patient had a full response to therapy and continues to do well.    The staff stated that BMS has exceeded their expectations for help with this patient.,Community TL in large practice offered information that they utilized Opdivo in patients before the FDA approval with good results and stated this now gives multiple patients hope.   He further offered that Opdivo is becoming the go-to drug for multiple tumor types and patients.,45
RTL from a major academic institution,Territory,  WI,529.54954955,1.86190911224e-27,20,232,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
community institution,Territory,  WI,476.594594595,9.32778144874e-25,31,221,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
026 Top 300,Territory,  WI,185.342342342,8.28680382978e-10,7,245,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
large community institution,Territory,  WI,158.864864865,8.73944874811e-16,13,1371,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",1384
NCI,Territory,  WI,105.90990991,1.74923411733e-10,16,112,"RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.","RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.",128
NOT Top 300,Territory,  WI,105.90990991,9.26509232324e-06,4,248,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
academic institution mentioned,Territory,  WI,66.1936936937,1.42822477905e-06,14,47,"[026 Top 300] NTL from a top academic institution pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients.
- At his institution, 20% exhibit mutations (e.g, EGFR, ALK, ROS1) with the remaining 80% eligible for PD-1/L1 inhibitors.  Of these, only 20-25% of those will exhibit PD-L1 50% or higher.
- This equates to more like 16-20% of NSCLC patients in the real world that would be eligible for first-line pembrolizumab.","RTL from an academic institution mentioned that that data for NSCLC patients who have ALK or ROS1 mutations is unclear for I-O therapies.  RTL is aware of trials looking at crizotinib and nivolumab, but mentioned there would be overlapping toxicities.","RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.",61
single-agent,Territory,  WI,52.954954955,2.69522861826e-05,5,0,"RTL from a community institution mentioned that 026 was an ""unfair"" trial due to the negative press and attention she was hearing from the media.  Moreover, RTL highlighted that it's pretty clear that single-agent I-O doesn't seem to be the ""cure-all"" for all comers in first-line NSCLC.  RTL is remaining hopeful and excited for 227, especially after hearing about the positive 012 WCLC results from the press.","RTL from a community institution mentioned that the ESMO data from 026 was disappointing, but mentioned that it's clear that single-agent I-O is insufficient in the front line.  RTL was excited for 227 based on the 012 data from ASCO presented earlier in the year.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",5
KEYNOTE-024,Territory,  WI,49.1724581725,2.4830280371e-14,19,76,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.",95
CheckMate 227,Territory,  WI,33.0968468468,8.03289029015e-06,8,8,"RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.","HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",16
second-line,Territory,  WI,26.4774774775,5.74934641285e-09,17,63,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",RTL at a major academic institution has been using nivolumab in second-line RCC with great results.  RTL is now encountering the problem of patients relapsing after progressing through nivolumab.,80
eager,Territory,  WI,22.0645645646,2.76145468446e-05,10,7,"HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""] NTL from a major academic institution expressed disappointment in 026 results from ESMO, as she was hoping for better efficacy.  NTL shared that female patients at her institution fare better than male patients, so she does agree this partly explaining higher OS with chemotherapy arm for 026.

NTL understands that it's impossible to cross-compare 026 with KEYNOTE-024.  NTL expressed little enthusiasm for pembro as not a lot of patients are at or above PD-L1 50%.  NTL is highly eager for CheckMate 227.",17
first-line,Territory,  WI,21.181981982,1.01977639502e-10,26,54,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",80
top,Territory,  WI,20.5935935936,8.99147204882e-07,23,0,"RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",23
major academic institution,Territory,  WI,17.6516516517,1.02846503519e-05,34,225,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",259
RTL mentioned,Territory,  WI,9.75486012328,3.67138849815e-05,27,0,RTL at a major academic institution has the top accrual in the US at his institution for IMvigor 010 (atezolizumab as adjuvant therapy for high risk muscle invasive disease).  RTL mentioned that patients are doing well in terms of efficacy and safety on atezo with about 40% of patients being PD-L1 positive according to the SP142 assay.,"RTL from a large community institution mentioned that he was ""surprised that the safety of PD-L1 inhibitors (i.e., avelumab) wasn't as good as PD-1 inhibitors"" in terms of reducing immune-mediated AEs (as originally thought).  RTL was actually one of the authors for the JAVELIN solid tumor trial for avelumab (anti-PD-L1) presented at ASCO.  Interestingly in that poster, RTL mentioned that there was also a 16% infusion-related reaction rate from the 1,300 patients enrolled (pan-tumor), which mandated a premed regimen of APAP and Benadryl into the protocol.","RTL from a major academic institution was not concerned that CheckMate 026 did not meet its primary endpoint.  Rationale: RTL was extremely encouraged with positive data from CheckMate 012 at ASCO on combination therapy.  RTL mentioned that PD-1 monotherapy is not likely to work as you would need something ""harder hitting"" such as nivo + ipi in the front-line setting.",27
Checkmate,Territory,  WI,7.00874403816,2.73105344076e-05,87,792,"[026 Top 300]  HCP from a community institution mentioned that he is still going to use nivo as he and his staff are extremely comfortable with the safety profile of nivo.

Discussed CheckMate 017 and 057 as well as KEYNOTE-010 reactively as it was evident he was getting nivo, pembro, and atezo mixed up.  When reactively discussing the Blueprint project and OS data, it became clear to him that he would choose nivo based on the efficacy and safety vs. the convenience factor of q3 weeks of pembro/atezo.","RTL from a large community practice questioned the difference between all the assays available and if there's any correlation between all 4.  Reactively presented the FDA blueprint project from AACR.  From here, RTL asked about OS data from both KN-010 and CheckMate 057.  RTL was surprised by the higher OS from nivo when compared at the 1% level.","RTL who's actually a lung speaker for both Merck and BMS let me know he tests for PD-L1 occasionally.  In those who are PD-L1 expressors, he uses pembrolizumab, but those who are negative, he uses nivolumab.  Reactively discussed data from Keynote 010 on OS data stratified by PD-L1 status as well as data from OS on 057 stratified by PD-L1 status.

RTL was shocked to hear the longer OS data with nivolumab at the 1% level compared to pembro.  He further mentioned that even though the Merck rep is his long-time friend, this OS data is important for him and his care for patients.",879
PD-L1 expression,Territory,  WI,6.61936936937,2.38676696074e-06,72,703,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",775
pembrolizumab,Territory,  WI,6.49447560768,1.13926870888e-06,65,45,RTL from a major academic institution mentioned that nivolumab still has a prominent place in second-line for the 70% of NSCLC patients out there because pembrolizumab from KEYNOTE-024 at its 50% or higher cutoff limits its use in the real world.,"NTL commented that the cancer center is opening a pembrolizumab vs. brentuximab vendotin trial, but noted that this trial does set up one drug to lose and ""neglects sequencing"" which could be an important part of using these new therapies.",RTL from a major academic institution mentioned that the anti-drug antibodies for nivolumab were reported to be higher than for pembrolizumab from a recent paper.,110
RTL,Territory,  WI,4.47136209057,2.84136784925e-14,690,801,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",RTL from a large community institution was very impressed with CheckMate 153 from ASCO in decreasing the nivolumab administration time from 60 min to 30 min as it would benefit a lot of his patients within the community.,1491
Verdict,Territory,  WV,869.428571429,2.31460897365e-05,2,5,"?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians","Additional Insights gathered from Profiling Discussion

Mehra moving to Hopkins- starting September 6.
Dr. Olshanski is going to be acting chair directory of the department ? HEM/ONC
Dr. Jessica Bauman ? taking over Mehra?s trials and H/N and Lung patients
              
o	In general, she sees the entire spectrum of H&N cancers at FCCC, principally oropharynx
o	Will employ Extreme Regimen in r/m setting
o	Having used cetuximab as part of extreme, single agent systemic therapy choices is wide open, and highly dependent on patient characteristics
o	P16 testing is routinely done at this institution
o	In terms of PD-L1 testing, Not routinely done for H&N pts, bu] FCCC ran many of the PD-1 trials.  Testing has become ?routine? as part of the protocols.  Specifically for H/N, not convinced that testing is mandatory and negative patients are still conferred benefit.  Verdict is still out. 
o	Current Treatment Gaps
?	Problem with PD-1 monotherapy up front 
?	ORR while acceptable, they are still quite low.  
?	There is a delayed benefit with PD-1 monotherapy that may be unacceptable for patients with very aggressive bulky disease
?	Most clinicians would find it unethical to give PD-1 therapy in this setting.
CI
o	KESTREL Trial ? Opening at FCCC 
?	NCT02551159
?	Phase III Open Label Study of Durvalumab With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
?	Local Investigator ? Dr. Jessica Bauman","Met with a local TL who is a main treater of both Lung/SCCHN at Penn State Hershey on 12/12/16 together with Andy L.
Lung
ESMO data
?	Any difference between pembro and nivo?
o	He said trials/populations are different, but didn?t regard the two agents differently
?	Lung Testing for PDL1
o	Hershey sends all testing out; currently not doing it in house though the goal is to internalize the process in the future
o	While the ?holy grail? of cancer therapy is targeting a specific biomarker, we have a long way to go regarding a good biomarker; PDL1 is not ideal for sure
o	They are able to get enough tissue for PDL1 testing. Tissue procurement is not an issue for them in lung
o	He said if a patient is 45% or greater PDL1 he might try to get them pembro
o	If 50% or higher no brainer to get pembro
o	He expects the % of patients that will be positive (>50%) to be lower than the CM-024 study %
?	1L Treatment
o	Has no problem treating a 1st line patient with chemo is they have a good PS. 
o	When patients get to second line, they are much worse PS and won?t be able to get chemo and IO becomes a much better option
o	They see very few EGFR and alk patients
o	They get the traditional heavy smoker and drinker
o	They haven?t been seeing many stage III lung patients, either get very early or very late patients
?	IO agents are overall very safe from and overall AE standpoint
o	Has run into some hypothyroid but he said it is very easy to manage
o	Has seen 1-2 cases of colitis but managed with dose interrupt and steroids
o	No hypophysitis/hepatitis or pneumonitis
o	They test for TSH every 6 weeks in lung but more frequently in H&N
?	SCCHN
o	Hershey is participating in the RTOG3504
o	EXTREME regimen
?	Sees value in using EXTREME if PS is good enough
?	?EXTREME regimen is very EXTREME? but still the best data is there
?	He said he has patients on each drug (P and N)
?	He did not differentiate between Pembro and Nivo in H&N
?	He has requested that patients be started on nivo prior to approval however
o	HPV+ patients respond well to therapy but relapse
o	Reiterated QOL is very good for nivo (discussed PROs from CM141); noted similar anecdotal QOL seen with Pembro",7
Phase III,Territory,  WV,62.1020408163,4.84426515258e-05,23,775,"Additional Insights gathered from Profiling Discussion

Mehra moving to Hopkins- starting September 6.
Dr. Olshanski is going to be acting chair directory of the department ? HEM/ONC
Dr. Jessica Bauman ? taking over Mehra?s trials and H/N and Lung patients
              
o	In general, she sees the entire spectrum of H&N cancers at FCCC, principally oropharynx
o	Will employ Extreme Regimen in r/m setting
o	Having used cetuximab as part of extreme, single agent systemic therapy choices is wide open, and highly dependent on patient characteristics
o	P16 testing is routinely done at this institution
o	In terms of PD-L1 testing, Not routinely done for H&N pts, bu] FCCC ran many of the PD-1 trials.  Testing has become ?routine? as part of the protocols.  Specifically for H/N, not convinced that testing is mandatory and negative patients are still conferred benefit.  Verdict is still out. 
o	Current Treatment Gaps
?	Problem with PD-1 monotherapy up front 
?	ORR while acceptable, they are still quite low.  
?	There is a delayed benefit with PD-1 monotherapy that may be unacceptable for patients with very aggressive bulky disease
?	Most clinicians would find it unethical to give PD-1 therapy in this setting.
CI
o	KESTREL Trial ? Opening at FCCC 
?	NCT02551159
?	Phase III Open Label Study of Durvalumab With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
?	Local Investigator ? Dr. Jessica Bauman","?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians","Spoke with Director of Medical Oncology and Hematology at UPMC
on 12/6/2016 together with Andy Lepisto

Spoke about blueprint data and the slide from asco 2015 showing difference in PDL1 expression on top vs bottom of the slide
3.	Explained that one of his patients tested 0% PDL1+ before chemo and then tested again after chemo and was 90% PDL1
a.	He said in general PDL1 test(s) are currently inadequate; UPMC performs two different tests (different platforms - Ventana/Dako 22C3) to confirm expression
4.	He said he doesn?t really know about the pathology details around which clone of antibody used for PDL1 test
5.	Discussed the 026 data at ESMO and the H&N approval and placement on the VIA pathways
6.	We spoke about 227 design and combo dosing moving forward
7.	He asked if we are still using a 1% or 5% cutoff in 227
8.	Talked about phase I vs Phase III data deciding factor for nivo vs pembro in H&N pathway
a.	Ellis was very direct and stated phase I data should not be used for FDA approvals",798
o,Territory,  WV,51.7517006803,4.74033032536e-07,46,220,"?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians","Met with a local TL who is a main treater of both Lung/SCCHN at Penn State Hershey on 12/12/16 together with Andy L.
Lung
ESMO data
?	Any difference between pembro and nivo?
o	He said trials/populations are different, but didn?t regard the two agents differently
?	Lung Testing for PDL1
o	Hershey sends all testing out; currently not doing it in house though the goal is to internalize the process in the future
o	While the ?holy grail? of cancer therapy is targeting a specific biomarker, we have a long way to go regarding a good biomarker; PDL1 is not ideal for sure
o	They are able to get enough tissue for PDL1 testing. Tissue procurement is not an issue for them in lung
o	He said if a patient is 45% or greater PDL1 he might try to get them pembro
o	If 50% or higher no brainer to get pembro
o	He expects the % of patients that will be positive (>50%) to be lower than the CM-024 study %
?	1L Treatment
o	Has no problem treating a 1st line patient with chemo is they have a good PS. 
o	When patients get to second line, they are much worse PS and won?t be able to get chemo and IO becomes a much better option
o	They see very few EGFR and alk patients
o	They get the traditional heavy smoker and drinker
o	They haven?t been seeing many stage III lung patients, either get very early or very late patients
?	IO agents are overall very safe from and overall AE standpoint
o	Has run into some hypothyroid but he said it is very easy to manage
o	Has seen 1-2 cases of colitis but managed with dose interrupt and steroids
o	No hypophysitis/hepatitis or pneumonitis
o	They test for TSH every 6 weeks in lung but more frequently in H&N
?	SCCHN
o	Hershey is participating in the RTOG3504
o	EXTREME regimen
?	Sees value in using EXTREME if PS is good enough
?	?EXTREME regimen is very EXTREME? but still the best data is there
?	He said he has patients on each drug (P and N)
?	He did not differentiate between Pembro and Nivo in H&N
?	He has requested that patients be started on nivo prior to approval however
o	HPV+ patients respond well to therapy but relapse
o	Reiterated QOL is very good for nivo (discussed PROs from CM141); noted similar anecdotal QOL seen with Pembro","?	Bleo shortage is a affecting practice
o	Internal Guidance is that a list of patients be maintained
o	Bleo is dispensed according to ?greatest? need
?	I.e. pts who are able to tolerate and have most aggressive disease
o	Personally feels that bleo can be omitted from front line therapy for most patients
?	Retrospective Analysis shows bleo added value seems questionable
?	However, in the absence of more robust data, will continue to use in appropriate patients
?	Will continue to remove Bleo ?whenever possible?, for example those that develop pneumonitis or rash
o	Seeing about 20% rash with Bleomycin, which she feels is suprising.
?	Nivo 
o	Currently has a patient where she is considering using Nivo prior to transplant (Patient has failed ABVD, ICE, Brentuximab, Bendamustine x 4 doses. Considering Nivo then Allo transplant) 
o	Views Nivo has a ?bridge? to Allo transplant ? however data is not clear
o	Believes Nivo will definitely have a role in earlier lines of therapy, but is cautions to make assertions in the absence of appropriate data
?	Still waiting on further data regarding adding Brent to AVD therapy, in the absence of Bleomycin. Is interested in doing so, but would feel comfortable with more data. They did participate in the clinical trial, so it?s not totally out of her line of comfort.",266
NW territory,Territory,  WY,347.86440678,5.50660117215e-19,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
ASCO'16,Territory,  WY,124.237288136,5.66705011285e-07,5,394,Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,"RTL, a NP with lots of I-O experience, stated that some physicians in their group are 'short-coursing' steroids when treating irAE's, as they are afraid steroids will negatively impact the anti-tumor T cell response.
This is a No-Access site, so there is no opportunity for me to educate those physicians.
TL said that the data from Hodi's ASCO'16 poster from CM-069 will be helpful in educating colleagues that steroid used to treat irAE's don't diminish the tumor response to Ipi+Nivo Regimen.
However, TL said that similar data for Nivo monotherapy in NSCLC would be even more impactful. The perception of irAE's on Nivo are less severe than when on Regimen. So physicians may still want to shorten the steroid treatment on Nivo monotherapy, unless they're shown that there's no reason to do so.","NP at a community hospital reported continued ""difficulty convincing some of my doctor colleagues to initiate steroids appropriately"". NP asked if we ""have a reference for anything published that demonstrates that if patients receive steroids for toxicity from immunotherapy, they don?t suffer worse outcomes?""
I reviewed the 209-069 Hodi poster from ASCO'16 and mentioned other similar analyses from prior Ipi studies. NP was very appreciative and is working to arrange a face-to-face meeting with HCPs to facilitate education on IMAR algorithms.",399
NeoGenomics,Territory,  WY,49.6949152542,2.99404493177e-07,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory,  WY,41.4124293785,4.93826438552e-06,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
like to see a trial,Territory,  WY,19.3258003766,1.33490987745e-06,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
Academic TL stated,Territory,  WY,17.393220339,2.18818801025e-06,16,162,"Academic TL stated he is using Nivo for all of his 2L RCC patients. ?It's a no-brainier versus Everolimus and is probably better than Cabo, due to better tolerability.?","Academic TL stated he would probably use Pembro (once approved) for 1L NSCLC that is >50% PDL1+, assuming ESMO data confirm everyone's expectations. Everyone else would receive 1L Chemo and then 2L Nivo.",Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,178
Ipi+Nivo,Territory,  WY,10.8707627119,2.46996126187e-09,45,338,"NTL predicts that, even with durable responses seen with PD1 monotherapy, eventually almost all NSCLC patients will progress.  With basically all NSCLC patients receiving PD1 monotherapy at some point in their treatment plan, there will be a huge unmet need for effective treatments post-PD1.  This NTL, who is an investigator on several studies with IO+IO combinations, voiced opinion (based on her experience) that Ipi+Nivo seems to be the only IO+IO combo that can resurrect a response in patients who have failed PD1 monotherapy.  4-1BB, anti-KIR, OX40 etc do not seem to have this activity. TL said this speaks to the ability of Ipi to prime new T cells, rather than just relieving inhibition of existing lymphocyte populations.","Melanoma RTL with lots of I/O experience (Investigator on 209-067), stated his belief that PDL1+ patients don't benefit from adding Ipi to Nivo.  He is testing for PDL1 to determine treatment choice between PD1 monotherapy and Ipi+Nivo combination. PDL1+ patients receive anti-PD1 mono therapy; PDL1neg patients receive Ipi+Nivo Regimen.","There is growing interest from my academic TLs in using Ipi to re-invigorate the T cell response in patients who progress on Nivo.  These could be patients who are on the Nivo maintenance after Ipi+Nivo regimen, or patients who only received Nivo monotherapy.

Rationale is similar as for MDX010-20 study with Ipi, except that in this case, the patient would continue to receive Nivo while adding a few doses of Ipi. TLs favor a Q6W Ipi dosing when added to Nivo.",383
medical oncologists,Territory,  WY,10.2313060818,3.0207702543e-05,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
insights,Territory,  WY,9.42489772063,3.610969978e-07,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
TL said,Territory,  WY,8.50044603033,9.10340444105e-08,86,62,"ENT/H&N surgeon is excited to add Opdivo to his arsenal of Tx options in SCCHN. TL said he would be referring several patients to the local med-onc. However, TL said his ENT office staff could use education around IMARs because patients often will call his office for advice, even after being handed off to the med-onc.  TL said patients strike up a very strong relationship with the surgeon, who is often the first physician to correctly diagnose and treat the disease.  TL requested an in-service by our IOCL (currently in training).","NTL at a large community hospital said he was previous dismissive of Ipi+Nivo for NSCLC but then saw the ""impressive"" Hellman ASCO'16 CM-012 presentation.  However, TL also said regimen may not be a slam-dunk, as KN-021 Pembro+Carbo+Pem data seem equally as impressive as CM-012 regimen data.","I met recently with an RTL and Opdivo Melanoma/NSCLC speaker, who is aware of CA209-384 (although is not participating in that study) and asked if we have addressed the same question in melanoma patients. 
TL stated he would consider stopping treatment for patients who show a CR or near-CR. 
In his opinion, the question 'when can we stop treatment with I/O agents' is interesting in lung but sadly not relevant for most patients due to the low CR rate.  
However, TL said that it's a very relevant question in melanoma, where the Ipi/Nivo combo is producing a higher frequency of CRs.",148
pathologist,Territory,  WY,6.90207156309,1.17810900981e-05,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
TL,Territory,  WY,2.91923682504,8.61972953493e-08,1157,51,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",1208
PD-L1 testing,Territory,  es,15.6501547988,2.77200594888e-08,123,444,"Regional lung TL stated the despite performing all diagnostic tests in-house up to this point, the pathologist at their major academic institution is reluctant to implement their own testing procedures for PDL1 assessment and is persistent in continuing to send out samples for this IHC assessment to a commercial company (which is not using the Dako platform and does not provide an actual level of expression but rather just a ""positive"" or ""negative"" designation.","A Lung RTL from NY City mentioned that his site does not routinely test for PD-L1 in any line of therapy for NSCLC patients.  He noted that of >200 patients treated in 2015 with I-O agents, a PD-L1 test was obtained in less than 10.  Primary reason to test was patient's request.  The Dermatopathology lab has chosen to use their own system with an IHC antibody from Cell Signaling.  The TL added that since his site is so busy, they often need 3-4 days ahead of time to get an open slot in the Infusion Center.  Thus, the TL and his colleagues are very uninterested in adding any delay for a test they see no value in.","Lung TL stated that Foundation is providing additional markers to their initial PD-L1 testing.  New analysis includes PD-L2 and PD-L1 expression on T-cells.  Tl added that Foundation seems to be able to pick up additional mutations (EGFR,ALK, etc) that IHC testing is missing.  TL indicated a preference for Foundation testing over his own lab's Pathology testing",567
mRCC,Territory,  for,182.4,3.32261864055e-06,7,232,An academic GU TL does not use cabozantinib or lenvatinib/everolimus combo in 2L mRCC. This TL prefers Nivolumab because of its efficacy and safety profile.,"An academic TL prefers Nivolumab in 2L for mRCC. However, in patients presenting with bulky disease at the time of diagnosis, the TL prefers Lenvatinib plus Everolimus.","A community oncologist prefers Nivolumab in 2L mRCC over cabozantinib because of their distinct MOA. The TL stated "" it makes more sense to use a drug with a different mechanism of action in patients who have failed TKI therapy in 1L than using another TKI"".",239
uveal,Territory,  n,168.444444444,5.52364195921e-06,5,424,"A melanoma TL from NY told me that he had two recent patients that for clinical reasons he chose to start their initial metastatic melanoma treatment with Opdivo monotherapy.  One patient (uveal) had no initial response to Opdivo, the 2nd patient a cutaneous melanoma patient had a Partial response but later developed disease progression in the brain.  In both cases the physician added Yervoy while continuing Opdivo.  Both patients immediately began to feel better and subsequent scans revealed Objective responses (2nd patient brain met completely resolved)","Several RTL in NY have all noted at least one patient case where a patient is currently responding to the Regimen and the ORR appears to be better than prior responses to a prior PD-1 / PD-L1 therapy.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.",429
years old,Territory,  n,134.755555556,2.47211809362e-07,8,0,"Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.","A melanoma NTL from DC volunteered that his site has performed an analysis of their experience with the Opdivo-Yervoy regimen (n=38 patients).  Stated that the Overall Survival data looks to be plateauing at about 70% at 12 months.  He recommends the Regimen for all patients under 80 years old irregardless of BRaf mutation status or PD-L1 status.  TL stated they do not perform PD-L1 testing at all.  TL stated about the Regimen ""I am a big fan""",8
objective responses,Territory,  n,84.2222222222,2.28262314044e-05,8,3,"A melanoma TL from NY told me that he had two recent patients that for clinical reasons he chose to start their initial metastatic melanoma treatment with Opdivo monotherapy.  One patient (uveal) had no initial response to Opdivo, the 2nd patient a cutaneous melanoma patient had a Partial response but later developed disease progression in the brain.  In both cases the physician added Yervoy while continuing Opdivo.  Both patients immediately began to feel better and subsequent scans revealed Objective responses (2nd patient brain met completely resolved)","Several RTL in NY have all noted at least one patient case where a patient is currently responding to the Regimen and the ORR appears to be better than prior responses to a prior PD-1 / PD-L1 therapy.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.",11
BRAF/MEK,Territory,  n,63.1666666667,4.43560116493e-05,10,362,"Following up on a previous insight from MB regarding the EA6134 trial, an melanoma NTL from MD relayed a conversation he had recently with Novartis.  The reason by the trial hold / insufficient drug supply resulted from unexpected greater commercial demand for the drugs.  GSK initially transferred the remaining inventory of the BRaf/Mek inhibitors to Novartis which allocated a small fraction for R&D purposes.  Novartis has been unable to get their own production going.  They asked GSK to make some additional drug but this will take time.  All Novartis would commit to was that drugs would be available for the trial sometime after April 1st.  The TL added that he did not expect the drugs to show up in April and had no clear idea when they would be available.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.","Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.",372
BRAF,Territory,  n,31.1934156379,2.57041474126e-06,38,209,"A community oncologist was positively impressed by the -067 efficacy data. However, he commented that he still prefers to use molecularly targeted therapies in 1L setting if a patient with metastatic melanoma harbors BRAF mutations. He further stated ?that is because it is targeted therapy?.","Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.","A melanoma NTL from DC volunteered that his site has performed an analysis of their experience with the Opdivo-Yervoy regimen (n=38 patients).  Stated that the Overall Survival data looks to be plateauing at about 70% at 12 months.  He recommends the Regimen for all patients under 80 years old irregardless of BRaf mutation status or PD-L1 status.  TL stated they do not perform PD-L1 testing at all.  TL stated about the Regimen ""I am a big fan""",247
regimen,Territory,  n,7.43137254902,3.03084981851e-05,243,465,"Several melanoma RTL have mentioned that  with regard to patients with a BRaf mutation, they still prefer I-O agents.  What has changed in the last year is that prior to the addition of a MEK inhibitor, the RTL routinely would dose a BRaf inhibitor for 2-3 months and then switch to a PD-1 inhibitor before the patient exhibited disease progression.  One RTL told me he will now go 3-4 months on a BRaf+MEK combo and then switch to a PD-1.  Several others have told me they are staying with a TKI combo until disease progression (>10 months)  since the rapidity of the progression seems to be less severe.  All the TL agree that a TKI combo is best reserved for patients >80 years old and/or have very bulky disease and are not a candidate for Opdivo+Yervoy regimen.","An HCP was considering nivo monotherapy for a first line melanoma patient.  When presented the data for Regimen, questioned why if Regimen had better efficacy than monotherapy it was category 2 in the guidelines while nivo monotherapy was category 1.","Several RTL seem consistent in their views for recommending an anti-PD-1 monotherapy as opposed to the Regimen in patients fitting any combination of one or more of the following criteria: 
a) low volume disease, 
b) greater than 80 years old,
c) poor performance status. 

Regimen following prior anti-PD-1 or Yervoy usage.  The TL have all noted at least one patient case where a patient is currently responding to the regimen and the ORR appears to be better than prior responses.  Appears to be trend to response to Regimen if some prior but minimal /transient response.  Examples:
-	Patient with uveal melanoma.  Minor /short duration response to Pembro.  Progressed quickly on targeted therapy clinical trial, responding well for 3+ months to Regimen
-	Patient with melanoma.  Progressed on anti-PD-L1 trial, stable disease for a few months with Pembro, progressed on BRAF/Mek, good response to Regimen
-	Service has tried Regimen after progression on Pembro as first line therapy in about 5 patients.  TL believes they have seen objective responses in 2 patients.",708
Biodesix,Territory,  petitor I,677.111111111,2.13941885293e-05,4,34,"A TL from Puerto Rico shared that a company called Biodesix is offering molecular testing for lung biomarkers such as ALK, EGFR, ROS, KRAS, BRAF and T790M mutations using only 20mls of peripheral blood.",TL shared that he was one of the top enrollers in the Biodesix lung biomarker study comparing tissue based vs blood based (circulating tumor cells) PDL1 assessment and said that the data show concordanance between tissue and blood based PDL1 testing and hopes that when PD1s move into 1L setting that FDA/payers will allow blood based assays for PDL1. He did not share info on what antibody(s) was used in the Biodesix biomarker study. Note - this is the third insight regarding this biomarker trial that I have heard.,A National TL at a lung cancer lecture at the PR Hem Onc Symposium noted that because of the complexity of the microenvironment not one biomarker would be truly predictive.,38
PR Hem Onc Symposium,Territory,  scape,104.172413793,2.043225083e-05,5,142,"A National TL at a lung cancer lecture at the PR Hem Onc Symposium highlighted that because of the complexities in PD-L1 testing, he does not use it to make treatment decisions.  He also highlighted that PD-L1 expression denotes properties of the microenvironment, not the tumor.","A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented that there is no difference in pembro or nivo biologically, just in the biomarker strategy.",A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented how most patients we don't know the driver mutations.  KRas is an important target that we still do not have any drugs to target.,147
atezolizumab,Territory,  t in 2nd,25.5218855219,6.1627601923e-06,37,3,"Lung RTL today at a large Academic site in NYC considers Atezolizumab a ?me too drug?.  Also since the Roche PD-L1 testing is complicated, does not see himself using it at all as a monotherapy.  Feels that it will be used just in the Bladder setting for foreseeable future.",Community RTL shared that his second line choice in NSCLC will be atezolizumab based solely off convenience of q3w dosing vs nivolumab. He has ample experience with all three currently approved pd1/pdl1 drugs and feels that they are all the same safety/efficacy wise and convenience wins. He made sure to point out that if -227 study is positive the q3 vs q2 issue will no longer be an issue as ipi+nivo would be new standard of care in 1L setting,"NTL shared preference for 2L IO would be atezolizumab, hands down, due to convenience of q3w dosing and no need to test. TL is of the opinion that all three agents are the same and interchangeable.",40
RAI,Territory, AL,419.128205128,7.84003126341e-17,15,701,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.",716
context of an online lecture,Territory, AL,266.717948718,7.83391827951e-11,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NAI,Territory, AL,266.717948718,7.83391827951e-11,7,282,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",289
NCCN 2016 Webex Congress Series,Territory, AL,266.717948718,7.83391827951e-11,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
proactive meeting to discuss CM-026,Territory, AL,266.717948718,7.83391827951e-11,7,257,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",264
Bone Marrow Transplant Director,Territory, AL,190.512820513,7.70101478647e-08,5,713,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.",718
academic institution in the HSL South,Territory, AL,152.41025641,2.36493907744e-06,10,110,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).","Having missed ASCO this year, an access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory asked on 08/05/16 to review Checkmate 012 data. The bar chart describing ORR with nivo (nivo+ipi) across tumor PD-L1 expression levels captured his attention (?nivo is truly a cool drug?). He commended BMS for studying nivo (nivo+ipi) efficacy across the entire range of PD-L1 expression, acknowledging that (many of) our competitors seemed reluctant to assume the risks associated with this strategy. He also noted that: 1) ORR values with nivo (nivo+ipi) at the ?50% expression level were most impressive; 2) ORR values at the <1% - ?1% levels were not negligible, even in comparison which ORR achieved with platinum-based chemotherapy; 3) nivo (nivo+ipi) may prove to be the best therapeutic options for some categories of patients with low PD-L1 expressing tumors (e.g., older or frail patients); 4) the medical community desperately needs more data to make informed decisions about who should receive what.  
The AI did not know the results of Checkmate 026. We did not address the issue since BMS official talking points had not yet been released.",120
Annual New Orleans Summer Cancer,Territory, AL,152.41025641,2.36493907744e-06,4,341,"On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Roche proposes to assess PD-L1 expression on tumor cells + immune cells. Complicated score: not convenient for clinicians.","On 07/22, a panel of speakers at the 11th Annual New Orleans Summer Cancer Meeting concluded that: 
?	PFS is very hard and costly to assess. It is a useful endpoint for phase I/II studies, but ORR and OS are much more important in phase III trials. Newer endpoints need to be explored such as ?time to next treatment.","On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Study Checkmate 141 showed a striking 1-year OS benefit in favor of nivolumab. This result will lead to approval (but pembro approved first?). Subgroup analyses also indicate that nivolumab can be used in almost everybody. Efficacy seems to be lower in P16-negative and PD-L1-negative patients, but it is still too early to make final conclusions.",345
LAI,Territory, AL,152.41025641,2.36493907744e-06,4,238,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",242
RAI/NSCLC,Territory, AL,152.41025641,2.36493907744e-06,8,175,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",183
made the following comments,Territory, AL,133.358974359,4.80260792096e-19,17,549,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.",566
South,Territory, AL,123.833333333,1.24628611364e-17,20,360,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",380
NCCN panelist for NSCLC,Territory, AL,114.307692308,1.63300262462e-12,11,482,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
territory,Territory, AL,101.606837607,1.023381284e-20,35,349,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",384
shared the following unsolicited insights,Territory, AL,92.5347985348,1.42354172362e-21,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
national access influencer,Territory, AL,76.2051282051,6.94079693657e-06,7,486,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",493
NSCLC NCCN panelist,Territory, AL,59.8754578755,1.76540933234e-13,17,665,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",682
large academic institution,Territory, AL,38.1025641026,2.96197374403e-09,15,478,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
HSL,Territory, AL,32.6593406593,1.29289389568e-12,29,239,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He does not see any clinically meaningful differences among the current PD-1 or PD-L1 inhibitors in terms of MOA, efficacy or safety; that the perfect niche for nivo is the 2L/3L space for patients who have progressed after initial systemic therapy (?in this context, nivo is probably the best option?); and that he does not see any advantage in moving nivo to the 1L setting until responders to IO therapy can be accurately identified.",268
CT,Territory, AL,30.4820512821,9.57057471617e-09,17,0,"During a proactive meeting to discuss ESMO lung data, a RAI/lung NTL/clinical-practice influencer at a large IDN organization shared the following insights:
?	When probed about clinical-practice implications of BMS and competitor data presented at ESMO, responded that there are still many unresolved issues and that the picture is unclear. Mentioned that she believes in the future of both IO/IO and IO/CT combination therapies in 1L. However also agreed that DOR with IO/CT has not yet been established and that no good therapeutic option would be available in 2L for patients who progress on/after IO/Pl-based CT combination therapy in 1L. Did not spontaneously mention the OAK study or anything else regarding atezo in 2L.","During a meeting to proactively discuss the results of CM-026, a NAI, chair of a pathway committee for lung cancer shared the following insight:
?	When asked about what he learned at ESMO that was important, his response was: ?Opdivo has had a nice ride, but based on ESMO data Keytruda has now won in the 1L setting and Tecentriq in the 2L setting?. 
?	For 1L, further explained that Keytruda will become SOC for patients with tumor PDL1 expression ?50% (PL-based CT still best option for patients with PDL1 expression <50%).
?	For 2L, and when asked ?why Tecentriq??, explained that nivo, pembro, and atezo are all equivalent. Rationale for giving preference to Tecentriq: 1) more experience with the agent (his institution has contributed to multiple atezo trials); 2) convenience of q3w for the patients (unnecessary to see patients more frequently than q3w to ensure optimal safety; insensitive to the argument that median number of doses is similar with q2w and q3w for a majority of patients given median duration of treatment of ~3mo). ?I also love nivo, but I have no reason to use it?. ?In 2L pembro is at the bottom of the list? (personal unhappiness with Merck in recent times ? bad customer experience).","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about how to monitor NSCLC patients on IO therapy for pneumonitis, indicated that short-term risk of pneumonitis seems to be low in patients with normal walking O2 blood saturation level. If O2 is normal there is no need for a CT scan.",17
ONS,Territory, AZ,215.857142857,1.46542441122e-07,5,198,"While meeting with a community oncology NP who treats solid tumor patients, she mentioned that she attended an Advisory Board for Pfizer at ONS congress. She stated the first half of the session was surrounding how she would choose a patient for Sutent and asking about treatment sequencing and safety for the Pfizer drugs. She stated the last half of the session was the representatives ""drilling"" her about how she would choose OPdivo for a patient with RCC and reactions to the Opdivo presence on the market.","During ONS Congress medical presentation for Research to Practice TL hypothesized that PDL status will be needed for 1st line NSCLC. This TL likes to have PD-l1 status for his patients, though believes other oncologist will simply give nivo without any testing. He believes the differences between Opdivo and Atezo is that ""PD2  goes free""  and has yet to know what this will unveil in practice. These comments gathered during lung presentation portions.",Nurses at a proactive dinner presentation for ONS chapter mentioned they had been using Sandostatin for treatment of colitis induced by Opdivo. Proper symptom management and use of algorithms reviewed in detail and nurses shared they would institute use of IMAR guides in their clinics and hospitals.,203
California,Territory, AZ,86.3428571429,1.19937906457e-06,8,290,"Community Oncologist in Northern California volunteered that he had heard many of the releases from Asco via his email and colleagues surrounding 1st line lung. He mentioned that he believed PDL1 testing in 1st line will be no problem as testing is getting easier and cheaper, and they will have tissue due to newer diagnosis. He mentioned positive impression from the data he saw come across.","Community Oncology Clinic in Northern California had internal discussions, meetings and challenges surrounding BMS materials. Nurses were wanting to use patient care check sheets, and they felt ""legally"" liable if they did not call the doc for any items that would be checked by nurse or patients regarding ongoing symptoms related or not found during assessments. The site did in the end favor using check sheets and made an internal plan on ""when to call the doc"", but the language on the form made them uncomfortable until a full plan was in place internally. Rep and Nurse Liaison worked with team to discuss their current practices and feeling safe in their care and administration of the immuno oncology drugs. Nurses feel confident with tools and plans in place at this time.",Speaking with Community Oncologist in California (very tough to access account) who disclosed that he knows that any denial he gets from insurance for Keytruda will be covered by Merck.,298
PD,Territory, AZ,53.9642857143,2.9384178849e-07,14,3,"Spoke with Community Onc in Arizona, who mentioned he uses Biocept liquid bx for PD status for any 2nd line lung pt due to underwhelming efficacy in his practice. He will use Opdivo if biocept comes back positive for pd, otherwise chemo. 

Same physician mentioned that Opdivo is a blockbuster in Melanoma and far more effective than lung. He uses Monotherapy due to past bad experiences with Yervoy, unless the patient is young and it is a more tough call, he will do pd testing through caris and if positive, use Opdivo monotherapy and if negative will use combination. Stated he has a young pd+ pt on monotherapy who is doing wonderful for a long period of time now. He does not do pd testing across the board due to time and expense for Melanoma pts.","Oncologist reports after hearing data presented at asco regarding SCLC, that this is encouraging but that ""chemo can control disease quite well"". It will be hard to distinguish who will respond to IO vs chemo best. 

Oncologist also mentioned H&N data looking good but no distinction between nivo and pembro. The main advantage is that bms has ""ipi"" to add to opdivo and get the best efficacy. He believes that Opdivo is exclusively used in 2nd line lung due to no testing requirements. He believes pd status will be more readily available in 1st line lung and the testing will not pose any challenges for clinicians.","Lung Presenters at Conference from podium stated:
SHOW ME THE DATA: in reference to 026 negative trial release. Believes docs need to look closer and decide for themselves. 
-Highlighted that NCCN supports use of Nivo in SCLC
-Believes Cabo is a tough drug to five in Ret NSCLS and always needs dose mods. 
-Believes all Lung pts should get comprehensive Next Gen Seq (NGS) and advised audience to get a very comprehensive tissue BX even if it means multiple attempts as the data is invaluable
-Had a small discussion point discussing IO tx and future: believes the real questions will begin to creep up as what to do with IO refractory disease and where to go with future trials. 

Other presenter mentioned the excitment around the DLL3 Molecule for SCLC (rovalpituzumab tesirine). 
-Has not experienced psuedoprogression, believes the pts who respond will respond, and has not experienced delayed responses either. 

In private conversation regarding lung info presenter shared she believes PD status in not reliable and would never test or use data unless a pt had a very aggressive autoimmune co-morbidity and was hesitant to use IO. 
Also mentioned she believes clinicians are getting more used to imAEs and that she is gearing up for 1st line txs",17
surrounding,Territory, AZ,43.1714285714,9.12552152042e-06,13,0,"While meeting with a community oncology NP who treats solid tumor patients, she mentioned that she attended an Advisory Board for Pfizer at ONS congress. She stated the first half of the session was surrounding how she would choose a patient for Sutent and asking about treatment sequencing and safety for the Pfizer drugs. She stated the last half of the session was the representatives ""drilling"" her about how she would choose OPdivo for a patient with RCC and reactions to the Opdivo presence on the market.","Renal/GU Onc TL discussed Pseudo-progression. His RCC patients had slight progression and he continued the Opdivo tx for additional 2-3 cycles with no regression and ended tx. Once pt returned to community, the Onc there called back to TL to challenge him for continuing tx. TL feels there is still some confusion in medical community and even Academic surrounding this concept. 

He also mentioned that he takes calls often from community asking about psuedo progression and how to determine what to do with a pt on Opdivo or ImmunoTherapy.","Community Oncology Clinic in Northern California had internal discussions, meetings and challenges surrounding BMS materials. Nurses were wanting to use patient care check sheets, and they felt ""legally"" liable if they did not call the doc for any items that would be checked by nurse or patients regarding ongoing symptoms related or not found during assessments. The site did in the end favor using check sheets and made an internal plan on ""when to call the doc"", but the language on the form made them uncomfortable until a full plan was in place internally. Rep and Nurse Liaison worked with team to discuss their current practices and feeling safe in their care and administration of the immuno oncology drugs. Nurses feel confident with tools and plans in place at this time.",13
tx,Territory, AZ,41.9722222222,5.46078815637e-09,24,100,Renal TL mentioned he puts in central line port for his RCC pts starting Opdivo because he anticipates them being on tx for an extended period of time. He has several patients on tx for many months currently.,"Renal/GU Onc TL discussed Pseudo-progression. His RCC patients had slight progression and he continued the Opdivo tx for additional 2-3 cycles with no regression and ended tx. Once pt returned to community, the Onc there called back to TL to challenge him for continuing tx. TL feels there is still some confusion in medical community and even Academic surrounding this concept. 

He also mentioned that he takes calls often from community asking about psuedo progression and how to determine what to do with a pt on Opdivo or ImmunoTherapy.",NP from large Cancer Academic Center conveyed that all pts with SCCHN are being pre-screened for Hashimotos Disease before starting IO tx. The NP and the providers she works for believe pts have higher incidences with H&N disease and they will be able to intervene or ward off potential thyroiditis with additional info or proper dx of thyroid conditions before starting IO tx.,124
Onc,Territory, AZ,25.6972789116,5.81460997947e-06,44,188,"Renal/GU Onc TL discussed Pseudo-progression. His RCC patients had slight progression and he continued the Opdivo tx for additional 2-3 cycles with no regression and ended tx. Once pt returned to community, the Onc there called back to TL to challenge him for continuing tx. TL feels there is still some confusion in medical community and even Academic surrounding this concept. 

He also mentioned that he takes calls often from community asking about psuedo progression and how to determine what to do with a pt on Opdivo or ImmunoTherapy.","Community ONc reports concerns with his patient being hospitalized for diarrhea with suspected collitis with RCC. He advised treating physician to institute steroid dose 1mg/kg. He was asking for info on remicade if refractory to steroids. Physician feels ER and hospitals do not know how to treat these IO patients, if he is unable to follow them in hospital.","Spoke with Community Onc in Arizona, who mentioned he uses Biocept liquid bx for PD status for any 2nd line lung pt due to underwhelming efficacy in his practice. He will use Opdivo if biocept comes back positive for pd, otherwise chemo. 

Same physician mentioned that Opdivo is a blockbuster in Melanoma and far more effective than lung. He uses Monotherapy due to past bad experiences with Yervoy, unless the patient is young and it is a more tough call, he will do pd testing through caris and if positive, use Opdivo monotherapy and if negative will use combination. Stated he has a young pd+ pt on monotherapy who is doing wonderful for a long period of time now. He does not do pd testing across the board due to time and expense for Melanoma pts.",232
NP,Territory, AZ,24.9065934066,8.39045792629e-07,31,704,"Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.",NP from large practice volunteered she uses minocyline for rash r/t Opdivo and/or Yervoy if refractory to hydro-cortisone cream. She reports some anecdotal benefit. Same event: Pharmacist also mentioned - why dont we put everyone on zyrtec as prophylactic for potential of rash with regimen pts. We discussed incidence rates and he decided it would not be necessary to use a premed or prophylaxis approach.,NP from large Cancer Center shared their facility has transitioned all Opdivo pts to 30 min infusion time with no issues. This has helped streamline their infusion process for pts and has been a positive switch. The NP and her nurse also metnioned the flat dosing transition has helped Opdivo be a much easier infusion process with these two changes occurring.,735
symptoms,Territory, AZ,22.4851190476,1.02114962093e-05,28,195,"nurse reported rheumatoid arthritis flares with several opdivo and regimen patients. One case was a pt who had a distant history of mild RA and it flared up until she could not walk, drug had to be stopped. Nurse reported seeing pts have unprovoked RA type inflammation and pain in joints of knees spreading bilaterally as well with no medical  history. (AE's reported to safety). Nurse mentioned drug would need to be held and steroids used to control these symptoms.",Nurses at a proactive dinner presentation for ONS chapter mentioned they had been using Sandostatin for treatment of colitis induced by Opdivo. Proper symptom management and use of algorithms reviewed in detail and nurses shared they would institute use of IMAR guides in their clinics and hospitals.,"Community ONc reports concerns with his patient being hospitalized for diarrhea with suspected collitis with RCC. He advised treating physician to institute steroid dose 1mg/kg. He was asking for info on remicade if refractory to steroids. Physician feels ER and hospitals do not know how to treat these IO patients, if he is unable to follow them in hospital.",223
nurse,Territory, AZ,21.5857142857,2.57547191639e-07,41,193,"Nurses at a large gathering for ONS dinner in Oregon, interested in comments regarding chemo precautions for infusion nurses and pharmacy staff in relation to historic uses of chemotherapy drugs and precautions. Article in ONS magazine regarding importance of implementing safety in administration of cancer agents triggered discussion. Nurse liaison retorted with the importance of safety precautions with mixing or administering Opdivo and Yervoy products and discussed potential for long term effects for patients (ie pregnancy precautions). Nurses volunteered they are reforming their current SOP's and practices in efforts to protect nurses, and provide specific guidance for pregnant nurses administering cancer agents.","Community Oncology Clinic in Northern California had internal discussions, meetings and challenges surrounding BMS materials. Nurses were wanting to use patient care check sheets, and they felt ""legally"" liable if they did not call the doc for any items that would be checked by nurse or patients regarding ongoing symptoms related or not found during assessments. The site did in the end favor using check sheets and made an internal plan on ""when to call the doc"", but the language on the form made them uncomfortable until a full plan was in place internally. Rep and Nurse Liaison worked with team to discuss their current practices and feeling safe in their care and administration of the immuno oncology drugs. Nurses feel confident with tools and plans in place at this time.",NP from large Cancer Center shared their facility has transitioned all Opdivo pts to 30 min infusion time with no issues. This has helped streamline their infusion process for pts and has been a positive switch. The NP and her nurse also metnioned the flat dosing transition has helped Opdivo be a much easier infusion process with these two changes occurring.,234
release,Territory, AZ,18.6083743842,2.28530576501e-05,61,66,"GI Onc mentioned he was very underwhelmed by Gastric Data at ASCO. He mentioned he knows that it is a small sampling size, but he was hoping for more efficacy.He is hoping there will be more data released at GI Asco in January with more mature data. He has Taiho trail and will put pts on that if they are refractory to standard of care tx.","Community Oncologist volunteered he had ""just read""  2 yr OS from 2nd line Lung data released at ASCO and was very impressed. He has a patient on Opdivo with 1 year of treatment and is hoping he joins this group of long term survivors.","Community Oncologist in Northern California volunteered that he had heard many of the releases from Asco via his email and colleagues surrounding 1st line lung. He mentioned that he believed PDL1 testing in 1st line will be no problem as testing is getting easier and cheaper, and they will have tissue due to newer diagnosis. He mentioned positive impression from the data he saw come across.",127
pts,Territory, AZ,8.4649859944,3.5766968759e-07,164,1624,Renal TL mentioned he puts in central line port for his RCC pts starting Opdivo because he anticipates them being on tx for an extended period of time. He has several patients on tx for many months currently.,"Spoke with Community Onc in Arizona, who mentioned he uses Biocept liquid bx for PD status for any 2nd line lung pt due to underwhelming efficacy in his practice. He will use Opdivo if biocept comes back positive for pd, otherwise chemo. 

Same physician mentioned that Opdivo is a blockbuster in Melanoma and far more effective than lung. He uses Monotherapy due to past bad experiences with Yervoy, unless the patient is young and it is a more tough call, he will do pd testing through caris and if positive, use Opdivo monotherapy and if negative will use combination. Stated he has a young pd+ pt on monotherapy who is doing wonderful for a long period of time now. He does not do pd testing across the board due to time and expense for Melanoma pts.","Biomedical Learning Institute 1st Annual Symposium on Integrating Immune Therapies & Target Therapies into Standards of Care for Heme and Solid Malignancies; San Fran Sept 10, 2016 
Well Attended with over 200 attendees/ Merck was a sponsor as well as other companies (foundation medicine).   BMS was not one of the major sponsors.  

Lung: One of the major questions was: Are antiPD-1 agents interchangeable, and the presenters overall argued for yes they are the same (nivo/pembro). The schedule differences were mentioned several times highlighting Pembro
Insights 
?	Oak Trial results were mentioned for Atezo (Atezo was alleged as More toxic of the agents)
?	Pembro and Nivo have same toxicity profile
?	We don?t need a cross trial comparison since the populations were very similar and Nivo performs regardless of pd staining percentages
?	Commented that there are so many duplicative 2nd line trials amongst PD-1 inhibitors.  There is pressure to move into front line setting.  
?	In reference to 1st line lung press releases ? ?Merck cherry picked their patients? for trial, and consensus was that no doc on panel board would use off label 1st line IO tx unless on trial, they are all waiting for data; they all concluded that BMS strategy in 1st line did not pay off, and chemo ?isn?t going anywhere?, since only 50% of pts likely have pd expression. One TL did comment that if he did he would use Pembro as the data is there and it has the best schedule. 
?	Awaiting Blueprint project for further information on which testing to use (docs agreed that most facilities will pick one test and use exclusively due to cost and training)
?	All panel board docs advised audience to get PD status on new dx pts.  The question was asked if testing should be mandatory for newly diagnosed patients and they all said yes.  
?	National TL discussed Nivo trial looking at OS by PDL1 expression and stated 10% had better OS and that PDL-1 staining does predict OS. 
?	A lot of excitement over Ipi/Nivo combo in Lung  
1.	Mentioned that it is very alluring to give a boost of Ipi when single agent IO is fizzling to boost responses (no data to support however)
?	*Pseudoprogression mentioned many times ?does not exist in lung? ?pts refuse to be taken off of tx even in the face of wild progression?
?	Mentioned BMS 153 trial looking at early stopping of tx  Discussed the need to look at how long to continue these therapies.  TL went on to say he wasn?t sure how the data would pan out with this trial since many patients don?t survive to 1 year which is the cutoff for the trial to continue without therapy.
Costs: Cost was mentioned many times with one quote from podium for Lung 1st Line ?The only thing more expensive than IO is IO combo? 


Melanoma: Dr. J. Weber was one of the 2 presenters- NTL 
*Discussed BRAF pts to use targeted or IO first line setting (no consensus, both sides argued)
*Weber alleged Ipi/Nivo regimen is ?very toxic? and ?very effective? tx. Targeted Tx?s are less toxic that Combo IO. 
*advised audience to use 8 weeks of Targeted tx and move on to regimen of ipi/nivo
*Tvec treatment cant compare to IO
*064 Trial highlighted as switch approach 
*Encouraged extrapolating data from Lung Trial 012 for melanoma and to use reversed dosing or Ipi Q6w or Q12w
*believes adding braf inh target tx to IO combo will be very effective

Other solid Tumor:
-Pancreas: stated due to hypoxic pancreas tumor micro-environment and no local tcells that single agent antiPD1 hasn?t worked so far
Prostate: Discussed ipi negative trial and that bone disease only arm did much better 
H&N: Stated Nivo is new standard of care",1788
mentioned,Territory, AZ,6.93119266055,4.68813527565e-07,289,130,"Community Oncologist in Northern California volunteered that he had heard many of the releases from Asco via his email and colleagues surrounding 1st line lung. He mentioned that he believed PDL1 testing in 1st line will be no problem as testing is getting easier and cheaper, and they will have tissue due to newer diagnosis. He mentioned positive impression from the data he saw come across.","Physician of large private practice setting mentions he does not test for PD-L1 very often. He feels he does not need the information and does not think he would have enough tissue left after molecular studies. Opdivo would be chosen regardless of PD testing. Mentioned Opdivo pnemonitis is a strong risk, he feels other drugs do not carry. Data presented, physician still likely to use Opdivo in 2nd line melanoma and 2nd line lung.","GI Onc mentioned he was very underwhelmed by Gastric Data at ASCO. He mentioned he knows that it is a small sampling size, but he was hoping for more efficacy.He is hoping there will be more data released at GI Asco in January with more mature data. He has Taiho trail and will put pts on that if they are refractory to standard of care tx.",419
bc,Territory, CENTRAL,127.787234043,3.00344026815e-12,11,12,Lung NTL stated LUNG-MAP accrual has accelerated since March 2016 with addition of Nivo and Ipi+Nivo arms.  Currently 80pts enrolled and 260 pts total will be enrolled into N+I and Nivo arms.  Stated it will complete enrollment in 2 years.  There is also an upcoming revision to add single agent PARP inhibitor (Medivation) for squamous pts who are DDR+.  TL wants to add Nivo in combination to the PARP inhibitor bc DDR+ pts have an inflamed tumor phenotype.,"NTL from podium spoke very positively of IO and Regimen (most data discussed from Nivo studies):
1)	We have 10y OS data with Yervoy and this will probably be even longer with Regimen.  Pts don?t want a response ?they want to be on the tail in of the curve?.  He stated with Regimen and other IO combinations that ?hopefully we?ll be talking to pts about a 30y OS plan in the future?
2)	Regimen 
a.	Presented data from -069 and -067 showing the PFS curve stating ?you don?t need statistics to tell the difference in the curve favoring regimen?. 
b.	Toxicity is a concern and for older pts he chooses single agent PD1
c.	Regimen demonstrates similar activity in PDL1- pts
d.	TL stated uses Regimen every day in the clinic and has seen some spectacular results.  It?s an ?excellent Regimen?.  Very potent regimen
3)	Stated the immune response is very rapid with PD1 agents and especially regimen
4)	PDL1 as biomarker:
a.	PDL1+ pts tend to have better responses across tumor types
b.	Showed Nivo OS curves in PDL+/- pts and stated most of the advantage is in PDL1+ pts.  However, he stated you ?don?t want to withhold nivolumab treatment based on PDL1 expression levels bc PDL1- pts can have significant benefit as well?
c.	He stated mutational load may be the best biomarker
d.	Pts with high levels of CD8+ T cells in tumor microenvironment and invasive margins tend to have better responses
e.	No T cells within in tumor microenvironment pts don?t seem to respond as well and this is an area ?we as researchers need to improve T cell recruitment with novel combinations of injectables/vaccines (referenced TVEC)
5)	Need to identify agents that have activity in checkpoint resistant pts ? TL has had success with adoptive T cell transfer with approximately 30% RR although the RR drops in checkpoint resistant pts from 50% (checkpoint nave) to about 30%.","Community TL mentioned he still struggles on whether to treat certain NSCLC pts with Opdivo who have moderate-severe compromised pulmonary function and symptomology overlaps with pneumonitis.  He still is more hesitant bc the potentially difficulty distinguishing between symptoms of pneumonitis and natural disease course.  We reviewed inclusion/exclusion criteria for studies, discussed incidence/symptoms of pneumonitis and management algorithms.  He said those pts make him ""nervous"" but will probably start treating them bc nothing else available as good and he's had great experience with Nivo (very positive on Nivo).",23
inflamed,Territory, CENTRAL,127.787234043,1.00819003259e-06,5,86,"RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.","RCC NTL mentioned the ?non-inflamed tumor phenotype? (no immune cells in the TME) could be related to the vasculature surrounding the tumor.  TL has unpublished data demonstrating immune cells roll along the endothelium latching onto cellular adhesion molecules (CAMs) and once they encounter the appropriate chemokines from immune cells they extravasate toward the tumor.  The tumor secretes substances that effect the permeability of the endothelium making it leaky and filled with gaps. T cells can no longer adhere to the endothelium and extravasate toward tumor so they just float through the vessel away from the tumor.  This may help explain the reason why there are no immune cells within TME. He stated he has unpublished data showing that treatment with a certain VEGF inhibitor re-establishes the vasculature to more ?normal? situation and the T cells are then able to receive the chemokine signals, adhere to endothelium, extravasate and enter TME.  He stated a combination of this particular VEGF inhibitor (didn?t mention which one but said he?ll let me know when published) and Nivo may lead to more T cell penetration of TME and better responses.  He stated we need to find ways to recruit T cells into this TME due to the lack of immune cells this setting.","Several TLs have referenced an ASCO abstract/presentations regarding the molecular characterization of immune exclusion through the ??-catenin pathway and the relation of the T cell ?inflamed? and ?non-inflamed? tumor microenvironment with immunotherapy resistance (abstract 8565).  TLs have also referenced the findings of Spranger et al. (Nature reference below) who investigated the gene-expression profiles of 266 cutaneous melanomas and divided them into inflamed and non-inflamed cohorts. They found that ?-catenin signaling was active in the non-inflamed cohort and an increased CTNNB1 (?-catenin) score was predictive for a lack of T-cell infiltration.  Reconstitution with Flt3 ligand dendritic cells reversed resistance to immunotherapy (anti-CTLA + anti-PD1). The WNT/?-catenin pathway may contribute to immune evasion in other tumor entities beyond melanoma and may represent one mechanism of primary resistance to immunotherapy.  This was investigated in ASCO 2016 abstract 8565 SCLC and similar trend was observed of increased ?-catenin signaling in non-inflamed phenotype and lack of t cell infiltration.  Two additional presentations mentioned were biomarkers in immunotherapy and inflammation as next checkpoint.  

Nature 523, 231?235 (09 July 2015) doi:10.1038/nature14404",91
non-inflamed,Territory, CENTRAL,95.8404255319,4.03378254165e-05,4,107,"Several TLs have referenced an ASCO abstract/presentations regarding the molecular characterization of immune exclusion through the ??-catenin pathway and the relation of the T cell ?inflamed? and ?non-inflamed? tumor microenvironment with immunotherapy resistance (abstract 8565).  TLs have also referenced the findings of Spranger et al. (Nature reference below) who investigated the gene-expression profiles of 266 cutaneous melanomas and divided them into inflamed and non-inflamed cohorts. They found that ?-catenin signaling was active in the non-inflamed cohort and an increased CTNNB1 (?-catenin) score was predictive for a lack of T-cell infiltration.  Reconstitution with Flt3 ligand dendritic cells reversed resistance to immunotherapy (anti-CTLA + anti-PD1). The WNT/?-catenin pathway may contribute to immune evasion in other tumor entities beyond melanoma and may represent one mechanism of primary resistance to immunotherapy.  This was investigated in ASCO 2016 abstract 8565 SCLC and similar trend was observed of increased ?-catenin signaling in non-inflamed phenotype and lack of t cell infiltration.  Two additional presentations mentioned were biomarkers in immunotherapy and inflammation as next checkpoint.  

Nature 523, 231?235 (09 July 2015) doi:10.1038/nature14404","RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.","RCC NTL mentioned the ?non-inflamed tumor phenotype? (no immune cells in the TME) could be related to the vasculature surrounding the tumor.  TL has unpublished data demonstrating immune cells roll along the endothelium latching onto cellular adhesion molecules (CAMs) and once they encounter the appropriate chemokines from immune cells they extravasate toward the tumor.  The tumor secretes substances that effect the permeability of the endothelium making it leaky and filled with gaps. T cells can no longer adhere to the endothelium and extravasate toward tumor so they just float through the vessel away from the tumor.  This may help explain the reason why there are no immune cells within TME. He stated he has unpublished data showing that treatment with a certain VEGF inhibitor re-establishes the vasculature to more ?normal? situation and the T cells are then able to receive the chemokine signals, adhere to endothelium, extravasate and enter TME.  He stated a combination of this particular VEGF inhibitor (didn?t mention which one but said he?ll let me know when published) and Nivo may lead to more T cell penetration of TME and better responses.  He stated we need to find ways to recruit T cells into this TME due to the lack of immune cells this setting.",111
phenotype,Territory, CENTRAL,79.8670212766,1.39783092483e-07,8,76,"RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.","RCC NTL mentioned the ?non-inflamed tumor phenotype? (no immune cells in the TME) could be related to the vasculature surrounding the tumor.  TL has unpublished data demonstrating immune cells roll along the endothelium latching onto cellular adhesion molecules (CAMs) and once they encounter the appropriate chemokines from immune cells they extravasate toward the tumor.  The tumor secretes substances that effect the permeability of the endothelium making it leaky and filled with gaps. T cells can no longer adhere to the endothelium and extravasate toward tumor so they just float through the vessel away from the tumor.  This may help explain the reason why there are no immune cells within TME. He stated he has unpublished data showing that treatment with a certain VEGF inhibitor re-establishes the vasculature to more ?normal? situation and the T cells are then able to receive the chemokine signals, adhere to endothelium, extravasate and enter TME.  He stated a combination of this particular VEGF inhibitor (didn?t mention which one but said he?ll let me know when published) and Nivo may lead to more T cell penetration of TME and better responses.  He stated we need to find ways to recruit T cells into this TME due to the lack of immune cells this setting.","Several TLs have referenced an ASCO abstract/presentations regarding the molecular characterization of immune exclusion through the ??-catenin pathway and the relation of the T cell ?inflamed? and ?non-inflamed? tumor microenvironment with immunotherapy resistance (abstract 8565).  TLs have also referenced the findings of Spranger et al. (Nature reference below) who investigated the gene-expression profiles of 266 cutaneous melanomas and divided them into inflamed and non-inflamed cohorts. They found that ?-catenin signaling was active in the non-inflamed cohort and an increased CTNNB1 (?-catenin) score was predictive for a lack of T-cell infiltration.  Reconstitution with Flt3 ligand dendritic cells reversed resistance to immunotherapy (anti-CTLA + anti-PD1). The WNT/?-catenin pathway may contribute to immune evasion in other tumor entities beyond melanoma and may represent one mechanism of primary resistance to immunotherapy.  This was investigated in ASCO 2016 abstract 8565 SCLC and similar trend was observed of increased ?-catenin signaling in non-inflamed phenotype and lack of t cell infiltration.  Two additional presentations mentioned were biomarkers in immunotherapy and inflammation as next checkpoint.  

Nature 523, 231?235 (09 July 2015) doi:10.1038/nature14404",84
Several TLs,Territory, CENTRAL,63.8936170213,1.71967692362e-08,11,14,"I?ve met with several community TLs at different locations recently who have been ?underwhelmed? by Nivo responses mainly in NSCLC.  The discussions were very similar across TLs making me think its competitor strategy.  TLs stated they have treated a number of pts with either no responses or 1 response.  For this reason, they?ve decided to test for PDL1 status and their next pt they?re treating with Pembro to see if it will increase likelihood of response.  Reactively discussed -057 and KN -010 data and the several TLs changed their mind favoring Opdivo in the PDL1 expressors and wasn?t aware of the depth of our data in PDL1 expressors.  A couple of TLs stated they were going to try Pembro ?just to get some experience with the drug?.  Also, did some probing and turns out their ?n? was small, some pts had prolonged SD, but their overall initial impression was negative.",Q2 v Q3 week:  if all NSCLC data is the same in terms of safety and efficacy q3 trumps q2 - the more convenient schedule wins (several Tls),Several TLs have mentioned they have used BMS Access Support or Compassionate use program to request Nivo for off-label use for their pts and they have received approval and used it in those settings.  TLs have been extremely please and applauded the Access Support Program and they are very thankful BMS could help their pts.,25
tumor microenvironment,Territory, CENTRAL,63.8936170213,2.75537070963e-07,9,84,"RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.","Several TLs have referenced an ASCO abstract/presentations regarding the molecular characterization of immune exclusion through the ??-catenin pathway and the relation of the T cell ?inflamed? and ?non-inflamed? tumor microenvironment with immunotherapy resistance (abstract 8565).  TLs have also referenced the findings of Spranger et al. (Nature reference below) who investigated the gene-expression profiles of 266 cutaneous melanomas and divided them into inflamed and non-inflamed cohorts. They found that ?-catenin signaling was active in the non-inflamed cohort and an increased CTNNB1 (?-catenin) score was predictive for a lack of T-cell infiltration.  Reconstitution with Flt3 ligand dendritic cells reversed resistance to immunotherapy (anti-CTLA + anti-PD1). The WNT/?-catenin pathway may contribute to immune evasion in other tumor entities beyond melanoma and may represent one mechanism of primary resistance to immunotherapy.  This was investigated in ASCO 2016 abstract 8565 SCLC and similar trend was observed of increased ?-catenin signaling in non-inflamed phenotype and lack of t cell infiltration.  Two additional presentations mentioned were biomarkers in immunotherapy and inflammation as next checkpoint.  

Nature 523, 231?235 (09 July 2015) doi:10.1038/nature14404","RCC NTL mentioned the ?non-inflamed tumor phenotype? (no immune cells in the TME) could be related to the vasculature surrounding the tumor.  TL has unpublished data demonstrating immune cells roll along the endothelium latching onto cellular adhesion molecules (CAMs) and once they encounter the appropriate chemokines from immune cells they extravasate toward the tumor.  The tumor secretes substances that effect the permeability of the endothelium making it leaky and filled with gaps. T cells can no longer adhere to the endothelium and extravasate toward tumor so they just float through the vessel away from the tumor.  This may help explain the reason why there are no immune cells within TME. He stated he has unpublished data showing that treatment with a certain VEGF inhibitor re-establishes the vasculature to more ?normal? situation and the T cells are then able to receive the chemokine signals, adhere to endothelium, extravasate and enter TME.  He stated a combination of this particular VEGF inhibitor (didn?t mention which one but said he?ll let me know when published) and Nivo may lead to more T cell penetration of TME and better responses.  He stated we need to find ways to recruit T cells into this TME due to the lack of immune cells this setting.",93
ll,Territory, CENTRAL,63.8936170213,4.57789392738e-06,7,16,"NTL from podium spoke very positively of IO and Regimen (most data discussed from Nivo studies):
1)	We have 10y OS data with Yervoy and this will probably be even longer with Regimen.  Pts don?t want a response ?they want to be on the tail in of the curve?.  He stated with Regimen and other IO combinations that ?hopefully we?ll be talking to pts about a 30y OS plan in the future?
2)	Regimen 
a.	Presented data from -069 and -067 showing the PFS curve stating ?you don?t need statistics to tell the difference in the curve favoring regimen?. 
b.	Toxicity is a concern and for older pts he chooses single agent PD1
c.	Regimen demonstrates similar activity in PDL1- pts
d.	TL stated uses Regimen every day in the clinic and has seen some spectacular results.  It?s an ?excellent Regimen?.  Very potent regimen
3)	Stated the immune response is very rapid with PD1 agents and especially regimen
4)	PDL1 as biomarker:
a.	PDL1+ pts tend to have better responses across tumor types
b.	Showed Nivo OS curves in PDL+/- pts and stated most of the advantage is in PDL1+ pts.  However, he stated you ?don?t want to withhold nivolumab treatment based on PDL1 expression levels bc PDL1- pts can have significant benefit as well?
c.	He stated mutational load may be the best biomarker
d.	Pts with high levels of CD8+ T cells in tumor microenvironment and invasive margins tend to have better responses
e.	No T cells within in tumor microenvironment pts don?t seem to respond as well and this is an area ?we as researchers need to improve T cell recruitment with novel combinations of injectables/vaccines (referenced TVEC)
5)	Need to identify agents that have activity in checkpoint resistant pts ? TL has had success with adoptive T cell transfer with approximately 30% RR although the RR drops in checkpoint resistant pts from 50% (checkpoint nave) to about 30%.","NTL mentioned he could not believe Lenvatinib plus everolimus was FDA approved for RCC.  He said ?I was astonished it gained approval for phase 2 data?.  He said the combination is very toxic (diarrhea) requiring numerous dose modifications.  The level of evidence for Nivo is far more robust with phase 3 data and the tolerability is much better, so he?ll choose Nivo over TKIs.","1.	Biomarker:  He?s not routinely testing for PDL-1 status. He?s making his treatment decisions purely on a clinical basis because he doesn?t have enough confidence in PDL1 as a biomarker.  He stated although the outcomes are better for PDL1 + pts, PDL1- can still respond durably so he does not want to deprive a pt of the opportunity for long term survival based on PDL1 status.  

2.	Treatment Landscape:  NTL?s approach to melanoma pts:  he will attempt to treat all pts with Regimen front-line bc it gives them the best chance for long term OS.  If a pt is elderly (>75y), has comorbidities, or has pre-existing autoimmune disorders that he feels could be exacerbated on Regimen, he?ll treat with single agent Nivolumab.  He said he treats most elderly pts with single agent Nivo. He was in agreement with the robust efficacy of regimen and potential benefit for long term OS versus single agent.   He said pts don?t want a median increase in survival of a few months.  He said pts want to be on the ?tail end of curve? and that?s what he discusses with pts and that?s what Regimen/IO can provide.  NTL was extremely positive on Regimen data and hopes it will have similar results in other tumor types

3.	R&D Research Opportunities:  NTL brought up a discussion regarding mutations and response to immunotherapy.  NTL mentioned pts with high mutational load and tumors associated with high mutational burden tend to have better responses to IO.  We discussed reasoning for this was bc mutations often result in abnormal proteins which are recognized by intracellular immunological machinery, chopped up into small peptides, and presented on the tumor cell surface for immune cells to recognize.  Pts with high mutation load may have more tumor antigens present on the cell surface making them more visible to the immune system. I asked him if it would be a worthwhile research approach to identify potential targets in the intracellular immunological machinery of tumors that could be targeted to enhance the processing of mutated proteins so that you essentially have more mutated proteins being recognized, chopped up, and presented on the cell surface making the tumor even more visible to the immune system.  TL had an ?aha moment? and was very interested in this idea.  He asked if he could take this idea to his scientists in the lab for further investigation. He felt if you could manipulate the intracellular immunological machinery in the tumor to enhance the processing of mutated proteins (which is inherent to tumors) in combination with immune checkpoint inhibitors, it could potentially result in a more synergistic response - exposing the tumor to the immune system",23
single agent Nivo,Territory, CENTRAL,31.9468085106,3.05406848031e-06,16,0,TL stated it is impressive that 70% of pts treated with regimen continued to respond even in the absence of the medication.  The question is what to do with the pts who have durable responses for long periods of time.  Next wave of research studies should evaluate the discontinuation of regimen or single agent Nivo for pts who have responded for long periods of time (CR or very deep PR) and retreatment upon progression.,"General trend emerging through multiple TL engagements:  Duration of treatment - how long to treat pts who have achieved CR or deep, durable PR.  Based on data presented at ASCO demonstrating pts respond after discontinuation of regimen or single agent Nivo, TLs are asking when is it appropriate to stop treatment.  This appears to be a hypothetical discussion at this point. I've only had a couple TLs mention they have pts on Nivo in CR for years and they have discontinued Nivo.  TLs have stated if pt achieved CR and maintained for 6 months to a year they would consider discontinuing treatment.","During Lung poster session, TL stated ""Nivolumab is everywhere"". Every poster and data set people are talking is Nivo related. He shared with another TL that BMS ""did it right"" when developing Nivo and designing our trials. He stated BMS took a risk by going straight to phase 3 in all comers with single agent Nivo against SOC and it has paid off. This separates BMS from competitors bc more robust data and you don't have to test. All companies ask him how he will positions these agents in 2nd line and he said he'll choose the agent with robust OS and no testing any day of week. He said that may change in front line but Nivo will be so entrenched by that point it will be tough to change.",16
deep,Territory, CENTRAL,31.9468085106,3.06525845167e-05,11,95,TL stated it is impressive that 70% of pts treated with regimen continued to respond even in the absence of the medication.  The question is what to do with the pts who have durable responses for long periods of time.  Next wave of research studies should evaluate the discontinuation of regimen or single agent Nivo for pts who have responded for long periods of time (CR or very deep PR) and retreatment upon progression.,"General trend emerging through multiple TL engagements:  Duration of treatment - how long to treat pts who have achieved CR or deep, durable PR.  Based on data presented at ASCO demonstrating pts respond after discontinuation of regimen or single agent Nivo, TLs are asking when is it appropriate to stop treatment.  This appears to be a hypothetical discussion at this point. I've only had a couple TLs mention they have pts on Nivo in CR for years and they have discontinued Nivo.  TLs have stated if pt achieved CR and maintained for 6 months to a year they would consider discontinuing treatment.","Melanoma RTL stated you need to approach treating a pt with regimen with flexibility.  First, make sure the patient is a good candidate (PS, comorbidities, can they tolerate).  Secondly, some pts may tolerate all 4 doses with no issue while others may have significant toxicity after 1 dose requiring discontinuation, but patient may respond to just 1 dose.  Physicians need to assure the patients may continue to respond after treatment or even when they discontinue the medicine.  TL referred to ASCO data where pts where off treatment and continued to respond durability.  She stated we need to under the biological underpinnings of these types observations.  What baseline immune characteristics allow one pt to only tolerate 1 dose and another patient can tolerate all 4 doses with no issue.  TL also stated BMS needs more studies looking at when to discontinue Regimen or single agent Nivo for pts who have achieved deep response and maintained it for a period of time.",106
front-line,Territory, CENTRAL,31.9468085106,3.06525845167e-05,11,142,"TL feels if pt is PDL1 + at all, they will get Pembro front-line bc FDA supports PD1 use, pts asking docs and insurance companies, and docs love it.  No push back expected.","TLs stated treatment decisions front-line will rely on PDL1 positivity
PDL1+:  Ipi+Nivo or Single agent PD1.  Poor PS may choose single agent PD1.  Based on -012 and KN-024, chemo will be not be a primary choice for most TLs.  In PDL1- pts,  Ipi+Nivo or Chemo+PD1 agent depending on symptoms","RCC NTL stated BMS has focused significant resources and strategy on development of Ipi+Nivo in multiple tumor types including RCC.  Although TL expressed this is an excellent strategy, he mentioned that if efficacy is not much better or the toxicity is too bad, BMS could be in trouble and ultimately lose in RCC.  He stated we are not aggressively pursuing many other TKI combinations with Nivo compared to our competitors.  Stated we need to start this immediately.  TL specifically mentioned Nivo+Cabo combination front-line RCC.  He stated Merck, AZ, and Genentech are already in discussions to combine Cabo with their anti-PD1/PDL1 agents.",153
T cells,Territory, CENTRAL,22.8191489362,1.11620542831e-05,18,46,"RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.","RCC NTL mentioned the ?non-inflamed tumor phenotype? (no immune cells in the TME) could be related to the vasculature surrounding the tumor.  TL has unpublished data demonstrating immune cells roll along the endothelium latching onto cellular adhesion molecules (CAMs) and once they encounter the appropriate chemokines from immune cells they extravasate toward the tumor.  The tumor secretes substances that effect the permeability of the endothelium making it leaky and filled with gaps. T cells can no longer adhere to the endothelium and extravasate toward tumor so they just float through the vessel away from the tumor.  This may help explain the reason why there are no immune cells within TME. He stated he has unpublished data showing that treatment with a certain VEGF inhibitor re-establishes the vasculature to more ?normal? situation and the T cells are then able to receive the chemokine signals, adhere to endothelium, extravasate and enter TME.  He stated a combination of this particular VEGF inhibitor (didn?t mention which one but said he?ll let me know when published) and Nivo may lead to more T cell penetration of TME and better responses.  He stated we need to find ways to recruit T cells into this TME due to the lack of immune cells this setting.","Several TLs have referenced an ASCO abstract/presentations regarding the molecular characterization of immune exclusion through the ??-catenin pathway and the relation of the T cell ?inflamed? and ?non-inflamed? tumor microenvironment with immunotherapy resistance (abstract 8565).  TLs have also referenced the findings of Spranger et al. (Nature reference below) who investigated the gene-expression profiles of 266 cutaneous melanomas and divided them into inflamed and non-inflamed cohorts. They found that ?-catenin signaling was active in the non-inflamed cohort and an increased CTNNB1 (?-catenin) score was predictive for a lack of T-cell infiltration.  Reconstitution with Flt3 ligand dendritic cells reversed resistance to immunotherapy (anti-CTLA + anti-PD1). The WNT/?-catenin pathway may contribute to immune evasion in other tumor entities beyond melanoma and may represent one mechanism of primary resistance to immunotherapy.  This was investigated in ASCO 2016 abstract 8565 SCLC and similar trend was observed of increased ?-catenin signaling in non-inflamed phenotype and lack of t cell infiltration.  Two additional presentations mentioned were biomarkers in immunotherapy and inflammation as next checkpoint.  

Nature 523, 231?235 (09 July 2015) doi:10.1038/nature14404",64
bladder cancer,Territory, CENTRAL,16.8141097424,3.79677129313e-05,23,36,RTL stated they are working on a bladder cancer spore grant that will combine Nivo + rAd-IFN/Syn3 oncolytic virus prior to cystectomy in superficial bladder cancer.  rAd-IFN/Syn3 is administered intravesically and expresses interferon and the molecule is designed to occupy the bladder for longer periods of time allowing deeper penetration into bladder cancer cells.  He stated the clinical data for rAd-IFN/Syn3 looks promising.  He also discussed the potential of investigating this combo in BCG-refractory pts.,RTL stated BMS should investigate Nivo as a bladder-sparing approach prior to cystectomy in the following pt populations:  1) superficial bladder cancer 2) muscle invasive stage 4 lymph node involvement chemo+Nivo (stated there?s more risk with this approach).  Neoadjuvant treatment prior to cystectomy may eliminate/reduce comorbidities associated with cystectomy and could be part of the clinical endpoint.,"RTL stated at this time, OS is not as important of an endpoint in bladder cancer just because the current treatments are so limited.  This may change with introduction of Atezo and Nivo.",59
tend,Territory, CENTRAL,16.8141097424,3.79677129313e-05,23,0,RTL stated when it comes to pseudoprogression he's much less concerned with the development of new lesions.  He tends to get more concerned when the tumor volume increases in size that it's true progression.  If pt feels good and is not deteriorating and develops new lesions he continues to treat.,"NTL from podium spoke very positively of IO and Regimen (most data discussed from Nivo studies):
1)	We have 10y OS data with Yervoy and this will probably be even longer with Regimen.  Pts don?t want a response ?they want to be on the tail in of the curve?.  He stated with Regimen and other IO combinations that ?hopefully we?ll be talking to pts about a 30y OS plan in the future?
2)	Regimen 
a.	Presented data from -069 and -067 showing the PFS curve stating ?you don?t need statistics to tell the difference in the curve favoring regimen?. 
b.	Toxicity is a concern and for older pts he chooses single agent PD1
c.	Regimen demonstrates similar activity in PDL1- pts
d.	TL stated uses Regimen every day in the clinic and has seen some spectacular results.  It?s an ?excellent Regimen?.  Very potent regimen
3)	Stated the immune response is very rapid with PD1 agents and especially regimen
4)	PDL1 as biomarker:
a.	PDL1+ pts tend to have better responses across tumor types
b.	Showed Nivo OS curves in PDL+/- pts and stated most of the advantage is in PDL1+ pts.  However, he stated you ?don?t want to withhold nivolumab treatment based on PDL1 expression levels bc PDL1- pts can have significant benefit as well?
c.	He stated mutational load may be the best biomarker
d.	Pts with high levels of CD8+ T cells in tumor microenvironment and invasive margins tend to have better responses
e.	No T cells within in tumor microenvironment pts don?t seem to respond as well and this is an area ?we as researchers need to improve T cell recruitment with novel combinations of injectables/vaccines (referenced TVEC)
5)	Need to identify agents that have activity in checkpoint resistant pts ? TL has had success with adoptive T cell transfer with approximately 30% RR although the RR drops in checkpoint resistant pts from 50% (checkpoint nave) to about 30%.","RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.",23
immune,Territory, CENTRAL,13.2193690389,2.13465608263e-05,80,2,"Several TLs have referenced an ASCO abstract/presentations regarding the molecular characterization of immune exclusion through the ??-catenin pathway and the relation of the T cell ?inflamed? and ?non-inflamed? tumor microenvironment with immunotherapy resistance (abstract 8565).  TLs have also referenced the findings of Spranger et al. (Nature reference below) who investigated the gene-expression profiles of 266 cutaneous melanomas and divided them into inflamed and non-inflamed cohorts. They found that ?-catenin signaling was active in the non-inflamed cohort and an increased CTNNB1 (?-catenin) score was predictive for a lack of T-cell infiltration.  Reconstitution with Flt3 ligand dendritic cells reversed resistance to immunotherapy (anti-CTLA + anti-PD1). The WNT/?-catenin pathway may contribute to immune evasion in other tumor entities beyond melanoma and may represent one mechanism of primary resistance to immunotherapy.  This was investigated in ASCO 2016 abstract 8565 SCLC and similar trend was observed of increased ?-catenin signaling in non-inflamed phenotype and lack of t cell infiltration.  Two additional presentations mentioned were biomarkers in immunotherapy and inflammation as next checkpoint.  

Nature 523, 231?235 (09 July 2015) doi:10.1038/nature14404","RCC NTL mentioned the differences in the tumor microenvironment (TME) that may influence response to Nivo.  
1)  ?Inflamed tumor phenotype? ? Immune cells have penetrated the TME (Immune Cell Rich Zone) and a battle is taking place between immune and tumor cells leading to inflammation. We were discussing the MSKCC intermediate and poor risk subgroup analysis.  He said some intermediate and especially poor risk pts tend to be associated with the inflamed tumor phenotype, IFN-gamma production, high PDL1 expression, and are more responsive to Nivo.  
2) ?Non-inflamed tumor phenotype? ? immune cells are not found within the TME (Immune Cell Free Zone).  He attributes this to the immunosuppressive nature of tumor cells suppressing chemokines/cytokines production that recruits the T cells into the microenvironment.  He said these pts tend to have less of a response to Nivo and novel strategies need to be employed to recruit T cells into the TME such as combinations with vaccines, anti-angiogenic agents, etc.","NTL stated they are currently in the process of ?bar coding? immune cells in order to separate different immune cells more efficiently for biomarker analysis.  Basically, they insert the appropriate sequences and bar code into the probe used to identify specific immune cells and it allows easy separation of immune cells.",82
RTL stated,Territory, CENTRAL,9.98337765957,5.30249437727e-07,93,556,RTL stated he has promising preclinical data in RCC demonstrating a synergistic response with IDO + Nivo providing a rationale for further investigation.  Didn?t state which IDO inhibitor.,RTL stated they are working on a bladder cancer spore grant that will combine Nivo + rAd-IFN/Syn3 oncolytic virus prior to cystectomy in superficial bladder cancer.  rAd-IFN/Syn3 is administered intravesically and expresses interferon and the molecule is designed to occupy the bladder for longer periods of time allowing deeper penetration into bladder cancer cells.  He stated the clinical data for rAd-IFN/Syn3 looks promising.  He also discussed the potential of investigating this combo in BCG-refractory pts.,"RTL stated at this time, OS is not as important of an endpoint in bladder cancer just because the current treatments are so limited.  This may change with introduction of Atezo and Nivo.",649
pt,Territory, CENTRAL,9.7464839524,2.18522151207e-06,67,23,"Potential Trend:  Several TLs have expressed that they wait to scan their opdivo treated pts until week 12 unless clinically necessary to bypass the potential ?nightmare? discussing pseudoprogression with pt.  They said if pt is feeling fine clinically and PS remains stable, they wait to scan.","General trend emerging through multiple TL engagements:  Duration of treatment - how long to treat pts who have achieved CR or deep, durable PR.  Based on data presented at ASCO demonstrating pts respond after discontinuation of regimen or single agent Nivo, TLs are asking when is it appropriate to stop treatment.  This appears to be a hypothetical discussion at this point. I've only had a couple TLs mention they have pts on Nivo in CR for years and they have discontinued Nivo.  TLs have stated if pt achieved CR and maintained for 6 months to a year they would consider discontinuing treatment.","Melanoma RTL stated you need to approach treating a pt with regimen with flexibility.  First, make sure the patient is a good candidate (PS, comorbidities, can they tolerate).  Secondly, some pts may tolerate all 4 doses with no issue while others may have significant toxicity after 1 dose requiring discontinuation, but patient may respond to just 1 dose.  Physicians need to assure the patients may continue to respond after treatment or even when they discontinue the medicine.  TL referred to ASCO data where pts where off treatment and continued to respond durability.  She stated we need to under the biological underpinnings of these types observations.  What baseline immune characteristics allow one pt to only tolerate 1 dose and another patient can tolerate all 4 doses with no issue.  TL also stated BMS needs more studies looking at when to discontinue Regimen or single agent Nivo for pts who have achieved deep response and maintained it for a period of time.",90
pts,Territory, CENTRAL,9.31781914894,5.48208088458e-12,164,1624,"I?ve met with several community TLs at different locations recently who have been ?underwhelmed? by Nivo responses mainly in NSCLC.  The discussions were very similar across TLs making me think its competitor strategy.  TLs stated they have treated a number of pts with either no responses or 1 response.  For this reason, they?ve decided to test for PDL1 status and their next pt they?re treating with Pembro to see if it will increase likelihood of response.  Reactively discussed -057 and KN -010 data and the several TLs changed their mind favoring Opdivo in the PDL1 expressors and wasn?t aware of the depth of our data in PDL1 expressors.  A couple of TLs stated they were going to try Pembro ?just to get some experience with the drug?.  Also, did some probing and turns out their ?n? was small, some pts had prolonged SD, but their overall initial impression was negative.","Several RTLs have mentioned they have been discussing with their colleagues unexpected responses observed post-Nivo. TLs state pts treated with Nivo who eventually progress (after a response or SD) or sometimes progress straight through Nivo are then treated with standard agents such as gem or docetaxel that go onto have a very robust response. TL thinks that although pts progressed in Nivo, it may have changed the tumor microenvironment or sensitized them to respond better to chemo. They said in the 3rd line setting with standard agents they've used for years they are seeing more robust responses post-Nivo.","Bladder RTL mentioned BMS should design trials in Cisplatin-ineligible pts, pts with poor kidney function, or pts ineligible/intolerant for adjuvant/neoadjuvant chemo.  He said there are a lot of these pts out there and -032 and -275 excluded these patients.",1788
TLs,Territory, CENTRAL,9.25994449584,9.77370491656e-07,98,6,Q2 v Q3 week:  if all NSCLC data is the same in terms of safety and efficacy q3 trumps q2 - the more convenient schedule wins (several Tls),TLs reports no one is investigating correlation of Microbiome and Response to IO in NSCLC and it's an especially hot topic in melanoma,"Potential trend of TLs are unaware of depth of data with Nivo in PDL1 expressors and believe keytruda is more efficacious PDL1 expressors.  After reactively discussing the -057 PDL1 data in more detail, TLs tend to change their mind and believe Nivo is superior in efficacy to Keytruda in the PDL1 expressors.",104
mentioned,Territory, CENTRAL,5.37422946908,2.5143349134e-07,289,130,"NTL mentioned the recent press release of Checkmate-141 early stoppage for OS advantage is a ""game changer"".  He was particularly impressed that it was against standard of care agents that included Erbitux.  He stated it would be adopted as standard of care upon approval and no treating oncologist is concerned with the toxicity profile bc it's so well tolerated.",NTL mentioned that the Opdivo commercial is the most successful ad campaign he's ever seen by industry.  He stated all his pts are aware of the ad and pts come to his clinic asking for the lung cancer drug on TV.,Several TLs have mentioned they have used BMS Access Support or Compassionate use program to request Nivo for off-label use for their pts and they have received approval and used it in those settings.  TLs have been extremely please and applauded the Access Support Program and they are very thankful BMS could help their pts.,419
NTL,Territory, CENTRAL,4.51773049645,2.28421851141e-05,311,710,"NTL mentioned the recent press release of Checkmate-141 early stoppage for OS advantage is a ""game changer"".  He was particularly impressed that it was against standard of care agents that included Erbitux.  He stated it would be adopted as standard of care upon approval and no treating oncologist is concerned with the toxicity profile bc it's so well tolerated.","RCC NTL stated BMS has focused significant resources and strategy on development of Ipi+Nivo in multiple tumor types including RCC.  Although TL expressed this is an excellent strategy, he mentioned that if efficacy is not much better or the toxicity is too bad, BMS could be in trouble and ultimately lose in RCC.  He stated we are not aggressively pursuing many other TKI combinations with Nivo compared to our competitors.  Stated we need to start this immediately.  TL specifically mentioned Nivo+Cabo combination front-line RCC.  He stated Merck, AZ, and Genentech are already in discussions to combine Cabo with their anti-PD1/PDL1 agents.","When speaking of rare tumor types (adrenal tumors, anal, etc) and subtypes of common tumors (MSI-H CRC, Renal Medullary Carcinoma, etc), NTL stated limited data will be needed in these ?orphan type diseases? for FDA approval because of the scarcity treatment options and very poor prognosis.  There is an opportunity in these settings to generate some data and if you see some responses it may be enough to present to FDA for approval in rare tumor types or recommendation on NCCN guidelines.",1021
Lung RTL shared,Territory, CHICAGO,60.325203252,2.49779154486e-12,15,59,Lung RTL shared that BMS will have an uphill climb trying to convince physicians how to use the regimen if CM-227 is positive.  He feels that physicians are scared off by the noise Ipi is creating in the adjuvant melanoma setting.  He commented that lung treaters at the institution level are asking their melanoma colleagues for guidance on how to manage toxicities with IO agents and if they haven't had positive experiences with Ipi then the rest of the treaters at the institution will have a skewed view of the drug.,Lung RTL shared that BMS better hope FDA doesn't add the KN-010 data to Pembro's data using the 1% cut-off.  He thinks that if that happens it will be simply a two way race between Merck and Roche because both agents are Q3W.,"Lung RTL shared that starting in September tumor mutation burden score will be available through Foundation One testing.  Scores will be stratified based on low, intermediate, and high.",74
suit,Territory, CHICAGO,48.2601626016,1.91748484504e-05,6,0,HCC TL has been extremely impressed with the access support program and wished other companies would follow suit.  She shared that she has been able to provide Nivolumab off-label for a few of her HCC pts. that have failed sorafenib.,"Head and neck RTL called Roche's assay ""trash"" based on the evidence supported in the blueprint initiative. He added that Roche should follow suit and use a cleaner system like ours and Merck's and just look at immune cells.","HCP applauded our access support program and shared that she wished other companies would follow suit.  She commented that she was able to get access to Opdivo for a renal (before approval), ovarian, and small cell patient within a matter of days after getting the patients entered into the access program.",6
Lung NTL,Territory, CHICAGO,14.4780487805,1.7919978254e-05,20,669,"Regional TL shared that the way IO has transformed the treatment landscape academic as well as community practices will need to shift their model and group their physicians into ""immunotherapists"" vs. ""targeted therapists.""","Lung NTL shared that she's treated a lot study pts. for both Opdivo and Atezo and felt that there is higher percentage of pts. with ""profound"" fatigue that she's seen with Atezo.","Lung NTL commented that she doesn't believe -026 was truly a ""failed"" trial because it didn't underperform the chemo arm. She added that the imbalance at the 25% and 50% PDL1 cutoffs probably played a big role in the discrepancy seen with PFS and OS.",689
pts,Territory, CHICAGO,8.37349836185,1.07961121728e-15,164,1624,Breast TL shared that she was able to get Opdivo for two of her triple negative pts. through our access support program.  Both pts. had failed at least 4 prior lines of therapy and both now have stable disease.  She commented that she thinks that the prior chemo regimens completely wiped out the patients' marrows and that limited the ability of Opdivo to work even better.,Melanoma NTL shared that at his institution all the pts. on PD1 that have stable disease eventually relapse.  He added that Merck has already shared with him a timeframe when pts. end up progressing after having stable disease based on their data.  He wondered whether we have this data as well?,Lung RTL shared that she is stretching out her scans past the 8 week mark.  She feels a majority of her patients are receiving clinical benefit (i.e. stable disease) but the early scan doesn't help much.  In fact she says that it probably induces unnecessary anxiety in pts. and they get discouraged when they hear that nothing much has changed with their scans.,1788
Lung RTL,Territory, CHICAGO,6.78658536585,3.01336431915e-05,71,1103,"Lung RTL shared that once Pembro is approved in the front-line space this will effect Opdivo use in the second line setting.  She stated Merck reps having been flying into her office touting that they got the ""PDL1 story right"" and that's why they won in firstline.   She also shared that they are ""aggressivley"" telling the physicians to test in the second line space because of the negative outcome from -026.","Lung RTL at an academic institution shared that based on the recent approval with Atezolizumab that it will be a ""no brainer"" that he'll be using this in the second line space given the Q3W dosing.",Lung RTL shared that BMS will have an uphill climb trying to convince physicians how to use the regimen if CM-227 is positive.  He feels that physicians are scared off by the noise Ipi is creating in the adjuvant melanoma setting.  He commented that lung treaters at the institution level are asking their melanoma colleagues for guidance on how to manage toxicities with IO agents and if they haven't had positive experiences with Ipi then the rest of the treaters at the institution will have a skewed view of the drug.,1174
added,Territory, CHICAGO,4.66149297857,1.88384350972e-06,148,0,Lung RTL shared that the patient population that she is seeing at her institution is changing.  With the approval of the PD1 inhibitors she is seeing less newly diagnosed metastatic pts. and more pts. that have failed PD1 therapy.  She added that she doesn't have many options for these pts. but that she was excited to note that they will be opening a Pembro + chemo study in pts. that progressed on PD1 inhibitors.,"Lung RTL shared that he has treated multiple Small cell pts. with Nivo but is hesitant to add Ipi.  He feels that these pts. are already ""beat up"" from prior lines of therapy and would not be able to handle the toxicities.  He added that the melanoma treaters at his institution put the ""fear of God"" into him that Ipi is not for the faint of heart and induces horrendous toxicities.",Lung RTL commented that there is no difference between PD1 or PDL1 agents.  The biggest advantage that any of these compounds have whether it's given every 2 weeks or 3 weeks.  She added that BMS better get a move on with CM-384 because our share in the second line space will begin to drop dramatically.,148
shared,Territory, CHICAGO,4.35794110449,1.69570013887e-10,507,1,Melanoma NTL shared that at his institution all the pts. on PD1 that have stable disease eventually relapse.  He added that Merck has already shared with him a timeframe when pts. end up progressing after having stable disease based on their data.  He wondered whether we have this data as well?,"Lung RTL at an academic institution shared that based on the recent approval with Atezolizumab that it will be a ""no brainer"" that he'll be using this in the second line space given the Q3W dosing.","Lung RTL in Illinois shared that he has been having difficulty obtaining enough tissue with his first line pts. to do PDL1 testing.  He shared that it's been frustrating because he knows that some of these pts. may be ""high expressors"" but won't have enough tissue to ever find out.",508
commented,Territory, CHICAGO,4.13658536585,1.52054198743e-06,295,327,Lung TL who serves on the NCCN panel shared that the reason they placed Nivo/Ipi on the guidelines for SCLC was for ease of approval with the insurance companies.  She also commented that they didn't provide any guidance as to which dose of Nivo of Ipi because it gives the physician the autonomy to choose what is best for the patient.  She also added that she was surprised that BMS was moving forward with the 3mg/kg dose of Ipi in the phase III studies given the toxicities seen with dose in melanoma.,"Lung TL commented that he has been using both smoking status and PDL1 expression to help determine how he is going to treat a patient.  In fact he added that the evidence regarding smoking status probably carries more ""weight"" at the moment than PDL1 expression since your're ultimately relying on a protein that fluctuates expression over time.",A head and neck RTL commented that he was thrilled to see the press release regarding the CHECKMATE 141 study since it will be easier now to fight with insurance in obtaining drug. He also shared that he would most likely try to get Opdivo for those pts. that are ineligble (i.e. PDL1 negative) for the AZ and Merck head and neck studies that he has open at his institution.,622
H&N cancer,Territory, Chicago,76.1,2.98968007795e-05,22,39,"An academic TL who treats mostly H&N cancer patients, stated that he tried to attend the -141 presentation, but he could not because ?the room was full?.",An academic TL who treats mostly H&N cancer patients stated that what is impressive about the Kaplan ?Meier curve of the OS in the -141 study is the tail of the curve.,An academic TL who treats mostly H&N cancer patients stated that in his experience he has not seen so far differences in response to chemo treatment in patients with p16 positive tumors compared to patients with p16 negative tumors.,61
corticosteroids,Territory, E. PA,22.8893203883,7.392548044e-08,17,260,"Community HCP holding treatment versus initiating corticosteroids to manage IMARs.  An APN from practice was present at our dinner program.  Discussion around MOA, half life of drug and incidence of IMARs off treatment.  HCP thought is ""drug will leave system"" and IMAR should resolve.",PCP in a community practice does not test for PD-L1 to make treatment decisions.  He uses OPDIVO on and off label. Discussion around using low dose corticosteroids to manage fatigue and continue to treat.  Advised NOT to use as such unless he has treated an IMAR and is tapering.  We had discussion around masking symptoms of potential IMAR and efficacy in absence of IMAR.  Reviewed IMAR guide and algorithm.,"Continued hesitancy of community HCPs in utilizing high dose corticosteroids in managing IMARs.  In some of these practices, nurse are well aware of benefits and efficacy in treating IMARs with corticosteroids.  Physicians do not have comfort using high dose, thus reporting inability to taper corticosteroids in some cases.",277
thought leader,Territory, E. PA,15.1473443746,1.51758714019e-07,25,22,Thought leader in a major institution treating patient with PEMBRO vs OPDIVO due to travel inconvenience for patient.,Community thought leader reporting that our competitor MERCK is offering 100% guaranteed coverage for their product on all off label use.  Thought leader continues to use OPDIVO for his patients because no testing required.,Thought leaders in a major institute having concerns using regimen in patients with comorbid conditions and/or older age.,47
National TL,Territory, E. PA,10.939748715,7.00775077462e-09,51,544,National TL who sits on advisory board for T-vec expressed that there has not been a concept presented for T-vec + regimen. He has been unofficially encouraged to do so.,National TL and NCCN panel member is concerned about the combination of nivo/ipi in the community settings. He feels that there is a general lack of knowledge in how to manage IMAEs in the community and not all of these docs are currently treating melanoma patients,National TL and NCCN panel member explained that he has had very high rate of PDL1 screen failures during an 1L atezo lung study. He struggles to find PDL1+ patients and wonders if there is a geographical relation. Is there higher rates of PDL1 positivity in the tobacco belt? He has turned down Merck studies with PDL1 >50% cut off because he seldom finds a patient with that high of expression.,595
competitor,Territory, E. PA,8.80358476475,1.81895677599e-05,33,0,"Patient was a close college colleague/friend of competitor Pharma, thus use of competitor PD-1 inhibitor.","In a large community practice, patient influenced use of competitor product because knows Merck employee.","Questions around competitor data in First-line Pembro KN 024, why such a positive trial versus CM 026.  Discussed trial design of 026 was not stratified according to PDL-1 testing.  Referred to trial CM 0227 with 3 arm study.  Concerns around testing.",33
PDL-1,Territory, E. PA,8.30660820545,8.33557366901e-06,50,881,Questions around PDL-1 testing.  Currently not testing in 2nd line.  Considering testing all patients since negative trial of CM 026.  Discussed questions around appropriate assay not yet determined.  Discussed data from trials CM 057 and 017.  Patients respond regardless of testing and Duration of response achieved in negative expressors versus chemotherapy.,"Thought leader in major institution treating PDL-1 negative patients with OPDIVO, PDL-1 positive patients with PEMBRO or may consider clinical trial.","Community TL reporting that testing for PDl-1 is standard of practice in their local institution.  Based on results, using Pembro for those patients testing positive.",931
Regional TL,Territory, E. PA,7.75909165707,9.23526502012e-09,100,1088,Regional TL who treats GU patients says he is participating in a CTEP study exploring cabo+nivo+ipi in prostate cancer and they is seeing great results.,"Regional TL who treats GU patients says that of all the departments they feel the least need for PDL1 testing. However, because of the recent 1st line lung indication with an IO agent requiring testing their institution is now working on doing an in house test. he doesn't feel like he will use it",Regional TL who treats GU patients says that he has treated double digits worth of patients with cabo and only one person has been able to tolerate the 60mg indicated dose. he starts patients at 20mg and then tried to increase as their tolerability allows.,1188
major,Territory, E. PA,7.62977346278,6.45677355609e-07,90,483,A major academic institute utilizing Regimen as standard of care in melanoma,NP at academic practice says that the number one major complaint that she is receiving from patients is a radiated arthralgia,Thought leaders in a major institute having concerns using regimen in patients with comorbid conditions and/or older age.,573
GYN ONC,Territory, E. TN,67.7647058824,4.86513262337e-05,4,69,Spoke with GYN/ONC who wondered if BMS would start any Opdivo/Yervoy cervical cancer trials.  Mentioned that his institution already has a Pembro trial (Phase 1?) looking at Cervical.,"GYN ONC spoke with me about IO in cervical cancer.  He stated, ""I know that there are trials looking at HPV+/- cervical patients and Nivo, but I really think that the combination (like the -012 Lung) will turn out to be better.""","GYN ONC spoke with me and stated:  It is unfortunate that GYN ONC is the last to ever get trials.  It is almost a secondary thought.  I would think that BMS would have been more aggressive in the cervical cancer space, since we know it can be driven by a virus, and we know that the immune system can be used to target the virus (referring to the vaccine).  You would think this would be an easy win.""",73
Neuro-ONC,Territory, E. TN,50.8235294118,1.24003412856e-09,11,39,"When discussing some contradicting data surrounding the effect of WBR and SRT on Tcell infiltration into GBM tumors, one study saying that if facilitated Tcell infiltration, and another study said that RT reduces Tcell's ability to infiltrate the tumor, Neuro-ONC expressed his frustration as ""F- me, we can't seem to figure out anything with this disease.""","Neuro-ONC stated that MGMT as a bio marker for GBM is just as bad as PDL1 status.  ""It can change after RT, or Chemo.  Recurrent tumors can change MGMT status as well.  It also has the same problems as PDL1 status in that there is heterogeneity within the tumor, intratumor and intertumor differences as well.  It is not a great bio marker, but it is all we have to go with now.""","Neuro-ONC stated that in ""slow growth"" recurrent GBM patients that he will try combinations of Opdivo, Opdivo+Bev, Opdivo+Yervoy.  Has had limited success with each possible, but stated that ""limited success is still success in GMB.""",50
National Thought leader,Territory, E. TN,39.5294117647,1.99854733424e-07,9,0,"A National Thought leader stated, when asked about the future of bio markers in NSCLC:  To solve the puzzle (in lung), people are going to have to forget about PDL1.  PD1 inhibitors work but that doesn't mean that PDL1 expression is the first place that people should look.","National Thought leader answering questions about PDL1 testing at a recent dinner presentation stated:
1.  I think PDL1 data will be big at ASCO this year, but I think it will take a big step back.  I think the data will muddy the water more than it already is.  
2. PDL1 (expression) will be something big in the future, but right now we just don't know enough about it to use the data correctly.  
3.  Regardless of the PDL1 expression you are doing your patients a disservice if you are not using Opdivo 2L in your NSCLC patients.","A National Thought leader stated, when asked about the future of bio markers in NSCLC: I think investigators should start looking at it from the end and work backwards.  We should focus on the responders.  Find out what commonalities they have and work from there.  We are currently testing for a bio marker (PDL1) from samples where we know the expression can be different than when treatment starts (biopsy before 1L treatmen) and then assuming that the marker we looked at is the same when determining the use of 2L treatment.",9
respect,Territory, E. TN,12.7058823529,1.0185475299e-06,20,122,"Regional meeting TL stated "" PD-1, PD-L1 and CTLA4 are not the whole story with respect to the immune system, there is much more that we need to find out""","With respect to Opdivo ""Cancer is the nail and you guys own the hammer""","With respect to 026, KOL in my territory noted, ""So single agent Nivo didn't meet PFS end point, big deal!  We're all waiting for the combination data with ipilimumab anyway in the front line!""",142
GBM,Territory, E. TN,5.34984520124,1.98248897721e-05,49,79,"Neuro-ONC stated that they look forward to seeing OPDIVO + OPTUNE in GBM patients.  When asked why she thought this combination would benefit patients she stated that OPTUNE will keep the tumor at bay, giving Opdivo time to mount a response.  She is an OPTUNE speaker, and stated that she will be submitting an ISR for this concept, and has already been told by NOVOCURE that they would like to participate jointly with an IO company.","Neuro-ONC stated that in ""slow growth"" recurrent GBM patients that he will try combinations of Opdivo, Opdivo+Bev, Opdivo+Yervoy.  Has had limited success with each possible, but stated that ""limited success is still success in GMB.""","Neuro-ONC stated that 18months is her average from initial diagnosis with GBM to death.  Recurrence at about 10-12 months and roughly 6 months post recurrence till death.  Patients where recurrence isn't until 20months are on the far end of the GBM spectrum, and not representative of the normal patient.  Stated this in discussion around the Pembro GBM population of -028.",128
IO therapy,Territory, E. TN,4.65051903114,1.63145940311e-05,64,26,"When asked what his criteria was for determining treatment beyond progression for RCC, National Thought leaders stated, that if the progression appears to be a ""slow growing"" or 1-2 new lesions, he will treat beyond this ""progression"" because he feels this is likely an IO induced progression/Non-traditional response.

However, if the primary grows rapidly, or if there are more than 2 new lesions then that is most likely true progression and it is unlikely that continuing IO therapy will sway the balance.",A National Lung TL stated that she thinks that Chemotherapy plus IO therapy is a mistake.  The tails of the OS curves will minimize 1L IO therapy because basically you are giving chemo to patients that don't need it.  So when those patients come off treatment because of the toxicities (likely from the chemo) you have lost the benefit of the IO therapy.,"A National Thought Leader (and NCCN member) stated that she feels community treaters of NSCLC with IO therapy are not experienced enough to treat appropriately.  She stated she has patients that show up to her that are 6 months past NSCLC diagnosis and have gone through sometimes 2 IO agents (used one PD1 fail, try other PD1).  

She says that she does not think community treaters wait long enough for IO agents to work and are too quick to call a treatment ""a failure"" and aren't providing the patients immune system with enough time to actually mount a response.

Too often they are associating a decrease in performance status, or more often, AEs with no tumors shrinkage seen within the first 3-6 weeks as an IO failure when that may not be the case.",90
Verdict,Territory," EAST
PA",869.428571429,2.31460897365e-05,2,5,"?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians","Additional Insights gathered from Profiling Discussion

Mehra moving to Hopkins- starting September 6.
Dr. Olshanski is going to be acting chair directory of the department ? HEM/ONC
Dr. Jessica Bauman ? taking over Mehra?s trials and H/N and Lung patients
              
o	In general, she sees the entire spectrum of H&N cancers at FCCC, principally oropharynx
o	Will employ Extreme Regimen in r/m setting
o	Having used cetuximab as part of extreme, single agent systemic therapy choices is wide open, and highly dependent on patient characteristics
o	P16 testing is routinely done at this institution
o	In terms of PD-L1 testing, Not routinely done for H&N pts, bu] FCCC ran many of the PD-1 trials.  Testing has become ?routine? as part of the protocols.  Specifically for H/N, not convinced that testing is mandatory and negative patients are still conferred benefit.  Verdict is still out. 
o	Current Treatment Gaps
?	Problem with PD-1 monotherapy up front 
?	ORR while acceptable, they are still quite low.  
?	There is a delayed benefit with PD-1 monotherapy that may be unacceptable for patients with very aggressive bulky disease
?	Most clinicians would find it unethical to give PD-1 therapy in this setting.
CI
o	KESTREL Trial ? Opening at FCCC 
?	NCT02551159
?	Phase III Open Label Study of Durvalumab With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
?	Local Investigator ? Dr. Jessica Bauman","Met with a local TL who is a main treater of both Lung/SCCHN at Penn State Hershey on 12/12/16 together with Andy L.
Lung
ESMO data
?	Any difference between pembro and nivo?
o	He said trials/populations are different, but didn?t regard the two agents differently
?	Lung Testing for PDL1
o	Hershey sends all testing out; currently not doing it in house though the goal is to internalize the process in the future
o	While the ?holy grail? of cancer therapy is targeting a specific biomarker, we have a long way to go regarding a good biomarker; PDL1 is not ideal for sure
o	They are able to get enough tissue for PDL1 testing. Tissue procurement is not an issue for them in lung
o	He said if a patient is 45% or greater PDL1 he might try to get them pembro
o	If 50% or higher no brainer to get pembro
o	He expects the % of patients that will be positive (>50%) to be lower than the CM-024 study %
?	1L Treatment
o	Has no problem treating a 1st line patient with chemo is they have a good PS. 
o	When patients get to second line, they are much worse PS and won?t be able to get chemo and IO becomes a much better option
o	They see very few EGFR and alk patients
o	They get the traditional heavy smoker and drinker
o	They haven?t been seeing many stage III lung patients, either get very early or very late patients
?	IO agents are overall very safe from and overall AE standpoint
o	Has run into some hypothyroid but he said it is very easy to manage
o	Has seen 1-2 cases of colitis but managed with dose interrupt and steroids
o	No hypophysitis/hepatitis or pneumonitis
o	They test for TSH every 6 weeks in lung but more frequently in H&N
?	SCCHN
o	Hershey is participating in the RTOG3504
o	EXTREME regimen
?	Sees value in using EXTREME if PS is good enough
?	?EXTREME regimen is very EXTREME? but still the best data is there
?	He said he has patients on each drug (P and N)
?	He did not differentiate between Pembro and Nivo in H&N
?	He has requested that patients be started on nivo prior to approval however
o	HPV+ patients respond well to therapy but relapse
o	Reiterated QOL is very good for nivo (discussed PROs from CM141); noted similar anecdotal QOL seen with Pembro",7
Phase III,Territory," EAST
PA",62.1020408163,4.84426515258e-05,23,775,"Additional Insights gathered from Profiling Discussion

Mehra moving to Hopkins- starting September 6.
Dr. Olshanski is going to be acting chair directory of the department ? HEM/ONC
Dr. Jessica Bauman ? taking over Mehra?s trials and H/N and Lung patients
              
o	In general, she sees the entire spectrum of H&N cancers at FCCC, principally oropharynx
o	Will employ Extreme Regimen in r/m setting
o	Having used cetuximab as part of extreme, single agent systemic therapy choices is wide open, and highly dependent on patient characteristics
o	P16 testing is routinely done at this institution
o	In terms of PD-L1 testing, Not routinely done for H&N pts, bu] FCCC ran many of the PD-1 trials.  Testing has become ?routine? as part of the protocols.  Specifically for H/N, not convinced that testing is mandatory and negative patients are still conferred benefit.  Verdict is still out. 
o	Current Treatment Gaps
?	Problem with PD-1 monotherapy up front 
?	ORR while acceptable, they are still quite low.  
?	There is a delayed benefit with PD-1 monotherapy that may be unacceptable for patients with very aggressive bulky disease
?	Most clinicians would find it unethical to give PD-1 therapy in this setting.
CI
o	KESTREL Trial ? Opening at FCCC 
?	NCT02551159
?	Phase III Open Label Study of Durvalumab With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
?	Local Investigator ? Dr. Jessica Bauman","?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians","Spoke with Director of Medical Oncology and Hematology at UPMC
on 12/6/2016 together with Andy Lepisto

Spoke about blueprint data and the slide from asco 2015 showing difference in PDL1 expression on top vs bottom of the slide
3.	Explained that one of his patients tested 0% PDL1+ before chemo and then tested again after chemo and was 90% PDL1
a.	He said in general PDL1 test(s) are currently inadequate; UPMC performs two different tests (different platforms - Ventana/Dako 22C3) to confirm expression
4.	He said he doesn?t really know about the pathology details around which clone of antibody used for PDL1 test
5.	Discussed the 026 data at ESMO and the H&N approval and placement on the VIA pathways
6.	We spoke about 227 design and combo dosing moving forward
7.	He asked if we are still using a 1% or 5% cutoff in 227
8.	Talked about phase I vs Phase III data deciding factor for nivo vs pembro in H&N pathway
a.	Ellis was very direct and stated phase I data should not be used for FDA approvals",798
o,Territory," EAST
PA",51.7517006803,4.74033032536e-07,46,220,"?	How are panelists thinking about the first-line lung space?
?	1L story is set
?	Testing will help to select those pts likely to respond up front
?	PD-L1+ High expressors are going to get PD-1 monotherapy
?	PD-L1(-) pts 
?	I would never offer up front mono-therapy in these patients
?	If patient presents with EGRF or ALK mutations, I would not give them up front PD-1 monotherapy
o	Traditional treatment is indicated here; combo therapy could challenge this
o	Unmet need still exists for the non-smoking population 
?	Verdict is still out on testing with combo
?	1L phase III trial ? should bring clarity to this question
o	Discussed high rate of PD-L1 screen failures for 1L Atezo study in his patients. Interested in whether geographic region has implications on PD-L1 expression (are there more high PD-L1 expressors in tobacco regions?)
o	Thoughts around IO sequencing with chemo, IO combined with chemo, IO monotherapy, and/or IO combination therapy
?	Combo regimens will require major educational efforts especially at the community setting
?	Input on the ASCO presentation on CM-012 
o	Strengths/limitations/gaps in the data/next steps in 1L space
?	I do worry about combos, and not necessarily only ipi/nivo but the combos in general
?	In particular, toxicities associated and general lack of knowledge in how to manage them; more education on safety management needed ? consider including management algorithms in publications
?	Despite favoring responses in the Ipi q12w arm, Q6w makes sense to move forward with due to imbalance of arms 
?	Issues: How do we explain ?Stable? disease?
?	This is a phenomenon that we are seeing with many patients and from a patient standpoinTime to next treatment?
?	Might be useful
o	Also consider highlighting duration of response
?	At some point the smoking situation is going to have to be addressed head on

?	Input on 2L NSCLC 
?	Felt the story for monotherapy in 2L NSCLC is clear and solid
?	CI
o	?With the Merck announcement, testing up front will become standard?
o	I don?t believe you guys are going to get an FDA label in ?all comers; the label will specify cutoffs studied in the trials? 
?	?That?s where Merck has you beat; they already have their tests in central labs; you need to get your test in there prior to publication?
?	?Nivo Advantage will be that 5% cutoff captures higher % of NSCLC patients than the 50% cutoff than Merck is pursuing?
?	Institution is currently ?getting labs ready? for mass PDL1 testing in anticipation of the 1st line indications 
?	Cytoscore 
o	Garnering interest from Interest Industry (Lilly-Celgene) / Clinicians","Met with a local TL who is a main treater of both Lung/SCCHN at Penn State Hershey on 12/12/16 together with Andy L.
Lung
ESMO data
?	Any difference between pembro and nivo?
o	He said trials/populations are different, but didn?t regard the two agents differently
?	Lung Testing for PDL1
o	Hershey sends all testing out; currently not doing it in house though the goal is to internalize the process in the future
o	While the ?holy grail? of cancer therapy is targeting a specific biomarker, we have a long way to go regarding a good biomarker; PDL1 is not ideal for sure
o	They are able to get enough tissue for PDL1 testing. Tissue procurement is not an issue for them in lung
o	He said if a patient is 45% or greater PDL1 he might try to get them pembro
o	If 50% or higher no brainer to get pembro
o	He expects the % of patients that will be positive (>50%) to be lower than the CM-024 study %
?	1L Treatment
o	Has no problem treating a 1st line patient with chemo is they have a good PS. 
o	When patients get to second line, they are much worse PS and won?t be able to get chemo and IO becomes a much better option
o	They see very few EGFR and alk patients
o	They get the traditional heavy smoker and drinker
o	They haven?t been seeing many stage III lung patients, either get very early or very late patients
?	IO agents are overall very safe from and overall AE standpoint
o	Has run into some hypothyroid but he said it is very easy to manage
o	Has seen 1-2 cases of colitis but managed with dose interrupt and steroids
o	No hypophysitis/hepatitis or pneumonitis
o	They test for TSH every 6 weeks in lung but more frequently in H&N
?	SCCHN
o	Hershey is participating in the RTOG3504
o	EXTREME regimen
?	Sees value in using EXTREME if PS is good enough
?	?EXTREME regimen is very EXTREME? but still the best data is there
?	He said he has patients on each drug (P and N)
?	He did not differentiate between Pembro and Nivo in H&N
?	He has requested that patients be started on nivo prior to approval however
o	HPV+ patients respond well to therapy but relapse
o	Reiterated QOL is very good for nivo (discussed PROs from CM141); noted similar anecdotal QOL seen with Pembro","?	Bleo shortage is a affecting practice
o	Internal Guidance is that a list of patients be maintained
o	Bleo is dispensed according to ?greatest? need
?	I.e. pts who are able to tolerate and have most aggressive disease
o	Personally feels that bleo can be omitted from front line therapy for most patients
?	Retrospective Analysis shows bleo added value seems questionable
?	However, in the absence of more robust data, will continue to use in appropriate patients
?	Will continue to remove Bleo ?whenever possible?, for example those that develop pneumonitis or rash
o	Seeing about 20% rash with Bleomycin, which she feels is suprising.
?	Nivo 
o	Currently has a patient where she is considering using Nivo prior to transplant (Patient has failed ABVD, ICE, Brentuximab, Bendamustine x 4 doses. Considering Nivo then Allo transplant) 
o	Views Nivo has a ?bridge? to Allo transplant ? however data is not clear
o	Believes Nivo will definitely have a role in earlier lines of therapy, but is cautions to make assertions in the absence of appropriate data
?	Still waiting on further data regarding adding Brent to AVD therapy, in the absence of Bleomycin. Is interested in doing so, but would feel comfortable with more data. They did participate in the clinical trial, so it?s not totally out of her line of comfort.",266
cHL patients,Territory, East,29.2007797271,1.07345906015e-10,31,150,"TL interested in using Nivo in a cHL patient who is post Auto, post brentuximab and post Allo transplant. The patient had experienced acute and chronic GVHD post transplant, managed with steroids and Rituxan. Patient is stable, no signs of GVHD at this point.","TL mentioned that he would like to use Nivo in a cHL patient who is post ASCT, post brent (26 y/o patient). They had the 205 trial open, but since it is closed, his concern is getting the product paid for prior to approval. His other concern is post approval, if this will not be our indication, will he still face access issues. He was able to be connected with the ARM to assist in coverage concerns.",TL mentioned that he has 2 RR cHL patients that he has prescribed Nivo+BV for. Both are post allo.  He has not seen any AEs of concern and no GVHD of note.,181
bleomycin,Territory, East,18.4938271605,2.74552048004e-05,25,100,RTL mentioned that he avoids Bleomycin in all patients > 60 y/o. Brentuximab is very effective alone with decent PFS. Other options for these patients are BV + DTIC or BV + Bendamustine.,A RTL mentioned that he is starting to substitute brentuximab for bleomycin in ABVD.,"LTL shared that in dealing with the bleomycin shortage at her institution in Philadelphia, they are maintaining a list of patients needing Bleomycin as part of their therapy. Bleo will then be dispensed to those who are in ""greatest need"", i.e. patients who are able to tolerate tx and have the most aggressive disease.",125
RTL mentioned,Territory, East,16.6444444444,7.26641919039e-06,27,0,Leukemia RTL mentioned that a colleague of his is giving pembrolizumab q4weeks post CAR-T therapy for cHL.,A RTL mentioned that he is starting to substitute brentuximab for bleomycin in ABVD.,"RTL mentioned that for patients that cannot tolerate bleo, or the elderly cHL patients, he will substitute BV 1.2mg/kg q2weeks. There is ""some data"" here which is good enough to consider using BV here.",27
TL mentioned,Territory, East,12.329218107,3.10368286535e-05,43,30,"TL mentioned that he has a young NHL patient who received RCHOP then RICE then CAR-T therapy, and failed all lines quickly. He is currently receiving Ipi/Nivo and doing well.",TL mentioned that he has treated 40+ patients with pd1 inhibitors and is interested in writing up his experiences for ASCO 2017.,TL mentioned that he has 2 RR cHL patients that he has prescribed Nivo+BV for. Both are post allo.  He has not seen any AEs of concern and no GVHD of note.,73
post,Territory, East,12.2059259259,2.56441792319e-08,69,146,"TL interested in using Nivo in a cHL patient who is post Auto, post brentuximab and post Allo transplant. The patient had experienced acute and chronic GVHD post transplant, managed with steroids and Rituxan. Patient is stable, no signs of GVHD at this point.","TL mentioned that he would like to use Nivo in a cHL patient who is post ASCT, post brent (26 y/o patient). They had the 205 trial open, but since it is closed, his concern is getting the product paid for prior to approval. His other concern is post approval, if this will not be our indication, will he still face access issues. He was able to be connected with the ARM to assist in coverage concerns.","Local TL who treats cHL said the approval of Nivo for r/r cHL was a huge development for those who fail ASCT and post ASCT brentuximab.  He did state that it would not typically affect his practice in that once the cHL patient was sent to transplant center, he typically does not see the patient again.  All follow up was done at transplant center.",215
HL,Territory, East,10.0875420875,6.06141161137e-06,51,171,"NP mentioned that she has truly witnessed Nivo saving lives of HL patients. ""It has been miraculous for so many of our HL patients"".","RTL mentioned that he has 1 patient, of 6 receiving nivo for HL, who had a prior allo transplant and the patient is doing well.",RTL stated that he has had great success with obtaining Opdivo off label for treatment of HL patients through BMS access support.,222
cHL,Territory, East,9.49025341131,2.2968920432e-08,116,190,"TL interested in using Nivo in a cHL patient who is post Auto, post brentuximab and post Allo transplant. The patient had experienced acute and chronic GVHD post transplant, managed with steroids and Rituxan. Patient is stable, no signs of GVHD at this point.","TL mentioned that he would like to use Nivo in a cHL patient who is post ASCT, post brent (26 y/o patient). They had the 205 trial open, but since it is closed, his concern is getting the product paid for prior to approval. His other concern is post approval, if this will not be our indication, will he still face access issues. He was able to be connected with the ARM to assist in coverage concerns.","Local TL who treats cHL said the approval of Nivo for r/r cHL was a huge development for those who fail ASCT and post ASCT brentuximab.  He did state that it would not typically affect his practice in that once the cHL patient was sent to transplant center, he typically does not see the patient again.  All follow up was done at transplant center.",306
q3week,Territory, FL,53.4642857143,8.84806558955e-06,7,4,"RTL does not see a major difference at this time between efficacy of Nivo, Pembro, and Atezo. Referred to them as coke, pepsi, and RC cola. Says that prefers q3week dosing rather than q2week as a convenience factor. RTL will be interested to see how maintenance q4week studies in Nivo result. He feels all three could likely be given q4week and be just as effective.","RTL stated that perhaps Atezo may have a slight upper hand now due to q3week dosing versus q2 week, but team still in the process of deciding where this will fit in their pathways.",RTL states that PD-1 inhibitor is now the standard of care in platinum refractory patients in rec/met setting. Either Nivo or Pembro are options. Has been using pembro since received FDA approval in August. Will use nivo also. Mentioned the q3week may be preferred for patients who have to travel long distances to the clinic.,11
rec/met setting,Territory, FL,30.5510204082,3.97543550583e-05,10,408,"Per HCP Platinum typically used in frontline LAD, therefore, prefer not to use EXTREME regimen or platinum in rec/met setting. Concern with toxicity and especially renal toxicity. If used EXTREME may use carbo instead of cisplatin or modify the dose. Options include Erbitux, radiation, taxane. Now preferred agent Nivo, and HCP has several patients on treatment thus far.","TL preference for rec/met setting now Nivo, except would prefer EXTREME regimen in patients with bulky disease. Prefers to save taxane for later down the line.",RTL states that PD-1 inhibitor is now the standard of care in platinum refractory patients in rec/met setting. Either Nivo or Pembro are options. Has been using pembro since received FDA approval in August. Will use nivo also. Mentioned the q3week may be preferred for patients who have to travel long distances to the clinic.,418
front,Territory, FL,22.9132653061,1.65094708091e-06,52,0,"RTL ss standard, now screening patients up front for PDL1 and notes about 20-25% thus far are > 50 % PDL1. Of the 4 patients he has given up front pembro to, he has 2 responding.",Per RTL all patients will be tested for PDL1 up front and expects about 2/3 of patients to have enough tissue for testing. They will offer pembro to patients with >50% PDL1 expression in 1L.,"TL stated in the front line setting for advanced metastatic NSCLC likely not using as much pembro as they should or could for the main reason of inefficiency in PD-L1 testing. All testing at their local facility is sent out and takes several weeks to return a result. Patients are anxious to get started on treatment during that interim. Therefore, they are started on chemotherapy. If the patient is doing well and responding, then once the PD-L1 test is available (if even enough tissue to run), then patient not likely to be changed to pembro at that time regardless of results. In their particular clinic, Nivo remains standard as second line in NSCLC.",52
second line,Territory, FL,7.74844720497,3.97324784642e-06,78,247,"Per HCP Platinum typically used in frontline LAD, therefore, prefer not to use EXTREME regimen or platinum in rec/met setting. Concern with toxicity and especially renal toxicity. If used EXTREME may use carbo instead of cisplatin or modify the dose. Options include Erbitux, radiation, taxane. Now preferred agent Nivo, and HCP has several patients on treatment thus far.","Per NP/HCP who works with NTL, does not feel that there is a big difference in Nivo versus Atezo in second line setting; however, prefers Nivo simply out of habit. Has history with Nivo and not inclined to change.","RTL sees no role for Atezo in the second line, and plans to keep Nivo as standard of care in this setting.",325
RTL,Territory, FL,3.7262987013,2.36314317596e-06,690,801,"RTL noted results of KN-021, but prefers sequencing chemo-IO rather than combination therapy up front.","RTL sees no role for Atezo in the second line, and plans to keep Nivo as standard of care in this setting.","RTl notes Foundation one reporting tumor mutational burden on reports, but not using at this time to guide treatment decisions.",1491
tolerance,Territory, GA,239.289473684,3.21366071546e-06,4,0,"NSCL metastatic lung pt who was treated with opdivo in academia with good tolerance and improved ECOG, however was found to have progressive disease on imaging while under care in academia and was switched to chemotherapy. The current oncology practice would like to offer him treatment with opdivo again if disease progression on chemo noted. Request for information on resuming opdivo therapy. MIRF was sent.","nsclc patient with presumed hx of colitis in the past who has been treated with opdivo and developed  G2 diarrhea. he was evaluated with colonoscopy that showed mild colitis. complete resolution with steroids however, patient has refused to continue with opdivo despite noticeble improvement in tumor burden. subsequent disease progression and poor tolerance of cytotoxic therapy. Decision to resume opdivo, subsequent diarrhea grade 2. opdivo was placed on hold, prednisone initiated and patient was  further kept on prednisone 10mg po qd and continued on opdivo with good response.",large GYN oncology practice has used opdivo in ovarian cancer with good tolerance and results in one patient. Opdivo was offered for another patient who refused treatment after reading about potential side effects.,4
oncology,Territory, GA,14.8396572827,6.58994130154e-07,97,148,"Pharmacist in a large hematology/oncology practice in Tupelo, MS stated that PI for opdivo  is not clear if premedication is needed. This practice has been premeditating with steroids due to it being a monoclonal antibody. discussed that in ordering guide it is stated that premedication including corticosteroids is not required.","Provider in VA reported a new decision in oncology clinic to no longer request opdivo use if not FDA approved for a specific tumor type. Previously, a non formulary request was filed in order to obtain drug that may not be FDA approved but is being studied.","regional TL has expressed his opinion re: more favorable billing to hospitals vs. private oncology practices based on recent publication by genentech on therapies cost sold to hospitals. TL expressed his concern that 430 billing is what is making a negative impact on revenue for private practices and growing difficulty to compete. He suggested that BMS will follow Genentech example and publish its data on chemo costs to the hospital thus "" uncovering one of the primary drivers of rising drug costs""",245
practice,Territory, GA,8.25136116152,1.32760286486e-05,258,718,"Pharmacist in a large hematology/oncology practice in Tupelo, MS stated that PI for opdivo  is not clear if premedication is needed. This practice has been premeditating with steroids due to it being a monoclonal antibody. discussed that in ordering guide it is stated that premedication including corticosteroids is not required.",physician in a large oncology practice has been changing opdivo schedule to q 3 weeks after patients were on the therapy for a year with good results. Stated that he observed that patient continue to respond after changing schedule to q 3 weeks.,large practice in california has been using opdivo in non-hodgkins lymphoma off label  with very positive results.,976
NCCN center in the midwest stated,Territory, IA,665.777777778,4.51805282813e-20,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
exercise,Territory, IA,277.407407407,1.3367760794e-08,5,238,"During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment he was surprised the FDA will allow Merck to have labeled indication without a comparator arm in their trials given the fact that there is a drug with proven efficacy that has a comparator arm","During a profiling exercise with a H&N panelist at an NCCN center, AI stated he defines refractory the same as we defined it in 141 (which he stated is a better design that the Pembro trial where you had to fail both cetuximab and a platinum therapy)","During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment the Nivo QOL is ?the best,? and he will highlight that data at his next post ASCO talk. He believes that data is impactful. He mentioned Pembro doesn?t have that data",243
P&T committee,Territory, IA,110.962962963,3.54720996095e-09,8,478,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",486
NCCN center,Territory, IA,83.2222222222,1.65488363827e-12,26,280,"P&T committee member/lung AI at an NCCN center stated the following

o	When asked if cost/cost avoidance discussion are part of their formulary discussions, he stated they are minimized at his institution. He stated decisions are NCCN/FDA approval/data driven.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",306
AI stated,Territory, IA,70.6127946128,6.07932796822e-18,24,171,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",195
payor,Territory, IA,55.4814814815,7.7146791151e-06,7,23,"For a small regional health plan assosicated with a national account institution (~200K lives): While discussing oncology management, the payor stated that he is excited to hear that there will be more PD1's enter the market as they will be able to manage the class; however, he stated it will be nearly impossible to manage the class if the indications vary from drug to drug. He cited the example of the TNF class of drugs where they are unable to restrict certain drugs due to niche indications. This specific plan does not currently manage oncology.","Specialty pharmacist at an academic SP stated he believes that I/O therapy will eventually be billed under the pharmacy benefit as PBMs will want to demonstrate their value in an increasingly generic blended market. As the health system with an integrated payor looks at total cost of care, he thinks the payor will demand white bagging as a cost saving through their own SP; however, he was uncomfortable with the concept of an outside SP delivering an infusible to his infusion clinic.",Regional payor stated they have a waste billing limit of 40 mg due to the vial size of Opdivo,30
order sets,Territory, IA,44.3851851852,1.36726717016e-05,8,321,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),329
reactive discussion,Territory, IA,36.987654321,2.24373460899e-05,9,310,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","?	While proactively discussing 2 year OS for 057/017, the reactive discussion led to 026. We discussed trial designed etc. We then began to discuss the 2L space in which the AI stated their system will likely begin to use atezo based on no testing and Q3 weeks (convenience) for traveling patients and chair time.  
?	The AI then discussed 227 (enrollment site)
?	This led to a reactive discussion on the early 012 data which demonstrated nearly a doubling ORR based on expression levels
?	The AI then led a discussion on what a treating physician would do if a patient was progressing on Nivo and the 227 reads out positive for regimen (would a treating physician add ipi?)
o	AI believed more data is need; however, this is an area of needed exploration
o	There is no data with Atezo or Pembro to add Ipi at Q 6 weeks","Advisor to the panelist at an NCCN center in the midwest stated, after a reactive discussion on the 227 trial design, that BMS should decide on one dose for the regimen (referencing 032 for SCLC). He stated different doses will increase confusion and errors if we use multiple doses in different tumors.",319
advisor,Territory, IA,35.8997821351,2.52019345726e-12,27,231,Advisor to the panelist at an NCCN center in the midwest stated Atezo won't be considered for formulary addition because they are so accustomed to using Nivo and it's challenging to change habits,"Advisor to the panelist at an NCCN center in the midwest stated that based on the 026 data, he'd like to offer Nivo in 1L","Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.",258
build,Territory, IA,31.7037037037,3.47169711024e-05,10,21,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),31
midwest,Territory, IA,26.4197530864,2.28687188179e-10,42,124,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,166
expression levels,Territory, IA,25.2188552189,8.25746972402e-06,41,170,"Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Payor insights from ~4 million life plan in the Midwest provided the following insights. They are not looking to manage PD1 inhibitors by PDL1 expression levels. He indicated the science is too new and there are too many unanswered questions.  Payor stated the PDL1 expression is informative, but not definitive. PDL1 expression is not in the PA criteria yet. He stated there is not an ICD10 code for PDL1 expression (+/-).",211
unsolicited,Territory, IA,23.1172839506,1.15082831901e-05,99,200,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",299
perspective,Territory, IA,20.440545809,4.16172070494e-07,25,0,P&T pharmacist chair at an NCCN center in the midwest stated that cost data (ie Nivo vs docetaxol lung-tx related adverse events-not shared) is irrelevant to them when there is a clear winner from a clinical trial in either efficacy OR safety from an institutional P&T perspective.,"Director of pharmacy at an NCCN center stated that from an operational perspective, there is an increase in human resources needed to use access support programs(foundation portion) (ie paperwork/drug management/dispensing cost). While these programs are important for the patient, they are expensive for her to implement because the pharmacy does not receive reimbursement for their role in drug delivery when drugs are received from foundations thereby increasing her ""costs.""","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",25
chair,Territory, IA,19.4185185185,5.51974824579e-07,26,260,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",286
panelist,Territory, IA,18.9448961156,3.1607756734e-12,134,164,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",298
minimal,Territory, IA,17.337962963,3.54520976813e-05,20,0,"During a profiling exercise, an NCCN H&N panelist offered the following unsolicited insights:
?	When asked how he treats LA-SCCHN he stated the following
o	First surgery
?	After surgery with minimal dz, pt would get RT
?	After surgery with moderate dz, pt would get a plateium therapy
?	After surgery with bulky dz, pt would get chemo/RT
?	He does not test for PDL1 expression but does test for P16
?	Research gaps-he?s like to see a trial sequencing I/O then chemo. He believes patients respond to chemo better post I/O.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",20
o,Territory, IA,13.1403508772,2.46870343135e-07,46,220,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Eric Mortenson and I met with a HL NCCN panelist for a profiling exercise. Below are NCCN related insights.

The panel meets every 12-18 months in person. The next panel meeting is August; however, he stated we should expect an update to the guidelines within 6 weeks.
?	How their update approval process is designed:
o	An admin sends out the proposed guidelines for comment from the rest of the panelists via email. AI stated the ?very loud? panelists typically get their way. He stated the PD-1?s have been sent out for review and ?you will be happy with the outcome.?
?	When asked what data is needed for an NCCN update, he stated heavier weight is given for FDA approvals; however, phase II or better data will be reviewed. He stated there was not a standard endpoint required for a given category rating (ie OS for category 1).

Each panel operates independantly with their own set of rules.",266
NCCN panelist,Territory, IA,12.1050505051,7.01776707208e-09,94,149,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,243
AI,Territory, IA,7.74160206718,5.1473269505e-07,121,70,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",191
nurse,Territory, IN,20.472972973,1.57510891405e-05,41,193,"Presented at a local ONS meeting, attended by 25 RNs/APRNs of several different clinical settings.  A hospice nurse has been active in getting Opdivo for some of her hospice patients, recognizing the possibility of a delayed response.  She has been able to work with different parts of Medicare and/or insurances to get therapy paid.","A very large community cancer center has a core group of nurses as a designated triage center.  Unfortunately, few of them had any experience/knowledge of immuno-oncology therapies.  They were educated on recognition/management of IMARs, which will hopefully impact safety of the many patients they have receiving our drugs.","Presented the pan tumor deck to a group of nurse navigators.  Reaction was very positive at the efficacy data, though safety was a concern.  Most comments related to the need for a specific method in busy offices to differentiate a patient receiving immuno-oncology therapies to facilitate early recognition of IMARs as well as proper management. They were enthusiastic about our resources (checklist, wallet card, etc) that will help them to identify AEs.",234
lots,Territory, IOCL Lead - HEME,182.7,3.30643500142e-06,12,0,"LTL with lots of Opdivo experience, need better guidance in treating endocrine and other adverse effects from the company-tired of hearing the clinical trial data of what BMS did.  LTL is very familiar with our approved materials the reps and medical can leave behind.  Drug has been out long enough now we should have retrospective data/pooled analysis of other management treatments. Most of his male patients feel ""bad"" while they receive Opdivo.  No guidance on who to treat the drop in testosterone, etc. Would like better management.","LTL at a large community practice stated that he is, ""very impressed"" with the response rates of OPDIVO in cHL patients.  He stated he has had a cHL patient on therapy for over a year, due to hospitalization, etc scanning schedule has been ""messed up"" his experience with solid tumors he does not always place a lot of merit on scanning. Lots of solid  tumor experience and has had no real problems to date in administrating Nivo. Had no concerns with Allo data when the cHL deck was presented.","LTL (community physician) has treated several patients (5) with Opdivo in cHL. He said it is per label, he is using opdivo after transplant failure/ bren failure.  He noted that patients fail bren more often then you would think due to neuopathies and/or other side effects.  LTL has lots of experience with Opdivo in other tumors and patients feel much better receiving Opdivo vs. BV.",12
Colorado,Territory, IOCL Lead - ST2- North,412.909090909,1.92931724232e-06,3,292,"Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.","NP attending dinner program in Colorado indicated that the provider she works with was unfamiliar with what labs should be drawn on IO patients and did not know rationale for drawing TSH, etc.  Stated she would be taking information from the dinner back to the practice and will help implement a change in order sets to insure that appropriate labs are being done on their IO patients.","Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.",295
Denver,Territory, IOCL Lead - ST2- North,412.909090909,1.92931724232e-06,3,80,"NP attending dinner program in Colorado indicated that the provider she works with was unfamiliar with what labs should be drawn on IO patients and did not know rationale for drawing TSH, etc.  Stated she would be taking information from the dinner back to the practice and will help implement a change in order sets to insure that appropriate labs are being done on their IO patients.","Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,83
suburban,Territory, IOCL Lead - ST2- North,412.909090909,1.92931724232e-06,3,421,"Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.","Opportunity to meet with 5 physicians at large suburban Chicago practice.  Several insights gained during discussions held as part of being there for a lunch presentation:

* Physician indicated he would not use Regimen for patients due to increased toxicities.  Discussed data for PFS and ORR in 067.  Also shared experience in early recognition and management of IMARs.  He then proceeded to say it was really due to patient's PS that he went with monotherapy.  His colleague overheard conversation and stated he would use Regimen for his eligible patients due to the better efficacy profile.  Same physician thought Nivo was a Pfizer agent - corrected misconception.

* Physician unaware of 2L approval in RCC - data shared

*Physician unaware of 2L approval in non-squamous NSCLC, data shared.  Same physician stated he hadn't seen much benefit in using Nivo, but also stated he has treated several squamous histology patients.  Noted he is also treating a small cell patient off label with Nivo

*Physician stated he didn't know how we (especially me as a clinician) could be positive about our IO agents due to their extraordinary costs and drain on the economy.  Allowed physician to verbalize his frustrations and shared the importance of all parties coming to the table to try and provide best quality care for all patients while being economically responsible

* Physician questioned use of Infliximab for diarrhea/colitis.  Stated he knew a physician colleague who had a patient in hospital on an IO agent with severe diarrhea.  Reviewed algorithms, use of consultative services and importance of early recognition and management of IMARs

* Physician shared he would see Opdivo as good 2L option for patients with met RCC, currently has 2 patients on treatment (with RCC)

* Physician commented on latest approval in cHL and states this will be a very limited patient population based on the approved indication","While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",424
breakfast,Territory, IOCL Lead - ST2- North,412.909090909,1.92931724232e-06,3,11,"While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.","Small community practice treating an ovarian cancer patient with Nivolumab.  Noted they were very pleased with the BMS program for access of this agent for an off label use and indicated that the patient is doing very well and responding to treatment.
The nursing staff at this facility had little knowledge related to IO agents and a breakfast program done was very well received.  Staff noted that they will start using wallet cards and will begin using IMAR patient checklist in ongoing patient assessment.",At another large community practice where discussion took place during a breakfast lecture regarding steroid use for IMARs. This practice noted that they have not been doing higher doses of steroids and tapers are typically not being done. Patients are being left on treatment while lower doses of steroids are continued. Recommendations/guidelines were reviewed in depth.,14
IMAR management,Territory, IOCL Lead - ST2- North,68.8181818182,1.9330008368e-06,11,373,"While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,Nursing TL from Johns Hopkins spoke at National Meeting and praised the BMS resources for IO patients and providers.  Made special note of the new APP for IMAR management,384
provider,Territory, IOCL Lead - ST2- North,41.8893280632,5.30537646667e-09,29,0,Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,"NP attending dinner program in Colorado indicated that the provider she works with was unfamiliar with what labs should be drawn on IO patients and did not know rationale for drawing TSH, etc.  Stated she would be taking information from the dinner back to the practice and will help implement a change in order sets to insure that appropriate labs are being done on their IO patients.",Community practice large volume TL expressed concern regarding flat dosing for patient slightly <60 kg. Reactive materials shared with provider who was satisfied with this following discussion.,29
nurse,Territory, IOCL Lead - ST2- North,18.5995085995,2.34579490408e-05,41,193,"Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,"Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.",234
indicated,Territory, IOCL Lead - ST2- North,15.2929292929,4.75007595318e-07,79,459,Large community practice indicated they are treating a significant number of patients are being treated with Nivolumab for Breast Cancer.  The provider who shared this was not sure if a specific subset of patients were those treated (I.e.. Triple negative).  Indicated that these patients have been doing very well and experiencing few toxicities.,"Opportunity to meet with 5 physicians at large suburban Chicago practice.  Several insights gained during discussions held as part of being there for a lunch presentation:

* Physician indicated he would not use Regimen for patients due to increased toxicities.  Discussed data for PFS and ORR in 067.  Also shared experience in early recognition and management of IMARs.  He then proceeded to say it was really due to patient's PS that he went with monotherapy.  His colleague overheard conversation and stated he would use Regimen for his eligible patients due to the better efficacy profile.  Same physician thought Nivo was a Pfizer agent - corrected misconception.

* Physician unaware of 2L approval in RCC - data shared

*Physician unaware of 2L approval in non-squamous NSCLC, data shared.  Same physician stated he hadn't seen much benefit in using Nivo, but also stated he has treated several squamous histology patients.  Noted he is also treating a small cell patient off label with Nivo

*Physician stated he didn't know how we (especially me as a clinician) could be positive about our IO agents due to their extraordinary costs and drain on the economy.  Allowed physician to verbalize his frustrations and shared the importance of all parties coming to the table to try and provide best quality care for all patients while being economically responsible

* Physician questioned use of Infliximab for diarrhea/colitis.  Stated he knew a physician colleague who had a patient in hospital on an IO agent with severe diarrhea.  Reviewed algorithms, use of consultative services and importance of early recognition and management of IMARs

* Physician shared he would see Opdivo as good 2L option for patients with met RCC, currently has 2 patients on treatment (with RCC)

* Physician commented on latest approval in cHL and states this will be a very limited patient population based on the approved indication",Nursing staff from a local practice in Denver attending a dinner lecture shared that the provider they work with believes they only need to  treat diarrhea with Imodium for their patients on Opdivo.  They believe they may have seen worsening diarrhea and steroids not initiated.  They were appreciative of being given information on IMAR management and indicated they would be sharing information with the providers at their facility to be sure that they are aware of algorithms for IMAR management.,538
noted,Territory, IOCL Lead - ST2- North,12.4183185236,1.12642455306e-08,144,0,"Following a discussion surrounding the concept of pseudoprogression in IO patients at a Colorado dinner program, a nurse/NP attending a dinner program in Colorado identified that they have treated several patients with Opdivo but notes that while patients seemed to be doing better, their CT scans seemed to show progression of cancer and so they were taken off treatment.  Questioned whether some of these may have been consistent with pseudoprogression and states she will discuss this with provider as future patients are being treated.","Opportunity to meet with 5 physicians at large suburban Chicago practice.  Several insights gained during discussions held as part of being there for a lunch presentation:

* Physician indicated he would not use Regimen for patients due to increased toxicities.  Discussed data for PFS and ORR in 067.  Also shared experience in early recognition and management of IMARs.  He then proceeded to say it was really due to patient's PS that he went with monotherapy.  His colleague overheard conversation and stated he would use Regimen for his eligible patients due to the better efficacy profile.  Same physician thought Nivo was a Pfizer agent - corrected misconception.

* Physician unaware of 2L approval in RCC - data shared

*Physician unaware of 2L approval in non-squamous NSCLC, data shared.  Same physician stated he hadn't seen much benefit in using Nivo, but also stated he has treated several squamous histology patients.  Noted he is also treating a small cell patient off label with Nivo

*Physician stated he didn't know how we (especially me as a clinician) could be positive about our IO agents due to their extraordinary costs and drain on the economy.  Allowed physician to verbalize his frustrations and shared the importance of all parties coming to the table to try and provide best quality care for all patients while being economically responsible

* Physician questioned use of Infliximab for diarrhea/colitis.  Stated he knew a physician colleague who had a patient in hospital on an IO agent with severe diarrhea.  Reviewed algorithms, use of consultative services and importance of early recognition and management of IMARs

* Physician shared he would see Opdivo as good 2L option for patients with met RCC, currently has 2 patients on treatment (with RCC)

* Physician commented on latest approval in cHL and states this will be a very limited patient population based on the approved indication","While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",144
take,Territory, IOCL Lead - ST2- North,11.6312419974,4.48499679929e-05,76,0,"Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.","While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.",At another large community practice where discussion took place during a breakfast lecture regarding steroid use for IMARs. This practice noted that they have not been doing higher doses of steroids and tapers are typically not being done. Patients are being left on treatment while lower doses of steroids are continued. Recommendations/guidelines were reviewed in depth.,76
physicians,Territory, IOCL Lead - ST2- North,8.80872727273,2.02517870968e-05,148,339,"Spoke with NP and Physician at suburban Colorado practice regarding IMAR management.  They have been instituting Medrol dose paks in patients where there is suspicion of an IMAR and have taken the approach that ""if the patient improves, we know it is an IMAR and if they don't, we feel it is something else.""  Took this opportunity to review IMAR management algorithms with them and how their current approach could potentially lead to wrong conclusions on either side.  Also discussed appropriate dosing of steroids based on algorithms and the appropriate tapering schedule / criteria for re-institution of agent.","While doing a breakfast IO presentation at a suburban Chicago practice, one of the physicians joined the discussion.  He listened as I discussed IMAR recognition and management and at the end of the presentation became quite vocal on the following topics:
- Described the Opdivo commercial as ""sleezy"" and noted BMS is just trying to get more patients on their drug
-Indicated he is using ""Keytruda"" in a SCCHN patient and pointed out that they got the indication before BMS and didn't need a commercial
-Brought up the ""Negative"" 026 trial and asked if BMS would be cutting back on TV time now 
-Discussed the enormous cost of Ipi and Nivo and questioned if it was worth giving it to patients since it is such a ""toxic"" drug

Obviously, this was a challenging discussion.  The physician was allowed to do the venting.  It was shared that my goal was to help provide education to his staff to help them.  I reinforced data, noting that approvals were based on Phase III studies, included that IMARs were noted in all trials, but manageable when identified and managed early and shared incidence rates of IMARs
Interestingly, at the end of the discussion, he did want a copy of the IMAR management booklet and took information on how to download the APP.  He also took my business card.","Opportunity to meet with 5 physicians at large suburban Chicago practice.  Several insights gained during discussions held as part of being there for a lunch presentation:

* Physician indicated he would not use Regimen for patients due to increased toxicities.  Discussed data for PFS and ORR in 067.  Also shared experience in early recognition and management of IMARs.  He then proceeded to say it was really due to patient's PS that he went with monotherapy.  His colleague overheard conversation and stated he would use Regimen for his eligible patients due to the better efficacy profile.  Same physician thought Nivo was a Pfizer agent - corrected misconception.

* Physician unaware of 2L approval in RCC - data shared

*Physician unaware of 2L approval in non-squamous NSCLC, data shared.  Same physician stated he hadn't seen much benefit in using Nivo, but also stated he has treated several squamous histology patients.  Noted he is also treating a small cell patient off label with Nivo

*Physician stated he didn't know how we (especially me as a clinician) could be positive about our IO agents due to their extraordinary costs and drain on the economy.  Allowed physician to verbalize his frustrations and shared the importance of all parties coming to the table to try and provide best quality care for all patients while being economically responsible

* Physician questioned use of Infliximab for diarrhea/colitis.  Stated he knew a physician colleague who had a patient in hospital on an IO agent with severe diarrhea.  Reviewed algorithms, use of consultative services and importance of early recognition and management of IMARs

* Physician shared he would see Opdivo as good 2L option for patients with met RCC, currently has 2 patients on treatment (with RCC)

* Physician commented on latest approval in cHL and states this will be a very limited patient population based on the approved indication",487
practice,Territory, IOCL Lead - ST2- North,8.8023255814,9.19347595847e-07,258,718,"Contacted by a large community practice regarding a melanoma ECOG study that they are involved in.  They had concerned that the protocol does not address safety/dose modifications surrounding potential infusion reactions.  They were advised that the PI of the study should be contacted and the question addressed.  It appears that there may need to be an amendment to this study.  A MIRF was filed specifically related to the topic of infusion reactions.  PI for this ECOG study is Dr. Hodi who, per the practice, is being contacted by the treating physician.",Large community practice indicated they are treating a significant number of patients are being treated with Nivolumab for Breast Cancer.  The provider who shared this was not sure if a specific subset of patients were those treated (I.e.. Triple negative).  Indicated that these patients have been doing very well and experiencing few toxicities.,At another large community practice where discussion took place during a breakfast lecture regarding steroid use for IMARs. This practice noted that they have not been doing higher doses of steroids and tapers are typically not being done. Patients are being left on treatment while lower doses of steroids are continued. Recommendations/guidelines were reviewed in depth.,976
cabozatanib,Territory, KS,140.088803089,2.1022725368e-13,13,190,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",203
trx,Territory, KS,107.760617761,2.38930507116e-10,10,0,"RTL, who is IL-2 referral center, stated that he has believes that all RCC patients should get any and all IO options as soon as possible.  For patients who are good candidates (~10% of RCC pts largely due to organ fxn), starts with IL-2.  Currently dissapointed that nivo PI and 025 trial req'd anti-angiogenic, rather than any prior trx (ie, IL-2 only). Has given several patients a short course of pazaponib until 'any first toxicity' as a pass-through to fulfill insurance requirements per PI.","pan-tumor community RTL states that in RCC he commonly sees patients with mixed responses (both to IO and TKI).  he states that he often sees a similiar phenomenon in SCCHN, but rarely sees mixed responses in lung.  

Due to this, in RCC, he very commonly adds nivolumab to a TKI (typically sunitinib or axitinib) if a patient is beginning to progress rather than switch trx completely.  He states that it has worked very well and he has had no toxicity issues, possibly as most patients are by then on a dose-reduced level of TKI.   He would like to see more nivo+TKI (ie cabo) and nivo-rescue trials being done.","GU RTL shared some factors he considers when deciding between nivo (~70% of pts) and TKI (now cabo, ~30% of pts) for 2L RCC trx:
- pace of progression (20% of pts exhibiting faster progression prefers TKI) 
- toxicity of 1L VEGF TKI (if had minimal tox/dose reduction, more likely to give cabo 2L due to convience of oral dosing)
- compliance to taking oral meds and reporting of side effects
- Performance status (lower PS would always get nivo)",10
pace,Territory, KS,86.2084942085,2.54463467988e-08,8,208,"GU RTL states that while he prefers to give nivolumab 2L in RCC patients, that he uses cabozatanib in patients who are progressing ""fast"" as he is concerned that IO works too slowly.  When asked to elaborate on his definition of 'fast progressors' he stated that it is at most 25% of patients and that he can often tell speed of progression by clinical appearances (PS, pain, fatigue) rather than scans.  

He stated that even in 'moderate pace' progressors, that at least 50% of the patients have their disease 'explode' once they come off of their 1L TKI, sometimes to the point he has no choice by to put them back on.  He had considered 'bridging' in nivolumab while weaning off the TKI but was concerned about safety.  Reactively reviewed TKI+nivo safety data from 209-017 and he thought that this was very acceptable and that he may begin to do this.","Academic TL stated that his nivo non-benefittors (ie, PD w/o any SD/PR) tend to progress at a much faster pace than their 1L progression, sometimes causing them to not be able to get a 3L therapy.  However if they have had any benefit, even a short term slowing of disease prior to progression, their progression is much more tapered and they tend to do better on 3L chemos","TL stated that while he initially treated 'everyone with aPD-1 regardless of PDL1 expression', his experience (pan-tumor) is that ""those who don't respond to IO, actually increase their speed of progression, compared to a chemo or TKI where even non-responders tend to get a temporary slow-down, and thus he feels IO can have a negative impact on ability to response to subsequent therapy.  In nonsq-NSCLC, he has started to test for PD-L1 and will often treat those with <1% with chemo+/-ramucirumab prior to IO in order to 'slow pace before moving on to IO'",216
aPD1,Territory, KS,75.4324324324,2.59474461908e-07,7,635,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","RTL reports that he has utilized ipi/nivo regimen 2L in several patients who have been referred to him following 1L pembro monotherapy failure.  While still early in treatment, he reports that so far patients have done extremely well, either stabilizing or responding. Physician would like to see a a trial specifically looking at 'rescuing' aPD1 non-responders with regimen second line.","NTL in lung stated that at this point, and ""maybe it will change if the numbers for KN-024 are actually much better than I think they will be"" he sees his use of pembro (or any aPD-1 monotherapy) in the first line to be very limited. He expects that the magnitude of benefit may be somewhat modest. ""significant doesn't always mean incredibly meaningful""  

He's states that either in 1L for trials, or in 2L, that he has seen such a ""tiny, maybe 15%"" of patients with >50% PDL1.  ""Whatever the trials data says for proportion of the population, I figure my experience is half of that it almost makes me questioning if I should bother holding up starting chemo for such a tiny fraction"".",642
Pan-tumor,Territory, KS,40.4102316602,3.55810849367e-13,18,464,"Community Pan-tumor TL at research-focused site stated that while their practice has started ordering PDL1 testing in NSCLC whenever possible, however he said ""I'm not really sure why I bother... I treat the negatives with nivo anyways...""

He wasn't sure what exact test they ordered and but stated that he gets an exact % expression reported back.","Community Pan-tumor TL seemed only very moderately aware of the outcomes of KN-024 and CM-026 reported at ESMO, but stated that he ""doesn't think we will be using platinum doublets in 1L in a couple years"".  He did not mention pembro's 1L approval (a few days after) and my impression was that he was not aware. When probed, this is because he thinks this is because IO+IO combinations will be SOC (rather than PD1 monotherapies being used widespread).","Community Pan-tumor TL at research focused site states that while the he is convinced that the efficacy is worth it, that managing toxicity for ipi+nivo in melanoma is ""high maintenance"".  Between him and one other partner (the two that see most of the melanomas), they have treated about 6 patients, and have ended up having to hospitaized a majority of those patients due to GI toxicity.  However they state that the toxicities resolved well with steroids or infliximab and that the majority of these patients have had profound responses.  He stated that he struggles with whether to put these patients back on nivo monotherapy, and has not to date based on the durability off trx in 069 and 067, but he sometimes feels very nervous ""not doing anything more""",482
ie,Territory, KS,36.8182110682,1.76241999882e-32,52,0,Very positive early feedback around AE management app.  Nurse manager requested a similar web-based version to be used at triage desks (ie wiht hyperlinks for the different AEs),"pan-tumor TL reports that he is not performing PDL1 testing in RCC patients.  He states that, of all his tumor types, he actually does the least amount of any genomic analysis (ie Foundation One, etc) in RCC patients as there aren't those 'characteristic and target-able' mutations like in other tumor types.","Med Academic lung TL inquired if there were any efforts to examine was to examine PDL1 in either a plasma/liquid biopsy form (ie, RNAexpression, etc.). Challenges around this were discussed (ie, systemic vs. local tumor environment, etc).",52
modest,Territory, KS,25.1441441441,3.3214570209e-06,9,142,"Despite being impressed by the efficacy benefit, LTL has been hesitant to prescribe commercial ipi3+nivo1 regimen for melanoma due what he considers an unacceptable toxicity profile, especially given lack of long term OS data to justify the toxicity. However, 'jumped' at chance to participate in CA209-568 1L NSCLC trial (ipi q6w, nivo q2w) as he was very impressed with the improvement in toxicity with this dosing in 012.  He hopes to that this dosing schedule will also be examined in melanoma.","Based on the median time to response and higher number of 'late' responses in 025, coupled with the overall slower progression of RCC patients, TL is considering doing first scan at 12 weeks rather than 8-9 weeks as he think it may better reflect the benefit without showing as much pseudoprogression.","GBM: RTL who attended SNO stated that 'each year the progress for GBM seems so incremental and they are still waiting for the 'break' that all these others tumor are seeming to have'.

Stated that he was 'so hopeful' around IO, but that it has been largely dampened due to the ""very modest"" data from nivo (143) and pembro (KN028).   He hopes that possibly 1L treatment will produce stronger results.",151
2L+,Territory, KS,24.2461389961,1.38207938949e-07,12,334,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.",346
GU RTL stated,Territory, KS,19.3969111969,3.56509127158e-07,13,433,"GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""","GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","GU RTL stated that while he was not overly impressed by the CABO-SUN data, he thinks that Cabo will get approved/on NCCN/etc. and become the the preferred 1L TKI. 

TL also stated that levatanib+everolimus was 'junk' and that nobody is using it.",446
Pan,Territory, KS,18.8581081081,8.43957065389e-06,10,0,"Pan tumor TL stated that the was ""Thrilled"" that pembro was added to the 1L NCCN guidelines so quickly.  He acknowledged that this was a very selected population, however believes that the magnitude of benefit 'absolutely' makes it worthwhile to put forth the effort to find these patients.","Pan Tumor community research TL:

Surprised at and impressed by how big the magnitude of benefit was in KN024.  Acknowledges that it is going to fit for a very small portion of patients (he estimated 20% for his practice based on his own synthesis of PDL1 prevalence reported and PS/brain mets/etc in his own patients), however think that it is worth testing everyone at diagnosis and would try to treat anyone with >50% PDL1 with pembro 1L.  He is completely perplexed by the CM026 >50% negative data.  Thinks that this is likely ?a fluke?, but given the magnitude of benefit in 024 doesn?t think that small difference in patient populations could make data from ?super positive? to ?solidly negative? between trials so ?could be a real difference?. 

Note that prior to ESMO data, TL had low expectations overall for KN024 data, thinking magnitude would likely be reasonably small and that he would not likely make a huge push to PDL1 test everyone at 1L, so this is a marked shift in his attitude after seeing data.  He was, and remains, strongly pro-nivo regardless of PDL1 expression, for 2L - views haven?t changed.","Pan tumor TL stated that his concern in giving IO earlier (across any tumor type) is that for the patients that is DOESN'T work for, it is almost detrimental.  He finds that these patients (lung, mel, GI, RCC) tend to have their disease 'explode' and progress quickly, making it impossible/challenging to get it a subsequent line of therapy.  He states that in the 2L and beyond, this is a gamble you take because there aren't a lot of other options, but in the 1L settings it is dangerous and there is still a lot to be said for chemo which at least 'slows down' almost everyone.",10
IL-2,Territory, KS,17.9601029601,1.14679450425e-07,16,48,"RCC TL shared that manuscript had just been accepted for publication around the RCC portion of the PROCLAIM registry and outcome based on sequences of IL-2, chkpt inhib, and TKIs (NCT01415167, PROMETHEUS).  Journal of Urologic Oncology.  
TL did not share any specific data but stated that 'IO first is always best'.","RTL in GU stated that he will be participating in an upcoming Nivolumab+HD-IL2 trial that is being sponsored by Prometheus - did not state specifically, but during implied that this was an ISR (possibly led by Michigan?) that will be bringing on about 10 sites nationwide.   TL had not seen final protocol yet, but believed that there would be a nivolumab lead in (~2 cycles) followed by a standard course of HD-IL2, 1 nivo dose between cycle 1 and 2 of IL2, and nivo mono therapy after completion of IL-2.","Melanoma RTL who has traditionally been a strong proponent and regional referral center for HD IL-2 stated that he hasn't treated a melanoma patient with IL-2 in over a year and that the efficacy of checkpoint inhibitors has nearly 'killed' IL-2.  He states that the 'CRs and cures from IL-2 can't be downplayed, but that you can't refute that way more patients are getting benefit from chkpt inhib without the ICU-type toxicity"" 

TL states that despite it being dropped from NCCN guidelines as a 1L recommendation, that he would still use IL-2 upfront in a young, fit patient as he feels the best strategy is to ""stimulate the immune system by as many different mechanisms that we can"".",64
not test for PDL1,Territory, KS,17.2416988417,2.63400958325e-06,14,651,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.","GU RTL stated the he has used Opdivo in 2 non-clear cell RCC patients.  Stated that in both cases was initially denied by insurance, but easily approved once he appealed and spoke with company.  Stated that this is incredibly common to agents when they first come on the RCC market due (experienced the same with axitinib) and does not concern him, however was thrilled to hear that we were already doing a study with nonCC patients (374) and he hopes this data will be incorporated into PI eventually.",665
axitinib,Territory, KS,12.3154991726,1.12129661681e-05,14,482,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",496
HN,Territory, KS,10.7760617761,5.8197612224e-07,21,1,"HN RTL stated that at their institution (NCCN), it is most common for Merkel Cell Carcinomas that are on the head to be seen by the HN team, rather than the melanoma team. This is in contrast to most other institutions in my region. 

Stated that he has used and seen some good responses to pembro, but is overall much more impressed by the avelumab data.","RTL in lung&HN shared that he is not currently, and does not plan, to test for PDL1 in HN. He likened the 141 data to being ""extremely reminiscent to the 057 and the lung space. Clearly PDL1 is enriching for nivo efficacy, but in 2L even it it was dead even with SOC, I would use it in everyone 2L based on safety and QOL one.  However, this argument might change in 1L HN like it does in 1L lung."" 

He stated that has several HN patients currently nivo off-label, however has started new patients on pembro since their approval due to ""similar data and ease of them having the approval"".  He sees himself using primarily nivo again if approved for HN.","Regarding HN choice of pembro vs. nivo.  Overall opinion is that data ""is very similar"" and few seem to be concerned with lack of OS or comparator for pembro.   Trend seems to be developing where pan-tumor physicians  who have already heavily utilized nivo over pembro to date (ie in lung) are stating that they will continue to use nivo for HN (""all things being pretty equal, we use what we are most comfortable with""). 

HN specialists or those with more limited PD1 experience, are utilizing pembro due to its first approved status and more sites having experience with pembro HN trials",22
sunitinib,Territory, KS,10.7760617761,1.89909578263e-06,19,348,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","community GU RTL who had significant experience with cabozatanib in previous prostate studies, shared that the he experienced very significant toxicities with the drug, even with dose reduction, in that trial and will likely not use it in RCC.  Current treatment strategy generally: sunitinib-->nivolumab->everolimus-->axitinib->single agent bevacizumab.  TL does not anticipate that he will change his patterns once cabo is approved, but states that if approved, would consider using levatinib+everolimus preferentially for 3L.","RTL believes that the data suggests that RCC patients should see nivolumab (or some PD-1 inhibitor) as early in therapy as possible due to possibility of long-term durable response.  Will continue to prefer nivo prior to cabozatanib even with OS benefit. 

Believes in MOA-switching more than recycling ('patients should see as many classes as possible because you never know what one they will respond to) and typically moves from sunitinib-->nivo-->everolimus-->axitinib/cabo.",367
GU,Territory, KS,9.57872157872,1.04851441055e-12,84,815,"RTL in GU (GU-only treat-er) states that he has never tested for PDL1 in any GU tumor (RCC or Bladder.  He does not believe that the assays are reliable (ie, due to intra-tumoral and intra-assay heterogeneity). 

He states that he has never heard of any colleagues testing in 2L RCC as the lack of any predictive utility is clear from 025.  He stated that as of now, very few test 2L badder as the other treatment options are so poor.","RTL who splits time between Academic GU specialists and community generalist (ie, also treats lung) shared that he is NOT testing for PDL1 in RCC  (Note that TL is also not currently testing NSCLC patients for PDL1 outside of trials).  TL did state that he thinks it is very 'intriguing' why PDL1 is enriching in some tumor types (ie, nonsq lung; mel) and not others (RCC).  

TL prefers to give nivo 2L in RCC (~70% of 2L cases), however if patient travels long distances will sometimes utilized cabozatanib due to oral conveniences and ""predictable toxicities that can almost be managed over the phone with dose reduction"".","Academic RTL states that he does not test for PDL1  in any GU tumors (RCC, bladder).  

This is consistent with trend observed in territory where no TLs (academic or community) report testing in RCC.  Very small minority report running genomic panels (ie Foundation One, etc) for RCC but are not making treatment decisions based on PDL1 testing obtained 'incidentally' from panels.",899
3L,Territory, KS,8.81677781678,1.83249428995e-05,19,518,"GU RTL stated that the used nivo 2L in about 70% of his 2L RCC patients.  Does not expect this to change dramatically with entry of cabo, however stated that cab will now be his preferred 2L/3L TKI instead of axitinib that he currently uses.  He would consider  levantnib+everolimus following cabo as believes value in adding a mTOR.  While TL believes that OS endpt trumps all, that especially for older patients, PFS endpoint is also very meaningful.","At an academic Grand Rounds, TL shared from podium that he was confident that nivo would remain clear 2L SOC for RCC even with cabozatanib demonstrating a significant OS benefit due to durability and favorable tox.  Much discussion about durability of responses in IO vs. TKIs.  Group was split as to whether they would prefer axitinib or cabo in 3L, but most agreed mTORs would be pushed to 4L.","GU TL shared his treatment-decision algorithm in RCC:
1L - VEGF TKI (currently pazopanib, but though CABO-SUN looked goog)
2L -  based on how responded to 1L TKI:   if tox was modest AND patient had strong response (not just SD) lasting for >6month --> TKI (cabozatanib).  If substantial tox, or low/short duration response in 1L TKI --> nivo.

Stated that about 60% of patients get nivo 2L, 30% cabo, 10% 'other'. Does not use levatanib+everolimus.  

TL stated 'reality is that none of these agents, including IO, are probably going to cure the vast majority patients. So our goal is really to string them together as best as we can and importantly, don't use an agent for too long such that pt crashes and can't get to the agent""",537
nearly,Territory, KS,7.6971869829,1.44920674143e-05,23,0,"LTL shared story of a PDL1 negative patient enrolled on CA209-153 who experienced a rapid near CR and has maintained response for nearly 1 year.  Based on this experience, TL stated that he ""would deny a 2L+ NSCLC patient nivo based on lack of PDL1 status""","NTL in sarcoma shared that he has personally treated nearly 100 sarcoma patients with I-O therapy/  About half were on trial (SARC028 or ALLIANCE A091401) and half off protocol.  Over half of the patient have been treated with ipi+nivo combination, and he shared that he has seen ""just amazing results, including probably 6-7 CRs, particularly good responses in Uterine Leiomyeosarcomas, Liposarcomas, and Osteosarcomas.  He shared that this is his standard 2L or 3L treatment for many patients now.  He stated that BMS Access support has been ""beyond wonderful"" and hat he has also had sporadic success in getting insurance reimbursement.","RTL shared that in his ~8 RCC patients (a few started off-label prior to approval and out ~5 months) he has not seen any response that would have qualified as RECIST responders, however nearly all have stabilized disease or modest shrinkage and are feeling markedly better.  States that he is perfectly comfortable with this and similar to many agents in GU landscape.  States that unless patients are feeling worse or have other 'triggers', he is starting to scan no earlier than 12-16 weeks as he would not discontinue drug based on that scan anyway.",23
completely,Territory, KS,7.40854247104,7.08442376579e-06,26,3,"RTL stated that he has 'very frequently' used nivolumab in combination with another agents for RCC such as sunitinib, everolimus, bevacizumab 2L+.  He stated that ""often times RCC it is like a game of whack-a-mole' with some lesions continuing to deepen respond while others start progressing on a particular therapy"".  Rather than completely pull drug that is still somewhat working, has started adding nivo on top while cycling out prior therapy over several weeks. He reports no toxicity problems with any combinations (""less than a 1+1 toxicity"") and has seen some good responses.","RTL stated that as more data has come out pan tumor, he has decided that 'psudoprogression is a extremely rare occurrence and not something that 'any longer plays into his decisions making'.  He stated that in RCC, given numerous trx options, he typically won't treat beyond progression with nivo alone.  State that he has found many people with PD on nivo have a mixed response and he hesitates to completely stop nivo. Instead, if patient is fit and experiencing minimal AE, he will continue nivo while adding in his next line of therapy at a reduced dose (3L typically cabo or axitinib).  To date has not experienced any addidive/unexpected toxicity","TL is not testing for PDL1 in bladder (and has no interest in doing so) and was completely unaware of the atezo data around responses in PDL1 neg vs. positive patients.  Reviewed our 275 data and TL stated that he like the fact that responses more consistent across all patients regardless of PDL1.  Stated that once approved, could see himself 'preferring' nivo over atezo due to thins, even though he believe all class agents are essentially the same.",29
testing for PDL1,Territory, KS,7.18404118404,5.50677897801e-07,39,575,"3 RCC TLs from distinct institutions (small academic, large academic/VA and community practice) state that they have never tested for PDL1 in RCC and see absolutely no value in it as the data has clearly shown no predictive benefit (note that some of the same TLs do routinely perform PDL1 testing in lung).  Multiple TLs also stated that they don't even typically run NGS-type panels in RCC patients (even though they may in other tumor types) as they rarely see any actionable mutations in these patients.","RTL at NCCN institution stated that he sees no value in testing for PDL1 in the rec/met setting.  Stated that he feels story in HN will be the same as in NSCLC... when aPD1 moves into initial treatment/pre-platinum setting, that patient selection by PDL1 will be necessary.  

He states that they 'try' to perform HPV testing, but it is not a reflex test, and rarely occurs outside of oropharyngeal.","LTL in large community practice has not yet used ipi/nivo combination and would reserve for only a young, fit, patient who was PDL1 negative. Otherwise would start with single agent PD-1 (preference for nivo due to familiarity, but feels that pembro is equivalent)  TL does not test for PDL1 in NSCLC and does not value test in that setting, but based on 067 PFS, 069 OS w/ crossover, and due to tox concerns with ipi believes that single agents probably have the best balance of tox and efficacy based on data right now and would reserve combo for PDL1neg.",614
RAI,Territory, LA,530.129032258,7.67697465127e-18,15,701,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.",716
context of an online lecture,Territory, LA,337.35483871,1.72040645962e-11,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NAI,Territory, LA,337.35483871,1.72040645962e-11,7,282,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",289
NCCN 2016 Webex Congress Series,Territory, LA,337.35483871,1.72040645962e-11,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
proactive meeting to discuss CM-026,Territory, LA,337.35483871,1.72040645962e-11,7,257,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",264
Bone Marrow Transplant Director,Territory, LA,240.967741935,2.57300994249e-08,5,713,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.",718
academic institution in the HSL South,Territory, LA,192.774193548,9.78673681984e-07,10,110,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).","Having missed ASCO this year, an access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory asked on 08/05/16 to review Checkmate 012 data. The bar chart describing ORR with nivo (nivo+ipi) across tumor PD-L1 expression levels captured his attention (?nivo is truly a cool drug?). He commended BMS for studying nivo (nivo+ipi) efficacy across the entire range of PD-L1 expression, acknowledging that (many of) our competitors seemed reluctant to assume the risks associated with this strategy. He also noted that: 1) ORR values with nivo (nivo+ipi) at the ?50% expression level were most impressive; 2) ORR values at the <1% - ?1% levels were not negligible, even in comparison which ORR achieved with platinum-based chemotherapy; 3) nivo (nivo+ipi) may prove to be the best therapeutic options for some categories of patients with low PD-L1 expressing tumors (e.g., older or frail patients); 4) the medical community desperately needs more data to make informed decisions about who should receive what.  
The AI did not know the results of Checkmate 026. We did not address the issue since BMS official talking points had not yet been released.",120
Annual New Orleans Summer Cancer,Territory, LA,192.774193548,9.78673681984e-07,4,341,"On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Roche proposes to assess PD-L1 expression on tumor cells + immune cells. Complicated score: not convenient for clinicians.","On 07/22, a panel of speakers at the 11th Annual New Orleans Summer Cancer Meeting concluded that: 
?	PFS is very hard and costly to assess. It is a useful endpoint for phase I/II studies, but ORR and OS are much more important in phase III trials. Newer endpoints need to be explored such as ?time to next treatment.","On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Study Checkmate 141 showed a striking 1-year OS benefit in favor of nivolumab. This result will lead to approval (but pembro approved first?). Subgroup analyses also indicate that nivolumab can be used in almost everybody. Efficacy seems to be lower in P16-negative and PD-L1-negative patients, but it is still too early to make final conclusions.",345
LAI,Territory, LA,192.774193548,9.78673681984e-07,4,238,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",242
RAI/NSCLC,Territory, LA,192.774193548,9.78673681984e-07,8,175,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",183
made the following comments,Territory, LA,168.677419355,2.67259574441e-20,17,549,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.",566
South,Territory, LA,156.629032258,8.39464788365e-19,20,360,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",380
NCCN panelist for NSCLC,Territory, LA,144.580645161,2.4055692872e-13,11,482,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
Assoc,Territory, LA,144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
RCTs,Territory, LA,144.580645161,3.62780141464e-05,3,541,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
To control costs in 2L NSCLC setting, starts with 4 doses of nivo or 3 doses of pembro or atezo (if tolerated). Continues treatment if observes PR/CR, SD or no more than a small progression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.",544
Vice Chancellor Clin Res,Territory, LA,144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
territory,Territory, LA,128.516129032,3.95289189196e-22,35,349,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",384
shared the following unsolicited insights,Territory, LA,117.041474654,4.59611035311e-23,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
national access influencer,Territory, LA,96.3870967742,2.88456084709e-06,7,486,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",493
NSCLC NCCN panelist,Territory, LA,75.732718894,1.7802590881e-14,17,665,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",682
1st line NSCLC,Territory, MA,46.65625,8.02687313399e-09,17,26,"A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).","A LTL in Boston stated that based on all the data coming out around 1st line NSCLC, they should be testing all pts for PD-L1 status.  However, he added that ""he has requested testing on 15 or so samples (1st line pts) and all of them have come back negative"".",43
rounds,Territory, MA,37.325,2.58986730437e-05,8,5,"A Local RPH in Maine asked, that their average pt receiving Opdivo over the last 12 months has been 67 Kgs.  Therefore, the flat dosing (based on a 80 kgs) would result in most of their pts receiving above 3mg/kg, and result in higher cost.  Therefore, the RPh suggested that for most pts they will stick with 3mg/kg dosing (rounded to nearest vial size), but for pts over 80kgs, they would use falt dosing of 240mg.",An RPh at a community site informed me that they are dose rounding Opdivo to the nearest full vial size (increments of 20mg) to prevent wastage.,"A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""",13
Boston,Territory, MA,21.7729166667,3.38057652358e-07,40,82,"A Melanoma NTL from Boston, stated that ""there is no value in doing PD-L1 testing in melanoma pts.""  He added that ""I don't test any of my pts""","A RTL from Boston shared a grand rounds a that ""No one PD-1/PD-L1 inhibitor is better then the other."" He added that ""Study design and the various endpoint give some advantage over others.""","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",122
3mg/kg,Territory, MA,17.9447115385,3.39530687444e-05,17,415,"An Pharmacist from major hospital in Rhode Island suggested, with regards to flat dosing, that for pts that weight less than 80kg, they will do 3mg/kg...while for pts that weight more than 80kgs, they will do 240 mg flat dosing.","A Local RPH in Maine asked, that their average pt receiving Opdivo over the last 12 months has been 67 Kgs.  Therefore, the flat dosing (based on a 80 kgs) would result in most of their pts receiving above 3mg/kg, and result in higher cost.  Therefore, the RPh suggested that for most pts they will stick with 3mg/kg dosing (rounded to nearest vial size), but for pts over 80kgs, they would use falt dosing of 240mg.","Over the last 2 weeks, regarding Opdivo flat dosing, I have received 3-4 calls around physicians showing concern that their 50-60 kg pts being overdosed (increase risk of toxicity) with 240 mg flat dose.  Many of the conversation led to MDs deciding to continue 3mg/kg for there underweight pts.",432
New England,Territory, MA,17.9447115385,3.39530687444e-05,17,970,"An Pharmacist from major hospital in Rhode Island suggested, with regards to flat dosing, that for pts that weight less than 80kg, they will do 3mg/kg...while for pts that weight more than 80kgs, they will do 240 mg flat dosing.","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.","An RTL from New England shared with me that while they are testing all their 1st line NSCLC pts for PD-L1, they are not doing the same for any other tumor type (ie: RCC).",987
pts,Territory, MA,11.6640625,6.44540932165e-20,164,1624,"An RTL shared that when a pts runs into toxicity with Nivo/Ipi combo, if the pts has a CR or PR at that time, then they stop treatment.  However, at the time of toxicity with the combo, if the pt only has SD or PD, then they continue PD-1 monotherapy.  The added that about 1 out of 4 times they continue with Pembro as oppose to Nivo.","A NTL in melanoma shared that combination IO therapy (mostly regimen) is their primary method of treatment all melanoma pts at their institution.  Even if the pts has bully, BRAF+ melanoma, because of the rapid RR scene with Nivo/Ipi, they would choose Nivo/Ipi over BRAF+MEK combo.",A RTL stated that he does not test PD-L1 for his RCC pts.,1788
inquired,Territory, MA,11.6640625,4.28519978734e-05,29,0,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","After reactive discussing the positive OS data announcement with CA209-141 for H&N, the RTL actually asked for a copy of the BMS Press Release.  Upon inquiring further why the need for a copy of the press release, the RTL shared that with that information in hand, he stated that they can start using nivolumab for H&N without having insurance companies pushing back on it.  The TL was excited to have another option for his H&N pts and was eager to start using it.","A National GBM TL inquire with regards to Checkmate 026.  After indepth discussion, he agreed that Keynote-24 can not be cross compared with Checkmate-26 and commended BMS from taking the learning from Checkmate 26 and applying to other clinical trials (ie, Checkmate 227).  He was impressed with the CheckMate 012 combo data, and stated that the future of IO therapy (lung and GBM).",29
LTL,Territory, MA,8.23345588235,2.7945495849e-07,79,800,"An LTL informed me that he doesn't test for PD-L1 status in the 2nd line NSCLC setting and stated that there is no need for it. He did add that his colleague is testing some of his/her pts for PD-L1 status in the 2nd line setting and is ordering PD-L1 status upon initial biopsy (pre-1st line treatment). Upon inquiring why? The LTL shared that by having this information, for PD-L1+ pts, both Pembro and Nivo would be good options with high ORR in the 2nd line setting, and if the pt was PD-L1 negative then opdivo (only) would still be an ""ok"" option.","An LTL/RTL stated/suggested that his plan for 2nd line NSCLC is to start nivolumab while waiting for PL-L1 test expression.  If the PD-L1 test comes back at 50%+ positive, he would switch the pt to Keytruda (view the data stronger as this sub-population was specifically studied by Merck).  If the test comes back between 1-49%, he said that it's a 50/50 choice between Opdivo/Keytruda and it would be up to the pts on q2w drug or q3w drug.  If the PD-L1<1%, he would choose Nivo...but if insurance had an issue, then he would switch to docetaxel.",A LTL stated that no one in her practice test for PD-L1 for her RCC pts.,879
1st line,Territory, MA,7.31862745098,4.80687642993e-05,69,712,"A LTL form Connecticut, was aware of the CHeckmate 026 data, and inquired further ""BMS studied failed"".  We reviewed the study design, discussed the 2nd line OS data in NSCLC is still valid, and transitioned to 1st line Checkmate 227.  The LTL agree/shared that he has heard great things about the Nivo/Ipi combo regimen (efficacy standpoint), he was not aware BMS was testing Ipi1q6w (with Nivo3q2w) and found that encouraging from an safety standpoint. He plans on continuing to use Nivo in the 2L NSCLC setting and looks forward to the data from Nivo/Ipi in the 1st-line.","A RTL for Lung shared that he was surprised to hear that CM26 was negative. He is looking forward to seeing the subgroup analysis based on other PD-L1 cut offs, but he added that this increases the need to do PD-L1 testing in all 1st line NSCLC pts. He also suggested the need to choose PD-1 agents in the 2nd line settting based on PD-L1 results.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",781
added,Territory, MA,6.0087594697,9.07218642305e-08,148,0,A Regional TL shared that they are testing all there NSCLC pts for PD-L1.  He added that his institution is still trying to figure out if they should internalize the PD-L1 test or just continue to send it out.,"An Academic TL shared that if a pt fails monotherapy PD-1 (either pembro or Nivo), they then add ipilimumab on top especially if the pt did not experience any AEs to monotherapy anti-PD-1 therapy.  The TL was hinting toward lack of toxicity equals 'not enough IO blockade' and hence they need to use combo IO in those pts.","A RTL from a Major Hospital in Boston shared at grand rounds that they do not perform PD-L1 testing for their NSCLC pts (beside if required by clinical trials).  He added that now that Keynote-024 is positive, they will have to test PD-L1 in all their 1st line NSCLC pts.  He did not specific which PD-L1 test his institution will be using.",148
PD-L1 testing,Territory, MA,5.4642454955,5.76991939871e-06,123,444,"NTL in Lung stated that because of Keynote 24, PD-L1 testing will become part of ""Reflex testing"".  He wondered whether the PD-L1 test should be reported back as percentage positive, or positive/negative for a 50% cut-off (based on KN24).  He added that his institution does not have an in-house PD-L1 test and has to current send out to an outside lab for PD-L1 testing.  He envisions the pathology developing there own PD-L1 test (or purchasing one) over the next 12 months.",A Regional TL shared that they are testing all there NSCLC pts for PD-L1.  He added that his institution is still trying to figure out if they should internalize the PD-L1 test or just continue to send it out.,"A LTL is requesting PD-L1 testing for all 1st line NSCLC pts.  She shared that she is having a difficult time figuring out what test to order and ""its very confusing"".",567
PD-L1,Territory, MA,4.91118421053,8.17036174269e-06,306,375,"A Lung RTL shared that he has ""ordered merck's PD-L1 test multiple times"" as part of his routine biomarker test prior to 1st line platinum doublet treatment, and ""it has come back negative every single time"". He inquired further around ""does PD-L1 levels go up after Pt resistance?""","An LTL/RTL stated/suggested that his plan for 2nd line NSCLC is to start nivolumab while waiting for PL-L1 test expression.  If the PD-L1 test comes back at 50%+ positive, he would switch the pt to Keytruda (view the data stronger as this sub-population was specifically studied by Merck).  If the test comes back between 1-49%, he said that it's a 50/50 choice between Opdivo/Keytruda and it would be up to the pts on q2w drug or q3w drug.  If the PD-L1<1%, he would choose Nivo...but if insurance had an issue, then he would switch to docetaxel.","An RT from Vermont shared that for NSCLC pts in the 1st line setting, if the PD-L1 test come back higher than 1%, she is choosing to place the pts on IO therapy over Platinum Doublet.",681
shared,Territory, MA,3.60048231511,2.18150252672e-06,507,1,"A Lung RTL shared that he heard about KN024 being positive.  He then ask to see BMS's data.  I shared that CM026 is still awaiting read out, however I shared CM012.  He prefers Nivolumab over Pembro in the 2nd-line NSCLC setting, and based on the data shared, he stated ""I am happy with your Phase I data and I would rather use Nivolumab over Pembro (in the 1st line NSCLC setting), as long as the insurance covers it"".","After reactive discussing the positive OS data announcement with CA209-141 for H&N, the RTL actually asked for a copy of the BMS Press Release.  Upon inquiring further why the need for a copy of the press release, the RTL shared that with that information in hand, he stated that they can start using nivolumab for H&N without having insurance companies pushing back on it.  The TL was excited to have another option for his H&N pts and was eager to start using it.","An LTL from community/academic location, shared that she used nivolumab (over pembro) in the 1st line metastatic melanoma setting.  upon progression, she will use 2nd line.  With regards to Regimen for 1st line (or any-line), she said the toxicity is too high and sends those pts into academic locations in Boston.",508
Northeast,Territory, ME,301.0,8.78016867068e-14,9,121,"Testing for PD-L1 in NSCLC is now part of the usual pathology and genetic tests conducted in a leading NCCN institution in Northeast US.  This hospital charges the payers a single bundled charge for all the tests they do on a patient.  Now, PD-L1 has been added to the pre-existing battery of tests.  This institution does its own immunohistochemistry assays for PD-L1 using the E1L3N antibody from Cell Signaling Technology.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",130
IME,Territory, ME,225.75,1.03059906794e-05,3,0,"In his presentation at an IME on immunotherapy in NSCLC, Naiyer Rizvi MD (Columbia University) summarized the data for nivolumab and pembrolizumab, stratified for PD-L1 levels and tumor histology.  The overall theme of his presentation was that both agents are very similar across all stratifications, even when the slides highlighted the differences (e.g. hazard ratio for pembrolizumab in squamous histology in Keynote-10).  BMS, Merck and Genentech funded this IME program.","Discussing therapeutic options in NSCLC patients expressing low levels of PD-L1, Leora Horn MD (Vanderbilt & NCCN panelist) indicated her preference for chemotherapy over IO agents.  She also believes that chemotherapy (with pemetrexed for NSQ NSCLC) and targeted therapy is more valuable in appropriate patients as first line therapy, instead of IO agents as monotherapy or in combination.  These opinions were expressed during the unscripted discussion following an IME program sponsored by BMS, Merck and Genentech.","Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.",3
New England,Territory, ME,150.5,2.506522524e-18,17,970,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.",987
cell carcinoma,Territory, ME,75.25,2.50530862486e-06,7,40,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",47
NCCN institution,Territory, ME,66.8888888889,4.29123557889e-11,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","A leading academic thought leader and clinical trials expert from a New England NCCN institution underplayed the significance of CheckMate 026 results disclosed so far.  He felt that PFS is not a good endpoint for IO therapies, as many IO trials have already shown positive response rates and overall survival despite a lack of PFS advantage.  In cancers with low T- lymphocyte infiltration, CTLA-4 inhibition using ipilimumab may enhance the efficacy of nivolumab by increasing infiltration.",125
immuno-oncology,Territory, ME,53.75,4.00828032701e-07,11,54,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.",65
produce,Territory, ME,37.625,1.68991039548e-05,11,0,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Physicians are reacting negatively to the direct-to-consumer advertisements for Opdivo and are raising their displeasure proactively during meetings.  The Medical Director of the Lung Cancer Program in an academic hospital in the Northeast told the HSLs that he had second thoughts about using Opdivo, just as a reaction to the DTC advertisement on television.  Another family practice physician involved in formulary decisions called the Opdivo TV ads ?cringe-inducing?.  He complained that the overall tenor of the TV ad grossly exaggerates the modest improvement in median overall survival produced by Opdivo in NSCLC.","A leading academic thought leader discussed the clinical trial results of cabozantinib and his own personal experience in using this agent.  Toxicity and adverse events remains the major concern with cabozantinib.  Though cabozantinib produced very good results in clinical trials, he is cautious about using this agent in his practice.  He has participated in nivolumab trials, and uses nivolumab frequently in his clinical practice.  However, he stressed that the TKIs will remain a staple part of therapy of RCC, and the right patient can derive significant benefit from them.",11
US,Territory, ME,37.625,1.46361607795e-06,14,24,"Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A clinical pharmacist at an academic medical center in the Northeast US indicated that they have added PD-L1 testing (IHC) to their usual battery of genetic tests for all tumors, including NSCLC and RCC.  At present, PD-L1 levels are not being used to make treatment decisions at this center.  But she implied that more granular instructions on the use of anti-PD-1 and anti-PD-L1 agents are expected in future from both regulatory agencies and payers.  This center wants to have all the procedures established before these changes become mandatory requirements.",38
thought leader,Territory, ME,33.4444444444,2.42576830707e-09,25,22,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","A national thought leader on renal cancer from a Northeast NCCN institution advocated a Q3W dosing for nivolumab in RCC as a cost-saving measure that also increased patient convenience.  He substantiated his argument by pointing out that the clinical efficacy in ORR, PFS and OS are identical for CheckMate 010 and CheckMate 025, though the former trial uses a Q3W dosing schedule.  He believes that FDA would accept a single arm trial that shows non-inferiority in OS to change the labeling to a Q3W dosing.",47
Boston,Territory, ME,28.21875,5.0253285218e-07,40,82,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",122
MD,Territory, ME,27.7236842105,6.47806926464e-08,29,71,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",100
ipilimumab,Territory, ME,26.5588235294,6.71018488851e-07,22,17,"David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.",39
renal,Territory, ME,20.9027777778,1.48378524388e-05,22,26,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",48
cabozantinib,Territory, ME,20.5227272727,2.34524140396e-06,27,137,"According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.","Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.",164
IO agents,Territory, ME,18.3040540541,2.05728361688e-08,45,174,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A key oncologist from a New England academic hospital shared information on his thinking and his clinical practice in managing IO agents in patients with endocrine-related immune-mediated adverse reactions.  In his opinion, adverse events affecting the endocrine organs such as the thyroid and pituitary glands can be managed by administering the appropriate hormone replacement with discontinuing the IO agent.  He believes that value provided by IO agents including the potential for a complete remission is too important to sacrifice to avoid an adverse event that can be easily managed.","The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.",219
major,Territory, ME,16.0106382979,1.11546964675e-08,90,483,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",573
advanced,Territory, ME,15.6770833333,4.85954723446e-05,36,0,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","A key NCCN panelist for SCCHN a major academic hospital in New England was profiled to understand the treatment landscape in SCCHN.  This panelist was an investigator in CheckMate 141, and therefore was intimately familiar with the data presented at AACR.  The panelist considers the efficacy in OS to be better than what is seen in clinical practice with single agent therapies (methotrexate, cetuximab, docetaxel etc.).  He has a very negative opinion on the efficacy and toxicity of these standard of care therapies.  

Combination therapies will enhance the potential of immune-oncology in difficult to treat cancers and advanced stage disease.  Robust data needs to be developed for all options with Opdivo such as IO combinations, IO + targeted therapies and IO + chemotherapy/RT.  He also stressed the need to do clinical trials in nasopharyngeal SCCHN due to its unique etiology and response to treatment.  He does not endorse extending the NCCN recommendations to include this population based on data from other types of SCCHN.","The Director of Hematologic Malignancies at a major academic hospital in Boston downplayed the incidence of GVHD in patients who received allogeneic stem cell transplantation after receiving nivolumab previously.  Hodgkin lymphoma patients with advanced disease in later lines of treatment are more susceptible to GVHD after allogeneic SCT generally, even without previous exposure to nivolumab.  As careful management of GVHD can reduce allo-associated mortality, nivolumab provides a good therapeutic option in advanced HL patients.",36
hospital,Territory, ME,15.6770833333,1.32785094524e-08,72,479,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The clinical pharmacist responsible for infused products at a leading academic hospital in New England expressed gratitude to BMS for its generous patient assistance program.  Most of their patients on nivolumab in off-label indications in this Disproportionate Share Hospital (DSH) currently receive free medication through the patient assistance program.  This hospital is now attempting to move some of these patients to their insurance plan, to reduce the burden on the assistance program.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",551
improved,Territory, ME,14.564516129,1.28660051308e-05,36,0,"The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.",36
care,Territory, ME,13.6818181818,1.75918689769e-05,75,12,"The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.",87
NCCN center in the midwest stated,Territory, MI,249.428571429,1.81700761119e-15,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
exercise,Territory, MI,103.928571429,1.29851672553e-06,5,238,"During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment he was surprised the FDA will allow Merck to have labeled indication without a comparator arm in their trials given the fact that there is a drug with proven efficacy that has a comparator arm","During a profiling exercise with a H&N panelist at an NCCN center, AI stated he defines refractory the same as we defined it in 141 (which he stated is a better design that the Pembro trial where you had to fail both cetuximab and a platinum therapy)","During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment the Nivo QOL is ?the best,? and he will highlight that data at his next post ASCO talk. He believes that data is impactful. He mentioned Pembro doesn?t have that data",243
P&T committee,Territory, MI,72.75,1.70961619235e-08,8,478,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",486
NCCN center,Territory, MI,31.1785714286,4.66286945501e-09,26,280,"P&T committee member/lung AI at an NCCN center stated the following

o	When asked if cost/cost avoidance discussion are part of their formulary discussions, he stated they are minimized at his institution. He stated decisions are NCCN/FDA approval/data driven.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",306
AI stated,Territory, MI,26.4545454545,9.64757718615e-13,24,171,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",195
advisor,Territory, MI,13.4495798319,2.88372902372e-08,27,231,Advisor to the panelist at an NCCN center in the midwest stated Atezo won't be considered for formulary addition because they are so accustomed to using Nivo and it's challenging to change habits,"Advisor to the panelist at an NCCN center in the midwest stated that based on the 026 data, he'd like to offer Nivo in 1L","Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.",258
TL commented,Territory, MI,11.4679802956,1.47652334347e-10,83,892,"TL commented that nivolumab is SOC for 2L RCC at their institution based on efficacy, tolerability, and patients demanding I-O treatment. RCC patients see the lung DTC marketing and ask for nivo treatment.","National lung TL commented that ROVA-T and ipi/nivo appear to be the most promising potential agents in SCLC. Regarding ORR reported for ipi/nivo, he mentioned that this is likely not the best outcome for I/O in general but that duration of response or even maintaining stable disease (duration of disease control) should be considered as more important measures of activity.","National lung TL commented that even in a never-smoker, low mutation burden, PDL1 non-expressing lung patient he?d still want to try one of the PD1 agents based on the current data showing that even this subset of patients, while more unlikely, still have a chance of having a long term benefit from this class of drug.",975
I/O,Territory, MI,11.2589285714,8.34304975425e-09,36,184,"Regarding 1L use of PD1 agents in NSCLC, RTL commented that he'd have to be really impressed with 024 results to consider replacing platinum doublet therapy. He's still much more comfortable reserving the I/O class of agents for platinum-refractory and given how restrictive the use would likely be (>50%) he may not bother unless the data is extremely compelling.",Local TL believes the best opportunity for increasing the utility of PD1 agents may be in the combination with RT setting. He's surprised there hasn't been more attention to this strategy in larger clinical trials across various tumor types given the rationale behind antigen release/exposure associated with RT and obvious synergistic potential of I/O with this modality.,"Local TL commented that he feels we may be jumping the gun trying to replace platinum doublet therapy as a 1L standard for NSCLC. He believe the role of immunotherapy may be better suited to work after chemotherapy due to the increased antigen presentation, etc, along with the fact that relegating chemo for later line will be more difficult to give once pts have already failed a 1L treatment. The best chance at getting a good response to doublet therapy will likely be in the 1L and the role for I/O may be better in the maintenance or 2L setting due to it's superior tox profile.",220
minimal,Territory, MI,10.3928571429,3.29863612997e-05,20,0,"During a profiling exercise, an NCCN H&N panelist offered the following unsolicited insights:
?	When asked how he treats LA-SCCHN he stated the following
o	First surgery
?	After surgery with minimal dz, pt would get RT
?	After surgery with moderate dz, pt would get a plateium therapy
?	After surgery with bulky dz, pt would get chemo/RT
?	He does not test for PDL1 expression but does test for P16
?	Research gaps-he?s like to see a trial sequencing I/O then chemo. He believes patients respond to chemo better post I/O.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",20
midwest,Territory, MI,9.89795918367,1.01957522716e-06,42,124,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,166
chair,Territory, MI,8.75187969925,2.4158125802e-05,26,260,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",286
panelist,Territory, MI,7.09756097561,2.25444406624e-07,134,164,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",298
Local TL,Territory, MI,6.2987012987,2.56863801757e-05,52,1414,Regional TL commented that cabozantinib being used in the phase 1 trial of cabo+nivo with or w/o ipilimumab in metastatic GU tumors was a different formulation. They are seeing less toxicity with this formulation of cabo. TL also shared that the combination of agents has a better AE profile than using as monotherapy.,A lung RTL commented that as the data keeps evolving he is starting to be more selective with which patients receive Opdivo. For patients that are PDL1 negative and have a notably low tumor mutation burden he's beginning to use the cyramza/docetaxel combination 2nd line given the higher response rate seen vs. the 9% that is reported in PDL1 negative pts from 057. He feels that he can always reserve nivo for 3L if pts fail this regimen. He did note it is quite toxic so he wouldn't use this approach with everyone but at least in those that could tolerate it in order to give them more overall treatment options.,"Local TL focused on lung commented that given the new data available with pembro it would now be unethical to not test for PDL1 for 1L treatment decision making. He added that despite a rather high volume of NSCLC, he's yet to see anyone express greater than 50% and feels the true number of high expressors must be much less than the 25-30% Merck has in their studies.",1466
H&N,Territory, MI,4.26373626374,9.94899790815e-06,117,300,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,"Community TL does not use Extreme regimen in SCCHN, referred to it as torture. His preference is cisplatin + 5-FU for recurrent or metastatic H&N","During a profiling exercise, an NCCN H&N panelist offered the following unsolicited insights:
?	When asked how he treats LA-SCCHN he stated the following
o	First surgery
?	After surgery with minimal dz, pt would get RT
?	After surgery with moderate dz, pt would get a plateium therapy
?	After surgery with bulky dz, pt would get chemo/RT
?	He does not test for PDL1 expression but does test for P16
?	Research gaps-he?s like to see a trial sequencing I/O then chemo. He believes patients respond to chemo better post I/O.",417
commented,Territory, MI,4.23412698413,8.26174864599e-10,295,327,"Local TL focused on lung commented that given the new data available with pembro it would now be unethical to not test for PDL1 for 1L treatment decision making. He added that despite a rather high volume of NSCLC, he's yet to see anyone express greater than 50% and feels the true number of high expressors must be much less than the 25-30% Merck has in their studies.","Local TL commented that BMS should really consider pulling the DTC Ad for Opdivo; that it just frustrates physicians because pts come in expecting Opdivo to be a ""miracle, homerun drug"" every time. She stated the only positive that's come from it is awareness of the drug among pts which encourages ongoing clinical trial participation.","Local TL commented that the 026 press release was disappointing but that it might finally answer the question of which PDL1 expression level is necessary. He feels the 50% level excludes many patients that could have benefit and suspects the right level is probably closer to 20%. He also feels that the results of this study now further support that testing is probably important and if nothing else, will give the physician a better idea of what to expect going into treatment.",622
MedOncs,Territory," MID-ATLANTIC
MI",913.5,1.17669588842e-07,4,131,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.",135
machines,Territory," MID-ATLANTIC
MI",609.0,2.69684184422e-05,3,147,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",150
standardized,Territory," MID-ATLANTIC
MI",487.2,4.33151984154e-09,8,132,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",140
complementary,Territory," MID-ATLANTIC
MI",406.0,4.4868917678e-05,4,138,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.",142
SP263,Territory," MID-ATLANTIC
MI",304.5,9.79727372844e-07,8,144,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",152
tumor cells,Territory," MID-ATLANTIC
MI",128.210526316,2.93484741697e-07,22,82,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",104
Dako,Territory," MID-ATLANTIC
MI",121.8,9.33045716196e-06,17,124,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.",141
staining,Territory," MID-ATLANTIC
MI",84.0,1.32143733614e-06,32,620,"TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",652
22C3,Territory," MID-ATLANTIC
MI",64.1052631579,3.53131630726e-06,49,112,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies",161
aware,Territory," MID-ATLANTIC
MI",45.1111111111,1.28447242544e-05,57,0,"?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.","?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL is a pathologist at a Large Health Network hospital in the territory.
?	TL was not interested in PD-L1 IHC when I met with him earlier in the year
?	Now they have the SP263 standardized on the Ventana platform
?	They report % PD-L1 positive tumor cells. 
?	TL is never told if it is a 1L or 2L NSCLC tissue. Volume of testing has increased after 1L Pembro approval. TL is aware of the 22C3 IVD but wants to keep all the testing in-house",57
PD-L1,Territory," MID-ATLANTIC
MI",21.4436619718,4.01692364035e-05,306,375,"?	As of summer 2016, test requests for PD-L1 used to be sent to Reference labs. TL was happy that they could request either 22C3 or 28-8.
?	However, as of this Fall, the community hospital became part of a large Hospital Network. As a result, the TL has to send PD-L1 test requests to the IHC lab of the main hospital. This lab has SP142 and SP263 standardized on Ventana machines.
?	TL is not happy because of the added confusion of using results from SP263/142 to read PD-L1 when the MedOncs are prescribing either Nivo or Pembro in 2L. TL is aware of the Complementary status but MedOncs send test requests
?	TL is also not happy that they are now being forced to read PD-L1 for 1L Pembro using SP263/142. Test report states the % tumor cells stained positive for PD-L1 for each of the 2 antibodies","TL mentioned that there has been a substantial increase in PD-L1 test requests since 1L approval of Keytruda 
2. They have the 22C3 Dako pharmDx assay standardized in-house
3. When asked about reporting format, he said that they report % tumor cells stained. They do not give a range nor do they suggest whether the % staining seen would make the patient eligible/ineligible for a given I/O therapy
4. When asked about how the Medoncs might interpret the result, he said that in 1L the medoncs are leaning towards keytruda when the % staining is anywhere more than 30%. He says that they are well aware of the >_50% cut-off for keytruda. According to him, the medoncs want to offer I/O to as many patients as possible, thereby not adhering strictly to the pdl1 cut-offs. 
5. Test requests at this institution never specify if the tissue is from a 1L or 2L setting. Pathologists do not want to know this as they do not want to make treatment eligibility decisions for the patients. Therefore they are avoiding mentioning that keytruda use in 1L requires PD-L1 staining of more than 50%.","?	They are a Ventana facility, so they have SP142 standardized for Atezo. But there is no request for PD-L1 data using SP142
?	PD-L1 test requests have increased in number since 1L approval of Pembro. 
?	MedOncs are requesting both 22C3 and 28-8 IHCs but are not communicating whether it is from a 1L or 2L setting
?	Now because of the increase in volume, TL is going to use SP263 to read PD-L1 test requests for NSCLC (indicated that this would be in lieu of 22C3 for Pembro) and report % tumor cells stained. Report is going to carry a disclaimer that the test is an LDT and will also list the Blueprint, Dr. Rimm?s data as well as the AZ concordance study. TL is aware that this cannot replace the IVD but they are not going to bring in Dako machines. TL communicates to MedOncs about the Complementary status of 28-8.",681
large academic,Territory," MID-ATLANTIC
SC",228.15,1.92161723611e-06,78,880,"RTL at a large academic cancer center stated that the 209-602 study was going to be limiting to accrue patients due to several factors.
1.  prior treatment with pomalidomide and elo are excluded
2.  >/=2 prior lines of therapy 
3.  the washout period for prior monoclonal antibody treatment

Concerned that patients from the community will have seen pom and/or elo prior to referral.
There will be patients that are not going to want to wait the 4 weeks for washout period and/or due to aggressiveness of progression may not be able to wait that length of time",RTL recently relocated to NCI designated cancer center to build I-O program.  Stated that even though immune-oncology is considered now another treatment pillar for cancer that many are still not buying into I-O.  Especially seeing at current institution.  One reason given was need longterm data.,RTL at a large academic cancer center stated that has treated first patient with opdivo in cHL and patient had 9 cycles and patient did not experience any toxicities.  Stated that was very surprised and had toxicity app on phone and was ready to use.,958
cancer center,Territory," MID-ATLANTIC
SC",35.3720930233,2.11043924797e-05,46,130,RTL recently relocated to NCI designated cancer center to build I-O program.  Stated that even though immune-oncology is considered now another treatment pillar for cancer that many are still not buying into I-O.  Especially seeing at current institution.  One reason given was need longterm data.,RTL at a large academic cancer center stated that has treated first patient with opdivo in cHL and patient had 9 cycles and patient did not experience any toxicities.  Stated that was very surprised and had toxicity app on phone and was ready to use.,"RTL at a large academic cancer center stated that treated a transplant ineligible patient, >1 prior treatments, with total 9 cycles of nivo and had CR post nivo treatment.  Will be admitted this week for allo transplant.  Stated was very concerned regarding GVHD",176
large academic center stated,Territory," MID-WEST
IL",166.6,1.41363069077e-28,25,347,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center stated that they will be opening up a Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission.  She anticipates this will answer a good clinical question.,NTL on the NCCN panel at a large academic center stated that she has some concerns for the increase in mortality with allo transplant after getting OPDIVO.  She would like to see additional data regarding follow up of data.,372
university hospital,Territory," MID-WEST
IL",52.8888888889,1.36433027985e-05,6,428,"NTL from large University hospital in midwest noted on results from 141 from podium ""The RR may have been 16% but the OS was stunning""",RTL at a large academic center stated that there is a strong need for education for academic center hematologists and HCPs on IO agents once agent is approved.  Unlike their community physician counterparts who have had experience with IO agents in solid tumors they do not have experience with OPDIVO in their practice.,NTL at a large academic center stated that they will be opening up a Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission.  She anticipates this will answer a good clinical question.,434
midwest,Territory," MID-WEST
IL",37.1875,6.00072244031e-16,42,124,AI at University Center in midwest (former NCCN panelist) shared at her institution for new Dx lung CA they are getting PDL-1 status as well as TTF1 marker (non-squamous) and P40 in squamous   Also feels re-bx is best option if changing therapy,AI and NCCN panelist in midwest stated that for both PD1 agents in cHL the RR is very good (60-70) but the 10-20% cRR still need to do better.  Noted heavily pre-treated pop.  Felt a big step will be first line w/o bleo,"I met with a NCCN NSCLC panelist in the midwest.  He offered these insights

On OAK at ESMO he stated he and the panel viewed the data to be good, roughly like Opdivo.  On the issue of the ESMO data showing ""positive"" results in the PDL-1 negative population, we went over the issues and he stated the panel recently discussed this.  Stated there was not strong enthusiasm of panel for the PDL-1 negative argument due to reasons we discussed internally, but also due to low numbers and at this point unpublished data (he stressed this).  That said given indication of atezo unlikely to get NCCN recommendation more restrictive than label.

Agreed with just about everybody else that 026 was surprise, likely trial design, etc.

On KN 021 stated panel felt the data way to early to recommend Chemo/Pembro in any way.  Had no opinion on whether IO/IO or IO/chemo likely to be superior

Stated NCCN was working on recommendation on how to use PDL-1 cutoffs in some future statement.  This is second NCCN panelist to mention this to me.  Other was in cHL.  Stated majority of effort was in the 1-100% area (as opposed to 0-3+)  Commended BMS for working with Ventana

Noted when voting any member whose name was on relevant paper must recuse self.",166
University,Territory," MID-WEST
IL",31.7333333333,4.70877861653e-05,14,366,RTL in SCCHN noted at his center (Major university in midwest) they were using mostly pembro off trial for HN cancer because it has been approved longer and his center feels access is easier.  This contrasts with another major center in same city who has been using nivo all yr without any insurance issues.,"RTL at university center in midwest noted that like most others results of 026/024 were surprise without clear explanation

Noted atezo would have strong potential at his institution mostly due to q 3 dosing

Noted little usage of pembro in first line so far

Felt chemo/IO had strong potential",AI at University Center in midwest (former NCCN panelist) shared at her institution for new Dx lung CA they are getting PDL-1 status as well as TTF1 marker (non-squamous) and P40 in squamous   Also feels re-bx is best option if changing therapy,380
RTL at a large academic center,Territory," MID-WEST
IL",28.3333333333,7.3705143734e-06,22,169,RTL at a large academic center stated that they are participating in the ABVD and AVD + brent study and depending on the results will possibly use Brentuximab upfront in cHL.  If that is the case then we can move Nivo to earlier lines of therapy as it would make clinical sense too.,"RTL at a large academic center with a high volume of HL patients treated (80 annually) stated that Brentuximab has an important role in the RR setting.  He has began to utilize in the pre-transplant, post-transplant consolidation setting and post transplant and brentuximab failure with great responses seen in all lines.    His preferred regiment in the relapse setting is ICE as salvage therapy common.  He has great success with Brentuximab and Bendamustine combination.  In addition, patient post auto-transplant started bendamustine as single agent in multiple patients with good responses.",RTL at a large academic center is ?not sold on brentuximab maintenance therapy due to lack of OS data.?  He does not see it as an established standard of care but will talk to pts about option post transplant.  He doesn?t use brentuximab as consolidative agent at this time but use at relapse.,191
PDL-1,Territory," MID-WEST
IL",17.0,3.38005688888e-10,50,881,"I met with NCCN panelist in NSCLC  He shared the following

He stated the NSCLC panel met recently.  He stated that Merck will get a first line listing for pembro in the greater than 50% staining population

Stated panel was surprised by 026 data.  Stated he felt that PFS was a poor choice for primary endpoint.

NCCN is working on a ?guideline? for PDL-1 testing in first line as it was becoming very important.  At this point it will involve only tumor staining.  It will not include the Roche method of including tumor infiltrating cells.  Stated the guideline will have a number cut-off, i.e. ~1-100%....Roche?s 0-3+ method will not be part of guideline.  Stated there would be some recommendation for pathologists who use Roche assay to convert the Roche result to a 0-100% scale.

Panel not impressed with atezo data

Stated that while  ipi/nivo data impressive in NSCLC the panel laughed a bit at it?s attention as the data was so early.  That said he felt there was great potential here

Stated he heard Merck was fairly far along with ipi/pembro data.  More so in melanoma but also lung

Stated he heard AZ combo data will likely come out shortly after BMS combo data in first line NSCLC

On the subject of likely CMSTO 2016 presentation of 026.  He stated if we had OS data that was positive at a particular cut-off there would be a good chance BMS could get a NCCN listing in first line consistent with that given 026 was a large phase 3 trial.","TL stated that last in-person meeting was 1-2 months ago.  Stated there is a call coming up in 1-2 weeks.  On the topic of PDL-1 cutoffs in first line, he stated that pembro would definitely not get a rating until the data was published.  On the possibility this would happen in the near future, he stated that he was somewhat new to panel, but his impression was that the NSCLC panel tried to be more ?inclusive? than ?exclusive?.   On the 50% cut-off issue he stated there could be different possibilities.  He mention there could be a certain recommendation but also some sort of footnote or comment.  It was difficult to tell if this was a general PDL-1 positive listing for pembro with a footnote stating the trial was 50% or greater, or if there could be a listing using a 50% cut-off with a footnote stating a wider range of patients may be appropriate.
 
In other notes he agreed with many that a cut-off is good but we don?t know what it is yet.  Someplace between 5 and 50.  Stated he was heavily involved in adjuvant trials but not metastatic disease.  Inquired as to whether 026 would include results at varying degrees of expression (answered affirmatively).","I met with NCCN panelist for SCLC (though sees mostly NSCLC) at an NCCN center in  midwest.  She offered these insights:

She stated in her patient population she is seeing patients come in with info, asking for pembro as it did not ""fail"" trial like nivo.  Patients on nivo not asking to switch

On NCCN panel and SCLC she stated that Nivo and Nivo/Ipi given 2B rather quickly and without much discussion.  Stated this was bar was so low in second line SC.  She stated this ""sort of thing"" is considered by panel.  Stated bar would be somewhat higher in first line SCLC  (Topo/etc. has good RR but poor DOR, both important)

She, like others, felt pembro would likely get NCCN listing at 50% when data published.  She felt for nivo in first line the bar for listing would be quite high.  i.e. as pembro failed primary endpoint, if there was positive data (say at ESMO) for a cut-off above 5%, that data would have to be very good to get a listing.  This contrasts to most other panelists opinions I have heard.

On the design of 026 she felt that BMS probably had good advice given to us at ad boards when designing trial but we did not listen (she did not expand on this)

She stated that her institution just started testing for PDL-1 in house.  Prior it took 2-3 weeks for results.  Now takes 2 days",931
mostly,Territory," MID-WEST
IL",15.8666666667,1.54544099922e-08,34,0,"NTL in midwest noted her institution had a number of patients that went through numerous lines of chemo in NSCLC prior to Nivo approval.  They went on Nivo on approval and a number of them are still doing well.  Got impression they were still getting Nivo q 2 but did not ask specifically

Same TL also sees fair bit of sarcoma (70 a yr., mostly peds)  and has had decent sucess with nivo generally through expanded access.","RTL at university center in midwest noted that like most others results of 026/024 were surprise without clear explanation

Noted atezo would have strong potential at his institution mostly due to q 3 dosing

Noted little usage of pembro in first line so far

Felt chemo/IO had strong potential",RTL in SCCHN noted at his center (Major university in midwest) they were using mostly pembro off trial for HN cancer because it has been approved longer and his center feels access is easier.  This contrasts with another major center in same city who has been using nivo all yr without any insurance issues.,34
line,Territory," MID-WEST
IL",7.48427672956,2.95023885509e-10,345,108,"NTL in midwest stated at her institution they generally push trials, especially after first line.  That said she stated in second line they almost always use Nivo over pembro.  She felt even though Roche had some ""iffy"" data in PDL-1 neg she felt it was minor and still thought her institution would use Nivo second line.  They have just started using pembro in first line in greater than 50% stainers.  They send out tissue (turnaround 10-14 days) but are working on getting test in house","RTL in a large community center shared that in the last 9 months, he has treated 3 young men with relapsed HL.  He stated that on patient failed standard first line relatively fast and started 2nd line.  Disease is ?not as responsive? after 1st relapse.   Therefore, at second line therapy after 3-4 cycles, patient was responding and he was able to obtain Opdivo through patient access and patient has continued in response.  He is impressed with the favorable side effect profile and feels this would have a great place in therapy.","NTL in midwest noted that now they are using Nivo first line, patients who progress move to cisP/pem or cisP/gem second line.  Taxol/Ram third",453
strong,Territory," MID-WEST
IL",7.37984496124,4.6826441292e-05,50,10,"Andy Lepesto and I met with a SCLC panelist.  Panelist also had strong knowledge of NSCLC panel workings.

He stated, as had many others, that he would think that Merck will, with very strong likelihood, get a first line recommendation based on 024 that is only for 50% and above.

Further, he stated that if BMS had OS data that was positive in 026 at a different cut-off, purely for example say 25%, that BMS would get positive rec at 25%, Merck at 50%.  He thought clinicians (at least at his institution) would use Nivo for 25-50 and either nivo or pembro for above 50","RTL at university center in midwest noted that like most others results of 026/024 were surprise without clear explanation

Noted atezo would have strong potential at his institution mostly due to q 3 dosing

Noted little usage of pembro in first line so far

Felt chemo/IO had strong potential",RTL at a large academic center stated that the clinical rationale for the 209-436 PHASE I/II study with NIVO + Brent will answer a strong clinical question.  The eligibility criteria is optimal in including an expansive number of subtypes of NHL which is not always rue for other NHL trials at the site.  He stated that he expects a favorable safety profile based on his experience with other checkpoint inhibitors use (Pembro).,60
issue,Territory," MID-WEST
IL",6.26315789474,3.52901864486e-06,87,0,"RTL at a large academic center yesterday mentioned that his colleague at the same institution has submitted a manuscript for publication this past week addressing PD-1 Inhibitors in the post allotransplant setting.  It specifically would be addressing the issue of early identification, safety standards, and treatment protocols.  
He mentioned a patient case manifestation of GVHD in as grade 4 hepatotoxicity (T-Bili at 40).  Interestingly, the patient is post-transplant after 5 years.  He stated that there seems to increasing concern expressed by his colleagues for GVHD post allo transplant and this manuscript hopes to address it.",RTL at a large academic center in stated that they have recently been moving brentuximab into earlier lines of therapy in their Hodgkin patients.  This is inclusive of pre-transplant along with post transplantation consolidation and if relapsed after transplant.  They have the expected adverse effect issues of peripheral neuropathy and thrombocytopenia.  He stated that PD1 inhibitors would play a critical role in patients who traditionally have exhausted all therapies.  There is a strong clinical rationale to move up IO agents to earlier lines of therapy.,"I met with an oncologist specializing in lung at a university hospital in south/Midwest.  He shared a number of interesting insights.  They centered on a theme or two and I will try and tie them together here:

He uses a lot of PD-1 agents and he mostly uses Pembro (though has used nivo appox 5 times with at least 2 responses).  The reasons were multi-factorial.  He mentioned he was swayed by a conversation he had with Roy Herbst a while back.  His reasons were:  1)  Felt pembro offered better SE profile (personal experience)    2) Pembro cheaper  3)  Better for patients being q3

We discussed all this in detail but briefly:

We discussed BMS cost data.  He felt the wastage issue does not help much.  For example he would use 200 pembro if the patients would ?require? say 220.  He said ?Think about it:  If there is an AE you do not dose reduce.  The reason is that going down the dose curve does not really change anything once a critical dose is there.?   He felt the same with efficacy, as long as it was ?close? the patient would get the benefit.   Did not worry about small mg differences and thus felt pembro cheaper.

We also discussed Keynote 10 data.  He did not feel Merck?s different dosages were an issue (again mentioned Roy Herbst)?He actually said BMS did studies poorly by taking all comers.

He felt patients with 1-2 years of life do not want to live in doctor office (q2 vs q3)

We discussed second line and he felt it was unfair to compare Nivo (and pembro I assume) to Doce in second line?Stated now the other standard in second line is docetaxel and Ramucirumab",87
recently,Territory," MID-WEST
IL",5.80487804878,7.02582904598e-06,93,0,Met with NCCN panelist for NSCLC recently.  He noted NCCN has been discussing the whole PDL-1 testing situation along with others.  Noted they found it odd that Foundation recently announced they were going to add PDL-1 test to assay using SP 142 Ab given that SP 142 was shown to have lowest concordance in multiple studies..  Assumed it was some sort of business issue,"A NTL from NCCN institution remarked from podium that Cancer Letter (publication) recently contacted him for a statement on which agent was better, Opdivo or Keytruda.  He demurred.  Advised audience to do same if contacted","Met with NCCN panelist for NSCLC recently.  He shared:

His Journal club met recently to discuss 026, 024 data to see if they could come up with explanation for discrepancy.  They could not.  He agreed chemo arm in 026 did better than expected.  Did not think much of male/female issue, smokers between trials.

Mentioned they have been using nivo for 3 years in one patient with NSCLC.  Patient presented with CNS mets and adrenal mets.  Responded initially and at 3 years either has SD or NAD but is doing well.  He noted recently patient had been feeling off and after DDX he was found to have pancreatic insufficiency.  Getting GI enzyme treatment and doing well.  MD did report this to BMS hotline

He noted in his PDL-1 first line trials he seems to be seeing a lot of SE in combo arms.  More than was reported by Antonio in phase 1 trials for BMS.  Mostly GI and pneumonitis",93
meeting,Territory," MID-WEST
IL",5.51655629139,1.35845464075e-08,239,35,Met with NTL in HN.  Stated now that we have HN approval we clearly should be the market leader given out larger phase 3 trial with OS.  Stated everyone at his institution would use Nivo after Pt in HN,Met with NCCN panelist for NSCLC recently.  He noted NCCN has been discussing the whole PDL-1 testing situation along with others.  Noted they found it odd that Foundation recently announced they were going to add PDL-1 test to assay using SP 142 Ab given that SP 142 was shown to have lowest concordance in multiple studies..  Assumed it was some sort of business issue,"In a meeting with a large national payer, AI mentioned that BMS should have a proactive source that reflects certain long term (1-5 yr) positive data (OS, PFS) to show IO value as opposed to just mOS, mPFS",274
noted,Territory," MID-WEST
IL",5.26822916667,4.36755466484e-07,144,0,"NTL from large University hospital in midwest noted on results from 141 from podium ""The RR may have been 16% but the OS was stunning""","Met with NCCN panelist for NSCLC recently.  He shared:

His Journal club met recently to discuss 026, 024 data to see if they could come up with explanation for discrepancy.  They could not.  He agreed chemo arm in 026 did better than expected.  Did not think much of male/female issue, smokers between trials.

Mentioned they have been using nivo for 3 years in one patient with NSCLC.  Patient presented with CNS mets and adrenal mets.  Responded initially and at 3 years either has SD or NAD but is doing well.  He noted recently patient had been feeling off and after DDX he was found to have pancreatic insufficiency.  Getting GI enzyme treatment and doing well.  MD did report this to BMS hotline

He noted in his PDL-1 first line trials he seems to be seeing a lot of SE in combo arms.  More than was reported by Antonio in phase 1 trials for BMS.  Mostly GI and pneumonitis",Met with NCCN panelist for NSCLC recently.  He noted NCCN has been discussing the whole PDL-1 testing situation along with others.  Noted they found it odd that Foundation recently announced they were going to add PDL-1 test to assay using SP 142 Ab given that SP 142 was shown to have lowest concordance in multiple studies..  Assumed it was some sort of business issue,144
NTL,Territory," MID-WEST
IL",4.13194444444,1.63374748757e-06,311,710,NTL at a large academic center stated that they will be opening up a Phase II Study of Pidilizumab in Patients with Diffuse Large B-Cell Lymphoma Following First Remission.  She anticipates this will answer a good clinical question.,"-NTL at a large academic center stated that there will be a symposium in San Francisco in sept which will be set up as a debate with him and another NTL 
o	Other NTL ? will be taking stance of PD1 inhibitors as replacement of allo transplant which he will",NTL at a large academic center  stated that there needs ot be F/u discussion on the Lugano Classification updates just published and implementation into practice and clarification for clinicians making clinical assesemen.   He stated that discussion on the abscopal effect seen in Lymphoma how it affects management ? discussion points to be clarified,1021
stated,Territory," MID-WEST
IL",2.55,1.66367599781e-05,860,118,"LTL at a large community practice stated that he is very optimistic about the hodgkins lymphoma approval.  He stated that he recently started a patient who has had 4 lines of prior therapies and responded ?beautifully and in CR? after 4 cycles.  Clinically he has seen responds right away.  He stated that he would use outside indications as he feels if patient not is CR after ICE then NIVO until CR and then transplant.  If not transplant eligible he would give Nivo right away.  He stated that BMS has marketed OPDIVO ?beautifully and is the real winner? and has a strong advantage over Keytruda.  He calculated that there is a $5,000 savings annually at current approved dose vs. Keytruda.",LTL at a large community practice stated that he is ?really impressed? with the response rates of OPDIVO in cHL patients.  He stated  that he would move use of OPDIVO to earlier lines to possibly avoid transplant as salvage therapy.  The goal other salvage therapy might be met with OPDIVO to maintain the durability of remission in this patient population and avoid transplant.  He is impressed with the solid tumor experience now with the great tolerability and ease of administration to patients.  So far he has only seen maybe increases in transaminases no immune related s/e.,Met with NTL in HN.  Stated now that we have HN approval we clearly should be the market leader given out larger phase 3 trial with OS.  Stated everyone at his institution would use Nivo after Pt in HN,978
NCCN center in the midwest stated,Territory, MN,665.777777778,4.51805282813e-20,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
exercise,Territory, MN,277.407407407,1.3367760794e-08,5,238,"During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment he was surprised the FDA will allow Merck to have labeled indication without a comparator arm in their trials given the fact that there is a drug with proven efficacy that has a comparator arm","During a profiling exercise with a H&N panelist at an NCCN center, AI stated he defines refractory the same as we defined it in 141 (which he stated is a better design that the Pembro trial where you had to fail both cetuximab and a platinum therapy)","During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment the Nivo QOL is ?the best,? and he will highlight that data at his next post ASCO talk. He believes that data is impactful. He mentioned Pembro doesn?t have that data",243
P&T committee,Territory, MN,110.962962963,3.54720996095e-09,8,478,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",486
NCCN center,Territory, MN,83.2222222222,1.65488363827e-12,26,280,"P&T committee member/lung AI at an NCCN center stated the following

o	When asked if cost/cost avoidance discussion are part of their formulary discussions, he stated they are minimized at his institution. He stated decisions are NCCN/FDA approval/data driven.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",306
AI stated,Territory, MN,70.6127946128,6.07932796822e-18,24,171,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",195
payor,Territory, MN,55.4814814815,7.7146791151e-06,7,23,"For a small regional health plan assosicated with a national account institution (~200K lives): While discussing oncology management, the payor stated that he is excited to hear that there will be more PD1's enter the market as they will be able to manage the class; however, he stated it will be nearly impossible to manage the class if the indications vary from drug to drug. He cited the example of the TNF class of drugs where they are unable to restrict certain drugs due to niche indications. This specific plan does not currently manage oncology.","Specialty pharmacist at an academic SP stated he believes that I/O therapy will eventually be billed under the pharmacy benefit as PBMs will want to demonstrate their value in an increasingly generic blended market. As the health system with an integrated payor looks at total cost of care, he thinks the payor will demand white bagging as a cost saving through their own SP; however, he was uncomfortable with the concept of an outside SP delivering an infusible to his infusion clinic.",Regional payor stated they have a waste billing limit of 40 mg due to the vial size of Opdivo,30
order sets,Territory, MN,44.3851851852,1.36726717016e-05,8,321,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),329
reactive discussion,Territory, MN,36.987654321,2.24373460899e-05,9,310,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","?	While proactively discussing 2 year OS for 057/017, the reactive discussion led to 026. We discussed trial designed etc. We then began to discuss the 2L space in which the AI stated their system will likely begin to use atezo based on no testing and Q3 weeks (convenience) for traveling patients and chair time.  
?	The AI then discussed 227 (enrollment site)
?	This led to a reactive discussion on the early 012 data which demonstrated nearly a doubling ORR based on expression levels
?	The AI then led a discussion on what a treating physician would do if a patient was progressing on Nivo and the 227 reads out positive for regimen (would a treating physician add ipi?)
o	AI believed more data is need; however, this is an area of needed exploration
o	There is no data with Atezo or Pembro to add Ipi at Q 6 weeks","Advisor to the panelist at an NCCN center in the midwest stated, after a reactive discussion on the 227 trial design, that BMS should decide on one dose for the regimen (referencing 032 for SCLC). He stated different doses will increase confusion and errors if we use multiple doses in different tumors.",319
advisor,Territory, MN,35.8997821351,2.52019345726e-12,27,231,Advisor to the panelist at an NCCN center in the midwest stated Atezo won't be considered for formulary addition because they are so accustomed to using Nivo and it's challenging to change habits,"Advisor to the panelist at an NCCN center in the midwest stated that based on the 026 data, he'd like to offer Nivo in 1L","Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.",258
build,Territory, MN,31.7037037037,3.47169711024e-05,10,21,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),31
midwest,Territory, MN,26.4197530864,2.28687188179e-10,42,124,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,166
expression levels,Territory, MN,25.2188552189,8.25746972402e-06,41,170,"Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Payor insights from ~4 million life plan in the Midwest provided the following insights. They are not looking to manage PD1 inhibitors by PDL1 expression levels. He indicated the science is too new and there are too many unanswered questions.  Payor stated the PDL1 expression is informative, but not definitive. PDL1 expression is not in the PA criteria yet. He stated there is not an ICD10 code for PDL1 expression (+/-).",211
unsolicited,Territory, MN,23.1172839506,1.15082831901e-05,99,200,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",299
perspective,Territory, MN,20.440545809,4.16172070494e-07,25,0,P&T pharmacist chair at an NCCN center in the midwest stated that cost data (ie Nivo vs docetaxol lung-tx related adverse events-not shared) is irrelevant to them when there is a clear winner from a clinical trial in either efficacy OR safety from an institutional P&T perspective.,"Director of pharmacy at an NCCN center stated that from an operational perspective, there is an increase in human resources needed to use access support programs(foundation portion) (ie paperwork/drug management/dispensing cost). While these programs are important for the patient, they are expensive for her to implement because the pharmacy does not receive reimbursement for their role in drug delivery when drugs are received from foundations thereby increasing her ""costs.""","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",25
chair,Territory, MN,19.4185185185,5.51974824579e-07,26,260,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",286
panelist,Territory, MN,18.9448961156,3.1607756734e-12,134,164,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",298
minimal,Territory, MN,17.337962963,3.54520976813e-05,20,0,"During a profiling exercise, an NCCN H&N panelist offered the following unsolicited insights:
?	When asked how he treats LA-SCCHN he stated the following
o	First surgery
?	After surgery with minimal dz, pt would get RT
?	After surgery with moderate dz, pt would get a plateium therapy
?	After surgery with bulky dz, pt would get chemo/RT
?	He does not test for PDL1 expression but does test for P16
?	Research gaps-he?s like to see a trial sequencing I/O then chemo. He believes patients respond to chemo better post I/O.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",20
o,Territory, MN,13.1403508772,2.46870343135e-07,46,220,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Eric Mortenson and I met with a HL NCCN panelist for a profiling exercise. Below are NCCN related insights.

The panel meets every 12-18 months in person. The next panel meeting is August; however, he stated we should expect an update to the guidelines within 6 weeks.
?	How their update approval process is designed:
o	An admin sends out the proposed guidelines for comment from the rest of the panelists via email. AI stated the ?very loud? panelists typically get their way. He stated the PD-1?s have been sent out for review and ?you will be happy with the outcome.?
?	When asked what data is needed for an NCCN update, he stated heavier weight is given for FDA approvals; however, phase II or better data will be reviewed. He stated there was not a standard endpoint required for a given category rating (ie OS for category 1).

Each panel operates independantly with their own set of rules.",266
NCCN panelist,Territory, MN,12.1050505051,7.01776707208e-09,94,149,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,243
AI,Territory, MN,7.74160206718,5.1473269505e-07,121,70,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",191
RAI,Territory, MS,530.129032258,7.67697465127e-18,15,701,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.",716
context of an online lecture,Territory, MS,337.35483871,1.72040645962e-11,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NAI,Territory, MS,337.35483871,1.72040645962e-11,7,282,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",289
NCCN 2016 Webex Congress Series,Territory, MS,337.35483871,1.72040645962e-11,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
proactive meeting to discuss CM-026,Territory, MS,337.35483871,1.72040645962e-11,7,257,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",264
Bone Marrow Transplant Director,Territory, MS,240.967741935,2.57300994249e-08,5,713,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.",718
academic institution in the HSL South,Territory, MS,192.774193548,9.78673681984e-07,10,110,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).","Having missed ASCO this year, an access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory asked on 08/05/16 to review Checkmate 012 data. The bar chart describing ORR with nivo (nivo+ipi) across tumor PD-L1 expression levels captured his attention (?nivo is truly a cool drug?). He commended BMS for studying nivo (nivo+ipi) efficacy across the entire range of PD-L1 expression, acknowledging that (many of) our competitors seemed reluctant to assume the risks associated with this strategy. He also noted that: 1) ORR values with nivo (nivo+ipi) at the ?50% expression level were most impressive; 2) ORR values at the <1% - ?1% levels were not negligible, even in comparison which ORR achieved with platinum-based chemotherapy; 3) nivo (nivo+ipi) may prove to be the best therapeutic options for some categories of patients with low PD-L1 expressing tumors (e.g., older or frail patients); 4) the medical community desperately needs more data to make informed decisions about who should receive what.  
The AI did not know the results of Checkmate 026. We did not address the issue since BMS official talking points had not yet been released.",120
Annual New Orleans Summer Cancer,Territory, MS,192.774193548,9.78673681984e-07,4,341,"On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Roche proposes to assess PD-L1 expression on tumor cells + immune cells. Complicated score: not convenient for clinicians.","On 07/22, a panel of speakers at the 11th Annual New Orleans Summer Cancer Meeting concluded that: 
?	PFS is very hard and costly to assess. It is a useful endpoint for phase I/II studies, but ORR and OS are much more important in phase III trials. Newer endpoints need to be explored such as ?time to next treatment.","On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Study Checkmate 141 showed a striking 1-year OS benefit in favor of nivolumab. This result will lead to approval (but pembro approved first?). Subgroup analyses also indicate that nivolumab can be used in almost everybody. Efficacy seems to be lower in P16-negative and PD-L1-negative patients, but it is still too early to make final conclusions.",345
LAI,Territory, MS,192.774193548,9.78673681984e-07,4,238,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",242
RAI/NSCLC,Territory, MS,192.774193548,9.78673681984e-07,8,175,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",183
made the following comments,Territory, MS,168.677419355,2.67259574441e-20,17,549,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.",566
South,Territory, MS,156.629032258,8.39464788365e-19,20,360,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",380
NCCN panelist for NSCLC,Territory, MS,144.580645161,2.4055692872e-13,11,482,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
Assoc,Territory, MS,144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
RCTs,Territory, MS,144.580645161,3.62780141464e-05,3,541,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
To control costs in 2L NSCLC setting, starts with 4 doses of nivo or 3 doses of pembro or atezo (if tolerated). Continues treatment if observes PR/CR, SD or no more than a small progression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.",544
Vice Chancellor Clin Res,Territory, MS,144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
territory,Territory, MS,128.516129032,3.95289189196e-22,35,349,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",384
shared the following unsolicited insights,Territory, MS,117.041474654,4.59611035311e-23,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
national access influencer,Territory, MS,96.3870967742,2.88456084709e-06,7,486,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",493
NSCLC NCCN panelist,Territory, MS,75.732718894,1.7802590881e-14,17,665,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",682
q3wk,Territory, N. CA,33.7142857143,9.62689772001e-09,14,425,Lung TL stated that convenience of dosing is critical for many of his patients if patients are stable (efficacy and safety) on nivo at 3 mg/kg q2weeks instead of switching to pembro q3week he switches some of his patients to nivo at q3wk interval.  Has not observed additional toxicities in the 3 patients thus far.,"Lung TL has a patient who has been stable on nivo for over 1 year with almost a complete response, however recently switched the patient to q4wk dosing using 3mg/kg dosing.","SCCHN RTL uses a modified version of EXTREME, PTC (platinum/taxane/cetuximab) due to toxicities from 5-FU.  He mentioned EXTREME is SOC because of the Vemorken study in Belgium where taxanes were not approved at the time.  

Patient selection: For patients who are young and fit (i.e. good ECOG PS) uses PTC in the metastatic setting.  Does not see benefit of single agent cetxuimab in recurrent metastatic setting based on low response rates and toxicities.  For patients with worse PS, would use a PD1 inhibitor

Dosing: majority of patients are started on pembro because of the convenience of the q3 week dosing, which has been echoed across two other TLs in the region.  RTL mentioned only one of his patient being on Opdivo but responding well to therapy.",439
myocarditis,Territory, N. CA,25.2857142857,2.10222109081e-06,12,62,Several local lung TLs are not clear if there are differences in the toxicities profiles between the PD-1s vs PD-L1 as they've seen both hyperglycemia and myocarditis in both nivo and pembro and more recently use of atezo leading to hyperglycemia in some of their patients including myocarditis.,Melanoma RTL has observed a few cases of acute heart failure due to immune-mediated myocarditis in patients on regimen or monotherapy nivo or pembro and is looking at routine troponin levels/ECG.,Melanoma RTL has observed a few cases of acute heart failure due to immune-mediated myocarditis in patients on regimen or monotherapy nivo or pembro and is looking at routine troponin levels/ECG.,74
TLs have stated,Territory, N. CA,14.75,3.98335642427e-06,21,203,Local H&N TLs have stated that pseudo-progression not observed at all with use of nivo or pembro vs melanoma.,"Several local RCC TLs have stated that while PDL1 testing is a ""hot topic"" for lung, in RCC patients they do not find the need to test.","Few local and regional lung TLs have stated that the best approach in the 1L setting is not combination therapy of IO-IO, or IO-Chemo/TKIs  but learning best how to sequence these agents or doing dosing holidays to minimize toxicities.",224
IO-IO,Territory, N. CA,13.7666666667,5.66375568628e-06,21,757,"RTL stated that regardless of what combinations in the 1L for lung, he feels that sequencing of agents should be the direction to minimize toxicities observed with either chemo-IO, IO-IO, or even targeted-IO.","Several lung RTLs have brought up sequencing agents either IO-IO, IO-Chemo, or IO-TKIs as oppose to combining agents to minimize toxicity and that may be the best approach in the future.","Few local and regional lung TLs have stated that the best approach in the 1L setting is not combination therapy of IO-IO, or IO-Chemo/TKIs  but learning best how to sequence these agents or doing dosing holidays to minimize toxicities.",778
PDL-1,Territory, N. CA,12.6428571429,6.78567111164e-09,50,881,Academic TL mentioned the community lung TLs are testing for PDL-1 because they believe pembro is more effective in PDL1+ patients.  He said that because we do not need to test there seems to be a perceived absence of benefit in the positive expressers.  He stated that when he shared with the community TLs BMS's data in the PDL1 >5% and >10% they were very surprised and frustrated to why they have not heard of the data but will likely switch to nivo.,"Post 026 release:
- 2 NTL and 2 RTL mentioned that had BMS selected a different PDL-1 cut-off the 026 trial may have been positive, perception is NOT that nivo is less effective than pembro from the 026 read-out
-  2 RTLs have stated that PFS may not have been the best endpoint and are waiting for OS readout
-  1 community TL and 2 academic TLs stated that they currently have patients who are asking for 1L monotherapy pembro based on the 024 press release, some patients are willing to pay out of pocket for treatment vs enrolling in clinical trials
-  1 RTL was less optimistic stating ?you shot yourselves in the foot by selecting a 5% cut-point and endpoint of PFS?.  Combo therapy (ipi+nivo) will have to demonstrate ?cure? or high % of CR to compete against monotherapy pembro in + expressers based on a more favorable toxicity profile
-  Consensus from academic to community TLs stating that they see pem and nivo as being the same and the Q3week is the key advantage that pembro has despite the differences in trial design because they now have a better understanding of MOA, activity, and safety in a collection of trials across nivo and pembro",Lung RTL shared that despite 026 not meeting primary endpoint with 5% PDL-1 cut-off she would consider using nivo if the PFS is similar to chemotherapy in higher expressers given nivo's safety profile.,931
TLs,Territory, N. CA,5.28358208955,1.66561368901e-05,98,6,Local lung TLs in a shared community practice have now adopted Merck assay as preferred for PDL-1 testing in 1 & 2L.,Academic TL mentioned the community lung TLs are testing for PDL-1 because they believe pembro is more effective in PDL1+ patients.  He said that because we do not need to test there seems to be a perceived absence of benefit in the positive expressers.  He stated that when he shared with the community TLs BMS's data in the PDL1 >5% and >10% they were very surprised and frustrated to why they have not heard of the data but will likely switch to nivo.,Local H&N TLs have stated that pseudo-progression not observed at all with use of nivo or pembro vs melanoma.,104
provided the following unsolicited insights,Territory, N.CA,482.192307692,7.18115684338e-61,45,146,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",191
Met with a national/regional lung,Territory, N.CA,459.230769231,4.55972086817e-16,10,211,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national melanoma and genitourinary AI/TL post-ESMO, who provided the following unsolicited insights from the podium and in conversation.
?	He expressed that we shouldn't forget about IL2 in kidney Ca, because of the durable CR?s seen in select patients.
?	When he was asked whether tumor burden is associated with response, he responded that with IL2 there is some evidence for this hypothesis.
?	He reitereated that we don't know the significance of Biomarker testing PDL1 yet in melanoma and genitourinary cancers.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",221
Met with a regional,Territory, N.CA,436.269230769,4.72532061277e-29,21,174,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
AI/TL post-ESMO,Territory, N.CA,413.307692308,1.69212874887e-14,9,660,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
AI/TL,Territory, N.CA,244.923076923,1.07618537801e-23,27,661,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",688
Met with a national,Territory, N.CA,199.0,3.51134134769e-19,25,644,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
genitourinary,Territory, N.CA,137.769230769,4.15922027829e-05,3,757,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",760
sensitivity,Territory, N.CA,137.769230769,4.15922027829e-05,3,7,"Met with a NSCLC NCCN Panelist national AI and regional head and neck AI, who reactively provided the following insights:

?	He thinks that failure of CM 026 trial to achieve a difference in PFS was due to the trial design, with BMS reaching for a patient population PDL1 greater than or equal to 5% as too broad.
?	He said that perhaps Merck reached for a population that was too narrow, having conducted the study at so many locations just to achieve the appropriate numbers of patients in KN.
?	He found it odd that sex was not stratified for in CM 026, given that it's a well-known prognosticator of how well patients tend to do.  
?	AI thinks that despite the negative result in CM 026, he thinks that Nivo and Pembro are not that different.
?	He expressed that KN trials combining chemo with IO have inflated response rates due to the chemo component.
?	In reactive discussion of the FDA Blueprint analysis showing great discordance between the higher sensitivity staining Merck and BMS assays compared to the lesser sensitivity of Atezo?s SP142 assay, AI pushed back asking why would you test using SP142 anyway, since testing is not required with Atezo and nonexpressers still may respond. Proceeded to walk him through Biomarker reactive slides outlining how Atezo?s less sensitive assay in theory may lead to classifying some expressors as non-expressors, due to the decreased sensitivity and discordance with BMS/Merck assays.
?	He expressed that Atezo?s q3w dosing frequency will be a factor in his institution?s selection of a 2L treatment, especially due to their impacted availability of infusion chair time and spaces.
?	After we informed him that the SCCHN indication is weight based dosing, He said that his institution might just use flat dosing for SCCHN like in other indications to reduce confusion and inconsistency in the pharmacy preparation.
?	He was already aware of the newly approved 141 SCCHN indication.  After reviewing the CM 141 QOL results showing favorable maintenance of PRO?s when comparing the Nivo group?s maintenance of QOL compared to the sharp decreases seen in the chemo group, he acknowledged the results and stated that QOL results are essential to any such trials in the head and neck space.
?	His institution is wanting to narrow available PD1 agents in their pathways and will be sitting down to evaluate the 2L lung space as well.","Met with a national/regional lung AI, who provided the following unsolicited insights:
?	AI reactively mentioned that his institution is currently sending to 3rd party labs to conduct both the BMS and Merck PDL1 assays, due to inability of their in-house lab/pathology to support this testing in-house.  
?	AI expressed frustration that the one test they can perform in-house is the Ventana (Atezo) assay, for which they recently bought a machine.  We reviewed the FDA blueprint analysis that showed the Ventana assay as highly discordant with BMS/Merck assays and how this could lead to misclassification of some PDL1 expressers as non-expressers due to lack of sensitivity, which he admitted to understanding.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.",10
Tony Wang,Territory, N.CA,137.769230769,4.15922027829e-05,3,100,"Met with a AI/RTL who treats multiple tumor types, but is also a Head and Neck national/regional NCCN panelist AI/RTL, during which AI/RTL shared the following unsolicited insights.
BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
?	Reactively shared that the NCCN panel will include an immunotherapy update to the guideline to include both nivo and pembro.
?	Stated that her recommendation does distinguish that the data supporting nivo (Phase III) vs pembro (single arm trial) are different and should have a different category of recommendation.
?	Commented that the SCCHN NCCN committee does not have ad hoc meetings based on recent data presented, and meetings/updates are generally every 6 months with the next update forthcoming. 
?	AI felt that in terms of trials presented overall at ASCO, there were too many trials with induction chemo combined with IO therapies.
?	She feels that induction chemo strategies with later Immunotherapy is not the right approach.
?	She inquired whether BMS has a process for partnering with other companies to explore IO combos, seeming to express a positive view of this approach. 
?	She shared that she feels BMS ""knows what they are doing"" in being very strategic about supporting ISR's and making decisions about research.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.","?	Attendees: Michael Turner (MSL) and Tony Wang (HSL)
?	Met with a RCC/Melanoma AI who provided the following unsolicited insights:
?	After my introduction of the HSL role that has a focus on access/value/access, AI expressed interest in the topic of oncology medication value.
o	He expressed interest in melanoma HEOR resources that review cost of patients treated with regimen versus monotherapy, cost of regimen (ipi-nivo) taking into consideration median number of doses received in 067 and 069 trials.
?	MSL conducting SIV visit for CA209-274 trial (adjuvant nivo post-surgical resection of high risk urothelial (bladder) CA.
?	He?s interested in proposing ISR for RCC patients after failure of IL2 without prior TKI treatment.  
o	He is a professed fan of IL2 in the front line
o	He says in front line, he prefers treating with IL2 rather than TKI?s.  He cites similar response rates between 2.
?	He says he doesn?t see many non-clear cell RCC patients (maybe 5 per year).  He thinks it makes sense to try these patients on IL 2 regimen and also nivo, but wants to see nivo data in this patient population.  Informed him BMS has post phase IIb trials in this patient population.",103
disclosed,Territory, N.CA,114.807692308,3.87493478142e-14,13,182,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
hit PFS,Territory, N.CA,114.807692308,1.1058239728e-07,6,224,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",230
CM 026,Territory, N.CA,96.9487179487,1.29008103473e-24,27,207,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",234
consideration,Territory, N.CA,78.7252747253,1.12981463802e-15,18,0,"Met with a regional oncology pharmacist manager AI, who provided the following unsolicited insights:
?	AI reactively mentioned that she?s observed instances of use of PD1 agents (Nivo, Pembro) as salvage therapy, in her institution, with unimpressive results.  
?	Due to the fact that her institution is not an IDN, comparative costs associated with IO therapy alternatives (eg. AE management costs associated with traditional Chemo) are not as important to them since they may generate revenue for interventions such as ER visits instead of being as sensitive to total spend for a patient.  
?	Due to this perspective, value measures such as the impact of seeing improved OS or positive impacts on quality of life are more important to her type of institution.  
?	She shared her institution?s P&T process as the following.  A physician (eg. Oncologist) requests an addition of a medication to formulary, which initiates pharmacy to create and present a drug monograph for P&T consideration.  With this info, the P&T committee then votes on this request for addition to formulary.  
?	The AI?s institution does have a formulary, but oncologists can order medicines not on formulary without a prior authorization process.  
?	If the medicine is on formulary, ease of access is faster since the medication is likely to be stocked by the infusion pharmacy.","Met with a regional oncology P&T Formulary AI, who provided the following unsolicited insights:
?	AI was impressed with the ORR of Nivo in cHL of 65%, noting that he expected the Independent Radiologic review ORR to be reduced from the prior Investigator assessed ORR, which made sense.
?	AI was familiar with 032 data presented at ASCO and expressed excitement at the 032 efficacy in SCLC, given that this is an unmet need given lack of current treatment options
?	AI was excited at the 141 OS rate/mOS and commented that OS advantage is what should be the overriding consideration in formulary considerations, which is what we have with the 141 data. 
?	He discounted the lack of PFS advantage in 141, repeating the sentiment above.","Met with a regional melanoma AI, who provided the following unsolicited insights:
?	AI mentioned that he is part of his institutional team that is looking at developing a home-grown treatment algorithm in terms of IO treatments.
?	This algorithm would take into account patient specific factors, such as patient?s performance status, and also baseline labs.  
?	It would define an algorithm in terms of class of agents, such as PD1 inhibitors, instead of be product specific.
?	AI currently does not test for PDL1 status prior to treatment initiation.
?	AI mentioned that he still considers individual patient specific characteristics in deciding whether to start on Nivo monotherapy versus regimen, such as performance status.
?	AI defines current practice in terms of nivolumab as 60% of patients getting monotherapy and 40% getting regimen.
?	He describes some anecdotal experience of seeing patients respond to regimen after not seeing a response on initial Pembro treatment.  He quantified that 1 out of 5 patients, he might see this type of occurrence.
?	When issue of cost arose, was able to reinforce with AI that the cost of regimen is only incrementally more expensive, around 6%, higher than the cost of sequential ipi followed by nivo.  
?	Reinforced with AI that the true cost of regimen treatment needs to take into account that 57% of patients in 069 received median number of doses (the full combo portion of treatment) and that only around 14% of patients were treated for 1 year.  
?	Broadened AI?s consideration of true cost parameters, as evidenced by his agreement that this needs to be considered in terms of true cost of regimen.  
?	In response to his question about sequential therapy, shared that nivo followed by ipi, as well as the reverse sequential regimens, did not show as good efficacy or more favorable AE profile compared to regimen.  
?	AI referenced his institution?s goal of conducting outcomes studies, in melanoma and beyond.  Offered connecting AI with BMS HEOR colleague to explore potential collaboration.
?	AI expressed that he was not particularly wowed with any melanoma data shared at ASCO 2016, as they were mostly comprised of updates on previously published studies.",18
P&T,Territory, N.CA,73.4769230769,8.25845175083e-11,18,182,"Met with a regional oncology P&T Formulary AI, who provided the following unsolicited insights:
?	AI disclosed that his organization?s medical policy was updated to allow for coverage of Pembro at PDL1>1% due to the Keynote 010 data (ORR PDL1>1% ~18%).","Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",200
following unsolicited insights,Territory, N.CA,64.2923076923,2.13564333699e-09,79,48,"Met with a AI/RTL who treats multiple tumor types, but is also a Head and Neck national/regional NCCN panelist AI/RTL, during which AI/RTL shared the following unsolicited insights.
BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
?	Reactively shared that the NCCN panel will include an immunotherapy update to the guideline to include both nivo and pembro.
?	Stated that her recommendation does distinguish that the data supporting nivo (Phase III) vs pembro (single arm trial) are different and should have a different category of recommendation.
?	Commented that the SCCHN NCCN committee does not have ad hoc meetings based on recent data presented, and meetings/updates are generally every 6 months with the next update forthcoming. 
?	AI felt that in terms of trials presented overall at ASCO, there were too many trials with induction chemo combined with IO therapies.
?	She feels that induction chemo strategies with later Immunotherapy is not the right approach.
?	She inquired whether BMS has a process for partnering with other companies to explore IO combos, seeming to express a positive view of this approach. 
?	She shared that she feels BMS ""knows what they are doing"" in being very strategic about supporting ISR's and making decisions about research.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.","2.	Met with regional Lung AI, who is also on the Head and Neck NCCN committee, who provided the following unsolicited insights:
a.	AI disclosed membership on the Head and Neck NCCN panel and is also the chair for the upcoming updates.
b.	AI shared some unsolicited insights on the topic of how NCCN committees in general consider and review guidelines and updates.  AI says that although the consent and approval of all panelists is sought, the process for doing that can be rather informal, depending on the specific chair of the committee.  For example, review/consent/approval may be done through email communication.",127
commitment,Territory, N.CA,61.2307692308,7.91304274667e-06,6,0,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that OS is what he cares about, and that PFS is not as important to him.
?	He questions whether in the real world, there will be any OS difference between patients receiving chemo 1L and then PDL1 2L, or vice versa.  
?	He doesn?t think that chemo-IO combo will be better than sequential therapy with chemo and IO.
?	He thinks the bigger risk to Nivo?s position 2L may be Atezo 2L use in unselected PDL1 patients.
?	He personally thinks that Atezo has a strong position in 2L in unselected patients based on the OAK data, with the advantage of Q3W dosing.  
?	He expresses that he sees combination therapy as the future, but not sure whether IO-IO combos or IO-chemo will be better, which will be determined by the data which we need to await.  
o	Reviewed with AI CM 012 results that lend credibility to the IO-IO combo argument for the future.  Also expressed BMS commitment to IO combo therapy with CM 227 in progress.
?	AI expressed that he used to be against IO combos, due to cost and toxicity, but the CM 012 positive data has him taking a more positive outlook for IO-IO combos.","Met with a national/regional lung AI/TL NSCLC NCCN panelist post-ESMO, who provided the following unsolicited insights.
?	He was disappointed with the lack of PFS advantage at PDL1 greater than or equal to 50% and asked about BMS internal perspective as to why there was no result.  We proceed to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	He thinks that Pembro, Nivo, and even Atezo are not that different agents.  
?	AI thinks the failure has to do with the CM 026 study design, with BMS taking a chance and reaching for a broad patient population strategy, which won in 2L, but lost in 1L.
?	AI says that this is just a stage on the way to combos and this will pass.
?	He is excited about combo treatments in the future, and believes this will be the relevant landscape instead of monotherapy.
?	He is not sure whether IO-IO or IO-chemo will be more efficacious, but he leans toward IO-IO because he believes in having chemo as a separate option by itself.  Reactively reminded him of the 227 combo 1L trial, representing the commitment of BMS to combo IO-IO in lung.
?	He thinks it's good that the lay public is more aware of myopathy AE with PD1's, with the NY times article citing NEJM article, and is something that he's seen that's important to monitor for.
?	He believes that at an academic center like his, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.  He asked whether BMS is considering less frequent dosing so discussed with AI reactively about BMS trials looking at q4w dosing, as well as q3w dosing arm in 227 (360mg q3w mono arm).  AI felt that such a strategy with less frequent dosing, such as q4wk dosing, may play a significant role in adoption of therapies.
?	He mentioned that the NCCN NSCLC panel has been busy with recent updates with Pembro and consideration of Atezo data, with emails flying around the group.","Met with a regional oncology P&T AI for a major national payer, who provided the following unsolicited insights:
?	AI mentioned that he is interested in a BMS produced, unbranded deck/package, which is meant to convey the value of IO agents (such as Nivo) in producing durability and potential for on-going responses in responders. 
?	AI says such a deck/information, targeted towards non-medical or non-subject matter experts, would be very valuable to justify the value of IO agents due to durability of response, even if efficacy endpoints such as PFS are not much greater than control groups, if OS benefit is seen. 
?	AI questioned in Lung studies why there are no major trials studying Ipi alone against the backdrop of 032 where high percentages of the patients were PDL1 non-expressors.  Responded to AI that BMS commitment is to follow the science and is committed to trying different IO combinations in different tumors, due to the responses seen with IO combinations in melanoma.",6
hypothesis,Territory, N.CA,61.2307692308,7.91304274667e-06,6,227,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national lung AI/TL radiation oncologist post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.",233
KN 024,Territory, N.CA,57.4038461538,1.54645202817e-12,17,248,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",265
SQ,Territory, N.CA,57.4038461538,6.38104680112e-07,8,0,"Met with a national lung AI/TL and advisor to NSCLC NCCN panelist post-ESMO, who provided the following unsolicited insights from the podium.
?	AI was debating from the podium for use of single agent Immunotherapy (PD1) in Squamous NSCLC
o	In the context of a debate, she stated that PD1 agents should be the standard of care for initial therapy in SQ NSCLC specifically.
o	She expressed that with CM 026 specificially in SQ NSCLC, based upon the subgroup HR analysis, the PFS was still higher than in CM 017.  
o	She referenced the impressive OS in CM 012 1L OS (19m)
o	She showed the subgroup analysis from CM 026, showing that for the SQ subgroup specifically, the HR was the lowest of all the subgroups evaluated.
o	She pointed to the much lower grade 3-4 AE?s seen with chemo compared to chemotherapy.","A national/regional lung AI and NCCN NSCLC Panelist provided the following insights from the podium at an Immunotherapy CME event.

?	AI says PDL1 not yet determinative in 2L, for example in 017 SQ NSCLC, why does it make no difference?
?	He says he will not deny treatment in 2L NSCLC, even if tested in 1L and has 0% PDL1 expression
?	Why less gr  AE?s in 012 lung versus melanoma?
o	AI says he doesn?t know.  Dose in 012 is different (lower ipi dose (nivo3/ipi1), may be factor.  
?	It?s highly unlikely that Nivo and Pembro are significantly different.
?	AI says that in the context of CM 026 negative result, he believes that Nivo and Pembro are not significantly different.  He also said PDL1 threshold cuts of data were different than in KN 024, so it will be interesting to see efficacy at different PDL1 cuts of data from CM 026.
?	In AI?s practice, he looks at whether a patient is having clinical deterioration, not just imaging, in determining whether to continue patient on Immunotherapy past progression on imaging.","1.	The following unsolicited Insights were shared by national AI in lung and RCC:
a.	He is interested in ISR?s with BMS in lung SQ cell population, for example with radiation
b.	He thinks that in the 2nd line setting, Keynote 010 results are not comparable to BMS data NSCLC and that Nivo is the choice that the majority of docs choose in the 2nd line.  He said ?BMS has nothing to worry about? with respect to Keynote 010.  
c.	 With respect to first line use of Nivo and Pembro, he shares the view that ?the scientist in him? would like to have a test (such as PDL1) that can determine which patients are most likely to respond, especially in light of the substantial costs of treatments.",8
organization,Territory, N.CA,52.4835164835,3.9540969849e-10,14,154,"Met with a regional drug use management and pathway implementation AI, who provided the following unsolicited insights.
?	He says they are still in contracting for past year with VIA, which has not been finalized.  
?	At this point in time, VIA pathway not yet implemented for his organization, but he has access to the VIA ?sandbox? so he is able to access the system and has knowledge of pathways for tumor types.
?	In regards to SCLC, he reactively disclosed that the pathway has been updated recently after the update of the NCCN guidelines (inclusion of regimen as option in 2L).
?	AI said that Nivo is on pathway for NSCLC.  If a patient does not have a PDL1 test, it?s unknown, or the test shows a low or non-expressor, then Nivo is the choice.  
?	The pathway asks if a NSCLC patient has a positive PDL1 test, without referring to specific PDL1 thresholds.  If it?s positive, then Keytruda is offered.  If it?s negative, Opdivo is offered.  
?	He mentioned that VIA pathway adherence goal is 80% for his organization (didn?t specific whether this is target across tumors or is goal for each tumor type).
?	He says VIA pathway is provider centric, which is useful in community practices, and less useful in an academic setting where providers are more familiar with SOC and understand the data. 
?	AI said that the VIA pathway adherence also has a patient choice component, such as a preference for orals over infusible medicines.  He said this is not fully incorporated into the system yet.","Met with a regional drug use management and pathway implementation AI, who provided the following unsolicited insights.

?	He says they are still in contracting for past year with VIA, which has not been finalized.  
?	At this point in time, VIA pathway not yet implemented for his organization, but he has access to the VIA ?sandbox? so he is able to access the system and has knowledge of pathways for tumor types.
?	In regards to SCLC, he reactively disclosed that the pathway has been updated recently after the update of the NCCN guidelines (inclusion of regimen as option in 2L).
?	AI said that Nivo is on pathway for NSCLC.  If a patient does not have a PDL1 test, it?s unknown, or the test shows a low or non-expressor, then Nivo is the choice.  
?	The pathway asks if a NSCLC patient has a positive PDL1 test, without referring to specific PDL1 thresholds.  If it?s positive, then Keytruda is offered.  If it?s negative, Opdivo is offered.  
?	He mentioned that VIA pathway adherence goal is 80% for his organization (didn?t specific whether this is target across tumors or is goal for each tumor type).
?	He says VIA pathway is provider centric, which is useful in community practices, and less useful in a academic setting where providers are more familiar with SOC and understand the data. 
?	AI said that the VIA pathway adherence also has a patient choice component, such as a preference for orals over infusible medicines.  He said this is not fully incorporated into the system yet.","Met with a regional melanoma AI at a high volume regional institution, who leads his institution?s lab and works collaboratively with melanoma medical oncologists at his institution, who provided the following unsolicited insights:
?	AI disclosed that his organization is attempting to establish multiple cancer centers of excellence across the bay area, with specific centers taking on expertise for specific types of cancers or service lines.
?	Centers of excellence would have the goal of becoming accredited as a cancer center of excellence in specific types of cancer, such as breast cancer, melanoma, lung, and liver as examples.
?	AI disclosed his organization has vision of creating an organizational specific cancer research consortium.
?	He said he sits on the organization?s oncology standards committee, which is tasked with realizing the above vision. 
?	His organization has launched the ?Precision Cancer Program? that focuses on the capability to collect tissue to do next generation sequencing and potential animal xenograft research.",168
RTL from a major academic institution,Territory, ND,445.648854962,3.92033143196e-26,20,232,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
community institution,Territory, ND,401.083969466,1.47674163757e-23,31,221,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
NCCN center in the midwest stated,Territory, ND,267.389312977,8.51088909426e-16,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
026 Top 300,Territory, ND,155.977099237,2.53153623257e-09,7,245,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",252
large community institution,Territory, ND,133.694656489,5.69923105966e-15,13,1371,"[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that the data from 026 does NOT impact his current use of nivolumab in second line, especially since 026 had such a high crossover rate.  LTL is still going to use nivo in second-line NSCLC as he's extremely comfortable with it.

LTL mentioned that chemo still has its place in the front-line setting: pem/carbo for non-squamous and gem/cis for squamous.

LTL doesn't believe PFS is the strongest endpoint for I-O trials and is extremely relieved that 227 has co-primary OS and PFS.",1384
exercise,Territory, ND,111.41221374,9.40557225138e-07,5,238,"During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment he was surprised the FDA will allow Merck to have labeled indication without a comparator arm in their trials given the fact that there is a drug with proven efficacy that has a comparator arm","During a profiling exercise with a H&N panelist at an NCCN center, AI stated he defines refractory the same as we defined it in 141 (which he stated is a better design that the Pembro trial where you had to fail both cetuximab and a platinum therapy)","During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment the Nivo QOL is ?the best,? and he will highlight that data at his next post ASCO talk. He believes that data is impactful. He mentioned Pembro doesn?t have that data",243
academic institution mentioned,Territory, ND,55.7061068702,3.16913951913e-06,14,47,"[026 Top 300] NTL from a top academic institution pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients.
- At his institution, 20% exhibit mutations (e.g, EGFR, ALK, ROS1) with the remaining 80% eligible for PD-1/L1 inhibitors.  Of these, only 20-25% of those will exhibit PD-L1 50% or higher.
- This equates to more like 16-20% of NSCLC patients in the real world that would be eligible for first-line pembrolizumab.","RTL from an academic institution mentioned that that data for NSCLC patients who have ALK or ROS1 mutations is unclear for I-O therapies.  RTL is aware of trials looking at crizotinib and nivolumab, but mentioned there would be overlapping toxicities.","RTL from a top academic institution mentioned that 026 was disappointing, but really the key to answer front line NSCLC is combination therapy.  RTL's institution was a potential site for KEYNOTE-024, but couldn't enroll a single patient as no one had PD-L1 expression 50% or higher.  RTL's institution is a site for 227 and RTL was glad 227 is less restrictive.",61
P&T committee,Territory, ND,44.5648854962,5.44829355678e-07,8,478,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",486
KEYNOTE-024,Territory, ND,41.3816793893,1.82196571005e-13,19,76,"[026 Top 300] RTL from a major academic institution was not surprised by the 026 ESMO data, but was fairly disappointed that the trial was negative.

RTL mentioned that even if 026 was not powered for survival, the PFS curves criss-crossing is expected given the high crossover, but the high crossover shouldn't impact the OS curves to criss-cross.

RTL was not too thrilled about KEYNOTE-024 at the 50% PD-L1 expression level.  RTL does not test routinely for PD-L1 expression up front.","[026 - Top 300] LTL from a large community institution mentioned that he does NOT test for PD-L1 in second-line NSCLC and doesn't want to.

Although data from KEYNOTE-024 shows an importance for the PD-L1 expression, he's NOT likely to have everyone test for PD-L1, wait for results, then go to pembro if they are very high expressors.  Because of this hassle, LTL is very hesitant to implement PD-L1 expression into clinical practice without seeing results from 227.

LTL is just fine with chemo x4 cycles, then go straight to nivo and bypass PD-L1 testing.","RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.",95
NCCN center,Territory, ND,33.4236641221,2.66250183352e-09,26,280,"P&T committee member/lung AI at an NCCN center stated the following

o	When asked if cost/cost avoidance discussion are part of their formulary discussions, he stated they are minimized at his institution. He stated decisions are NCCN/FDA approval/data driven.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",306
AI stated,Territory, ND,28.3594725885,4.12087973089e-13,24,171,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",195
CheckMate 227,Territory, ND,27.8530534351,1.76254155897e-05,8,8,"RTL from a large community institution who also happens to be the PI for KEYNOTE-024 at his site mentioned that the results of CheckMate 026 has no importance to him as I-O monotherapy isn't the way to go for 1st line NSCLC.

RTL said that the upcoming CheckMate 227 was a very ""ballsy"" (bold) move by BMS.  RTL mentioned that he was relieved not to see nivo monotherapy in any of the arms for the upcoming CheckMate 227.  On the other hand, RTL was curious on why the 1% PD-L1 level was chosen.  Showed the ORR by PD-L1 expression from CheckMate 012 from ASCO in response and mentioned that there seems to be ORR benefit from the ipi/nivo combination across all expression levels.  Overall, RTL was very impressed at the ipi/nivo combo from CheckMate 012 and intrigued to see how this will play out for CheckMate 227.","HCP from a community institution was very excited to see CheckMate 012 and 032 results for first-line NSCLC and SCLC, respectively.  For 012, HCP was shocked at the ORR by PD-L1 expression level for the pooled patients for combination of nivo and ipi.  HCP is eager to see additional results from CheckMate 227.","[026 Top 300] NTL from a top academic institution was disappointed that the 026 trial was negative, but admits that it was important since patients with PD-L1 expression <50% may not benefit from single-agent I-O.

NTL pointed out that the number of patients eligible for pembrolizumab is even lower than 20-25% of NSCLC patients (more like 16-20%).

Best case scenario for first-line (according to NTL) is that pembro stays approved for 50% and higher, and nivo/ipi combo (CheckMate 227) shows efficacy for 50% and lower.",16
second-line,Territory, ND,22.2824427481,2.2793364456e-08,17,63,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.",RTL at a major academic institution has been using nivolumab in second-line RCC with great results.  RTL is now encountering the problem of patients relapsing after progressing through nivolumab.,80
first-line,Territory, ND,15.3191793893,9.51895331197e-09,26,54,"[026 Top 300]  HCP from a community institution was somewhat disappointed that the 026 trial was negative, but also disappointed in how many patients will realistically qualify for pembrolizumab.

HCP mentioned that the positive data from KEYNOTE-024 at the 50% PD-L1 expression level will impact his use of pembrolizumab in first-line patients.  However, HCP emphasized that way less than 25% of his patients are 50% or higher (actually more like 10-15% at his practice).

As a result, HCP mentioned that chemo still has its place in the front-line setting.  HCP is eager to see results from 227.  In second-line NSCLC, HCP is still going to use nivo as he and his staff are extremely comfortable with nivo.","NTL from a top academic institution said that ""you gotta fix your dosing [for nivolumab in second-line NSCLC]"" and that atezolizumab is ""killing you guys because of the 3-week dosing.""

Since pembrolizumab's approval in first-line, the infusion clinics at NTL's institution have been getting busier with longer wait times and a bigger queue volume.  NTL mentioned that the longer q3w dosing of pembro/atezo in second-line shortens the queue, which is why he uses it.

Reactively highlighted CheckMate 384 (CA209-384) that compares 240 mg q2w vs. 480 mg q4w when NTL asked if there were any trials/plans to look at extended dosing.  NTL was relieved that we're investigating that for patients in the community.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.",80
major academic institution,Territory, ND,14.8549618321,2.56573241023e-05,34,225,"[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution (who also happens to be an investigator for KEYNOTE-021) was NOT thrilled about 026.

RTL is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.  All NSCLC patients at his institution and its satellites get tested for PD-L1 expression. RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.

RTL is eager to see the results for 227.  As he was also a PI for KEYNOTE-021, RTL is interested how the patients do in the nivo + chemo arm for PD-L1 <1%.","[026 - NOT Top 300; ""opted in""]  RTL from a large, progressive community institution is very ready to adopt pembro in first-line NSCLC based on KEYNOTE-024 for patients >50% PD-L1 expression.

All NSCLC patients at his institution and its satellites get tested for PD-L1 expression.  RTL will otherwise give chemo for patients <50% PD-L1 in first-line based on 026.","[026 - NOT Top 300; ""opted in""]  RTL from a major academic institution mentioned that 026 was a ""dirtier"" trial than 017, 057, and KEYNOTE-024, given high crossover between each arm bleeding into the other (60% chemo-->nivo and 44% nivo-->chemo).

Due to high crossover, RTL wasn't surprised by the criss-crossing of the PFS curves...RTL believes that the majority (60%) of patients on chemo was essentially receiving nivo as 2nd line.  This is like a repeat of 057 (criss-crossing of the PFS curves) as the majority of 026 was non-squamous.

026 has NOT changed RTL's perceptions and he is still going to use nivo in the first line.  For healthy, younger patients, RTL is more inclined to use pemetrexed/carboplatin x4 cycles, then go to nivo immediately based on 026 data.  KEYNOTE-024 is not compelling enough for him as RTL does not test for PD-L1 routinely...RTL is eagerly anticipating CheckMate 227.",259
advisor,Territory, ND,14.4180511899,1.50137661327e-08,27,231,Advisor to the panelist at an NCCN center in the midwest stated Atezo won't be considered for formulary addition because they are so accustomed to using Nivo and it's challenging to change habits,"Advisor to the panelist at an NCCN center in the midwest stated that based on the 026 data, he'd like to offer Nivo in 1L","Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.",258
expression levels,Territory, ND,13.3694656489,3.94796130566e-05,41,170,"Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Payor insights from ~4 million life plan in the Midwest provided the following insights. They are not looking to manage PD1 inhibitors by PDL1 expression levels. He indicated the science is too new and there are too many unanswered questions.  Payor stated the PDL1 expression is informative, but not definitive. PDL1 expression is not in the PA criteria yet. He stated there is not an ICD10 code for PDL1 expression (+/-).",211
poster,Territory, ND,11.141221374,5.69262955565e-06,23,284,"RTL from a large community institution mentioned that he was ""surprised that the safety of PD-L1 inhibitors (i.e., avelumab) wasn't as good as PD-1 inhibitors"" in terms of reducing immune-mediated AEs (as originally thought).  RTL was actually one of the authors for the JAVELIN solid tumor trial for avelumab (anti-PD-L1) presented at ASCO.  Interestingly in that poster, RTL mentioned that there was also a 16% infusion-related reaction rate from the 1,300 patients enrolled (pan-tumor), which mandated a premed regimen of APAP and Benadryl into the protocol.",SCLC panel chair at an NCCN institution had trouble understanding how these cost calculations were completed for the Venkatachalam poster presented at ASCO. He said the costs are too far off to be plausible. He stated grade  reactions with chemo are typically hematologic which are manageable and not terribly expensive. He stated that hospitalizations are approximately equal for chemo and I/O in his experience.,"RTL from a large community institution mentioned that ""pseudoprogression is overrated, especially in the community setting.""  He clarified by saying that it is rather uncommon and referred to an ASCO poster (Abstract 6580, Poster Board #67 by Kurra) by highlighting that there was only a 2% (7/356) incidence from I-O agents (including nivo) per RECIST criteria.

RTL pointed out that there's a danger with community oncologists new to I-O agents that they might misinterpret true progression by dismissing it as pseudoprogression.",307
midwest,Territory, ND,10.6106870229,5.70421827954e-07,42,124,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,166
perspective,Territory, ND,9.90330788804,1.1141473161e-05,25,0,P&T pharmacist chair at an NCCN center in the midwest stated that cost data (ie Nivo vs docetaxol lung-tx related adverse events-not shared) is irrelevant to them when there is a clear winner from a clinical trial in either efficacy OR safety from an institutional P&T perspective.,HCP from a community practice mentioned that flat-dose nivolumab made sense and much more convenient from a nursing and pharmacy perspective.,"Director of pharmacy at an NCCN center stated that from an operational perspective, there is an increase in human resources needed to use access support programs(foundation portion) (ie paperwork/drug management/dispensing cost). While these programs are important for the patient, they are expensive for her to implement because the pharmacy does not receive reimbursement for their role in drug delivery when drugs are received from foundations thereby increasing her ""costs.""",25
Northeast,Territory," NEW ENGLAND
MA",301.0,8.78016867068e-14,9,121,"Testing for PD-L1 in NSCLC is now part of the usual pathology and genetic tests conducted in a leading NCCN institution in Northeast US.  This hospital charges the payers a single bundled charge for all the tests they do on a patient.  Now, PD-L1 has been added to the pre-existing battery of tests.  This institution does its own immunohistochemistry assays for PD-L1 using the E1L3N antibody from Cell Signaling Technology.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",130
IME,Territory," NEW ENGLAND
MA",225.75,1.03059906794e-05,3,0,"In his presentation at an IME on immunotherapy in NSCLC, Naiyer Rizvi MD (Columbia University) summarized the data for nivolumab and pembrolizumab, stratified for PD-L1 levels and tumor histology.  The overall theme of his presentation was that both agents are very similar across all stratifications, even when the slides highlighted the differences (e.g. hazard ratio for pembrolizumab in squamous histology in Keynote-10).  BMS, Merck and Genentech funded this IME program.","Discussing therapeutic options in NSCLC patients expressing low levels of PD-L1, Leora Horn MD (Vanderbilt & NCCN panelist) indicated her preference for chemotherapy over IO agents.  She also believes that chemotherapy (with pemetrexed for NSQ NSCLC) and targeted therapy is more valuable in appropriate patients as first line therapy, instead of IO agents as monotherapy or in combination.  These opinions were expressed during the unscripted discussion following an IME program sponsored by BMS, Merck and Genentech.","Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.",3
New England,Territory," NEW ENGLAND
MA",150.5,2.506522524e-18,17,970,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.",987
cell carcinoma,Territory," NEW ENGLAND
MA",75.25,2.50530862486e-06,7,40,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",47
NCCN institution,Territory," NEW ENGLAND
MA",66.8888888889,4.29123557889e-11,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","A leading academic thought leader and clinical trials expert from a New England NCCN institution underplayed the significance of CheckMate 026 results disclosed so far.  He felt that PFS is not a good endpoint for IO therapies, as many IO trials have already shown positive response rates and overall survival despite a lack of PFS advantage.  In cancers with low T- lymphocyte infiltration, CTLA-4 inhibition using ipilimumab may enhance the efficacy of nivolumab by increasing infiltration.",125
immuno-oncology,Territory," NEW ENGLAND
MA",53.75,4.00828032701e-07,11,54,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.",65
produce,Territory," NEW ENGLAND
MA",37.625,1.68991039548e-05,11,0,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Physicians are reacting negatively to the direct-to-consumer advertisements for Opdivo and are raising their displeasure proactively during meetings.  The Medical Director of the Lung Cancer Program in an academic hospital in the Northeast told the HSLs that he had second thoughts about using Opdivo, just as a reaction to the DTC advertisement on television.  Another family practice physician involved in formulary decisions called the Opdivo TV ads ?cringe-inducing?.  He complained that the overall tenor of the TV ad grossly exaggerates the modest improvement in median overall survival produced by Opdivo in NSCLC.","A leading academic thought leader discussed the clinical trial results of cabozantinib and his own personal experience in using this agent.  Toxicity and adverse events remains the major concern with cabozantinib.  Though cabozantinib produced very good results in clinical trials, he is cautious about using this agent in his practice.  He has participated in nivolumab trials, and uses nivolumab frequently in his clinical practice.  However, he stressed that the TKIs will remain a staple part of therapy of RCC, and the right patient can derive significant benefit from them.",11
US,Territory," NEW ENGLAND
MA",37.625,1.46361607795e-06,14,24,"Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A clinical pharmacist at an academic medical center in the Northeast US indicated that they have added PD-L1 testing (IHC) to their usual battery of genetic tests for all tumors, including NSCLC and RCC.  At present, PD-L1 levels are not being used to make treatment decisions at this center.  But she implied that more granular instructions on the use of anti-PD-1 and anti-PD-L1 agents are expected in future from both regulatory agencies and payers.  This center wants to have all the procedures established before these changes become mandatory requirements.",38
thought leader,Territory," NEW ENGLAND
MA",33.4444444444,2.42576830707e-09,25,22,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","A national thought leader on renal cancer from a Northeast NCCN institution advocated a Q3W dosing for nivolumab in RCC as a cost-saving measure that also increased patient convenience.  He substantiated his argument by pointing out that the clinical efficacy in ORR, PFS and OS are identical for CheckMate 010 and CheckMate 025, though the former trial uses a Q3W dosing schedule.  He believes that FDA would accept a single arm trial that shows non-inferiority in OS to change the labeling to a Q3W dosing.",47
Boston,Territory," NEW ENGLAND
MA",28.21875,5.0253285218e-07,40,82,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",122
MD,Territory," NEW ENGLAND
MA",27.7236842105,6.47806926464e-08,29,71,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",100
ipilimumab,Territory," NEW ENGLAND
MA",26.5588235294,6.71018488851e-07,22,17,"David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.",39
renal,Territory," NEW ENGLAND
MA",20.9027777778,1.48378524388e-05,22,26,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",48
cabozantinib,Territory," NEW ENGLAND
MA",20.5227272727,2.34524140396e-06,27,137,"According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.","Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.",164
IO agents,Territory," NEW ENGLAND
MA",18.3040540541,2.05728361688e-08,45,174,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A key oncologist from a New England academic hospital shared information on his thinking and his clinical practice in managing IO agents in patients with endocrine-related immune-mediated adverse reactions.  In his opinion, adverse events affecting the endocrine organs such as the thyroid and pituitary glands can be managed by administering the appropriate hormone replacement with discontinuing the IO agent.  He believes that value provided by IO agents including the potential for a complete remission is too important to sacrifice to avoid an adverse event that can be easily managed.","The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.",219
major,Territory," NEW ENGLAND
MA",16.0106382979,1.11546964675e-08,90,483,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",573
advanced,Territory," NEW ENGLAND
MA",15.6770833333,4.85954723446e-05,36,0,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","A key NCCN panelist for SCCHN a major academic hospital in New England was profiled to understand the treatment landscape in SCCHN.  This panelist was an investigator in CheckMate 141, and therefore was intimately familiar with the data presented at AACR.  The panelist considers the efficacy in OS to be better than what is seen in clinical practice with single agent therapies (methotrexate, cetuximab, docetaxel etc.).  He has a very negative opinion on the efficacy and toxicity of these standard of care therapies.  

Combination therapies will enhance the potential of immune-oncology in difficult to treat cancers and advanced stage disease.  Robust data needs to be developed for all options with Opdivo such as IO combinations, IO + targeted therapies and IO + chemotherapy/RT.  He also stressed the need to do clinical trials in nasopharyngeal SCCHN due to its unique etiology and response to treatment.  He does not endorse extending the NCCN recommendations to include this population based on data from other types of SCCHN.","The Director of Hematologic Malignancies at a major academic hospital in Boston downplayed the incidence of GVHD in patients who received allogeneic stem cell transplantation after receiving nivolumab previously.  Hodgkin lymphoma patients with advanced disease in later lines of treatment are more susceptible to GVHD after allogeneic SCT generally, even without previous exposure to nivolumab.  As careful management of GVHD can reduce allo-associated mortality, nivolumab provides a good therapeutic option in advanced HL patients.",36
hospital,Territory," NEW ENGLAND
MA",15.6770833333,1.32785094524e-08,72,479,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The clinical pharmacist responsible for infused products at a leading academic hospital in New England expressed gratitude to BMS for its generous patient assistance program.  Most of their patients on nivolumab in off-label indications in this Disproportionate Share Hospital (DSH) currently receive free medication through the patient assistance program.  This hospital is now attempting to move some of these patients to their insurance plan, to reduce the burden on the assistance program.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",551
improved,Territory," NEW ENGLAND
MA",14.564516129,1.28660051308e-05,36,0,"The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.",36
care,Territory," NEW ENGLAND
MA",13.6818181818,1.75918689769e-05,75,12,"The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.",87
NTL in the Boston area mentioned,Territory," NEW ENGLAND
N.NY",694.846153846,2.58773432679e-16,9,137,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.",NTL in the Boston area mentioned that those patients who don't achieve a CR with BV then their response will be short lived. Also mentioned that BV is easy to give with a focused toxicity. Regarding Nivo - toxicity is broader and harder to manage but that Nivo CRs seem to do better,NTL in the Boston area mentioned that regarding AVD - A is the most active agent. Also mentioned that stopping A  after 6 cycles patient are doing fine 20 years out,146
Boston area,Territory," NEW ENGLAND
N.NY",347.423076923,1.40275139119e-15,19,27,RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,NTL in the Boston area mentioned that he does not like pembro cause there is more drug wastage and inconvenience. He also mentioned that it makes sense what nivo did with flat dosing.,NTL from the Boston area mentioned that AVD with BV better have a big KM curve separation otherwise its useless data.,46
RTL at a large academic center,Territory," NEW ENGLAND
N.NY",38.6025641026,1.53952743948e-05,22,169,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.","RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",RTL at a large academic center mentioned that auto transplant in HL is decreasing due to more agents being available and combo therapies are being explored.,191
bleo,Territory," NEW ENGLAND
N.NY",29.6942800789,3.58772469774e-06,17,114,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.",Lymphoma TL at a large academic center mentioned they experienced a bleo shortage which during this time she substituted with BV. She mentioned that she does not like bleo due to its' toxicities. She had seen toxicities with short courses of bleo and is scared to use it. But since its still part of SOC regimen she continues to use it. Waiting for BV to replace bleo.,"RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",131
Boston,Territory," NEW ENGLAND
N.NY",28.9519230769,4.38963170359e-07,40,82,NTL in Boston mentioned that patients who have progressive cHL disease may have other pathways for tumor cell death via CD4 and NK. She also mentioned that [patients who progress on Nivo have a change in the micro environment which is being researched,NTL in Boston mentioned that 026 and 024 are looking at two different patient populations based on PDL1 expression. He mentioned that there are differences in the trial designs and comparing them should not be done.,Pharmacist in the Boston are mentioned that in cHL Opdivo has a higher rate of infusion related reactions. Since this rate is higher than what we see in other indications is there a need for pre-medication?,122
BV,Territory," NEW ENGLAND
N.NY",20.0161443495,4.07324923983e-07,33,158,"RTL at a large academic center mentioned that elder patients with HL are being treated with AVD without Bleo due to toxicity. Also mentioned that he will use BV earlier in this patient population due to ability to tolerate chemotherapy. Feels using BV in place of bleo is very real/possible although he does not see bleo toxicity too often. However, replacing bleo in the young population to minimize long term toxicity complications makes sense.","RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",NTL from the Boston area mentioned that AVD with BV better have a big KM curve separation otherwise its useless data.,191
stop,Territory," NEW ENGLAND
N.NY",15.1053511706,8.61937426542e-08,67,137,NTL in the Boston area mentioned that he currently has patients on commercial nivo for cHL. For his patients he does not consider stopping treatment and continues until progression of toxicities. He does not stop treatment at a fixed duration even thought patients seem to have a good second response rate.,RTL at a teaching hospital mentioned that some patients are asking if they can stop Opdivo after a certain period of time. Some are asking to stop at the one year mark and others are saying they will stay on as long as the drug is working and keeping disease under control.,NTL in the Boston area mentioned that he would not stop nivo in cHL patients. Lots of these patients are last graspers so you would be wrong stopping the drug.,204
mentioned,Territory," NEW ENGLAND
N.NY",11.4661081493,1.35631601412e-17,289,130,"RTL at a large academic center mentioned that national bleo shortage has not affected them until now. With that said, as a group they will discuss plan of action. He mentioned possibly dropping to 2 cycles of bleo or eliminating it all together and adding BV. He mentioned that he would like to eliminate bleo due to toxicities.",RTL In the Boston area mentioned that his practice has not been effected by the bleo shortage. He mentioned that if his patient in in CR after two cycles he will trim back on bleo.,NTL in Boston mentioned that patients who have progressive cHL disease may have other pathways for tumor cell death via CD4 and NK. She also mentioned that [patients who progress on Nivo have a change in the micro environment which is being researched,419
Northeast,Territory, NH,301.0,8.78016867068e-14,9,121,"Testing for PD-L1 in NSCLC is now part of the usual pathology and genetic tests conducted in a leading NCCN institution in Northeast US.  This hospital charges the payers a single bundled charge for all the tests they do on a patient.  Now, PD-L1 has been added to the pre-existing battery of tests.  This institution does its own immunohistochemistry assays for PD-L1 using the E1L3N antibody from Cell Signaling Technology.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",130
IME,Territory, NH,225.75,1.03059906794e-05,3,0,"In his presentation at an IME on immunotherapy in NSCLC, Naiyer Rizvi MD (Columbia University) summarized the data for nivolumab and pembrolizumab, stratified for PD-L1 levels and tumor histology.  The overall theme of his presentation was that both agents are very similar across all stratifications, even when the slides highlighted the differences (e.g. hazard ratio for pembrolizumab in squamous histology in Keynote-10).  BMS, Merck and Genentech funded this IME program.","Discussing therapeutic options in NSCLC patients expressing low levels of PD-L1, Leora Horn MD (Vanderbilt & NCCN panelist) indicated her preference for chemotherapy over IO agents.  She also believes that chemotherapy (with pemetrexed for NSQ NSCLC) and targeted therapy is more valuable in appropriate patients as first line therapy, instead of IO agents as monotherapy or in combination.  These opinions were expressed during the unscripted discussion following an IME program sponsored by BMS, Merck and Genentech.","Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.",3
New England,Territory, NH,150.5,2.506522524e-18,17,970,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.",987
cell carcinoma,Territory, NH,75.25,2.50530862486e-06,7,40,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",47
NCCN institution,Territory, NH,66.8888888889,4.29123557889e-11,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","A leading academic thought leader and clinical trials expert from a New England NCCN institution underplayed the significance of CheckMate 026 results disclosed so far.  He felt that PFS is not a good endpoint for IO therapies, as many IO trials have already shown positive response rates and overall survival despite a lack of PFS advantage.  In cancers with low T- lymphocyte infiltration, CTLA-4 inhibition using ipilimumab may enhance the efficacy of nivolumab by increasing infiltration.",125
immuno-oncology,Territory, NH,53.75,4.00828032701e-07,11,54,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.",65
produce,Territory, NH,37.625,1.68991039548e-05,11,0,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Physicians are reacting negatively to the direct-to-consumer advertisements for Opdivo and are raising their displeasure proactively during meetings.  The Medical Director of the Lung Cancer Program in an academic hospital in the Northeast told the HSLs that he had second thoughts about using Opdivo, just as a reaction to the DTC advertisement on television.  Another family practice physician involved in formulary decisions called the Opdivo TV ads ?cringe-inducing?.  He complained that the overall tenor of the TV ad grossly exaggerates the modest improvement in median overall survival produced by Opdivo in NSCLC.","A leading academic thought leader discussed the clinical trial results of cabozantinib and his own personal experience in using this agent.  Toxicity and adverse events remains the major concern with cabozantinib.  Though cabozantinib produced very good results in clinical trials, he is cautious about using this agent in his practice.  He has participated in nivolumab trials, and uses nivolumab frequently in his clinical practice.  However, he stressed that the TKIs will remain a staple part of therapy of RCC, and the right patient can derive significant benefit from them.",11
US,Territory, NH,37.625,1.46361607795e-06,14,24,"Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A clinical pharmacist at an academic medical center in the Northeast US indicated that they have added PD-L1 testing (IHC) to their usual battery of genetic tests for all tumors, including NSCLC and RCC.  At present, PD-L1 levels are not being used to make treatment decisions at this center.  But she implied that more granular instructions on the use of anti-PD-1 and anti-PD-L1 agents are expected in future from both regulatory agencies and payers.  This center wants to have all the procedures established before these changes become mandatory requirements.",38
thought leader,Territory, NH,33.4444444444,2.42576830707e-09,25,22,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","A national thought leader on renal cancer from a Northeast NCCN institution advocated a Q3W dosing for nivolumab in RCC as a cost-saving measure that also increased patient convenience.  He substantiated his argument by pointing out that the clinical efficacy in ORR, PFS and OS are identical for CheckMate 010 and CheckMate 025, though the former trial uses a Q3W dosing schedule.  He believes that FDA would accept a single arm trial that shows non-inferiority in OS to change the labeling to a Q3W dosing.",47
Boston,Territory, NH,28.21875,5.0253285218e-07,40,82,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",122
MD,Territory, NH,27.7236842105,6.47806926464e-08,29,71,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",100
ipilimumab,Territory, NH,26.5588235294,6.71018488851e-07,22,17,"David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.",39
renal,Territory, NH,20.9027777778,1.48378524388e-05,22,26,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",48
cabozantinib,Territory, NH,20.5227272727,2.34524140396e-06,27,137,"According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.","Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.",164
IO agents,Territory, NH,18.3040540541,2.05728361688e-08,45,174,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A key oncologist from a New England academic hospital shared information on his thinking and his clinical practice in managing IO agents in patients with endocrine-related immune-mediated adverse reactions.  In his opinion, adverse events affecting the endocrine organs such as the thyroid and pituitary glands can be managed by administering the appropriate hormone replacement with discontinuing the IO agent.  He believes that value provided by IO agents including the potential for a complete remission is too important to sacrifice to avoid an adverse event that can be easily managed.","The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.",219
major,Territory, NH,16.0106382979,1.11546964675e-08,90,483,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",573
advanced,Territory, NH,15.6770833333,4.85954723446e-05,36,0,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","A key NCCN panelist for SCCHN a major academic hospital in New England was profiled to understand the treatment landscape in SCCHN.  This panelist was an investigator in CheckMate 141, and therefore was intimately familiar with the data presented at AACR.  The panelist considers the efficacy in OS to be better than what is seen in clinical practice with single agent therapies (methotrexate, cetuximab, docetaxel etc.).  He has a very negative opinion on the efficacy and toxicity of these standard of care therapies.  

Combination therapies will enhance the potential of immune-oncology in difficult to treat cancers and advanced stage disease.  Robust data needs to be developed for all options with Opdivo such as IO combinations, IO + targeted therapies and IO + chemotherapy/RT.  He also stressed the need to do clinical trials in nasopharyngeal SCCHN due to its unique etiology and response to treatment.  He does not endorse extending the NCCN recommendations to include this population based on data from other types of SCCHN.","The Director of Hematologic Malignancies at a major academic hospital in Boston downplayed the incidence of GVHD in patients who received allogeneic stem cell transplantation after receiving nivolumab previously.  Hodgkin lymphoma patients with advanced disease in later lines of treatment are more susceptible to GVHD after allogeneic SCT generally, even without previous exposure to nivolumab.  As careful management of GVHD can reduce allo-associated mortality, nivolumab provides a good therapeutic option in advanced HL patients.",36
hospital,Territory, NH,15.6770833333,1.32785094524e-08,72,479,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The clinical pharmacist responsible for infused products at a leading academic hospital in New England expressed gratitude to BMS for its generous patient assistance program.  Most of their patients on nivolumab in off-label indications in this Disproportionate Share Hospital (DSH) currently receive free medication through the patient assistance program.  This hospital is now attempting to move some of these patients to their insurance plan, to reduce the burden on the assistance program.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",551
improved,Territory, NH,14.564516129,1.28660051308e-05,36,0,"The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.",36
care,Territory, NH,13.6818181818,1.75918689769e-05,75,12,"The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.",87
NCI,Territory," NORTH CENTRAL
IA",234.888888889,2.43185756077e-12,16,112,"RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.","RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","NTL at a NCI cancer center stated at a conference that the data with nivolumab in cHL are ""stellar"" particularly in that most of patients on the trial were very sick and that re-treatment can be conducted.",128
hematologic malignancies,Territory," NORTH CENTRAL
IA",100.666666667,2.24588091977e-05,5,4,"TL presenting at a national congress stated that even though cHL is the ""poster child"" for  PD-1 blockade in hematologic malignancies, there may be a role in DLBCL and FL, but will be limited to certain populations.",NTL mentioned the requirement for more education and understanding around the development and/or persistence of AEs over time following IO therapy in hematologic malignancies.,"NTL at an academic center noted that although the topic of pseudoprogression is being understood in solid tumors, there is a gap in the understanding of how to interpret responses when using IO agents in hematologic malignancies.  NTL suggested that either BMS internally, or in partnership, review available PET data from trials  in HL and correlate with outcomes for patients. This information would  help clinicians understand responses of hematologic malignancies during treatment with IO agents.",9
PET,Territory," NORTH CENTRAL
IA",50.3333333333,5.89618055358e-06,11,0,"RTL from an NCI Cancer Center stated that be believes in a PET directed approach to treating lymphoma,  but that changing treatment modifications based on PET results should only be done on trail at this point. In addition, if changes to therapy are going to be made based on a positive PET result, a second biopsy should be conducted to prove disease.","A NTL commented that at the recent IWNHL meeting there was a major discussion on the use of scans in lymphoma trials. There is concern that FDA is too heavy on scans for therapies (ie. requiring both contrast CT and PET). Moreover, as scans become utilized more frequently, and the ability to detect MRD increases patients will develop ""scan-xiety"" and always be afraid of what the next scan will say. Thus, there is a need to have a healthy balance between understanding MRD and what level of disease really affects QoL and survival.","NTL at an academic center confirmed that the shortage of bleomycin has had an impact on their practice, even though this institution has a stock pile.  As a result, they are treating patients according to the RATHL study by dropping bleomycin from ABVD after two cycles if the PET scan is negative.  In addition, belomycin is not being used for treatment of testicular lymphoma.",11
cancer center,Territory," NORTH CENTRAL
IA",23.8421052632,2.89341812071e-09,46,130,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.","RTL from a NCI cancer center involved in CA209-039 trial showed stated at a regional conference that data with nivolumab in DLBCL are ""disappointing"" and this therapy is not ready for DLBCL right now.",176
lymphoma,Territory," NORTH CENTRAL
IA",17.0621468927,7.2179131819e-09,73,12,TL at academic center noted that there is a big gap in secondary CNS lymphoma and that the population is bigger than primary. Offered that Merck is doing a trial in primary CNS lymphoma and is missing an bigger opportunity.,A NTL and NCCN panel member noted that the International Workshop on Non-Hodgkin Lymphoma has a manuscript in review that proposes updated response evaluation criteria. This criteria will be ?uni-dimensional? (one rather than two measurements).  One impetus for the update was to reduce compounding errors that occur in the two dimension criteria. There was no clear timeline for publication as it is only the review process.,"RTL and academic center spoke positively about anti-PD1 therapy in lymphoma, noted that transformed lymphoma and EBV-driven lymphomas are gaps in research, offered anecdote that they treated nasal NK driven lymphoma off-study with promising reuslts.",85
academic center,Territory," NORTH CENTRAL
IA",12.9892473118,1.22328134791e-06,103,319,"NTL at an academic center confirmed that the shortage of bleomycin has had an impact on their practice, even though this institution has a stock pile.  As a result, they are treating patients according to the RATHL study by dropping bleomycin from ABVD after two cycles if the PET scan is negative.  In addition, belomycin is not being used for treatment of testicular lymphoma.",TL at academic center noted that there is a big gap in secondary CNS lymphoma and that the population is bigger than primary. Offered that Merck is doing a trial in primary CNS lymphoma and is missing an bigger opportunity.,"RTL and academic center spoke positively about anti-PD1 therapy in lymphoma, noted that transformed lymphoma and EBV-driven lymphomas are gaps in research, offered anecdote that they treated nasal NK driven lymphoma off-study with promising reuslts.",422
noted,Territory," NORTH CENTRAL
IA",9.91414141414,2.29338086149e-08,144,0,"RTL at a NCI cancer center noted that nivolumab for cHL is ""fabulous"". In this individuals experience the drug is well tolerated and providing results.","RTL noted that he is still trying to wrap his head around the ATHERA trial data for high-risk young HL patients noting the PFS benefit with BV but not OS benefit. Thus, not sure if maintenance in cHL is useful.","A TL at an NCI cancer center noted that Pembrolizumab is ?taking over? at their institution and that there was something big coming, the details of which he could not discuss but that is was in both hematology and solid tumors,  noting that pembrolizumab is ?very hot?. In addition, this TL stated if  BMS wants to keep the lead they need to have nivolumab data generation in hematology.",144
NCCN center in the midwest stated,Territory," NORTH CENTRAL
WI",665.777777778,4.51805282813e-20,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
exercise,Territory," NORTH CENTRAL
WI",277.407407407,1.3367760794e-08,5,238,"During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment he was surprised the FDA will allow Merck to have labeled indication without a comparator arm in their trials given the fact that there is a drug with proven efficacy that has a comparator arm","During a profiling exercise with a H&N panelist at an NCCN center, AI stated he defines refractory the same as we defined it in 141 (which he stated is a better design that the Pembro trial where you had to fail both cetuximab and a platinum therapy)","During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment the Nivo QOL is ?the best,? and he will highlight that data at his next post ASCO talk. He believes that data is impactful. He mentioned Pembro doesn?t have that data",243
P&T committee,Territory," NORTH CENTRAL
WI",110.962962963,3.54720996095e-09,8,478,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",486
NCCN center,Territory," NORTH CENTRAL
WI",83.2222222222,1.65488363827e-12,26,280,"P&T committee member/lung AI at an NCCN center stated the following

o	When asked if cost/cost avoidance discussion are part of their formulary discussions, he stated they are minimized at his institution. He stated decisions are NCCN/FDA approval/data driven.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",306
AI stated,Territory," NORTH CENTRAL
WI",70.6127946128,6.07932796822e-18,24,171,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",195
payor,Territory," NORTH CENTRAL
WI",55.4814814815,7.7146791151e-06,7,23,"For a small regional health plan assosicated with a national account institution (~200K lives): While discussing oncology management, the payor stated that he is excited to hear that there will be more PD1's enter the market as they will be able to manage the class; however, he stated it will be nearly impossible to manage the class if the indications vary from drug to drug. He cited the example of the TNF class of drugs where they are unable to restrict certain drugs due to niche indications. This specific plan does not currently manage oncology.","Specialty pharmacist at an academic SP stated he believes that I/O therapy will eventually be billed under the pharmacy benefit as PBMs will want to demonstrate their value in an increasingly generic blended market. As the health system with an integrated payor looks at total cost of care, he thinks the payor will demand white bagging as a cost saving through their own SP; however, he was uncomfortable with the concept of an outside SP delivering an infusible to his infusion clinic.",Regional payor stated they have a waste billing limit of 40 mg due to the vial size of Opdivo,30
order sets,Territory," NORTH CENTRAL
WI",44.3851851852,1.36726717016e-05,8,321,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),329
reactive discussion,Territory," NORTH CENTRAL
WI",36.987654321,2.24373460899e-05,9,310,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","?	While proactively discussing 2 year OS for 057/017, the reactive discussion led to 026. We discussed trial designed etc. We then began to discuss the 2L space in which the AI stated their system will likely begin to use atezo based on no testing and Q3 weeks (convenience) for traveling patients and chair time.  
?	The AI then discussed 227 (enrollment site)
?	This led to a reactive discussion on the early 012 data which demonstrated nearly a doubling ORR based on expression levels
?	The AI then led a discussion on what a treating physician would do if a patient was progressing on Nivo and the 227 reads out positive for regimen (would a treating physician add ipi?)
o	AI believed more data is need; however, this is an area of needed exploration
o	There is no data with Atezo or Pembro to add Ipi at Q 6 weeks","Advisor to the panelist at an NCCN center in the midwest stated, after a reactive discussion on the 227 trial design, that BMS should decide on one dose for the regimen (referencing 032 for SCLC). He stated different doses will increase confusion and errors if we use multiple doses in different tumors.",319
advisor,Territory," NORTH CENTRAL
WI",35.8997821351,2.52019345726e-12,27,231,Advisor to the panelist at an NCCN center in the midwest stated Atezo won't be considered for formulary addition because they are so accustomed to using Nivo and it's challenging to change habits,"Advisor to the panelist at an NCCN center in the midwest stated that based on the 026 data, he'd like to offer Nivo in 1L","Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.",258
build,Territory," NORTH CENTRAL
WI",31.7037037037,3.47169711024e-05,10,21,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),31
midwest,Territory," NORTH CENTRAL
WI",26.4197530864,2.28687188179e-10,42,124,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,166
expression levels,Territory," NORTH CENTRAL
WI",25.2188552189,8.25746972402e-06,41,170,"Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Payor insights from ~4 million life plan in the Midwest provided the following insights. They are not looking to manage PD1 inhibitors by PDL1 expression levels. He indicated the science is too new and there are too many unanswered questions.  Payor stated the PDL1 expression is informative, but not definitive. PDL1 expression is not in the PA criteria yet. He stated there is not an ICD10 code for PDL1 expression (+/-).",211
unsolicited,Territory," NORTH CENTRAL
WI",23.1172839506,1.15082831901e-05,99,200,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",299
perspective,Territory," NORTH CENTRAL
WI",20.440545809,4.16172070494e-07,25,0,P&T pharmacist chair at an NCCN center in the midwest stated that cost data (ie Nivo vs docetaxol lung-tx related adverse events-not shared) is irrelevant to them when there is a clear winner from a clinical trial in either efficacy OR safety from an institutional P&T perspective.,"Director of pharmacy at an NCCN center stated that from an operational perspective, there is an increase in human resources needed to use access support programs(foundation portion) (ie paperwork/drug management/dispensing cost). While these programs are important for the patient, they are expensive for her to implement because the pharmacy does not receive reimbursement for their role in drug delivery when drugs are received from foundations thereby increasing her ""costs.""","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",25
chair,Territory," NORTH CENTRAL
WI",19.4185185185,5.51974824579e-07,26,260,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",286
panelist,Territory," NORTH CENTRAL
WI",18.9448961156,3.1607756734e-12,134,164,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",298
minimal,Territory," NORTH CENTRAL
WI",17.337962963,3.54520976813e-05,20,0,"During a profiling exercise, an NCCN H&N panelist offered the following unsolicited insights:
?	When asked how he treats LA-SCCHN he stated the following
o	First surgery
?	After surgery with minimal dz, pt would get RT
?	After surgery with moderate dz, pt would get a plateium therapy
?	After surgery with bulky dz, pt would get chemo/RT
?	He does not test for PDL1 expression but does test for P16
?	Research gaps-he?s like to see a trial sequencing I/O then chemo. He believes patients respond to chemo better post I/O.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",20
o,Territory," NORTH CENTRAL
WI",13.1403508772,2.46870343135e-07,46,220,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Eric Mortenson and I met with a HL NCCN panelist for a profiling exercise. Below are NCCN related insights.

The panel meets every 12-18 months in person. The next panel meeting is August; however, he stated we should expect an update to the guidelines within 6 weeks.
?	How their update approval process is designed:
o	An admin sends out the proposed guidelines for comment from the rest of the panelists via email. AI stated the ?very loud? panelists typically get their way. He stated the PD-1?s have been sent out for review and ?you will be happy with the outcome.?
?	When asked what data is needed for an NCCN update, he stated heavier weight is given for FDA approvals; however, phase II or better data will be reviewed. He stated there was not a standard endpoint required for a given category rating (ie OS for category 1).

Each panel operates independantly with their own set of rules.",266
NCCN panelist,Territory," NORTH CENTRAL
WI",12.1050505051,7.01776707208e-09,94,149,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,243
AI,Territory," NORTH CENTRAL
WI",7.74160206718,5.1473269505e-07,121,70,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",191
Path TL,Territory," NORTHEAST
NY",914.242424242,1.06492764937e-18,18,230,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,248
Path,Territory," NORTHEAST
NY",365.696969697,2.23240122083e-14,19,0,"Path TL stated they do PD-L1 testing on all types of tissue and cytology samples except for smears and do not require a minimum of exactly 100 tumor cells
-Path TL said that 95% of the time there is no matching H&E slide and therefore it can be hard to know what they are looking at (macrophages etc.)",Path TL stated that Integrated Oncology sends the 28-8 testing to a third party and they don?t send back a stained slide so TL refuses to send out for 28-8 testing,Path TL stated PD-L1 scoring takes longer than any other type of scoring and TPS in 40-60% range is very difficult due to tumor intra-heterogeneity in lung samples,19
LDT,Territory," NORTHEAST
NY",137.136363636,1.47969066698e-05,4,22,"Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",Path TL from a large academic center using E1L3N on Leica LDT reported that since 1st line pembro approval pulm med oncs have complained that PD-L1 expression is routinely low and requested re-validation,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary",26
IVD,Territory," NORTHEAST
NY",121.898989899,6.20120235102e-07,6,146,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT","Pathology TL at a mid-size academic center has completed validation of 22C3 IVD 12/2/2016, testing is now available in-house.
-TL reported validation of platform and antibody were simple and straightforward
-TL reported training by watching Dako online module for scoring
-TL reported training on scoring was an ""uphill battle""",152
score,Territory," NORTHEAST
NY",42.6646464646,5.4212097354e-09,21,156,"TL pathologist doesn't agree with the scoring protocol for Roche's SP142 assay as they are counting all immune cells in their scoring even ones that are not near tumor tissue, which are not considered tumor infiltrating lymphocytes.","Path TL reports percent tumor cells positive and percent tumor infiltrating lymphocytes positive
-TL states that if the percent tumor score is above 1% then the report states that ?the result is considered positive?
-Lymphocytes are not included in the ?result?",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,177
pathologist,Territory," NORTHEAST
NY",36.015610652,1.97830311963e-14,45,211,"Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer","Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times","Path TL reports since pembro 1st line approval TL has  integrated PD-L1 test ordering into EPIC system and is available for all solid tumors
-There are 2 check boxes in EPIC for ordering testing:
1. ?PD-L1 keytruda/pembrolizumab (IHC)?
2. ?PD-L1 opdivo/nivolumab (IHC)?
-Since integrating with EPIC, requests increased to 2-3/day
-TL states more experienced/specialized oncs all select ?PD-L1 keytruda? while oncs at satellite centers or less experienced oncs select both boxes
-TL said no one ever selects ?PD-L1 opdivo? box alone",256
22C3,Territory," NORTHEAST
NY",28.5700757576,9.5004223507e-11,49,112,"Path TL states that there were a few 22C3 requests when pembro was approved 1L but once the oncologists were educated in PD-L1 testing they were ok with E1L3N LDT
-TL states that if reimbursement doesn?t care about the antibody or assay then bringing in-house an FDA-approved IVD is not necessary","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",TL pathologist reports being pushed to use the SP142 assay internally but has seen lower staining of tumor cells and does not feel good about the amplification step to intensify the staining so has switched to SP263 on Ventana platform.,161
reported,Territory," NORTHEAST
NY",8.67951668585,1.12172252438e-08,182,10,Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,"Path TL send all tests out to Integrated Oncology for 22C3 testing only
-TL reviews all reports and stained slides sent back from Integrated Oncology
-TL reports he has found 2 mistakes, both were false negatives as the pathologist read the negative control instead of the stained slide
-TL sent back and they corrected the error both times","Path TL (IHC CAP committee) reported that CAP is releasing a PD-L1 proficiency test offered in 2017
-It will be antibody and platform agnostic
-Blinded samples will be sent by TMA to any lab who requests
-CAP will collect all data and potentially publish any interesting anomalies
-TL predicts that most clinical labs will certify 1 test and most diagnostic companies will certify all PD-L1 tests they offer",192
TL stated,Territory," NORTHEAST
NY",6.83054684779,9.95464799992e-07,202,488,"Path TL states there have been 200 lung cases tested reflexively in the last 6 months
-TL reports that less than 10% of lung cases seen have had 50% PD-L1 expression or higher",Path TL stated 1-3 cases come in per day since pembro 1L approval and all are reflex tested on 22C3 IVD in-house,"Path TL stated that more NCCN guidelines for PD-L1 were coming next year but TL was unable to be specific because of a confidentiality agreement
-TL hinted that this change may be associated with reflex testing vs testing patients who are negative in molecular diagnostics
-TL stated their opinion that NCCN does not have the data to support more specific recommendations",690
TL,Territory," NORTHEAST
NY",5.69917355372,5.31490117467e-09,1157,51,"Pathology TL at a mid-size academic center has completed validation of 22C3 IVD 12/2/2016, testing is now available in-house.
-TL reported validation of platform and antibody were simple and straightforward
-TL reported training by watching Dako online module for scoring
-TL reported training on scoring was an ""uphill battle""","Path TL is validating 22C3 on the Ventana platform in-house and has just completed antibody titration
-TL is using the protocol published in August in JTO by Neuman et. al. for the LDT",Path TL reports Ventana has trained TL and 4 other pathologists at TL's center on SP142 scoring in bladder and lung but there have been zero requests,1208
southeast region,Territory," NORTHEAST
NYC",1327.375,3.96177270316e-15,7,169,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
gathered the following unsolicited,Territory," NORTHEAST
NYC",1137.75,4.6094393923e-13,6,175,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",181
Ritchie,Territory," NORTHEAST
NYC",1137.75,4.6094393923e-13,6,170,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",176
NCI-designated,Territory," NORTHEAST
NYC",663.6875,1.77055972604e-14,8,157,"Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).",165
Joseph,Territory," NORTHEAST
NYC",568.875,1.83189043882e-12,7,170,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",177
junior,Territory," NORTHEAST
NYC",284.4375,2.02509819564e-06,4,394,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",398
faculty,Territory," NORTHEAST
NYC",284.4375,2.02509819564e-06,4,394,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",398
yield,Territory," NORTHEAST
NYC",189.625,4.03032697059e-06,5,0,"Following a recent panel discussion, Eric Chamot and I consolidated the opinions of 4 NTLs and RTLs regarding testing for PD-L1 in NSCLC:
-All 4 test for PD-L1 now, and accept that it will be standard practice once checkpoint inhibitors move to 1L.
-All 4 panelists await a better and more predictive biomarker for identifying which patients will respond to checkpoint inhibitors.
-One of the RTLs mentioned that during his talks and lectures, he'll show a slide of a lung tissue sample where three separate sections of the same slide yield three significantly different levels of PD-L1.
-Two of the RTLs referred to an ASCO poster that assessed Total Mutation Burden (TMB) and response to PD-1 checkpoint inhibitors, with 15 mutations being the threshold for a consistent response to Nivo or Pembro. Both believe that it needs additional investigation (http://meetinglibrary.asco.org/content/165567-176).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","During a Best of ASCO post-Melanoma talk, a discussion with 3 AIs/ RTLs (one is likely a future NCCN panelist) yielded insights about discontinuation of Nivo +/- Ipi in melanoma: 
-All 3 agreed that BMS needs real data on when it's safe to discontinue the Regimen in patients that respond.
-All 3 point to how much benefit patients derive from the Regimen after they discontinue due to AEs as proof that this treatment isn't needed indefinitely.
-One AI said that he would treat a patient for 2 years after achieving a CR and then discontinue, while a second AI said that he would treat for 3 years after achieving a CR and then discontinue.
-The AI (and likely future NCCN panelist) that would treat for 2 years after achieving a CR then discontinue mentioned that Nivo maintenance indefinitely isn't just inconvenient for a patient, but also financially toxic and an unnecessary burden on the system.",5
evolving,Territory," NORTHEAST
NYC",158.020833333,4.10271054952e-09,10,77,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",87
comparable,Territory," NORTHEAST
NYC",142.21875,1.89003593754e-10,13,498,"A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen",511
wasn,Territory," NORTHEAST
NYC",94.8125,1.66797583263e-05,8,109,"Heather Copher-Sweeney and I recently met with a NTL/ Lymphoma NCCN panelist from an NCI-designated academic institution to discuss the role of I-O in the treatment of cHL. The panelist offered the following insights:
Panelist use of I-O in treating HL:
  ? Has been using Nivo in the treatment of lymphoma for a while, and is very comfortable with its MoA and AE profile.
  ? Has used Nivo compassionate use almost exclusively in patients post-BV that never received an aSCT (due to not being candidates). 
  ? Has not had a Nivo patient since launch, and only treats lymphoma patients, the majority of which are RR patients. 
  ? Reported has only had experience with Nivo (no pembro use)
  ? When the discussion of post-Opdivo allo-SCT arose, this panelist shared that patients receiving immunosuppressants would not receive I-O, at least until it?s better understood
    ? Experienced one GVHD death due to autoimmune hepatitis 
    ?	Requested med info regarding use post- allo (Herbaux et al data was reviewed and med info request for abstract was sent)
  ? Opportunities for I-O in HL:
        o Doesn?t believe ceiling for treatment of HL has been reached. Sees unmet need in 2L, and believes that I-O can challenge high-dose chemos, like ICE with better outcomes and less toxicity
    ?  Sees the 1L therapies firmly entrenched
Bleomycin shortage:
  ? Was recently informed by institution?s pharmacy that they were having difficulty obtaining Bleomycin and had a limited supply, so panelist should think about who really needs it
  ? Participated in BV+AVD study, and thinks the results aren?t just useful during this Bleomycin shortage
      o Has a BV+AD (minus bleomycin and vinblastine) trial open, and would even look to more actively place patients on that trial if bleomycin shortage continues indefinitely
Checkmate 205:
  ? The panelist had not seen the data for 205 that had been presented at ASCO. Upon presentation of the data, the panelist responded favorably, (i.e., reacting as if it were comparable to expectations).
New NCCN Guidelines:
  ? The panelist was unaware that the updated guidelines had already been published, and asked what changes were finally made. This panelist remembered having received an email from NCCN the day earlier but hadn?t yet read it and hadn?t seen the new guidelines.
    o When we listed the changes, the panelist seemed surprised that there weren?t additional changes. The panelist mentioned that the most recent TC of NCCN panelists was almost entirely devoted to Nivo, and was surprised that the category wasn?t changed for Nivo. The panelist couldn?t understand why Nivo was left in same category with Pembro (that has less data, no meaningful publication, or FDA approval).","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a recent meeting with a lung cancer AI, the topic of PD-1 inhibitors in 1L was addressed in the context of CM-026 and KN-024. 
This AI leaves open the possibility of changing opinion once data is shared at ESMO, but believes that in the 28% of NSCLC patients that express PD-L1 >50%, testing and use of Pembro in 1L will surpass chemotherapy.
However, the biggest concern is whether oncologists will make the mistake of equating PD-L1 positive expression with PD-L1 >50% and just give Pembro to all PD-L1 positive patients. To this AI, the CM-026 study proved that use of PD-1 inhibitor monotherapy will not benefit all PD-L1 positive patients in 1L, and although not its intended purpose, this BMS study magnified the importance of cutoffs.
This AI was also surprised that more attention wasn?t given to an ASCO poster showing that in patients given a PD-1 inhibitor who developed pneumonitis, treated, and then re-challenged with a PD-1 inhibitor, 60% would re-develop pneumonitis.",117
symposium,Territory," NORTHEAST
NYC",81.2678571429,2.34700676694e-09,26,152,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",178
NTLs,Territory," NORTHEAST
NYC",75.85,1.2688849364e-06,13,120,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",133
thoracic,Territory," NORTHEAST
NYC",71.109375,3.24439844936e-05,10,142,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",152
position,Territory," NORTHEAST
NYC",68.9545454545,1.72083016637e-06,14,383,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",397
landscape,Territory," NORTHEAST
NYC",47.40625,5.94296457381e-06,40,0,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
There was unanimous agreement that the results of KN-024 have opened the doors on PD-L1 testing in 1L, and that future treatment/ management of NSCLC will be driven almost exclusively by biomarkers and genetic testing. 
There was emphasis on choosing the right assay for PD-L1 testing with the notion that the BMS biomarker assay is not as strong as Merck?s.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",40
doesn,Territory," NORTHEAST
NYC",44.2458333333,4.18001500953e-09,36,94,"Heather Copher-Sweeney and I recently met with a NTL/ Lymphoma NCCN panelist from an NCI-designated academic institution to discuss the role of I-O in the treatment of cHL. The panelist offered the following insights:
Panelist use of I-O in treating HL:
  ? Has been using Nivo in the treatment of lymphoma for a while, and is very comfortable with its MoA and AE profile.
  ? Has used Nivo compassionate use almost exclusively in patients post-BV that never received an aSCT (due to not being candidates). 
  ? Has not had a Nivo patient since launch, and only treats lymphoma patients, the majority of which are RR patients. 
  ? Reported has only had experience with Nivo (no pembro use)
  ? When the discussion of post-Opdivo allo-SCT arose, this panelist shared that patients receiving immunosuppressants would not receive I-O, at least until it?s better understood
    ? Experienced one GVHD death due to autoimmune hepatitis 
    ?	Requested med info regarding use post- allo (Herbaux et al data was reviewed and med info request for abstract was sent)
  ? Opportunities for I-O in HL:
        o Doesn?t believe ceiling for treatment of HL has been reached. Sees unmet need in 2L, and believes that I-O can challenge high-dose chemos, like ICE with better outcomes and less toxicity
    ?  Sees the 1L therapies firmly entrenched
Bleomycin shortage:
  ? Was recently informed by institution?s pharmacy that they were having difficulty obtaining Bleomycin and had a limited supply, so panelist should think about who really needs it
  ? Participated in BV+AVD study, and thinks the results aren?t just useful during this Bleomycin shortage
      o Has a BV+AD (minus bleomycin and vinblastine) trial open, and would even look to more actively place patients on that trial if bleomycin shortage continues indefinitely
Checkmate 205:
  ? The panelist had not seen the data for 205 that had been presented at ASCO. Upon presentation of the data, the panelist responded favorably, (i.e., reacting as if it were comparable to expectations).
New NCCN Guidelines:
  ? The panelist was unaware that the updated guidelines had already been published, and asked what changes were finally made. This panelist remembered having received an email from NCCN the day earlier but hadn?t yet read it and hadn?t seen the new guidelines.
    o When we listed the changes, the panelist seemed surprised that there weren?t additional changes. The panelist mentioned that the most recent TC of NCCN panelists was almost entirely devoted to Nivo, and was surprised that the category wasn?t changed for Nivo. The panelist couldn?t understand why Nivo was left in same category with Pembro (that has less data, no meaningful publication, or FDA approval).","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
KN-024:
The biggest discrepancy among the AI/ TLs was in the % of patients that KN-024 addresses:
-AI/ TL #1: 30-35%
-AI/ TL #2: closer to 20% (after excluding EGFR and ALK patients) ? just slightly more than the percentage of patients with EGFR mutation
-Remainder thought the number was between 25-30%
Rescanning:
-AI/ TL#3: Q6W for Pembro in 1L (~ to chemo rescanning)
-AI/ TL #2: Q9W for Pembro in 1L, then begin to decrease frequency
KN-021:
-AI/ TL #4: doesn?t believe that this will be adopted. There doesn?t seem to be an OS benefit, so why would PFS benefit matter
-AI/ TL #1: unconvinced that Pembro + chemo provides any tangible additional benefit",130
volunteered,Territory," NORTHEAST
NYC",39.5052083333,9.47002339709e-07,28,243,"Brian Carriere and I met with a NTL/ NSCLC NCCN panelist at an NCI-designated academic institution in the mid-Atlantic who volunteered these unsolicited views regarding the rapidly evolving NSCLC treatment landscape:
Current Immunotherapy landscape:
?	This panelist believes that because of the MoA, anti-PD1s will eventually be seen as interchangeable, and believes that payers will prefer whichever pharma/ biotech company?s therapy is most cost-effective
o	Upon review of Keynote-010 versus Checkmate 057 mOS and HR to illustrate outcome differences, panelist pointed out BMS omitting Squamous NSCLC
?	Believes that the difference (if any) is negligible when introducing Squamous population in to Checkmate data
?	Acknowledges that BMS is dominating in 2L market share because of no testing strategy
o	As long as new efficacy and safety data matches Merck?s and timing of indications is roughly the same, panelist believes BMS will maintain its lead in 1L because oncologists are accustomed to using Nivo and habits are difficult to break
I-O shift to first line:
?	Awaiting Merck to release results of Keynote-024
o	Expects presentation of data at ESMO, and hopes to see BMS present findings from Checkmate-026 at that time
o	Understands why BMS would be a little anxious after Merck?s most recent press release, but views Keynote-024 as only impacting 15% (at best) of NSCLC because of its PD-L1 >50% requirement
?	Review of Checkmate-012:
o	Panelist expressed befuddlement at amount of press Checkmate-012 garnered post-ASCO considering how few patients were involved in trial 
?	Appreciated the 57% versus 28% ORR in PD-L1 expressers in the Nivo+Ipi versus Nivo mono groups, respectively, and found it impactful
?	Expressed concern with combination of Nivo+Ipi because of its toxicity profile
?	Upon review of Checkmate-012 safety data, panelist acknowledged that 19% versus 33% Grade 3-4 AEs was NOT drastically different, and 13% versus 10% and 8% versus 10% discontinuation rates for all Grade AEs and Grade 3-4 AEs, respectively, were essentially the same
o	Nevertheless, panelist mentioned multiple times throughout meeting that Ipi was toxic 
?	Bryan and I then differentiated Nivo+Ipi dosing in melanoma versus NSCLC, stressing small Ipi dose of 1mg/kg in NSCLC
o	Panelist mentioned at least twice that Nivo+Ipi should only be used in a clinical trial setting and not in a community setting
?	When asked what evidence/ data is missing to calm safety concerns, panelist responded that BMS would need much more safety data than what was presented on 30+ patients
?	Expressed how often Phase 1 data can?t be replicated in a Phase 3 setting
PD-L1 testing:
?	Does not believe that PD-L1 is an accurate marker of disease in NSCLC
o	This panelist believes that too much time is spent on PD1 inhibitors in NSCLC when PD-L1 doesn?t fully explain disease outcome
?	Adamantly believes that someone will one day be able to explain how NSCLC can best be managed, and doesn?t believe PD-1 will be a relevant factor
?	Doesn?t believe that anyone in the community practice setting cares about PD-L1 levels for treatment
o	Community oncologists only want to know PD-L1 cutoffs so that they know what to prescribe in order for payers to reimburse
?	This will become less of an issue when Merck is also indicated for all PD-L1 expressers
Payers and NCCN:
?	Mentioned that several NCCN panel members had received angry and disturbing letters from payers when NCCN had decided to include testing for use of Pembro because it added to payer?s expenses 
?	Laughed at the idea that payers and pathway companies use guidelines to create their medical policies when guidelines are only meant to be one group?s opinion
?	When asked about how NCCN would communicate PD-L1 cutoffs for therapeutic recommendations, (i.e., Checkmate-012 presentation where Nivo+Ipi PD-L1 status cutoff was 1% but Nivo monotherapy cutoff in Gettinger paper was 5% ), the panelist mentioned similarly to what they?ve done in the past for Pembro
o	This panelist believes that NCCN panel has gone far enough in clearly stating Pembro?s required testing and cutoff in the Guidelines, and doesn?t need additional or more forceful language
Financial Concerns:
?	This panelist says that Nivo?s introduction and applicability across tumor types is unprecedented in oncology, and that its cost as it continues to gain indications is unsustainable to the healthcare system
o	Several times used the term ?financially toxic? to describe the cost of Nivo+Ipi 
?	Recently co-authored and submitted a commentary to Francisco Tartari?s article on economic stability of PD1 inhibitors - Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges, where calculated cost of Nivo was $44k and Pembro was $130k: (http://www.cancertreatmentreviews.com/article/S0305-7372(16)30041-X/abstract)","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",271
CM-026,Territory," NORTHEAST
NYC",36.7016129032,1.26237441036e-07,52,177,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN panelist (medical oncologist) at an NCI-designated cancer center in the Midwest region
-best guess as to why KN-024 met its primary endpoint and CM-026 did not was because -026 wasn?t able to select the right patient population. He continued that BMS? biomarker strategy has yet to be defined, whereas Merck knows exactly the type of patients to target.
-biggest question is whether testing should be reflex (all patients) or oncology-driven. The downside to reflex testing is the expense and that it would be pathologist-driven, who won?t have relevant patient information, including cancer staging","During a recent meeting with a lung cancer AI, the topic of PD-1 inhibitors in 1L was addressed in the context of CM-026 and KN-024. 
This AI leaves open the possibility of changing opinion once data is shared at ESMO, but believes that in the 28% of NSCLC patients that express PD-L1 >50%, testing and use of Pembro in 1L will surpass chemotherapy.
However, the biggest concern is whether oncologists will make the mistake of equating PD-L1 positive expression with PD-L1 >50% and just give Pembro to all PD-L1 positive patients. To this AI, the CM-026 study proved that use of PD-1 inhibitor monotherapy will not benefit all PD-L1 positive patients in 1L, and although not its intended purpose, this BMS study magnified the importance of cutoffs.
This AI was also surprised that more attention wasn?t given to an ASCO poster showing that in patients given a PD-1 inhibitor who developed pneumonitis, treated, and then re-challenged with a PD-1 inhibitor, 60% would re-develop pneumonitis.","During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from 5 NCCN panelists or NTLs regarding the evolving NSCLC management landscape, with particular focus on KN-024, CM-026, and PD-L1 testing.
Unanimous that even without cross-trial comparison, Nivo, Pembro, and Atezo have comparable efficacy in 2L.
?	When asked how to decide which of  the 3 checkpoint inhibitors to use in 2L:
-AI/ TL #1: no real differences and you?re going to use the drug ?you grew up with??those like him that participated in Nivo trials will likely stick with Nivo because of familiarity
-AI/ TL #2: no testing and most convenient
1) doesn?t need more paperwork and will avoid filling out forms to test, which eliminates Pembro from consideration
2) Q3W > Q2W, so will use Atezo over Nivo
-AI/ TL #3: PD-1s ORR generally better than PD-L1s ORR, even though comparable OS",229
member,Territory," NORTHEAST
NYC",30.34,2.77366504474e-05,37,111,"During a lung cancer symposium in the southeast region, Joseph Ritchie and I gathered the following unsolicited opinions from a NTL/ NCCN adviser (medical oncologist) who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the southeast region
-CM-026: results were unfortunate
-Pembro will be used at his institution for PD-L1 expressors >50%; however, only relevant for ~ 1 year until CM-227 reads out, and believes that if CM-227 approaches the results of CM-012, then Nivo+Ipi will be Standard of Care (SoC) in 1L
-Nivo will likely remain SoC for PD-L1 negative in 2L, (although believes that Nivo will lose some share of 2L PD-L1 positives, especially with introduction of Atezo because of more convenient dosing schedule with (perceived) comparable efficacy).","Ann Saylors and I met with a NTL/ former lung NCCN panelist who recently gave the position to a junior RadOnc faculty member/ Thoracic Oncology chair at an NCI-designated cancer center in the Southeast region who volunteered these insights regarding the implications of the BMS NSCLC and SCLC data presented at ASCO:

NSCLC:
?	Believes that Nivo3+Ipi1q6w will eventually become standard of care (SoC) for all patients with NSCLC regardless of PD-L1 status
o	Since chemo still yields better ORR, thinks it can still be primary option in 1L
?	Doesn?t believe that concurrent I-O and chemo will have better efficacy than when sequenced and will produce worse AEs
o	Doesn?t see I-O monotherapy as a realistic future treatment option, unless patient is very frail, (made analogy to current use of chemo monotherapy versus doublets or triplets)
?	Checkmate-012:
o	ORR: expects the number in PD-L1 non-expressers to be higher in future studies than that seen in the -012 study
?	Rationale: if Nivo monotherapy yields 14% and Durva+Treme can approach 30%, there?s no reason to think that Nivo+Ipi won?t reach ORR comparable to Durva+Treme
?	Attributed to small sample size
o	Understands that safety/ toxicity will be a concern for some oncologists, but thinks that most will become comfortable monitoring for and managing the AEs associated with regimen  
?	Reiterated that % of patient that discontinued because of AEs was comparable to Nivo monotherapy and that there were 0 treatment-related deaths
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Considers the impactful enough to allow payers to justify coverage/ reimbursement
SCLC:
?	Checkmate -032:
o	Says that Nivo1+Ipi3 will eventually become standard of care (SoC) for all patients with SCLC, regardless of PD-L1 status, (particularly since <25% of patients are PD-L1 expressers)
?	Particularly encouraged by response in platinum-resistant where there are no good treatment options and great unmet need
o	Finds ORR to be very encouraging and a good surrogate for OS in this patient population
o	Believes that data is strong and robust enough to allow community oncologists to use in practice
?	Believes educating community practices about monitoring and IMARs is crucial considering the 3 deaths in the two regimen arms
?	Doesn?t want one bad experience to tarnish an oncologist?s perception of regimen","A former lung NCCN panelist who recently gave position to junior faculty member/ Thoracic Oncology chair at an NCI-designated cancer center volunteered these insights regarding the evolving NSCLC space and how it will most likely be managed once the market has 3-4 PD1 and PDL1 inhibitors:
  ?	Believes the only legitimate advantage that Pembro has over Nivo monotherapy in NSCLC is q3w versus q2w dosing
    ?	Believes that PK shows that Nivo (and possibly Pembro) are administered too frequently
  ?	Has moved patients on Nivo maintenance (after initial response) to q3w and q4w without sacrificing efficacy
   o	PD-L1 testing: ALWAYS tests in 1L and NEVER tests in 2L and beyond
   o	Hasn?t seen sufficient evidence to change mindset that PD1s all have comparable efficacy, and any differences will be negligible to most oncologists 
   o	Found review of Keynote 010 versus Checkmate 057 data interesting and compelling, but likely of little value to the NCCN panel
    ?	Believes that showcasing PD-L1 positive 057 (>1%) data only serves to try to show superiority over Pembro
  ?	Doesn?t think the NCCN committee will feel comfortable acknowledging a significant difference between the 2 therapies because there are too many variables (NonSq+Sq in 010 versus NonSq only in 057, different tests to assess PD-L1, etc.) between the 2 data sets to allow for meaningful comparisons
  ?	Regardless, thinks it would be a short-lived victory because the real winners and losers will be decided over the next 18 months with launches of Atezo and Durva.  
  ?	Future of NSCLC NCCN Guidelines:
   o	Understands that NCCN guidelines will need to evolve as multiple checkpoint inhibitors are approved in order to avoid developing guidelines that resemble Multiple Myeloma?s NCCN Guidelines, which is just a list of approved therapies rather than any attempt to guide
   o	Envisions that future NCCN guidelines may look something like this in 1L:
?	For bulky tumors that need drastic reduction: Chemo +/- immunotherapy
?	PD-L1-positive tumor: PD1 montherapy (Nivo or Pembro)
  ?	PD-L1 inhibitors (Atezo) will show lower efficacy than PD-1 inhibitors with better tox profile, so will likely be used for more fragile patients or those experiencing severe toxicity from PD1s
    ?	PD-L1-negative tumor: regimen therapy (Ipi+Nivo or Durva+Treme)
  ?	Although Durva+Treme may not have the efficacy of Ipi+Nivo, believes that being first to market to will allow D+T to play meaningful role
  ?	Hadn?t heard of NSCLC Evidence Blocks, but after explanation didn?t see their value
   o	Finds assessment process to be arbitrary and results meaningless
   o	When told that Pembro and Nivo were given identical scores, exclaimed that example serves as proof of tool?s irrelevance",148
cHD,Territory," NORTHEAST
NYC-NY",1401.69230769,1.67757885037e-13,6,318,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,RTL perspective for cHD is the bar for deferring transplant is a durable PFS at 2 years then can consider the treatment instead of transplant.,324
bar,Territory," NORTHEAST
NYC-NY",93.4461538462,6.28237539883e-07,13,0,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,?	BV/Nivo ? Bar is set at PFS of 60% 1 yr and atleast 50% CR rate. If these results aren't reach in cHD then the results were not succesfull.,RTL perspective for cHD is the bar for deferring transplant is a durable PFS at 2 years then can consider the treatment instead of transplant.,13
Community TL,Territory," NORTHWEST
AK",29.6793145655,5.30943347814e-09,73,820,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Local TL in a large community practice stated that many HCP's are upset with the direct to consumer marketing that BMS is doing with Opdivo.   She said that the commercial has led to many patients coming into clinics wanting Opdivo with high hopes and expecting a cure.     She further stated that the commercials reflect everyone looking healthy and feels that is leading to false hopes for many patients..  She further stated that she is aware that the speaker bureau has no funds for speaking so why isn't the money better utilized for this instead of the money being put into commericals.,Local community TL in large practice offered that he would like to see trials with Nivolumab in patients with MDS.    He offered that many trials being done have limitations with regards to platelet or neutrophil count which leads to ineligibility for trials as many still involve chemotherapy.   He feels this is a huge unmet need and that immunotherapy could potentially help these patients.,893
utilized,Territory," NORTHWEST
AK",23.9289473684,1.10239272146e-06,45,0,Regional TL in large community practice stated that a front line trial utilizing Nivolumab in GBM would be ideal because once a patient is diagnosed it is hard to get in front of it once it progresses.  She would like to see a trial with it along with high dose methotrexate and/ or radiation or other combination front line treatments,Community TL offered information that they have utilized Opdivo off-label for a patient with leiomyosarcoma who had gone through multiple treatments including going to a local academic center.   Patient came back to this site and MD started Opdivo.  The patient had a full response to therapy and continues to do well.    The staff stated that BMS has exceeded their expectations for help with this patient.,Community TL in large practice offered information that they utilized Opdivo in patients before the FDA approval with good results and stated this now gives multiple patients hope.   He further offered that Opdivo is becoming the go-to drug for multiple tumor types and patients.,45
offered,Territory," NORTHWEST
AK",17.9467105263,3.49946477591e-08,88,0,Local community TL in large practice offered that he would like to see trials with Nivolumab in patients with MDS.    He offered that many trials being done have limitations with regards to platelet or neutrophil count which leads to ineligibility for trials as many still involve chemotherapy.   He feels this is a huge unmet need and that immunotherapy could potentially help these patients.,"National TL in community based practice offered information that his oncology group is doing multiple trials with Merck, specifically Pembro in hematologic trials.  He feels that they are much more advanced in the hematologic space than BMS.",Community TL offered that he is impressed with the indications coming forth with Opdivo.    He would like to see data in patients front line for more tumor types including hematologic cancers.  He stated that Opdivo has been a game changer in his practice.,88
HL,Territory," NORTHWEST
AK",16.9708846585,3.6364241117e-05,51,171,Academic TL stated that he would not omit bleomycin in the first couple of cycles of ABVD for newly diagnosed HL patients as the cure rate drops 8% if it is totally omitted during this time.  He would only do it if patients are over the age of 60 to prevent potential fatal toxicity.,"When discussing the new Opdivo indication in Hodgkin, a community TL offered that he had utilized it via compassionate use for a HL patient and the patient did very well with the drug.",Community TL with focus on hematology offered that she is very excited about the HL indication for Opdivo and that she used it off-label with success.    She feels that it should be studied in lymphoma patients in earlier lines of therapy particularly those patients who are not transplant eligible.,222
NW territory,Territory," NORTHWEST
CO",3036.0,8.33386102995e-30,14,1448,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",1462
sky-rocketed,Territory," NORTHWEST
CO",650.571428571,5.71534680333e-07,3,577,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.",580
NeoGenomics,Territory," NORTHWEST
CO",433.714285714,2.84130171907e-12,8,554,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",562
laboratory,Territory," NORTHWEST
CO",361.428571429,2.89813476965e-10,7,1271,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",1278
clone,Territory," NORTHWEST
CO",216.857142857,2.8324859683e-06,5,149,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",154
diagnostics,Territory," NORTHWEST
CO",173.485714286,1.03958511784e-07,8,1288,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",1296
medical director,Territory," NORTHWEST
CO",173.485714286,1.03958511784e-07,8,365,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",373
healthcare,Territory," NORTHWEST
CO",162.642857143,4.93497565307e-06,6,688,"Insights from 1:1 meeting with chief of pathology at large healthcare network in NW territory: i) within network, payment in regards to PD-L1 testing is not an issue, whatever medical oncologists order for testing is ultimately covered including PD-L1 testing; ii) no in-house PD-L1 testing is performed, all testing sent out to NeoGenomics; iii) medical oncologists only order 22C3 test but are not reflex testing although TL suggests this will happen very soon; iv) currently reconsidering using ARUP as the prices may be better; v) reports provided by paper/PDF copy which is then scanned and entered into patient records upon receipt; vi) PD-L1 reported as % positive tumor cells and binned into one of the three bins: >50% (high expressers), 1-49% (low expressers), <1% (non-expressers);",Pathologist (IHC lab director) practicing in community hospital setting affiliated with large university medical center in NW territory mentioned 3 RCC patient success stories on nivolumab. TL is not testing for nivolumab use in RCC setting but has done investigational studies on these 3 patients treated with nivolumab looking at PD-L1 status and mutation burden. At least one of the responders to nivolumab lacked PD-L1 expression but had high mutation burden.,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",694
Ventana platform,Territory," NORTHWEST
CO",130.114285714,7.86113526667e-06,7,145,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",152
reflex testing,Territory," NORTHWEST
CO",123.918367347,2.69576798449e-07,11,91,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.",102
medical oncologists,Territory," NORTHWEST
CO",89.2941176471,7.35500176948e-11,23,176,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",199
platform,Territory," NORTHWEST
CO",86.7428571429,8.05617792021e-07,18,149,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",167
IHC,Territory," NORTHWEST
CO",79.8947368421,1.38045570756e-10,25,536,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",561
insights,Territory," NORTHWEST
CO",72.2857142857,6.80940292148e-14,137,0,Insight from TL from private pathology practice in NW territory: 10 NSCLC cases have been sent out for 22C3 PD-L1 testing to Neogenomics in the month of November.,Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,137
molecular,Territory," NORTHWEST
CO",61.9591836735,2.41434585398e-06,17,42,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from medical oncologist giving featured podium presentation at pathology conference in NW territory: i) TL stated that only 22C3 guides 1L NSCLC decisions; ii) TL stated the following: ""In 2L NSCLC setting: if the tissue is PD-L1 positive, pembrolizumab is the therapy of choice. If the tissue is PD-L1 negative, atezolizumab and nivolumab are therapies of choice. Pembrolizumab is favored for PD-L1 positive patients""; iii) TL made the statement that ""FDA invented the term 'complementary diagnostics' just for the sake of 28-8 assay as FDA did not know what to do with this assay""; iv) TL is reflex testing using 22C3 for PD-L1 along with molecular testing (EGFR, ALK, ROS1); v) TL stated that ""22C3 is the test to do"".",59
SP142,Territory," NORTHWEST
CO",61.9591836735,2.41434585398e-06,17,146,"Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies",Insight from molecular/lung pathologist TL (CAP/NCCN panelist) from an academic institution in NW territory: i) TL is not a fan of PD-L1 testing; ii) TL?s molecular lab has seen a recent increase in MMR/MSI testing in colorectal cancer; iii) TL described observing lack of concordance between IHC-based and molecular based MMR/MSI assays; iv) all samples are sent out to Neogenomics for PD-L1 testing but TL would like to bring PD-L1 testing in-house; v) institution only has Ventana platform but TL is not excited on SP142 antibody based IHC; vi) TL favors Ventana over Dako platforms and would like to have a reliable IHC assay on the Ventana platform; vii) TL was very interested to learn more on the Blueprint study and potentially importing SP263 clone into her lab for clinical testing as a result of this study; viii) conclusions from Blueprint study were briefly discussed with TL and link to publication was provided to TL after the meeting; ix) TL mentioned that CAP and NCCN ?near-future guidelines are under strict confidentiality? but that the requests for rolling out new guidelines have been made (in NCCN setting). Revision of guidelines is driven by requests to release new guidelines.,"Insights from 1:1 meeting with lung pathologist at large community hospital in NW territory: i) NSCLC samples sent out to Neogenomics for 22C3 PD-L1 testing; ii) PD-L1 testing is reported as >50% (high expressers), 1-49% (expressers), and <1% (non-expressers); iii) PD-L1 testing is reported through Epic medical records system and made available through the network for viewing by pathologists and medical oncologists; iv) institution has Ventana platform and SP142 clone is validated for use on lung and mUC tissues; v) TL stated that they will start using the validated SP142 IHC for internal testing in NSCLC.",163
pathologist,Territory," NORTHWEST
CO",60.2380952381,3.13304006788e-13,45,211,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","Insights from TL working at large community hospital who is also Ventana consultant in NW territory: i) since 1L pembro NSCLC approval, PD-L1 testing has sky-rocketed to about 5 cases per week; ii) medical oncologists at institution will start reflex PD-L1 testing (22C3) for all NSCLC patients in the next couple of weeks along with ALK and EGFR; iii) laboratory only has Ventana platform and uses SP142 assay and is currently trying to validate Dako Abs (22C3 and 28-8) on Ventana platform; iv) since 2L atezo approval for NSCLC, no requests have yet been made for SP142 IHC in NSCLC samples; v) all Dako platform based tests are sent out to Clarient/NeoGenomics for testing; vi) TL fully aware of conclusions from Blueprint studies","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",256
network,Territory," NORTHWEST
CO",57.8285714286,3.04305772666e-06,18,441,"Insights from 1:1 meeting with chief of pathology at large healthcare network in NW territory: i) within network, payment in regards to PD-L1 testing is not an issue, whatever medical oncologists order for testing is ultimately covered including PD-L1 testing; ii) no in-house PD-L1 testing is performed, all testing sent out to NeoGenomics; iii) medical oncologists only order 22C3 test but are not reflex testing although TL suggests this will happen very soon; iv) currently reconsidering using ARUP as the prices may be better; v) reports provided by paper/PDF copy which is then scanned and entered into patient records upon receipt; vi) PD-L1 reported as % positive tumor cells and binned into one of the three bins: >50% (high expressers), 1-49% (low expressers), <1% (non-expressers);",Insights from TL from large healthcare network NW territory: i) molecular pathologists in the group have carefully assessed available testing methodologies and have as a result established their referral testing practices; ii) 3-5 cases per week are sent out for PD-L1 testing; iii) all PD-L1 tests are sent out to PhenoPath; iv) pembro is not considered for all NSCLC patients and as a result reflex testing for PD-L1 is not performed.,"Insight from three different TLs from the same large healthcare network in NW territory: i) all NSCLC samples are sent out for testing to Neogenomics; ii) none of the pathologists have any granularity on the numbers of cases sent out, exact tests performed, nor whether PD-L1 is currently reflex tested for; iii) no near future effort will be made to bring testing in-house.",459
pathology,Territory," NORTHWEST
CO",54.2142857143,3.78503245281e-06,19,213,"Insights from 1:1 meeting with anatomic and clinical pathologist, IHC expert, and director of pathology laboratory from academic institution/large medical center in NW territory: i) PD-L1 is a challenge for this institution in trying to meet specific needs of medical oncologists in part as PD-L1 diagnostics are linked to individual FDA approved PD-1 and PD-L1 inhibitors; ii) institution would like to start testing in-house but only has Leica Bond III platform; iii) institution pathologists are very interested in PD-L1 bridging studies that identify PD-L1 clone for Leica platform and is concordant with PD-L1 IHC diagnostics on the market; iv) all PD-L1 tests are sent out to PhenoPath; v)reflex testing for 22C3 for stage III and IV NSCLC patients along with molecular ALK and EGFR testing; v) volume of requests has sky-rocketed with pembro 1L approval to a current rate of about 5-10 per week; vi) TL estimates 300-500 NSCLC cases will be tested for PD-L1 in a calendar year at this rate; vii) TL is very interested in MMR/MSI testing in GI space and focused on bridging IHC based to molecular based tests; viii) TL requested regular updates and information on Blueprint project and I plan to follow-up accordingly.","The following insights were gained from a pathologist and medical director of a large reference laboratory in NW territory: i) Since pembrolizumab 1L approval, PD-L1 testing has sky-rocketed in this reference lab. The lab tests about 20 tissues per day yielding 75-100 cases per week. 80-90% of tests are 22C3 and 10-20% are 28-8; ii) TL stated that several medical oncologists order both 22C3 and 28-8 staining for individual patients. Reference lab is not made aware of what specific therapy is being considered by medical oncologists who order tests; iii. For PD-L1 tests, this reference lab reports scores as the specific percentage of positive tumor cells and positive/negative status based on the appropriate cut-off for the individual test; iv. TL is not a fan of SP142 assay due to complexity of scoring paradigms as well as challenges posed to pathologists in differentiating immune cells from tumor cells; v. Checkmate-026 data was presented to TL. TL was surprised at imbalances (% women in chemo v. nivo arm; % high PD-L1 expressers in chemo v. nivo arm). TL stated that one of the ways to explain the study was that PD-L1 testing may have been suboptimal in Checkmate-026.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.",232
gained,Territory," NORTHWEST
CO",54.2142857143,3.78503245281e-06,19,86,"The following insights were gained from a surgical pathologist and medical director at large university hospital in NW territory: i) Last week, medical oncologists at this university hospital have made a decision to reflex test all NSCLC patients for PD-L1 expression. All tests are done in-house, the institution has only Dako platforms, and only 22C3 tests are performed. ~4 NSCLC samples are tested per week; ii) Laboratory reports PD-L1 test results as approximate percent positive tumor cells. In addition, they report tests as high (>50% PD-L1 expression), low (1-50% PD-L1 expression), and negative (0% PD-L1 expression); iii) very interested in idea of IHC multiplexing in immuno-oncology space.","Insights gained from medical director, clinical and anatomic pathologist at community hospital in NW territory: i) PD-L1 tests are sent out to GenPath diagnostics; ii) no near-future efforts will be made to bring testing in-house; iii) 3-4 NSCLC cases are sent for testing per month; iv) Med-oncs are not reflex testing for PD-L1 as of yet but TL expects this is likely to change in the near future.","The following insights were gained from a pathologist and medical director of a diagnostics laboratory at large academic institution in NW territory: i) TL believes that rather than a single biomarker (e.g. PD-L1), combination of biomarkers (e.g. immune cell markers) will provide higher precision in predicting response to IO; ii) TL is spearheading efforts in developing multiplex IHC using immune cell markers in CAP/CLIA certified lab; iii) TL is involved in pembrolizumab studies in prostate cancer (PC) setting. Initial study was published and now they are performing larger scale studies in PC; iv) TL is excited about combination therapies (IO + IO and IO + chemo) and believes that these will provide patients with strong therapeutic benefit.",105
provided the following unsolicited insights,Territory," NORTHWEST
OR",482.192307692,7.18115684338e-61,45,146,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",191
Met with a national/regional lung,Territory," NORTHWEST
OR",459.230769231,4.55972086817e-16,10,211,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national melanoma and genitourinary AI/TL post-ESMO, who provided the following unsolicited insights from the podium and in conversation.
?	He expressed that we shouldn't forget about IL2 in kidney Ca, because of the durable CR?s seen in select patients.
?	When he was asked whether tumor burden is associated with response, he responded that with IL2 there is some evidence for this hypothesis.
?	He reitereated that we don't know the significance of Biomarker testing PDL1 yet in melanoma and genitourinary cancers.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",221
Met with a regional,Territory," NORTHWEST
OR",436.269230769,4.72532061277e-29,21,174,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
AI/TL post-ESMO,Territory," NORTHWEST
OR",413.307692308,1.69212874887e-14,9,660,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
AI/TL,Territory," NORTHWEST
OR",244.923076923,1.07618537801e-23,27,661,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",688
Met with a national,Territory," NORTHWEST
OR",199.0,3.51134134769e-19,25,644,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
genitourinary,Territory," NORTHWEST
OR",137.769230769,4.15922027829e-05,3,757,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",760
sensitivity,Territory," NORTHWEST
OR",137.769230769,4.15922027829e-05,3,7,"Met with a NSCLC NCCN Panelist national AI and regional head and neck AI, who reactively provided the following insights:

?	He thinks that failure of CM 026 trial to achieve a difference in PFS was due to the trial design, with BMS reaching for a patient population PDL1 greater than or equal to 5% as too broad.
?	He said that perhaps Merck reached for a population that was too narrow, having conducted the study at so many locations just to achieve the appropriate numbers of patients in KN.
?	He found it odd that sex was not stratified for in CM 026, given that it's a well-known prognosticator of how well patients tend to do.  
?	AI thinks that despite the negative result in CM 026, he thinks that Nivo and Pembro are not that different.
?	He expressed that KN trials combining chemo with IO have inflated response rates due to the chemo component.
?	In reactive discussion of the FDA Blueprint analysis showing great discordance between the higher sensitivity staining Merck and BMS assays compared to the lesser sensitivity of Atezo?s SP142 assay, AI pushed back asking why would you test using SP142 anyway, since testing is not required with Atezo and nonexpressers still may respond. Proceeded to walk him through Biomarker reactive slides outlining how Atezo?s less sensitive assay in theory may lead to classifying some expressors as non-expressors, due to the decreased sensitivity and discordance with BMS/Merck assays.
?	He expressed that Atezo?s q3w dosing frequency will be a factor in his institution?s selection of a 2L treatment, especially due to their impacted availability of infusion chair time and spaces.
?	After we informed him that the SCCHN indication is weight based dosing, He said that his institution might just use flat dosing for SCCHN like in other indications to reduce confusion and inconsistency in the pharmacy preparation.
?	He was already aware of the newly approved 141 SCCHN indication.  After reviewing the CM 141 QOL results showing favorable maintenance of PRO?s when comparing the Nivo group?s maintenance of QOL compared to the sharp decreases seen in the chemo group, he acknowledged the results and stated that QOL results are essential to any such trials in the head and neck space.
?	His institution is wanting to narrow available PD1 agents in their pathways and will be sitting down to evaluate the 2L lung space as well.","Met with a national/regional lung AI, who provided the following unsolicited insights:
?	AI reactively mentioned that his institution is currently sending to 3rd party labs to conduct both the BMS and Merck PDL1 assays, due to inability of their in-house lab/pathology to support this testing in-house.  
?	AI expressed frustration that the one test they can perform in-house is the Ventana (Atezo) assay, for which they recently bought a machine.  We reviewed the FDA blueprint analysis that showed the Ventana assay as highly discordant with BMS/Merck assays and how this could lead to misclassification of some PDL1 expressers as non-expressers due to lack of sensitivity, which he admitted to understanding.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.",10
Tony Wang,Territory," NORTHWEST
OR",137.769230769,4.15922027829e-05,3,100,"Met with a AI/RTL who treats multiple tumor types, but is also a Head and Neck national/regional NCCN panelist AI/RTL, during which AI/RTL shared the following unsolicited insights.
BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
?	Reactively shared that the NCCN panel will include an immunotherapy update to the guideline to include both nivo and pembro.
?	Stated that her recommendation does distinguish that the data supporting nivo (Phase III) vs pembro (single arm trial) are different and should have a different category of recommendation.
?	Commented that the SCCHN NCCN committee does not have ad hoc meetings based on recent data presented, and meetings/updates are generally every 6 months with the next update forthcoming. 
?	AI felt that in terms of trials presented overall at ASCO, there were too many trials with induction chemo combined with IO therapies.
?	She feels that induction chemo strategies with later Immunotherapy is not the right approach.
?	She inquired whether BMS has a process for partnering with other companies to explore IO combos, seeming to express a positive view of this approach. 
?	She shared that she feels BMS ""knows what they are doing"" in being very strategic about supporting ISR's and making decisions about research.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.","?	Attendees: Michael Turner (MSL) and Tony Wang (HSL)
?	Met with a RCC/Melanoma AI who provided the following unsolicited insights:
?	After my introduction of the HSL role that has a focus on access/value/access, AI expressed interest in the topic of oncology medication value.
o	He expressed interest in melanoma HEOR resources that review cost of patients treated with regimen versus monotherapy, cost of regimen (ipi-nivo) taking into consideration median number of doses received in 067 and 069 trials.
?	MSL conducting SIV visit for CA209-274 trial (adjuvant nivo post-surgical resection of high risk urothelial (bladder) CA.
?	He?s interested in proposing ISR for RCC patients after failure of IL2 without prior TKI treatment.  
o	He is a professed fan of IL2 in the front line
o	He says in front line, he prefers treating with IL2 rather than TKI?s.  He cites similar response rates between 2.
?	He says he doesn?t see many non-clear cell RCC patients (maybe 5 per year).  He thinks it makes sense to try these patients on IL 2 regimen and also nivo, but wants to see nivo data in this patient population.  Informed him BMS has post phase IIb trials in this patient population.",103
disclosed,Territory," NORTHWEST
OR",114.807692308,3.87493478142e-14,13,182,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
hit PFS,Territory," NORTHWEST
OR",114.807692308,1.1058239728e-07,6,224,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",230
CM 026,Territory," NORTHWEST
OR",96.9487179487,1.29008103473e-24,27,207,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",234
consideration,Territory," NORTHWEST
OR",78.7252747253,1.12981463802e-15,18,0,"Met with a regional oncology pharmacist manager AI, who provided the following unsolicited insights:
?	AI reactively mentioned that she?s observed instances of use of PD1 agents (Nivo, Pembro) as salvage therapy, in her institution, with unimpressive results.  
?	Due to the fact that her institution is not an IDN, comparative costs associated with IO therapy alternatives (eg. AE management costs associated with traditional Chemo) are not as important to them since they may generate revenue for interventions such as ER visits instead of being as sensitive to total spend for a patient.  
?	Due to this perspective, value measures such as the impact of seeing improved OS or positive impacts on quality of life are more important to her type of institution.  
?	She shared her institution?s P&T process as the following.  A physician (eg. Oncologist) requests an addition of a medication to formulary, which initiates pharmacy to create and present a drug monograph for P&T consideration.  With this info, the P&T committee then votes on this request for addition to formulary.  
?	The AI?s institution does have a formulary, but oncologists can order medicines not on formulary without a prior authorization process.  
?	If the medicine is on formulary, ease of access is faster since the medication is likely to be stocked by the infusion pharmacy.","Met with a regional oncology P&T Formulary AI, who provided the following unsolicited insights:
?	AI was impressed with the ORR of Nivo in cHL of 65%, noting that he expected the Independent Radiologic review ORR to be reduced from the prior Investigator assessed ORR, which made sense.
?	AI was familiar with 032 data presented at ASCO and expressed excitement at the 032 efficacy in SCLC, given that this is an unmet need given lack of current treatment options
?	AI was excited at the 141 OS rate/mOS and commented that OS advantage is what should be the overriding consideration in formulary considerations, which is what we have with the 141 data. 
?	He discounted the lack of PFS advantage in 141, repeating the sentiment above.","Met with a regional melanoma AI, who provided the following unsolicited insights:
?	AI mentioned that he is part of his institutional team that is looking at developing a home-grown treatment algorithm in terms of IO treatments.
?	This algorithm would take into account patient specific factors, such as patient?s performance status, and also baseline labs.  
?	It would define an algorithm in terms of class of agents, such as PD1 inhibitors, instead of be product specific.
?	AI currently does not test for PDL1 status prior to treatment initiation.
?	AI mentioned that he still considers individual patient specific characteristics in deciding whether to start on Nivo monotherapy versus regimen, such as performance status.
?	AI defines current practice in terms of nivolumab as 60% of patients getting monotherapy and 40% getting regimen.
?	He describes some anecdotal experience of seeing patients respond to regimen after not seeing a response on initial Pembro treatment.  He quantified that 1 out of 5 patients, he might see this type of occurrence.
?	When issue of cost arose, was able to reinforce with AI that the cost of regimen is only incrementally more expensive, around 6%, higher than the cost of sequential ipi followed by nivo.  
?	Reinforced with AI that the true cost of regimen treatment needs to take into account that 57% of patients in 069 received median number of doses (the full combo portion of treatment) and that only around 14% of patients were treated for 1 year.  
?	Broadened AI?s consideration of true cost parameters, as evidenced by his agreement that this needs to be considered in terms of true cost of regimen.  
?	In response to his question about sequential therapy, shared that nivo followed by ipi, as well as the reverse sequential regimens, did not show as good efficacy or more favorable AE profile compared to regimen.  
?	AI referenced his institution?s goal of conducting outcomes studies, in melanoma and beyond.  Offered connecting AI with BMS HEOR colleague to explore potential collaboration.
?	AI expressed that he was not particularly wowed with any melanoma data shared at ASCO 2016, as they were mostly comprised of updates on previously published studies.",18
P&T,Territory," NORTHWEST
OR",73.4769230769,8.25845175083e-11,18,182,"Met with a regional oncology P&T Formulary AI, who provided the following unsolicited insights:
?	AI disclosed that his organization?s medical policy was updated to allow for coverage of Pembro at PDL1>1% due to the Keynote 010 data (ORR PDL1>1% ~18%).","Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",200
following unsolicited insights,Territory," NORTHWEST
OR",64.2923076923,2.13564333699e-09,79,48,"Met with a AI/RTL who treats multiple tumor types, but is also a Head and Neck national/regional NCCN panelist AI/RTL, during which AI/RTL shared the following unsolicited insights.
BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
?	Reactively shared that the NCCN panel will include an immunotherapy update to the guideline to include both nivo and pembro.
?	Stated that her recommendation does distinguish that the data supporting nivo (Phase III) vs pembro (single arm trial) are different and should have a different category of recommendation.
?	Commented that the SCCHN NCCN committee does not have ad hoc meetings based on recent data presented, and meetings/updates are generally every 6 months with the next update forthcoming. 
?	AI felt that in terms of trials presented overall at ASCO, there were too many trials with induction chemo combined with IO therapies.
?	She feels that induction chemo strategies with later Immunotherapy is not the right approach.
?	She inquired whether BMS has a process for partnering with other companies to explore IO combos, seeming to express a positive view of this approach. 
?	She shared that she feels BMS ""knows what they are doing"" in being very strategic about supporting ISR's and making decisions about research.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.","2.	Met with regional Lung AI, who is also on the Head and Neck NCCN committee, who provided the following unsolicited insights:
a.	AI disclosed membership on the Head and Neck NCCN panel and is also the chair for the upcoming updates.
b.	AI shared some unsolicited insights on the topic of how NCCN committees in general consider and review guidelines and updates.  AI says that although the consent and approval of all panelists is sought, the process for doing that can be rather informal, depending on the specific chair of the committee.  For example, review/consent/approval may be done through email communication.",127
commitment,Territory," NORTHWEST
OR",61.2307692308,7.91304274667e-06,6,0,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that OS is what he cares about, and that PFS is not as important to him.
?	He questions whether in the real world, there will be any OS difference between patients receiving chemo 1L and then PDL1 2L, or vice versa.  
?	He doesn?t think that chemo-IO combo will be better than sequential therapy with chemo and IO.
?	He thinks the bigger risk to Nivo?s position 2L may be Atezo 2L use in unselected PDL1 patients.
?	He personally thinks that Atezo has a strong position in 2L in unselected patients based on the OAK data, with the advantage of Q3W dosing.  
?	He expresses that he sees combination therapy as the future, but not sure whether IO-IO combos or IO-chemo will be better, which will be determined by the data which we need to await.  
o	Reviewed with AI CM 012 results that lend credibility to the IO-IO combo argument for the future.  Also expressed BMS commitment to IO combo therapy with CM 227 in progress.
?	AI expressed that he used to be against IO combos, due to cost and toxicity, but the CM 012 positive data has him taking a more positive outlook for IO-IO combos.","Met with a national/regional lung AI/TL NSCLC NCCN panelist post-ESMO, who provided the following unsolicited insights.
?	He was disappointed with the lack of PFS advantage at PDL1 greater than or equal to 50% and asked about BMS internal perspective as to why there was no result.  We proceed to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	He thinks that Pembro, Nivo, and even Atezo are not that different agents.  
?	AI thinks the failure has to do with the CM 026 study design, with BMS taking a chance and reaching for a broad patient population strategy, which won in 2L, but lost in 1L.
?	AI says that this is just a stage on the way to combos and this will pass.
?	He is excited about combo treatments in the future, and believes this will be the relevant landscape instead of monotherapy.
?	He is not sure whether IO-IO or IO-chemo will be more efficacious, but he leans toward IO-IO because he believes in having chemo as a separate option by itself.  Reactively reminded him of the 227 combo 1L trial, representing the commitment of BMS to combo IO-IO in lung.
?	He thinks it's good that the lay public is more aware of myopathy AE with PD1's, with the NY times article citing NEJM article, and is something that he's seen that's important to monitor for.
?	He believes that at an academic center like his, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.  He asked whether BMS is considering less frequent dosing so discussed with AI reactively about BMS trials looking at q4w dosing, as well as q3w dosing arm in 227 (360mg q3w mono arm).  AI felt that such a strategy with less frequent dosing, such as q4wk dosing, may play a significant role in adoption of therapies.
?	He mentioned that the NCCN NSCLC panel has been busy with recent updates with Pembro and consideration of Atezo data, with emails flying around the group.","Met with a regional oncology P&T AI for a major national payer, who provided the following unsolicited insights:
?	AI mentioned that he is interested in a BMS produced, unbranded deck/package, which is meant to convey the value of IO agents (such as Nivo) in producing durability and potential for on-going responses in responders. 
?	AI says such a deck/information, targeted towards non-medical or non-subject matter experts, would be very valuable to justify the value of IO agents due to durability of response, even if efficacy endpoints such as PFS are not much greater than control groups, if OS benefit is seen. 
?	AI questioned in Lung studies why there are no major trials studying Ipi alone against the backdrop of 032 where high percentages of the patients were PDL1 non-expressors.  Responded to AI that BMS commitment is to follow the science and is committed to trying different IO combinations in different tumors, due to the responses seen with IO combinations in melanoma.",6
hypothesis,Territory," NORTHWEST
OR",61.2307692308,7.91304274667e-06,6,227,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national lung AI/TL radiation oncologist post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.",233
KN 024,Territory," NORTHWEST
OR",57.4038461538,1.54645202817e-12,17,248,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",265
SQ,Territory," NORTHWEST
OR",57.4038461538,6.38104680112e-07,8,0,"Met with a national lung AI/TL and advisor to NSCLC NCCN panelist post-ESMO, who provided the following unsolicited insights from the podium.
?	AI was debating from the podium for use of single agent Immunotherapy (PD1) in Squamous NSCLC
o	In the context of a debate, she stated that PD1 agents should be the standard of care for initial therapy in SQ NSCLC specifically.
o	She expressed that with CM 026 specificially in SQ NSCLC, based upon the subgroup HR analysis, the PFS was still higher than in CM 017.  
o	She referenced the impressive OS in CM 012 1L OS (19m)
o	She showed the subgroup analysis from CM 026, showing that for the SQ subgroup specifically, the HR was the lowest of all the subgroups evaluated.
o	She pointed to the much lower grade 3-4 AE?s seen with chemo compared to chemotherapy.","A national/regional lung AI and NCCN NSCLC Panelist provided the following insights from the podium at an Immunotherapy CME event.

?	AI says PDL1 not yet determinative in 2L, for example in 017 SQ NSCLC, why does it make no difference?
?	He says he will not deny treatment in 2L NSCLC, even if tested in 1L and has 0% PDL1 expression
?	Why less gr  AE?s in 012 lung versus melanoma?
o	AI says he doesn?t know.  Dose in 012 is different (lower ipi dose (nivo3/ipi1), may be factor.  
?	It?s highly unlikely that Nivo and Pembro are significantly different.
?	AI says that in the context of CM 026 negative result, he believes that Nivo and Pembro are not significantly different.  He also said PDL1 threshold cuts of data were different than in KN 024, so it will be interesting to see efficacy at different PDL1 cuts of data from CM 026.
?	In AI?s practice, he looks at whether a patient is having clinical deterioration, not just imaging, in determining whether to continue patient on Immunotherapy past progression on imaging.","1.	The following unsolicited Insights were shared by national AI in lung and RCC:
a.	He is interested in ISR?s with BMS in lung SQ cell population, for example with radiation
b.	He thinks that in the 2nd line setting, Keynote 010 results are not comparable to BMS data NSCLC and that Nivo is the choice that the majority of docs choose in the 2nd line.  He said ?BMS has nothing to worry about? with respect to Keynote 010.  
c.	 With respect to first line use of Nivo and Pembro, he shares the view that ?the scientist in him? would like to have a test (such as PDL1) that can determine which patients are most likely to respond, especially in light of the substantial costs of treatments.",8
organization,Territory," NORTHWEST
OR",52.4835164835,3.9540969849e-10,14,154,"Met with a regional drug use management and pathway implementation AI, who provided the following unsolicited insights.
?	He says they are still in contracting for past year with VIA, which has not been finalized.  
?	At this point in time, VIA pathway not yet implemented for his organization, but he has access to the VIA ?sandbox? so he is able to access the system and has knowledge of pathways for tumor types.
?	In regards to SCLC, he reactively disclosed that the pathway has been updated recently after the update of the NCCN guidelines (inclusion of regimen as option in 2L).
?	AI said that Nivo is on pathway for NSCLC.  If a patient does not have a PDL1 test, it?s unknown, or the test shows a low or non-expressor, then Nivo is the choice.  
?	The pathway asks if a NSCLC patient has a positive PDL1 test, without referring to specific PDL1 thresholds.  If it?s positive, then Keytruda is offered.  If it?s negative, Opdivo is offered.  
?	He mentioned that VIA pathway adherence goal is 80% for his organization (didn?t specific whether this is target across tumors or is goal for each tumor type).
?	He says VIA pathway is provider centric, which is useful in community practices, and less useful in an academic setting where providers are more familiar with SOC and understand the data. 
?	AI said that the VIA pathway adherence also has a patient choice component, such as a preference for orals over infusible medicines.  He said this is not fully incorporated into the system yet.","Met with a regional drug use management and pathway implementation AI, who provided the following unsolicited insights.

?	He says they are still in contracting for past year with VIA, which has not been finalized.  
?	At this point in time, VIA pathway not yet implemented for his organization, but he has access to the VIA ?sandbox? so he is able to access the system and has knowledge of pathways for tumor types.
?	In regards to SCLC, he reactively disclosed that the pathway has been updated recently after the update of the NCCN guidelines (inclusion of regimen as option in 2L).
?	AI said that Nivo is on pathway for NSCLC.  If a patient does not have a PDL1 test, it?s unknown, or the test shows a low or non-expressor, then Nivo is the choice.  
?	The pathway asks if a NSCLC patient has a positive PDL1 test, without referring to specific PDL1 thresholds.  If it?s positive, then Keytruda is offered.  If it?s negative, Opdivo is offered.  
?	He mentioned that VIA pathway adherence goal is 80% for his organization (didn?t specific whether this is target across tumors or is goal for each tumor type).
?	He says VIA pathway is provider centric, which is useful in community practices, and less useful in a academic setting where providers are more familiar with SOC and understand the data. 
?	AI said that the VIA pathway adherence also has a patient choice component, such as a preference for orals over infusible medicines.  He said this is not fully incorporated into the system yet.","Met with a regional melanoma AI at a high volume regional institution, who leads his institution?s lab and works collaboratively with melanoma medical oncologists at his institution, who provided the following unsolicited insights:
?	AI disclosed that his organization is attempting to establish multiple cancer centers of excellence across the bay area, with specific centers taking on expertise for specific types of cancers or service lines.
?	Centers of excellence would have the goal of becoming accredited as a cancer center of excellence in specific types of cancer, such as breast cancer, melanoma, lung, and liver as examples.
?	AI disclosed his organization has vision of creating an organizational specific cancer research consortium.
?	He said he sits on the organization?s oncology standards committee, which is tasked with realizing the above vision. 
?	His organization has launched the ?Precision Cancer Program? that focuses on the capability to collect tissue to do next generation sequencing and potential animal xenograft research.",168
international GI conference,Territory, NYC - ST2,126.083333333,2.68210069678e-14,17,43,"At an international GI conference, three HCC NTLs had a brief discussion of PD1s:

NTL1:  We are all tempted to use pembrolizumab and jump on the bandwagon; Merck has made it very available through access support.  However, we need more data before using it when systemic therapies that have shown benefit are exhausted.
NTL2: We use PD1 inhibitors in patients that are MSI high.
NTL3: There may be rationale in MSI high patients for the use of PD1 inhibitors but data is still not conclusive and it is inappropriate to use without testing.","At an international GI conference, three NTLs had a discussion about immunotherapy in CRC:

NTL1:  Why is there a difference between single agent nivo and pembro in MSI high.  
NTL2:  Pembro study is a higher response rate but not a global study.  Both look to have very durable responses.  This could be due to different populations and there are questions about the dosing that is used for pembro.
NTL2:  There is a potential that pts with Lynch syndrome do worse but we need a better sample size to really judge.  It seems that these patients can have very late responses.
NTL2:  BMS may have more data in BRAF mutated pts in MSI CRC study but all of the pts that I have treated have responded
NTL3:   pseudoprogression real?
NTL2:  I think that there were a couple but they are not common.  Most responses are quite early.
NTL3:  I think it?s more of a myth.  Are you trying to lie to yourself and say it?s pseudoprogression to keep treating.
NTL3:  Do you think that there is potential for treating in the adjuvant setting rather than in tumor reductive setting?  
NTL2:  Melanoma data shows that there is great potential for immunotherapy in adjuvant.
NTL3:  When I see high responses across tumor types, I am now seeing that MSI testing is the most important thing.  Should we be testing for MSI in all patients?
NTL2:  It is hard to globally recommend MSI but if there is a potential for immunotherapy use, you should try.","At an international GI conference, two NTLs agreed that the Hong Kong staging system is superior to BCLC.  One says It outperforms BCLC at every stage of the disease.  Validated with a western cohort.  Especially important at stage IIIB.  Makes it easier to determine benefit of drugs within this population.  The other says that Hong Kong staging system is the best way to identify critical patients for future treatment within the locally advanced subgroup.",60
said,Territory, NYC - ST2,4.8618251928,1.4298492842e-05,479,0,RTL in melanoma at a major academic institution says that he sees no need for PDL-1 testing at his institution and still does not do this unless it is as part of a research protocol.  He says the data is clear for benefit of PD1 inhibitors across populations and this would be just an unnecessary test.  He did offer some advice to not call the PDL-1 negative patients true negatives because they are really just low expressors in his eyes.  He believes that PDL-1 is being expressed to some extent in all tumors and are just undetectable.,RTL says bleomycin shortage is affecting her own practice at a large academic institution in OH.  She believes in RATHL data and says that her strategy is to conserve bleo by using ABVD for two cycles up front and then continuing/discontinuing bleo in ABVD based upon PET2 status.  She says that she has no desires to move brentuximab into this space because data is lacking and AVD is both cheap and effective.,"At an international GI conference, a NTL in HCC said that Nivoluma has shown quite a bit of impressive data in patients with critical 20%+ ORR",479
international GI conference,Territory, NYC -ST2,161.866666667,1.06461090414e-13,17,43,"At an international GI conference, two NTLs had a brief discussion about atezo in CRC.

NTL1:  How do you sell a trial patient on a trial (NCT02788279), knowing that they could be placed on a study arm for Atezolizumab monotherapy? This is something that is understood to be a very expensive placebo in this setting.
NTL2: We don?t know that atezolizumab has no effect in this setting because our experience is limited and the alternatives, such as regorafenib, have a very low response rate.
NTL1:  This phase III was launched after a phase I with a response rate of less than 20% in a population of fewer than 50 patients.  It seems we are desperate for immunotherapy to work in every cancer.","At an international GI conference, a NTL said, about advances in immunotherapy in CRC:

We continue to pursue immunotherapy because although conventional therapies push survival curves to the right, IO pushes it up

ORR about 16% with nivolumab. Interestingly, the responses were across the board and were durable.

In GI cancers, there are nice and deep responses with MMR deficiency.  Responses are durable and pt are ready for treatment holiday after 2 years of therapy with maintained response.","At an international GI conference, a NTL said that a ?thorny? question is if you should give treatment in absence of positive margins after surgery.  She said she would give additional treatment up through six months of total treatment.  Even though there is a lack of evidence, she gives a full six month course from start of treatment to end (including surgery/recovery time). Her preference is to continue the treatment that they were already receiving if they were responding prior to surgery and/or tolerating it well.",60
pancreatic cancer,Territory, NYC -ST2,86.7142857143,2.00020946835e-05,9,57,"At an international GI conference, an NTL in pancreatic cancer said that he had lynch syndrome pt with MLH1 frameshift and MLH somatic LOH.  Was treated with conventional chemo.  Not doing well.  Started immunotherapy.  After cycle six of immunotherapy, significant shrinkage of tumor and lymph node involvement.  Called this an unusual case.","At an international GI conference, an pathologist speaker said that there is a low prevalence of somatic mutations in pancreatic cancer and the majority of mutations are not even actionable.  There is a significant cost associated with sequencing and analysis but the value is not very high for the patient.  In an era where value has become so important, we should think very hard whether or not sequencing is useful.  $5-6000 cost of sequencing and analysis plus co-pay to the patient and you are still left scratching your head.","At an international GI conference, an NTL in pancreatic cancer said, ""About 10% of pancreatic tumors have increased immune activity: conclusion is that 5-10 or 15% may have increased immune activity.  Immunotherapies have not been effective but maybe with more targeting of patient populations, we can find the best way to see benefit from targeted immunotherapy.""",66
NY,Territory, New York City - ST1,93.4461538462,6.28237539883e-07,13,194,"A Lung RTL form NY told me he utilized the BMS Support program to obtain Opdivo for a patient with refractory Hoidgkins Lymphoma late last year.  The TL described the patient's response ""as my greatest Save in my entire Medical career"". The TL noted that by the time the paperwork had been processed, the patient's performance status had declined so quickly that she was admitted to the ICU.  Opdivo was begun immediately and w week later the patient was discharged.  Six months later the patient has achieved a good Partial Response and her KPS has reached zero.","A TL at a midsize center in NY told me had submitted a concept to Merck looking to combine RT (via radio-labeled probes) in the tumor with a PD-1 agent.  He said Merck kept telling him that they would finalize funding ""soon"" for 6 months and then recently told him they decided they are no longer interested.  The TL was rather displeased with the way Merck handled this",A melanoma RTL from NY told me in the USA there a very few dedicated Medical Oncologists that specialize in treating Ovarian cancers with most cases being treated by GYN Oncologists.  The latter tend to be surgeons by trade and my TL suggested that BMS will have a very difficult time teaching them about the Safety algorithms if the Opdivo+Yervoy regimen gains an approval in Ovarian cancer.,207
told,Territory, New York City - ST1,28.8018967334,1.39939259934e-09,136,65,"A Lung RTL form NY told me he utilized the BMS Support program to obtain Opdivo for a patient with refractory Hoidgkins Lymphoma late last year.  The TL described the patient's response ""as my greatest Save in my entire Medical career"". The TL noted that by the time the paperwork had been processed, the patient's performance status had declined so quickly that she was admitted to the ICU.  Opdivo was begun immediately and w week later the patient was discharged.  Six months later the patient has achieved a good Partial Response and her KPS has reached zero.",A Lung RTL told me that he doesn't know how he will use Atezolizumab yet.  The TL thought the Overall Survival was good but didn't like the Response rate.  The TL wondered if anyone would be able to get an anti-PD-1 approved after failure of an anti-PD-L1,A Lung RTL told me his academic site's laboratory has not implemented a PD-L1 test and does not expect any to be in place until 2017.  He occasionally gets the PD-L1 staining via Foundation Medicine (if insurance doesn't balk) but can never use it in the 1st line setting because of the prolonged turnaround time.  The TL said he will likely use Opdivo as his primary choice in the 2nd line.,201
affiliation,Territory, No longer with FM,1522.0,7.07406647056e-08,3,467,"A TL and clinical trials PI with academic affiliation commented that Merck is active opening Keytruda clinical trial sites in Puerto Rico. In this way, Merck provides opportunities for patients to receive promising new therapies locally, by making available local clinical trial sites for patients in need that cannot travel to the US to participate in a clinical trial. It also gives local oncologists familiarity and confidence using Keytruda based on the experience they acquire when performing clinical trials. In contrast, he does not see BMS actively performing Opdivo clinical trials in Puerto Rico.","A Regional TL clinical trials PI with academic affiliation at a VA hospital commented that he has not used Keytruda since Opdivo can be used without testing for PD-L1. He discussed with his hema/onco fellows the possibility of using chemo instead of Opdivo in PD-L1 negative NSCLC patients since, even though OS was numerically higher in the Opdivo arm, no statistically significant difference in OS was found between treatment arms. Nevertheless they concluded that, worst case scenario, Opdivo is still as effective as chemo in this population but with a better safety profile. Therefore, Opdivo is clearly the best option for NSCLC patients irrespective of PD-L1 expression. In his opinion Opdivo is very well tolerated by patients, much better than chemo. Commented that it is like ""administering water"".","A TL with academic affiliation commented that he believed the previous Opdivo + Yervoy Regimen approval for BRAF wild type only could change current clinical practice since before the Regimen approval oncologists in PR usually started patients on Yervoy first-line irrespective of BRAF status. Most even started treatment without knowing the BRAF status. But with the previous Regimen approval based on 069, the oncologists had to perform BRAF testing to determine if the patient was eligible for treatment. In case the patient was BRAF mutant, the oncologists had to consider the option of prescribing a BRAF or BRAF+MEK combo since the Regimen was not FDA approved for mutant patients. Now with this new approval irrespective of BRAF status, he believes this is no longer an issue and most PR oncologists will keep selecting immunotherapy as their first-line choice irrespective of mutation status.",470
voluntarily,Territory, OK,281.513513514,5.52533191953e-11,7,0,"Local TL voluntarily made a general comment regarding the data he has seen with nivolumab in lymphoma, sharing that he thinks nivolumab will be much safer than any other treatment options for HL patients",Regional lung TL voluntarily shared that he has recently received a grant specific to looking at patients with autoimmune diseases and the use of I-O agents in this population,NTL voluntarily shared that KESTREL is accruing well and they expect it to be done by year-end; KN-048 not yet done but could be this year with potential to see pembro monotherapy in the 1L R/M SCCHN setting,7
I-O agents,Territory, OK,35.1891891892,3.76560012019e-08,14,6,TL inquired as to incidence of autoimmune disease development while on I-O agents; referencing recent publication from Johns Hopkins in Ann of Rheum (June 2016) of 13 patients that received either ipi or nivo that went on to develop rheumatological AEs - TL shared that they were confused as to why there was no mention of pembro at all as he felt the article gave the perception that these may only be caused by ipi or nivo; TL said he had to ask a Merck rep for clarification on whether these AEs could be seen with pembro as well,"Dermatologist expressed opinion that all dermatologists should be educated around the new I-O agents as well as be more closely involved in the treatment process, with oncologists, specifically in the adjuvant setting","RTL stated that there is a high percentage of patients with auto-immune disease, specifically in the NSCLC patient population, that precludes them from qualifying for I-O treatment; RTL feels more information is needed for I-O agents in this population and/or more treatment options are needed for these patients",20
H&N cancer,Territory, OK,17.5945945946,1.18819483836e-06,22,39,NTL felt that adding nivo to CRT in H&N cancer won't have a significant increase in benefit and perhaps it would be more beneficial to look at nivo with RT alone (referenced data with cetuximab+CRT vs. Bonner study of cetux+RT),NTL stated that buparlisib is the most promising targeted agent currently being researched in H&N cancer with a 40% ORR being extremely remarkable for this patient population,NTL stated he does not feel pseudoprogression is an issue in H&N cancer (only truly in melanoma) and he would not expect that giving a PD1 agent prior to RT would increase the incidence of pseudoprogression although he has had debates with colleagues around this potential issue,61
CM-026,Territory, OK,11.0941286114,3.62908626292e-06,52,177,NTL commented in regards CM-026 and the various cut-offs of PDL1 expression in -026: seeing ~75% of patients in each arm at >/= 5% PDL1+ seemed very high; NTL also felt that when looking at the 50% cut-off and understanding that the study was not designed to look at this as well as the imbalances that the data is still quite discouraging to see those results,NTL seemed unaware of the fact that CM-026 failed to meet primary endpoint; was surprised and vaguely shocked to the sharing of data and having a conversation around this trial since it had a failed primary endpoint.  He stated multiple times it was very discouraging and he would've expected it to be much more like CM-012,"RTL shared his thoughts on CM-026 presented as ESMO and stated ""it happens"", referencing the failure to meet the primary endpoint of PFS; he felt it was not significant and only continued to highlight the need for further options for patients, in which he thinks combo I-O / I-O will play a critical role",229
TL shared,Territory, OK,7.91138679663,4.09844945296e-07,119,1081,TL stated that in RCC he always uses nivo prior to cabo stating his preference is to get I-O in as soon as possible in any treatment regimen for patients specifying that he truly believes in the durability we see with I-O - went on to refer to how many physicians are using I-O before a BRAF inhibitor in melanoma; TL also shared that he dislikes everolimus (and associated toxicities) so much that he refuses to use lev+ever,"TL shared that he treated a metastatic H&N patient with the Extreme regimen, followed by Abraxane, in which the patient progressed on both lines of therapy; the TL then used nivo as 3L and the patient has now achieved a CR within a couple months of therapy","TL shared that he doesn't use sorafenib in HCC patients because ""it doesn't work"" and patients can't remotely tolerate the level of fatigue",1200
feels,Territory, OK,3.22651591419,2.34238826911e-06,397,56,"TL commented on the OS curves by p16 status from AACR -141 presentation, stating that he felt the ICC arm in p16-positive patients should have ""done better"" than what was shown; he felt it looked similar to the ICC arm of the p16-negative patients whereas typically in practice p16-positive patients respond better to treatment than p16-negative patients - thus making it hard to really compare response to nivo vs response to ICC in the p16-positive patients since he felt it underperformed",RTL shared that thus far when using pembro in the 1L NSCLC setting for patients < 50% PDL1 expression they have met no resistance in having it covered by insurance; TL feels that the insurance company only really looking for 1L data in general and the specifics to PDL1 status aren't necessary (so far) in reimbursement,Regional TL felt that the number of patients on CM-026 receiving maintenance with pemetrexed was lower than what he feels he sees in clinical practice going on to reflect whether this affected the time at which patients potentially crossed over from the chemo to the nivo arm,453
lung TL said,Territory, PA,168.461538462,8.07821583641e-19,16,1110,National lung TL said that the KN10 data in the squamous population was ?disappointing? however he wouldn?t steer away from using pembro in a squamous patient based on the KN10 data.,"National lung TL said that they do not enforce everyone testing for PDL1 but if they do test and it is positive, pembro is the choice. He said that even in his clinic, he rarely bothers testing for PDL1 and most often checks the box on the pathway that says ?PDL1 not tested?. He did mention that the PDL1 test is readily available for them and said it is reflexive to do just like EGFR or alk.","National lung TL said that he expects to see first line IO trials like CA209-026 to look like the data from 057. he stated that ""There wont be too much of a mOS difference but the curves will look like the 057 data since most of the patients will be adeno"".",1126
atezi,Territory, PA,112.307692308,9.0623455182e-07,5,27,"At Fall ECOG meeting thoracic TL in the audience voiced his opinion that since atezi is approved now does it replace nivo second line since 026 was negative.
1.	Audience member stated  that since we don?t have atezi first line data (in a similar study design like 026), so we cant make changes based on nivo fail first line. She said if we are making decisions on stopping use of nivo in 2nd line setting based on first line data, then we need atezi first line data as well to make a fair comparison.
2.	Thoracic chair said ""HR are all same between atezi and pembro and nivo in salvage setting""
3.	National lung TL said that toxicity is better with atezi (1% pneum) vs nivo (6%)
4.	Comment was made on atezi efficacy in PDL1 neg patients is based on sp142 antibody which misses about half of positive patients","Local lung TL commented that he currently uses about 80% nivo in his second line NSCLC patients vs 20% pembro. He doesnt think there is much room for atezi in that space. He did say that with the 026 results, he expects some hit to the amount of nivo being used second line.",Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,32
Regional lung TL told,Territory, PA,101.076923077,4.34208902411e-21,21,2,"Regional lung TL told me that he hasn?t treated any patient with autoimmune disease with IO intentionally, he has however seen a patient develop RA following nivo treatment. Patient has been managed with steroids and will be restarting nivo.","Regional lung TL told me about a recent op-edd piece that he saw in either The New York Times or Wall Street Journal where someone (he suspects this person was from merck) wrote in and criticized oncologists about not using pembro in pdl1-. He said the piece basically called out the oncologists as being very dumb people. He said that it ""is typical Merck tactics"".","Regional lung TL told me that he isn?t convinced that the Keynote 024 data is that great, he said ?lets wait to see the data before we get too excited?.",23
Fall ECOG,Territory, PA,89.8461538462,1.71205620441e-05,4,148,"At Fall ECOG meeting thoracic TL in the audience voiced his opinion that since atezi is approved now does it replace nivo second line since 026 was negative.
1.	Audience member stated  that since we don?t have atezi first line data (in a similar study design like 026), so we cant make changes based on nivo fail first line. She said if we are making decisions on stopping use of nivo in 2nd line setting based on first line data, then we need atezi first line data as well to make a fair comparison.
2.	Thoracic chair said ""HR are all same between atezi and pembro and nivo in salvage setting""
3.	National lung TL said that toxicity is better with atezi (1% pneum) vs nivo (6%)
4.	Comment was made on atezi efficacy in PDL1 neg patients is based on sp142 antibody which misses about half of positive patients","At Fall ECOG meeting, thoracic chair polled the audience about how is PDL1 testing being handled at their institutions.
i.	Mass Gen reflex testing but not with 22C3. 
ii.	More institutions sending out samples vs in house testing
1.	Audience responded that they are getting results within 3-5 days of sending out samples
2.	They are getting actual % positive PDL1","At Fall ECOG meeting thoracic presenter told the audience that 026 is technically a negativestudy and she commented that the forest plots of 026 subsets showed most actually favored chemo (she said ""the dots in the forest plots were mostly on the chemo arm vs the nivo arm"").",152
voiced his opinion,Territory, PA,67.3846153846,1.8073479167e-07,7,16,"Academic lung TL voiced his opinions that the ""OAK data  is bad"". He said that it is clear that the assay used is not as good as the 22C3 or 28-8 based assays. He also said that he doesn?t think much of the never smoker data in OAK.","Academic lung TL voiced his opinion that Keynote 024 and pembro first line ""is the single best thing that has ever happened in NSCLC for patients"".","Academic lung TL voiced his opinion that Keynote 024 and pembro first line ""is the single best thing that has ever happened in NSCLC for patients"".",23
Local lung TL commented,Territory, PA,44.9230769231,7.11846286708e-11,14,0,"Local lung TL commented that even with the 026 trial results, he still thinks pembro and nivo are basically the same agent.",Local lung TL commented that he isnt worried about the 026 data as you cant go back and retrospectively analyze the data using a 50% cutoff. He said the study wasnt designed that way and thus you cant get meaningful data from that kind of analysis.,Local lung TL commented that he is impressed with the data on Nivo plus Ipi data in SCLC and is happy to see it included in the NCCN guidelines. He was curious as to why the dose of ipi used in the combination is higher than in the NSCLC trials.,14
isn,Territory, PA,44.9230769231,5.92688721385e-09,11,106,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",Community TL shared that he uses mostly nivo (vs pembro) for his lung patients. He said it wasn?t due to any specific reason (i.e. better efficacy or better toxicity) other than the fact that he is comfortable with nivo and doesn?t see any reason to even try pembro. He said he thinks nivo is better especially in squamous patients.,117
GR,Territory, PA,44.9230769231,4.95492170287e-05,5,0,"National H&N TL indicated during GR that KN-012 showed ""only a smattering of CRs"" and that one should remember the tail of the curve ""represents only 4 patients"".",Melanoma NTL said from GR podium that the incidence of nivolumab-related myocarditis/myositis is ~ 0.25%.  Estimates deaths in nivo clinical development program to be 5 from myositits and 6 from myocarditis.,"National H&N TL said during GR that in Checkmate 141, nivo and ic OS tracked during the first three months which was surprising to them.   They said the OS rate was similar to KN-012 and that PD-L1- patients ""derived little benefit"" from nivo.",5
second,Territory, PA,44.9230769231,4.95492170287e-05,5,0,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.",Local RCC TL said his strategy for second line RCC it that he was always under the impression that its best to switch MOAs when failure occurs. He said that was how he was trained. He said that he doesn?t think anything can replace nivo second line given the very limited toxicity profile seen with it. He said he doesn?t think cabo can replace it,"Local lung TL commented that pathway company at his institution does not differentiate % of cell positive for PDL1 to determine who can get pembro second line. He said ""positive is positive"" according to the medical director of the pathway and doesnt think it will change first line. He said he thinks the same will hold true for first line use of pembro, any positivity will result in use of pembro first line.",5
H&N TL,Territory, PA,28.0769230769,1.69965923429e-05,20,432,"National H&N TL provided the following comment regarding pembro approval in H&N: He said that pembro got approved based on the 141 data set. His exact words were ?pembro was approved based on Checkmate data? because everyone expects Keynote 40 to be positive just like checkmate 141 was. He said Merck was lucky that they hit the sweet spot in terms of timing and that?s why they got approval. He said that everyone expects pembro to ultimately have as strong of data as nivo but as of right now, nivo has the best data out there and thus should be the preferred option on their institutional pathway.","Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.",Regional H&N TL told me that KESTREL will close (due to full accrual)  in October 2016.,452
sutent,Territory, PA,28.0769230769,1.69965923429e-05,8,3,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.","Local RCC TL told me that Pazop toxicities are the same but less significant vs sutent. She said they only use pazop for frail older patients first line. Everyone else gets sutent first line. She said that they use 2 on, one off dosing of sutent even though it isn?t recommended in their PI.","Local RCC TL said his strategy for 1st line RCC used to be pazopanib first line but he said he really likes the 2 weeks on, 1 week off Sutent strategy. He said he has been using that in his new patients. He said that the biggest issues he used to have with sutent every four weeks was weight loss as a result of significant diarrhea coupled with taste issues. He said patient won?t eat because of the taste problems.",11
TL told,Territory, PA,12.4786324786,1.88631056051e-10,65,938,"Local H&N TL told me that the RTOG 3504 study in locally advanced H&N is very important because that is most common type of patient that they see. She said that they only see 10-15% of patients being metastatic at presentation and at least at their institution, the h&n isnt treated at the community sites, instead all of the patients are referred to the main hospital.","Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.",Local H&N TL told me that it was first time she has seen standing room only space at a H&N presentation when referring to the 141 data presented by DR Ferris at ASCO.,1003
Local,Territory, PA,9.70560303894,5.95366712416e-19,184,1056,"Regional H&N TL told me that he wouldn't want to participate in 651 as he already has the KESTREL study open and he really doesn't like the idea of randomizing patients to the EXTREME regimen. He said that the treatment is just too ""extreme"" in terms of toxicity. Interesting, another local H&N TL at a sister institution down the road told me that she tried to start her patients on EXTREME as ""that's where the best data is"" in terms of efficacy.","Local community TL told me that when she gets her reports back for PDL1 testing, the company provides her with a % positive for PDL1 for pembro as well as a % positive for nivo on the same sheet. I asked her if the numbers match up based on Blueprint analysis and she said they are usually about 10% different with the nivo number being lower. This was based on a single patient and she couldnt remember the company's name that did this testing but she said she would let me know.","Local H&N TL told me that the RTOG 3504 study in locally advanced H&N is very important because that is most common type of patient that they see. She said that they only see 10-15% of patients being metastatic at presentation and at least at their institution, the h&n isnt treated at the community sites, instead all of the patients are referred to the main hospital.",1240
t,Territory, PA,7.29270729271,5.00781418171e-12,117,0,Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",117
doesn,Territory, PA,7.21978021978,2.48864767972e-05,36,94,"National lung TL volunteered the following about the 026 study:He said that it is all about patient selection. He said the 026 study failed because it is analogous to doing a trial of Tarceva in an unselected patient population. The agent (nivo) just doesn?t work as well in unselected patients. PDL1 is the best biomarker we have right now, but it isn?t perfect for many reasons.","Regional lung TL told me that Merck was smart in only testing pembro in PDL1+ (50%) patients. He said the data always looks better in that enriched group. He said he isn?t sure whether insurers will require PDL1+ > 50% to use pembro (i.e the 50% number might not be needed, it could just be plus or minus at 1% or 5%, etc) . He said he has had success in getting a 1st line NSCLC patient pembro without having to provide the % PDL1 positive. He said that it will come down to dosing frequency that will determine Nivo vs Pembro use. He said he doesn?t think that there is much difference efficacy wise between the two, so convenience might be the deciding factor
.",Local lung TL said that he hardly ever does PDL1 testing in second line and uses predominately nivo because of the lack of need for testing. He said tissue availability is always an issue and patients don?t want to wait for results. He said that he doesn?t think he will use much atezi in his second line patients as he is more comfortable with nivo.,130
TL said,Territory, PA,6.17692307692,1.15759629663e-05,86,62,Regional GU TL said he does not order PD-L1 testing in RCC or bladder outside of a clinical trial.  Said there is no data to support treatment decision making in RCC.,Regional TL said no data supports testing for PD-L1 in RCC in any line.,"National H&N TL said during GR that in Checkmate 141, nivo and ic OS tracked during the first three months which was surprising to them.   They said the OS rate was similar to KN-012 and that PD-L1- patients ""derived little benefit"" from nivo.",148
said,Territory, PA,5.89615384615,2.85420644098e-27,479,0,Local RCC TL said his strategy for second line RCC it that he was always under the impression that its best to switch MOAs when failure occurs. He said that was how he was trained. He said that he doesn?t think anything can replace nivo second line given the very limited toxicity profile seen with it. He said he doesn?t think cabo can replace it,"Local H&N TL said that at the recent ASCO review, the speaker highlighted the 1 yr OS as being very important.Local TL also said that ORR is OK as an endpoint, but OS is the king of outcomes. He said that ORR is tough to use due to the potential for pseudoprogression with immunotherapy. He said EXTREME regimen very difficult for most patients. He isn?t a fan. He uses some weekly taxotere, some gem","Regional lung TL said that he ""doesn?t think there is ultimately any difference between nivo and pembro even with 026 press release"". He is impressed that pembro hit both pfs and OS data. He said BMS gambled right for second line but not so much for 1st line. He also said that it?s clear that PDL1 positive patients do better. ""It always better to be PDL1 positive"". He wants to see the data from pembro and from 026 to really see if there is any difference.",479
line,Territory, PA,4.75147928994,5.90756762208e-08,345,108,"Local RCC TL said his strategy for 1st line RCC used to be pazopanib first line but he said he really likes the 2 weeks on, 1 week off Sutent strategy. He said he has been using that in his new patients. He said that the biggest issues he used to have with sutent every four weeks was weight loss as a result of significant diarrhea coupled with taste issues. He said patient won?t eat because of the taste problems.",Regional lung TL told me he heard about the 026 press release and said that we now need to know if nivo can be effective in patients that fail first line pembro. He said he has tried to use nivo in a NSCLC patient that failed a first line anti-PDL1 antibody (EMD Serono antibody) and it didn't work.,"Local RCC TL described his sequencing strategy in RCC:1st line is sutent or pazop. He doesn?t believe pazop is that much better tolerated. LFTs are a real issue with pazop but the trial design was done so that qol was analyzed by quesitonairre at the end of week 4 which is when the tox of sutent is the worst. Sutent toxicities of note are taste changes and diarrhea resulting in weight loss.If the patient had a response of greater than 2 year to first line tki and then relapsed, he would probably most likely try another tki before nivo. If the patient had responses less than 2 year on tki, he would treat second line with nivo. Also, if the patient had a bad tki AE, he would use nivo second line instead of trying another tki. He uses cabo 3rd or 4th line. He said that the side effects with cabo are ?troublesome? and it still works late line so he will save it for there.",453
told,Territory, PA,4.62443438914,1.48224821259e-05,136,65,Regional lung TL told me that the Merck people are telling him that 70% of 2nd line patients are getting tested for pdl1. He laughed and said he doesn't believe that.,"Local pharmacist told me that the ""Merck people are pushing the fact that they achieved an OS benefit in their 024 study even with cross over"" and are telling him that ""BMS cant use cross over as an explanation why nivolumab failed to achieve any OS benefit in 026"".",Local lung TL told me that the Merck sales folks visited him yesterday and his description of them was ?they were salivating about their data at ESMO and the incoming first line business?,201
national,Territory, PA,4.08391608392,4.87316891553e-05,183,979,"National H&N TL provided the following comment regarding pembro approval in H&N: He said that pembro got approved based on the 141 data set. His exact words were ?pembro was approved based on Checkmate data? because everyone expects Keynote 40 to be positive just like checkmate 141 was. He said Merck was lucky that they hit the sweet spot in terms of timing and that?s why they got approval. He said that everyone expects pembro to ultimately have as strong of data as nivo but as of right now, nivo has the best data out there and thus should be the preferred option on their institutional pathway.","National lung TL said that they do not enforce everyone testing for PDL1 but if they do test and it is positive, pembro is the choice. He said that even in his clinic, he rarely bothers testing for PDL1 and most often checks the box on the pathway that says ?PDL1 not tested?. He did mention that the PDL1 test is readily available for them and said it is reflexive to do just like EGFR or alk.",National lung TL said that the KN10 data in the squamous population was ?disappointing? however he wouldn?t steer away from using pembro in a squamous patient based on the KN10 data.,1162
HCP,Territory, Puerto Rico,35.0114942529,4.22548788338e-05,115,124,"An HCP commented how he was not convinced of the activity of Yervoy in the regimen, he feels most of the activity is coming from Opdivo.","An HCP shared that in pancreatic cancer, checkpoint inhibitors have not shown efficacy because the microenvironment is not ideal.","An HCP shared that MSI testing for all CRC specimens is routinely done in Puerto Rico, part of a standard panel.",239
consultant,Territory, Puerto Rico MSL,121.0,1.35352544398e-05,5,207,"An Access Influencer consultant for a Pathway Company shared how she is routinely testing for PD-L1 before starting first line treatment, not before second line.",An Access Influencer consultant for a Pathway Company shared how excited she was to have her first patient in Opdivo.  The patient was and the family was also very enthusiastic about using the new drug with high hopes for the outcome.,"An Access Influencer consultant for a Pathway Company discussed the challenges in PD-L1 testing.  In Puerto Rico core biopsies are not routinely performed, so with needle biopsies only a few biomarkers could be tested. The PD-L1 and EGFR require less tissue, difficult to do Alk testing.",212
Post-ASCO,Territory, Puerto Rico MSL,90.75,2.351837739e-05,6,418,"A melanoma speaker at a Post-ASCO review who is a Merck speaker, spent 75% of the lecture discussing KN001, KN006 and KN029 data from ASCO.  When discussing KN029, did not mention the commercially available combination of Regimen.  Discussed CK067 but completely undermined activity of Regimen over the two comparators.  Rather highlighted how the two Nivo arms were superior to Yervoy.","A lung cancer speaker at a Post-ASCO review described OAK and KN024 as ""practice changing"".  Described CK227 as ""BMS's way to redeem itself in lung cancer"".  However, provided a well balanced discussion on biomarkers and highlighted CK012 and SCLC data from CK032.","A speaker at a local Post-ASCO presented a study of nivolumab to treat anal SCC cancer which was very well received by the audience, particularly because it included HIV+ patients.",424
Northeast,Territory, RI,301.0,8.78016867068e-14,9,121,"Testing for PD-L1 in NSCLC is now part of the usual pathology and genetic tests conducted in a leading NCCN institution in Northeast US.  This hospital charges the payers a single bundled charge for all the tests they do on a patient.  Now, PD-L1 has been added to the pre-existing battery of tests.  This institution does its own immunohistochemistry assays for PD-L1 using the E1L3N antibody from Cell Signaling Technology.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",130
IME,Territory, RI,225.75,1.03059906794e-05,3,0,"In his presentation at an IME on immunotherapy in NSCLC, Naiyer Rizvi MD (Columbia University) summarized the data for nivolumab and pembrolizumab, stratified for PD-L1 levels and tumor histology.  The overall theme of his presentation was that both agents are very similar across all stratifications, even when the slides highlighted the differences (e.g. hazard ratio for pembrolizumab in squamous histology in Keynote-10).  BMS, Merck and Genentech funded this IME program.","Discussing therapeutic options in NSCLC patients expressing low levels of PD-L1, Leora Horn MD (Vanderbilt & NCCN panelist) indicated her preference for chemotherapy over IO agents.  She also believes that chemotherapy (with pemetrexed for NSQ NSCLC) and targeted therapy is more valuable in appropriate patients as first line therapy, instead of IO agents as monotherapy or in combination.  These opinions were expressed during the unscripted discussion following an IME program sponsored by BMS, Merck and Genentech.","Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.",3
New England,Territory, RI,150.5,2.506522524e-18,17,970,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.",987
cell carcinoma,Territory, RI,75.25,2.50530862486e-06,7,40,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",47
NCCN institution,Territory, RI,66.8888888889,4.29123557889e-11,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","A leading academic thought leader and clinical trials expert from a New England NCCN institution underplayed the significance of CheckMate 026 results disclosed so far.  He felt that PFS is not a good endpoint for IO therapies, as many IO trials have already shown positive response rates and overall survival despite a lack of PFS advantage.  In cancers with low T- lymphocyte infiltration, CTLA-4 inhibition using ipilimumab may enhance the efficacy of nivolumab by increasing infiltration.",125
immuno-oncology,Territory, RI,53.75,4.00828032701e-07,11,54,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.",65
produce,Territory, RI,37.625,1.68991039548e-05,11,0,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Physicians are reacting negatively to the direct-to-consumer advertisements for Opdivo and are raising their displeasure proactively during meetings.  The Medical Director of the Lung Cancer Program in an academic hospital in the Northeast told the HSLs that he had second thoughts about using Opdivo, just as a reaction to the DTC advertisement on television.  Another family practice physician involved in formulary decisions called the Opdivo TV ads ?cringe-inducing?.  He complained that the overall tenor of the TV ad grossly exaggerates the modest improvement in median overall survival produced by Opdivo in NSCLC.","A leading academic thought leader discussed the clinical trial results of cabozantinib and his own personal experience in using this agent.  Toxicity and adverse events remains the major concern with cabozantinib.  Though cabozantinib produced very good results in clinical trials, he is cautious about using this agent in his practice.  He has participated in nivolumab trials, and uses nivolumab frequently in his clinical practice.  However, he stressed that the TKIs will remain a staple part of therapy of RCC, and the right patient can derive significant benefit from them.",11
US,Territory, RI,37.625,1.46361607795e-06,14,24,"Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A clinical pharmacist at an academic medical center in the Northeast US indicated that they have added PD-L1 testing (IHC) to their usual battery of genetic tests for all tumors, including NSCLC and RCC.  At present, PD-L1 levels are not being used to make treatment decisions at this center.  But she implied that more granular instructions on the use of anti-PD-1 and anti-PD-L1 agents are expected in future from both regulatory agencies and payers.  This center wants to have all the procedures established before these changes become mandatory requirements.",38
thought leader,Territory, RI,33.4444444444,2.42576830707e-09,25,22,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","A national thought leader on renal cancer from a Northeast NCCN institution advocated a Q3W dosing for nivolumab in RCC as a cost-saving measure that also increased patient convenience.  He substantiated his argument by pointing out that the clinical efficacy in ORR, PFS and OS are identical for CheckMate 010 and CheckMate 025, though the former trial uses a Q3W dosing schedule.  He believes that FDA would accept a single arm trial that shows non-inferiority in OS to change the labeling to a Q3W dosing.",47
Boston,Territory, RI,28.21875,5.0253285218e-07,40,82,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",122
MD,Territory, RI,27.7236842105,6.47806926464e-08,29,71,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",100
ipilimumab,Territory, RI,26.5588235294,6.71018488851e-07,22,17,"David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.",39
renal,Territory, RI,20.9027777778,1.48378524388e-05,22,26,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",48
cabozantinib,Territory, RI,20.5227272727,2.34524140396e-06,27,137,"According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.","Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.",164
IO agents,Territory, RI,18.3040540541,2.05728361688e-08,45,174,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A key oncologist from a New England academic hospital shared information on his thinking and his clinical practice in managing IO agents in patients with endocrine-related immune-mediated adverse reactions.  In his opinion, adverse events affecting the endocrine organs such as the thyroid and pituitary glands can be managed by administering the appropriate hormone replacement with discontinuing the IO agent.  He believes that value provided by IO agents including the potential for a complete remission is too important to sacrifice to avoid an adverse event that can be easily managed.","The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.",219
major,Territory, RI,16.0106382979,1.11546964675e-08,90,483,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",573
advanced,Territory, RI,15.6770833333,4.85954723446e-05,36,0,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","A key NCCN panelist for SCCHN a major academic hospital in New England was profiled to understand the treatment landscape in SCCHN.  This panelist was an investigator in CheckMate 141, and therefore was intimately familiar with the data presented at AACR.  The panelist considers the efficacy in OS to be better than what is seen in clinical practice with single agent therapies (methotrexate, cetuximab, docetaxel etc.).  He has a very negative opinion on the efficacy and toxicity of these standard of care therapies.  

Combination therapies will enhance the potential of immune-oncology in difficult to treat cancers and advanced stage disease.  Robust data needs to be developed for all options with Opdivo such as IO combinations, IO + targeted therapies and IO + chemotherapy/RT.  He also stressed the need to do clinical trials in nasopharyngeal SCCHN due to its unique etiology and response to treatment.  He does not endorse extending the NCCN recommendations to include this population based on data from other types of SCCHN.","The Director of Hematologic Malignancies at a major academic hospital in Boston downplayed the incidence of GVHD in patients who received allogeneic stem cell transplantation after receiving nivolumab previously.  Hodgkin lymphoma patients with advanced disease in later lines of treatment are more susceptible to GVHD after allogeneic SCT generally, even without previous exposure to nivolumab.  As careful management of GVHD can reduce allo-associated mortality, nivolumab provides a good therapeutic option in advanced HL patients.",36
hospital,Territory, RI,15.6770833333,1.32785094524e-08,72,479,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The clinical pharmacist responsible for infused products at a leading academic hospital in New England expressed gratitude to BMS for its generous patient assistance program.  Most of their patients on nivolumab in off-label indications in this Disproportionate Share Hospital (DSH) currently receive free medication through the patient assistance program.  This hospital is now attempting to move some of these patients to their insurance plan, to reduce the burden on the assistance program.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",551
improved,Territory, RI,14.564516129,1.28660051308e-05,36,0,"The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.",36
care,Territory, RI,13.6818181818,1.75918689769e-05,75,12,"The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.",87
CLL,Territory," ROCKY MOUNTAIN
UT",77.2051282051,4.6940921577e-05,5,98,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,103
like to see a trial,Territory," ROCKY MOUNTAIN
UT",60.0484330484,1.10284505016e-09,15,14,"Academic TL knows that Nivo does not work well in CLL, but feels it would be effective in Richter transformation CLL.  She would like to see a trial testing Nivo in this difficult disease state.",TL would like to see a trial combining Nivo with ibrutinub in the treatment of advanced CLL.,Local TL stated interest in collaboration with BMS to look at Richter's transformation in CLL with Opdivo and ibrutinib.,29
GVHD,Territory," ROCKY MOUNTAIN
UT",22.7073906486,1.05004233994e-05,21,118,GVHD can be managed with PD-1 inhibitor and allo transplants.,TL indicated that a trial should be done to mitigate GVHD following SCT with PD-1 inhibition by reducing the dose and/or waiting more time following the transplant to initiate PD-1 inhibition.,TL said that about 60% of patients who had problems with GVHD (grade 3-4 and acute) when re-challenged would react again.,139
high-grade,Territory, S. CA,78.7912087912,4.65004817729e-06,5,192,"Speaking at a dinner program, melanoma NTL answered a question that he doesn't believe incidence of imAE corresponds with patient responsiveness, and that he sees danger in the idea. Specifically, he thinks that if patients learn of the idea that having a side effect might correspond with having a better response, they might be less open about reporting AEs thinking it might lead to discontinuation. He described a ""otherwise very smart"" patient who wouldn't report high-grade colitis for this reason. He only eventually learned of it because the patient's wife called. The patient was admitted for in-patient service.","RTL she feels that high-grade nausea and fatigue are underreported in our studies as compared to her clinical experience. Although she wouldn?t withhold patient treatment based on these AEs, they do make her question the reported toxicity profile as a whole.","With regards to possible radiation + Nivo studies, TL states that he tries to avoid using radiation for some tissue types (e.g. gliomas) due to potential to transform them from low-grade to high-grade.",197
NTL in GU,Territory, S. CA,63.032967033,7.74979181976e-09,9,499,NTL in GU shared that IO may have some activity in prostrate. He shared that his colleagues have shown about a 20% RR with single agent pembro as well as in combination with ?the vaccine?. He shared that the best way to administer the combination was concurrently rather than sequentially.,NTL in GU shared that nivo needs to get into the hands of community med oncs to become familiar with it in bladder cancer. He shared that he thought the data was good but not necessarily distinguishing and hoped that ipi/nivo will have some traction.,NTL in GU shared that the press release from Merck?s phase III bladder trial was good news and that it was the most important data to in bladder cancer because the comparator arm would give a lot of insights into the treatment landscape.,508
NTL said,Territory, S. CA,27.0141287284,9.97168136022e-11,24,14,"In reference to Atezo data, NTL said he's most impressed with the CR rate, which is a vast departure from anything seen before with Chemo. He was next most impressed by ORR in PD-L1+ population. He went on to say he would use Atezo regardless of PD-L1 expression at this point due to lack of other options. He doesn't expect there to be much difference based on anti-PD-1 vs anti-PD-L1, but acknowledges dosing schedules could be significant.","NTL said if not for the Blueprint Project, he would have attributed the differences in CM-026 and KN-024 to differences in the biomarkers and, as a result, different patient populations being included in each study. Blueprint would suggest that wasn?t true. He does feel that the overwhelming history of the clinical trial history suggests the agents are interchangeable. As a result, he?s unsure of how to explain the differences.
He didn?t think the imbalance in -026 in which more patients with 50+% PD-L1 expression were in the chemo arm was a sufficient explanation for the differences in PFS/OS. He mentioned that high PD-L1 expression is otherwise thought to be a negative prognostic factor in chemo-treated patients, and would thus negatively affect the survival metrics in those patients","Several lung TLs mentioned that the Q4W dosing in -384 could have very significant impact on prescribing habits, giving Opdivo a significant advantage over Keytruda. One NTL said he would want to do 480 mg flat Q4W dosing immediately without any Q2W or Q3W lead-in phase.",38
Academic NTL,Territory, S. CA,22.0615384615,1.86198148361e-06,11,12,"Academic NTL in melanoma shared that he had a patient who was treated with and progressed after ipi monotherapy, BRAF/MEK, and IL-2. The patient developed brain mets and was treated with ipi/nivo and has a complete response in the brain.",Academic NTL in melanoma shared that he used TVec in front line patients with less burden of disease but the big question is when you stop treating. He is not participating in the pembro plus TVec study but will send patients to a site that has it.,"Academic NTL in melanoma shared that he prefers to use the regimen in treating most patients and that he is suspicious of a ?kinder, gentler approach? to treatment that is being investigated. He further shared that he is interested in seeing GMCSF data in combination with ipi/nivo with long-term follow up to see whether toxicities might be reduced. He also shared that he feels that there is a data gap in patients who fail ipi/nivo and that giving more doses would be a good way to elicit a response. He also shared that he thought that the nano-strings approach to understanding which patients would respond to PD-1 therapy looked promising.",23
RTL said,Territory, S. CA,20.60693153,1.74175536111e-13,31,0,"RTL said she feels that Keytruda first-line use will be limited to the 20-25% of patients that reach the 50% PD-L1 expression, with minimal off-label use. She believes that Opdivo will still remain preferred in the second-line because ""oncologists are creatures of habit"" and many community sites will prefer Q2W for billing reasons.","RTL said for 2L NSCLC, the Q3W schedule for Atezo is the differentiating factor, and that he put his most recent patient on Atezo. However, he thinks we?ll still have majority market share based on prior experience.","RTL said he would ""essentially have to"" use Opdivo at his institution since the formulary will have a strong preference for OS data, limiting the use of Keytruda. He said this might not be true for community practices.",31
anti-PD-1,Territory, S. CA,20.2605965463,4.16603075149e-14,31,661,"RTL feels that anti-PD-1 and anti-PD-L1 agents are interchangeable, and that press release differences from KN-024 and CM-026 are related to patient populations. She offered that she expects -227 to be positive and to become SOC in 1st-line.","Citing data across tumor types, an NTL said there doesn't appear to be much of an effect of previous lines of therapy (i.e. prior chemo) on the efficacy of immunotherapy agents. However, IT does seem to increase response to subsequent chemo. As such, he would be strongly predisposed to incorporate IT agents into patient treatment as early as possible. He did say that 1st-line Opdivo monotherapy might not make sense for patients with low PD-L1 expression, but demurred from citing a specfic PD-L1 expression level at which he'd prefer anti-PD-1 versus chemo.","Community TL says that anti-PD-1 and anti-PD-L1 agents are likely similar, but that he has more confidence in the BMS diagnostic approach as compared to the Roche/Genentech method. He feels that immune-cell based approach isn't well-formulated.",692
KN-024 and CM-026,Territory, S. CA,15.7582417582,1.57608595402e-06,15,310,"NTL said if not for the Blueprint Project, he would have attributed the differences in CM-026 and KN-024 to differences in the biomarkers and, as a result, different patient populations being included in each study. Blueprint would suggest that wasn?t true. He does feel that the overwhelming history of the clinical trial history suggests the agents are interchangeable. As a result, he?s unsure of how to explain the differences.
He didn?t think the imbalance in -026 in which more patients with 50+% PD-L1 expression were in the chemo arm was a sufficient explanation for the differences in PFS/OS. He mentioned that high PD-L1 expression is otherwise thought to be a negative prognostic factor in chemo-treated patients, and would thus negatively affect the survival metrics in those patients","RTL says consensus he's heard from colleagues is that Opdivo and Keytruda are still considered functionally equivalent, and that differences in CM-026 and KN-024 were related to study design.","RTL is having difficulty making sense of the study readouts in KN-024 and CM-026. He thinks the reasons being discussed (population differences, scan times, etc.) would only account for relatively small (~0.1) differences in PFS HR, and not the actual difference that was seen. He suspects there are differences in the PD-L1 assays that have not been identified, although he was familiar with the results of the Blueprint Initiative.",325
cited,Territory, S. CA,9.75510204082,4.97484984517e-08,33,0,"NTL believes Cutaneous Squamous Cell Carcinoma is a prime candidate for immunotherapy, citing mutational load and evidence of immune cell invasion. She believes Merck is investigating this area.","TL does not believe dogma that monoclonal antibodies don't enter the TME for brain tumors. Specifically, he believes the ""blood-tumor barrier"" is different from and more permeable the blood-brain barrier (BBB). Also, he cites how studies of BBB have typically been conducted in non-inflamed tissue, and not applicable to situations in which a tumor and active immune response are present.","NTL feels that PD-L1 testing that focuses exclusively on tumor cells (rather than including or focusing on immune cells) is much more informative, citing the dynamic nature of inflammation.",33
first-line,Territory, S. CA,9.26955397544,2.354930391e-06,26,54,"RTL who worked on KN-001 expects the Pembro label to be updated to 50% PD-L1 expression cut-off in first-line (post-approval), and 1% PD-L1 expression cut-off in second-line.","RTL said she feels that Keytruda first-line use will be limited to the 20-25% of patients that reach the 50% PD-L1 expression, with minimal off-label use. She believes that Opdivo will still remain preferred in the second-line because ""oncologists are creatures of habit"" and many community sites will prefer Q2W for billing reasons.","In discussing the treatment landscape, NTL said that now that high PD-L1 expressers will be treated with Pembro in first-line and therefore removed as candidates for anti-PD-1/PD-L1 treatment in second-line, he is no longer sure that anti-PD-1/PD-L1 therapy has enough differential activity as compared to Docetaxel to justify the cost",80
guide,Territory, S. CA,7.09120879121,3.81443627568e-05,28,116,"TL regularly does PDL1 testing across tumor types, but doesn?t use it to guide therapy for lung. He does it so he can better manage his own and the patient?s expectations. However, given how easy it is to do for many tumor types, he feels it will become a standard part of treatment algorithms as more treatment options become available.","While discussing the issues with PD-L1 testing as a whole, RTL said she isn't optimistic about the potential applicability of fluid biopsies. She feels they will most likely provide limited information about the TME, and not be useful for guiding treatment.","Lung RTL who intermittently uses PDL1 testing in the second-line setting thinks there?s much stronger rationale for using it in the first-line. He feels that it?s getting easy enough to test that it could become a standard part of the front-line approach. As far as how to use it for guiding treatment in the front-line, he thinks IO therapy will need more than a 25% ORR to be considered instead of platinum-based doublet chemotherapy.",144
shared,Territory, S. CA,4.16255442671,2.34715522329e-17,507,1,NTL in GU shared that nivo needs to get into the hands of community med oncs to become familiar with it in bladder cancer. He shared that he thought the data was good but not necessarily distinguishing and hoped that ipi/nivo will have some traction.,NTL in GU shared that IO may have some activity in prostrate. He shared that his colleagues have shown about a 20% RR with single agent pembro as well as in combination with ?the vaccine?. He shared that the best way to administer the combination was concurrently rather than sequentially.,NTL in GU shared that the press release from Merck?s phase III bladder trial was good news and that it was the most important data to in bladder cancer because the comparator arm would give a lot of insights into the treatment landscape.,508
feels,Territory, S. CA,2.74910136592,7.46785355915e-09,397,56,Community LTL shared that he really didn?t understand pseudo-progression because he felt that there were conflicting reports in the field. He would like a data review of the tumor types and different agents used to completely understand.,Community LTL shared that he really didn?t understand pseudo-progression because he felt that there were conflicting reports in the field. He would like a data review of the tumor types and different agents used to completely understand.,Academic NTL on NCCN panel shared that one of the biggest concerns in lung treatment is how long to treat. We discussed the 153 trial design but she shared that issue is really community oncologists who don?t fully understand pseudo-progression and that they will keep treating patients unnecessarily with PD-1 inhibitors rather than switching. She was not aware of the data sets from 017 and 057 on patients who were treated through progression. She further shared that she felt that the field needed a definition and understanding of pseudo-progression to help identify patients who may benefit.,453
NCCN center in the midwest stated,Territory, SD,665.777777778,4.51805282813e-20,12,299,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",311
exercise,Territory, SD,277.407407407,1.3367760794e-08,5,238,"During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment he was surprised the FDA will allow Merck to have labeled indication without a comparator arm in their trials given the fact that there is a drug with proven efficacy that has a comparator arm","During a profiling exercise with a H&N panelist at an NCCN center, AI stated he defines refractory the same as we defined it in 141 (which he stated is a better design that the Pembro trial where you had to fail both cetuximab and a platinum therapy)","During a profiling exercise with a H&N panelist at an NCCN center, AI stated in an unsolicited comment the Nivo QOL is ?the best,? and he will highlight that data at his next post ASCO talk. He believes that data is impactful. He mentioned Pembro doesn?t have that data",243
P&T committee,Territory, SD,110.962962963,3.54720996095e-09,8,478,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",486
NCCN center,Territory, SD,83.2222222222,1.65488363827e-12,26,280,"P&T committee member/lung AI at an NCCN center stated the following

o	When asked if cost/cost avoidance discussion are part of their formulary discussions, he stated they are minimized at his institution. He stated decisions are NCCN/FDA approval/data driven.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",306
AI stated,Territory, SD,70.6127946128,6.07932796822e-18,24,171,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",195
payor,Territory, SD,55.4814814815,7.7146791151e-06,7,23,"For a small regional health plan assosicated with a national account institution (~200K lives): While discussing oncology management, the payor stated that he is excited to hear that there will be more PD1's enter the market as they will be able to manage the class; however, he stated it will be nearly impossible to manage the class if the indications vary from drug to drug. He cited the example of the TNF class of drugs where they are unable to restrict certain drugs due to niche indications. This specific plan does not currently manage oncology.","Specialty pharmacist at an academic SP stated he believes that I/O therapy will eventually be billed under the pharmacy benefit as PBMs will want to demonstrate their value in an increasingly generic blended market. As the health system with an integrated payor looks at total cost of care, he thinks the payor will demand white bagging as a cost saving through their own SP; however, he was uncomfortable with the concept of an outside SP delivering an infusible to his infusion clinic.",Regional payor stated they have a waste billing limit of 40 mg due to the vial size of Opdivo,30
order sets,Territory, SD,44.3851851852,1.36726717016e-05,8,321,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),329
reactive discussion,Territory, SD,36.987654321,2.24373460899e-05,9,310,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","?	While proactively discussing 2 year OS for 057/017, the reactive discussion led to 026. We discussed trial designed etc. We then began to discuss the 2L space in which the AI stated their system will likely begin to use atezo based on no testing and Q3 weeks (convenience) for traveling patients and chair time.  
?	The AI then discussed 227 (enrollment site)
?	This led to a reactive discussion on the early 012 data which demonstrated nearly a doubling ORR based on expression levels
?	The AI then led a discussion on what a treating physician would do if a patient was progressing on Nivo and the 227 reads out positive for regimen (would a treating physician add ipi?)
o	AI believed more data is need; however, this is an area of needed exploration
o	There is no data with Atezo or Pembro to add Ipi at Q 6 weeks","Advisor to the panelist at an NCCN center in the midwest stated, after a reactive discussion on the 227 trial design, that BMS should decide on one dose for the regimen (referencing 032 for SCLC). He stated different doses will increase confusion and errors if we use multiple doses in different tumors.",319
advisor,Territory, SD,35.8997821351,2.52019345726e-12,27,231,Advisor to the panelist at an NCCN center in the midwest stated Atezo won't be considered for formulary addition because they are so accustomed to using Nivo and it's challenging to change habits,"Advisor to the panelist at an NCCN center in the midwest stated that based on the 026 data, he'd like to offer Nivo in 1L","Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.",258
build,Territory, SD,31.7037037037,3.47169711024e-05,10,21,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",SCLC panelist at an NCCN instituion in the midewest confirmed that sometimes order sets aren?t even built if the team decides the value of an oncolytic is minimal (he referenced ramucirumab),31
midwest,Territory, SD,26.4197530864,2.28687188179e-10,42,124,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,166
expression levels,Territory, SD,25.2188552189,8.25746972402e-06,41,170,"Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Payor insights from ~4 million life plan in the Midwest provided the following insights. They are not looking to manage PD1 inhibitors by PDL1 expression levels. He indicated the science is too new and there are too many unanswered questions.  Payor stated the PDL1 expression is informative, but not definitive. PDL1 expression is not in the PA criteria yet. He stated there is not an ICD10 code for PDL1 expression (+/-).",211
unsolicited,Territory, SD,23.1172839506,1.15082831901e-05,99,200,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",299
perspective,Territory, SD,20.440545809,4.16172070494e-07,25,0,P&T pharmacist chair at an NCCN center in the midwest stated that cost data (ie Nivo vs docetaxol lung-tx related adverse events-not shared) is irrelevant to them when there is a clear winner from a clinical trial in either efficacy OR safety from an institutional P&T perspective.,"Director of pharmacy at an NCCN center stated that from an operational perspective, there is an increase in human resources needed to use access support programs(foundation portion) (ie paperwork/drug management/dispensing cost). While these programs are important for the patient, they are expensive for her to implement because the pharmacy does not receive reimbursement for their role in drug delivery when drugs are received from foundations thereby increasing her ""costs.""","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.",25
chair,Territory, SD,19.4185185185,5.51974824579e-07,26,260,"AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that when the dose of a drug is not consistent with a therapy or drug regimen, it provides additional challenges to the pharmacy department (from a dose verification/safety perspective). Additionally, she has concerns about the community physicians ability to correctly dose therapies if there are different doses for each indication.","AI (and chair of the P&T committee) at an NCCN center in the Midwest stated that his institution uses Beacon (order set within EPIC) to pull HEOR data for his institution. He stated they have a clinical team build it out, so there are hard stops built in for safety issues. He stated because of the clinical build out, they do more testing (TSH etc); however, they believe they have lower total costs because they prevent hospitalizations due to IMARs being caught early. When asked if they share their order sets (to pull multi-institutional data), he stated the functionality is available within EPIC to share the order sets with other institutions; however, they copyright their ordersets.",286
panelist,Territory, SD,18.9448961156,3.1607756734e-12,134,164,"Advisor to the panelist at an NCCN center in the midwest stated in an unsolicited comment on the 384 trial design that if it reads out positive, it will be an easy ""sell"" to patients to reduce the frequency because you can explain to them that they have stabilized.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",298
minimal,Territory, SD,17.337962963,3.54520976813e-05,20,0,"During a profiling exercise, an NCCN H&N panelist offered the following unsolicited insights:
?	When asked how he treats LA-SCCHN he stated the following
o	First surgery
?	After surgery with minimal dz, pt would get RT
?	After surgery with moderate dz, pt would get a plateium therapy
?	After surgery with bulky dz, pt would get chemo/RT
?	He does not test for PDL1 expression but does test for P16
?	Research gaps-he?s like to see a trial sequencing I/O then chemo. He believes patients respond to chemo better post I/O.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.","Advisor to the panelist at an NCCN center in the midwest stated that after seeing IMARs while on service with melanoma patients, he believes that lung patients have much less toxicity. In an unsolicited comment, he stated that he's used the regimen off label for SCLC in many patients with minimal toxicity.",20
o,Territory, SD,13.1403508772,2.46870343135e-07,46,220,"The following insights were gleaned from an NCCN NSCLC panelist in the Midwest institution

?	After reviewing the 026 deck, AI commented that the study design was flawed. She stated they were really hoping for Nivo in an all comers population in the 1L.
?	A discussion around the discussant?s (Soria) comments/tweets at ESMO when he compared the trials (we confirmed that you can?t compare data across trials, but can look at differences in trials)
o	Differences in trial designs (CM026/KN 024)  and imbalances were discussed (never smokers, PDL1 expression differences, non-stratified PDL1 expression, cross over rates, females, health of pt pop). We discussed that Soria stated only ~10-15% of the patients in the real world would match the patient population in KN 024. 
?	This led to the question of why BMS designed their trial this way. She stated she is accustomed to BMS having stronger trials. 
?	Panelist confirmed that females do better in her experience
?	Panelist is aware of ICER, but is not participating in the review. 
?	In a reactive discussion around the NCCN guidelines, I explained BMS? stance that we do not think Nivo should be placed in the guidelines based on the science. She stated she?s heard in the community that people want to begin to use it in the 1L setting due to decreased toxicity. She?s unsure how they will get paid. She agreed with BMS request to not be in the guidelines as their institution and BMS align in their EBM thinking.
?	AI stated the biggest unmet need for patients with 1L lung cancer is to provide an effective therapy with minimal toxicity to patients with poor PS. She stated that?s were I/O can really show it?s benefit. 012 and 227 design were reactively discussed. She?s excited about 227. 
?	She stated there?s a big education gap on the side of the patient. She feels patients are still trying to push through their IMAR. 
?	AI stated she orders both the Pembro/Nivo assays when doing PDL1 expression testing. Discussion on FDA blue print ensued. She stated, in her experience, patients rarely test for >50%. 
?	She brought up OAK being an all comers population. She didn?t comment further, and only stated, we?ll have to see if the FDA gives them an indication.
?	When asked how this data changes her practice, AI closed with, ?I will use Pembro in 1L in healthy patients who are high expressers and Nivo in 2L for all comers who have not had Pembro.?","The following insights were from an Rad-Onc NCCN panelist

-	Was aware of CM026 and KN024 studies? outcomes. Overall insights very consistent with previous insighths communicated (RE: differences in patient population 026/024, imbalance between the 2 arms in 026)
-	Happy to see that ?we now have a very clear offer for very specific patient population (RE: PDL1 > 50%)?
-	Shared that panelist would NOT recommend the use of pembro for patients who are below the 50% expression level
-	Raised the question about the need ?re-test? patients in 2L even if they were tested in 1L. Her rational was to be also more selective in 2L and not to use agents who have no approval / no data for low PDL1 expression. This comment was more about pembro in 2L.  
-	Asked what data we was recently presented in lung cancer with nivo
o	Was not aware of small cell lung cancer 032 data. Asked for data through medical information
o	Was not aware of 1L non-small cell lung cancer 012 data. . Asked for data through medical information","Eric Mortenson and I met with a HL NCCN panelist for a profiling exercise. Below are NCCN related insights.

The panel meets every 12-18 months in person. The next panel meeting is August; however, he stated we should expect an update to the guidelines within 6 weeks.
?	How their update approval process is designed:
o	An admin sends out the proposed guidelines for comment from the rest of the panelists via email. AI stated the ?very loud? panelists typically get their way. He stated the PD-1?s have been sent out for review and ?you will be happy with the outcome.?
?	When asked what data is needed for an NCCN update, he stated heavier weight is given for FDA approvals; however, phase II or better data will be reviewed. He stated there was not a standard endpoint required for a given category rating (ie OS for category 1).

Each panel operates independantly with their own set of rules.",266
NCCN panelist,Territory, SD,12.1050505051,7.01776707208e-09,94,149,Advisor to the H&N NCCN panelist in the midwest stated that the revisions to the most recent guideline update is due at the end of June.,Advisor to the H&N NCCN panelist in the midwest stated their system typically uses in the LA SCCHN 1L HPV + setting surgery followed by adjuvant chemotherapy.,NCCN panelist (med onc treater) for head and neck cancer in the midwest stated that the panel reviewed and discussed the most up to date guidelines for Head and Neck on August 12th. He stated the new version of the guidelines should be published in the next 1-2 months.,243
AI,Territory, SD,7.74160206718,5.1473269505e-07,121,70,"AI at an NCCN center in the south provided the following unsolicited insights with regards to CM026

Subsequent Therapy:  He found the fact that ~60% of Nivo patients didn?t get 2L therapy intriguing as these pts still did very well.  He further questioned what happed to the 40% who received subsequent therapy (from a subgroup analysis perspective). He wondered if the mOS improved substantially in this group and that drove the mOS for the Nivo arm.  This lead to a discussion of pts who received 2nd/3rd line Nivo and go on to receive subsequent therapy with a standard chemo agent (Gem, Doc) and have dramatic unexpected responses.  His team is actually analyzing internal data to address this question Nivo ? Chemo.  They?re evaluating ~50-60 patients who received a PD1 inhibitor followed by chemo.  Scans are being reviewed by a blinded radiologist to see if there is a signal that these patients do better with this sequencing. He hypothesizes this sequence will improve mOS and stated they have seen an early positive trend in RR and OS in this subgroup.  From a hypothesis perspective, the exposure to Nivo may ?reprogram? the tumor microenvironment in such a way that allows the tumor become more accessible and vulnerable to subsequent therapies.  He mentioned Nivo impacted both treatment groups as the mOS for chemo due to crossover and single agent Nivo are better than historical controls.","Biomarkers: AI stated if their health system is using Pembro in 1L in expression levels >50%  based on the KN 024 data, they will use the Pembro PDL1 assay. (Blueprint discussed in which the AI is on the peer-review panel)

The health system will not re-test PDL1 expression in 2L based on Nivo data (testing not required). AI stated that obtaining enough tissue will be an issue if using more than 1 assay.","Via pathway AI stated the following from the podium at a small GPO conference.
?	While on stage, he spoke highly of Nivo. He pointed out the HR 0.59 for 017. He then showed the Pembro data and stated the HR ?isn?t as dramatic? as the nivo data. He emphasized the low number of patients enrolled (vs total screened) for the KN024 trial and stated it was highly selected pt pop. He continuously reminded the audience of >50% expressers pt pop in KN-024.  He highlighted that BMS did the right trials (017/057) and showed the KM curves. He spoke briefly on atezo
?	When speaking on CM 026, he stressed and differentiated the broad pt population (vs KN024). He stressed that a single agent is clearly performing as well as a doublet and you don?t need a statistician to see that from the curves.  He stated that even though the trial was not powered to show non-inferiority, it was clear to him the drugs performed the same.",191
RAI,Territory," SOUTH
AK",530.129032258,7.67697465127e-18,15,701,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.",716
context of an online lecture,Territory," SOUTH
AK",337.35483871,1.72040645962e-11,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NAI,Territory," SOUTH
AK",337.35483871,1.72040645962e-11,7,282,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",289
NCCN 2016 Webex Congress Series,Territory," SOUTH
AK",337.35483871,1.72040645962e-11,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
proactive meeting to discuss CM-026,Territory," SOUTH
AK",337.35483871,1.72040645962e-11,7,257,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",264
Bone Marrow Transplant Director,Territory," SOUTH
AK",240.967741935,2.57300994249e-08,5,713,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.",718
academic institution in the HSL South,Territory," SOUTH
AK",192.774193548,9.78673681984e-07,10,110,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).","Having missed ASCO this year, an access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory asked on 08/05/16 to review Checkmate 012 data. The bar chart describing ORR with nivo (nivo+ipi) across tumor PD-L1 expression levels captured his attention (?nivo is truly a cool drug?). He commended BMS for studying nivo (nivo+ipi) efficacy across the entire range of PD-L1 expression, acknowledging that (many of) our competitors seemed reluctant to assume the risks associated with this strategy. He also noted that: 1) ORR values with nivo (nivo+ipi) at the ?50% expression level were most impressive; 2) ORR values at the <1% - ?1% levels were not negligible, even in comparison which ORR achieved with platinum-based chemotherapy; 3) nivo (nivo+ipi) may prove to be the best therapeutic options for some categories of patients with low PD-L1 expressing tumors (e.g., older or frail patients); 4) the medical community desperately needs more data to make informed decisions about who should receive what.  
The AI did not know the results of Checkmate 026. We did not address the issue since BMS official talking points had not yet been released.",120
Annual New Orleans Summer Cancer,Territory," SOUTH
AK",192.774193548,9.78673681984e-07,4,341,"On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Roche proposes to assess PD-L1 expression on tumor cells + immune cells. Complicated score: not convenient for clinicians.","On 07/22, a panel of speakers at the 11th Annual New Orleans Summer Cancer Meeting concluded that: 
?	PFS is very hard and costly to assess. It is a useful endpoint for phase I/II studies, but ORR and OS are much more important in phase III trials. Newer endpoints need to be explored such as ?time to next treatment.","On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Study Checkmate 141 showed a striking 1-year OS benefit in favor of nivolumab. This result will lead to approval (but pembro approved first?). Subgroup analyses also indicate that nivolumab can be used in almost everybody. Efficacy seems to be lower in P16-negative and PD-L1-negative patients, but it is still too early to make final conclusions.",345
LAI,Territory," SOUTH
AK",192.774193548,9.78673681984e-07,4,238,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",242
RAI/NSCLC,Territory," SOUTH
AK",192.774193548,9.78673681984e-07,8,175,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",183
made the following comments,Territory," SOUTH
AK",168.677419355,2.67259574441e-20,17,549,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.",566
South,Territory," SOUTH
AK",156.629032258,8.39464788365e-19,20,360,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",380
NCCN panelist for NSCLC,Territory," SOUTH
AK",144.580645161,2.4055692872e-13,11,482,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
Assoc,Territory," SOUTH
AK",144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
RCTs,Territory," SOUTH
AK",144.580645161,3.62780141464e-05,3,541,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
To control costs in 2L NSCLC setting, starts with 4 doses of nivo or 3 doses of pembro or atezo (if tolerated). Continues treatment if observes PR/CR, SD or no more than a small progression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.",544
Vice Chancellor Clin Res,Territory," SOUTH
AK",144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
territory,Territory," SOUTH
AK",128.516129032,3.95289189196e-22,35,349,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",384
shared the following unsolicited insights,Territory," SOUTH
AK",117.041474654,4.59611035311e-23,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
national access influencer,Territory," SOUTH
AK",96.3870967742,2.88456084709e-06,7,486,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",493
NSCLC NCCN panelist,Territory," SOUTH
AK",75.732718894,1.7802590881e-14,17,665,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",682
Pediatric Oncology/ Hematology,Territory," SOUTH
TN",344.571428571,1.12493334824e-07,4,319,Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,"Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.",Director of Pediatric Oncology/ Hematology at a large academic center would like to see a study in pediatrics in first relapse looking at Nivolumab vs. Brentuximab vs the combination of Nivolumab and Brentuximab. She stated that she would like to see regimens that reduce the amount of chemotherapy given in this setting due to the risk of long term toxicities.,323
Pediatric,Territory," SOUTH
TN",301.5,1.92714725693e-12,11,367,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,378
Brentuximab vedotin,Territory," SOUTH
TN",61.5306122449,2.17964663027e-07,11,135,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.",RTL at an academic medical mentioned that they have used Brentuximab vedotin off label in place of Bleomycin due to the shortage of Bleo.,"Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.",146
ASCT,Territory," SOUTH
TN",49.2244897959,6.9710981016e-06,10,190,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.","Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.","Pharmacist at a large community hospital described the first cHL patient they used Opdivo on after approval. The patient was a hospitalized 89 y/o male who had failed both AVD and BV. Three hours after the first dose the patient experienced a severe reaction with acute respiratory failure, SOB and bilateral stridor requiring a rapid response team intervention. He was treated with Xopenex and Racemic Epinephrine and the symptoms resolved over the next 24 hours. The patient was discharged home 3 days later and future plans for Opdivo was discontinued. (The event has been reported as an AE.)",200
academic center,Territory," SOUTH
TN",21.5357142857,7.79054953788e-13,103,319,NTL for MM at a large academic center thinks a trial with Urelumab and Nivolumab would be interesting.,NTL for MM at a large academic center thinks the check point inhibitors will remain only in the RR space secondary to their safety profile.,Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,422
described,Territory," SOUTH
TN",21.5357142857,6.1101340153e-09,44,0,"RTL from a large academic center presented the 209-205 data at an ASCO review. He described the data as very impressive, commenting on the indication in the post ASCT/BV space and the approval of Opdivo prior to ASCO. He commented on the ""very impressive reduction in tumor volume"" seen in the trial.",NTL for Pediatric lymphoma at a large academic center thinks Nivolumab should be studied in the first relapse setting. She described a COG trial which is being developed with Nivolumab and Brentuximab vedotin.,RTL from a large academic center during an ASCO review commented on the data from the phase 1 trial of Nivolumab in both DLBCL and FL published in JCO. He described it as impressive single agent activity with 36% and 40% ORR.,44
brentuximab,Territory," SOUTH
TN",20.5102040816,1.54865606778e-05,36,163,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.","Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.","Pharmacist at a large community hospital described the first cHL patient they used Opdivo on after approval. The patient was a hospitalized 89 y/o male who had failed both AVD and BV. Three hours after the first dose the patient experienced a severe reaction with acute respiratory failure, SOB and bilateral stridor requiring a rapid response team intervention. He was treated with Xopenex and Racemic Epinephrine and the symptoms resolved over the next 24 hours. The patient was discharged home 3 days later and future plans for Opdivo was discontinued. (The event has been reported as an AE.)",199
lymphoma,Territory," SOUTH
TN",14.6004842615,2.48911264915e-08,73,12,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,NTL for Pediatric lymphoma at a large academic center discussed that increased IRR could be related to fact that cHL is an immune driven and mediated disease with paraneoplastic phenomenon.,NTL for Pediatric lymphoma at a large academic center thinks Nivolumab should be studied in the first relapse setting. She described a COG trial which is being developed with Nivolumab and Brentuximab vedotin.,85
transplant,Territory," SOUTH
TN",12.06,7.870402165e-06,92,193,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.",RTL at an academic medical described a cHL patient who had failed induction and salvage chemotherapy. The patient was placed on Brentuximab vendotin but only achieved a PR. They decided to add Nivolumab prior to its approval and the patient then achieved a CR and was able to go to an Autologous transplant. Unfortunately the patient experienced a transplant related complication with an RSV infection and subsequent pneumonia and expired.,"NTL BM transplanter feels there is a large unmet need in the post Allo transplant area with check 
Point inhibitors and feels we need phase 1 trials investigating different doses and schedules of these agents to reduce impact on exacerbating GVHD.",285
cHL,Territory," SOUTH
TN",10.904159132,2.84910967164e-07,116,190,RTL at an academic medical described a cHL patient who had failed induction and salvage chemotherapy. The patient was placed on Brentuximab vendotin but only achieved a PR. They decided to add Nivolumab prior to its approval and the patient then achieved a CR and was able to go to an Autologous transplant. Unfortunately the patient experienced a transplant related complication with an RSV infection and subsequent pneumonia and expired.,"Transplant physician at an academic center discussed 2 recent patients who were both young and demonstrated refractory disease despite ABVD, ICE salvage and Brentuximab vedotin. He placed both patients on Nivolumab before transplant, the first patient achieved a CR after 2 cycles and the other achieved a PR. Both are now transplant eligible and will receive Auto transplant in November. Due to their refractory disease the TL had originally considered trying to get them eligible for Allo transplant but stated the responses after Nivo were so good he will now proceed with an Auto transplant instead.","Pharmacist at a large community hospital described the first cHL patient they used Opdivo on after approval. The patient was a hospitalized 89 y/o male who had failed both AVD and BV. Three hours after the first dose the patient experienced a severe reaction with acute respiratory failure, SOB and bilateral stridor requiring a rapid response team intervention. He was treated with Xopenex and Racemic Epinephrine and the symptoms resolved over the next 24 hours. The patient was discharged home 3 days later and future plans for Opdivo was discontinued. (The event has been reported as an AE.)",306
large,Territory," SOUTH
TN",7.23889555822,8.12607615e-06,283,242,"LTL at a large community practice stated his biggest issue and concern with Nivolumab is around the concept of pseudoprogression. He is fearful that researchers are over estimating this effect. He stated that he gets patients from other centers stating they have pseudoprogression, but he's just not sure how long to assume this.",Director of Pediatric Oncology/ Hematology at a large academic center has used Nivolumab in patients as young as 15-18.,"Director of Pediatric Oncology/ Hematology at a large academic center attended at COG meeting recently where a new trial concept was discussed. They are planning a phase 2 trial in first relapse or greater with the combination of Nivolumab and Brentuxiamb vedotin and then based upon response the subjects would be receive either ASCT or if inadequate response the combination of Nivolumab, Brentuximab vedotin and Bendamustine.",525
nivolumab,Territory," SOUTH
TN",5.34679802956,4.26368390663e-07,335,5,TL at an academic center described a patient who she has treated with nivolumab for cHL with the Nivolumab given prior to transplant. She described that the patient was placed on Brentuximab and did not respond so Nivolumab was added to it. The patient subsequently achieved a CR within 3 months and then proceeded to ASCT. The patient is doing well and had no IMARs.,"RTL discussed a recent RR HL patient who was heavily pre-treated and ineligible for transplant, had been denied because he would not stop smoking. The patient had failed all other therapies including chemotherapy. The patient was started on Nivolumab and is now in a PR 4 months into treatment.",NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,340
NTL,Territory," SOUTH
TN",5.16857142857,2.85878500394e-05,311,710,NTL for Pediatric lymphoma at a large academic center stated that Nivolumab is very good for PRs with not as many CRs so it would likely not be used as a single agent earlier in the disease.,"NTL for Pediatric lymphoma at a large academic center stated they have stock-piled Bleomycin and do not have issues with shortage at this time. TL stated she would like to get rid of it from the regimen, looking forward to changing it out for brentuximab vedotin.",NTL for Pediatric lymphoma at a large academic center stated the long term goal for studies in the 1L with cHL should be to reduce the cytotoxic therapy in order to reduce long term AEs. She mentioned omitting Bleomycin and reducing total Adriamycin exposure.,1021
auto,Territory," SOUTHEAST
GA",50.8922558923,3.6038875618e-07,15,204,"HCP at large institutional practice in S FL reports he has one patient to begin opdivo for cHL. 
Pt is s/p auto, s/p auto BV and s/p MRD allo transplant (approx 1 year ago).","RTL at community transplant center reported has one patient on opdivo for cHL who relapsed (post auto, post auto BV and post mismatched allo transplant). Currently receiving opdivo. Has received 2 doses. Reported ""watching patient like a hawk"". Patient did not have a history of GVH.",RTL at academic center has pt on nivo for HL. Dialysis pt so intent was to be able to take off dialysis. MRD caused the nephritis resulting in dialysis. Increased Cr so had to stop Nivo and give steroids. Did short taper and restarted Nivo but Cr increased again. Explained needing longer taper so IMAR could resolve and not re-occur.  He has 6 HL pts now on ABVD. No issues with Bleo shortage. He has an ISR Pembro/ICE then Auto.,219
pt,Territory," SOUTHEAST
GA",19.3039591315,2.70249883173e-09,67,23,"Largest Community Practice in state: Regional TL Opdivo H&N and Elo Speaker: 
Pt w HCC on off label bms provided Opdivo and pt is 1yr out in response. He was about to go to hospice. Stated he was excited for pt as he just bought a car. No tox issues. He was previously on sorafinib and adria w tox issues.",Community HCP has pt on Genentech's PDL-1 for bladder ca with no response.,Largest Community Practice in state: Community TL stated no use of opdivo in HL yet. Has a pt progressing on BV so opdivo will be next step.,90
reported,Territory," SOUTHEAST
GA",9.09699074074,6.63037831672e-08,182,10,RTL and transplanter at large community center reports treating one cHL patient post allo (mismatched unrelated donor) with nivolumab. Reports patient has received 4 cycles and is doing well (without any s/s GVHD).,"RTL at large academic center in Ga reports using Nivo off label for several different refractory/relapsed heme malignancies including AML, lymphoma, etc. Reports no issues with infusion reactions.",LTL heme only focused reports has utitilized nivo prior to approval and after approval for cHL. Reports has seen pr more than cr.,192
like to see a trial,Territory," SOUTHWEST
S.CA",87.75,1.87695101092e-05,15,14,RTL from academic center doing trial for ABVD vs AVD would like to have Bleo totally removed but would also like to see trial to see if IRT can be excluded as well.  Feels gaps are in RR HD and as RR NHL.,"Lymphoma TL at Academic center would like to see trials using Opdivo in FL as well as relapse in both HL, NHL.  He is very interested in how IO will work especially in relation to CART-cell studies. He has 2 CART-cell studies currently and would like to study those patients that fail CART-cell tx with IO products.",NTL would like to see trials with Nivo vs BV in RRHL.,29
BMS-sponsored,Territory," TEXAS
TX",608.0,4.24066384578e-05,2,50,"A regional CLL RTL, who is PI on BMS-sponsored study stated there is no standard of care in the treatment of Richter's transformation, which occurs in about 5-10% patients with CLL and an unmet need remains how to treat Richter transformation. Richter's transformation has an escape mechanism for Ibrutinib that's certainly real and important to recognize. Interestingly, Nivolumab + Ibrutinib combination is showing convincing clinical benefit in patients with Richter's transformation.","A RTL who is PI of BMS-sponsored study stated that combination of hypo-methylating agent and Nivolumab has generated remarkable clinical efficacy in patients with relapsed AML. Study results show an increase in frequency of CD3 T-cells and decrease in T-regs in post-treatment tumor samples among responder-patients, and identified novel biomarkers of response. All immune mediated toxicities (pneumonitis, the most common) respond to steroids.","A regional lymphoma TL delivered a presentation on ""therapeutic potential of MAbs in cHL"", at a regional hematology-oncology meeting. A national TL asked him ? out of these, which one is your favorite antibody and why? The speaker said-NIVOLUMAB; because of its safety, durable clinical benefit/remission, and potential for combination with other small molecules and checkpoint inhibitors.",52
novel,Territory," TEXAS
TX",114.0,9.68952467963e-06,10,9,"A RTL who is PI of BMS-sponsored study stated that combination of hypo-methylating agent and Nivolumab has generated remarkable clinical efficacy in patients with relapsed AML. Study results show an increase in frequency of CD3 T-cells and decrease in T-regs in post-treatment tumor samples among responder-patients, and identified novel biomarkers of response. All immune mediated toxicities (pneumonitis, the most common) respond to steroids.","A national MDS TL stated that some of the toxicities observed in patients treated with IO agents such as Nivolumab and Ipilimumab may not be associated with treatment alone as most investigators don?t have much experience with these novel agents. However, as we develop better understanding of MOAs of these therapies, we will be able to interpret the associated toxicities effectively.","A national lymphoma TL at a scientific workshop highlighted the clinical/survival benefit of Nivolumab across various tumor types and emphasized that it causes almost negligible toxicity. However, this novel drug can lead to ?financial toxicity?.",19
RAI,Territory, TN,530.129032258,7.67697465127e-18,15,701,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.",716
context of an online lecture,Territory, TN,337.35483871,1.72040645962e-11,7,659,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",666
NAI,Territory, TN,337.35483871,1.72040645962e-11,7,282,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",289
NCCN 2016 Webex Congress Series,Territory, TN,337.35483871,1.72040645962e-11,7,657,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",664
proactive meeting to discuss CM-026,Territory, TN,337.35483871,1.72040645962e-11,7,257,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",264
Bone Marrow Transplant Director,Territory, TN,240.967741935,2.57300994249e-08,5,713,"An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
.?	Not enough practical experience and not enough research data to differentiate between nivo and pembro safety and efficacy in cHL setting. Thus far has prescribed nivo to his patients (2 or 3) because BMS has most mature data. Too early to say anything about possible role of PD-L1 inhibitors.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:.
?	Did not know about upcoming shortage of bleomycin in the U.S. If needed clinicians at his institution are likely to replace ABVD with BV+AVD.","An academic RAI and Bone Marrow Transplant Director shared the following unsolicited insights while discussing his clinical practice and the HL treatment landscape:
?	Nivo might address great unmet need for treatment of R/R lymphomas or AML in elderly patients ineligible for allo-SCT. Did not know about ?FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancer? and found results very encouraging.",718
academic institution in the HSL South,Territory, TN,192.774193548,9.78673681984e-07,10,110,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).","Having missed ASCO this year, an access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory asked on 08/05/16 to review Checkmate 012 data. The bar chart describing ORR with nivo (nivo+ipi) across tumor PD-L1 expression levels captured his attention (?nivo is truly a cool drug?). He commended BMS for studying nivo (nivo+ipi) efficacy across the entire range of PD-L1 expression, acknowledging that (many of) our competitors seemed reluctant to assume the risks associated with this strategy. He also noted that: 1) ORR values with nivo (nivo+ipi) at the ?50% expression level were most impressive; 2) ORR values at the <1% - ?1% levels were not negligible, even in comparison which ORR achieved with platinum-based chemotherapy; 3) nivo (nivo+ipi) may prove to be the best therapeutic options for some categories of patients with low PD-L1 expressing tumors (e.g., older or frail patients); 4) the medical community desperately needs more data to make informed decisions about who should receive what.  
The AI did not know the results of Checkmate 026. We did not address the issue since BMS official talking points had not yet been released.",120
Annual New Orleans Summer Cancer,Territory, TN,192.774193548,9.78673681984e-07,4,341,"On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Roche proposes to assess PD-L1 expression on tumor cells + immune cells. Complicated score: not convenient for clinicians.","On 07/22, a panel of speakers at the 11th Annual New Orleans Summer Cancer Meeting concluded that: 
?	PFS is very hard and costly to assess. It is a useful endpoint for phase I/II studies, but ORR and OS are much more important in phase III trials. Newer endpoints need to be explored such as ?time to next treatment.","On 07/22, a speaker at the 11th Annual New Orleans Summer Cancer Meeting indicated that: 
?	Study Checkmate 141 showed a striking 1-year OS benefit in favor of nivolumab. This result will lead to approval (but pembro approved first?). Subgroup analyses also indicate that nivolumab can be used in almost everybody. Efficacy seems to be lower in P16-negative and PD-L1-negative patients, but it is still too early to make final conclusions.",345
LAI,Territory, TN,192.774193548,9.78673681984e-07,4,238,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",242
RAI/NSCLC,Territory, TN,192.774193548,9.78673681984e-07,8,175,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? frequently made comments+++
?	Seemed to be already aware that CM-026 had not met any of its endpoints.
?	Attributed negative results to weak study design and risky research hypotheses.  
?	At this stage, would not change anything to CM-227.
?	Is comfortable with recommendations for nivo and pembro in latest NSCLC NCCN guidelines.",183
made the following comments,Territory, TN,168.677419355,2.67259574441e-20,17,549,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++CM-026 ? more personal comments+++ 
?	Does not like the way BMS presents biomarker-outcome relations: results by overlapping PDL1 categories (?1%, ?5%, ?50%) should be supplemented with results by mutually-exclusive categories (1%-4.9%, 5%-49%, ?50%).
?	BMS research in lung is critically important to patients. Is glad that nivo+ipi development in NSCLC will continue unabated. Reassured by latest CM-012 data.
?	Is not sensitive to the argument that only 16% of patients entering screening in KN-024 received assigned treatments vs. 40% in CM-026: situation is even much worse in RCTs of targeted therapies.",566
South,Territory, TN,156.629032258,8.39464788365e-19,20,360,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",380
NCCN panelist for NSCLC,Territory, TN,144.580645161,2.4055692872e-13,11,482,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","A regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that medical oncologists for lung at this institution try to test all patients for PD-L1 expression at diagnosis, but they do so more to increase their understanding of when/how PD-L1 inhibitors work than to make 2L treatment decisions. ?But it is a fight: pathologists constantly push back against PD-L1 testing, though typically not for the right reasons? (because testing for PD-L1 expression erodes their benefit as they receive a set fee to test tumor biopsies for biomarkers and all biopsies are tested for EGFR and ALK abnormalities).",493
Assoc,Territory, TN,144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
RCTs,Territory, TN,144.580645161,3.62780141464e-05,3,541,"During a proactive meeting to discuss CM-026 data, a RAI/NSCLC panelist advisor made the following comments: 
+++OAK study+++
?	Study results will not results in big changes at his academic institution because most patients in 2L are enrolled in RCTs.
?	Atezo will be approved in 2L NSCLC regardless of PDL1 expression level.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
To control costs in 2L NSCLC setting, starts with 4 doses of nivo or 3 doses of pembro or atezo (if tolerated). Continues treatment if observes PR/CR, SD or no more than a small progression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.",544
Vice Chancellor Clin Res,Territory, TN,144.580645161,3.62780141464e-05,3,312,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",315
territory,Territory, TN,128.516129032,3.95289189196e-22,35,349,"While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",384
shared the following unsolicited insights,Territory, TN,117.041474654,4.59611035311e-23,26,724,"A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	A company proposing a biosimilar to nivo accompanied by a highly-predictive biomarker may be able to steal BMS current competitive advantage.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS moves of its therapeutic agents from 2L to 1L setting is too precipitous and scientifically unsound. In 1L setting what matters most is that treatment offers some benefit to as many patients who receive it as possible, not that treatment offers substantial benefit to a small fraction of patients and nothing to another larger fraction of treated patients.","A LAI/RTL/former melanoma NCCN panelist/Assoc. Vice Chancellor Clin Res at an academic institution shared the following unsolicited insights during a reactive discussion about ESMO 2016 data:
?	BMS predominant way of presenting biomarker ? outcome relationships in overlapping biomarker categories is flawed and potentially misleading. This can be demonstrated by examining what happens in the extreme, and hypothetical, scenario of a study population of 400 patients where PDL1 expression is distributed as follows - <1%, 100 patients; 1%-to-4.9%, 100 patients; 5%-to-49.9%, 100 patients; ?50%, 100 patients ?, and where ORR is 0% in patients with PDL1 expression <50% and 100% in patients with PDL1 expression ?50%.
PDL1 expression	<1%	1%-to-4.9%	5%-to-49.9%	?50%
N	100	100	100	100
True ORR	0%	0%	0%	100%
BMS way of presenting biomarker-response relationships
PDL1 expression	<1%	?1%	?5%	?50%
N	100	300	200	100
Patients responding	0	100	100	100
ORR reported	0%	33.3%	50%	100%
The latter representation of the data suggests that treatment is active at PDL1 expression levels of 1%-to49% when it is not.
?	BMS might have become so used to the intrinsically-biased way of presenting dose-response relationships in overlapping biomarker categories that, as a company, it misinterpreted evidence (or lack thereof) for nivo activity among NSCLC patients with low PDL1 expression, which in turns detrimentally influenced the way study CM-026 was designed. In other words, it is possible that many in the company, potentially including personnel involved in trial design, developed a tunnel vision for evaluating PDL1-outcome relationships.",750
national access influencer,Territory, TN,96.3870967742,2.88456084709e-06,7,486,"On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
He never test anybody for PD-L1 expression and would certainly not choose one PD-1/PD-L1 inhibitor over another based on a patient?s tumor level of PD-L1 expression.","While reactively discussing the results of Checkmate 012, a regional access influencer, radiation oncologist, and new NCCN panelist for NSCLC at a large academic institution in the HSL South territory indicated that new therapeutic options are added to the NCCN guidelines very easily in the 2L+ settings when the SOC is BSC or an obsolete therapy; then a simple conference abstract and the enthusiasm of one of the panel leaders can be all that is needed. Things are very different in the 1L setting ? results from a phase III RCT are typically required to displace or compete with a SOC that has been validated in phase III RCTs. The NCCN panel for lung received some flack in the past for having prematurely given a broad recommendation for Tarceva in the 1L, and then having to back track. Now everybody is more cautious.","On 7/29/16, a national access influencer and NCCN panelist for NSCLC at a large academic center in the HSL South territory reactively indicated that: 
Things are likely to substantially slowdown in the IO field in the coming year(s), because the low-hanging fruits have already been harvested.",493
NSCLC NCCN panelist,Territory, TN,75.732718894,1.7802590881e-14,17,665,"In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In study CM-012, very impressive results were observed with nivo+ipi regimen in patients with PD-L1 expression levels of ?1% and ?5%, but cohorts were very small. In KN-021, the pembro+ipi combination regimen was very toxic and more toxic than nivo+ipi. Let?s wait for results of CM-227.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium:

 KN-021 was a small phase II study. The high response rate, short time to response, improved PFS, and good safety profile observed in the pembro+CT arm are encouraging, but there was no OS benefit with this combination regimen. OS and safety results are extremely immature. Phase 1b study GP28328 of atezo+CT combination therapy has provided quite impressive results, but it included < 20 patients per group. It is too early to switch to IO+CT in 1L NSCLC. Let?s see what happens in a large phase III study.","In the context of an online lecture about IO role in NSCLC (NCCN 2016 Webex Congress Series), a NSCLC NCCN panelist made the following comment from the podium::
In response to a question about the role of nivo in 1L NSCLC, said: the scientific community is grappling to explain differences in results of KN-024 and CM-026. Both nivo and pembro are good, but there is no role for nivo in 1L NSCLC at this point.",682
Numerous TLs,Territory, UT,149.04040404,2.42489688019e-07,6,253,"Numerous TLs expressed maintains a rigid threshold for pembro use 1L to only those with >50% PDL1 expression. With them stating the reasoning is the current science and that you ""don't want to burn a therapeutic bridge by using an IO in the wrong setting (using in the wrong PDL1 population in 1L when all comers can derive benefit from 2L).","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.","TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",259
tone,Territory, UT,119.232323232,5.94448950203e-06,4,0,"With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",4
restriction,Territory, UT,39.7441077441,3.9380553835e-05,6,16,"TLs all feel that the pembro data is ""practice changing"" and that the use of pembro is now established in 1L for >50% PDL1 expression. TLs are split however on how to will impact 2L Nivo use. Some state they will have the PDL1 data from 1L and if a patient was not eligible then they will use Pembro 2L (anticipating coverage at >1% or through Merck's access support for non-expressors) due to not having the biopsy restriction any longer and a preference for q3wk. Other's state they will only reserve pembro for the select small 1L population and Nivo will remain SOC in 2L.",Many community TLs aware of Pembro 1L press release and asking about Nivo data in the 1L NSCLC. When review -026 trial design many express surprise that Nivo had a PdL1 restriction in the trial design. They then emphasize the problems with pdl1 testing and why they like Nivo in 2L is because it is unrestricted. State the main differentiating factor in 1L given both Nivo and pembro will require testing is which company makes the testing process easier/faster/more understandable.,"Many community TLs are supportive of the biomarker label restriction for Merck because it provides clear direction for using IO, otherwise ""there is no clear guidelines on the use of PDL1 expression as a biomarker of response"" which leaves too much room for interpretation/confusion and inconsistent clinical practice.",22
AE profile,Territory, UT,34.0663780664,8.93247069232e-09,14,338,"In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",Several NTLs/RTLs have commented that there is significant hesitancy to incorporate Ipi into treatment in RCC (either bad previous experience with Ipi from melanoma or prostate or heard about the combination from melanoma colleagues). When discuss the different dosing of Nivo+Ipi in RCC vs melanoma they become a little more supportive. State the key deciding factor between Ipi+Nivo and Cabo in the 1L will not be efficacy rather it will be the safety profiles and the QoL data.,TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,352
comers,Territory, UT,22.3560606061,1.21906855471e-08,20,0,"TLs state the OAK data is intriguing in that the agent works in the all comer population, has apparent efficacy in the PDL1 non-expressing population, has q3w convenience, and a highly tolerable safety profile. When questioned about how to choose between agents in the 2L the TLs in general still feel that atezo is a ""me too"" drug and that nivo has such broad indications across tumor types with proven efficacy and support for many others that there is an established loyalty to nivo. Hence, the TLs predict varied physician preference (""choose one or the other and neither are wrong"") in the 2L.",TLs with close Roche relationships have all stated the indication for atezolizumab will be in an all comer 2L NSCLC population (not restricted by PDL1).,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",20
q3wk,Territory, UT,19.8720538721,5.45899429929e-06,14,425,"When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""","With the press release around OAK it is anticipated that Roche is a significant competitor to BMS in 2L NSCLC, numerous TLs expect an indication irrespective of PDL1 status, a flat dose, and a Q3wk dosing schedule. Hence, these TLs expect the dosing discussion/convenience to become a significant topic.",TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,439
TLs,Territory, UT,17.2886868687,1.38778076237e-21,98,6,"Numerous community TLs all had high level knowledge of -026 not meeting primary endpoint and KN -024 having very positive data. When I described the differences in trial design the TLs seemed very satisfied about why the outcomes were divergent and did not see the data as impacting 2L treatment choices. However, did state that when Pembro is indicated in 1L PDL1 testing will become a standard practice - which is not what is occurring today.","NTLs and local TLs agree that pembro will not be the ""end of the story for 1L, with significant potential of Ipi/Nivo to affect a broader patient population."" However these TLs caution that there is a significant safety concern that has to be overcome with the combination (especially for the community).","Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.",104
established,Territory, UT,14.904040404,1.85115466116e-05,17,0,"NTL regards PD1/PDL1 inhibitors as the same and regards the lack of testing as a significant advantage for Nivo. When thinking about 1L NSCLC TL believes PDL1 testing will be required across all agents, hence the differentiating factor will be the agent with the most diagnostic support to help practitioners establish SOPs for ordering and understanding the PDL1 diagnostic.","TL was very upset that BMS had ""such a stupid trial design for 1L NSCLC."" Specifically pointing out the PFS endpoint and treatment arm imbalances.  In addition, TL was upset that they are now forced to test for PD-L1 status even though the assays are complicated and not fully established. When asked about testing the TL stated they solely leave the process to the pathologists stating they call the pathologist and say ""I want to use pembro in 1L test PDL1."" Further TL was upset because does not want to be in a position to decide on treatment if less than 50% but close to the threshold (e.g 45-50%, below 45 they were very clear they would choose chemo). Nivo was still regarded as the agent of choice for 2L.","TL applauded BMS for its scientific integrity and rigor. However, given the 1L data states that Merck applied a smart strategy with their approach. Specifically stating that using the PDL1 biomarker in a restricted population proved the utility of the biomarker and established its utility to select for patient's with maximal benefit. The approach is one that many physicians feel very good about because they feel their treatment has a higher likelihood of impact and that they are using the agent in an appropriate patient. In addition, payers like the approach because of the clear value in these patients. Hence, Merck has generated a more clear and useful message regarding the use of IO, compared with the the more muddled/confusing idea of using IO in an all comer population for mixed efficacy/value results.",17
IO-IO,Territory, UT,13.9104377104,5.31649624112e-06,21,757,TL feels that BMS will be in a challenging position until -227 reads out with intense competition from pembro use 1L spilling into 2L and atezo q3wk convenience in 2L. Believes future will be IO-IO but concerned the combination will meet endpoints in non-expressing population leaving need chemo - IO sequencing (does not believe in IO-chemo). Thinks BMS has the right dosing for Ipi/Nivo and that Durva/Treme will not be popular because the dosing is wrong.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.","In regards to KN-021 the TL feels that the trial has potentially promising activity and disregards the no difference in OS as not being reliable because of the short duration of follow-up. When discussing CM012 also stated that IO-IO was also promising and the AE profile seemed favorable (especially with the low discontinuation rates) ""at least so far."" But more data that is more mature for safety needs to be shown to increase comfort with Nivo+Ipi in NSCLC. In regards,
To Ipi+Nivo combination ""it's good against the cancer but not good for the rest of the patient's organs.""",778
highly,Territory, UT,12.194214876,6.05730823766e-07,30,34,"Many TLs have voiced surprise at the highly discrepancy data between KN-024 and CM-026. However, all have stated that they do not believe Pembro and Nivo have different efficacy profiles, rather the study designs and biomarker strategies are the differentiating factors.","In regards to -026, thinks if the data is equivalent to chemo then it will still be practice changing based on AE profile. Highly excited for IO in front line and would prefer not to have to test for PDL1.","TL summarized how he is communicating testing and clinical implications in NSCLC that has resonated well with community HCPs: ""Focus on Merck's assay for testing given pembro's 1L lung indication but realize that using Merck's test does not exclude other therapies (e.g. Nivo) for 2L."" The TL then expands ""In fact projects like Blueprint and NCCN specifically support the idea that the Merck assay and the BMS assay are highly alike so the assay you use only matters if you are thinking about Atezo.""",64
key,Territory, UT,12.1440329218,3.81235062658e-08,37,0,"Per NTL a large question in bladder field is how the geriatric oncology patients will respond to IO. Hence increased data on efficacy, safety, and QoL in that specific population will be a key differentiator between agents.","Mixed TL opinions regarding IO+Chemo, some are excited about the potential to overcome PDL1 and the ORR, others feel the strategy is a ""shame"" as it does not seem to provide added efficacy and more toxicity. All TLs have applauded BMS forthe -227 trial design as addressing the key IO+Chemo or IO+IO question.","NTL who does not believe in PDL1 testing in 2L NSCLC, stated that the key impact from -026 is the renewed emphasis on PDL1 as a biomarker. While the data is unknown the -026 and KN-024 press releases leads one to assume that there will be a specific threshold of PDL1 expression that adequately identifies a population that derives clinical benefit from checkpoint inhibition. The consequence will be 1L PDL1 expression level will be used for treatment decisions, in 2L the expression level may start being used for clinical decisions to ensure economic justification.",37
PDL1 status,Territory, UT,7.45202020202,4.86332578326e-05,39,874,TL stated he was testing all patients for PD-L1 and using Opdivo if patients were 2L+ and high PDL1 expressors in non-indicated disease states. Only using expression for treatment decisions in 1L lung (not 2L or SCCHN or Mel or RCC). Inquired about testing time and TL stated they have an agreement with Caris where the PDL1 status is expeditidly  reported within 3 days and the rest of the genomic panel is then reported later.,Complete change in perception regarding PDL1 testing in NSCLC over last year - went from believing needed to test patients based on MOA and cost rationale to using clinical experience determine that PDL1 status is unnecessary for treatment decisions (had patients respond who were PDL1 non expressors). Now only tests when planning on using Opdivo in a non-indicated disease states.,"Does not feel that PDL1 status should be used to make treatment decisions with Opdivo, hence is looking toward novel Biomarkers. Heard that Foundation One will be releasing data at ASCO that reports a tumor mutational index score and how that score correlates with response to checkpoint inhibitors. Believes the score will start being reported by Foundation One in addition to their current mutation panel.",913
SOC,Territory, UT,6.69160997732,5.24340103421e-06,69,492,"NCCN panelist expects Cabo to be SOC in 1L with Nivo remaining SOC in 2L with lenvantinib/Everolimus or axitinib in 3L. The TL is highly skeptical of Ipi/Nivo adoption in 1L mostly due to ""bad Ipi experiences in melanoma and prostate"" (a theme that has been echoed by several GU TLs with Ipi experience in prostate). However, willing to change opinion if the HR significantly outperforms sunitinib, has an AE profile similar to Nivo monotherapy, and good QoL outcomes.","All GU treating TLs at academic cancer center (including RCC NCCN panelist) met to develop institutional RCC treatment algorithm (so practice decisions are standardized across all providers). Evaluated all RCC asco data. For 2L have decided to keep Nivo as SOC (even though the cabo and lenvantinib is good, all would prefer to give a patient an IO agent sooner than later). 
There were key populations that were discussed as exceptions: 
1) bone met population (initially were thinking cabo but as increasing Nivo data in that population have decided Nivo in that group) 
2) Those with autoimmune disease will most likely receive a TKI, until additional data with Nivo
3) Those with non-clear cell histology will be decided in a case by case, sarcomatoid will most likely get Nivo but others are debated until -374 data is available.","Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",561
specifically,Territory, UT,6.38744588745,4.82857330344e-05,50,48,"During a talk on IO in SCLC the TL stated from the podium ""the data for IO in SCLC is small but apparently big enough to get in the NCCN guidelines...controversially and surprisingly."" I discussed the statement with the TL after the presentation and the TL has no concerns with the inclusion of Nivo but has significant concerns about Ipi. Specifically, the TL does think the combination has added efficacy however they are greatly concerned with the AE profile and that there were 3 deaths on trial...to the TL the AE profile warrants a larger trial before being able to be used as a treatment option.","Several TLs have mentioned they are concerned about Nivo in SCCHN due to the length of time for indication. Specifically, these TLs were under the impression KN -012 and checkmate -141 were similar trial designs and were confused how Merck had already received the indication, hence they started questioning the integrity of -141... After review of the trial designs and a reminder of the -141 data the concerns appeared alleviated.","TL generally regards PD1s/PDL1s as the same but is beginning to doubt that perception and has expressed ""concern"" for Nivo. Specifically with durvalumab recently announcing they will not be pursuing a monotherapy indication based on lack of efficacy in NSCLC and Nivo not showing an efficacy difference in CM026 in the >50% population there may true differences in agents with the benefit of doubt leaning toward pembro.",98
increase,Territory, UT,5.58901515152,9.4137871251e-08,113,36,"Increasing concern among community physicians around infusion chair time. With the continual Nivo dosing and the increased OS in patients, several community clinics are struggling to manage the increased demand. Numerous community HCPs emphasized a need for shorter infusion times and a more robust effort in studying when to stop IO therapy (especially if a patient had a PR/CR). These physicians are now considering switching to keytruda in NSCLC because of the q3wk 30min infusion convenience.","Increasing tone that the benefit from Opdivo therapy in all comer patients is not ""living up"" to the excitement of last year and the ""cost in proving Opdivo to everyone when most do not respond is significantly more than providing keytruda in the selected population."" Hence, there is increasing pressure to test PDL1 status to ""more appropriately choose patients for IO therapy.""","With many experienced Ipi+Nivo TLs, the tone is increasing that the imAE profile is ""toxic"" and that they are significantly in need of alternatives. The top two strategies are: clinical trials (with those that have IDO+PD1 as a significant favorite - reporting ORRs above 50% with a highly manageable AE profile) or reserving Ipi+Nivo to a salvage therapy post PD1 progression.",149
regards,Territory, UT,5.27851430976,4.06371525227e-07,112,0,"In regards to nccRCC the NCCN panelist stated there will. It be any updates to the guidelines until there is evidence for use in that population because of the transition of the panel to emphasizing evidence blocks. Panelist specifically stated ""everyone should receive Nivo in principle but there is just no evidence to support it in nccRCC.""","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","When discussing atezo in the 2L several NTLs expect an all comer indication based on the OAK data. These TLs in general do not see the PDL1 inhibitor as different from a PD1 inhibitor in regards to safety/efficacy, The differentiator will be q3w dosing and the convenience of atezo ""will take a bite out of Nivo.""",112
population,Territory, UT,4.07448586585,2.95969418422e-06,222,248,"NTL who does not believe in PDL1 testing in 2L NSCLC, stated that the key impact from -026 is the renewed emphasis on PDL1 as a biomarker. While the data is unknown the -026 and KN-024 press releases leads one to assume that there will be a specific threshold of PDL1 expression that adequately identifies a population that derives clinical benefit from checkpoint inhibition. The consequence will be 1L PDL1 expression level will be used for treatment decisions, in 2L the expression level may start being used for clinical decisions to ensure economic justification.","When discussing -026 many TLs understand the reasoning behind including a broad patient population. However, there is push back regarding the imbalances in the trial regarding PDL1 status, with many not understanding how PDL1 status at various levels was so imbalanced and not taken into account during the planning of the trial. These TLs are not surprised by the result and simply state ""you need to redo the trial and design it right.""","TL generally regards PD1s/PDL1s as the same but is beginning to doubt that perception and has expressed ""concern"" for Nivo. Specifically with durvalumab recently announcing they will not be pursuing a monotherapy indication based on lack of efficacy in NSCLC and Nivo not showing an efficacy difference in CM026 in the >50% population there may true differences in agents with the benefit of doubt leaning toward pembro.",470
IO,Territory, UT,3.72601010101,1.49859933288e-05,242,52,"TLs very split about the role of IO+Chemo in 1L. Some find the atezo and pembro plus chemo data highly impressive others consider it a ""waste"" with added toxicity for minimal benefit.",TL stated the greatest limitation for IO-IO in NSCLC is convincing HCPs to be comfortable with the AE profile since it is different and less predicative than what they are traditionally a construed to with IO monotherapy and chemotherapy.,"Since the press release of -026 several academic TLs have renewed there focus on ORR in 1L NSCLC and believe that monotherapy IO in 1L is not truly a beneficial option compared to targeted agents and chemotherapy...hence they now have an increased interest in IO-IO, IO-chemo, or IO-targeted to increase the ORR.",294
1L,Territory, UT,3.55509220647,7.46006462697e-07,288,292,"NCCN panelist expects Cabo to be SOC in 1L with Nivo remaining SOC in 2L with lenvantinib/Everolimus or axitinib in 3L. The TL is highly skeptical of Ipi/Nivo adoption in 1L mostly due to ""bad Ipi experiences in melanoma and prostate"" (a theme that has been echoed by several GU TLs with Ipi experience in prostate). However, willing to change opinion if the HR significantly outperforms sunitinib, has an AE profile similar to Nivo monotherapy, and good QoL outcomes.",TLs still do not like the PDL1 assay and find the landscape confusing...however all agree that with KN-024 the Merck assay will become SOC for testing in 1L. These TLs then say those patients with >50% will receive pembro and everyone else will receive chemo. Nivo is still regarded as SOC in 2L for those progressing on chemo.,"Nivo is regarded as SOC in 2L RCC by numerous TLs, however there is Increasing tone that if a patient had a good response to a TKI in 1L then they are in higher favor of using Cabo in 2L because of the comfort with the AE profile and the potential for another good response and then reserving nivo for when the targeted therapies fail. Data about using a TKI after IO would help with the MOA switch discussion.",580
no PD-L1 testing,Territory, VA&P Sales,62.2105263158,1.48026912793e-05,5,36,"University Hospitals IDN (Cleveland, OH):  Notified by by oncology community field rep and confirmation from ITS rep that for 1st line pembro, there is no PD-L1 testing requirement included within the verbiage of UH order sets; UH also uses Allscripts; ITS rep uncovered a point of contact in the cancer center who is responsible for writing order sets; once I have more information from ITS and the point of contact, I will follow up accordingly at system level (to include medical matrix) if necessary.","Medical Mutual (Regional payer/ESI downstream):  During a recent post-ESMO call w/ MM clinical pharmacists and BMS HSL/HEOR, MM revealed their current medical policies for PD-1 agents (ie Keytruda) are non-restrictive; currently no PD-L1 testing requirement language is included in medical policy for use in NSCLC; MM uses Care Continuum to manage medical policies; also mentioned they monitor drug spend based on annualized cost; will follow up with customer in early Q1 around updates they have related to medical policy and management of PD-1s","Montefiore Health Pharmacy team is looking to do PD-1, & PD-L1 inhibitor class review as more products come out. Breadth of indications and having Phase III trials will be important considerations of value. They are trying to determine Biomarker.PD-L1 testing strategy. Want to learn from the cetuximab-KRAS mutation efficacy issue. They understand BMS strategy of all comers in trials, no PD-L1 testing required, efficacy in  expressors and non-expressors.",41
IDN,Territory, VA&P Sales,38.8815789474,3.83889151117e-06,8,100,Regional IDN has an ACO that has grown to almost 60K lives. The ACO has risk for Medical and Hospital costs. They are working to control costs and looking at Oncology class. Non employed Oncologists are the physicians driving cost. Efforts are being made to 'educate' them on cost and efficacy of drugs.  IDN will be looking to implement pathways in the future as a means to streamline and control costs.,"Oncology Clinical Pharmacist at Beth Israel Deaconness Hospital in Boston stated that he believes that if A-Z's PD-1 product is approved in December it could lead to IDNs choosing 1 preferred agent if it enters the market at a reduced price.  He said it would be difficult if an IDN chose one product and a payer chose another product as their preferred agent, if that happened.","HEOR and I met with large academic IDN who shared that they are planning to head in a direction of managing access to oncology medications. Customers were interested in discussions/partnership pertaining to a need and development of a tool - using Epidemiological data and Budget modeling. Examples of current gaps include, EPI data, ability to estimate cost when there is an indication update or change of therapy and adjust for things like site of care and risk stratification. 

They are interested in Combining this type of data with clinical outcomes to make the best health economic and outcomes decision. Customer shared that they are interested in having best opportunity to leverage tools and technology at their disposal to treat disease.",108
customer,Territory, VA&P Sales,35.5488721805,6.57047934015e-09,14,0,"Medical Mutual (Regional payer/ESI downstream):  During a recent post-ESMO call w/ MM clinical pharmacists and BMS HSL/HEOR, MM revealed their current medical policies for PD-1 agents (ie Keytruda) are non-restrictive; currently no PD-L1 testing requirement language is included in medical policy for use in NSCLC; MM uses Care Continuum to manage medical policies; also mentioned they monitor drug spend based on annualized cost; will follow up with customer in early Q1 around updates they have related to medical policy and management of PD-1s","HEOR and I met with large academic IDN who shared that they are planning to head in a direction of managing access to oncology medications. Customers were interested in discussions/partnership pertaining to a need and development of a tool - using Epidemiological data and Budget modeling. Examples of current gaps include, EPI data, ability to estimate cost when there is an indication update or change of therapy and adjust for things like site of care and risk stratification. 

They are interested in Combining this type of data with clinical outcomes to make the best health economic and outcomes decision. Customer shared that they are interested in having best opportunity to leverage tools and technology at their disposal to treat disease.","PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.",14
medical policy,Territory, VA&P Sales,25.9210526316,1.33149802374e-05,10,161,"PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.",Group Health NW has CONFIRMED that the P&T decision 'against' coverage for Opdivo ns-NSCLC coverage has been OVERTURNED by Medical Policy Committee.  Medical Policy will be published for coverage at a future date.,"While FL Blue considers clinical trial data (and trial inclusion / exclusion criteria), FDA labeling and NCCN guidelines in the development of their medical policy, NCCN guidelines are generally prioritized. 
- They take a product by product approach vs looking at specific disease states.
- Particularly within I/O?.they tend to be lenient in approving requests for use of therapies that may fall outside of their established Medical Policy.  E.g. with Opdivo RCC 
- They have a number of value based arrangements with providers with a focus on quality (OS / Patient satisfaction) as well as cost.",171
health,Territory, VA&P Sales,25.4497607656,5.12172533498e-09,25,0,"Met with Director, Oncology Pharmacy for Monterfiore Health with fHEOR. Discussed NSCLC, were informed that demand for Opdivo hasn't slowed down, in spite of 1L Lung (026) trial results. Lung cancer is their #1 tumor they see. They havent seen much increase in demand for Keytruda.  Oncology DOP said they will look to evaluate and narrow PD-1, PD-L1 inhibitors as more continue to come to market. Very interested in understanding the value that Opdivo brings, and wants to continua to meet & discuss.",Group Health NW has CONFIRMED that the P&T decision 'against' coverage for Opdivo ns-NSCLC coverage has been OVERTURNED by Medical Policy Committee.  Medical Policy will be published for coverage at a future date.,OpdivoFlat Dose: Group Health NW shared that for their 'closed' book of business (450K lives) they will be enforcing a blended dosing approach (weight based up to 80Kg and 240 mg flat dose above 80Kg).  The rationale provided was cost savings and minimization of waste.,25
pharmacy,Territory, VA&P Sales,23.786377709,4.27009225908e-12,29,48,"Myself and Francis Lobo, HEOR met  with Michael Lessard, Pharmacy Director at Dartmouth Hitchcock and we had a  discussion around our Oncology portfolio and no real concerns regarding NSCLC and Opdivo.  Customer continues to cover Opdivo to label and have no plans on changing that. We reinforced our strong clinical profile in our approved indications and they believe in our data. Although they did request that we give discount for orphan drug for all classes of 340 b accounts. Currently we give discount for DSH account but not Rural Referral Center which they are.","Michael Lessard, Pharmacy Operations Director at Dartmouth Hitchcock reports that the following companies are giving 340 B discounts on Orphan Drugs: Amgen; J&J; Ipsen; Grifols and Abbvie.",BCBS SC Jan 1st they are moving to incorporate ICER recommendations in their reviews. HEOR provided update on ICER and outlined the methodology. Pharmacy Director said that he would allow us to provide additional updates/ information that is not included in the 1 year assessment period.  They are also reviewing the drugs that are rejected by the EU and looking for consistency with their formulary management.,77
HEOR,Territory, VA&P Sales,21.7736842105,5.42200118911e-07,16,20,"Myself and Francis Lobo, HEOR met  with Michael Lessard, Pharmacy Director at Dartmouth Hitchcock and we had a  discussion around our Oncology portfolio and no real concerns regarding NSCLC and Opdivo.  Customer continues to cover Opdivo to label and have no plans on changing that. We reinforced our strong clinical profile in our approved indications and they believe in our data. Although they did request that we give discount for orphan drug for all classes of 340 b accounts. Currently we give discount for DSH account but not Rural Referral Center which they are.",BCBS SC Jan 1st they are moving to incorporate ICER recommendations in their reviews. HEOR provided update on ICER and outlined the methodology. Pharmacy Director said that he would allow us to provide additional updates/ information that is not included in the 1 year assessment period.  They are also reviewing the drugs that are rejected by the EU and looking for consistency with their formulary management.,Cigna AVP of Pharma Contracting inquired about the BMS position on recent NICE and ICER negative comments on Opdivo and I/O therapy in general.  NAE and HEOR Director deferred the question to a later date as we did not feel adequately prepared to respond at this time.,36
contract,Territory, VA&P Sales,19.4407894737,3.50909124449e-05,12,83,"Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","Josh Whittington, HSL reports that at CCK in Wichita, KS, that they are already receiving contracting discounts on all infusible Genentech products, including Tecentriq.  I believe it is 4.3%.","Dickenson Community Hospital has recently been affected by the 340-b orphan drug court order and the enforcement of our policy around this issue.  In a previous meeting, The Director of Pharmacy Laura Casanova and the Oncology Pharmacist Mark Hagen stated they were going to contact each Pharmaceutical company and request they supply a contract to compensate for their lack of pricing for the 340-b orphan drugs. They stated they would move all utilization to drugs that have contracts and restrict those that do not. 

I  followed-up with the account and reinforced the BMS policy as it relates to ?newly eligible? 340-b entities and orphan drugs.  I then shifted the conversation away from cost and moved into value of our medicines, patient assistance program and our reimbursement support. 

Mark Hagen did not mention Merck or anything they might be offering to address this situation.  The conversation moved away from what he addressed in our last discussion of restricting one agent over another based on contract offering.  I believe Mark realized he needs to move his energy away from restricting these important drugs and focus on other ways to address the 340-b issue.   He said he is going to check into other wholesalers for potential better contracts for specialty drugs, look into getting his class of trade status changed, and potentially setting up his purchasing into in-patient and out-patient outlets to potentially move away from in-patient bundle payments from Medicaid/Medicare where he feels he is losing money.",95
class,Territory, VA&P Sales,14.5157894737,4.09995402557e-06,21,0,"Dickenson Community Hospital has recently been affected by the 340-b orphan drug court order and the enforcement of our policy around this issue.  In a previous meeting, The Director of Pharmacy Laura Casanova and the Oncology Pharmacist Mark Hagen stated they were going to contact each Pharmaceutical company and request they supply a contract to compensate for their lack of pricing for the 340-b orphan drugs. They stated they would move all utilization to drugs that have contracts and restrict those that do not. 

I  followed-up with the account and reinforced the BMS policy as it relates to ?newly eligible? 340-b entities and orphan drugs.  I then shifted the conversation away from cost and moved into value of our medicines, patient assistance program and our reimbursement support. 

Mark Hagen did not mention Merck or anything they might be offering to address this situation.  The conversation moved away from what he addressed in our last discussion of restricting one agent over another based on contract offering.  I believe Mark realized he needs to move his energy away from restricting these important drugs and focus on other ways to address the 340-b issue.   He said he is going to check into other wholesalers for potential better contracts for specialty drugs, look into getting his class of trade status changed, and potentially setting up his purchasing into in-patient and out-patient outlets to potentially move away from in-patient bundle payments from Medicaid/Medicare where he feels he is losing money.","PBM customer writes Medical Policy for clients and found this (unsolicited requested) ESMO update very valuable. SVP of Pharmacy was speculating that in the future, the efficacy of the PD1s will be considered class effect and commoditize the class. 
Right now he will continue to have all Medical Policies follow FDA labels.","Montefiore Health Pharmacy team is looking to do PD-1, & PD-L1 inhibitor class review as more products come out. Breadth of indications and having Phase III trials will be important considerations of value. They are trying to determine Biomarker.PD-L1 testing strategy. Want to learn from the cetuximab-KRAS mutation efficacy issue. They understand BMS strategy of all comers in trials, no PD-L1 testing required, efficacy in  expressors and non-expressors.",21
product,Territory, VA&P Sales,9.65335753176,2.84607822109e-06,37,20,"Large PBM quote:

The reason for Price Protection should be self-evident in the media ? price inflation of prescription drugs has been excessive and exposes our clients to unpredictable costs when setting budgets/premiums/etc.   

As a result, clients are demanding that we enter ?fixed cost? contracts where the pricing of a product is predetermined based on a set WAC during the course of an agreement, or else a Price Protection ceiling above which the net cost effect of a manufacturer?s pricing strategy will not affect the plan?s cost for the product. 

Additionally, when looking to prefer products, Price Protection is becoming an increasingly important feature of rebate contracts. For example, if I have price protection for Xarelto and Pradaxa, but not Eliquis, clients may be inclined to select your competitors because of the predictable nature of the spend.   A single price increase by BMS/Pfizer could wipe out much or all of the rebate value for a plan over the course of a contract If they select your  product, while they can be assured that the decision to prefer the other products would make sure a plan can?t go too far astray during the life of the contract for competitors offering PP.","Oncology Clinical Pharmacist at Beth Israel Deaconness Hospital in Boston stated that he believes that if A-Z's PD-1 product is approved in December it could lead to IDNs choosing 1 preferred agent if it enters the market at a reduced price.  He said it would be difficult if an IDN chose one product and a payer chose another product as their preferred agent, if that happened.","Josh Whittington, HSL reports that at CCK in Wichita, KS, that they are already receiving contracting discounts on all infusible Genentech products, including Tecentriq.  I believe it is 4.3%.",57
oncology,Territory, VA&P Sales,5.90606262492,5.12590326124e-07,97,148,"Lead Oncology Pharmacist expressed level of concern with new market entries when the approval leads to a shift 'from' Medical Benefit 'to' pharmacy benefit vs. the other way around.  The issue driving this concern was stated as being a 'much higher level of scrutiny' on the pharmacy benefit and that, for a reason not specified, there is less concern when there is a shift toward the Medical Benefit.  May be an 'n of 1' perspective, but given that BMS approvals can drive that shift 'from' oral 'to' IV and visa versa, felt it a meaningful IDN/payer perspective.","Oncology Clinical Pharmacist at Beth Israel Deaconness Hospital in Boston stated that he believes that if A-Z's PD-1 product is approved in December it could lead to IDNs choosing 1 preferred agent if it enters the market at a reduced price.  He said it would be difficult if an IDN chose one product and a payer chose another product as their preferred agent, if that happened.","Dickenson Community Hospital has recently been affected by the 340-b orphan drug court order and the enforcement of our policy around this issue.  In a previous meeting, The Director of Pharmacy Laura Casanova and the Oncology Pharmacist Mark Hagen stated they were going to contact each Pharmaceutical company and request they supply a contract to compensate for their lack of pricing for the 340-b orphan drugs. They stated they would move all utilization to drugs that have contracts and restrict those that do not. 

I  followed-up with the account and reinforced the BMS policy as it relates to ?newly eligible? 340-b entities and orphan drugs.  I then shifted the conversation away from cost and moved into value of our medicines, patient assistance program and our reimbursement support. 

Mark Hagen did not mention Merck or anything they might be offering to address this situation.  The conversation moved away from what he addressed in our last discussion of restricting one agent over another based on contract offering.  I believe Mark realized he needs to move his energy away from restricting these important drugs and focus on other ways to address the 340-b issue.   He said he is going to check into other wholesalers for potential better contracts for specialty drugs, look into getting his class of trade status changed, and potentially setting up his purchasing into in-patient and out-patient outlets to potentially move away from in-patient bundle payments from Medicaid/Medicare where he feels he is losing money.",245
clinical,Territory, VA&P Sales,5.11319394376,2.19579779254e-05,213,0,"Most recent update to AIM clinical pathways utilized by Anthem effective 5-1-16 include a new pathway for kidney cancer.   Other updates can be viewed:
 
https://anthem.aimoncology.com/","HEOR and I met with large academic IDN who shared that they are planning to head in a direction of managing access to oncology medications. Customers were interested in discussions/partnership pertaining to a need and development of a tool - using Epidemiological data and Budget modeling. Examples of current gaps include, EPI data, ability to estimate cost when there is an indication update or change of therapy and adjust for things like site of care and risk stratification. 

They are interested in Combining this type of data with clinical outcomes to make the best health economic and outcomes decision. Customer shared that they are interested in having best opportunity to leverage tools and technology at their disposal to treat disease.","Oncology Clinical Pharmacist at Beth Israel Deaconness Hospital in Boston stated that he believes that if A-Z's PD-1 product is approved in December it could lead to IDNs choosing 1 preferred agent if it enters the market at a reduced price.  He said it would be difficult if an IDN chose one product and a payer chose another product as their preferred agent, if that happened.",213
Opdivo,Territory, VA&P Sales,2.55096073517,3.65738144233e-05,445,28,"Field sales provided onc clinician feedback that for 2L lung, they are committed to staying with Opdivo (versus Keytruda or Tecentriq) based on their positive clinical experience with their patients.  Also, feels Keytruda's 1L Lung data hasn't convinced of an unmet need to move vs their surrent standard of care.","Spoke with DOP at RWJ UH, which purchases Oncology medicine for the Cancer Institute of NJ. Discussed SCCHN, 10/05 approvals/tumors and NSCLC (017/057 & 026).  DOP said they are seeing a lot of Opdivo utilized. DOP also prefers that Keytruda be used to label/NCCN guidelines in 1L NSCLC, so patients have more options, including Opdivo, in 2L NSCLC. Made the analogy to antibiotics, why use your big gun antibiotic 1st line, should reserve for when its truly needed.
They have a Pharmacy Business manager that is looking at Value, asked for data on Quality of Life in Opdivo trials.","ESI Clinical lead questioned whether there are any significant differences between Opdivo and Keytruda during a recent SCCHN and post-ESMO discussion.  HSL and HEOR response focused on the broader range of indications, well designed clinical trials with OS for most, and comprehensive R&D program as distinguishing advantages for Opdivo that have led to a strong market leadership position.",473
Northeast,Territory, VT,301.0,8.78016867068e-14,9,121,"Testing for PD-L1 in NSCLC is now part of the usual pathology and genetic tests conducted in a leading NCCN institution in Northeast US.  This hospital charges the payers a single bundled charge for all the tests they do on a patient.  Now, PD-L1 has been added to the pre-existing battery of tests.  This institution does its own immunohistochemistry assays for PD-L1 using the E1L3N antibody from Cell Signaling Technology.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A leading kidney cancer specialist from an NCCN institution in the Northeast commented that no oncologist in his institution tests for PD-L1 levels before initiating anti-PD1 therapy in RCC.  This is also true of his colleagues nationally.  He does not see the logic in testing for PD-L1 levels to choose between a new TKI and immuno-oncology agents.  As nivolumab has a broad approval in RCC, he does not anticipate payers asking for PD-L1 tests nor denying claims for lack of prior testing.",130
IME,Territory, VT,225.75,1.03059906794e-05,3,0,"In his presentation at an IME on immunotherapy in NSCLC, Naiyer Rizvi MD (Columbia University) summarized the data for nivolumab and pembrolizumab, stratified for PD-L1 levels and tumor histology.  The overall theme of his presentation was that both agents are very similar across all stratifications, even when the slides highlighted the differences (e.g. hazard ratio for pembrolizumab in squamous histology in Keynote-10).  BMS, Merck and Genentech funded this IME program.","Discussing therapeutic options in NSCLC patients expressing low levels of PD-L1, Leora Horn MD (Vanderbilt & NCCN panelist) indicated her preference for chemotherapy over IO agents.  She also believes that chemotherapy (with pemetrexed for NSQ NSCLC) and targeted therapy is more valuable in appropriate patients as first line therapy, instead of IO agents as monotherapy or in combination.  These opinions were expressed during the unscripted discussion following an IME program sponsored by BMS, Merck and Genentech.","Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.",3
New England,Territory, VT,150.5,2.506522524e-18,17,970,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.",987
cell carcinoma,Territory, VT,75.25,2.50530862486e-06,7,40,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",47
NCCN institution,Territory, VT,66.8888888889,4.29123557889e-11,16,109,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","A leading academic thought leader and clinical trials expert from a New England NCCN institution underplayed the significance of CheckMate 026 results disclosed so far.  He felt that PFS is not a good endpoint for IO therapies, as many IO trials have already shown positive response rates and overall survival despite a lack of PFS advantage.  In cancers with low T- lymphocyte infiltration, CTLA-4 inhibition using ipilimumab may enhance the efficacy of nivolumab by increasing infiltration.",125
immuno-oncology,Territory, VT,53.75,4.00828032701e-07,11,54,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.",65
produce,Territory, VT,37.625,1.68991039548e-05,11,0,"A leading expert of immuno-oncology and immune checkpoint inhibition highlighted the differences between CTLA-4 inhibition and PD-1 inhibition at the Evergrande Symposium in Boston.  As CTLA-4 pathway acts at the priming level, an earlier step in mounting an immune response, he expects a better long term immune-memory with anti-CTLA-4 agents.  This is likely to lead to a higher long-term survival with ipiliumumab than nivolumab.  Nivolumab acts in the periphery and relieves the inhibition mechanisms are a much later stage of immune activation, and thus will produce less impressive long-term survival.","Physicians are reacting negatively to the direct-to-consumer advertisements for Opdivo and are raising their displeasure proactively during meetings.  The Medical Director of the Lung Cancer Program in an academic hospital in the Northeast told the HSLs that he had second thoughts about using Opdivo, just as a reaction to the DTC advertisement on television.  Another family practice physician involved in formulary decisions called the Opdivo TV ads ?cringe-inducing?.  He complained that the overall tenor of the TV ad grossly exaggerates the modest improvement in median overall survival produced by Opdivo in NSCLC.","A leading academic thought leader discussed the clinical trial results of cabozantinib and his own personal experience in using this agent.  Toxicity and adverse events remains the major concern with cabozantinib.  Though cabozantinib produced very good results in clinical trials, he is cautious about using this agent in his practice.  He has participated in nivolumab trials, and uses nivolumab frequently in his clinical practice.  However, he stressed that the TKIs will remain a staple part of therapy of RCC, and the right patient can derive significant benefit from them.",11
US,Territory, VT,37.625,1.46361607795e-06,14,24,"Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.","A clinical pharmacist at an academic medical center in the Northeast US indicated that they have added PD-L1 testing (IHC) to their usual battery of genetic tests for all tumors, including NSCLC and RCC.  At present, PD-L1 levels are not being used to make treatment decisions at this center.  But she implied that more granular instructions on the use of anti-PD-1 and anti-PD-L1 agents are expected in future from both regulatory agencies and payers.  This center wants to have all the procedures established before these changes become mandatory requirements.",38
thought leader,Territory, VT,33.4444444444,2.42576830707e-09,25,22,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","A national thought leader on renal cancer from a Northeast NCCN institution advocated a Q3W dosing for nivolumab in RCC as a cost-saving measure that also increased patient convenience.  He substantiated his argument by pointing out that the clinical efficacy in ORR, PFS and OS are identical for CheckMate 010 and CheckMate 025, though the former trial uses a Q3W dosing schedule.  He believes that FDA would accept a single arm trial that shows non-inferiority in OS to change the labeling to a Q3W dosing.",47
Boston,Territory, VT,28.21875,5.0253285218e-07,40,82,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",122
MD,Territory, VT,27.7236842105,6.47806926464e-08,29,71,"Eric Wong MD (BIDMC, Boston & CAC member) expressed disappointment in the low response rates achieved in recurrent glioblastoma patients in CheckMate 143 trial.  This is in reference to the poster presented at ASCO 2016.  He was particularly surprised by the lack of response to the combination of nivolumab and ipilimumab.  Dr. Wong has received nivolumab previously to treat his glioblastoma patients through the compassionate access program of BMS.  He is hopeful that the larger phase III trial will give a more positive outcome in this disease with major unmet needs.","David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","Omar Eton MD (Boston Medical Center, past President of MSCO) commented that the updated ASCO Value Framework reflects a mindset more suitable for assessment of chemotherapeutic agents, and not the recent advances such as anti PD-1 agents.  He feels that the bonus points for long term survival in the ASCO Value Framework are insufficient for capturing the long term survival benefits offered by IO agents.  He also expressed concern about the inaccurate cost estimate for ipilimumab in adjuvant setting in melanoma used in the updated value framework.  Dr. Eton is planning to alert Lowell Schnipper MD (ASCO Value Task Force) to correct this error.",100
ipilimumab,Territory, VT,26.5588235294,6.71018488851e-07,22,17,"David McDermott MD (BIDMC Boston) an expert on melanoma and RCC, and a leading clinical trials leader discussed the safety issues in using checkpoint inhibitors in patients with autoimmune disorders.  He made a cautious endorsement, pointing out the range of possible results with ipilimumab (Johnson DB, Jama Oncol. 2016).  Despite being treated with immune modulatory therapy to treat immune-mediated AEs, many patients maintained the response of ipilimumab, including one complete response.  He also presented one of his cases, a patient with metastatic melanoma and psoriatic arthritis who was treated with pembrolizumab.  When the psoriatic arthritis flared, the patient was treated with apremilast (a PDE4 inhibitor) without compromising efficacy of pembrolizumab.  He also presented the data from Weber (2015) publication in JCO, to point out that immunosuppressants does not appear to affect the efficacy of nivolumab either.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","During a discussion on CheckMate-026 data, an academic thought leader from the Northeast US downplayed the utility of nivolumab-ipilimumab combination regimen in first line NSCLC.  He considers ipilimumab to be a therapy with significant toxicity and he always refers his melanoma patients who are candidates for ipilimumab to the NCCN centers in the state.  He uses nivolumab frequently in his second line NSCLC patients, but he was lukewarm in his enthusiasm for immuno-oncology in first line.  Though the data in first line is still emerging, he is more likely to use IO+chemotherapy combinations than IO/IO regimen or IO monotherapy in this setting.  This institution now checks for PD-L1 expression in all NSCLC patients as the turnaround time for testing has improved, but this information impacts clinical decisions in the first line only.",39
renal,Territory, VT,20.9027777778,1.48378524388e-05,22,26,"Bernard Escudier, an internationally renowned thought leader in renal cell carcinoma expressed his confidence in cabozantinib at an IME program during ASCO 2016.  He believes the efficacy of cabozantinib comes from its targeting of MET and AXL kinases, particularly in overcoming sunitinib resistance.  As nivolumab shows better efficacy in third and fourth line therapy in CheckMate 025, he prefers to use cabozantinib in second line and keep nivolumab for later lines of therapy.","According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.",48
cabozantinib,Territory, VT,20.5227272727,2.34524140396e-06,27,137,"According to a regional thought leader from Boston, the latest results from ASCO 2016 adds little to the treatment of renal cell carcinoma.  He does not consider the data presented for cabozantinib and lenvatinib to be practice changing.  This physician uses nivolumab in RCC as second line frequently.  He has also expressed gratitude to BMS for its generous support to patients through its patient access programs, even before the approval of nivolumab in RCC.","An NCCN panelist for renal cell carcinoma explained the rationale for limiting targeted therapy as second line only to patients treated with TKI therapy.  Bevacizumab in combination with interferon is no longer a preferred therapy due to toxicity.  So very few patients are currently started on bevacizumab. Also, in clinical trials for targeted agents such as nivolumab and cabozantinib, there are not enough patients treated with bevacizumab to warrant an explicit recommendation for targeted therapies in this group. Therefor the NCCN Guidelines are unlikely to change it language to include all anti-angiogenic therapies.  However, oncologists should have no concern in using targeted therapies patients previously treated with bevacizumab.","Thomas Hudson DO (Texas A&M, US Oncology/McKesson) discussed the challenge of sequencing TKI therapies and IO agents in kidney cancers.  He indicated that cabozantinib might replace sunitinib in first line therapy for clear cell RCC, if the final results reflect the improvement in PFS already released by a press release from Exelixis.  However, he was dismissive of either of the new TKIs (cabozantinib and lenvatinib) as second line therapy in RCC.  His patients are well educated and are demanding IO therapy.  In addition, there is no data to indicate superiority for TKIs over nivolumab in this setting.  The next generation TKIs will be relegated to third line therapy after IO failure.",164
IO agents,Territory, VT,18.3040540541,2.05728361688e-08,45,174,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.","A key oncologist from a New England academic hospital shared information on his thinking and his clinical practice in managing IO agents in patients with endocrine-related immune-mediated adverse reactions.  In his opinion, adverse events affecting the endocrine organs such as the thyroid and pituitary glands can be managed by administering the appropriate hormone replacement with discontinuing the IO agent.  He believes that value provided by IO agents including the potential for a complete remission is too important to sacrifice to avoid an adverse event that can be easily managed.","The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.",219
major,Territory, VT,16.0106382979,1.11546964675e-08,90,483,"To address potential concerns arising from CheckMate 026 results, I met with the Medical Director of Clinical Pathways of a major NCCN institution in New England.  Though he was not interested in discussing the 026 results in detail, he commented that potential positive signals would have been masked by the very low PD-L1 cutoff for enrollment.  Commenting on Keynote 024 results, he felt that the positive results from this trial will likely strengthen the case for pembrolizumab in second-line use.  In their institution-specific pathway, they are already using pembrolizumab as their preferred agent for PD-L1 positive patients, with a cutoff of PD-L1>1%.  Upon being challenged by the HSL for the rationale for this low cut off for pembrolizumab in second line, he pointed to Keynote 10 data where patients with PD-L1>1% did better than docetaxel.  This AI and his institution gives high weightage to q3w dosing, discounting factors such as PD-L1 cutoff levels and differences between squamous/non-squamous histologies.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",573
advanced,Territory, VT,15.6770833333,4.85954723446e-05,36,0,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","A key NCCN panelist for SCCHN a major academic hospital in New England was profiled to understand the treatment landscape in SCCHN.  This panelist was an investigator in CheckMate 141, and therefore was intimately familiar with the data presented at AACR.  The panelist considers the efficacy in OS to be better than what is seen in clinical practice with single agent therapies (methotrexate, cetuximab, docetaxel etc.).  He has a very negative opinion on the efficacy and toxicity of these standard of care therapies.  

Combination therapies will enhance the potential of immune-oncology in difficult to treat cancers and advanced stage disease.  Robust data needs to be developed for all options with Opdivo such as IO combinations, IO + targeted therapies and IO + chemotherapy/RT.  He also stressed the need to do clinical trials in nasopharyngeal SCCHN due to its unique etiology and response to treatment.  He does not endorse extending the NCCN recommendations to include this population based on data from other types of SCCHN.","The Director of Hematologic Malignancies at a major academic hospital in Boston downplayed the incidence of GVHD in patients who received allogeneic stem cell transplantation after receiving nivolumab previously.  Hodgkin lymphoma patients with advanced disease in later lines of treatment are more susceptible to GVHD after allogeneic SCT generally, even without previous exposure to nivolumab.  As careful management of GVHD can reduce allo-associated mortality, nivolumab provides a good therapeutic option in advanced HL patients.",36
hospital,Territory, VT,15.6770833333,1.32785094524e-08,72,479,"The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital summarized the treatment algorithm for uveal melanoma, during a meeting with the HSLs.  In this institution, ocular brachytherapy is the treatment of choice for primary disease limited to the eye.  Proton beam is not used in this center.  He lamented the lack of options for patients once the disease progresses with metastasis primarily to the liver.  Systemic chemotherapy and targeted agents have produce very low response rates and does little to improve overall survival in these patients.  Hence, the preferred option for advanced uveal melanoma is enrolment in a clinical trial with IO agents.  According to him, immuno-oncology therapies, particularly the ipilimumab/nivolumab combination are the most significant advances in treating uveal melanoma in recent years, though their response rates are likely to be lower than what seen in cutaneous melanoma.","The clinical pharmacist responsible for infused products at a leading academic hospital in New England expressed gratitude to BMS for its generous patient assistance program.  Most of their patients on nivolumab in off-label indications in this Disproportionate Share Hospital (DSH) currently receive free medication through the patient assistance program.  This hospital is now attempting to move some of these patients to their insurance plan, to reduce the burden on the assistance program.","The NCCN Guidelines panelist (ophthalmology/medical oncology) for melanoma from a major New England academic hospital highlighted the variability in ocular adverse events associated with immuno-oncology therapies.  The majority of the patients continue IO therapy with intense management of ocular adverse events.  But in the most extreme cases, adverse reactions can progress from perfect vision to complete non-responsiveness to light within 48 hours.  Factors that increase the risk of ocular AEs are currently unknown.  

Less serious AEs are managed with topical corticosteroids, while serious AEs warrant withholding IO therapy and treating with IV corticosteroids, particularly when the optic nerve is involved.  Cyclosporine and artificial tears are used to manage dry eyes associated with IO agents.  As the AEs can worsen very quickly, both ophthalmologists and medical oncologists should identify and treat them without delay, as well as educate patients proactively on the symptoms.  This NCCN panelist also stressed the need to train community and academic oncologists as well as ophthalmologists to identify the symptoms of ocular IMARs, given the propensity of these AEs to worsen very quickly.",551
improved,Territory, VT,14.564516129,1.28660051308e-05,36,0,"The Executive Director of large community practice in New England solicited the help of BMS improving the value of immune-oncology products to the payers.  He believes that the value-based payment models that interpret cost from a holistic perspective are imminent, in spite of the recent change in political leadership.  He is interested in co-sponsoring educational efforts targeting community physicians particularly those working in emergency rooms.  His goal is to ensure that family practice/ER physicians diagnose immune-mediated adverse events in patients receiving IO therapy and treat them appropriately to avoid preventable AE-related costs of IO agents.  He was very positive about the ancillary customer support for reimbursement, compassionate use and medical information he receives from BMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.","The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.",36
care,Territory, VT,13.6818181818,1.75918689769e-05,75,12,"The president of a large physician-owned community oncology group affiliated with US Oncology explained the relationship between these two entities.  US Oncology provides this with practice management tool, and access to McKesson?s purchasing and distribution network.  This facility uses the Clear Value clinical pathway for the purpose of improving quality of care and reducing reimbursement issues.  This physician indicated that neither McKesson nor US Oncology provides any financial incentive in adhering to the pathway.  This facility is 80% compliant with the pathway, which according to the physician reflects the NCCN guidelines.  They are not using any payer-implemented pathways, and they have faced no reimbursement hurdles so far.","Elizabeth Blanchard MD (President, MSCO) discussed her views on alternate payment models that are currently being piloted in oncology care.  Overall, she was disappointed by the lack of financial impact and cost savings by these models, given the initial investment required to meet the standards of payers.  COME HOME project, though improved the quality of care significantly, did not make a major impact on the overall cost.  She is also skeptical whether the Part B Demo model being rolled out will reduce the cost of care incurred by CMS.","A large NCCN institution in New England is deploying its own clinical pathway across its main hospital and its satellite hospitals.  The goal of this effort is to harmonize care across the network and improve patient outcomes.  Cost to the hospital system and the patients did not influence the stratification of therapies and treatment modalities.  Commenting on payer-initiated pathways, the clinical lead for pathways predicted that the commercial pathways will get progressively stringent, once payers realize that the earlier versions are not providing the cost savings anticipated.",87
regional TL shared,Territory, W. TN,15.6455525606,2.03859037827e-08,18,18,A regional TL shared with me that he is now doing PDL1 testing in his firstline NSCLC patients because of the KN-24 approval.  He acknowledged that most patients will not be over 50% positive and confirmed that Nivo will still be SOC for those patients 2nd line.,A regional TL shared that he has had no problems getting insurance to approve off-label 1L usage of Nivo monotherapy in RCC.  He said that he has seen durable responses approaching 2 years.,"A regional TL shared with me that he believes hypophysitis is exclusive to Ipi rather than Nivo.  He hypothesizes that Ipi cross-reacts with common proto-antigens shared between melanosomes and the pituitary as both originate from a common cell lineage in the neural crest.  He does not think that Nivo recognizes that common antigen, hence the higher incidence of primary thyroiditis with that drug.",36
TL told,Territory, W. TN,5.96519395289,1.51415049466e-07,65,938,A SCCHN TL told me that his site participated in the AZN Durvalumab+Tremelimumab 1st line H&N trial that had a recent clinical hold for bleeding.  The TL confirmed the hold was lifted and that the adverse event was not due to the treatment but most likely a result of the nature of the disease and its proximity to significant amounts of vasculature.  The TL stated he had enrolled 4 patients on trial and none had any issues with bleeding,A SCCHN TL told me that he hasn't seen any data that makes him think testing for PD-L1 testing is necessary for his H&N patients.  This TL also treat Lung and has recently begun asking for the results on all new patients he sees,"A large regional GU TL told me that his order of using agents for metastatic RCC is first pazopanib, 2nd line nivolumab, 3rd line cabo, 4th line axitinib, and 5th line levantinib.",1003
anti-PD1,Territory, W. TN,5.57988238177,1.25982836146e-06,38,55,"A national TL mentioned that he has treated ~8 GBM pts with Nivo and saw ?only a couple responders.? ?Nivo or Pembro monotherapy is not going to be the answer.?
Same TL said he was skeptical of the efficacy of anti-PD1 plus radiation. He said that he thinks PD1 plus another checkpoint inhibitor is going to be key, saying that he has not given up on Nivo plus Ipi.",Melanoma TL believes HLA-DR may be a better biomarker for use as a patient selection marker in utilization of anti-PD1 therapies,"A TL shared that he felt we are overtreating patients with anti-PD1 therapy. He believes chronic PD1 blockade encourages resistance and we need to identify the optimal induction schedule to ""let the immune system kick in and get out of the way""",93
TL shared,Territory, W. TN,4.49308176101,1.94002753818e-08,119,1081,Academic RCC TL shared that he would consider cabozatinib over nivolumab in a patient with bone mets based on METEOR data presented at ASCO with the caveat being that the patient must be tolerating prior TKI as the toxicity with cabo is much worse than nivolumab. If patient had a tough time with prior TKI then he would go straight to nivolumab,"A national melanoma TL shared that he has seen a few thyroids preserved with steroids using Nivo, but he never saw that with adrenal insufficiency.",Community lung TL shared pdl1 testing is now reflexive for all nsclc patients and they are working to establish pdl1 testing In house.,1200
offered,Territory, W. TN,2.98010524965,2.01217845725e-05,88,0,"A national H&N TL at an NCI designated cancer center offered that she substitutes Taxol for 5FU in the EXTREME regimen. She said that she ""loves"" weekly taxol and erbitux because she always sees responses.",A local HCP offered that she was able to get Nivolumab for a prostate cancer patient and he achieved a CR.,"A regional TL offered that he will readily use pembro 1L when they receive their FDA indication for NSCLC.  He said that he will use pembro preferentially because of the positive experience he had with their compassionate use, and he had an extremely bad experience with BMS's program involving ""more than 100 emails back and forth"".  With further discussion, he did not use the local ARM but rather used the online compassionate use link on the BMS website; regardless, the ARM has been notified of this.",88
commented,Territory, W. TN,2.16630727763,3.26183152784e-05,295,327,A local TL when discussing OS data in squamous vs. non-squamous NSCLC based on PD-L1 expression commented that with a higher cut-off our 1L trial would have been positive.,"A National TL at a lung cancer lecture at the PR Hem Onc Symposium commented that there is no difference in pembro or nivo biologically, just in the biomarker strategy.",Regional lung TL commented that he was stunned by how much of an overreaction there has been to the 026 study. He feels the vast majority of it all has been negative coverage from the media and investors who clearly don't understand how clinical research works. He said none of the investigators or any physician that's ever participated in a trial should be surprised...sometimes clinical trials fail...even with the best drugs.,622
provided the following unsolicited insights,Territory, WA,235.846153846,1.46274840685e-50,45,146,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",191
Met with a national/regional lung,Territory, WA,224.615384615,3.09321684384e-13,10,211,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national melanoma and genitourinary AI/TL post-ESMO, who provided the following unsolicited insights from the podium and in conversation.
?	He expressed that we shouldn't forget about IL2 in kidney Ca, because of the durable CR?s seen in select patients.
?	When he was asked whether tumor burden is associated with response, he responded that with IL2 there is some evidence for this hypothesis.
?	He reitereated that we don't know the significance of Biomarker testing PDL1 yet in melanoma and genitourinary cancers.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",221
Met with a regional,Territory, WA,213.384615385,6.642943834e-24,21,174,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
AI/TL post-ESMO,Territory, WA,202.153846154,6.1507481503e-12,9,660,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
AI/TL,Territory, WA,119.794871795,2.61473911534e-19,27,661,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",688
ASCO'16,Territory, WA,112.307692308,9.0623455182e-07,5,394,Academic TL stated he had seen METEOR data showing Cabo is effective for RCC bone mets and was thinking Cabo might be a better option than Nivo for those patients.  TL said Motzer's subgroup analysis of CheckMate025 (ASCO'16) was helpful in making him comfotable that Nivo is a good choice for those patients too. TL remarked that the 5-month benefit of Nivo vs Everolimus is maintained even in the Bone mets population.,"RTL, a NP with lots of I-O experience, stated that some physicians in their group are 'short-coursing' steroids when treating irAE's, as they are afraid steroids will negatively impact the anti-tumor T cell response.
This is a No-Access site, so there is no opportunity for me to educate those physicians.
TL said that the data from Hodi's ASCO'16 poster from CM-069 will be helpful in educating colleagues that steroid used to treat irAE's don't diminish the tumor response to Ipi+Nivo Regimen.
However, TL said that similar data for Nivo monotherapy in NSCLC would be even more impactful. The perception of irAE's on Nivo are less severe than when on Regimen. So physicians may still want to shorten the steroid treatment on Nivo monotherapy, unless they're shown that there's no reason to do so.","NP at a community hospital reported continued ""difficulty convincing some of my doctor colleagues to initiate steroids appropriately"". NP asked if we ""have a reference for anything published that demonstrates that if patients receive steroids for toxicity from immunotherapy, they don?t suffer worse outcomes?""
I reviewed the 209-069 Hodi poster from ASCO'16 and mentioned other similar analyses from prior Ipi studies. NP was very appreciative and is working to arrange a face-to-face meeting with HCPs to facilitate education on IMAR algorithms.",399
Met with a national,Territory, WA,97.3333333333,1.43386236302e-15,25,644,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",669
FDA blueprint,Territory, WA,89.8461538462,1.71205620441e-05,6,57,"Met with two national/regional Mckesson Clear Value Pathway P&T AIs who provided the following unsolicited insights:
?	AIs disclosed that they have access to both the Merck and BMS PDL1 assays, and are able to order the appropriate assay for the medication the patient is taking. 
?	They are aware of the great concordance between Merck and BMS assays, and are considering just ordering the Merck assay for patients on both Nivo and Pembro due to the concordance shown by the FDA blueprint analysis.
?	One of the AI?s also mentioned that the Yale analysis on concordance between PDL1 assays was also convincing of their consideration above, which also came to the same conclusion of great concordance between Merck and BMS assays, but great disparity of these two with the Ventana assay.  
o	Reviewed conclusions of FDA blueprint analysis to confirm their understanding.
?	AI expressed recognition of Empliciti?s positioning in MM as the medication with great potential for duration of response, with 3y PFS/OS after reviewing 3y updates with him.  He pointed to the current low utilization of Elotuzumab as the reason he?s currently unwilling to add to pathway, but stated that he may reconsider once he sees an increase in utilization.","Met with a national/regional lung AI, who provided the following unsolicited insights:
?	AI reactively mentioned that his institution is currently sending to 3rd party labs to conduct both the BMS and Merck PDL1 assays, due to inability of their in-house lab/pathology to support this testing in-house.  
?	AI expressed frustration that the one test they can perform in-house is the Ventana (Atezo) assay, for which they recently bought a machine.  We reviewed the FDA blueprint analysis that showed the Ventana assay as highly discordant with BMS/Merck assays and how this could lead to misclassification of some PDL1 expressers as non-expressers due to lack of sensitivity, which he admitted to understanding.","Met with a NSCLC NCCN Panelist national AI and regional head and neck AI, who reactively provided the following insights:

?	He thinks that failure of CM 026 trial to achieve a difference in PFS was due to the trial design, with BMS reaching for a patient population PDL1 greater than or equal to 5% as too broad.
?	He said that perhaps Merck reached for a population that was too narrow, having conducted the study at so many locations just to achieve the appropriate numbers of patients in KN.
?	He found it odd that sex was not stratified for in CM 026, given that it's a well-known prognosticator of how well patients tend to do.  
?	AI thinks that despite the negative result in CM 026, he thinks that Nivo and Pembro are not that different.
?	He expressed that KN trials combining chemo with IO have inflated response rates due to the chemo component.
?	In reactive discussion of the FDA Blueprint analysis showing great discordance between the higher sensitivity staining Merck and BMS assays compared to the lesser sensitivity of Atezo?s SP142 assay, AI pushed back asking why would you test using SP142 anyway, since testing is not required with Atezo and nonexpressers still may respond. Proceeded to walk him through Biomarker reactive slides outlining how Atezo?s less sensitive assay in theory may lead to classifying some expressors as non-expressors, due to the decreased sensitivity and discordance with BMS/Merck assays.
?	He expressed that Atezo?s q3w dosing frequency will be a factor in his institution?s selection of a 2L treatment, especially due to their impacted availability of infusion chair time and spaces.
?	After we informed him that the SCCHN indication is weight based dosing, He said that his institution might just use flat dosing for SCCHN like in other indications to reduce confusion and inconsistency in the pharmacy preparation.
?	He was already aware of the newly approved 141 SCCHN indication.  After reviewing the CM 141 QOL results showing favorable maintenance of PRO?s when comparing the Nivo group?s maintenance of QOL compared to the sharp decreases seen in the chemo group, he acknowledged the results and stated that QOL results are essential to any such trials in the head and neck space.
?	His institution is wanting to narrow available PD1 agents in their pathways and will be sitting down to evaluate the 2L lung space as well.",63
disclosed,Territory, WA,56.1538461538,2.47623990863e-11,13,182,"Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.",195
hit PFS,Territory, WA,56.1538461538,3.05435448456e-06,6,224,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",230
CM 026,Territory, WA,47.4188034188,1.56766563906e-19,27,207,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",234
distinction,Territory, WA,44.9230769231,4.95492170287e-05,5,14,"Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a NSCLC national AI/TL advisor to NCCN panelist, during which AI/TL shared the following unsolicited insights.

?	She proactively brought up that she supports distinguishing PDL1 expression levels in treatment decisions and applying data thresholds to what's studied. 
?	She thinks community oncologists don't understand the point above and need to be educated that PD1 agent decisions should follow the data available for specific threshold expression levels studied and that efficacy results are not necessarily equivalent and translatable for different agents studied at different expression levels.
?	AI thinks that the NCCN should delineate in terms of distinguishing recommendations based on the efficacy/safety data available for specific PDL1 expression thresholds studied, which would help to educate the community and prevent confusion that all agents and expression levels are necessarily equal.
?	AI shared that she thinks Merck has not been active to educate community about above point. She gave example that if a patient is positive for PDL1 expression greater than 50%, then you can apply that specific data to treatment decisions, but not if that?s not the patient you have.
?	She thinks BMS needs to provide better education about how to manage patients with immune AE's in patients who are refractory to steroid management.  
o	For example, for a patient on Nivo who experiences immune mediated pneumonitis or colitis AE?s who is refractory to steroids, there needs to be better data to support how to best manage that patient with infliximab.  
?	She thinks that in 1L, it?s absolutely critical to test for PDL1 and there?s a need to educate community docs about this distinction from the 2L setting, where a test may not be needed for decisions.
?	She currently doesn't test for PDL1 in 2L.
?	AI was familiar with 012 and 032 and says she has used Nivo/Ipi for patients who are not candidates for chemo (she didn?t elaborate further).
?	She says that she has many patients experiencing that prolonged duration of response tail on Nivo.
?	AI feels that patients on PD1 treatment who don't have a response are often patients whose disease is really already progressing despite treatment with the PD1.  She feels that this explains the sometimes unimpressive PFS seen in trials like 057.
?	She says the above scenario is different than when a patient is treated with chemo because nothing is suppressing the immune system in patients who are non-responders to Nivo and thus they progress rapidly.  In contrast, chemo patients are still experiencing some suppression of their immune system, so we see some response.
?	Thus, she says OS is the better evaluator of a PD1 agent, not PFS, nor ORR which is just the fastest endpoint.
?	She cautions a need to wait for phase 3 1L trials to compare against chemo, and that phase 1 trials like 012 have a small N (patients).  
?	AI feels that PDL1 testing needs to be standardized and be able to be easily performed at providers? own institutions, instead of being hard to access and having a gamut of different tests.","Met with a regional AI/TL melanoma NCCN panelist, who provided the following unsolicited insights.
?	AI disclosed that he also treats Head and Neck cancer in his practice and is the chair of the Head and Neck department at his institution.  
?	In regards to NCCN H&N guidelines, he expressed that the phase of a study, for example phase 3 versus phase 1, should lead to a distinction in level of evidence, although not a great distinction since he believes Nivo and Pembro are not that different agents.
o	For example in the head and neck context, he said Keytruda should receive a category 2A recommendation due to phase 1 studies while Nivo should receive perhaps a category 1 due to phase 3 studies.  
?	In regards to melanoma, reactively shared ASCO CM 069 (Hodi) subset analysis comparing PFS/OS in patients who discontinued regimen as being similar to the general randomized population on regimen.  
o	He shared that he was not surprised, as he?s seen examples of on-going responses in his melanoma patients who have discontinued regimen due to AE?s.",19
consideration,Territory, WA,38.5054945055,2.32208627364e-12,18,0,"Met with a regional oncology pharmacist manager AI, who provided the following unsolicited insights:
?	AI reactively mentioned that she?s observed instances of use of PD1 agents (Nivo, Pembro) as salvage therapy, in her institution, with unimpressive results.  
?	Due to the fact that her institution is not an IDN, comparative costs associated with IO therapy alternatives (eg. AE management costs associated with traditional Chemo) are not as important to them since they may generate revenue for interventions such as ER visits instead of being as sensitive to total spend for a patient.  
?	Due to this perspective, value measures such as the impact of seeing improved OS or positive impacts on quality of life are more important to her type of institution.  
?	She shared her institution?s P&T process as the following.  A physician (eg. Oncologist) requests an addition of a medication to formulary, which initiates pharmacy to create and present a drug monograph for P&T consideration.  With this info, the P&T committee then votes on this request for addition to formulary.  
?	The AI?s institution does have a formulary, but oncologists can order medicines not on formulary without a prior authorization process.  
?	If the medicine is on formulary, ease of access is faster since the medication is likely to be stocked by the infusion pharmacy.","Met with a regional oncology P&T Formulary AI, who provided the following unsolicited insights:
?	AI was impressed with the ORR of Nivo in cHL of 65%, noting that he expected the Independent Radiologic review ORR to be reduced from the prior Investigator assessed ORR, which made sense.
?	AI was familiar with 032 data presented at ASCO and expressed excitement at the 032 efficacy in SCLC, given that this is an unmet need given lack of current treatment options
?	AI was excited at the 141 OS rate/mOS and commented that OS advantage is what should be the overriding consideration in formulary considerations, which is what we have with the 141 data. 
?	He discounted the lack of PFS advantage in 141, repeating the sentiment above.","Met with a regional melanoma AI, who provided the following unsolicited insights:
?	AI mentioned that he is part of his institutional team that is looking at developing a home-grown treatment algorithm in terms of IO treatments.
?	This algorithm would take into account patient specific factors, such as patient?s performance status, and also baseline labs.  
?	It would define an algorithm in terms of class of agents, such as PD1 inhibitors, instead of be product specific.
?	AI currently does not test for PDL1 status prior to treatment initiation.
?	AI mentioned that he still considers individual patient specific characteristics in deciding whether to start on Nivo monotherapy versus regimen, such as performance status.
?	AI defines current practice in terms of nivolumab as 60% of patients getting monotherapy and 40% getting regimen.
?	He describes some anecdotal experience of seeing patients respond to regimen after not seeing a response on initial Pembro treatment.  He quantified that 1 out of 5 patients, he might see this type of occurrence.
?	When issue of cost arose, was able to reinforce with AI that the cost of regimen is only incrementally more expensive, around 6%, higher than the cost of sequential ipi followed by nivo.  
?	Reinforced with AI that the true cost of regimen treatment needs to take into account that 57% of patients in 069 received median number of doses (the full combo portion of treatment) and that only around 14% of patients were treated for 1 year.  
?	Broadened AI?s consideration of true cost parameters, as evidenced by his agreement that this needs to be considered in terms of true cost of regimen.  
?	In response to his question about sequential therapy, shared that nivo followed by ipi, as well as the reverse sequential regimens, did not show as good efficacy or more favorable AE profile compared to regimen.  
?	AI referenced his institution?s goal of conducting outcomes studies, in melanoma and beyond.  Offered connecting AI with BMS HEOR colleague to explore potential collaboration.
?	AI expressed that he was not particularly wowed with any melanoma data shared at ASCO 2016, as they were mostly comprised of updates on previously published studies.",18
P&T,Territory, WA,35.9384615385,1.47895353514e-08,18,182,"Met with a regional oncology P&T Formulary AI, who provided the following unsolicited insights:
?	AI disclosed that his organization?s medical policy was updated to allow for coverage of Pembro at PDL1>1% due to the Keynote 010 data (ORR PDL1>1% ~18%).","Met with a regional Pharmacy & Therapeutics Oncology and VIA institutional consultant AI, who provided the following unsolicited insights.
?	AI disclosed that her institution is closely involved as a pharmacy oncology and informatics consultant to the VIA pathway, across indications.
?	She disclosed that they have fully implemented the VIA pathway at her institution, along with continuing to be an external consultant in capacity noted above.  
?	They have developed pharmacist managed medication reconciliation and compliance programs with great success and look to expand such programs, including with oral oncology medicines.
?	AI states they are planning on opening a home infusion pharmacy service that would prepare home infusible medicines, including oncology infusion meds.  This is method to reduce costs of care associated with in-clinic infusion care.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",200
following unsolicited insights,Territory, WA,31.4461538462,2.02639142616e-07,79,48,"Met with a AI/RTL who treats multiple tumor types, but is also a Head and Neck national/regional NCCN panelist AI/RTL, during which AI/RTL shared the following unsolicited insights.
BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
?	Reactively shared that the NCCN panel will include an immunotherapy update to the guideline to include both nivo and pembro.
?	Stated that her recommendation does distinguish that the data supporting nivo (Phase III) vs pembro (single arm trial) are different and should have a different category of recommendation.
?	Commented that the SCCHN NCCN committee does not have ad hoc meetings based on recent data presented, and meetings/updates are generally every 6 months with the next update forthcoming. 
?	AI felt that in terms of trials presented overall at ASCO, there were too many trials with induction chemo combined with IO therapies.
?	She feels that induction chemo strategies with later Immunotherapy is not the right approach.
?	She inquired whether BMS has a process for partnering with other companies to explore IO combos, seeming to express a positive view of this approach. 
?	She shared that she feels BMS ""knows what they are doing"" in being very strategic about supporting ISR's and making decisions about research.","BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
 
Met with a Head and Neck national/regional NCCN panelist AI/TL, during which AI/TL shared the following unsolicited insights.
?	He says for locally advanced setting, he chooses based upon if the patient is fit or not. If he is, he uses cisplatin with concurrent radiation, but also could be other treatments, which he terms the ?wild west?, meaning other treatment options are on the table as well.
?	If the patient has had platinum prior, he could try a single taxane as next treatment.  
?	In the recurrent/metastatic setting, if the patient is fit, he prefers to use PTC (platinum/taxane/cetuximab), instead of the EXTREME regimen.  
?	He said that part of the reason he believes in PTC instead of EXTREME is because the 5-FU in the EXTREME regimen leads to a bad toxicity profile.
?	He says the only reason the EXTREME regimen included 5-FU instead of a taxane was because the investigator Vemorken was in Belgium where taxane was not approved in this indication.
?	In the recurrent/metastatic setting, he uses a PD1 inhibitor after the PTC regimen.
?	If the patient is not fit in the recurrent/metastatic setting, he?ll go directly to a PD1 inhibitor.
?	He says he was involved in BMS head and neck early trials and believes that BMS got it wrong by not pursuing every 3 week dosing, instead of every 2 week dosing.  
?	He said he starts most patients on pembrolizumab solely because it is more convenient for the patient with less frequency of dosing.  He believes BMS should pursue strategy of investigating less frequent dosing.  
?	In the recurrent metastatic setting, he never uses cetuximab single agent, due to the low response rate.
?	He says he stratifies patients in terms of sensitivity to platinum.  If patient progressed on platinum 6 months to 1 year ago, he considers them refractory and does not use platinum again.  
?	If a patient progressed and had platinum 2 years ago, he might try platinum again.  
?	He expressed that an area of H&N research gap is how to utilize PD1 agents in incurable patients who do not have a response to initial PD1 therapy.","2.	Met with regional Lung AI, who is also on the Head and Neck NCCN committee, who provided the following unsolicited insights:
a.	AI disclosed membership on the Head and Neck NCCN panel and is also the chair for the upcoming updates.
b.	AI shared some unsolicited insights on the topic of how NCCN committees in general consider and review guidelines and updates.  AI says that although the consent and approval of all panelists is sought, the process for doing that can be rather informal, depending on the specific chair of the committee.  For example, review/consent/approval may be done through email communication.",127
KN 024,Territory, WA,28.0769230769,9.12811855951e-10,17,248,"Met with a regional lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that the impact in CM 026 of the Nivo subgroup having a high percentage (37%) of patients having been previously treated with radiotherapy is unclear in whether it contributed to the failure to hit PFS.  
o	It could represent the fact that the Nivo group was a sicker patient population, stacking the deck against the reaching the PFS primary endpoint.  
o	Alternatively, there are some studies that show a hypothesis for potentiation of response to IO therapy when patients are treated with IO post-radiation, due to increase in neo-antigen response.  
o	The key is the temporal relationship of IO after radiation.  
?	She was surprised with the lack of PFS advantage at PDL1 greater than or equal to 50% since she believes that the PD1 agents (Nivo, Pembro) are not different.  We proceeded to review the lack of PDL1 50% or greater stratification of populations, which evidences that the study was not designed to read out PFS for this population, as well as imbalances in sex and PDL1 expression populations as possible contributing factors.  
?	AI thinks the failure has to do with the CM 026 study design, again referencing the fact that she doesn?t believe Nivo and Pembro are different, which leads her to believe that the study design lead to divergent results in KN 024 and CM 026.
?	AI says that this is just a stage on the way to combos and this stage will pass.  She believes this will be the relevant landscape instead of monotherapy.
?	AI believes that at a major cancer center like hers, q3w dosing of Atezo in 2L is an important consideration that may push treatment towards Atezo, since many patients come from far-away places via referrals, which is a big motivator for having a q3w regimen for these patients.","Attended a personalized lung therapies conference post-ESMO where a national lung AI/TL provided the following unsolicited insights from the podium.
?	In response to discussion of why the CM 026 trial would be negative when the KN 024 trial was positive, he stated that?
o	The CM trial had an overly broad patient population in terms of the primary PFS endpoint.  
o	He expressed that it was hard to reconcile why the PDL1 greater than or equal to 50% subgroup had a negative result.  I had an opportunity to meet with AI and explain to him that the study was not designed to test PFS at greater than or equal to 50%.  Also, due to imbalances in patient populations, including PDL1 expression levels between the 2 groups and imbalances in sex, PFS at this subgroup was not within the trial design.  
o	He stated that the negative result shakes the prior belief that agents are the same.
o	He referenced the above discussed imbalances in patient population and the lack of stratification of subgroups as possible explanations of the negative result, along with possibly bad luck.
o	He said that we need to hold off judgment until the combo data is available.","Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.",265
SQ,Territory, WA,28.0769230769,1.69965923429e-05,8,0,"Met with a national lung AI/TL and advisor to NSCLC NCCN panelist post-ESMO, who provided the following unsolicited insights from the podium.
?	AI was debating from the podium for use of single agent Immunotherapy (PD1) in Squamous NSCLC
o	In the context of a debate, she stated that PD1 agents should be the standard of care for initial therapy in SQ NSCLC specifically.
o	She expressed that with CM 026 specificially in SQ NSCLC, based upon the subgroup HR analysis, the PFS was still higher than in CM 017.  
o	She referenced the impressive OS in CM 012 1L OS (19m)
o	She showed the subgroup analysis from CM 026, showing that for the SQ subgroup specifically, the HR was the lowest of all the subgroups evaluated.
o	She pointed to the much lower grade 3-4 AE?s seen with chemo compared to chemotherapy.","A national/regional lung AI and NCCN NSCLC Panelist provided the following insights from the podium at an Immunotherapy CME event.

?	AI says PDL1 not yet determinative in 2L, for example in 017 SQ NSCLC, why does it make no difference?
?	He says he will not deny treatment in 2L NSCLC, even if tested in 1L and has 0% PDL1 expression
?	Why less gr  AE?s in 012 lung versus melanoma?
o	AI says he doesn?t know.  Dose in 012 is different (lower ipi dose (nivo3/ipi1), may be factor.  
?	It?s highly unlikely that Nivo and Pembro are significantly different.
?	AI says that in the context of CM 026 negative result, he believes that Nivo and Pembro are not significantly different.  He also said PDL1 threshold cuts of data were different than in KN 024, so it will be interesting to see efficacy at different PDL1 cuts of data from CM 026.
?	In AI?s practice, he looks at whether a patient is having clinical deterioration, not just imaging, in determining whether to continue patient on Immunotherapy past progression on imaging.","1.	The following unsolicited Insights were shared by national AI in lung and RCC:
a.	He is interested in ISR?s with BMS in lung SQ cell population, for example with radiation
b.	He thinks that in the 2nd line setting, Keynote 010 results are not comparable to BMS data NSCLC and that Nivo is the choice that the majority of docs choose in the 2nd line.  He said ?BMS has nothing to worry about? with respect to Keynote 010.  
c.	 With respect to first line use of Nivo and Pembro, he shares the view that ?the scientist in him? would like to have a test (such as PDL1) that can determine which patients are most likely to respond, especially in light of the substantial costs of treatments.",8
organization,Territory, WA,25.6703296703,6.81206924661e-08,14,154,"Met with a regional drug use management and pathway implementation AI, who provided the following unsolicited insights.
?	He says they are still in contracting for past year with VIA, which has not been finalized.  
?	At this point in time, VIA pathway not yet implemented for his organization, but he has access to the VIA ?sandbox? so he is able to access the system and has knowledge of pathways for tumor types.
?	In regards to SCLC, he reactively disclosed that the pathway has been updated recently after the update of the NCCN guidelines (inclusion of regimen as option in 2L).
?	AI said that Nivo is on pathway for NSCLC.  If a patient does not have a PDL1 test, it?s unknown, or the test shows a low or non-expressor, then Nivo is the choice.  
?	The pathway asks if a NSCLC patient has a positive PDL1 test, without referring to specific PDL1 thresholds.  If it?s positive, then Keytruda is offered.  If it?s negative, Opdivo is offered.  
?	He mentioned that VIA pathway adherence goal is 80% for his organization (didn?t specific whether this is target across tumors or is goal for each tumor type).
?	He says VIA pathway is provider centric, which is useful in community practices, and less useful in an academic setting where providers are more familiar with SOC and understand the data. 
?	AI said that the VIA pathway adherence also has a patient choice component, such as a preference for orals over infusible medicines.  He said this is not fully incorporated into the system yet.","Met with a regional drug use management and pathway implementation AI, who provided the following unsolicited insights.

?	He says they are still in contracting for past year with VIA, which has not been finalized.  
?	At this point in time, VIA pathway not yet implemented for his organization, but he has access to the VIA ?sandbox? so he is able to access the system and has knowledge of pathways for tumor types.
?	In regards to SCLC, he reactively disclosed that the pathway has been updated recently after the update of the NCCN guidelines (inclusion of regimen as option in 2L).
?	AI said that Nivo is on pathway for NSCLC.  If a patient does not have a PDL1 test, it?s unknown, or the test shows a low or non-expressor, then Nivo is the choice.  
?	The pathway asks if a NSCLC patient has a positive PDL1 test, without referring to specific PDL1 thresholds.  If it?s positive, then Keytruda is offered.  If it?s negative, Opdivo is offered.  
?	He mentioned that VIA pathway adherence goal is 80% for his organization (didn?t specific whether this is target across tumors or is goal for each tumor type).
?	He says VIA pathway is provider centric, which is useful in community practices, and less useful in a academic setting where providers are more familiar with SOC and understand the data. 
?	AI said that the VIA pathway adherence also has a patient choice component, such as a preference for orals over infusible medicines.  He said this is not fully incorporated into the system yet.","Met with a regional melanoma AI at a high volume regional institution, who leads his institution?s lab and works collaboratively with melanoma medical oncologists at his institution, who provided the following unsolicited insights:
?	AI disclosed that his organization is attempting to establish multiple cancer centers of excellence across the bay area, with specific centers taking on expertise for specific types of cancers or service lines.
?	Centers of excellence would have the goal of becoming accredited as a cancer center of excellence in specific types of cancer, such as breast cancer, melanoma, lung, and liver as examples.
?	AI disclosed his organization has vision of creating an organizational specific cancer research consortium.
?	He said he sits on the organization?s oncology standards committee, which is tasked with realizing the above vision. 
?	His organization has launched the ?Precision Cancer Program? that focuses on the capability to collect tissue to do next generation sequencing and potential animal xenograft research.",168
AI,Territory, WA,25.3913043478,5.98395443411e-41,121,70,"Met with a national lung AI/TL post-ESMO, who provided the following unsolicited insights.
?	AI stated that he, along with his institutional colleagues, can?t come to a convincing hypothesis about why CM 026 failed to hit its primary endpoint PFS.
?	AI noted that he is even more puzzled by why there was no signal in PDL1>50% subgroup, despite the noted demographic imbalances in sex and PDL1 expression levels between groups.  Reminded AI that CM 026 was not designed or powered to read out a result in this subgroup, partly due to imbalances and lack of stratification of PDL1 expression (eg. 88 patients in nivo group PDL1>50% versus ~120 in chemo group)
?	He thinks the failure to hit primary endpoint PFS (at 5% or greater) has to do with the trial design in CM 026.
?	He noted that Nivo will still be SOC in other tumors, such as RCC.
?	In 2L lung, Nivo is likely to lose market share simply due to the fact that Atezo has efficacy in an all comer population and most importantly is Q3 weeks instead of Q2 weeks with Nivo.","Met with a national/regional lung AI/TL post-ESMO, who is also an NCCN Head and Neck panelist, who provided the following unsolicited insights.
	
SCCHN:
?	She said she agreed to recent inclusion of Nivo as cat. 1 and Pembro 2A, validating appropriate process for distinguishing recommendations based upon level of evidence.
?	She will make comment to panel again supporting this distinction of recommendations based upon level of evidence, for future recommendations, as the panel has done here.","Met with a national/regional lung AI/TL post-ESMO, who provided the following unsolicited insights.

RE CM 026:
?	She says she doesn't believe that Pembro and Nivo are different agents.
?	She doesn't believe the failure had to do with drugs being different; she says perhaps it's related to study design in CM 026.",191
reactively,Territory, WA,22.4615384615,2.9389102809e-12,41,170,"Met with a AI/RTL who treats multiple tumor types, but is also a Head and Neck national/regional NCCN panelist AI/RTL, during which AI/RTL shared the following unsolicited insights.
BMS Attendees: Cynthia Chan (MSL), Tony Wang (HSL)
?	Reactively shared that the NCCN panel will include an immunotherapy update to the guideline to include both nivo and pembro.
?	Stated that her recommendation does distinguish that the data supporting nivo (Phase III) vs pembro (single arm trial) are different and should have a different category of recommendation.
?	Commented that the SCCHN NCCN committee does not have ad hoc meetings based on recent data presented, and meetings/updates are generally every 6 months with the next update forthcoming. 
?	AI felt that in terms of trials presented overall at ASCO, there were too many trials with induction chemo combined with IO therapies.
?	She feels that induction chemo strategies with later Immunotherapy is not the right approach.
?	She inquired whether BMS has a process for partnering with other companies to explore IO combos, seeming to express a positive view of this approach. 
?	She shared that she feels BMS ""knows what they are doing"" in being very strategic about supporting ISR's and making decisions about research.","Met with the drug information department of a key national/regional institution AI, who provided the following unsolicited insights:
?	AI reactively shared that her institution conducted some internal analysis comparing the cost of Nivo and Pembro.  
?	We reviewed the HEOR data comparing Nivo and Pembro showing the trend of less wastage with Nivo compared to Pembro and potential savings across a range of patient weights due to the vial disposition.  
?	She shared that due to the reduced wastage with Nivo use, with the availability of 40mg and 100mg vials, and the fact that Pembro only comes in 100mg vials, Nivo came out as more cost effective due to the reduced wastage in their analysis.","Met with a regional AI/TL melanoma NCCN panelist, who provided the following unsolicited insights.
?	AI disclosed that he also treats Head and Neck cancer in his practice and is the chair of the Head and Neck department at his institution.  
?	In regards to NCCN H&N guidelines, he expressed that the phase of a study, for example phase 3 versus phase 1, should lead to a distinction in level of evidence, although not a great distinction since he believes Nivo and Pembro are not that different agents.
o	For example in the head and neck context, he said Keytruda should receive a category 2A recommendation due to phase 1 studies while Nivo should receive perhaps a category 1 due to phase 3 studies.  
?	In regards to melanoma, reactively shared ASCO CM 069 (Hodi) subset analysis comparing PFS/OS in patients who discontinued regimen as being similar to the general randomized population on regimen.  
o	He shared that he was not surprised, as he?s seen examples of on-going responses in his melanoma patients who have discontinued regimen due to AE?s.",211
cytology,Territory," WEST
AZ",406.0,4.4868917678e-05,4,159,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",163
volume,Territory," WEST
AZ",121.8,9.33045716196e-06,31,9,"?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.",40
in-house,Territory," WEST
AZ",110.727272727,4.91640716262e-07,25,127,"Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like","Met with a Regional TL in West territory that is part of a network of mid to large size community hospitals. Receives approximately 6 tests for PDL1 testing per week, most of which are 22C3, and has no plans to bring staining in-house. Does not believe pathologists are incentivized at his institution to stain slides in-house based on their reimbursement rate. Had negative views on using a 1% cutoff, stating that the company thought it was smart to have any staining be positive, but it ended up hurting them in the end.",152
score,Territory," WEST
AZ",96.1578947368,1.74548273723e-05,21,156,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",177
requests,Territory," WEST
AZ",42.0,1.67161390826e-05,61,545,"Pathology TL in the West that scores PD-L1 testing for a large reference lab. Sees about 50 requests per week, volumes up 500% lately. Most requests are on label, but says he gets requests for all tumor types. If they get a request that is off-label, they will state that the test is not approved in that tumor type. Accepts cytology and FNA samples without any disclaimer; believes that as long as there are 100 tumor cells, it's on label. Believes most clients are too small to bring testing in-house and will keep sending to them.","Met with a local pathology TL at a mid-size community hospital. Personally receives 3-4 requests for PD-L1 testing per month, mostly for 22C3, and sends these to NeoGenomics. Has no intention of bringing this testing in-house due to low volume but has both Ventana and Dako platforms available for use. Believes that NeoGenomics will sometimes just stain the slide and send it back without scoring so that he can score it himself. For cases that are borderline for 22C3 (40-50%), he will ask for other opinions instead of just calling negative.","?	The institution has thus far been sending out to BioGenomics for PD-L1 testing, but is now validating 22C3 in-house due to large volume of requests (950 requests institution-wide since March 2016, mostly 22C3)
?	Report from BioGenomics provides test used, % PD-L1 positive, a bar graph showing % positive and cut-off point, and positive/negative. All of this information is transcribed into medical record.
?	Very interested in PD-L1 testing in FNA/cytology samples, willing to collaborate regarding this
?	Would like companies to provide a flashcard-like scoring guidelines sheet, for example, that shows what 1% vs 5% vs 10% looks like",606
